



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 457 558 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

**15.09.2004 Bulletin 2004/38**

(21) Application number: **02770234.9**

(22) Date of filing: **17.10.2002**

(51) Int Cl.7: **C12N 15/12, C07K 14/705, C07K 16/28, C12N 5/10, A61K 38/17, A61K 39/395, G01N 33/50, G01N 33/15, C12P 21/02, C12P 21/08, A01H 5/00 // C12N15:12, C12R1:19, C12N5:10, C12R1:91, C12P21:02, C12R1:91, C12P21:08, C12R1:91**

(86) International application number:

**PCT/JP2002/010789**

(87) International publication number:

**WO 2003/040370 (15.05.2003 Gazette 2003/20)**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **19.10.2001 JP 2001321307**

**07.06.2002 JP 2002167239**

(71) Applicant: **Sumitomo Chemical Company, Limited**

**Chuo-ku Osaka 541-8550 (JP)**

(72) Inventors:

- **NAKAJIMA, Hiroki**  
**Nishinomiya-shi, Hyogo 669-1133 (JP)**
- **MUKUMOTO, Fujio**  
**Toyonaka-shi, Osaka 561-0802 (JP)**
- **TAKAISHI, Masanao**  
**Toyonaka-shi, Osaka 560-0021 (JP)**

(74) Representative: **VOSSIUS & PARTNER**

**Siebertstrasse 4**  
**81675 München (DE)**

(54) **WEED CONTROLLER METABOLISM PROTEINS&comma; GENES THEREOF AND USE OF THE SAME**


(57) The present invention provides, for example, DNA encoding a herbicide metabolizing protein selected from the protein group below. Such DNA may, for example, be employed to produce herbicidally resistant plants.

<protein group>


a protein comprising the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224,

a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II):

**EP 1 457 558 A1**



to a compound of formula (III):



and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3, 108, 159, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, 215, 216, 218, 222 or 224.

## Description

## TECHNICAL FIELD

**[0001]** The present invention relates to a protein having the ability to metabolize a herbicidal compound (Herbicide metabolizing protein), a gene thereof and use thereof.

## BACKGROUND ART

**[0002]** Herbicides are utilized in a necessary amount of diluted solution when applied. There are situations in which extra amounts are left over. There are also situations in which the applied herbicide, after its application for awhile, remains in the soil or plant residue. Originally, given that the safety of such herbicides has been checked, such small amounts of left-over solutions or residues presented small effects to the environment or to the crops cultivated thereafter. However, if there is a method in which the contained herbicidal compound is converted to one of lower herbicidal activity, then for example there can be conducted treatments to inactivate the left-over solutions or residues described above as needed.

**[0003]** Further, in the case of using the herbicide, there were situations in which it was difficult to distinguish cultivated plants from weeds of allied species to selectively control only weeds. Then, there is a desire to develop a new method for conferring herbicidal resistance to a target plant.


## DISCLOSURE OF THE INVENTION

**[0004]** Under such the circumstances, the present inventors intensively studied and, as a result, have found that a protoporphyrinogen oxidase (hereinafter, sometimes referred to as "PPO") inhibitory-type herbicidal compound may be converted by being reacted with a particular protein to a compound of lower herbicidal activity, which resulted in completion of the present invention.


**[0005]** That is, the present invention provides:

1. A DNA encoding a herbicide metabolizing protein, wherein said protein is selected from the group consisting of:

- (A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;
- (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;
- (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;
- (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;
- (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II):



to a compound of formula (III):



and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces omatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*;

2. A DNA comprising a nucleotide sequence selected from the group consisting of:

- (a1) the nucleotide sequence shown in SEQ ID NO: 6;
- (a2) the nucleotide sequence shown in SEQ ID NO: 7;
- 5 (a3) the nucleotide sequence shown in SEQ ID NO: 8;
- (a4) the nucleotide sequence shown in SEQ ID NO: 109;
- (a5) the nucleotide sequence shown in SEQ ID NO: 139;
- (a6) the nucleotide sequence shown in SEQ ID NO: 140;
- (a7) the nucleotide sequence shown in SEQ ID NO: 141;
- 10 (a8) the nucleotide sequence shown in SEQ ID NO: 142;
- (a9) the nucleotide sequence shown in SEQ ID NO: 143;
- (a10) the nucleotide sequence shown in SEQ ID NO: 225;
- (a11) the nucleotide sequence shown in SEQ ID NO: 226;
- (a12) the nucleotide sequence shown in SEQ ID NO: 227;
- 15 (a13) the nucleotide sequence shown in SEQ ID NO: 228;
- (a14) the nucleotide sequence shown in SEQ ID NO: 229;
- (a15) the nucleotide sequence shown in SEQ ID NO: 230;
- (a16) the nucleotide sequence shown in SEQ ID NO: 231;
- (a17) the nucleotide sequence shown in SEQ ID NO: 232;
- 20 (a18) the nucleotide sequence shown in SEQ ID NO: 233;
- (a19) the nucleotide sequence shown in SEQ ID NO: 234;
- (a20) a nucleotide sequence encoding an amino acid sequence of a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), said nucleotide sequence having at least 80% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 109; and
- 25 (a21) a nucleotide sequence encoding an amino acid sequence of a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), said nucleotide sequence having at least 90% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233 or SEQ ID NO: 234;
- 30

3. The DNA according to the above 1, comprising a nucleotide sequence encoding an amino acid sequence of said protein, wherein the codon usage in said nucleotide sequence is within the range of plus or minus 4% of the codon usage in genes from the species of a host cell to which the DNA is introduced and the GC content of said nucleotide sequence is at least 40% and at most 60%;

4. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 214;

5. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 368;

6. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 393;

7. A DNA in which a DNA having a nucleotide sequence encoding an intracellular organelle transit signal sequence is linked upstream of the DNA according to the above 1 in frame;

8. A DNA in which the DNA according to the above 1 and a promoter functional in a host cell are operably linked.;

9. A vector comprising the DNA according to the above 1;

10. A method of producing a vector comprising a step of inserting the DNA according to the above 1 into a vector replicable in a host cell;

11. A transformant in which the DNA according to the above 1 is introduced into a host cell;

12. The transformant according to the above 11, wherein the host cell is a microorganism cell or a plant cell;

13. A method of producing a transformant comprising a step of introducing into a host cell, the DNA according to the above 1;

14. A method of producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a steps of culturing the transformant according to the above 11 and recovering the produced said protein;

15. Use of the DNA according to the above 1 for producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III);

16. A method of giving a plant resistance to a herbicide, said method comprising a step of introducing into and expressing in a plant cell, the DNA according to the above 1;

17. A polynucleotide having a partial nucleotide sequence of a DNA according to the above 1 or a nucleotide sequence complimentary to said partial nucleotide sequence;

18. A method of detecting a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting a DNA to which a probe is hybridized in a hybridization using as the probe the DNA according to the above 1 or the polynucleotide according to the above 17;

19. A method of detecting a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting a DNA amplified in a polymerase chain reaction with the polynucleotide according to the above 17 as a primer;

20. The method according to the above 19, wherein at least one of the primers is selected from the group consisting of a polynucleotide comprising the nucleotide sequence shown in any one of SEQ ID NOs:124 to 128 and a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129;

21. A method of obtaining a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of recovering the DNA detected by the method according to the above 18 or 19.

22. A method of screening a cell having a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting said DNA from a test cell by the method according to the above 18 or 19;

23. A herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces omatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*;

24. An antibody recognizing a herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;  
 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;  
 (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and  
 (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence

shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*,  
 5 *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*;

25. A method of detecting a herbicide metabolizing protein, said method comprising:

- 10 (1) a step of contacting a test substance with an antibody recognizing said protein and  
 (2) a step of detecting a complex of said protein and said antibody, arising from said contact,

wherein said protein is selected from the group consisting of:

- 15 (A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 20 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence  
 25 encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;  
 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 30 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;  
 (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 35 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 40 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 45 sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an  
 50 electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID  
 55 NO: 224; and  
 (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucle-

otide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-*  
*coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*,  
*Streptomyces olivochromogenes*, *Streptomyces ornat*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*,  
*Streptomyces steffisburgensis* or *Saccharopolyspora taberi*;

26. An analysis or detection kit comprising the antibody according to the above 24;

27. A DNA encoding a ferredoxin selected from the group consisting of:

- (B1) a protein comprising an amino acid sequence shown in SEQ ID NO: 12;
- (B2) a protein comprising an amino acid sequence shown in SEQ ID NO: 13;
- (B3) a protein comprising an amino acid sequence shown in SEQ ID NO: 14;
- (B4) a protein comprising an amino acid sequence shown in SEQ ID NO: 111;
- (B5) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;
- (B6) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;
- (B7) a protein comprising an amino acid sequence shown in SEQ ID NO: 149;
- (B8) a protein comprising an amino acid sequence shown in SEQ ID NO: 150;
- (B9) a protein comprising an amino acid sequence shown in SEQ ID NO: 151;
- (B10) a protein comprising an amino acid sequence shown in SEQ ID NO: 152;
- (B11) a protein comprising an amino acid sequence shown in SEQ ID NO: 153;
- (B12) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;
- (B13) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253 or SEQ ID NO: 254;
- (B14) a protein comprising the amino acid sequence shown in SEQ ID NO: 245;
- (B15) a protein comprising the amino acid sequence shown in SEQ ID NO: 247;
- (B16) a protein comprising the amino acid sequence shown in SEQ ID NO: 248;
- (B17) a protein comprising the amino acid sequence shown in SEQ ID NO: 249;
- (B18) a protein comprising the amino acid sequence shown in SEQ ID NO: 250;
- (B19) a protein comprising the amino acid sequence shown in SEQ ID NO: 251;
- (B20) a protein comprising the amino acid sequence shown in SEQ ID NO: 252;
- (B21) a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and
- (B22) a protein comprising the amino acid sequence shown in SEQ ID NO: 254;

28. A DNA comprising a nucleotide sequence selected from the group consisting of:

- (b1) a nucleotide sequence shown in SEQ ID NO: 15;
- (b2) a nucleotide sequence shown in SEQ ID NO: 16;
- (b3) a nucleotide sequence shown in SEQ ID NO: 17;
- (b4) a nucleotide sequence shown in SEQ ID NO: 112;
- (b5) a nucleotide sequence shown in SEQ ID NO: 154;
- (b6) a nucleotide sequence shown in SEQ ID NO: 155;
- (b7) a nucleotide sequence shown in SEQ ID NO: 156;
- (b8) a nucleotide sequence shown in SEQ ID NO: 157;
- (b9) a nucleotide sequence shown in SEQ ID NO: 158;
- (b10) a nucleotide sequence shown in SEQ ID NO: 255;
- (b11) a nucleotide sequence shown in SEQ ID NO: 257;

(b12) a nucleotide sequence shown in SEQ ID NO: 258;  
 (b13) a nucleotide sequence shown in SEQ ID NO: 259;  
 (b14) a nucleotide sequence shown in SEQ ID NO: 260;  
 (b15) a nucleotide sequence shown in SEQ ID NO: 261;  
 (b16) a nucleotide sequence shown in SEQ ID NO: 262;  
 (b17) a nucleotide sequence shown in SEQ ID NO: 263;  
 (b18) a nucleotide sequence shown in SEQ ID NO: 264; and  
 (b19) a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 112, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263 or SEQ ID NO: 264;

29. A vector comprising a DNA according to the above 28;

30. A transformant in which the DNA according to the above 28 is introduced into a host cell;

31. A ferredoxin selected from the group consisting of:

(B1) a protein comprising an amino acid sequence shown in SEQ ID NO: 12;  
 (B2) a protein comprising an amino acid sequence shown in SEQ ID NO: 13;  
 (B3) a protein comprising an amino acid sequence shown in SEQ ID NO: 14;  
 (B4) a protein comprising an amino acid sequence shown in SEQ ID NO: 111;  
 (B5) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;  
 (B6) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;  
 (B7) a protein comprising an amino acid sequence shown in SEQ ID NO: 149;  
 (B8) a protein comprising an amino acid sequence shown in SEQ ID NO: 150;  
 (B9) a protein comprising an amino acid sequence shown in SEQ ID NO: 151;  
 (B10) a protein comprising an amino acid sequence shown in SEQ ID NO: 152;  
 (B11) a protein comprising an amino acid sequence shown in SEQ ID NO: 153;  
 (B12) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;  
 (B13) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253 or SEQ ID NO: 254;  
 (B14) a protein comprising the amino acid sequence shown in SEQ ID NO: 245;  
 (B15) a protein comprising the amino acid sequence shown in SEQ ID NO: 247;  
 (B16) a protein comprising the amino acid sequence shown in SEQ ID NO: 248;  
 (B17) a protein comprising the amino acid sequence shown in SEQ ID NO: 249;  
 (B18) a protein comprising the amino acid sequence shown in SEQ ID NO: 250;  
 (B19) a protein comprising the amino acid sequence shown in SEQ ID NO: 251;  
 (B20) a protein comprising the amino acid sequence shown in SEQ ID NO: 252;  
 (B21) a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and  
 (B22) a protein comprising the amino acid sequence shown in SEQ ID NO: 254;

32. A DNA comprising a nucleotide sequence selected from the group consisting of:

(ab1) a nucleotide sequence shown in SEQ ID NO: 9;  
 (ab2) a nucleotide sequence shown in SEQ ID NO: 10;  
 (ab3) a nucleotide sequence shown in SEQ ID NO: 11;  
 (ab4) a nucleotide sequence shown in SEQ ID NO: 110;  
 (ab5) a nucleotide sequence shown in SEQ ID NO: 144;  
 (ab6) a nucleotide sequence shown in SEQ ID NO: 145;

(ab7) a nucleotide sequence shown in SEQ ID NO: 146;  
 (ab8) a nucleotide sequence shown in SEQ ID NO: 147;  
 (ab9) a nucleotide sequence shown in SEQ ID NO: 148;  
 (ab10) a nucleotide sequence shown in SEQ ID NO: 235;  
 (ab11) a nucleotide sequence shown in SEQ ID NO: 236;  
 (ab12) a nucleotide sequence shown in SEQ ID NO: 237;  
 (ab13) a nucleotide sequence shown in SEQ ID NO: 238;  
 (ab14) a nucleotide sequence shown in SEQ ID NO: 239;  
 (ab15) a nucleotide sequence shown in SEQ ID NO: 240;  
 (ab16) a nucleotide sequence shown in SEQ ID NO: 241;  
 (ab17) a nucleotide sequence shown in SEQ ID NO: 242;  
 (ab18) a nucleotide sequence shown in SEQ ID NO: 243; and  
 (ab19) a nucleotide sequence shown in SEQ ID NO: 244;

**33.** A vector comprising the DNA according to the above 32;

**34.** A transformant in which the DNA according to the above 32 is introduced into a host cell;

**35.** The transformant according to the above 34, wherein the host cell is a microorganism cell or a plant cell;

**36.** A method of producing a transformant comprising a step of introducing into a host cell the DNA according to the above 32;

**37.** A method of producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of culturing the transformant according to the above 34 and recovering the produced said protein;

**38.** A method of controlling weeds comprising a step of applying a compound to a cultivation area of a plant expressing at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to Streptomyces or Saccharopolyspora;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;


(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;


(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224,


wherein said compound is a compound of formula (I):




wherein in formula (I) G represents a group shown in any one of the following G-1 to G-9:




G-1




G-2




G-3




G-4




G-5




G-6



G-7



G-8



G-9

wherein in G-1 to G-9,

X represents an oxygen atom or sulfur atom;

Y represents an oxygen atom or sulfur atom;

R<sup>1</sup> represents a hydrogen atom or halogen atom;

R<sup>2</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, halogen atom, hydroxyl group, -OR<sup>9</sup> group, -SH group, -S(O)pR<sup>9</sup> group, -COR<sup>9</sup> group, -CO<sub>2</sub>R<sup>9</sup> group, -C(O)SR<sup>9</sup> group, -C(O)NR<sup>11</sup>R<sup>12</sup> group, -CONH<sub>2</sub> group, -CHO group, -CR<sup>9</sup>=NOR<sup>18</sup> group, -CH=CR<sup>19</sup>CO<sub>2</sub>R<sup>9</sup> group, -CH<sub>2</sub>CHR<sup>19</sup>CO<sub>2</sub>R<sup>9</sup> group, -CO<sub>2</sub>N=CR<sup>13</sup>R<sup>14</sup> group, nitro group, cyano group, -NHSO<sub>2</sub>R<sup>15</sup> group, -NHSO<sub>2</sub>NHR<sup>15</sup> group, -NR<sup>9</sup>R<sup>20</sup> group, -NH<sub>2</sub> group or phenyl group that may be substituted with one or more C<sub>1</sub>-C<sub>4</sub> alkyl groups which may be the same or different;

p represents 0, 1 or 2;

R<sup>3</sup> represents C<sub>1</sub>-C<sub>2</sub> alkyl group, C<sub>1</sub>-C<sub>2</sub> haloalkyl group, -OCH<sub>3</sub> group, -SCH<sub>3</sub> group, -OCHF<sub>2</sub> group, halogen atom, cyano group, nitro group or C<sub>1</sub>-C<sub>3</sub> alkoxy group substituted with a phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, OR<sup>28</sup> group, NR<sup>11</sup>R<sup>28</sup> group, SR<sup>28</sup> group, cyano group, CO<sub>2</sub>R<sup>28</sup> group and nitro group;

R<sup>4</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group or C<sub>1</sub>-C<sub>3</sub> haloalkyl group;

R<sup>5</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, cyclopropyl group, vinyl group, C<sub>2</sub> alkynyl group, cyano group, -C(O)R<sup>20</sup> group, -CO<sub>2</sub>R<sup>20</sup> group, -C(O)NR<sup>20</sup>R<sup>21</sup> group, -CHR<sup>16</sup>R<sup>17</sup>CN group, -CR<sup>16</sup>R<sup>17</sup>C(O)R<sup>20</sup> group, -C<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>20</sup> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NR<sup>20</sup>R<sup>21</sup> group, -CHR<sup>16</sup>OH group, -CHR<sup>16</sup>OC(O)R<sup>20</sup> group or -OCHR<sup>16</sup>OC(O)NR<sup>20</sup>R<sup>21</sup> group, or, when G represents G-2 or G-6, R<sup>4</sup> and R<sup>5</sup> may represent C=O group together with the carbon atom to which they are attached;


R<sup>6</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group or C<sub>3</sub>-C<sub>6</sub> alkynyl group;

R<sup>7</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, halogen atom, -S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl) group or -C(=O)R<sup>22</sup> group;

R<sup>8</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>3</sub>-C<sub>8</sub> cycloalkyl group, C<sub>3</sub>-C<sub>8</sub> alkenyl group, C<sub>3</sub>-C<sub>8</sub>

alkynyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, C<sub>3</sub>-C<sub>8</sub> alkoxyalkoxyalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkynyl group, C<sub>3</sub>-C<sub>8</sub> haloalkenyl group, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl group, C<sub>1</sub>-C<sub>8</sub> haloalkylsulfonyl group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, -S(O)<sub>2</sub>NH(C<sub>1</sub>-C<sub>8</sub> alkyl) group, -C(O)R<sup>23</sup> group or benzyl group which may be substituted with R<sup>24</sup> on the phenyl ring;

R<sup>9</sup> represents C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>3</sub>-C<sub>8</sub> cycloalkyl group, C<sub>3</sub>-C<sub>8</sub> alkenyl group, C<sub>3</sub>-C<sub>8</sub> alkynyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylthioalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylsulfinylalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylsulfonylalkyl group, C<sub>4</sub>-C<sub>8</sub> alkoxyalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkylalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> alkenyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> alkynyloxyalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> haloalkenyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> haloalkynyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkylthioalkyl group, C<sub>4</sub>-C<sub>8</sub> alkenylthioalkyl group, C<sub>4</sub>-C<sub>8</sub> alkynylthioalkyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group substituted with a phenoxy group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group substituted with a benzyloxy group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group, C<sub>4</sub>-C<sub>8</sub> trialkylsilylalkyl group, C<sub>2</sub>-C<sub>8</sub> cyanoalkyl group, C<sub>3</sub>-C<sub>8</sub> halocycloalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkenyl group, C<sub>5</sub>-C<sub>8</sub> alkoxyalkenyl group, C<sub>5</sub>-C<sub>8</sub> haloalkoxyalkenyl group, C<sub>5</sub>-C<sub>8</sub> alkylthioalkenyl group, C<sub>3</sub>-C<sub>8</sub> haloalkynyl group, C<sub>5</sub>-C<sub>8</sub> alkoxyalkynyl group, C<sub>5</sub>-C<sub>8</sub> haloalkoxyalkynyl group, C<sub>5</sub>-C<sub>8</sub> alkylthioalkynyl group, C<sub>2</sub>-C<sub>8</sub> alkylcarbonyl group, benzyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, -OR<sup>28</sup> group, -NR<sup>11</sup>R<sup>28</sup> group, -SR<sup>28</sup> group, cyano group, -CO<sub>2</sub>R<sup>28</sup> group and nitro group, -CR<sup>16</sup>R<sup>17</sup>COR<sup>10</sup> group, -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>20</sup> group, -CR<sup>16</sup>R<sup>17</sup>P(O)(OR<sup>10</sup>)<sub>2</sub> group, -CR<sup>16</sup>R<sup>17</sup>P(S)(OR<sup>10</sup>)<sub>2</sub> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NR<sup>11</sup>R<sup>12</sup> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NH<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)COR<sup>10</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)CO<sub>2</sub>R<sup>20</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)P(O)(OR<sup>10</sup>)<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)P(S)(OR<sup>10</sup>)<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)C(O)NR<sup>11</sup>R<sup>12</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)C(O)NH<sub>2</sub> group, or any one of rings shown in Q-1 to Q-7:



which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>2</sub>-C<sub>6</sub> alkenyl group, C<sub>2</sub>-C<sub>6</sub> haloalkenyl group, C<sub>2</sub>-C<sub>6</sub> alkynyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, -OR<sup>28</sup> group, -SR<sup>28</sup> group, -NR<sup>11</sup>R<sup>28</sup> group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, C<sub>2</sub>-C<sub>4</sub> carboxyalkyl group, -CO<sub>2</sub>R<sup>28</sup> group and cyano group;

R<sup>10</sup> represents a C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>2</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group or tetrahydrofuran group;

R<sup>11</sup> and R<sup>13</sup> independently represent a hydrogen atom or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>12</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group and C<sub>1</sub>-C<sub>4</sub> alkoxy group or -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>25</sup> group; or,

R<sup>11</sup> and R<sup>12</sup> together may represent -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>4</sub>- or -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>-, or in that case the resulting ring may be substituted with a substituent selected from a C<sub>1</sub>-C<sub>3</sub> alkyl group, a phenyl group and benzyl group;

R<sup>14</sup> represents a C<sub>1</sub>-C<sub>4</sub> alkyl group or phenyl group which may be substituted on the ring with a substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group; or,

R<sup>13</sup> and R<sup>14</sup> may represent C<sub>3</sub>-C<sub>8</sub> cycloalkyl group together with the carbon atom to which they are attached;

R<sup>15</sup> represents C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group or C<sub>3</sub>-C<sub>6</sub> alkenyl group;

R<sup>16</sup> and R<sup>17</sup> independently represent a hydrogen atom or C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>2</sub>-C<sub>4</sub> haloalkenyl group, C<sub>2</sub>-C<sub>4</sub> alkynyl group, C<sub>3</sub>-C<sub>4</sub> haloalkynyl group; or,

R<sup>16</sup> and R<sup>17</sup> may represent C<sub>3</sub>-C<sub>6</sub> cycloalkyl group with the carbon atom to which they are attached, or the ring thus formed may be substituted with at least one substituent selected from a halogen atom, a C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group;

R<sup>18</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group or C<sub>3</sub>-C<sub>6</sub> alkynyl group;

R<sup>19</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group or halogen atom,

R<sup>20</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group and -OR<sup>28</sup> group, or -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>25</sup> group;

R<sup>21</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>2</sub> alkyl group or -CO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) group;

R<sup>22</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group or NH(C<sub>1</sub>-C<sub>6</sub> alkyl) group;

R<sup>23</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, NH(C<sub>1</sub>-C<sub>6</sub> alkyl) group, benzyl group, C<sub>2</sub>-C<sub>8</sub> dialkylamino group or phenyl group which may be substituted with R<sup>24</sup>;

R<sup>24</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, 1 to 2 halogen atoms, C<sub>1</sub>-C<sub>6</sub> alkoxy group or CF<sub>3</sub> group;

R<sup>25</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group or C<sub>3</sub>-C<sub>6</sub> haloalkynyl group;

R<sup>26</sup> and R<sup>27</sup> each represent independently a hydrogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>2</sub>-C<sub>4</sub> haloalkenyl group, C<sub>2</sub>-C<sub>4</sub> alkynyl group, C<sub>3</sub>-C<sub>4</sub> haloalkynyl group, -OR<sup>28</sup> group, -NHR<sup>28</sup> group, or -SR<sup>28</sup> group; or,

R<sup>26</sup> and R<sup>27</sup> may represent C<sub>3</sub>-C<sub>8</sub> cycloalkyl group with the carbon atom to which they are attached, or each of the ring thus formed may be substituted with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group; and,

R<sup>28</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, C<sub>2</sub>-C<sub>4</sub> carboxyalkyl group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkoxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> alkenyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> haloalkenyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> alkynyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> haloalkynyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> cycloalkoxycarbonylalkyl group or C<sub>5</sub>-C<sub>9</sub> halocycloalkoxycarbonylalkyl group;

39. A method of controlling weeds comprising a step of applying a compound to a cultivation area of a plant expressing at least one protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide se-

quence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*;

40. A method of evaluating the resistance of a cell to a compound of formula (I), said method comprising:

(1) a step of contacting said compound with a cell expressing at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(2) a step of evaluating the degree of damage to the cell which contacted the compound in the above step (1);

41. The method according to the above 40, wherein the cell is a microorganism cell or plant cell;
42. A method of selecting a cell resistant to a compound of formula (I), said method comprising a step of selecting a cell based on the resistance evaluated in the method according to the above 40;
43. The cell resistant to herbicide selected by the method according to the above 42, or the culture thereof;
44. A method of evaluating the resistance of a plant to a compound of formula (I), said method comprising:

(1) a step of contacting said compound with a plant expressing at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequences shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to Streptomyces or Saccharopolyspora;  
 (A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;  
 (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;  
 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(2) a step of evaluating the degree of damage to the plant which contacted the compound described in step (1);

**45.** A method of selecting a plant resistant to a compound of formula (I), said method comprising a step of selecting a plant based on the resistance evaluated in the method according to the above 44;

**46.** A herbicidally resistant plant selected from the method according to the above 45, or the progeny thereof;

**47.** A method of treating a compound of formula (I), said method comprising reacting said compound in the presence of an electron transport system containing an electron donor, with at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to Streptomyces or

Saccharopolyspora;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224;

48. the method according to the above 47, wherein reacting the compound with the herbicide metabolizing protein by contacting the compound with a transformant in which a DNA encoding the herbicide metabolizing protein is introduced into a host cell in a position enabling its expression in said cell;

49. Use for treating the compound of formula (I) of a herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding any one of the amino acid sequences shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid

sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template chromosome of a microorganism belonging to Streptomyces or Saccharopolyspora;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding the amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

50. Use for treating a compound of formula (I) of a polynucleotide encoding a herbicide metabolizing protein selected from the group consisting of

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide

sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein comprising an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224.

## BRIEF DESCRIPTION OF DRAWINGS

### [0006]

Fig. 1 shows the annealing site of the PCR primers utilized to obtain the present invention DNA (A1) and the present invention DNA (B1). Each of the numbers refers to the SEQ ID number showing the nucleotide sequence of the primers. The arrows show the annealing sites of the oligonucleotide primers having the nucleotide sequence shown with the SEQ ID number thereof and the extension direction of the DNA polymerase reaction from the primers. The dotted lines represent the DNA amplified by the PCR utilizing the primers. The thick line represents the region adjacent to the DNA insertion site of the vector utilized to produce the chromosomal DNA library.

Fig. 2 shows the annealing site of the PCR primers utilized to obtain the present invention DNA (A2) and the present invention DNA (B2). Each of the numbers refers to the SEQ ID number showing the nucleotide sequence of the primers. The arrows show the annealing sites of the oligonucleotide primers having the nucleotide sequence shown with the SEQ ID number thereof and the extension direction of the DNA polymerase reaction from the primers. The dotted lines represent the DNA amplified by the PCR utilizing the primers. The thick line represents the region adjacent to the DNA insertion site of the vector utilized to produce the chromosomal DNA library.

Fig. 3 shows the annealing site of the PCR primers utilized to obtain the present invention DNA (A4) and the present invention DNA (B4). Each of the numbers refers to the SEQ ID number showing the nucleotide sequence of the primers. The arrows show the annealing sites of the oligonucleotide primers having the nucleotide sequence shown with the SEQ ID number thereof and the extension direction of the DNA polymerase reaction from the primers. The dotted lines represent the DNA amplified by the PCR utilizing the primers. The thick line represents the region adjacent to the DNA insertion site of the vector utilized to produce the chromosomal DNA library. However, the oligonucleotide primer represented by 57, is a primer which anneals to the region adjacent to the DNA insertion site of the vector utilized to produce the chromosomal DNA library, and fails to anneal with the present

invention DNA (A4).

Fig. 4 shows the restriction map of the plasmid pKSN2.

Fig. 5 shows the restriction map of the plasmid pCRrSt12.

Fig. 6 shows the restriction map of the plasmid pCR657ET.

Fig. 7 shows the restriction map of the plasmid pCR657FET.

Fig. 8 shows the restriction map of the plasmid pCR657Bs.

Fig. 9 shows the restriction map of the plasmid pCR657FBs.

Fig. 10 shows the restriction map of the plasmid pUCrSt12.

Fig. 11 shows the restriction map of the plasmid pUCrSt657.

Fig. 12 shows the restriction map of the plasmid pUCrSt657F.

Fig. 13 shows the restriction map of the plasmid pUCCR16G6-p/t.

Fig. 14 shows the structure of the linker NotI-EcoRI produced by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 89 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 90.

Fig. 15 shows the restriction map of the plasmid pUCCR16G6-p/t Δ.

Fig. 16 shows the structure of the linker HindIII-NotI produced by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 91 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 92.

Fig. 17 shows the restriction map of the plasmid pNdG6- Δ T.

Fig. 18 shows the restriction map of the plasmid pSUM-NdG6-rSt657.

Fig. 19 shows the restriction map of the plasmid pSUM-NdG6-rSt657F.

Fig. 20 shows the restriction map of the plasmid pKFrSt12.

Fig. 21 shows the restriction map of the plasmid pKFrSt12-657.

Fig. 22 shows the restriction map of the plasmid pKFrSt12-657F.

Fig. 23 shows the restriction map of the plasmid pSUM-NdG6-rSt12-657.

Fig. 24 shows the restriction map of the plasmid pSUM-NdG6-rSt12-657F.

Fig. 25 shows the structure of the linker HindIII-NotI-EcoRI produced by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 98 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 99.

Fig. 26 shows the restriction map of the plasmid pBI121S.

Fig. 27 shows the restriction map of the plasmid pBI-NdG6-rSt-657.

Fig. 28 shows the restriction map of the plasmid pBI-NdG6-rSt-657F.

Fig. 29 shows the restriction map of the plasmid pBI-NdG6-rSt12-657.

Fig. 30 shows the restriction map of the plasmid pBI-NdG6-rSt12-657F.

Fig. 31 shows the restriction map of the plasmid pCR923Sp.

Fig. 32 shows the restriction map of the plasmid pNdG6-rSt12.

Fig. 33 shows the restriction map of the plasmid pSUM-NdG6-rSt-923.

Fig. 34 shows the restriction map of the plasmid pKFrSt12-923.

Fig. 35 shows the restriction map of the plasmid pSUM-NdG6-rSt12-923.

Fig. 36 shows the restriction map of the plasmid pBI-NdG6-rSt-923.

Fig. 37 shows the restriction map of the plasmid pBI-NdG6-rSt12-923.

Fig. 38 shows the restriction map of the plasmid pCR671ET.

Fig. 39 shows the restriction map of the plasmid pCR671Bs.

Fig. 40 shows the restriction map of the plasmid pUCrSt671.

Fig. 41 shows the restriction map of the plasmid pSUM-NdG6-rSt-671.

Fig. 42 shows the restriction map of the plasmid pKFrSt12-671.

Fig. 43 shows the restriction map of the plasmid pSUM-NdG6-rSt12-671.

Fig. 44 shows the restriction map of the plasmid pBI-NdG6-rSt-671.

Fig. 45 shows the restriction map of the plasmid pBI-NdG6-rSt12-671.

Fig. 46 shows the results obtained by detecting with agarose gel electrophoresis the DNA amplified by the PCR using as a primer the oligonucleotide having a partial nucleotide sequence of the present invention DNA(A). Lanes 1, 7, 8, 12, 19, 26, 27, 32, 37, 42 and 47 represent the electrophoresis of a DNA marker (ϕ 174/HaeIII digest). The other lanes represent the electrophoresis of the samples shown in Tables 20 and 21.

Fig. 47 shows the structure of the linker produced by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 134 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 135.

Fig. 48 shows the restriction map of the plasmid pUCrSt657soy.

Fig. 49 shows the restriction map of the plasmid pSUM-NdG6-rSt-657soy.

Fig. 50 shows the restriction map of the plasmid pKFrSt12-657soy.

Fig. 51 shows the restriction map of the plasmid pSUM-NdG6-rSt12-657soy.

Fig. 52 shows the restriction map of the plasmid pBI-NdG6-rSt-657soy.

Fig. 53 shows the restriction map of the plasmid pBI-NdG6-rSt12-657soy.

Fig. 54 shows the restriction map of the plasmid pUCrSt1584soy.

Fig. 55 shows the restriction map of the plasmid pSUM-NdG6-rSt-1584soy.

Fig. 56 shows the restriction map of the plasmid pKFrSt12-1584soy.

Fig. 57 shows the restriction map of the plasmid pSUM-NdG6-rSt12-1584soy.

Fig. 58 shows the restriction map of the plasmid pBI-NdG6-rSt-1584soy.

Fig. 59 shows the restriction map of the plasmid pBI-NdG6-rSt12-1584soy.

Fig. 60 shows the restriction map of the plasmid pUCrSt1609soy.

Fig. 61 shows the restriction map of the plasmid pSUM-NdG6-rSt-1609soy.

Fig. 62 shows the structure of the linker EcoT22I-12aa-EcoT22I produced by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 402 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 403.

Fig. 63 shows the restriction map of the plasmid pUCrSt12-1609soy.

Fig. 64 shows the restriction map of the plasmid pSUM-NdG6-rSt12-1609soy.

Fig. 65 shows the restriction map of the plasmid pBI-NdG6-rSt-1609soy.

Fig. 66 shows the restriction map of the plasmid pBI-NdG6-rSt12-1609soy.

**[0007]** The abbreviations described in the above figures are explained below.

DNA A1:	the present invention DNA (A1)
DNA A2:	the present invention DNA (A2)
DNA A3:	the present invention DNA (A3)
DNA A4:	the present invention DNA (A4)
DNA B1:	the present invention DNA (B1)
DNA B2:	the present invention DNA (B2)
DNA B4:	the present invention DNA (B4)
DNA A1S:	the present invention DNA (A1)S
DNA A23S:	the present invention DNA (A23)S
DNA A25S:	the present invention DNA (A25)S
tac p:	tac promoter
rrnB t:	rrnB terminator
ColE1 ori:	the replication origin of plasmid ColE1
Amp <sup>r</sup> :	the ampicillin resistance gene
RuBPCssCTP:	the nucleotide sequence encoding the chloroplast transit peptide of the small subunit of ribulose-1,5-bisphosphate carboxylase of soybean (cv. Jack).
12aa:	the nucleotide sequence encoding the 12 amino acids of a mature protein, following the chloroplast transit peptide of the small subunit of ribulose-1,5-bisphosphate carboxylase of soybean (cv. Jack).
Km <sup>r</sup> :	kanamycin resistance gene
F1 ori:	replication origin of plasmid F1
CR16G6p:	CR16G6 promoter
CR16t:	CR16 terminator
CR16t Δ:	DNA in which the nucleotide sequence downstream of restriction site of the restriction enzyme ScaI is removed from the CR16 terminator
CR16G6p Δ:	DNA in which the nucleotide sequence upstream of restriction site of the restriction enzyme NdeI is removed from the CR16G6 terminator
NOSp:	promoter of the nopaline synthase gene
NPTII:	kanamycin resistance gene
NOST:	terminator of nopaline synthase gene
GUS:	β-glucuronidase gene
RB:	the right border sequence of T-DNA
LB:	the left border sequence of T-DNA
NdeI, HindIII, BspHI, EcoRI, BamHI, EcoT221, SphI, KpnI, SacI, BglII, NotI, ScaI:	the restriction sites of the respective restriction enzyme

## BEST MODE FOR CARRYING OUT THE INVENTION

[0008] The present invention is explained in detail below.

[0009] The herbicide metabolizing protein selected from the following protein group (hereinafter, sometimes referred to as "the present invention protein (A)") has the ability to convert the compound of formula (II) (hereinafter, sometimes referred to as "compound (II)") to the compound of formula (III) (hereinafter, sometimes referred to as "compound (III)").

<protein group>

[0010]

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;  
 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;  
 (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and  
 (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermocoeruleus*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces*

omatus, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*.

**[0011]** As specific examples of the present invention protein (A), there is mentioned:

a protein comprising the amino acid sequence shown in SEQ ID NO: 1 (hereinafter, sometimes referred to as "present invention protein (A1)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 2 (hereinafter, sometimes referred to as "present invention protein (A2)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 3 (hereinafter, sometimes referred to as "present invention protein (A3)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 108 (hereinafter, sometimes referred to as "present invention protein (A4)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 159 (hereinafter, sometimes referred to as "present invention protein (A11)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 160 (hereinafter, sometimes referred to as "present invention protein (A 12)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 136 (hereinafter, sometimes referred to as "present invention protein (A13)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 137 (hereinafter, sometimes referred to as "present invention protein (A14)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 138 (hereinafter, sometimes referred to as "present invention protein (A 15)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 215 (hereinafter, sometimes referred to as "present invention protein (A16)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 216 (hereinafter, sometimes referred to as "present invention protein (A17)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 217 (hereinafter, sometimes referred to as "present invention protein (A18)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 218 (hereinafter, sometimes referred to as "present invention protein (A19)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 219 (hereinafter, sometimes referred to as "present invention protein (A20)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 220 (hereinafter, sometimes referred to as "present invention protein (A21)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 221 (hereinafter, sometimes referred to as "present invention protein (A22)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 222 (hereinafter, sometimes referred to as "present invention protein (A23)");  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 223 (hereinafter, sometimes referred to as "present invention protein (A24)"); and  
 a protein comprising the amino acid sequence shown in SEQ ID NO: 224 (hereinafter, sometimes referred to as "present invention protein (A25)").

**[0012]** For example, by reacting the PPO inhibitory-type herbicidal compound of formula (I) (hereinafter, sometimes referred to as "compound (I)") with the present invention protein (A), it is capable to convert the compound to a compound with lower herbicidal activity.

**[0013]** Further, in treatment to convert compound (I) to a compound of a lower herbicidal activity, there can also be utilized a herbicide metabolizing protein selected from the following group (hereinafter, sometimes referred to as "present protein (A)");

<protein group>

**[0014]**

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224.

**[0015]** As examples of the present protein (A), there can be mentioned the present invention protein A, described above. Further, as other examples, there can be mentioned

a protein comprising the amino acid sequence shown in SEQ ID NO: 4 (hereinafter, sometimes referred to as "present protein (A9)") and

a protein comprising the amino acid sequence shown in SEQ ID NO: 5 (hereinafter, sometimes referred to as "present protein (A10)").

**[0016]** In the amino acid sequence of the protein shown in (A5), (A6), (A7), (A8), (A26), (A27) or (A28) in the above protein groups, the differences which may be observed from the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224, are such as deletion, substitution, and addition of certain amino acids. Such differences include, for example, the deletion from the processing which the

above protein comprising the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224 receives within the cell. Further, there are included a polymorphic variation which occurs naturally resulting from the difference by such as the species, individual or the like of the organism from which the protein is derived; amino acid deletions, substitutions, and additions arising from genetic mutations artificially introduced by such as a site-directed mutagenesis method, a random mutagenesis method, a mutagenic treatment and the like.

**[0017]** The number of amino acids undergoing such deletions, substitutions and additions may be within the range in which the present protein (A) can develop the ability to convert compound (II) to compound (III). Further, as a substitution of the amino acid, there can be mentioned, for example, substitutions to an amino acid which is similar in hydrophobicity, charge, pK, stereo-structural feature, or the like. As such substitutions, specifically for example, there are mentioned substitutions within the groups of: (1.) glycine and alanine; (2.) valine, isoleucine and leucine; (3.) aspartic acid, glutamic acid, asparagine and glutamine; (4.) serine and threonine; (5.) lysine and arginine; (6.) phenylalanine and tyrosine; and the like.

**[0018]** Further, in the present protein (A), it is preferable that the cysteine present at the position aligning to the cysteine of amino acid number 357 in the amino acid sequence shown in SEQ ID NO: 1 is conserved (not undergo a deletion or substitution): examples of such cysteine include the cysteine shown at amino acid number 350 in the amino acid sequence shown in SEQ ID NO: 2, the cysteine shown at amino acid number 344 in the amino acid sequence shown in SEQ ID NO: 3, the cysteine shown at amino acid number 360 in the amino acid sequence shown in SEQ ID NO: 108; the cysteine shown at amino acid number 359 in the amino acid sequence shown in SEQ ID NO: 4, the cysteine shown at amino acid number 355 in the amino acid sequence shown in SEQ ID NO: 5, the cysteine shown at amino acid number 358 in the amino acid sequence shown in SEQ ID NO: 159, the cysteine shown at amino acid number 374 in the amino acid sequence shown in SEQ ID NO: 160, the cysteine shown at amino acid number 351 in the amino acid sequence shown in SEQ ID NO: 136, the cysteine shown at amino acid number 358 in the amino acid sequence shown in SEQ ID NO: 137, the cysteine shown at amino acid number 358 in the amino acid sequence shown in SEQ ID NO: 138, the cysteine shown at amino acid number 347 in the amino acid sequence shown in SEQ ID NO: 222, the cysteine shown at amino acid number 347 in the amino acid sequence shown in SEQ ID NO: 224 and the like.

**[0019]** As methods of artificially causing such amino acid deletions, additions or substitutions (hereinafter, sometimes, collectively referred to as "amino acid modification"), for example, there is mentioned a method comprising the steps of carrying out site-directed mutagenesis on the DNA encoding an amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224, and then allowing the expression of such DNA by a conventional method. As the site-directed mutagenesis method, for example, there is mentioned a method which utilizes amber mutations (Gapped Duplex method, *Nucleic Acids Res.*, 12, 9441-9456 (1984)), a method by PCR utilizing primers for introducing a mutation and the like. Further, as methods of artificially modifying amino acids, for example, there is mentioned a method comprising the steps of carrying out random mutagenesis on the DNA encoding any one of the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224 and then allowing the expression of such DNA by a conventional method. As the random mutagenesis method, for example, there is mentioned method of conducting PCR by utilizing the DNA encoding any one of the above amino acid sequences as a template and by utilizing a primer pair which can amplify the full length of each of the DNA, under the condition in which the concentration of each of dATP, dTTP, dGTP and dCTP, utilized as a substrate, are different than usual or under the condition in which the concentration of  $Mg^{2+}$  that promotes the polymerase reaction is increased to more than usual. As such methods of PCR, for example, there is mentioned the method described in *Method in Molecular Biology*, (31), 1994, 97-112. Further, there may be mentioned the method described in PCT patent publication WO 00/09682.

**[0020]** In the present invention, "sequence identity" refers to the homology and identity between two nucleotide sequences or two amino acid sequences. Such "sequence identity" may be determined by comparing the two sequences, each aligned in an optimal state, over the whole region of the test sequences. As such, additions or deletions (for example, gaps) can be utilized in the optimal alignment of the test nucleic acid sequences or amino acid sequences. Such sequence identity can be calculated through the step of producing the alignment conducted by a homology analysis using a program such as FASTA (Pearson & Lipman, *Proc. Natl. Acad. Sci. USA*, 4, 2444-2448 (1988)), BLAST (Altschul et al., *Journal of Molecular Biology*, 215, 403-410 (1990)), CLUSTAL W (Thompson, Higgins & Gibson, *Nucleic Acid Research*, 22, 4673-4680 (1994a)) and the like. Such programs, for example, can be typically utilized on the webpage (<http://www.ddbj.nig.ac.jp>) of the DNA Data Bank of Japan (the international databank operated within the Center for Information Biology and DNA Data Bank of Japan). Further, the sequence identity may be determined by utilizing a commercially available sequence analysis software. Specifically for example, it can be calculated by producing an alignment conducted by a homology analysis by the Lipman-Pearson method (Lipman, D.J. and Pearson, W.R., *Science*, 227, 1435-1441, (1985)) utilizing GENETYX-WIN Ver.5 (Software Development Company, Ltd.).

**[0021]** As the "stringent condition" described in (A7), there can be mentioned, for example, the conditions under which a hybrid is formed at 45°C in a solution containing 6xSSC (let the solution containing 1.5 M NaCl and 0.15 M

trisodium citrate be  $10\times\text{SSC}$ ) and then the hybrid is washed at  $50^{\circ}\text{C}$  with  $2\times\text{SSC}$  (Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6) in a hybridization conducted according to the conventional method described in such as Sambrook, J., Frisch, E.F., and Maniatis, T.; Molecular Cloning 2nd edition, Cold Spring Harbor Press. The salt concentration in the washing step can be selected, for example, from the conditions of  $2\times\text{SSC}$  (low stringency condition) to the conditions of  $0.2\times\text{SSC}$  (high stringency conditions). A temperature in the washing step can be selected, for example, from room temperature (low stringency condition) to  $65^{\circ}\text{C}$  (high stringency condition). Alternatively, both of the salt concentration and temperature may be changed.

**[0022]** As a DNA which "hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108", specifically for example, there can be mentioned a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3, 4, 5, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224, a DNA comprising a nucleotide sequence shown in any one of SEQ ID NO: 6, 7, 8, 78, 84, 109, 139, 140, 141, 142, 143, 225, 226, 227, 228, 229, 230, 231, 232, 233 or 234, and the like. There can also be mentioned DNA comprising a nucleotide sequence having at least about 60% identity to a nucleotide sequence shown in any one of SEQ ID NO: 6, 7, 8, 78, 84, 109, 139, 140, 141, 142, 143, 225, 226, 227, 228, 229, 230, 231, 232, 233 or 234.

**[0023]** The molecular weight of the present protein (A) is about 30,000 to 60,000 and is typically about 40,000 to 50,000 (comparable to, for example, a protein consisting of the amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224), as the molecular weight identified by a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (hereinafter, referred to as "SDS-PAGE"). Further, the present protein (A), as long as the ability to convert compound (I) to compound (II) is not eliminated, can be utilized as a protein to which amino acid sequence is added upstream to its amino terminus or downstream to its carboxy terminus.

**[0024]** As the marker of the ability of the present protein (A) to metabolize the PPO inhibitory-type herbicidal compound of formula (I), there can be mentioned the ability to convert compound (II) to compound (III). Such ability, for example, can be confirmed by reacting compound (II) with the present protein (A) in the presence of an electron transport system containing an electron donor such as coenzyme NADPH and by detecting the produced compound (III).

**[0025]** The "electron transport system containing an electron donor" refers to a system in which a redox chain reaction occurs and an electron is transferred from the electron donor to the present protein (A). As the electron donor, for example, there is mentioned coenzymes NADPH, NADH and the like. For example, as proteins which may constitute the electron transport system from NADPH to the present protein (A), there is mentioned ferredoxin and ferredoxin-NADP<sup>+</sup> reductase, NADPH-cytochrome P-450 reductase, and the like.

**[0026]** To confirm the ability of converting compound (II) to compound (III), for example, a reaction solution of about pH 7, comprising the present protein (A),  $\beta$ -NADPH, ferredoxin, ferredoxin-NADP<sup>+</sup> reductase and compound (II) labeled with a radioisotope, is incubated at about  $30^{\circ}\text{C}$  for about 10 minutes to 1 hour. Subsequently, after making the reaction solution acidic by adding hydrochloric acid, it is extracted with ethyl acetate. After subjecting the recovered ethyl acetate layer to thin layered chromatography (hereinafter referred to as "TLC"), autoradiography is conducted and the ability to convert compound (II) to compound (III) can be confirmed by detecting the labeled compound (III).

**[0027]** To prepare the present protein (A), for example, first, the DNA encoding the present protein (A) (hereinafter, sometimes collectively referred to as "present DNA (A)") is obtained according to the conventional genetic engineering methods (for example, the methods described in Sambrook, J., Frisch, E.F., Maniatis, T.; Molecular Cloning 2nd Edition, Cold Spring Harbor Laboratory press).

**[0028]** As examples of the present DNA (A), there can be mentioned a DNA encoding the present invention protein (A) (hereinafter, sometimes referred to as "present invention DNA (A)"). As specific examples of the present invention DNA (A), there can be mentioned:

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 1 (hereinafter, sometimes referred to as "present invention DNA (A1)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 2 (hereinafter, sometimes referred to as "present invention DNA (A2)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 3 (hereinafter, sometimes referred to as "present invention DNA (A3)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 108 (hereinafter, sometimes referred to as "present invention DNA (A4)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 159 (hereinafter, sometimes referred to as "present invention DNA (A11)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 160 (hereinafter, sometimes referred to as "present invention DNA (A12)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 136 (hereinafter, sometimes

referred to as "present invention DNA (A13)";

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 137 (hereinafter, sometimes referred to as "present invention DNA (A14)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 138 (hereinafter, sometimes referred to as "present invention DNA (A15)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 215 (hereinafter, sometimes referred to as "present invention DNA (A16)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 216 (hereinafter, sometimes referred to as "present invention DNA (A17)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 217 (hereinafter, sometimes referred to as "present invention DNA (A18)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 218 (hereinafter, sometimes referred to as "present invention DNA (A19)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 219 (hereinafter, sometimes referred to as "present invention DNA (A20)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 220 (hereinafter, sometimes referred to as "present invention DNA (A21)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 221 (hereinafter, sometimes referred to as "present invention DNA (A22)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 222 (hereinafter, sometimes referred to as "present invention DNA (A23)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 223 (hereinafter, sometimes referred to as "present invention DNA (A24)");

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 224 (hereinafter, sometimes referred to as "present invention DNA (A25)"); and the like.

**[0029]** Further as more specific examples of the present invention DNA (A), there can be mentioned:

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 6;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 9;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 7;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 10;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 8;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 11;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 109;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 110;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 139;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 144;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 140;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 145;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 141;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 146;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 142;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 147;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 143;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 148;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 225;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 235;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 226;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 236;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 227;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 237;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 228;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 238;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 229;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 239;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 230;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 240;

a DNA comprising the nucleotide sequence shown in SEQ ID NO: 231;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 241;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 232;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 242;  
 5 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 233;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 243;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 234;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 244;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 214;  
 10 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 368;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 393;  
 a DNA encoding a protein having an ability to convert in the presence of an electron transport system containing  
 an electron donor a compound of formula (II) to a compound of formula (III), and having at least 80% sequence  
 identity with a nucleotide sequence shown in any one of SEQ ID NO: 6, 7, 8 or 109;  
 15 a DNA encoding a protein having an ability to convert in the presence of an electron transport system containing  
 an electron donor a compound of formula (II) to a compound of formula (III), and having at least 90% sequence  
 identity with a nucleotide sequences shown in any one of SEQ ID NO: 139, 140, 141, 142, 143, 225, 226, 227,  
 228, 229, 230, 231, 232, 233 or 234; and the like.

20 **[0030]** Further, as examples of the present DNA (A), other than the present invention DNA (A) above, there is men-  
 tioned:

a DNA comprising the nucleotide sequence encoding a protein comprising the amino acid sequence shown in  
 SEQ ID NO: 4 (hereinafter, sometimes referred to as "present DNA (A9)");  
 25 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 78;  
 a DNA comprising the nucleotide sequence encoding a protein comprising the amino acid sequence shown in  
 SEQ ID NO: 5 (hereinafter, sometimes referred to as "present DNA (A10)");  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 84;  
 a DNA comprising the nucleotide sequence shown in SEQ ID NO: 85; and the like.

30 **[0031]** The present DNA(A), for example, may be a DNA cloned from nature and may be a DNA in which a deletion,  
 substitution or addition of nucleotide(s) has been introduced to the DNA cloned from nature by such as a site-directed  
 mutagenesis method, a random mutagenesis method, and may be an artificially synthesized DNA. Subsequently, the  
 present protein (A) can be produced or obtained by expressing the obtained present DNA (A) according to the con-  
 35 ventional genetic engineering methods. In such ways, the present protein (A) can be prepared.

**[0032]** The present DNA (A) can be prepared, for example, by the following methods. First, chromosomal DNA is  
 prepared by conventional genetic engineering methods, such as those described in Molecular Cloning: A Laboratory  
 Manual 2nd edition (1989), Cold Spring Harbor Laboratory Press; and Current Protocols in Molecular Biology (1987),  
 John Wiley & Sons, Incorporated, from microorganisms belonging to Streptomyces, such as Streptomyces phaeochro-  
 40 mogenes, Streptomyces testaceus, Streptomyces achromogenes, Streptomyces griseolus, Streptomyces car-  
 bophilus, Streptomyces griseofuscus, Streptomyces thermocoeruleus, Streptomyces nogalater, Streptomyces  
 tsusimaensis, Streptomyces glomerochromogenes, Streptomyces olivochromogenes, Streptomyces ornatus, Strep-  
 tomyces griseus, Streptomyces lanatus, Streptomyces misawanensis, Streptomyces pallidus, Streptomyces roseoru-  
 bens, Streptomyces rutgersensis and Streptomyces steffisburgensis, and more specifically, Streptomyces phaeochro-  
 45 mogenes IFO 12898, Streptomyces testaceus ATCC21469, Streptomyces achromogenes IFO 12735, Streptomyces  
 griseolus ATCC11796, Streptomyces carbophilus SANK62585, Streptomyces griseofuscus IFO 12870t, Streptomyces  
 thermocoeruleus IFO 14273t, Streptomyces nogalater IFO 13445, Streptomyces tsusimaensis IFO 13782, Strep-  
 tomyces glomerochromogenes IFO 13673t, Streptomyces olivochromogenes IFO 12444, Streptomyces ornatus IFO  
 13069t, Streptomyces griseus ATCC 10137, Streptomyces griseus IFO 13849T, Streptomyces lanatus IFO 12787T,  
 50 Streptomyces misawanensis IFO 13855T, Streptomyces pallidus IFO 13434T, Streptomyces roseorubens IFO 13682T,  
 Streptomyces rutgersensis IFO 15875T and Streptomyces steffisburgensis IFO 13446T, and the like; or microorgan-  
 isms belonging to Saccharopolyspora, such as Saccharopolyspora taberi, more specifically, Saccharopolyspora taberi  
 JCM 9383t and the like. Next, after partial digestion of the chromosomal DNA with a restriction enzyme such as Sau3AI,  
 a DNA of about 2kb is recovered. The recovered DNA is cloned into a vector according to the conventional genetic  
 engineering methods described in "Molecular Cloning: A Laboratory Manual 2nd edition" (1989), Cold Spring Harbor  
 Laboratory Press; and "Current Protocols in Molecular Biology" (1987), John Wiley & Sons, Incorporated. As the vector,  
 55 specifically for example, there can be utilized pUC 119 (TaKaRa Shuzo Company), pTVA 118N (Takara Shuzo Com-  
 pany), pBluescript II (Toyobo Company), pCR2.1-TOPO (Invitrogen), pTrc99A (Amersham Pharmacia Biotech Com-

pany), pKK331-1A (Amersham Pharmacia Biotech Company), and the like. A chromosomal DNA library can be obtained by extracting the plasmid from the obtained clone.

**[0033]** The present DNA (A) can be obtained by hybridizing a probe with the obtained chromosomal DNA library under the conditions described below, and by detecting and recovering the DNA which bound specifically with the probe. The probe can be a DNA consisting of about at least 20 nucleotides comprising the nucleotides sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3 or 108. As specific examples of the DNA which can be utilized as probes, there is mentioned a DNA comprising a nucleic acid shown in any one of SEQ ID NO: 6, 7, 8 or 109; a DNA comprising a partial nucleotide sequence of the nucleic acid sequence shown in any one of SEQ ID NO: 6, 7, 8 or 109; a DNA comprising a nucleotide sequence complimentary to said partial nucleotide sequence; and the like.

**[0034]** The DNA utilized as the probe is labeled with a radioisotope, fluorescent coloring or the like. To label the DNA with a radioisotope, for example, there can be utilized the Random Labeling Kit of Boehringer or Takara Shuzo Company. Further, a DNA labeled with  $^{32}\text{P}$  can be prepared by conducting PCR. The DNA to be utilized for the probe is utilized as the template. The dCTP typically utilized in the PCR reaction solution is exchanged with ( $\alpha$ - $^{32}\text{P}$ )dCTP. Further, when labeling the DNA with fluorescent coloring, for example, there can be utilized DIG-High Prime DNA labeling and Detection Starter Kit II (Roche Company).

**[0035]** A specific example of preparing the probe is explained next. For example, a DNA labeled with digoxigenin, comprising the full length of the nucleotide sequence shown in SEQ ID NO: 6 can be obtained by utilizing the chromosomal DNA prepared from *Streptomyces phaeochromogenes* IFO12898 as described above or a chromosomal DNA library as a template, by utilizing as primers an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 93 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 94, and by conducting PCR as described in the examples described below with, for example, PCR DIG Probe Synthesis Kit (Roche Diagnostics GmbH) according to the attached manual. Similarly, a DNA labeled with digoxigenin, comprising the nucleotide sequence of from nucleotide 57 to nucleotide 730 shown in SEQ ID NO: 6 can be obtained by utilizing the chromosomal DNA prepared from *Streptomyces phaeochromogenes* IFO12898 as described above or a chromosomal DNA library as the template. As primers, the PCR is conducted with an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 130 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 131. Further, a DNA labeled with digoxigenin, comprising the full length of the nucleotide sequence shown in SEQ ID NO: 7 can be obtained by utilizing the chromosomal DNA prepared from *Saccharopolyspora taberi* JCM 9383t as described above or a chromosomal DNA library as the template. As primers, the PCR is conducted with an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 61 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 62. Further, a DNA labeled with digoxigenin, comprising the full length of the nucleotide sequence shown in SEQ ID NO: 8 can be obtained by utilizing the chromosomal DNA prepared from *Streptomyces testaceus* ATCC21469 as described above or a chromosomal DNA library as the template. As primers, the PCR is conducted with an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 70 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 71. Further, a DNA labeled with digoxigenin, comprising the nucleotide sequence of from nucleotide 21 to nucleotide 691 shown in SEQ ID NO: 8 can be obtained by utilizing the chromosomal DNA prepared from *Streptomyces testaceus* ATCC21469 as described above or a chromosomal DNA library as the template. As primers, the PCR is conducted with an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 132 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 133.

**[0036]** The methods by which a probe is allowed to hybridize with the chromosomal DNA library may include colony hybridization and plaque hybridization, and an appropriate method may be selected, which is compatible with the type of vector used in the library preparation. When the utilized library is constructed with the use of plasmid vectors, colony hybridization is conducted. Specifically first, transformants are obtained by introducing the DNA of the library into microorganism in which the plasmid vector utilized to construct the library is replicable. The obtained transformants are diluted and spread onto an agar plate and cultured until colonies appear. When a phage vector is utilized to construct the library, plaque hybridization is conducted. Specifically, first, the microorganism in which the phage vector utilized to produce the library is replicable is mixed with the phage of the library, under the conditions in which infection is possible. The mixture is then further mixed with soft agar. This mixture is then spread onto an agar plate. Subsequently, the mixture is cultured until plaques appear.

**[0037]** Next, in the case of any one of the above hybridizations, a membrane is placed on the surface of the agar plate in which the above culturing was conducted and the colonies of the transformants or the phage particles in the plaques are transferred to the membrane. After alkali treatment of the membrane, there is a neutralization treatment. The DNA eluted from the transformants or the phage particles is then fixed onto the membrane. More specifically for example, in the event of plaque hybridization, the phage particles are absorbed onto the membrane by placing a nitrocellulose membrane or a nylon membrane, specifically for example, Hybond-N<sup>+</sup> (Amersham Pharmacia Biotech Company) on the agar plate and waiting for 1 minute. The membrane is soaked in an alkali solution (1.5M NaCl and 0.5N NaOH) for about 3 minutes to dissolve the phage particles and elute the phage DNA onto the membrane. The

membrane is then soaked in neutralization solution (1.5M NaCl and 0.5M tris-HCl buffer pH7.5) for about 5 minutes. After washing the membrane in washing solution (0.3M NaCl, 30mM sodium citrate, 0.2M tris-HCl buffer pH7.5) for about 5 minutes, for example, the phage DNA is fixed onto the membrane by incubating about 80°C for about 90 minutes in vacuo.

5 **[0038]** By utilizing the membrane prepared as such, hybridization is conducted with the above DNA as a probe. Hybridization can be conducted, for example, according to the description in "Molecular Cloning: A Laboratory Manual 2nd edition (1989)" Cold Spring Harbor Laboratory Press, and the like.

**[0039]** While various temperature conditions and reagents are available for conducting hybridization, the membrane prepared as described above is soaked with and maintained for 1 hour to 4 hours at 42°C to 65°C in a prehybridization solution, which is prepared at a ratio of from 50μl to 200μl per 1cm<sup>2</sup> of the membrane. The prehybridization solution, for example, may contain 450mM to 900mM NaCl and 45mM to 90mM sodium citrate, contain sodium dodecyl sulfate (hereinafter, referred to as "SDS") at a concentration of 0.1% to 1.0%, and contain denatured unspecific DNA at a concentration of from 0μg/ml to 200μg/ml, and may sometimes contain albumin, phycol, and polyvinyl pyrrolidone, each at a concentration of 0% to 0.2%. Subsequently, for example, the membrane is soaked with and maintained for 10 12 hours to 20 hours at 42°C to 65°C in a hybridization solution, which is prepared at a ratio of from 50μl to 200μl per 1cm<sup>2</sup> of the membrane. The hybridization solution is, for example, a mixture of the prehybridization solution, which may contain 450mM to 900mM NaCl and 45mM to 90mM sodium citrate, contain SDS at a concentration of 0.1% to 1.0%, and contain denatured unspecific DNA at a concentration of from 0μg/ml to 200μg/ml, and may sometimes contain albumin, phycol, and polyvinyl pyrrolidone, each at a concentration of 0% to 0.2%, with the probe obtained 20 with the preparation method described above (in a relative amount of 1.0x10<sup>4</sup> cpm to 2.0x10<sup>6</sup> cpm per 1cm<sup>2</sup> of the membrane). Subsequently, the membrane is removed and a wash of 5 minutes to 15 minutes is conducted about 2 to 4 times, utilizing a washing solution of 42°C to 65°C that contains 15mM to 300mM of NaCl, 1.5mM to 30mM of sodium citrate and 0.1% to 1.0% of SDS. Further, after lightly rinsing with 2xSSC solution (300mM NaCl and 30mM sodium citrate), the membrane is dried. By detecting the position of the probe on the membrane by subjecting the membrane 25 to autoradiography, the position of the DNA hybridizing to the utilized probe on the membrane is identified. Alternatively, prehybridization and hybridization can be conducted with the use of a commercially available hybridization kit, such as with the use of hybridization solution contained in the DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche). After hybridization, for example, the membrane is washed twice for 5 minutes at room temperature in 2xSSC containing 0.1% SDS, followed by washing twice for 15 minutes at 65°C in 0.5xSSC containing 0.1% SDS. The positions 30 of DNAs on the membrane hybridizing with the utilized probe are detected, by treating in turn the washed membrane with the detection solution contained in the kit and by detecting the position of the probe on the membrane.

**[0040]** The clones corresponding to the positions of the detected DNAs on the membrane are identified on the original agar medium, and can be picked up to isolate clones carrying those DNAs.

**[0041]** The present DNA (A) obtained according to the above can be cloned into a vector according to conventional genetic engineering methods described in "Molecular Cloning: A Laboratory Manual 2nd edition" (1989), Cold Spring Harbor Laboratory Press, "Current Protocols in Molecular Biology" (1987), John Wiley & Sons Incorporated, and the like. As the vector, specifically for example, there can be utilized pUCA 119 (Takara Shuzo Company), pTVA118N (Takara Shuzo Company), pBluescriptII (Toyobo Company), pCR2.1-TOPO (Invitrogen Company), pTrc99A (Pharmacia Company), pKK331-1A (Pharmacia Company) and the like.

40 **[0042]** Further, the nucleotide sequence of the present DNA (A) obtained according to the above description can be analyzed by the dideoxy terminator method described in F. Sanger, S. Nicklen, A.R. Coulson, Proceeding of National Academy of Science U.S.A. (1977) 74:5463-5467. In the sample preparation for the nucleotide sequence analysis, a commercially available reagent may be utilized, such as the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit of Perkin Elmer Company.

45 **[0043]** The present DNA (A) can also be prepared as follows. The present DNA (A) can be amplified by conducting PCR. The PCR may utilize as a template the chromosomal DNA or chromosomal DNA library prepared as described above from microorganisms belonging to Streptomyces, such as Streptomyces phaeochromogenes, Streptomyces testaceus, Streptomyces achromogenes, Streptomyces griseolus, Streptomyces carbophilus, Streptomyces griseofuscus, Streptomyces thermocoeruleus, Streptomyces nogalater, Streptomyces tsusimaensis, Streptomyces glomerochromogenes, Streptomyces olivochromogenes, Streptomyces ornatus, Streptomyces griseus, Streptomyces lanatus, Streptomyces misawanensis, Streptomyces pallidus, Streptomyces roseorubens, Streptomyces rutgersensis and Streptomyces steffisburgensis, and more specifically, Streptomyces phaeochromogenes IFO12898, Streptomyces testaceus ATCC21469, Streptomyces achromogenes IFO 12735, Streptomyces griseolus ATCC 11796, Streptomyces carbophilus SANK62585, Streptomyces griseofuscus IFO 12870t, Streptomyces thermocoeruleus IFO 14273t, Streptomyces nogalater IFO 13445, Streptomyces tsusimaensis IFO 13782, Streptomyces glomerochromogenes IFO 13673t, Streptomyces olivochromogenes IFO 12444, Streptomyces ornatus IFO 13069t, Streptomyces griseus ATCC 10137, Streptomyces griseus IFO 13849T, Streptomyces lanatus IFO 12787T, Streptomyces misawanensis IFO 13855T, Streptomyces pallidus IFO 13434T, Streptomyces roseorubens IFO 13682T, Streptomyces rutgersensis IFO 55

15875T and *Streptomyces steffisburgensis* IFO 13446T, and the like; or microorganisms belonging to *Saccharopolyspora*, such as *Saccharopolyspora taberi*, more specifically, *Saccharopolyspora taberi* JCM 9383t and the like. The PCR may also utilize an oligonucleotide comprising at least about 20 nucleotides of the 5' terminus of the nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, 2, 3, 4, 5, 108, 159, 160, 136, 137, 138, 215, 216, 217, 218, 219, 220, 221, 222, 223 or 224, with an oligonucleotide comprising a nucleotide sequence complimentary to at least about 20 nucleotides adjacent to 3' terminus or downstream of the 3' terminus of the nucleotide sequence encoding any one of the amino acid sequences above. The PCR may be conducted under the conditions described below. On the 5' terminus side of the primer utilized for the PCR as described above, a restriction enzyme recognition sequence may be added.

[0044] More specifically for example, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 6, or the like can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces phaeochromogenes* IFO12898 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 51 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 52. Alternatively, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 9 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1) can be amplified by conducting PCR by utilizing as primers the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 51 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 53.

[0045] For example, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 7, or the like can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Saccharopolyspora taberi* JCM 9383t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 61 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 62. Alternatively, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 10 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2) can be amplified by conducting PCR by utilizing as primers the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 61 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 63.

[0046] For example, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 108, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 109, or the like can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces achromogenes* IFO 12735 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 119 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 120. Alternatively, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 110 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 108) can be amplified by conducting PCR by utilizing as primers the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 119 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 121.

[0047] For example, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 144 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 159) can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces nogalater* IFO 13445 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 165 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 166.

[0048] For example, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 145 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 160) can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces tsusimaensis* IFO 13782 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 171 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 172.

[0049] For example, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 146 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 136) can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces thermocoeruleus* IFO 14273t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 177 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 178.

[0050] For example, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 147 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 137) can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces glomerochromogenes* IFO13673t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 183 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 184.

[0051] For example, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 148 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 138) can be prepared by conducting PCR by

utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces olivochromogenes* IFO 12444 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 184 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 185.

[0052] When utilizing as the template the DNA library in which the chromosomal DNA is introduced into the vector, for example, the present DNA (A) can also be amplified by conducting PCR by utilizing as primers an oligonucleotide comprising a nucleotide sequence selected from a nucleotide sequence encoding any one of the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 4, 5, 108, 159, 160, 136, 137 or 138 (for example, an oligonucleotide comprising a nucleotide sequence of at least about 20 nucleotides of the 5' terminus side of the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1) and an oligonucleotide of at least about 20 nucleotides comprising a nucleotide sequence complementary to the nucleotide sequence adjacent to the DNA insertion site of the vector utilized to construct the library. On side of the 5' terminus of the primer utilized for the PCR as described above, a restriction enzyme recognition sequence may be added.

[0053] As the conditions for the such PCR described above, specifically for example, there can be mentioned the condition of maintaining 97°C for 2 minutes, then repeating for 10 cycles a cycle that includes maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds, and then 72°C for 2 minutes; then conducting for 15 cycles a cycle that includes maintaining 97°C for 15 seconds, followed by 68°C for 30 seconds, and followed by 72°C for 2 minutes (adding 20 seconds to every cycle in turn); and then maintaining 72°C for 7 minutes. The PCR can utilize a reaction solution of 50µl, containing 50ng of chromosomal DNA, containing 300nM of each of the 2 primers in such pairings described above, containing 5.0µl of dNTP mixture (a mixture of 2.0mM each of the 4 types of dNTPs), containing 5.0µl of 10x Expand HF buffer (containing MgCl<sub>2</sub>, Roche Molecular Biochemicals Company) and containing 0.75µl of Expand HiFi enzyme mix (Roche Molecular Biochemicals Company).

[0054] Alternatively, there can be mentioned the condition of maintaining 97°C for 2 minutes, then repeating for 30 cycles a cycle that includes 97°C for 15 seconds, followed by 60°C for 30 seconds, and followed by 72°C for 90seconds, and then maintaining the reaction solution at 72°C for 4 minutes. The PCR can utilize a reaction solution of 50µl containing 250ng of chromosomal DNA, containing 200nM of each of the 2 primers in such pairings described above, containing 5.0µl of dNTP mixture (a mixture of 2.5mM each of the 4 types of dNTPs), 5.0 µl of 10x ExTaq buffer (containing MgCl<sub>2</sub>, Takara Shuzo Company) and containing 0.5µl of ExTaq Polymerase (Takara Shuzo Company).

[0055] Alternatively, for example, oligonucleotides can be designed and prepared for use as primers, based on the nucleotide sequence of a region to which the sequence identity is particularly high in the nucleotide sequence shown in SEQ ID NO: 6, 7, 8 or 109. The present DNA (A) can also be obtained by conducting PCR by utilizing the obtained oligonucleotides as primers and a chromosomal DNA or chromosomal DNA library. The chromosomal DNA or chromosomal DNA library can be prepared as described above from microorganisms belonging to *Streptomyces*, such as *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseolus*, *Streptomyces carbophilus*, *Streptomyces griseofuscus*, *Streptomyces thermocoeruleus*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis* and *Streptomyces steffisburgensis*, and more specifically, *Streptomyces phaeochromogenes* IFO12898, *Streptomyces testaceus* ATCC21469, *Streptomyces achromogenes* IFO 12735, *Streptomyces griseolus* ATCC 11796, *Streptomyces carbophilus* SANK62585, *Streptomyces griseofuscus* IFO 12870t, *Streptomyces thermocoeruleus* IFO 14273t, *Streptomyces nogalater* IFO 13445, *Streptomyces tsusimaensis* IFO 13782, *Streptomyces glomerochromogenes* IFO 13673t, *Streptomyces olivochromogenes* IFO 12444, *Streptomyces ornatus* IFO 13069t, *Streptomyces griseus* ATCC 10137, *Streptomyces griseus* IFO 13849T, *Streptomyces lanatus* IFO 12787T, *Streptomyces misawanensis* IFO 13855T, *Streptomyces pallidus* IFO 13434T, *Streptomyces roseorubens* IFO 13682T, *Streptomyces rutgersensis* IFO 15875T and *Streptomyces steffisburgensis* IFO 13446T, and the like; or microorganisms belonging to *Saccharopolyspora*, such as *Saccharopolyspora taberi*, more specifically, *Saccharopolyspora taberi* JCM 9383t and the like. As the "region to which the sequence identity is particularly high in the nucleotide sequence shown in SEQ ID NO: 6, 7, 8 or 109," for example, there is mentioned the region corresponding to the region shown with each of nucleotides 290 to 315, 458 to 485, 496 to 525 or 1046 to 1073 in the nucleotide sequence shown in SEQ ID NO: 6. As the primers designed on the basis of such regions of the nucleotide sequence, for example, there can be mentioned a primer comprising the nucleotide sequence shown in any one of SEQ ID NO: 124 to 129.

SEQ ID NO: 124; based on the nucleotide sequence of the region corresponding to the region shown with the above nucleotides 290 to 315;

SEQ ID NO: 125; based on the nucleotide sequence of the region corresponding to the region shown with the above nucleotides 458 to 485;

SEQ ID NO: 126; based on the nucleotide sequence of the region corresponding to the region shown with the above nucleotides 458 to 485;

SEQ ID NO: 127; based on the nucleotide sequence of the region corresponding to the region shown with the

above nucleotides 496 to 525;

SEQ ID NO: 128; based on the nucleotide sequence of the region corresponding to the region shown with the above nucleotides 496 to 525; and

SEQ ID NO: 129; based on the nucleotide sequence of the region corresponding to the region shown with the above nucleotides 1046 to 1073.

**[0056]** For example, a DNA of approximately 800bp is amplified by utilizing as primers the pairing of the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA of approximately 600bp is amplified by utilizing, as primers the pairing of the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 125 and the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA of approximately 600bp is amplified by utilizing as primers the pairing of the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 126 and the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA of approximately 580bp is amplified by utilizing as primers the pairing of the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 127 and the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. Further, a DNA of approximately 580bp is amplified by utilizing as primers the pairing of the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 128 and the oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129.

**[0057]** As the conditions for PCR, specifically for example, there is mentioned the condition of maintaining 95°C for 1 minute; repeating for 30 cycles a cycle that includes maintaining 94°C for 15 seconds, followed by 60°C for 30 seconds, and followed by 72°C for 1 minute; and then maintaining 72°C for 5 minutes. There can be utilized the reaction solution of 25µl containing 10ng of chromosomal DNA, containing 200nM of each of the 2 primers, containing 0.5µl of dNTP mix (a mixture of 10mM each of the 4 types of dNTPs), containing 5µl of 5xGC genomic PCR reaction buffer, containing 5µl of 5M GC-Melt and containing 0.5µl of Advantage-GC genomic polymerase mix (Clontech Company).

**[0058]** By recovering the DNA amplified as described above, a DNA comprising a partial nucleotide sequence of the present DNA (A) can be obtained. Next, based on the nucleotide sequence possessed by the obtained "DNA comprising a partial nucleotide sequence of the present DNA (A)", there is designed and prepared an oligonucleotide comprising a partial nucleotide sequence of at least about 20 nucleotides of said nucleotide sequence or an oligonucleotide comprising a nucleotide sequence complimentary to the partial nucleotide sequence of at least about 20 nucleotides of said nucleotide sequence. A DNA comprising a partial nucleotide sequence of the present DNA (A) extended downstream of the 3' terminus or upstream of the 5' terminus of the "DNA comprising a partial nucleotide sequence of the present DNA (A)" obtained as described above can be obtained by conducting PCR. The PCR may utilize as primers a pairing of an oligonucleotide prepared as described above based on the nucleotide sequence of the "DNA comprising a partial nucleotide sequence of the present DNA (A)" and an oligonucleotide of at least about 20 nucleotides comprising a nucleotide sequence of the region adjacent to the DNA insertion site of the vector utilized to construct the above library or an oligonucleotide of at least about 20bp comprising a nucleotide sequence complimentary to such nucleotide sequence thereof. The PCR may, for example, utilize as the template the chromosomal DNA library prepared from the microorganisms which have the ability to convert compound (II) to compound (III), as described above. By connecting such DNA comprising the partial nucleotide sequence of the present DNA (A), there can be obtained the present DNA (A). In such a production method, there can be utilized a commercially available kit, such as the Universal Genome Walker (Clontech Company). Alternatively, the present DNA (A) can be obtained by conducting PCR by preparing primers based on the full length nucleotide sequence of the present DNA (A) obtained by connecting the partial nucleotide sequences of the present DNA (A) as described above, by utilizing such primers and by utilizing as the template the chromosomal DNA library as described above.

**[0059]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 316 to 1048 of SEQ ID NO: 139 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 159), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces nogalater* IFO 13445 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 144 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 159 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 149) can be obtained by connecting the resulting DNA.

**[0060]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 364 to 1096 of SEQ ID NO: 140 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 160), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces tsusimaensis* IFO 13782 and by utilizing as primers an oligonucleotide comprising

the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 145 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 150 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 160) can be obtained by connecting the resulting DNA.

**[0061]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 295 to 1027 of SEQ ID NO: 141 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 136), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces thermocoeruleus* IFO 14273t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 146 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 136 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 151) can be obtained by connecting the resulting DNA.

**[0062]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 316 to 1048 of SEQ ID NO: 142 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 137), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces glomerochromogenes* IFO 13673t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 147 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 137 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 152) can be obtained by connecting the resulting DNA.

**[0063]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 316 to 1048 of SEQ ID NO: 143 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 138), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces olivochromogenes* IFO 12444 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 148 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 138 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 153) can be obtained by connecting the resulting DNA.

**[0064]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 289 to 1015 of SEQ ID NO: 232 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 222), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces roseorubens* IFO 13682T and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 242 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 232 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 252) can be obtained by connecting the resulting DNA.

**[0065]** For example, a DNA comprising the nucleotide sequence shown in nucleotides 289 to 1015 of SEQ ID NO: 234 (a partial nucleotide sequence of nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 224), can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces steffisburgensis* IFO 13446T and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 124 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129. A DNA comprising a nucleotide sequence extended downstream of the 3' terminus or upstream of the 5' terminus thereof is obtained according to the above description based on the nucleotide sequence of the obtained DNA. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 244 (containing a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 234 and the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 254) can be obtained by connecting the resulting DNA.

**[0066]** The present DNA (A) obtained by utilizing the PCR described above can be cloned into a vector by a method according to conventional genetic engineering methods described in "Molecular Cloning: A Laboratory Manual 2nd

edition" (1989), Cold Spring Harbor Laboratory Press, "Current Protocols in Molecular Biology" (1987), John Wiley & Sons, Incorporated and the like. Specifically for example, cloning can be conducted by utilizing plasmid vectors such as pBluescriptII of Stratagene Company or a plasmid vector contained in the TA Cloning Kit of Invitrogen Company.

**[0067]** Further, the present DNA (A) can be prepared, for example, as described below. First, a nucleotide sequence is designed. The nucleotide sequence encodes an amino acid sequence of a protein encoded by the present DNA (A). The nucleotide sequence has a GC content of at most 60% and at least 40%, preferably at most 55% and at least 45%. The codon usage in the nucleotide sequence encoding the amino acid sequence of the above protein is within the range of plus or minus 4% of the codon usage in genes from the species of a host cell to which the present DNA (A) is introduced. By preparing a DNA having the designed nucleotide sequence according to conventional genetic engineering methods, the present DNA (A) can be obtained.

**[0068]** For example, there can be designed in the way described below, a nucleotide sequence encoding an amino acid sequence (SEQ ID NO: 1) of the present invention protein (A1) and having a GC content of at most 55% and at least 45%, where the codon usage in the nucleotide sequence encoding the amino acid sequence of the above protein is within the range of plus or minus 4% of the codon usage in genes from soybean. First, for example, the codon usage (Table 22 and Table 23) in the nucleotide sequence (SEQ ID NO: 6) encoding the amino acid sequence of the present invention protein (A1) which can be obtained from *Streptomyces phaeochromogenes* IFO 12898 and soybean codon usage (Table 24 and Table 25) are compared. Based on the result of the comparison, nucleotide substitutions are added to the nucleotide sequence shown in SEQ ID NO: 6, so that the GC content is at most 55% and at least 45% and the codon usage is within the range of plus or minus 4% of the soybean codon usage. As such a nucleotide substitution, there is selected a nucleotide substitution which does not result in an amino acid substitution. For example, the usage of the CTG codon encoding leucine is 1.22% in soybean genes and 7.09% in the nucleotide sequence shown in SEQ ID NO: 6. As such, for example, each of the CTG codons starting from nucleotides 106, 163, 181, 226, 289, 292, 544, 1111, and 1210 of the nucleotide sequence shown in SEQ ID NO: 6 is substituted to CTT codons; each of the CTG codons starting from nucleotides 211, 547 and 1084 is substituted to CTA codons; the CTG codon starting from nucleotide 334 is substituted to a TTA codon; each of the CTG codons starting from nucleotides 664, 718, 733, 772, 835, 1120 and 1141 is substituted to a TTG codon; and the CTG codon starting from nucleotide 787 is substituted to a TTA codon. One sequence of a nucleotide sequence designed in such a way is shown in SEQ ID NO: 214, the codon usage in which is shown in Table 26 and Table 27. In the nucleotide sequence shown in SEQ ID NO: 214, for example, the usage of the CTG codon encoding leucine is 1.71% and is within the range of plus or minus 4% of the codon usage (1.22%) for soybean. The DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 can be prepared by introducing nucleotide substitutions to the DNA having the nucleotide sequence shown in SEQ ID NO: 6, according to site-directed mutagenesis methods described in such as Sambrook, J., Frisch, E.F., and Maniatis, T.; *Molecular Cloning 2nd Edition*, Cold Spring Harbor Press. Alternatively, the DNA having the nucleotide sequence shown in SEQ ID NO: 214 can be prepared by a DNA synthesis method employing the PCR described in Example 46 below.

**[0069]** Similarly, the nucleotide sequence shown in SEQ ID NO: 368 is an example of designing a nucleotide sequence encoding the amino acid sequence (SEQ ID NO: 222) of the present invention protein (A23) and having a GC content of at most 55% and at least 45%, where the codon usage in the nucleotide sequence encoding the amino acid sequence of the above protein is within the range of plus or minus 4% with the codon usage for genes from soybean. Further, the nucleotide sequence shown in SEQ ID NO: 393 is an example of designing a nucleotide sequence encoding the amino acid sequence (SEQ ID NO: 224) of the present invention protein (A25) and having a GC content of at most 55% and at least 45%, where the codon usage in the nucleotide sequence encoding the amino acid sequence of the above protein is within the range of plus or minus 4% with the codon usage for genes from soybean.

**[0070]** The present DNA (A) obtained in such a way can be cloned into a vector according to conventional genetic engineering methods described in such as Sambrook, J., Frisch, E.F., and Maniatis, T.; *"Molecular Cloning 2nd Edition"* (1989), Cold Spring Harbor Press; *"Current Protocols in Molecular Biology"* (1987), John Wiley & Sons, Incorporated, and the like. As the vector, specifically for example, there can be utilized pUC 119 (TaKaRa Shuzo Company), pTVA 118N (Takara Shuzo Company), pBluescript II (Toyobo Company), pCR2.1-TOPO (Invitrogen), pTrc99A (Pharmacia Company), pKK331-1A (Pharmacia Company), and the like.

**[0071]** Further, the nucleotide sequence of the present DNA (A) obtained in such a way can be analyzed by the dideoxy terminator method described in F. Sanger, S. Nicklen, A.R. Coulson, *Proceeding of National Academy of Science U.S.A.* (1977) 74:5463-5467.

**[0072]** The ability to metabolize the PPO inhibitory-type herbicidal compound of formula (I) of the present protein (A), which is encoded by the present DNA (A) obtained in such a way described above, can be confirmed with the ability of converting compound (II) to compound (III) as a marker in the way described below. First, as described below, said DNA is inserted into a vector so that it is connected downstream of a promoter which can function in the host cell and that is introduced into a host cell to obtain a transformant. Next, the culture of the transformant or the extract obtained from disrupting the culture is reacted with compound (II) in the presence of an electron transport system

containing an electron donor, such as coenzyme NADPH. The reaction products resulting therefrom are analyzed to detect compound (III). In such a way, there can be detected a transformant having the ability of metabolizing compound (II) and producing compound (III), and be determined that such a transformant bears the present DNA (A) encoding the protein having such ability. More specifically for example, there is prepared 30 $\mu$ l of a reaction solution consisting of a 0.1M potassium phosphate buffer (pH 7.0) comprising the culture or extract of the above transformant, an electron donor such as  $\beta$ -NADPH at a final concentration of about 2mM, ferredoxin derived from spinach at a final concentration of about 2mg/ml, ferredoxin reductase at a final concentration of about 0.1U/ml and 3ppm of compound (II) labeled with a radioisotope. The reaction solution is incubated at about 30°C to 40°C for 10 minutes to 1 hour. After such incubation, 3 $\mu$ l of 2N HCl and 90 $\mu$ l of ethyl acetate are added, stirred and centrifuged at 8,000g to recover the supernatant. After drying the supernatant in vacuo, the residue is dissolved in ethyl acetate and the obtained solution is developed on a silica gel TLC plate. The TLC plate is analyzed by radio autography. By identifying the spots corresponding to compound (III) labeled with a radioisotope, there can be confirmed the ability to convert compound (II) to compound (III).

**[0073]** A DNA encoding a protein having the ability to convert compound (II) to compound (III) or a microorganism having such a DNA may be further searched by conducting the hybridizations or PCR as described above, utilizing the present invention DNA (A) or the polynucleotide comprising a partial nucleotide sequence of said DNA or a nucleotide sequence complimentary to the partial nucleotide sequence.

**[0074]** Specifically for example, hybridization as described above is conducted and the DNA to which a probe is hybridized is identified. The hybridization is conducted with the use of the present invention DNA (A) or a polynucleotide comprising a partial nucleotide sequence of the present invention DNA (A) of a nucleotide sequence complimentary to the partial nucleotide sequence as a probe, and genomic DNA derived from a natural microorganism, for example, microorganisms belonging to streptomyces such as *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseolus*, *Streptomyces carbophilus*, *Streptomyces griseofuscus*, *Streptomyces thermocoeruleus*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis* and *Streptomyces steffisburgensis*; microorganisms belonging to *Saccharopolyspora* such as *Saccharopolyspora taberi*; and the like. As specific examples of DNA which can be utilized as the probe, there can be mentioned a DNA comprising the full length of the nucleotide sequence shown in any one of SEQ ID NO: 6, 7, 8, 109, 139, 140, 141, 142, 143, 225, 226, 227, 228, 229, 230, 231, 232, 233 or 234; a DNA comprising a nucleotide sequence shown in nucleotides 57 to 730 of the nucleotide sequence shown in SEQ ID NO: 6; a DNA comprising a nucleotide sequence shown in nucleotides 21 to 691 of the nucleotide sequence shown in SEQ ID NO: 8; and the like.

**[0075]** Alternatively, PCR can be conducted as described above and the amplified DNA can be detected. The PCR utilizes a polynucleotide comprising a partial nucleotide sequence of the present invention DNA (A) or a nucleotide sequence complimentary to the partial nucleotide sequence. The PCR utilizes as the template genomic DNA derived from a natural microorganism, for example, microorganisms belonging to streptomyces such as *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseolus*, *Streptomyces carbophilus*, *Streptomyces griseofuscus*, *Streptomyces thermocoeruleus*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis* and *Streptomyces steffisburgensis*; microorganisms belonging to *Saccharopolyspora* such as *Saccharopolyspora taberi*; and the like. As the primers, there can be mentioned primers which were designed, based on the nucleotide sequence of the "region to which the sequence identity is particularly high in the nucleotide sequence shown in SEQ ID NO: 6, 7, 8 or 109" as described above. As more specific examples of the primers, there is mentioned pairings of a primer comprising a nucleotide sequence shown in any one of SEQ ID NO: 124 to 128 and a primer comprising a nucleotide sequence shown in SEQ ID NO: 129.

**[0076]** The DNA detected in such a way is recovered. When the recovered DNA does not contain the full length nucleotide sequence of the present DNA (A), such DNA is utilized and made into a DNA corresponding to the full length nucleotide sequence in a way described above. The obtained DNA is introduced into a host cell to produce a transformant. The ability to convert compound (II) to compound (III) of the protein encoded by the DNA introduced into the transformant can be evaluated by utilizing the culture of the obtained transformant and measuring the ability to convert compound (II) to compound (III) in a way described above.

**[0077]** To express the present DNA (A) in a host cell, the present DNA (A) is introduced into the host cell in a position enabling its expression in said cell. By introducing the present DNA (A) into a "position enabling its expression", it means that the present DNA (A) is introduced into a host cell so that it is placed in a position adjacent to a nucleotide sequence directed to transcription and translation from the nucleotide sequence thereof (that is, for example, a nucleotide sequence promoting the production of the present protein (A) and an RNA encoding the present protein (A)).

**[0078]** To introduce the present DNA (A) into the host cell so that it is placed in a position enabling its expression,

for example, a DNA in which the present DNA (A) and a promoter functional in the host cell are operably linked is introduced into the host cell. The term "operably linked" here means that a condition in which the present DNA (A) is linked to a promoter so that it is expressed under the control of the promoter, when the DNA is introduced into a host cell.

**[0079]** When the host cell is a microorganism cell, as a functional promoter, for example, there can be mentioned the lactose operon promoter of *E. coli*, tryptophan operon promoter of *E. coli*, T7 phage promoter or artificial promoters functional in *E. coli* such as *tac* promoter or *trc* promoter and the like. Further, there may be utilized the promoter originally present upstream of the present DNA (A) in the chromosome of the microorganism belonging to *Streptomyces* or *Saccharopolyspora*.

**[0080]** When the host cell is a plant cell, as a functional promoter, for example, there is mentioned T-DNA derived constitutive promoters such as nopaline synthase gene promoter and octopine synthase gene promoter; plant virus-derived promoters such as cauliflower mosaic virus derived 19S and 35S promoters; inducible promoters such as phenylalanine ammonia-lyase gene promoter, chalcone synthase gene promoter and pathogenesis-related protein gene promoter; the plant promoter described in Japanese Unexamined Patent Publication No. 2000-166577. Further, a terminator functional in a plant cell may be connected to the DNA in which the promoter functional in a plant cell and the present DNA (A) are operably linked. In this case, it is generally preferred that the terminator is connected downstream from the present DNA (A). As the functional terminator, for example, there is mentioned T-DNA derived constitutive terminators such as nopaline synthase gene (NOS) terminator; plant virus derived terminators such as terminators of allium virus GV1 or GV2; the plant terminator described in Japanese Unexamined Patent Publication No. 2000-166577; and the like.

**[0081]** When introducing the present DNA (A) so that the DNA is placed in a position enabling its expression, for example, there can be utilized a DNA having a nucleotide sequence encoding a transit signal to an intracellular organelle, linked upstream of the present DNA (A), so that the reading frames are in frame. By being linked "so that the reading frames are in frame" it means that reading frame of the sequence of the transit signal to an intracellular organelle and the reading frame of the present DNA (A) are connected to form one continuous reading frame. As a transit signal sequence providing the transition and localization of a protein in an intracellular organelle in a plant cell, for example, there can be mentioned a transit signal derived from a cytoplasmic precursor of a protein localizing in the chloroplast of a plant as described in U. S. Pat. No. 5,717,084, the chimeric sequences formed from the variety of the transit signal sequences described in U. S. Pat. No. RE36449. More specifically, there is mentioned the chloroplast transit peptide derived from the small subunit of ribulose-1,5-bisphosphate carboxylase of soybean, which is obtainable according to the method described in Example 15 below.

**[0082]** Typically, the present DNA (A), the present DNA (A) to which a DNA having a nucleotide sequence encoding a transit signal to an intracellular organelle is connected as described above, or a DNA in which such DNA is operably linked to a promoter functional in the host cell, can each be inserted into a vector usable in a host cell and this is introduced into the host cell. When utilizing a vector already possessing a promoter functional in the host cell, the present DNA (A) may be inserted downstream of a promoter present in the vector so that said promoter and the present DNA (A) can be operably linked.

**[0083]** As the vector, specifically when utilizing *E. coli* as the host cell, for example, there can be mentioned pUC 119 (Takara Shuzo Company), pTVA 118N (Takara Shuzo Company), pBluescript II (Stratagene Company), pCR2.1-TOPO (Invitrogen), pTrc99A (Amersham Pharmacia Biotech Company), pKK331-1A (Amersham Pharmacia Biotech Company), pET11d (Novagen) and the like. By utilizing a vector containing a selective marker (for example, genes conferring resistance to an antibiotic such as a kanamycin resistance gene, neomycin resistance gene, and the like), it is convenient in that the transformant to which the present DNA is introduced can be selected with the phenotype of the selective marker as an indicator.

**[0084]** As the method of introducing the present DNA (A) or a vector containing the present DNA (A) into a host cell, there can be mentioned the method described in Shin Seikagaku Zikken Kouza (Nippon-Seikagaku-Kai eds., Tokyo Kagaku Dozin), Vol. 17, Biseibutu-Zikken-Hou when the host cell is a microorganism, for example, *E. coli*, *Bacillus subtilis*, *Bacillus brevis*, *Pseudomonas* sp., *Zymomonas* sp., lactic acid bacteria, acetic acid bacteria, *Staphylococcus* sp., *Streptomyces* sp., *Saccharopolyspora* sp., or yeast such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, fungus such as *Aspergillus*, and the like. Alternatively, for example, there may be utilized the calcium chloride method described in Sambrook, J., Fritsch, E.F., and Maniatis, T.; "Molecular Cloning 2nd edition", Cold Spring Harbor Press (Molecular Biology, John Wiley & Sons, N.Y. (1989) or in "Current Protocols in Molecular Biology" (1987), John Wiley & Sons, Incorporated or the electroporation method described in "Methods in Electroporation: Gene Pulser / *E. coli* Pulser System", Bio-Rad Laboratories (1993).

**[0085]** The transformant to which the present DNA (A) or the vector containing the present DNA (A) has been introduced, for example, can be selected by selecting for the phenotype of the selective marker contained in the vector to which the present DNA (A) has been inserted as described above as an indicator. Further, whether the transformant contains the present DNA (A) or a vector containing the present DNA (A) can be confirmed by preparing the DNA from the transformant and then conducting with the prepared DNA genetic engineering analysis methods described in, for

example, "Molecular Cloning 2nd edition", Cold Spring Harbor Press (Molecular Biology, John Wiley & Sons, N.Y. (1989) (such as confirming restriction enzyme sites, DNA sequencing, southern hybridizations, PCR and the like).

**[0086]** When the host cell is a plant cell, plant types can be mentioned, for example, dicotyledones such as tobacco, cotton, rapeseed, sugar beet, Arabidopsis, canola, flax, sunflower, potato, alfalfa, lettuce, banana, soybean, pea, legume, pine, poplar, apple, grape, orange, lemon, other citrus fruits, almond, walnut other nuts; monocotyledones such as corn, rice, wheat, barley, rye, oat, sorghum, sugar cane and lawn; and the like. As the cell to which the present DNA (A) is introduced there can be utilized plant tissue, plant body, cultured cells, seeds and the like.

**[0087]** As methods of introducing the present DNA (A) or the vector containing the present DNA (A) into a host cell, there is mentioned methods such as infection with Agrobacterium (Japanese Examined Patent Publication No.2-58917 and Japanese Unexamined Patent Publication No. 60-70080), electroporation into protoplasts (Japanese Unexamined Patent Publication No. 60-251887 and Japanese Unexamined Patent Publication No. 5-68575) or particle gun method (Japanese Unexamined Patent Publication No. 5-508316 and Japanese Unexamined Patent Publication No. 63-258525).

**[0088]** In such cases, for example, the transformant to which the present DNA has been introduced can be selected with the phenotype of a selective marker as an indicator, by introducing into the plant cell at the same time with the vector containing the present DNA (A), a selective marker selected from the hygromycin phosphotransferase gene, neomycin phosphotransferase gene and chloramphenicol acetyltransferase gene. The selective marker gene and the present DNA (A) may be inserted into the same vector and introduced. A vector comprising the selective marker gene and a vector comprising the present DNA (A) may also be introduced at the same time. A transformant to which the present DNA (A) has been introduced may also be selected by culturing with a medium containing the PPO inhibitory-type herbicidal compound of formula (I) and by isolating a clone multipliable therein. Whether the transformant contains the present DNA (A) can be confirmed by preparing the DNA from the transformant and then conducting with the prepared DNA genetic engineering analysis methods described in, for example, "Molecular Cloning 2nd edition", Cold Spring Harbor Press (Molecular Biology, John Wiley & Sons, N.Y. (1989) (such as confirming restriction enzyme sites, DNA sequencing, southern hybridizations, PCR and the like). The present DNA (A) introduced in the plant cell may be maintained at locations in the cell other than the DNA contained in the nucleus, by being inserted into the DNA contained in intracellular organelles such as the chloroplast.

**[0089]** From the transformed plant cell obtained in such a way, a transgenic plant to which the present DNA (A) has been introduced can be obtained, by regenerating a plant body by the plant cell culturing method described in Shokubutu-Idenshi-Sosa-Manual: Transgenic-Shokubutu-No-Tukurikata (Uchimiya, Kodansha-Scientific, 1990), pp. 27-55. Further, a targeted plant type to which the present DNA (A) has been introduced can be produced by mating the targeted type of plant with the transgenic plant to which the present DNA (A) has been introduced, so that the present DNA (A) is introduced into a chromosome of the targeted type of plant.

**[0090]** Specifically, for example, rice or Arabidopsis having introduced therein the present DNA (A) and expressing the present protein (A) can be obtained by the method described in Model-Shokubutu-No-Jikken-Protocol: Ine, Shiroyunazuna-Hen (Supervisors: Koh SHIMAMOTO and Kiyotaka OKADA, Shujun-sha, 1996), Fourth chapter. Further, there can be obtained a soybean having introduced therein the present DNA (A) and expressing the present protein (A) by an introduction into a soybean somatic embryo with a particle gun according to the method described in Japanese Unexamined Patent Publication No. 3-291501. Likewise, a maize having introduced therein the present DNA (A) and expressing the present protein (A) can be obtained by an introduction into maize somatic embryo with a particle gun according to the method described by Fromm, M.E., et al., Bio/Technology, 8; p 838 (1990). Wheat having introduced therein the present DNA (A) and expressing the present protein (A) can be obtained by introducing the gene into sterile-cultured wheat immature scutellum with a particle gun according to a conventional method described by TAKUMI et al., Journal of Breeding Society (1995), 44: Extra Vol. 1, p 57. Likewise, barley having introduced therein the present DNA (A) and expressing the present protein (A) can be obtained by an introduction into sterile-cultured barley immature scutellum with a particle gun according to a conventional method described by HAGIO, et al., Journal of Breeding Society (1995), 44; Extra Vol. 1, p 67.

**[0091]** The transformant having introduced therein the present DNA (A) and expressing the present protein (A) can reduce the plant damage by compound (I), by converting said herbicidal compound into a compound of lower herbicidal activity within its cells. Specifically, for example, by spreading the microorganism expressing the present protein (A) to the cultivation area of the desired cultivated plant before sowing seeds of the desired plant, the herbicidal compound remaining in the soil can be metabolized and the damage to the desired plant can be reduced. Further, by getting the desired variety of plant to express the present protein (A), the ability to metabolize the PPO inhibitory-type herbicidal compound of formula (I) to a compound of lower activity is conferred to said plant. As a result, the plant damage from the herbicidal compound in the plant is reduced and resistance to said compound is conferred.

**[0092]** The present protein (A) can be prepared, for example, by culturing a cell comprising the present DNA (A). As such a cell, there is mentioned a microorganism expressing the present DNA (A) and having the ability to produce the present protein (A), such as a microorganism strain isolated from nature comprising the present DNA (A), mutant

strains derived from the natural strain by treatment with agents or ultraviolet rays or the like. More specifically for example, there is mentioned microorganisms belonging to *Streptomyces*, such as *Streptomyces phaeochromogenes* IFO 12898, *Streptomyces testaceus* ATCC21469, *Streptomyces achromogenes* IFO 12735, *Streptomyces griseolus* ATCC11796, *Streptomyces carbophilus* SANK62585, *Streptomyces griseofuscus* IFO 12870t, *Streptomyces thermocoerulescens* IFO 14273t, *Streptomyces nogalater* IFO 13445, *Streptomyces tsusimaensis* IFO 13782, *Streptomyces glomerochromogenes* IFO 13673t, *Streptomyces olivochromogenes* IFO 12444, *Streptomyces omatus* IFO 13069t, *Streptomyces griseus* ATCC 10137, *Streptomyces griseus* IFO 13849T, *Streptomyces lanatus* IFO 12787T, *Streptomyces misawanensis* IFO 13855T, *Streptomyces pallidus* IFO 13434T, *Streptomyces roseorubens* IFO 13682T, *Streptomyces rutgersensis* IFO 15875T and *Streptomyces steffisburgensis* IFO 13446T, and the like; or microorganisms belonging to *Saccharopolyspora*, such as *Saccharopolyspora taberi* JCM 9383t and the like. Further, there can be mentioned a transformant in which the present DNA (A) or a vector containing the present DNA (A) has been introduced. Specifically for example, there is mentioned a transformant in which the present DNA (A) operably linked to a tac promoter, trc promoter, lac promoter or t7 phage promoter is introduced into *E. coli*. As more specific examples, there is mentioned *E. coli* JM109/pKSN657, *E. coli* JM109/pKSN657F, *E. coli* JM109/pKSN923, *E. coli* JM109/pKSN923F, *E. coli* JM109/pKSN11796, *E. coli* JM109/pKSN1 1796F, *E. coli* JM109/pKSN671, *E. coli* JM109/pKSN671F, *E. coli* JM109/pKSNNSCA, *E. coli* JM109/pKSN646, *E. coli* JM109/pKSN646F, *E. coli* JM109/pKSN849AF, *E. coli* JM109/pKSN1618F, *E. coli* JM109/pKSN474F, *E. coli* JM109/pKSN1491AF, *E. coli* JM109/pKSN1555AF, *E. coli* JM109/pKSN1584F, *E. coli* JM109/pKSN1609F and the like, described in the examples described below.

[0093] As a medium for culturing the above microorganisms comprising the present DNA (A), there can be utilized any of those employed usually for culturing a microorganism which contains carbon sources and nitrogen sources, organic and inorganic salts as appropriate. A compound which is a precursor to heme, such as aminolevulinic acid, may be added.

[0094] As the carbon source, for example, there is mentioned saccharides such as glucose, fructose, sucrose and dextrin; sugar alcohols such as glycerol and sorbitol; and organic acids such as fumaric acid, citric acid and pyruvic acid; and the like. The amount of carbon sources listed above to be added to a medium is usually about 0.1% (w/v) to about 10% (w/v) based on a total amount of the medium.

[0095] As the nitrogen source, for example, there is mentioned ammonium salts of inorganic acids such as ammonium chloride, ammonium sulfate and ammonium phosphate; ammonium salts of organic acids such as ammonium fumarate and ammonium citrate; organic nitrogen sources, such as meat extract, yeast extract, malt extract, soybean powder, corn steep liquor, cotton seed powder, dried yeast, casein hydrolysate; as well as amino acids. Among those listed above, ammonium salts of organic acids, organic nitrogen sources and amino acids may mostly be employed also as carbon sources. The amount of nitrogen sources to be added is usually about 0.1% (w/v) to about 10% (w/v) based on the total amount of the medium.

[0096] As the inorganic salt, for example, there is mentioned phosphates such as potassium phosphate, dipotassium phosphate, sodium phosphate, disodium phosphate; chlorides such as potassium chloride, sodium chloride, cobalt chloride hexahydrate; sulfates such as magnesium sulfate, ferrous sulfate heptahydrate, zinc sulfate heptahydrate, manganese sulfate trihydrate; and the like. The amount to be added is usually about 0.0001% (w/v) to about 1% (w/v) based on a total amount of the medium.

[0097] In case of culturing a transformant retaining the present DNA (A) connected downstream of a T7 phage promoter and a DNA in which the nucleotide sequence encoding T7 RNA polymerase ( $\lambda$ DE3 lysogen) is connected downstream of a lac UV5 promoter, typically, a small amount of, for example, isopropyl- $\beta$ -D-thiogalactoside (hereinafter referred to as "IPTG") may be added as an inducer for inducing the production of the present protein (A). IPTG can also be added to the medium in case of culturing a transformant having introduced therein a DNA in which the present DNA (A) is operably linked to a type of promoter which is induced by lactose, such as tac promoter, trc promoter and lac promoter.

[0098] A microorganism comprising the present DNA (A) can be cultivated in accordance with a method employed usually to culture a microorganism, including a liquid phase cultivation such as a rotatory shaking cultivation, a reciprocal shaking cultivation, ajar fermentation (Jar Fermenter cultivation) and a tank cultivation; or a solid phase cultivation. When ajar fermenter is employed, aseptic air should be introduced into the Jar Fermenter usually at an aeration rate of about 0.1 to about 2 times culture fluid volume per minute. The temperature at which the cultivation is performed may vary within a range allowing a microorganism to be grown, and usually ranges from about 15°C to about 40°C, and the pH of the medium ranges from about 6 to about 8. The cultivation time may vary depending on the cultivation conditions, and is usually about 1 day to about 10 days.

[0099] The present protein (A) produced by a microorganism comprising the present DNA (A), for example, can be utilized in various forms in the treatment of the PPO inhibitory-type herbicidal compound of formula (I), such as a culture of a microorganism producing the present protein (A), a cell of a microorganism producing the present protein (A), a material obtained by treating such a cell, a cell-free extract of a microorganism, a crudely purified protein, a purified protein and the like. A material obtained by treating a cell described above includes for example a lyophilized cell, an

acetone-dried cell, a ground cell, an autolysate of a cell, an ultrasonically treated cell, an alkali-treated cell, an organic solvent-treated cell and the like. Alternatively, the present protein (A) in any of the various forms described above may be immobilized in accordance with known methods such as a support binding method employing an adsorption onto an inorganic carrier such as a silica gel or a ceramic material, a polysaccharide derivative such as a DEAE-cellulose, a synthesized polymer such as Amberite IRA-935 (Trade Name, manufactured by Rohm and Haas) and the like, and an inclusion method employing an inclusion into a network matrix of a polymer such as a polyacrylamide, a sulfur-containing polysaccharide gel (e.g. carrageenan gel), an alginic acid gel, an agar gel and the like, and then used in the treatment of the herbicidal compound described above.

**[0100]** As methods of purifying the present protein (A) from a culture of a microorganism comprising the present DNA (A), there can be employed conventional methods utilized in a purification of protein. For example, there can be mentioned the following method.

**[0101]** First, cells are harvested from a culture of a microorganism by centrifugation or the like, and then disrupted physically by an ultrasonic treatment, a DYNOMILL treatment, a FRENCH PRESS treatment and the like, or disrupted chemically by utilizing a surfactant or a cell-lyzing enzyme such as lysozyme. From the resultant lysate thus obtained, insoluble materials are removed by centrifugation, membrane filtration or the like to prepare a cell-free extract, which is then fractionated by any appropriate means for separation and purification, such as a cation exchange chromatography, an anion exchange chromatography, a hydrophobic chromatography, a gel filtration chromatography and the like, whereby purifying the present protein (A). Supporting materials employed in such chromatography include for example a resin support such as cellulose, dextran and agarose connected with a carboxymethyl (CM) group, a diethylaminoethyl (DEAE) group, a phenyl group or a butyl group. A commercially available column already packed with any support such as Q-Sepharose FF, Phenyl-Sepharose HP, PD-10 and HiLoad 26/10 Q Sepharose HP (Trade Name, from Amersham Pharmacia Biotech), TSK-gel G3000SW (Trade Name, TOSOH CORPORATION) may also be employed.

**[0102]** One example of purifying the present protein (A) is given.

**[0103]** Cells of a microorganism producing the present protein (A) are harvested by centrifugation, and then suspended in a buffer such as 0.1M potassium phosphate (pH7.0). The suspension is treated ultrasonically to disrupt the cells, and the resultant lysate thus obtained is centrifuged at about 40,000g for about 30 minutes to obtain a supernatant, which is then centrifuged at 150,000g for about 1 hour to recover the supernatant (the cell-free extract). The obtained cell-free extract is subjected to ammonium sulfate fractionation to obtain the fraction that is soluble in the presence of 45%-saturated ammonium sulfate and precipitates at 55%-saturated ammonium sulfate. After the solvent of the fraction is exchanged with a buffer containing no ammonium sulfate, such as 1M potassium phosphate, utilizing a PD10 column (Amersham Pharmacia Biotech Company), the resulting fraction is loaded, for example, onto a HiLoad 26/10 Q Sepharose HP column (Amersham Pharmacia Biotech Company). The column is eluted with 20mM bistrispropane with a linear gradient of NaCl to obtain a series of fractions of eluate. The fractions showing activity in converting compound (II) to compound (III) in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, are recovered. Next, after exchanging the buffer in the fractions by utilizing for example the PD10 column (Amersham Pharmacia Biotech Company), the recovered fractions are loaded onto a Bio-Scale Ceramic, for example, Hydroxyapatite, Type I column CHT10-I (BioRad Company). After washing the column with Buffer A (2mM potassium phosphate buffer containing 1.5mM of  $\text{CaCl}_2$ ; pH7.0), the column is eluted with Buffer A with a linear gradient of Buffer B (100mM potassium phosphate buffer containing 0.03mM  $\text{CaCl}_2$ ) to obtain a series of fractions of eluate. The fractions showing activity in converting compound (II) to compound (III) in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, are recovered. After exchanging the buffer in the fractions by utilizing for example the PD10 column (Amersham Pharmacia Biotech Company), the recovered fractions are concentrated by for example ultrafiltration (microcon filter unit microcon-30; Millipore Company). The resulting fraction is injected for example into a HiLoad 16/60 Superdex column 75pg column (Amersham Pharmacia Biotech Company) and eluted with a 0.05M potassium phosphate buffer containing 0.15M NaCl (pH7.0) to obtain a series of fractions of eluate. The fractions showing activity in converting compound (II) to compound (III) in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, are recovered. The present protein (A) can be purified by a separation with an SDS-PAGE as needed.

**[0104]** By purifying the present invention protein (A) in the way described above, followed by utilizing the obtained present invention protein (A) as an immune antigen, there can be produced an antibody recognizing the present invention protein (A) (hereinafter sometimes referred to as the "present invention antibody (A)").

**[0105]** Specifically, for example, an animal is immunized with the present protein (A) purified in the way described above, as an antigen. For example, to immunize an animal such as a mouse, hamster, guinea pig, chicken, rat, rabbit, dog and the like, the antigen is administered at least once, utilizing a conventional method of immunization described in, for example, W.H. Newsome, J. Assoc. Off. Anal. Chem. 70(6) 1025-1027 (1987). As the schedule of administration, for example, there is mentioned an administration of 2 or 3 times at 7- to 30-day intervals, preferably, 12- to 16-day intervals. The dose thereof is, for example, from about 0.05mg to 2mg of the antigen for each administration. The

administration route may be selected from subcutaneous administration, intracutaneous administration, intraperitoneal administration, intravenous administration, and intramuscular administration and an injection given intravenously, intraabdominally or subcutaneously is a typical administration form. The antigen is typically used after being dissolved in a suitable buffer, for example, sodium phosphate buffer or physiological saline containing at least one type of ordinarily used adjuvant such as complete Freund's adjuvant (a mixture of Aracel A, Bayol F and dead tubercule bacillus), RAS [MPL (monophosphoryl lipid A) + TDM (synthetic trehalose dicorynomycolate) + CWS (cell wall skeleton) adjuvant system] or aluminum hydroxide. However, depending on the administration route or conditions, the adjuvants described above may not be used. The "adjuvant" is a substance which upon administration with the antigen, enhances a immune reaction unspecifically against the antigen. After nurturing the animal administered with the antigen for 0.5 to 4 months, a small amount of blood is sampled from e.g. an ear vein of the animal and measured for antibody titer. When the antibody titer is increasing, then the antigen is further administered for an appropriate number of times, depending on cases. For example, the antigen may be administered for one more time at a dose of about 100 $\mu$ g to 1000 $\mu$ g. One or two months after the last administration, blood is collected in a usual manner from the immunized animal. By having the blood fractionated by conventional techniques such as precipitation by centrifugation or with ammonium sulfate or with polyethylene glycol, chromatography such as gel filtration chromatography, ion-exchange chromatography and affinity chromatography, and the like, the present invention antibody (A) may be obtained as a polyclonal antiserum. Further, the antiserum may be incubated e.g. at 56 °C for 30 minutes to inactivate the complement system.

[0106] Alternatively, a polypeptide comprising a partial amino acid sequence of the present invention protein (A) is synthesized chemically and administered as an immune antigen to an animal, whereby producing the present invention antibody (A). As the amino acid sequence of a polypeptide employed as an immune antigen, an amino acid sequence which has as a low homology as possible with the amino acid sequences of other proteins is selected from amino acid sequences of the present invention protein (A). A polypeptide having a length of 10 amino acids to 15 amino acids consisting of the selected amino acid sequence is synthesized chemically by a conventional method and crosslinked for example with a carrier protein such as Limulus polyhemus hemocyanin using MBS and the like and then used to immunize an animal such as a rabbit as described above.

[0107] The resultant present invention antibody (A) is then brought into contact with a test sample, and then a complex of the protein in the test sample with the antibody described above is detected by a conventional immunological method, whereby detecting the present invention protein (A) or a polypeptide comprising a partial amino acid thereof in the test sample. Specifically, for example, it is possible to evaluate the presence of the present invention protein (A) or to quantify the present invention protein (A) in the examined test sample by a western blot analysis utilizing the present invention antibody (A) as shown in Examples 45 or 73 described below.







[0108] Further, for example, a cell expressing the present protein (A) can be detected, by contacting the present invention antibody (A) with a test cell or a test sample prepared from the test cell followed by detecting a complex of the above antibody and the protein in the test cell or a test sample prepared from the test cell, according to conventional immunology methods. By detecting the cell expressing the present invention protein (A) in such a way, it is also possible to select from a variety of cells, a cell expressing the present invention protein (A). It is also possible to clone or select a clone containing the present invention protein (A) with the use of the present invention antibody (A). For example, a genomic library can be produced by extracting genomic DNA from a cell that expresses the present invention protein (A) followed by inserting the genomic DNA into an expression vector. The genomic library is introduced into a cell. From the obtained cell group, a cell expressing the present invention protein (A) is selected with the use of the present invention antibody (A) in the way described above.

[0109] A kit comprising the present invention antibody (A) can be utilized to detect the present invention protein (A) as described above or to analyze, detect or search for a cell expressing the present invention protein (A). The kit of the present invention may contain the reagents necessary for the above analysis methods, other than the present invention antibody (A), and may have such a reagent used together with the present invention antibody (A).



[0110] By reacting a PPO inhibitory-type herbicidal compound of formula (I) in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, with the present protein (A), the above compound is metabolized and is converted into a compound of lower herbicidal activity. Specifically for example, by reacting compound (II) in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, with the present protein (A), compound (II) is converted to compound (III), which shows substantially no herbicidal activity. An example of protein (A) in such cases is the present invention protein (A). One variation of the present protein (A) may be utilized and multiple variations may be utilized together.







[0111] The compound of formula (I) is a compound having a uracil structure. As specific examples, there can be mentioned compound (II) or a compound of any one of formulas (IV) to (IX) (hereinafter, referred respectively to as compound (IV) to compound (IX)). It is possible to synthesize compound (II) and compound (IX) according to the method described in Japanese Unexamined Patent Publication No. 2000-319264, compound (IV) and compound (V) according to the method described in U. S. Pat. No. 5183492, compound (VI) according to the method described in U. S. Pat. No. 5674810, compound (VII) according to the method described in Japanese Unexamined Patent Publication

No. 3-204865, and compound (VIII) according to the method described in Japanese Unexamined Patent Publication No. 6-321941.



[0112] Further, as specific examples of the compound of formula (I), there can be mentioned a compound of any one of formulas (X) to (XVII) (hereinafter, respectively referred to as compound (X) to compound (XVII)).





[0113] Compounds which can be a substrate of the metabolizing reaction by the present protein (A) can be selected by having the compound present in a reaction in which compound (II) labeled with a radioisotope is reacted with the present protein (A), in the presence of an electron transport system containing an electron donor, such as coenzyme NADPH, and detecting as a marker the competitive inhibition of the conversion reaction by the present protein (A) of the labeled compound (II) to the labeled compound (III). When assaying for the presence of the competitive inhibition from a test compound, the test compound is typically added to amount to a molar concentration of from 1 to 100 times of the labeled compound (II).

[0114] The reaction in which compound (I) is reacted with the present protein (A) can be conducted, for example, in an aqueous buffer containing salts of inorganic acids such as an alkaline metal phosphate such as sodium phosphate and potassium phosphate; or salts of organic acids such as an alkaline metal acetate such as sodium acetate and potassium acetate; or the like. The concentration of the compound of formula (I) in a metabolizing reaction solution is typically at most about 30% (w/v) and preferably about 0.001% (w/v) to 20% (w/v). The amount of the electron transport system containing the electron donor, such as NADPH, or of the present protein (A) may vary, for example, depending on reaction time period. The reaction temperature is chosen from the range of typically from about 10°C to 70°C, and is preferably about 20°C to 50°C. The pH of the reaction solution is chosen from the range of typically from about 4 to 12 and is preferably about 5 to 10. The reaction time period may vary as desired, and is typically from about 1 hour to 10 days.

[0115] Further, the reaction in which compound (I) is reacted with the present protein (A) can be conducted in a cell comprising the present DNA (A). As the cells comprising the present DNA (A), for example, there is mentioned a

microorganism having the ability to express the present DNA (A) and produce the present protein (A), such as, a strain of those microorganisms isolated from nature comprising the present DNA (A), a mutant strain derived from the microorganism strain by treatment with chemicals or ultraviolet rays, a transformed microorganism cell in which the present DNA (A) or a vector containing the present DNA (A) is introduced into a host cell. Further, there is mentioned a transformed plant cell to which the present DNA (A) is introduced or a cell of a transformed plant to which the present DNA (A) is introduced. In such cases, the compound of formula (I) may be directly applied to a cell comprising the present DNA (A) or may be added to the culturing medium of the cell or the soil coming into contact with the cell, so as to enter the cell. The electron transport system containing the electron donor, such as NADPH, can be the system originally present in the cell and can be added from outside of the cell.

**[0116]** The metabolism of compound (I) by the present protein (A) can be confirmed, for example, by detecting the compound produced by the metabolism of compound (I). Specifically for example, compound (III) produced from metabolizing compound (II) can be detected with the HPLC analysis or TLC analysis, described above.

**[0117]** Further, the metabolism of compound (I) by the present protein (A) can be confirmed on the basis that the herbicidal activity in the reaction solution after compound (I) is reacted with the present protein (A) is comparatively lower than the case in which compound (I) is not reacted with the present protein (A). As a method of testing the herbicidal activity, for example, there is mentioned a method in which the above reaction solutions are applied onto weeds such as barnyardgrass (*Echinochloa crus-galli*), Blackgrass (*Alopercurus myosuroides*), Ivyleaf morningglory (*Ipomoea hederacea*) and Velvetleaf (*Abutilon theophrasti*), and the herbicidal effects are examined; or a method in which the weeds are cultivated on soil samples to which the above reaction solutions are applied and the herbicidal effects are examined; and the like. Further, there is mentioned a method in which the above reaction solutions may be spotted onto a leaf disk taken from a plant and the presence of plant damage (whitening) caused by the reaction solution is examined.

**[0118]** Further, the metabolism of compound (I) by the present protein (A) can be confirmed by detecting as a marker, the PPO inhibitory activity in the reaction solution after compound (I) is reacted with the present protein (A), which is comparatively lower than the activity in the reaction solution in which compound (I) is not reacted with the present protein (A). PPO is an enzyme catalyzing the conversion of protoporphyrinogen IX to protoporphyrin IX (hereinafter referred to as "PPIX"). For example, after adding the above reaction solutions to a reaction system of PPO, protoporphyrinogen IX, which is a substrate of PPO, is added and incubated for about 1 to 2 hours at 30°C in the dark. Subsequently, the amount of PPIX in each of the incubated solutions is measured, utilizing an HPLC or the like. When the amount of PPIX in system to which the reaction solution after compound (I) is reacted with the present protein (A) is added is more than the amount of PPIX in system to which the reaction solution in which compound (I) is not reacted with the present protein (A) is added, it is determined that compound (I) had been metabolized by the present protein (A). As PPO, there may be utilized a protein purified from plants and the like or chloroplast fraction extracted from a plant. When utilizing the chloroplast fractions, aminolevulinic acid may be utilized in the reaction system of PPO, instead of protoporphyrinogen IX. Aminolevulinic acid is the precursor of protoporphyrinogen IX in the chlorophyll-heme biosynthesis pathway. A more specific example is given in Example 42 below.

**[0119]** By reacting with the present protein (A) in such a way, there can be conducted a treatment of the PPO inhibitory-type herbicidal compound of formula (I), which results in metabolization and conversion of the compound to a compound of lower herbicidal activity. The plant damage from said compound can be reduced by the treatment in which said compound which was sprayed onto the cultivation area of a plant, specifically for example, the compound which was sprayed onto the cultivation area of a plant and remains in plant residue or the soil or the like, is reacted with the present protein (A).

**[0120]** As the "electron transport system containing the electron donor" which can be utilized to react compound (I) with the present protein (A), for example, there can be mentioned a system containing NADPH, ferredoxin and ferredoxin-NADP<sup>+</sup> reductase.

**[0121]** As a method of presenting the "electron transport system containing an electron donor" in a system for reacting compound (I) with the present protein (A), for example, there is mentioned a method of adding to the above reaction system, NADPH, ferredoxin derived from a plant such as spinach and ferredoxin-NADP<sup>+</sup> reductase derived from a plant such as spinach. Further, there may be added to said reaction system, a fraction containing a component functional for the electron transport system in the reaction system of the present protein (A), which may be prepared from a microorganism such as *E. coli*. In order to prepare such a fraction, for example, after cells are harvested from a culture of a microorganism by centrifugation or the like, the cells are disrupted physically by an ultrasonic treatment, a DYNOMILL treatment, a FRENCH PRESS treatment and the like, or disrupted chemically by utilizing a surfactant or a cell-lyzing enzyme such as lysozyme. From the resultant lysate thus obtained, insoluble materials are removed by centrifugation, membrane filtration or the like to prepare a cell-free extract. The cell-free extract as is can be utilized in exchange of the above ferredoxin as the fraction containing a component functional for the electron transport system in the reaction system of the present protein (A). Further, when a system which can transport an electron from an electron donor to the present protein (A) is present in such a cell, as with the case in which the reaction of the present

protein (A) with compound (I) is conducted in a cell such as a microorganism or a plant cell, no electron transport system may be newly added.

[0122] As the ferredoxin, for example, there can be utilized a ferredoxin derived from microorganisms belonging to Streptomyces, such as Streptomyces phaeochromogenes, Streptomyces testaceus, Streptomyces achromogenes, Streptomyces griseolus, Streptomyces thermocoerulescens, Streptomyces nogalater, Streptomyces tsusimaensis, Streptomyces glomerochromogenes, Streptomyces olivochromogenes, Streptomyces ornatus, Streptomyces griseus, Streptomyces lanatus, Streptomyces misawanensis, Streptomyces pallidus, Streptomyces roseorubens, Streptomyces rutgersensis and Streptomyces steffisburgensis, and more specifically, Streptomyces phaeochromogenes IFO12898, Streptomyces testaceus ATCC21469, Streptomyces achromogenes IFO 12735, Streptomyces griseolus ATCC11796, Streptomyces thermocoerulescens IFO 14273t, Streptomyces nogalater IFO 13445, Streptomyces tsusimaensis IFO 13782, Streptomyces glomerochromogenes IFO 13673t, Streptomyces olivochromogenes IFO 12444, Streptomyces ornatus IFO 13069t, Streptomyces griseus ATCC 10137, Streptomyces griseus IFO 13849T, Streptomyces lanatus IFO 12787T, Streptomyces misawanensis IFO 13855T, Streptomyces pallidus IFO 13434T, Streptomyces roseorubens IFO 13682T, Streptomyces rutgersensis IFO 15875T and Streptomyces steffisburgensis IFO 13446T, and the like; or microorganisms belonging to Saccharopolyspora, such as Saccharopolyspora taberi, more specifically, Saccharopolyspora taberi JCM 9383t and the like (hereinafter, sometimes collectively referred to as the "present protein (B)"). Specifically for example, there can be mentioned a ferredoxin selected from the protein group below (hereinafter, sometimes referred to as the "present invention protein (B)").

<protein group>

#### [0123]

(B1) a protein comprising an amino acid sequence shown in SEQ ID NO: 12 (hereinafter, sometimes referred to as the "present invention protein (B1)");

(B2) a protein comprising an amino acid sequence shown in SEQ ID NO: 13 (hereinafter, sometimes referred to as the "present invention protein (B2)");

(B3) a protein comprising an amino acid sequence shown in SEQ ID NO: 14 (hereinafter, sometimes referred to as the "present invention protein (B3)");

(B4) a protein comprising an amino acid sequence shown in SEQ ID NO: 111 (hereinafter, sometimes referred to as the "present invention protein (B4)");

(B5) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;

(B6) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO 14 or SEQ ID NO: 111;

(B7) a protein comprising an amino acid sequence shown in SEQ ID NO: 149 (hereinafter, sometimes referred to as the "present invention protein (B7)");

(B8) a protein comprising an amino acid sequence shown in SEQ ID NO: 150 (hereinafter, sometimes referred to as the "present invention protein (B8)");

(B9) a protein comprising an amino acid sequence shown in SEQ ID NO: 151 (hereinafter, sometimes referred to as the "present invention protein (B9)");

(B10) a protein comprising an amino acid sequence shown in SEQ ID NO: 152 (hereinafter, sometimes referred to as the "present invention protein (B 10)");

(B11) a protein comprising an amino acid sequence shown in SEQ ID NO: 153 (hereinafter, sometimes referred to as the "present invention protein (B 11)");

(B12) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with any one of the amino acid sequence shown in SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with any one of the amino acid sequence shown in SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;

(B13) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with any of the nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253 or SEQ ID NO: 254;

(B14) a protein comprising the amino acid sequence shown in SEQ ID NO: 245;

(B15) a protein comprising the amino acid sequence shown in SEQ ID NO: 247;

(B16) a protein comprising the amino acid sequence shown in SEQ ID NO: 248;  
 (B17) a protein comprising the amino acid sequence shown in SEQ ID NO: 249;  
 (B18) a protein comprising the amino acid sequence shown in SEQ ID NO: 250;  
 (B19) a protein comprising the amino acid sequence shown in SEQ ID NO: 251;  
 (B20) a protein comprising the amino acid sequence shown in SEQ ID NO: 252;  
 (B21) a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and  
 (B22) a protein comprising the amino acid sequence shown in SEQ ID NO: 254.

**[0124]** A DNA encoding the present protein (B) (hereinafter, sometimes referred to as the "present DNA (B)") can be obtained according to conventional genetic engineering methods described in Molecular Cloning: A Laboratory Manual 2nd edition (1989), Cold Spring Harbor Laboratory Press; Current Protocols in Molecular Biology (1987), John Wiley & Sons, Incorporated and the like, based on the nucleotide sequences encoding the amino acid sequences of the present invention protein (B) shown in SEQ ID NO: 12, 13, 14, 111, 149, 150, 151, 152, 153, 245, 247, 248, 249, 250, 251, 252, 253 or 254.

**[0125]** As the DNA encoding the present invention protein (B) (hereinafter, sometimes collectively referred to as the "present invention DNA (B)"), there is mentioned

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 12 (hereinafter, sometimes referred to as the "present invention DNA (B1)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 13 (hereinafter, sometimes referred to as the "present invention DNA (B2)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 14 (hereinafter, sometimes referred to as the "present invention DNA (B3)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 111 (hereinafter, sometimes referred to as the "present invention DNA (B4)");

a DNA encoding a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;

a DNA encoding a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 149 (hereinafter, sometimes referred to as the "present invention DNA (B7)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 150 (hereinafter, sometimes referred to as the "present invention DNA (B8)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 151 (hereinafter, sometimes referred to as the "present invention DNA (B9)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 152 (hereinafter, sometimes referred to as the "present invention DNA (B10)");

a DNA encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 153 (hereinafter, sometimes referred to as the "present invention DNA (B11)");

a DNA encoding a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;

a DNA encoding a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253 or SEQ ID NO: 254;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 245;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 247;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 248;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 249;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 250;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 251;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 252;

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and

a DNA encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 254.

**[0126]** As more specific examples of the present invention DNA (B), there can be mentioned a DNA comprising a nucleotide sequence shown in any one of SEQ ID NO: 15, 16, 17, 112, 154, 155, 156, 157, 158, 255, 257, 258, 259, 260, 261, 262, 263 or 264, or a DNA comprising a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 15, 16, 17, 112, 154, 155, 156, 157, 158, 255, 257, 258, 259, 260, 261, 262, 263 or 264.

**[0127]** Such DNA can be prepared by conducting methods in which PCR is conducted with DNA comprising a partial nucleotide sequence of the nucleotide sequences thereof as primers or hybridization methods in which such DNA is used as probes, according to the conditions described above in the methods of preparing the present DNA (A).

**[0128]** Specifically for example, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 12 or a DNA comprising the nucleotide sequence shown in SEQ ID NO: 15, can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces phaeochromogenes* IFO12898 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 105 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 53.

**[0129]** Further, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 13 or a DNA comprising the nucleotide sequence shown in SEQ ID NO: 16, can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Saccharopolyspora taberi* JCM 9383t and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 106 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 63.

**[0130]** Further, a DNA comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 14 or a DNA comprising the nucleotide sequence shown in SEQ ID NO: 17, can be prepared by conducting PCR by utilizing as the template the chromosomal DNA or chromosomal DNA library prepared from *Streptomyces testaceus* ATCC21469 and by utilizing as primers an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 107 and an oligonucleotide comprising the nucleotide sequence shown in SEQ ID NO: 72.

**[0131]** Further, for example, the present invention DNA (B) can be obtained by hybridizing with a chromosomal DNA library, a DNA consisting of about at least 20 nucleotides comprising the nucleotides sequence encoding an amino acid sequences shown in any one of SEQ ID NO: 12, 13, 14, 111, 149, 150, 151, 152 or 153, as a probe under the conditions described above, followed by detecting and recovering the DNA which bound specifically with said probe. The chromosomal DNA library can be prepared as described above from microorganisms belonging to *Streptomyces*, such as *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces thermocoeruleus*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis* and *Streptomyces steffisburgensis*, and more specifically, *Streptomyces phaeochromogenes* IFO12898, *Streptomyces testaceus* ATCC21469, *Streptomyces achromogenes* IFO 12735, *Streptomyces thermocoeruleus* IFO 14273t, *Streptomyces nogalater* IFO 13445, *Streptomyces tsusimaensis* IFO 13782, *Streptomyces glomerochromogenes* IFO 13673t, *Streptomyces olivochromogenes* IFO 12444, *Streptomyces ornatus* IFO 13069t, *Streptomyces griseus* ATCC 10137, *Streptomyces griseus* IFO 13849T, *Streptomyces lanatus* IFO 12787T, *Streptomyces misawanensis* IFO 13855T, *Streptomyces pallidus* IFO 13434T, *Streptomyces roseorubens* IFO 13682T, *Streptomyces rutgersensis* IFO 15875T and *Streptomyces steffisburgensis* IFO 13446T, and the like; or microorganisms belonging to *Saccharopolyspora*, such as *Saccharopolyspora taberi*, more specifically, *Saccharopolyspora taberi* JCM 9383t and the like. As specific examples of the DNA which can be utilized as such probes, there is mentioned a DNA comprising a nucleotide sequence shown in any one of SEQ ID NO: 15, 16, 17, 112, 154, 155, 156, 157, 158, 255, 257, 258, 259, 260, 261, 262, 263 or 264; DNA comprising a partial nucleotide sequence of such nucleotide sequences; or a DNA comprising a nucleotide sequence complementary to said partial nucleotide sequences.

**[0132]** To express the present DNA (B) with a host cell, for example, a DNA in which the present DNA (B) and a promoter functional in a host cell are operably linked is prepared according to conventional genetic engineering methods described in "Molecular Cloning: A Laboratory Manual 2nd edition (1989)", Cold Spring Harbor Laboratory Press; "Current Protocols in Molecular Biology (1987)", John Wiley & Sons, Incorporated and the like, and is introduced into a host cell. Whether the obtained transformant contains the present DNA (B) can be confirmed by preparing the DNA from the transformant and then conducting with the prepared DNA genetic engineering analysis methods described in, for example, "Molecular Cloning 2nd edition", Cold Spring Harbor Press (Molecular Biology, John Wiley & Sons, N. Y. (1989) (such as confirming restriction enzyme sites, DNA sequencing, southern hybridizations, PCR and the like).

**[0133]** The present DNA (B) and the present DNA (A) can be expressed in the same cell, by introducing into a cell comprising the present DNA (A), the DNA in which the present DNA (B) and a promoter functional in a host cell are operably linked.

**[0134]** The present protein (B) can be prepared, for example, by culturing a cell comprising the present DNA (B). As such a cell, there is mentioned a microorganism expressing the present DNA (B) and having the ability to produce the present protein (B), such as microorganism strain isolated from nature comprising the present DNA (B), mutant strains

derived from said natural strain by treatment with agents or ultraviolet rays or the like. For example, there is mentioned microorganisms belonging to *Streptomyces*, such as *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseolus*, *Streptomyces thermocoerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis* and *Streptomyces steffisburgensis*, and more specifically, *Streptomyces phaeochromogenes* IFO 12898, *Streptomyces testaceus* ATCC21469, *Streptomyces achromogenes* IFO 12735, *Streptomyces griseolus* ATCC11796, *Streptomyces thermocoerulescens* IFO 14273t, *Streptomyces nogalater* IFO 13445, *Streptomyces tsusimaensis* IFO 13782, *Streptomyces glomerochromogenes* IFO 13673t, *Streptomyces olivochromogenes* IFO 12444, *Streptomyces ornatus* IFO 13069t, *Streptomyces griseus* ATCC 10137, *Streptomyces griseus* IFO 13849T, *Streptomyces lanatus* IFO 12787T, *Streptomyces misawanensis* IFO 13855T, *Streptomyces pallidus* IFO 13434T, *Streptomyces roseorubens* IFO 13682T, *Streptomyces rutgersensis* IFO 15875T and *Streptomyces steffisburgensis* IFO 13446T, and the like; or microorganisms belonging to *Saccharopolyspora*, such as *Saccharopolyspora taberi*, more specifically, *Saccharopolyspora taberi* JCM 9383t and the like. Further, there can be mentioned a transformant in which the present DNA (B) has been introduced. Specifically for example, there is mentioned a transformant in which the present DNA (B) operably linked to a *tac* promoter, *trc* promoter, *lac* promoter or T7 phage promoter has been introduced into *E. coli*. As more specific examples, there is mentioned *E. coli* JM109/pKSN657FD, *E. coli* JM109/pKSN923FD, *E. coli* JM109/pKSN671FD and the like described in the examples described below.

**[0135]** The microorganism comprising the present DNA (B) can be cultivated in accordance with a method employed usually to culture a microorganism, and more specifically, conducted according to the conditions described above in the methods of culturing the microorganism comprising the present DNA (A).

**[0136]** The present protein (B) produced by the microorganism comprising the present DNA (B), for example, can be utilized in various forms in reaction system of the present protein (A), such as a culture of a microorganism producing the present protein (B), a cell of a microorganism producing the present protein (B), a material obtained by treating such a cell, a cell-free extract of a microorganism, a crudely purified protein, a purified protein and the like. A material obtained by treating a cell described above includes for example a lyophilized cell, an acetone-dried cell, a ground cell, an autolysate of a cell, an ultrasonically treated cell, an alkali-treated cell, an organic solvent-treated cell and the like. Alternatively, the present protein (B) in any of the various forms described above may be immobilized in accordance with known methods such as a support binding method employing an adsorption onto a synthesized polymer and the like, and an inclusion method employing an inclusion into a network matrix of a polymer, and then used in the reaction system of the present protein (A).

**[0137]** As methods of purifying the present protein (B) from a culture of a microorganism comprising the present DNA (B), there can be employed conventional methods utilized in a purification of protein. For example, there can be mentioned the following method.

**[0138]** First, cells are harvested from a culture of a microorganism by centrifugation or the like, and then disrupted physically by an ultrasonic treatment and the like, or disrupted chemically by utilizing a surfactant or a cell-lyzing enzyme such as lysozyme. From the resultant lysate thus obtained, insoluble materials are removed by centrifugation, membrane filtration or the like to prepare a cell-free extract, which is then fractionated by any appropriate means for separation and purification, such as a cation exchange chromatography, an anion exchange chromatography, a hydrophobic chromatography, a gel filtration chromatography and the like, whereby purifying the present protein (B). By separation of the fraction thus obtained with an SDS-PAGE, the present protein (B) can be further purified.

**[0139]** The function of the present protein (B) as ferredoxin can be confirmed as a function of electron transporter from ferredoxin-NADP<sup>+</sup> reductase to the present protein (A) in the reaction system in which compound (I) is reacted with the present protein (A). Specifically for example, there can be a confirmation by adding the present protein (B) with NADPH, ferredoxin-NADP<sup>+</sup> reductase and the present protein (A) to the reaction system in which compound (I) is reacted with the present protein (A), followed by detecting the conversion of compound (II) to compound (III).

**[0140]** In the method of controlling weeds of the present invention, compound (I) is applied to the cultivation area of a plant expressing the present protein (A). Such a plant may express one variation of the present protein (A) or may express multiple variations of the present protein (A). As the present protein (A), for example, there may be mentioned the present invention protein (A). Plants expressing the present protein (A) can be obtained as a transgenic plant to which the present DNA (A) has been introduced. Such introduction involves introducing the present DNA (A) into a plant cell in the way described above so that the DNA is placed in a position enabling its expression, followed by regenerating a plant from the obtained transformed cell. The present DNA (A) introduced into the plant cell may have linked upstream therefrom, a nucleotide sequence encoding a transit signal to an intracellular organelle, so that the reading frames are in frame.

**[0141]** The plant having introduced therein the present DNA (A) and expressing the present protein (A) metabolizes compound (I), within its cells, into a compound of lower herbicidal activity. As a result, the plant damage from the herbicidal compound in the plant is reduced and resistance to said compound is conferred. As such, the plant having

introduced therein the present DNA (A) and expressing the present protein (A) can grow well even in a case in which compound (I) is applied to a cultivation area thereof. Weeds other than the plant having introduced therein the present DNA (A) and expressing the present protein (A) can be removed effectively by cultivating said plant and applying the above herbicidal composition to the cultivation area. It is possible to improve the yield of the above plant, improve the quality, reduce the amount of utilized herbicide and save labor.

**[0142]** The evaluation of resistance of the cell expressing the present protein (A) to the compound of formula (I) or a herbicidal composition comprising said compound can be carried out by contacting the cell expressing the gene encoding the present protein (A) with said compound or said herbicidal composition and evaluating the degree of damage to the cell.

**[0143]** Specifically, to evaluate the resistance of a microorganism cell expressing the present protein (A) to compound (I) or the herbicidal composition comprising compound (I), a transformed E. coli expressing plant PPO and the present protein (A) may be prepared. Such preparation involves additionally introducing the present DNA (A) into, for example, a transformed E. coli which can be utilized to evaluate PPO activity inhibition and has been described in Japanese patent application No. 11-102534, more specifically, a transformed E. coli in which a plant PPO gene described in U. S. Pat. No. 5939602 or the like is operably introduced into the E. coli BT3 strain and expressing the PPO gene. The E. coli BT3 strain has a defect in PPO gene and has no proliferation ability, as described in F. Yamamoto, H. Inokuti, H. Ozaki, (1988) Japanese Journal of Genetics, Vol. 63, pg. 237-249. The resistance to the compound or the herbicidal composition can be evaluated by cultivating the resulting transformed E. coli with shaking for about 18 to 24 hours at 37°C in a liquid culture medium containing compound (I) or the herbicidal composition comprising said compound in an amount of from 0 to 1.0 ppm and measuring the proliferation of said transformed E. coli with an optical density at 600nm. As the present protein (A), for example, there can be mentioned the present invention protein (A).

**[0144]** As a method of evaluating the degree of resistance of a plant expressing the present protein (A) to the compound of formula (I) or a herbicidal composition comprising said compound, there is mentioned a method of applying the herbicidal composition to the plant and measuring the degree of growth of the plant. For more quantitative confirmation, for example, first, pieces of leaves of the plant are dipped in aqueous solutions containing compound (I) at various concentrations, or the aqueous solutions of compound (I) are sprayed on pieces of leaves of the plant, followed by allowing to stand on an agar medium in the light at room temperature. After several days, chlorophyll is extracted from the plant leaves according to the method described by Mackenney, G., J. Biol. Chem., 140; p 315 (1941) to determine the content of chlorophyll. Specifically for example, leaves of the plant are taken and are split equally into 2 pieces along the main vein. The herbicidal composition is spread onto the full surface of one of the leaf pieces. The other leaf piece is left untreated. These leaf pieces are placed on MS medium containing 0.8% agar and allowed to stand in the light at room temperature for 7 days. Then, each leaf piece is ground with pestle and mortar in 5 ml of 80% aqueous acetone solution to extract chlorophyll. The extract liquid is diluted 10 fold with 80% aqueous acetone solution and the absorbance is measured at 750 nm, 663nm and 645 nm to calculate total chlorophyll content according to the method described by Mackenney G., J. Biol. Chem. (1941) 140, p 315. The degree of resistance to compound (I) can be comparatively evaluated by showing in percentiles the total chlorophyll content of the treated leaf piece with the total chlorophyll content of the untreated leaf piece. As the present protein (A), for example, the present invention protein (A) can be mentioned.

**[0145]** Based on the above method of evaluating the degree of resistance to compound (I) or a herbicidal composition comprising compound (I), there can be selected a plant or a plant cell showing a resistance to compound (I) or a herbicidal composition comprising compound (I). For example, there is selected a plant where no damage can be seen from spraying compound (I) or a herbicidal composition comprising the compound to the cultivation area of the plant, or plant cell that continuously grows through culturing in the presence of compound (I). Specifically, for example, soil is packed into a plastic pot having, for example, a diameter of 10cm and a depth of 10cm. Seeds of the plant are sowed and cultivated in a greenhouse. An emulsion is prepared by mixing 5 parts of a herbicidal composition comprising compound (I), 6 parts of sorpol3005X (Toho chemicals) and 89 parts of xylene. A certain amount thereof was diluted with water containing 0.1% (v/v) of a sticking agent at a proportion of 1000L for 1 hectare and is spread uniformly with a spray-gun onto the all sides of the foliage from above the plant cultivated in the above pot. After cultivating the plants for 16 days in a greenhouse, the damage to the plants is investigated. The plants in which the damage is not observed or the plants in which the damage is reduced may be selected. Further, progeny plants can be obtained by mating such selected plants.

## EXAMPLES

**[0146]** The present invention is explained in more detail with the Examples below, but the present invention is not limited to such examples.

**[0147]** The HPLC for content analysis in Examples 1, 41 and 42 and fraction purification of the compound was conducted under the conditions shown below.

(HPLC analysis condition 1)

**[0148]**

column	SUMIPAX ODS211 (Sumika Chemical Analysis Service)
column temperature	35°C
flow rate	1ml/minute
detection wave length	UV254nm
eluent A	0.01% TFA aqueous solution
eluent B	acetonitrile
elution conditions	The sample is injected to the column equilibrated with a solvent mixture of 90% of eluent A and 10% eluent B. The solvent mixture of 90% of eluent A and 10% eluent B is then flowed for 5 minutes. This is followed by flowing a solvent mixture of eluent A and eluent B for 20 minutes, while increasing the proportion of eluent B from 10% to 90%. A solvent mixture of 10% of eluent A and 90% of eluent B is then flowed for 8 minutes.

**Example 1 The Metabolism of Compound (II) by a Microorganism****(1) Metabolism of compound (II)**

**[0149]** The various microorganisms shown in Tables 1 and 2 were grown in ISP2 agar medium (1.0%(w/v) malt extract, 0.4%(w/v) yeast extract, 0.4% (w/v) glucose, 2.0%(w/v) agar, pH 7.3). A "loopful" of the each microorganism was added to TGY medium (0.5%(w/v) tryptone, 0.5%(w/v) yeast extract, 0.1%(w/v) glucose, 0.01%(w/v)  $\text{KH}_2\text{PO}_4$ , pH 7.0) and incubated with shaking at 30°C for 2 to 4 days. One-tenth milliliter (0.1ml) of the obtained culture was incubated with shaking in 3 ml of sporulation medium (0.1 % (w/v) of meat extract, 0.2%(w/v) tryptose, 1% glucose, pH 7.1) containing compound (II) at 100ppm for 7 to 8 days at 30°C. Fifty microliters (50μl) of 2N HCl was added to the resulting culture and this was extracted with 3ml of ethyl acetate. The obtained ethyl acetate layer was analyzed on the HPLC. The concentration of compound (II) was reduced (column retention time of 23.9 minutes) and new peaks were detected for compounds at retention times of 21.6 minutes and 22.2 minutes (each referred to as metabolite (I) and metabolite (II)). The results are shown in Tables 1 and 2.

Table 1

strain of the microorganism	concentration of compound (II) (ppm)	peak area of metabolite (I) ( $\times 10^4$ )	peak area of metabolite (II) ( $\times 10^4$ )
<i>Streptomyces cacaoiasoensis</i> IFO13813	77.8	3.43	3.57
<i>Streptomyces griseofuscus</i> IFO12870t	49.5	7.96	9.86
<i>Streptomyces ornatus</i> IFO13069t	65.3	4.30	5.00
<i>Streptomyces thermocoeruleus</i> IFO14273t	51.7	7.47	9.16
<i>Streptomyces roseochromogenes</i> ATCC 13400	81.9	0.71	0.82
<i>Streptomyces lavendulae</i> ATCC 11924	89.6	1.02	1.50
<i>Streptomyces griseus</i> ATCC 10137	65.6	6.19	1.30

EP 1 457 558 A1

Table 1 (continued)

strain of the microorganism	concentration of compound (II) (ppm)	peak area of metabolite (I) (x10 <sup>4</sup> )	peak area of metabolite (II) (x10 <sup>4</sup> )
Streptomyces griseus ATCC11429	30.3	12.8	15.6
Streptomyces griseus ATCC 12475	51.1	0.52	2.27
Streptomyces griseus ATCC15395	75.2	1.91	2.26
Streptomyces erythreus ATCC11635	54.6	4.94	6.05
Streptomyces scabies IFO3111	88.3	3.28	4.40
Streptomyces griseus IFO3102	22.6	14.4	18.5
Streptomyces catenulae IFO12848	85.3	3.81	1.59
Streptomyces kasugaensis ATCC15714	92.4	1.08	0.91
Streptomyces rimosus ATCC 10970	70.9	2.30	2.87
Streptomyces achromogenes IFO 12735	0.0	15.9	21.8
Streptomyces lydicus IFO13058	62.0	5.48	6.69

Table 2

strain of the microorganism	concentration of compound (II) (ppm)	peak area of metabolite (I) (x10 <sup>4</sup> )	peak area of metabolite (II) (x10 <sup>4</sup> )
Streptomyces phaeochromogenes IFO12898	46.4	8.28	10.5
Streptomyces afghaniensis IFO12831	80.6	2.54	3.59
Streptomyces hachijoensis IFO12782	83.9	4.99	2.91
Streptomyces argenteolus var. toyonakensis ATCC21468	13.0	14.9	19.2
Streptomyces testaceus ATCC21469	18.4	11.6	14.4
Streptomyces purpurascens ATCC25489	70.9	5.37	6.11

Table 2 (continued)

strain of the microorganism	concentration of compound (II) (ppm)	peak area of metabolite (I) ( $\times 10^4$ )	peak area of metabolite (II) ( $\times 10^4$ )
Streptomyces griseochromogenes ATCC14511	53.9	3.00	3.97
Streptomyces kasugaensis IFO13851	66.3	12.1	12.6
Streptomyces argenteolus var. toyon ATCC21468t	90.1	2.75	3.01
Streptomyces roseochromogenes ATCC13400t	71.8	4.66	4.00
Streptomyces nogalater IFO13445	12.8	21.9	24.9
Streptomyces roseochromogenus ATCC21895	74.2	4.14	5.87
Streptomyces fimicarius ATCC21900	46.5	8.33	11.3
Streptomyces chartreusis ATCC21901	61.1	3.70	3.94
Streptomyces globisporus subsp. globisporus ATCC21903	79.9	2.86	2.52
Streptomyces griseolus ATCC 11796	0	14.4	19.9
Saccharopolyspora taberi JCM9383T	82.9	5.83	7.71
Streptomyces sp. SANK62585	54.6	2.30	3.44

## (2) Structure Determination of the metabolite (I) and metabolite (II)

[0150] A frozen stock of *Streptomyces griseus* ATCC11429 was added to 3ml of a microorganism culture medium (0.7%(w/v) polypeptone, 0.5%(w/v) yeast extract, 1.0%(w/v) of glucose, 0.5%(w/v) of  $K_2HPO_4$ , pH7.2) and incubated with shaking in a test tube overnight to obtain a pre-culture. Such pre-culture was added to 300ml of the microorganism medium containing compound (II) at a concentration of 100ppm. This was divided into 100 small test tubes at 3ml each and incubated with shaking at 30°C for 6 days. After 250ml of such culture was adjusted to a pH2 by adding HCl, this was extracted with 250ml of ethyl acetate. The solvents were removed from the ethyl acetate layer. The residue was dissolved in 3ml of acetone and spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thickness, Merck Company). The TLC plate was developed with 5:7:1 (v/v/v) mixture of toluene, formic acid and ethyl formate. The R<sub>f</sub> value around 0.58 of the silica gel was taken. Such contents of the TLC plate were extracted with acetone. The acetone was removed from the extraction layer. The residue was dissolved in 10ml of acetonitrile and fractionated with a HPLC. The fractions containing only metabolite (I) and metabolite (II) were recovered to obtain 3.7mg of metabolites (hereinafter referred to as "metabolite A").

[0151] Mass spectrometry analysis of metabolite A was conducted. Metabolite A had a mass that was 14 smaller than compound (II). Further, from H-NMR analysis, it was determined that metabolite (A) was a compound having the structure shown in formula (III).

**(3) Herbicidal activity test of compound (III)**

**[0152]** Soil was packed into a round plastic pot having a diameter of 10cm and depth of 10cm. Barnyardgrass, Blackgrass, Ivyleaf morningglory were seeded and cultivated in a greenhouse for 10 days. Five (5) parts of the test compound, 6 parts of sorpo13005X (Toho Chemical Company) and 89 parts of xylene were well mixed to produce an emulsion. A certain amount thereof was diluted with water containing 0.1% (v/v) of a sticking agent at a proportion of 1000L for 1 hectare and was spread uniformly with a spray-gun onto the all sides of the foliage from above the plant cultivated in the above pot. After cultivating the plants for 16 days in a greenhouse, the herbicidal activity of the test compound was investigated. The results are shown in Table 3.

Table 3

test compounds	concentration (g/ha)	Herbicidal Activity		
		Barnyardgrass	Blackgrass	Ivyleaf Morningglory
compound (II)	500	10	10	10
	125	10	10	10
compound (III)	500	0	0	0
	125	0	0	0

**[0153]** Soil was packed into a round plastic pot having a diameter of 10cm and depth of 10cm. Barnyardgrass, Blackgrass, Ivyleaf morningglory were seeded. Five (5) parts of the test compound, 6 parts of sorpo13005X (Toho Chemical Company) and 89 parts of xylene were well mixed to produce an emulsion. A certain amount thereof was diluted with water containing 0.1% (v/v) of a sticking agent at a proportion of 1000L for 1 hectare and was spread uniformly with a spray-gun onto the surface of the soil. After cultivating the plants for 19 days in a greenhouse, the herbicidal activity was investigated. The results are shown in Table 4.

Table 4

test compounds	concentration (g/ha)	Herbicidal Activity		
		Barnyardgrass	Blackgrass	Ivyleaf Morningglory
compound (II)	500	10	10	10
compound (III)	500	0	0	0

**[0154]** In the above Tables 3 and 4, the strength of the herbicidal activity is shown stepwise as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. The number "0" represents situations in which the condition of sprouting or vegetation at the time of examination of the plant utilized for the test was compared with and showed totally or substantially no difference with that of the untreated application. The number "10" represents situations in which the plant completely withered or the sprouting or vegetation was completely suppressed.

**Example 2 Preparation of the Present Invention Protein (A1)****(1) Preparation of the crude cell extract**

**[0155]** A frozen stock of *Streptomyces phaeochromogenes* IFO12898 was added to 100ml of A medium (0.1%(w/v) glucose, 0.5%(w/v) tryptone, 0.5%(w/v) yeast extract, 0.1%(w/v) of dipotassium hydrogenphosphate, pH7.0) in a 500ml triangular flask and incubated with rotary shaking at 30°C for 1 day to obtain a pre-culture. Eight milliliters (8ml) of the pre-culture was added to 200ml of A medium and was incubated with rotary shaking in 500ml a baffled flask at 30°C for 2 days. Cell pellets were recovered by centrifuging (3,000g, 5 min.) the resulting culture. These cell pellets were suspended in 100ml of B medium (1%(w/v) glucose, 0.1% beef extract, 0.2%(w/v) tryptose) containing compound (II) at 100ppm and were incubated with reciprocal shaking in a 500ml Sakaguchi flask for 16 hours at 30°C. Cell pellets were recovered by centrifuging (3,000g, 5 min.) 10L of the resulting culture. The resulting cell pellets were washed twice with 1L of 0.1M potassium phosphate buffer (pH7.0) to provide 162g of the cell pellets.

**[0156]** These cell pellets were suspended in 0.1M potassium phosphate buffer (pH7.0) at 2ml for 1g of the cell pellets, and 1mM PMSF, 5mM benzamidine HCl, 1mM EDTA and 1mM of dithiotritol were added thereto. A cell lysate solution was obtained by disrupting twice repetitively the suspension with a French press (1000kg/cm<sup>2</sup>) (Ohtake Seisakusho).

After centrifuging the cell lysate solution (40,000xg, 30 minutes), the supernatant was recovered and centrifuged for 1 hour at 150,000xg to recover the supernatant (hereinafter referred to as the "crude cell extract").

## (2) Determination of the ability of converting compound (II) to compound (III)

[0157] There was prepared 30 $\mu$ l of a reaction solution of 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with  $^{14}$ C, 2.4mM of  $\beta$ -NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.5mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18 $\mu$ l of the crude cell extract recovered in Example 2(1). The reaction solution was maintained at 30°C for a hour. Further, there was prepared and maintained similarly a reaction solution having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3 $\mu$ l) of 2N HCl and 90  $\mu$ l of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75 $\mu$ l of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0 $\mu$ l of ethyl acetate. Five microliters (5.0 $\mu$ l) thereof was spotted to a TLC plate (TLC plate silica gel 60F<sub>254</sub> 20cm x 20cm, 0.25 thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with  $^{14}$ C were examined (Rfvalue 0.24 and 0.29). The results are shown in Table 5.

Table 5

Reaction components					spot of compound (III)
component A	component B	component C	crude cell extract	compound (II) labeled with $^{14}$ C	
+	+	+	-	+	-
+	+	+	+	+	+
-	+	+	+	+	-
+	-	-	+	+	-

## (3) Fractionation of the crude cell extract

[0158] Ammonium sulfate was added to the crude cell extract obtained in Example 2(1) to amount to 45% saturation. After stirring in ice-cooled conditions, the supernatant was recovered by centrifugation for 10 minutes at 12,000xg. After adding ammonium sulfate to the obtained supernatant to amount to 55% saturation and stirring in ice-cooled conditions, a pellet was recovered by centrifuging for 10 minutes at 12,000xg. The pellet was dissolved with 27.5ml of 20mM bistrispropane buffer (pH7.0). This solution was subjected to a PD10 column (Amersham Pharmacia Company) and eluted with 20mM of bistrispropane buffer (pH7.0) to recover 38.5ml of fractions containing proteins (hereinafter referred to as the "45-55% ammonium sulfate fraction").

## (4) Isolation of the present invention protein (A1)

[0159] The 45-55% ammonium sulfate fraction prepared in Example 2(3) was injected into a HiLoad26/10 Q Sepharose HP column (Amersham Pharmacia Company). Next, after flowing 106ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.001415M/minute, range of NaCl concentration was from 0M to 0.375M, flow rate was 3ml/minute) to fraction recover 25ml of fractions eluting at the NaCl concentration of from 0.21M to 0.22M. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 20mM bistrispropane buffer (pH7.0) to recover the fractions containing protein.

[0160] The recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) with the elution with Buffer A (2mM potassium phosphate buffer containing 1.5mM of NaCl, pH 7.0), in order to recover the fractions containing protein. Next, the fractions were injected into a Bio-Scale Ceramic Hydroxyapatite Type I column CHT10-I (BioRad Company). Thirty milliliters (30ml) of Buffer A was flown into the column. Subsequently, Buffer A was flown with a linear gradient of Buffer B (100mM potassium phosphate buffer containing 0.03mM of NaCl; the linear

gradient started at 100% Buffer A to increase to 50% Buffer B over a 100 minute period, flow rate was 2ml/minute) to fraction recover the fractions eluting at a Buffer B concentration of from 17% to 20%. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 0.05M potassium phosphate buffer (pH7.0) to recover the fractions containing protein.

[0161] The recovered fractions were concentrated 20 fold using an ultrafilter membrane (Microcon YM-30, Millipore Company) and injected into a HiLoad 16/60 Superdex 75pg column (Amersham Pharmacia Biotech Company). Fifty millimolar (50mM) potassium phosphate buffer containing 0.15M of NaCl (pH7.0) was flown (flow rate 1ml/minute) into the column. The elution was fractionated at 2ml each. The fractions eluting at the elution volumes of from 56ml to 66ml were each fraction recovered. The protein contained in each of the fractions was analyzed with a 10%-20% SDS-PAGE.

[0162] Instead of the crude cell extract in the reaction solution described in Example 2(2), the recovered fractions were added and maintained in the presence of component A, component B, component C and compound (II) labeled with  $^{14}\text{C}$ , similarly to Example 2(2). The reaction solutions after the maintenance were TLC analyzed to examine the intensity of the spots corresponding to compound (III) labeled with  $^{14}\text{C}$ . The protein moving to the position to 47kDa in the above SDS-PAGE was observed to have its fluctuations in the concentrations of the bands of the fractions added in turn to be parallel with the fluctuations of the intensity of the spots corresponding to compound (III). Said protein was recovered from the SDS-PAGE gel and was subjected to an amino acid sequence analysis with a protein sequencer (Applied Biosystems Company, Procise 494HT, pulsed liquid method). As a result, the amino acid sequence shown in SEQ ID NO: 18 was provided. Further, after digesting the above protein with trypsin, the obtained digestion material was analyzed on a mass spectrometer (ThermoQuest Company, Ion Trap Mass Spectrometer LCQ, column: LC Packings Company PepMap C18 75 $\mu\text{m}$  x 150mm, solvent A: 0.1%HOAc-H<sub>2</sub>O, solvent B: 0.1% HOAc-methanol, gradient: a linear gradient starting at an elution with a mixture of 95% of solvent A and 5% of solvent B and increasing to a concentration of 100% of solvent B over 30 minutes, flow rate: 0.2 $\mu\text{l}$ /minute). As a result, the sequence shown in SEQ ID NO: 19 was provided.

### Example 3 Obtaining the Present Invention DNA (A1)

#### (1) Preparation of the chromosomal DNA of *Streptomyces phaeochromogenes* IFO12898

[0163] *Streptomyces phaeochromogenes* IFO12898 was incubated with shaking at 30°C for 1 day to 3 days in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34% (w/v) sucrose and 0.2%(v/v) 2.5M MgCl<sub>2</sub>·6H<sub>2</sub>O). The cells were recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cells. Two hundred micrograms per milliliter (200 $\mu\text{g}$ /ml) of egg-white lysozyme were added. The cell suspension was incubated with shaking at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with mixture of phenol, chloroform and isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with mixture of chloroform and isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitation from the aqueous layer.

#### (2) Preparation of the chromosomal DNA library of *Streptomyces phaeochromogenes* IFO12898

[0164] Nine hundred forty-three nanograms (943ng) of the chromosomal DNA prepared in Example 3(1) were digested with 1unit of restriction enzyme Sau3AI at 37°C for 60 minutes. The obtained digestion solution was separated with 0.7% agarose gel electrophoresis. The DNA of about 2.0kbp was recovered from the gel. The DNA was purified with a Prep-A-Gene<sup>R</sup> DNA purification kit (Bio-Rad company) according to the instructions attached to said kit to obtain 10 $\mu\text{l}$  of the solution containing the target DNA. A microliter (1 $\mu\text{l}$ ) of the DNA solution, 98ng of plasmid vector pUC118 digested with restriction enzyme BamHI and treated with dephosphorylation and 11 $\mu\text{l}$  of the I solution from Ligation Kit Ver. 2 (Takara Shuzo Company) were mixed and incubated overnight at 16°C. *E. coli* DH5 $\alpha$  was transformed utilizing 5 $\mu\text{l}$  of the ligation solution. The *E. coli* was cultured with shaking overnight at 30°C. From the obtained culture medium, the *E. coli* was recovered. The plasmid was extracted to provide the chromosomal DNA library.

#### (3) Isolation of the present invention DNA (A1)

[0165] PCR was conducted by utilizing as the template the chromosomal DNA prepared in Example 3(1) (Fig. 1). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 35 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 36 (hereinafter referred to as "primer paring 1"). The nucleotide sequence shown in SEQ ID NO: 35 was designed based on a nucleotide sequence

encoding the amino acid sequence shown in SEQ ID NO: 18. Further, the nucleotide sequence shown in SEQ ID NO: 36 was designed based on a nucleotide sequence complementary to the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 19. The PCR reaction solution amounted to 25 $\mu$ l by adding the 2 primers each amounting to 200nM, 250ng of the above chromosomal DNA, 0.5 $\mu$ l of dNTP mix (a mixture of 10mM of each of the 4 types of dNTP; Clontech Company), 5 $\mu$ l of 5xGC genomic PCR reaction buffer (Clontech Company), 1.1 $\mu$ l of 25mM Mg(OAc)<sub>2</sub>, 5 $\mu$ l of 5M GC-Melt (Clontech Company) and 0.5 $\mu$ l of Advantage-GC genomic polymerase mix (Clontech Company) and distilled water. The reaction conditions of the PCR were after maintaining 95°C for 1 minute, repeating 30 cycles of a cycle that included maintaining 94°C for 15 seconds, followed by 60°C for 30 seconds, followed by 72°C for 1 minute, and then maintaining 72°C for 5 minutes. After the maintenance, the reaction solution was subjected to 4% agarose gel electrophoresis. The gel area containing the DNA of about 150bp was recovered. The DNA was purified from the recovered gel by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to the TA cloning vector pCR2.1 (Invitrogen Company) according to the instructions attached to said vector and was introduced into E. Coli TOP10F'. The plasmid DNA was prepared from the obtained E. coli transformant, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company) and M13Rev primer (Applied Biosystems Japan Company). The sequencing reaction utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 36 to 132 of the nucleotide sequence shown in SEQ ID NO: 9 was provided. Said nucleotide sequence encoded the amino acid sequence shown in amino acids 12 to 23 of the amino acid sequence shown in SEQ ID NO: 18. In this regard, it was expected that said DNA encoded a part of the present invention protein (A1).

**[0166]** Next, PCR was conducted similar to the above with Advantage-GC genomic polymerase mix (Clontech Company) and by utilizing the chromosomal DNA prepared in Example 3(2) as the template. There was utilized as primers, a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 37 with an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 38 (hereinafter referred to as the "primer pairing 2") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 39 with an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 40 (hereinafter referred to as the "primer pairing 3").

**[0167]** Next, there was amplified by PCR a DNA having a nucleotide sequence in which the 3' terminus extends past the nucleotide shown as nucleotide 132 of the nucleotide sequence shown in SEQ ID NO: 9. The PCR was conducted by utilizing as the template solution the reaction solution obtained with the use of primer pairing 2 and by utilizing as primers a pairing of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 41 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 38 (hereinafter referred to as "primer pairing 4"). Similarly, there was amplified by PCR a DNA having a nucleotide sequence in which the 5' terminus extends past the nucleotide shown as nucleotide 36 of the nucleotide sequence shown in SEQ ID NO: 9. The PCR was conducted by utilizing as the template solution the reaction solution obtained with the use of primer pairing 3 and by utilizing as primers a pairing of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 42 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 40 (hereinafter referred to as "primer pairing 5"). The 2kbp DNA amplified with the use of primer pairing 4 and the 150bp DNA amplified with the use of primer pairing 5 are cloned into TA cloning vector pCR2.1, similar to the above. Plasmid DNA was prepared from the obtained E. coli transformant, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company), M13Rev primer (Applied Biosystems Japan Company) and the oligonucleotides shown in SEQ ID NO: 43-50. The sequencing reaction utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result of sequencing the nucleotide sequence of the 2kbp DNA amplified by utilizing primer pairing 4, the nucleotide sequence shown in nucleotides 133 to 1439 of the nucleotide sequence shown in SEQ ID NO: 9 was provided. Further, as a result of sequencing the nucleotide sequence of the 150bp DNA amplified by utilizing primer pairing 5, the nucleotide sequence shown in nucleotides 1 to 35 of the nucleotide sequence shown in SEQ ID NO: 9 was provided. As a result of connecting the obtained nucleotide sequences, the nucleotide sequence shown in SEQ ID NO: 9 was obtained. Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 6) consisting of 1227 nucleotides (inclusive of the stop codon) and encoding a 408 amino acid residue as well as a nucleotide sequence (SEQ ID NO: 15) consisting of 201 nucleotides (inclusive of the stop codon) and encoding a 66 amino acid residue. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 1) encoded by the nucleotide sequence shown in SEQ ID NO: 6 was calculated to be 45213Da. Further, the amino acid sequence encoded by said nucleotide sequence contained the amino acid sequence (SEQ ID NO: 18) determined from the amino acid sequencing of from the N terminus of the present invention protein (A1) and the amino acid sequence (SEQ ID NO: 19) determined from the amino acid sequencing of the trypsin

digestion fragments with the mass spectrometer analysis. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 12) encoded by the nucleotide sequence shown in SEQ ID NO: 15 was calculated to be 6818Da.

#### 5 Example 4 Expression of the Present Invention Protein (A1) in E. coli

##### (1) Production of a transformed E. coli having the present invention protein (A1)

[0168] PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Streptomyces phaeochromogenes* IFO12898 in Example 3(1) and by utilizing Expand High Fidelity PCR System (Roche Molecular Biochemicals Company). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 51 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 52 (hereinafter referred to as "primer pairing 19") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 51 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 53 (hereinafter referred to as "primer pairing 20"). The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 300nM, 50ng of the above chromosomal DNA, 5.0 $\mu$ l of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP), 5.0 $\mu$ l of 10x Expand HF buffer (containing MgCl<sub>2</sub>) and 0.75 $\mu$ l of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 2 minutes; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 68°C for 30 seconds and followed by 72°C for 2 minutes (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, the reaction solution was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1.2kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 19. The gel area containing the DNA of about 1.5kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 20. The DNA were purified from each of the recovered gels by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA were ligated to the TA cloning vector pCR2.1 (Invitrogen Company) according to the instructions attached to said vector and were introduced into E. Coli TOP10F'. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). Sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company), M13Rev primer (Applied Biosystems Japan Company), the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 43 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 46. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 6 was designated as pCR657 and the plasmid having the nucleotide sequence shown in SEQ ID NO: 9 was designated as pCR657F.

[0169] Furthermore, the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 134 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 135 were annealed together to provide a linker (Fig. 47). Plasmid pKSN24R2 (Akiyoshi-ShibaTa M. et al., Eur. J. Biochem. 224: P335(1994)) was digested with HindIII and XmnI. The linker was inserted into the obtained DNA of about 3kb. The obtained plasmid was designated as pKSN2 (Fig. 4).

[0170] Next, each of plasmids pCR657 and pCR657F was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.2kbp was cut from the gel subjected to the digestion products of pCR657. The gel area containing a DNA of about 1.5kbp was cut from the gel subjected to the digestion products of pCR657F. The DNA were purified from each of the recovered gels by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. Each of the obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 6, in which the DNA of about 1.2kbp encoding the present invention protein (A1) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN657. Further, the plasmid containing the nucleotide sequence shown in SEQ ID NO: 9, in which the DNA of about 1.5kbp encoding the present invention protein (A1) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN657F. Each of the above plasmids of pKSN657 and pKSN657F were introduced into E. coli JM109. The obtained E. coli transformants were designated, respectively, JM109/pKSN657 and JM109/pKSN657F. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

**(2) Expression of the present invention protein (A1) in E. coli and recovery of said protein**

**[0171]** E. coli JM109/pKSN657, JM109/pKSN657F and JM109/pKSN2 were each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) of yeast extract, 0.4%(w/v) of glycerol, 17mM potassium dihydrogen-phosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5- aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thrity (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing for 17 hours.

**[0172]** The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of the above buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN657 is referred to as "E. coli pKSN657 extract", the supernatant fraction obtained from E. coli JM109/pKSN657F is referred to as "E. coli pKSN657F extract", and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract"). A microliter (1µl) of the above supernatant fractions was analyzed on a 15% to 25% SDS-PAGE and stained with Coomassie Blue (hereinafter referred to as "CBB"). As a result, notably more intense bands were detected in both E. coli pKSN657 extract and E. coli pKSN657F extract than the E. coli pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 47kDa. A more intense band was detected in E. coli pKSN657F extract than E. coli pKSN657 extract. It was shown that E. coli JM109/pKSN657F expressed the present invention protein (A1) to a higher degree than E. coli JM109/pKSN657.

**(3) Detection of the ability to convert compound (II) to compound (III)**

**[0173]** Reaction solutions of 30µl were prepared and maintained for 1 hour at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18µl of the supernatant fraction recovered in Example 4(2). Further, there were prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3µl) of 2N HCl and 90 µl of ethyl acetate were added and stirred into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75µl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0µl of ethyl acetate. Five microliters (5.0µl) thereof was spotted to a TLC plate (TLC plate silica gel 60F<sub>254</sub> 20cm x 20cm, 0.25 thick, Merck Company). The TLC plate was developed with a 6: 1:2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). The results are shown in Table 6.

Table 6

Reaction components					spot of compound (III)
component A	component B	component C	E. coli extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	pKSN2	+	-
+	+	+	pKSN657	+	+
-	+	+	pKSN657	+	-
+	-	+	pKSN657	+	-
+	+	-	pKSN657	+	+

Table 6 (continued)

Reaction components					spot of compound (III)
component A	component B	component C	E. coli extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	pKSN657F	+	+
-	+	+	pKSN657F	+	-
+	-	+	pKSN657F	+	-
+	+	-	pKSN657F	+	+

**Example 5 Preparation of the Present Invention Protein (A2)****(1) Preparation of the crude cell extract**

[0174] A frozen stock of *Saccharopolyspora taberi* JCM 9383t was added to 10ml of A medium (0.1%(w/v) glucose, 0.5%(w/v) tryptone, 0.5%(w/v) yeast extract, 0.1%(w/v) of dipotassium hydrogenphosphate, pH7.0) in a 10ml test tube and incubated with shaking at 30°C for 1 day to obtain a pre-culture. Eight milliliters (8ml) of the pre-culture was added to 200ml of A medium and was revolve cultured in 500ml a baffled flask at 30°C for 2 days. Cell pellets were recovered by centrifuging (3,000xg, 10 min.) 10L of the resulting culture. These cell pellets were suspended in 100ml of B medium (1%(w/v) glucose, 0.1% beef extract, 0.2%(w/v) tryptone) containing compound (II) at 100ppm and were incubated with reciprocal shaking in a 500ml Sakaguchi flask for 20 hours at 30°C. Cell pellets were recovered by centrifuging (3,000xg, 10 min.) 10L of the resulting culture. The resulting cell pellets were washed twice with 1L of 0.1 M potassium phosphate buffer (pH7.0) to provide 119g of the cell pellets.

[0175] These cell pellets were suspended in 0.1M potassium phosphate buffer (pH7.0) at 2ml for 1g of the cell pellets. A millimolar of (1mM) PMSF, 5mM of benzamidine HCl, 1mM of EDTA, 3μg/ml of leupeptin, 3μg/ml of pepstatin and 1mM of dithiothritol were added. A cell lysate solution was obtained by disrupting twice repetitively the suspension with a French press (1000kg/cm<sup>2</sup>) (Ohtake Seisakusho). After centrifuging the cell lysate solution (40,000xg, 30 minutes), the supernatant was recovered and centrifuged for 1 hour at 150,000xg to recover the supernatant (hereinafter referred to as the "crude cell extract").

**(2) Determination of the ability of converting compound (II) to compound (III)**

[0176] There was prepared 30μl of a reaction solution of 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2.4mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.5mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18μl of the crude cell extract recovered in Example 5(1). The reaction solution was maintained at 30°C for a hour. Further, there was prepared and maintained similarly a reaction solution having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3μl) of 2N HCl and 90 μl of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75μl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0μl of ethyl acetate. Five microliters (5.0μl) thereof was spotted to a TLC plate (TLC plate silica gel 60F<sub>254</sub> 20cm x 20cm, 0.25 thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 7.

Table 7

Reaction components					spot of compound (III)
component A	component B	component C	crude cell extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-

Table 7 (continued)

5	Reaction components					spot of compound (III)
	component A	component B	component C	crude cell extract	compound (II) labeled with <sup>14</sup> C	
	+	+	+	+	+	+
	-	+	+	+	+	-
10	+	-	-	+	+	-

**(3) Fractionation of the crude cell extract**

**[0177]** Ammonium sulfate was added to the crude cell extract obtained in Example 5(1) to amount to 45% saturation. After stirring in ice-cooled conditions, the supernatant was recovered by centrifuging for 10 minutes at 12,000xg. After adding ammonium sulfate to the obtained supernatant to amount to 55% saturation and stirring in ice-cooled conditions, a pellet was recovered by centrifuging for 10 minutes at 12,000xg. The pellet was dissolved with 32.5ml of 20mM bistrispropane buffer (pH7.0). This solution was subjected to a PD10 column (Amersham Pharmacia Company) and eluted with 20mM of bistrispropane buffer (pH7.0) to recover 45.5ml of fractions containing proteins (hereinafter referred to as the "45-55% ammonium sulfate fraction").

**(4) Isolation of the present invention protein (A2)**

**[0178]** The 45-55% ammonium sulfate fraction prepared in Example 5(3) was injected into a HiLoad26/10 Q Sepharose HP column (Amersham Pharmacia Company). Next, after flowing 100ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.004M/minute, range of NaCl concentration was from 0M to 0.5M, flow rate was 8ml/minute) to fraction recover 30ml of fractions eluting at the NaCl concentration of from 0.25M to 0.26M. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 20mM bistrispropane buffer (pH7.0) to recover the fractions containing protein.

**[0179]** The recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) with the elution with Buffer A (2mM potassium phosphate buffer containing 1.5mM of NaCl, pH 7.0), in order to recover the fractions containing protein. Next, the fractions were injected into a Bio-Scale Ceramic Hydroxyapatite Type I column CHT10-I (BioRad Company). Twenty milliliters (20ml) of Buffer A was flown into the column. Subsequently, Buffer A was flown with a linear gradient of Buffer B (100mM potassium phosphate buffer containing 0.03mM of NaCl; the linear gradient started at 100% Buffer A to increase to 50% Buffer B over a 100 minute period, flow rate was 2ml/minute) to fraction recover 10ml of fractions eluting at a Buffer B concentration of from 23% to 25%. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 0.05M potassium phosphate buffer (pH7.0) to recover the fractions containing protein.

**[0180]** The recovered fractions were concentrated to about 770μl using an ultrafilter membrane (Microcon YM-30, Millipore Company) and injected into a HiLoad 16/60 Superdex 75pg column (Amersham Pharmacia Biotech Company). Fifty millimolar (50mM) potassium phosphate buffer containing 0.15M of NaCl (pH7.0) was flown (flow rate 1ml/minute) into the column. The elution was fractionated at 2ml each. The fractions eluting at the elution volumes of more or less 61ml were each fraction recovered. The protein contained in each of the fractions was analyzed with a 10%-20% SDS-PAGE.

**[0181]** Instead of the crude cell extract in the reaction solution described in Example 5(2), the recovered fractions were added and maintained in the presence of component A, component B, component C and compound (II) labeled with <sup>14</sup>C, similarly to Example 5(2). The reaction solutions after the maintenance were TLC analyzed to examine the intensity of the spots corresponding to compound (III) labeled with <sup>14</sup>C. The protein moving to the position to 47kDa in the above SDS-PAGE was observed to have its fluctuations in the concentrations of the bands of the fractions added in turn to be parallel with the fluctuations of the intensity of the spots corresponding to compound (III). Said protein was recovered from the SDS-PAGE gel and was subjected to an amino acid sequence analysis with a protein sequencer (Applied Biosystems Company, Procise 494HT, pulsed liquid method) to sequence the N terminus amino acid sequence. As a result, the amino acid sequence shown in SEQ ID NO: 20 was provided. Further, after digesting the above protein with trypsin, the obtained digestion material was analyzed on a mass spectrometer (ThermoQuest Company, Ion Trap Mass Spectrometer LCQ, column: LC Packings Company PepMap C18 75μm x 150mm, solvent A: 0.1% HOAc-H<sub>2</sub>O, solvent B: 0.1% HOAc-methanol, gradient: a linear gradient starting at an elution with a mixture of

95% of solvent A and 5% of solvent B and increasing to a concentration of 100% of solvent B over 30 minutes, flow rate: 0.2 $\mu$ l/minute). As a result, the sequence shown in SEQ ID NO: 21 was provided.

#### Example 6 Obtaining the present invention DNA (A2)

##### (1) Preparation of the chromosomal DNA of *Saccharopolyspora taberi* JCM 9383t

[0182] *Saccharopolyspora taberi* JCM 9383t was shake cultured at 30°C for 1 day to 3 days in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34%(w/v) sucrose and 0.2%(v/v) 2.5M MgCl<sub>2</sub>·6H<sub>2</sub>O). The cells were recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cell pellets. Two hundred micrograms per milliliter (200 $\mu$ g/ml) of egg-white lysozyme were added. The cell suspension was shaken at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with phenol-chloroform-isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with chloroform-isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitating the aqueous layer.

##### (2) Preparation of the chromosomal DNA library of *Saccharopolyspora taberi* JCM 9383t

[0183] Nineteen micrograms (19 $\mu$ g) of the chromosomal DNA prepared in Example 5(1) were digested with 0.78U of restriction enzyme Sau3AI at 37°C for 60 minutes. The obtained digestion solution was separated with 1% agarose gel electrophoresis. The DNA of about 2.0kbp was recovered from the gel. The DNA was purified with QIAquick Gel Extraction Kit (Qiagen Company) according to the instructions attached to said kit and was concentrated with an ethanol precipitation to obtain 10 $\mu$ l of the solution containing the target DNA. Eight microliters (8 $\mu$ l) of the DNA solution, 100ng of plasmid vector pUC 118 digested with restriction enzyme BamHI and treated with dephosphorylation and 12 $\mu$ l of the I solution from Ligation Kit Ver. 2 (Takara Shuzo Company) were mixed and maintained for 3 hours at 16°C. *E. coli* DH5  $\alpha$  was transformed with the ligation solution. The *E. coli* transformants were cultured overnight at 37°C in LB agar medium containing 50mg/l of ampicillin. The obtained colonies were recovered from an agar medium. The plasmids were extracted and were designated as the chromosomal DNA library.

##### (3) Isolation of the present invention DNA (A2)

[0184] PCR was conducted by utilizing the chromosomal DNA prepared in Example 6(1) as the template with Expand HiFi PCR System (Boehringer Mannheim Company) (Fig. 2). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 54 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 55 (hereinafter referred to as "primer pairing 6"). The nucleotide sequence shown in SEQ ID NO: 54 was designed based on a nucleotide sequence encoding the N terminus amino acid sequence shown in SEQ ID NO: 20. Further, the nucleotide sequence shown in SEQ ID NO: 55 was designed based on a nucleotide sequence complimentary to the nucleotide sequence encoding the inner amino acid sequence shown in SEQ ID NO: 21. The PCR reaction solution amounted to 25 $\mu$ l by adding 300ng of the above chromosomal DNA, the 2 primers each amounting to 7.5pmol, 0.2 $\mu$ l of dNTP mix (a mixture of 2mM of each of the 4 types of dNTP), 2.5 $\mu$ l of 10x buffer (containing MgCl<sub>2</sub>), 0.19 $\mu$ l of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes, repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, the reaction solution was subjected to 2% agarose gel electrophoresis. The gel area containing the DNA of about 800bp was recovered. The DNA was purified from the recovered gel by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to the TA cloning vector pCR11-TOPO (Invitrogen Company) according to the instructions attached to said vector and was introduced into *E. coli* TOP10F'. The plasmid DNA was prepared from the obtained *E. coli* transformant, utilizing Qiagen Tip20 (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company) and M13Rev primer (Applied Biosystems Japan Company). The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 36 to 819 of the nucleotide sequence shown in SEQ ID NO: 10 was provided. Nucleotides 37-60

of the nucleotide sequence shown in SEQ ID NO: 10 encoded a part of the amino acid sequence shown in SEQ ID NO: 20. In this regard, it was expected that that said DNA encoded a part of the present invention protein (A2).

[0185] Next, PCR was conducted by utilizing the chromosomal DNA prepared in Example 6(2) as the template and similar to the above with Expand HiFi PCR system. There was utilized as primers, a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 56 with an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 57 (hereinafter referred to as the "primer pairing 7"). By conducting the PCR with such primers, there was amplified a DNA having a nucleotide sequence in which the 5' terminus elongates past the nucleotide shown as nucleotide 36 of the nucleotide sequence shown in SEQ ID NO: 10. Further, there was utilized as primers, a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 58 with an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 59 (hereinafter referred to as the "primer pairing 8"). By conducting the PCR with such primers, there was amplified a DNA having a nucleotide sequence in which the 3' terminus elongates past the nucleotide shown as nucleotide 819 of the nucleotide sequence shown in SEQ ID NO: 10. Each of the 1.3kb DNA amplified with the use of primer pairing 7 and the 0.4kb DNA amplified with the use of primer pairing 8 was cloned into TA cloning vector pCRII-TOPO. Plasmid DNA was prepared from the obtained E. coli transformant, utilizing Qiagen Tip 20 (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company), M13Rev primer (Applied Biosystems Japan Company) and the oligonucleotide shown in SEQ ID NO: 60. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result of sequencing the nucleotide sequence of the 1.3kb DNA amplified by utilizing primer pairing 7, the nucleotide sequence shown in nucleotides 1 to 35 of the nucleotide sequence shown in SEQ ID NO: 10 was provided. Further, as a result of sequencing the nucleotide sequence of the 0.4kb DNA amplified by utilizing primer pairing 8, the nucleotide sequence shown in nucleotides 819 to 1415 of the nucleotide sequence shown in SEQ ID NO: 10 was provided. As a result of connecting the obtained nucleotide sequences, the nucleotide sequence shown in SEQ ID NO: 10 was obtained. Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 7) consisting of 1206 nucleotides (inclusive of the stop codon) and encoding a 401 amino acid residue as well as a nucleotide sequence (SEQ ID NO: 16) consisting of 198 nucleotides (inclusive of the stop codon) and encoding a 65 amino acid residue. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 2) encoded by the nucleotide sequence shown in SEQ ID NO: 7 was calculated to be 43983Da. Further, the amino acid sequence encoded by said nucleotide sequence contained the amino acid sequence (SEQ ID NO: 20) determined from the amino acid sequencing of from the N terminus of the present invention protein (A2) and the amino acid sequence (SEQ ID NO: 21) determined from the amino acid sequencing of the mass spectrometer analysis with the trypsin digestion fragments. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 13) encoded by the nucleotide sequence shown in SEQ ID NO: 16 was calculated to be 6707Da.

#### **Example 7 Expression of the Present Invention Protein (A2) in E. coli**

##### **(1) Production of a transformed E. coli having the present invention protein (A2)**

[0186] PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Saccharopolyspora taberi* JCM 9383t in Example 6(1) and by utilizing Expand HiFi PCR System (Boehringer Mannheim Company). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 61 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 62 (hereinafter referred to as "primer pairing 21") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 61 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 63 (hereinafter referred to as "primer pairing 22"). The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 300nM, 50ng of the above chromosomal DNA, 5.0 $\mu$ l of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP), 5.0 $\mu$ l of 10x Expand HF buffer (containing MgCl<sub>2</sub>) and 0.75 $\mu$ l of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, the reaction solution was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1.2kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 21. The gel area containing the DNA of about 1.4kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 22. The DNA were purified from each of the recovered gels by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA were ligated to the cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and were introduced into E.

Coli TOP10F'. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing Qiagen Tip20 (Qiagen Company). Next, sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company), M13Rev primer (Applied Biosystems Japan Company), the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 56 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 64. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 7 was designated as pCR923 and the plasmid having the nucleotide sequence shown in SEQ ID NO: 10 was designated as pCR923F.

[0187] Next, each of plasmids pCR923 and pCR923F was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.2kbp was cut from the gel subjected to the digestion products of pCR923. The gel area containing a DNA of about 1.4kbp was cut from the gel subjected to the digestion products of pCR923F. The DNA were purified from each of the recovered gels by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. Each of the obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 7, in which the DNA of about 1.2kbp encoding the present invention protein (A2) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN923. Further, the plasmid containing the nucleotide sequence shown in SEQ ID NO: 10, in which the DNA of about 1.4kbp encoding the present invention protein (A2) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN923F. Each of the above plasmids of pKSN923 and pKSN923F was introduced into E. coli JM109. The obtained E. coli transformants were designated, respectively, JM109/pKSN923 and JM109/pKSN923F. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

## (2) Expression of the present invention protein (A2) in E. coli and recovery of said protein

[0188] E. coli JM109/pKSN657, JM109/pKSN657F and JM109/pKSN2 were each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5-aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing for 17 hours.

[0189] The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10 ml of said buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN923 is referred to as "E. coli pKSN923 extract", the supernatant fraction obtained from E. coli JM109/pKSN923F is referred to as "E. coli pKSN923F extract", and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract"). A microliter (1µl) of the above supernatant fractions was analyzed on a 15% to 25% SDS-PAGE and stained with CBB. As a result, notably more intense bands were detected in both E. coli pKSN923 extract and E. coli pKSN923F extract than the E. coli pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 47kDa. It was confirmed that E. coli JM109/pKSN923 and E. coli JM109/pKSN923F expressed the present invention protein (A2).

## (3) Detection of the ability to convert compound (II) to compound (III)

[0190] Reaction solutions of 30µl were prepared and maintained for 10 minutes at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18µl of the supernatant fraction recovered in Example 7(2). Further, there were prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3µl) of 2N HCl and 90 µl of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75µl of the ethyl acetate layer.

After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0μl of ethyl acetate. Five microliters (5.0μl) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 8.

Table 8

Reaction components					spot of compound (III)
component A	component B	component C	E. coli extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	pKSN2	+	-
+	+	+	pKSN923	+	+
-	+	+	pKSN923	+	-
+	-	+	pKSN923	+	-
+	+	-	pKSN923	+	+
+	+	+	pKSN923F	+	+
-	+	+	pKSN923 F	+	-
+	-	+	pKSN923F	+	-
+	+	-	pKSN923F	+	+

#### Example 8 Preparation of the Present Protein (A10)

##### (1) Preparation of the crude cell extract

[0191] A frozen stock of *Streptomyces griseolus* ATCC 11796 was added to 250ml of B medium (1%(w/v) glucose, 0.1%(w/v) meat extract, 0.2%(w/v) tryptose) in a 500ml baffled flask and incubated with rotary shaking at 30°C for 3 days to obtain a pre-culture. Forty milliliters (40ml) of the pre-culture was added to 400ml of B medium and was incubated with rotary shaking in a 1L triangular flask at 30°C for 24 hours. After stopping the culturing, the culture was allowed to settle. Two hundred and twenty milliliters (220ml) of only the supernatant was removed. Two hundred and twenty milliliters (220ml) of fresh medium similarly prepared was added to the remaining 220ml of the culture medium to amount to 440ml. Compound (II) was added thereto to amount to 100ppm. The cells were incubated with rotary shaking in the 1L triangular flask at 30°C for 40 hours. Cell pellets were recovered by centrifuging (3,000g, 5 min.) 2.6L of the resulting culture. The resulting cell pellets were washed with 1 L of 0.1M PIPES-NaOH buffer (pH6.8) to provide 26g of the cell pellets.

[0192] These cell pellets were suspended of 0.1M PIPES-NaOH buffer (pH6.8) at 3ml for 1g of the cell pellets, and 1 mM of PMSF, 5mM of benzamidine HCl, 1mM of EDTA, 3μg/ml of leupeptin, 3μg/ml of pepstatin A and 1mM of dithiothritol were added. A cell lysate solution was obtained by disrupting twice repetitively the suspension with a French press (1000kg/cm<sup>2</sup>) (Ohtake Seisakusho). After centrifuging the cell lysate solution (40,000xg, 30 minutes), the supernatant was recovered and centrifuged for 1 hour at 150,000xg to recover the supernatant (hereinafter referred to as the "crude cell extract").

##### (2) Determination of the ability of converting compound (II) to compound (III)

[0193] There was prepared 30μl of a reaction solution of 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2.4mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.5mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18μl of the crude cell extract recovered in Example 8(1). The reaction solution was maintained at 30°C for a hour. Further, there was prepared and maintained similarly a reaction solution having no addition of at least one component utilized in the composition

of the above reaction solution, selected from component A, component B and component C. Three microliters (3 $\mu$ l) of 2N HCl and 90  $\mu$ l of ethyl acetate were added and stirred into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75 $\mu$ l of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0 $\mu$ l of ethyl acetate. Five microliters (5.0 $\mu$ l) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25 thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 9.

Table 9

Reaction components					spot of compound (III)
component A	component B	component C	crude cell extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	+	+	+
-	+	+	+	+	-
+	-	-	+	+	-

### (3) Fractionation of the crude cell extract

[0194] Ammonium sulfate was added to the crude cell extract obtained in Example 8(1) to amount to 45% saturation. After stirring in ice-cooled conditions, the supernatant was recovered by centrifuging for 10 minutes at 12,000xg. After adding ammonium sulfate to the obtained supernatant to amount to 55% saturation and stirring in ice-cooled conditions, a pellet was recovered by centrifuging for 10 minutes at 12,000xg. The pellet was dissolved with 20mM bistrispropane buffer (pH7.0) to amount to 10ml. This solution was subjected to a PD10 column (Amersham Pharmacia Company) and eluted with 20mM of bistrispropane buffer (pH7.0) to recover 14ml of fractions containing proteins (hereinafter referred to as the "45-55% ammonium sulfate fraction").

### (4) Isolation of the present protein (A10)

[0195] The 45-55% ammonium sulfate fraction prepared in Example 8(3) was injected into a MonoQ HR 10/10 column (Amersham Pharmacia Company). Next, after flowing 16ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.00625M/minute, range of NaCl concentration was from 0M to 0.5M, flow rate was 4ml/minute) to fraction recover 15ml of fractions eluting at the NaCl concentration of from 0.28M to 0.31M. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 20mM bistrispropane buffer (pH7.0) to recover the fractions containing protein.

[0196] The recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) with the elution with Buffer A (2mM potassium phosphate buffer containing 1.5mM of NaCl, pH 7.0), in order to recover the fractions containing protein. Next, the fractions were injected into a Bio-Scale Ceramic Hydroxyapatite Type I column CHT10-I (BioRad Company). Fifty milliliters (50ml) of Buffer A was flown into the column. Subsequently, Buffer A was flown with a linear gradient of Buffer B (100mM potassium phosphate buffer containing 0.03mM of NaCl; the linear gradient started at 100% Buffer A to increase to 50% Buffer B over a 40 minute period, flow rate was 5ml/minute) to fraction recover the fractions eluting at a Buffer B concentration of from 16% to 31%. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 0.05M potassium phosphate buffer (pH7.0) to recover the fractions containing protein. The protein contained in each of the fractions were analyzed on a 10%-20% SDS-PAGE.

[0197] Instead of the crude cell extract in the reaction solution described in Example 8(2), the recovered fractions were added and maintained in the presence of component A, component B, component C and compound (II) labeled with <sup>14</sup>C, similarly to Example 8(2). The reaction solutions after the maintenance were TLC analyzed to examine the intensity of the spots corresponding to compound (III) labeled with <sup>14</sup>C. The protein moving to the position to 47kDa in the above SDS-PAGE was observed to have its fluctuations in the concentrations of the bands of the fractions added

in turn to be parallel with the fluctuations of the intensity of the spots corresponding to compound (III). Said protein was recovered from the SDS-PAGE gel and digested with trypsin. The obtained digestion material was analyzed on a mass spectrometer (ThermoQuest Company, Ion Trap Mass Spectrometer LCQ, column: LC Packings Company Pep-Map C18 75µm x 150mm, solvent A: 0.1%HOAc-H<sub>2</sub>O, solvent B: 0.1% HOAc-methanol, gradient: a linear gradient starting at an elution with a mixture of 95% of solvent A and 5% of solvent B and increasing to a concentration of 100% of solvent B over 30 minutes, flow rate: 0.2µl/minute). As a result, the amino acid sequences shown in each and any one of SEQ ID NO: 22-34 were provided.

#### Example 9 Preparation of the Chromosomal DNA of *Streptomyces Griseolus* ATCC 11796

[0198] *Streptomyces griseolus* ATCC 11796 was incubated with shaking at 30°C for 1 day to 3 days in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34%(w/v) sucrose and 0.2%(v/v) 2.5M MgCl<sub>2</sub>·6H<sub>2</sub>O). The cells were recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cells. Two hundred micrograms per milliliter (200µg/ml) of egg-white lysozyme were added. The cell suspension was shaken at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with phenol-chloroform-isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with chloroform-isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitating the aqueous layer.

#### Example 10 Obtaining a DNA Encoding the Present DNA (A10) and Expression in *E. coli*

##### (1) Production of a transformed *E. coli* having the present DNA

[0199] PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Streptomyces griseolus* ATCC 11796 in Example 9 and by utilizing Expand High Fidelity PCR System (Roche Molecular Biochemicals Company). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 79 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 80 (hereinafter referred to as "primer pairing 23") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 79 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 81 (hereinafter referred to as "primer pairing 24"). The PCR reaction solutions amounted to 50µl by adding the 2 primers each amounting to 300nM, 50ng of the above chromosomal DNA, 5.0µl of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP), 5.0µl of 10x Expand HF buffer (containing MgCl<sub>2</sub>) and 0.75µl of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 2 minutes; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 68°C for 30 seconds and followed by 72°C for 2 minutes (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, each of the reaction solutions was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1.2kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 23. The gel area containing the DNA of about 1.5kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 24. The DNA were purified from each of the recovered gels by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA were ligated to the cloning vector pCR2.1-TOPO (Invitrogen Company) according to the instructions attached to said vector and were introduced into *E. Coli* TOP10F'. The plasmid DNA were prepared from the obtained *E. coli* transformants, utilizing Qiaprep Spin Miniprep Kit (Qiagen Company). Next, sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the -21M13 primer (Applied Biosystems Japan Company), M13Rev primer (Applied Biosystems Japan Company), the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 82 and the oligonucleotide having the nucleotide sequence shown in SEQ LD NO: 83. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 84 was designated as pCR11796 and the plasmid having the nucleotide sequence shown in SEQ ID NO: 85 was designated as pCR11796F. Two open reading frames (ORF) were present in said nucleotide sequence shown in SEQ ID NO: 85. As such, there was contained a nucleotide sequence (SEQ ID NO: 84) consisting of 1221 nucleotides (inclusive of the stop codon) and encoding a 406 amino acid residue (the amino acid sequence shown in SEQ ID NO: 5) and a nucleotide sequence consisting of 210 nucleotides (inclusive of the stop codon) and encoding a 69 amino

acid residue.

[0200] Next, each of pCR11796 and pCR11796F was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.2kbp was cut from the gel subjected to the digestion products of pCR11796. The gel area containing a DNA of about 1.5kbp was cut from the gel subjected to the digestion products of pCR11796F. The DNA were purified from each of the recovered gels by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. Each of the obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 84, in which the DNA of about 1.2kbp encoding the present protein (A 10) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN11796. Further, the plasmid containing the nucleotide sequence shown in SEQ ID NO: 85, in which the DNA of about 1.5kbp encoding the present protein (A 10) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN11796F. Each of the above plasmids of pKSN11796 and pKSN11796F was introduced into E. coli JM109. The obtained E. coli transformants were designated, respectively, JM109/pKSN11796 and JM109/pKSN11796F. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

### (2) Expression of the present protein (A10) in E. coli and recovery of said protein

[0201] E. coli JM109/pKSN11796, JM109/pKSN11796F and JM109/pKSN2 were each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5-aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing for 17 hours.

[0202] The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of the above buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN11796 is referred to as "E. coli pKSN11796 extract", the supernatant fraction obtained from E. coli JM109/pKSN11796F is referred to as "E. coli pKSN11796F extract", and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract"). A microliter (1µl) of the above supernatant fractions was analyzed on a 15% to 25% SDS-PAGE and stained with Coomassie Blue (hereinafter referred to as "CBB"). As a result, notably more intense bands were identified in both E. coli pKSN11796 extract and E. coli pKSN11796F extract than the E. coli pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 45kDa. A more intense band was identified in E. coli pKSN11796F extract than E. coli pKSN11796 extract. It was shown that E. coli JM109/pKSN11796F expressed the present protein (A10) to a higher degree than E. coli JM109/pKSN11796.

### (3) Detection of the ability to convert compound (II) to compound (III)

[0203] Reaction solutions of 30µl were prepared and maintained for 1 hour at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18µl of the supernatant fraction recovered in Example 10(2). Further, there were prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3µl) of 2N HCl and 90µl of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75µl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0µl of ethyl acetate. Five microliters (5.0µl) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub> 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29).

The results are shown in Table 10.

Table 10

Reaction components					spot of compound (III)
component A	component B	component C	E. coli extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	pKSN2	+	-
+	+	+	pKSN11796	+	+
-	+	+	pKSN11796	+	-
+	-	+	pKSN11796	+	-
+	+	-	pKSN11796	+	+
+	+	+	pKSN11796F	+	+
-	+	+	pKSN11796F	+	-
+	-	+	pKSN11796F	+	-
+	+	-	pKSN11796F	+	+

#### Example 11 Obtaining the Present Invention DNA (A3)

##### (1) Preparation of the Chromosomal DNA of *Streptomyces testaceus* ATCC21469

[0204] *Streptomyces testaceus* ATCC21469 was incubated with shaking at 30°C for 1 day to 3 days in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34%(w/v) sucrose and 0.2%(v/v) 2.5M MgCl<sub>2</sub>·6H<sub>2</sub>O). The cells were recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cells. Two hundred micrograms per milliliter (200μg/ml) of egg-white lysozyme were added. The cell suspension was shaken at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with phenol · chloroform · isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with chloroform · isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitating the aqueous layer.

##### (2) Isolation of the present invention DNA (A3)

[0205] PCR was conducted by utilizing the chromosomal DNA prepared in Example 11(1) as the template. As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 65 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 66 (hereinafter referred to as "primer pairing 9"). The PCR reaction solution amounted to 50μl by adding 250ng of the above chromosomal DNA, the 2 primers each amounting to 200nM, 4μl of dNTP mix (a mixture of 2.5mM of each of the 4 types of dNTP), 5μl of 10x ExTaq buffer, 0.5μl of ExTaq polymerase (Takara Shuzo Company) and distilled water. The reaction conditions of the PCR were maintaining 97°C for 2 minutes; repeating 30 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 90 seconds; and then maintaining 72°C for 4 minutes. After the maintenance, the reaction solution was subjected to 0.8% agarose gel electrophoresis. The gel area containing the DNA of about 1.4kbp was recovered. The DNA was purified from the recovered gel by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to the TA cloning vector pCR2.1 (Invitrogen Company) according to the instructions attached to said vector and was introduced into *E. coli* TOP10F'. The plasmid DNA was prepared from the obtained *E. coli* transformant, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 67 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 68. The sequencing reactions utilized the obtained plasmid as the template. The

reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in SEQ ID NO: 69 was provided. Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence consisting of 1188 nucleotides (inclusive of the stop codon) and encoding a 395 amino acid residue and a nucleotide sequence (SEQ ID NO: 17) consisting of 195 nucleotides (inclusive of the stop codon) and encoding a 64 amino acid residue. The molecular weight of the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 17 was calculated to be 6666Da.

## Example 12 Expression of the Present Invention Protein (A3) in E. Coli

### (1) Production of a transformed E. coli having the present invention DNA (A3)

[0206] PCR was conducted by utilizing as a template the chromosomal DNA prepared in Example 11(1) and by utilizing ExTaq polymerase (Takara Shuzo Company) under similar conditions as above. As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 70 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 71 (hereinafter referred to as "primer pairing 10") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 70 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 72 (hereinafter referred to as "primer pairing 11"). The DNA of 1.2kb amplified by utilizing the primer pairing 10 and the DNA of 1.5kbp amplified by utilizing the primer pairing 11 were cloned into TA cloning vector pCR2.1 according to the above methods. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). Sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 67 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 68. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result, the plasmid cloned with the DNA amplified by the primer pairing 10 was confirmed to have the nucleotide sequence shown in SEQ ID NO: 8. The plasmid cloned with the DNA amplified by primer pairing 11 was confirmed to have the nucleotide sequence shown in SEQ ID NO: 11. Two open reading frames (ORF) were present in said nucleotide sequence shown in SEQ ID NO: 11. As such, there was contained a nucleotide sequence (SEQ ID NO: 8) consisting of 1188 nucleotides (inclusive of the stop codon) and encoding a 395 amino acid residue and a nucleotide sequence consisting of 195 nucleotides (inclusive of the stop codon) and encoding a 64 amino acid residue. The molecular weight of the protein consisting of the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 8 was calculated to be 43752Da. With the obtained plasmids, the plasmid having the nucleotide sequence shown in SEQ ID NO: 8 was designated as pCR671 and the plasmid having the nucleotide sequence shown in SEQ ID NO: 11 was designated as pCR671F.

[0207] Next, each of pCR671 and pCR671 F was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.2kbp was cut from the gel subjected to the digestion products of pCR671. The gel area containing a DNA of about 1.5kbp was cut from the gel subjected to the digestion products of pCR671F. The DNA were purified from each of the recovered gels by utilizing Qiagen quick gel extraction kit (Qiagen Company) according to the attached instructions. Each of the obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 8, in which the DNA of about 1200bp encoding the present invention protein (A3) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN671. Further, the plasmid containing the nucleotide sequence shown in SEQ ID NO: 11, in which the DNA of about 1400bp encoding the present invention protein (A3) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN671F. Each of the above plasmids of pKSN671 and pKSN671F was introduced into E. coli JM109. The obtained E. coli transformants were designated, respectively, JM109/pKSN671 and JM109/pKSN671F. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

### (2) Expression of the present invention protein (A3) in E. coli and recovery of said protein

[0208] E. coli JM109/pKSN671, JM109/pKSN671F and JM109/pKSN2 were each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5-aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing

for 17 hours.

[0209] The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of said buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN671 is referred to as "E. coli pKSN671 extract", the supernatant fraction obtained from E. coli JM109/pKSN671F is referred to as "E. coli pKSN671F extract", and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

### (3) Detection of the ability to convert compound (II) to compound (III)

[0210] Reaction solutions of 30μl were prepared and maintained for 1 hour at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18μl of the supernatant fraction recovered in Example 12(2). Further, there were prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3μl) of 2N HCl and 90μl of ethyl acetate were added and stirred into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75μl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0μl of ethyl acetate. Five microliters (5.0μl) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 11.

Table 11

Reaction components					spot of compound (III)
component A	component B	component C	E. coli extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	pKSN2	+	-
+	+	+	pKSN671	+	+
-	+	+	pKSN671	+	-
+	-	+	pKSN671	+	-
+	+	-	pKSN671	+	+
+	+	+	pKSN671F	+	+
-	+	+	pKSN671F	+	-
+	-	+	pKSN671F	+	-
+	+	-	pKSN671F	+	+

### Example 13 Obtaining the Present DNA (A9)

#### (1) Preparation of the chromosomal DNA of Streptomyces carbophilus SANK62585

[0211] Streptomyces carbophilus SANK62585 (FERM BP-1145) was incubated with shaking at 30°C for 1 day in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34%(w/v) sucrose and 0.2%(v/v) 2.5M MgCl<sub>2</sub>·6H<sub>2</sub>O). The cells were then recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The

cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cells. Two hundred micrograms per milliliter (200µg/ml) of egg-white lysozyme were added. The cell suspension was shaken at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with phenol-chloroform-isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with chloroform-isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitating the aqueous layer.

## (2) Isolation of the present DNA (A9)

[0212] PCR was conducted by utilizing as the template the chromosomal DNA prepared in Example 13(1). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 74 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 75 (hereinafter referred to as "primer pairing 12") or the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 76 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 77 (hereinafter referred to as "primer pairing 13"). The PCR reaction solution amounted to 50µl by adding the 2 primers each amounting to 200nM, 250ng of the above chromosomal DNA, 4µl of dNTP mix (a mixture of 2.5mM of each of the 4 types of dNTP), 5µl of 10x ExTaq buffer, 0.5µl of ExTaq polymerase (Takara Shuzo Company) and distilled water. The reaction conditions of the PCR were maintaining 95°C for 2 minutes; repeating 30 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds, followed by 72°C for 90 seconds, and then maintaining 72°C for 4 minutes. After the maintenance, the reaction solution was subjected to 0.8% agarose gel electrophoresis. The gel area containing the DNA of about 500bp was recovered from the gel subjected to the PCR reaction solution utilizing primer pairing 12. The gel area containing the DNA of about 800bp was recovered from the gel subjected to the PCR reaction solution utilizing primer pairing 13. The DNA were purified from each of the recovered gels by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA were ligated to the TA cloning vector pCR2.1 (Invitrogen Company) according to the instructions attached to said vector and was introduced into E. Coli TOP10F'. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO:67 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 68. The sequencing reaction utilized the obtained plasmid DNA as the templates. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 1 to 498 of the nucleotide sequence shown in SEQ ID NO: 78 was provided by the DNA obtained by the PCR utilizing primer pairing 12. The nucleotide sequence shown in nucleotides 469 to 1233 of the nucleotide sequence shown in SEQ ID NO: 78 was provided by the DNA obtained by the PCR utilizing primer pairing 13. The plasmid having the nucleotide sequence of nucleotides 1 to 498 shown in SEQ ID NO: 78 was designated as pCRSCA1. The plasmid having the nucleotide sequence of nucleotides 469 to 1233 shown in SEQ ID NO: 78 was designated as pCRSCA2.

## Example 14 Expression of the Present Protein (A9) in E. Coli

### (1) Production of a transformed E. coli having the present DNA (A9)

[0213] With the plasmids obtained in Example 13(2), the above plasmid pCRSCA1 was digested with NdeI and NcoI and pCRSCA2 was digested with NdeI and NcoI. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 500bp was cut from the gel subjected to the digestion products of pCRSCA2. The gel area containing a DNA of about 800bp was cut from the gel subjected to the digestion products of pCRSCA2. The DNA were purified from each of the recovered gels by utilizing QIAquick gel extraction kit (Qiagen Company) according to the attached instructions. The 2 types of the obtained DNA were ligated together with the plasmid pKSN2 digested with NdeI and HindIII, utilizing ligation kit Ver.1 (Takara Shuzo Company) in accordance with the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA was prepared from the obtained E. coli transformants. The structure thereof was analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 78, in which the DNA encoding the present protein (A9) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSNSCA.

### (2) Expression of the present protein (A9) in E. coli and recovery of said protein

[0214] E. coli JM109/pKSNSCA was cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/

v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate containing 50µg/ml of ampicillin. The obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C, so that the OD660 was 0.2. When OD660 reached about 2.0, 5-aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 200µM, and there was further culturing for 5 hours.

[0215] The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of said buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from *E. coli* JM109/pKSNSCA is referred to as "*E. coli* pKSNSCA extract").

### (3) Detection of the ability to convert compound (II) to compound (III)

[0216] Reaction solutions of 30µl were prepared and maintained for 10 minutes at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18µl of the supernatant fraction recovered in Example 14(2). Further, there were prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3µl) of 2N HCl and 90µl of ethyl acetate were added and stirred into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75µl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0µl of ethyl acetate. Five microliters (5.0µl) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 12.

Table 12

Reaction components					spot of compound (III)
component A	component B	component C	<i>E. coli</i> extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	pKSNSCA	+	+

### Example 15 Isolation of Soybean RuBPC Gene

[0217] After seeding soybean (cv. Jack), the soybean was cultivated at 27°C for 30 days and the leaves were gathered. Two-tenths grams (0.2g) to 0.3g of the gathered leaves were frozen with liquid nitrogen and were milled with a mortar and pestle. Subsequently, the total RNA was extracted from the milled product according to the manual attached with RNA extraction solvent ISOGEN (Nippon Gene Company). Further, cDNA was synthesized with the use of Superscript First-strand Synthesis System for RT-PCR (Invitrogen Company), by conducting the procedures in accordance with the attached manual. Specifically, a 1st strand cDNA was synthesized by utilizing the Oligo(dT)<sub>12-18</sub> primer provided by the kit as a primer and the total soybean RNA as the template and by adding thereto the reverse transcriptase provided by the kit. Next, there is amplified by PCR a DNA encoding the chloroplast transit peptide of the small subunit of ribulose-1,5-bisphosphate carboxylase (hereinafter, the ribulose-1,5-bisphosphate carboxylase is referred to as "RuBPC") of soybean (cv. Jack) followed by the 12 amino acids of a mature protein (hereinafter, the chloroplast transit peptide of the small subunit of RuBPC of soybean (cv. Jack) is sometimes referred to as "rSt"; and the DNA encoding the chloroplast transit peptide of the small subunit of RuBPC of soybean (cv. Jack) followed by the 12 amino acids of a mature protein is referred to as "the present rSt12 DNA"). The PCR utilized the obtained cDNA as a template and as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 86 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 87. The PCR utilized LA Taq polymerase (Takara Shuzo Company). The PCR was conducted by maintaining once 94°C for 3 minutes; conducting 30 cycles of a cycle

that included maintaining 98°C for 25 seconds and then 68°C for 1 minute; and maintaining once 72°C for 10 minutes. Plasmid pCRrSt12 (Fig. 5) was obtained by inserting the amplified DNA into the PCR-product cloning site of plasmid pCR2.1 (Invitrogen Company). Next, plasmid was introduced into the competent cells of *E. coli* JM109 strain and the ampicillin resistant strains were selected. Further, the nucleotide sequence of the plasmid contained in the selected ampicillin resistant strains was determined by utilizing the Dye Terminator Cycle Sequencing FS Ready Reaction kit (PE Applied Biosystems Company) and the DNA sequencer 373S (PE Applied Biosystems Company). As a result, the nucleotide sequence shown in SEQ ID NO: 88 was provided. It was confirmed that plasmid pCRrSt12 contained the present rSt12 DNA.

## **Example 16 Construction of a Chloroplast Expression Plasmid Containing the Present Invention DNA (A1) for Direct Introduction**

### **(1) Isolation of the present invention DNA (A1)**

**[0218]** A DNA comprising the nucleotide sequence shown in SEQ ID NO: 6 was amplified by PCR. The PCR was conducted by utilizing as the template the genomic DNA of *Actinomyces Streptomyces phaeochromogenes* IFO12898 and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 93 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 94. Further, a DNA comprising the nucleotide sequence shown in SEQ ID NO: 9 was amplified by PCR. The PCR was conducted by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 93 and the oligonucleotide sequence shown in SEQ ID NO: 95. Said PCR utilized the Expand High Fidelity PCR System (Boehringer Company). There was conducted after maintaining once 97°C for 2 minutes; conducting 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds were added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. Plasmids pCR657ET (Fig. 6) and pCR657FET (Fig. 7) were produced by inserting the amplified DNA into the PCR product cloning region of pCR2.1 (Invitrogen Company). Furthermore, other than utilizing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 96 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 94, plasmid pCR657Bs (Fig. 8) was obtained with procedures similar to the method described above. Even further, other than utilizing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 96 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 97, plasmid pCR657FBs (Fig. 9) was obtained with procedures similar to the method described above. Next, the plasmids were introduced into *E. Coli* DH5  $\alpha$  competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v2.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmids pCR657ET and pCR657Bs have the nucleotide sequence shown in SEQ ID NO: 6. It was confirmed that plasmids pCR657FET and pCR657FBs have the nucleotide sequence shown in SEQ ID NO: 9.

### **(2) Construction of a chloroplast expression plasmid having the present invention DNA (A1) for direct introduction - part (1)**

**[0219]** A plasmid containing a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit (hereinafter sometimes referred to as the "sequence encoding the chloroplast transit peptide") without a change of frames in the codons was constructed as a plasmid for introducing the present invention DNA (A1) into a plant with the particle gun method.

**[0220]** First, pCRrSt12 was digested with restriction enzyme HindIII and KpnI. The DNA comprising the present rSt12DNA was isolated. Further, a DNA of about 2640bp was obtained by removing about a 40bp DNA from plasmid vector pUC19 (Takara Shuzo Company) with a digestion with restriction enzymes HindIII and KpnI. Next, the 5' terminus of the DNA was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). The DNA containing the present rSt12DNA, obtained from pCRrSt12, was inserted thereto to obtain pUCrSt12 (Fig. 10). Next, DNA comprising the present invention DNA (A1) were isolated by digesting each of plasmids pCR657ET and pCR657FET with restriction enzymes EcoT22I and SacI. Each of the obtained DNA was inserted between the EcoT22I restriction site and the SacI restriction site of pUCrSt12 to obtain plasmids pUCrSt657 (Fig. 11) and pUCrSt657F (Fig. 12) containing a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

[0221] pBICR16G6PT (described in Japanese unexamined patent 2000-166577) was digested with restriction enzyme EcoRI to isolate a DNA of about 3kb. (Hereinafter, the promoter contained in the DNA described in the above Japanese unexamined patent is referred to as the "CR16G6 promoter". Further, the terminator contained in the DNA described in the above Japanese unexamined patent is referred to as the "CR16 terminator".) After digesting the plasmid vector pUC19 (Takara Shuzo Company) with restriction enzyme EcoRI, the 5' terminus of said DNA was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). The 3kb DNA derived from pBICR16G6PT was inserted thereto to obtain plasmid pUCCR16G6-p/t (Fig. 13). pUCCR16G6-p/t was digested with restriction enzymes HindIII and SacI to isolate a DNA comprising the CR16G6 promoter. Further, by digesting plasmid vector pUC19 (Takara Shuzo Company) with restriction enzymes HindIII and EcoRI, a DNA of 51bp was removed and the remaining DNA consisting of 2635bp was obtained. Next, the 5' terminus of said DNA was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). The above DNA comprising the CR16G6 promoter obtained from pUCCR16G6-p/t and a NotI-EcoRI linker (Fig. 14) obtained from annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID No: 89 with the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID No: 90 were inserted thereto to obtain pUCCR12G6-p/t  $\Delta$  (Fig. 15). pUCCR12G6-p/t  $\Delta$  was digested with restriction enzymes NdeI and EcoRI to isolate a DNA having a partial nucleotide sequence of the CR16t terminator. Further, plasmid vector pUC 19 (Takara Shuzo Company) was digested with restriction enzymes HindIII and EcoRI to obtain a DNA of 2635bp. The 5' terminus of said DNA was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). The above DNA having a partial nucleotide sequence of the CR16t terminator obtained from pUCCR12G6-p/t  $\Delta$  and a HindIII-NotI linker (Fig. 16) obtained by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 91 with the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 92 were inserted thereto to obtain pNdG6- $\Delta$ T (Fig. 17).

[0222] Next, by digesting each of plasmids pUCrSt657 and pUCr657F with restriction enzymes BamHI and SacI, there was isolated the DNA comprising a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons. The DNA were inserted between the restriction enzyme site of BglII and the restriction enzyme site of SacI of plasmid pNdG6- $\Delta$ T to obtain each of plasmid pSUM-NdG6-rSt-657 (Fig. 18) and plasmid pSUM-NdG6-rSt-657F (Fig. 19).

### (3) Construction of a chloroplast expression plasmid having the present invention DNA (A1) for direct introduction - part (2)

[0223] A plasmid containing a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons was constructed as a plasmid for introducing the present invention DNA (A1) into a plant with the particle gun method. First, after digesting plasmid vector pKF19 (Takara Shuzo Company) with restriction enzyme BspHI, the DNA termini were blunt ended by adding nucleotides to the double stranded gap, utilizing KOD DNA polymerase (Toyobo Corporation). Plasmid pKF19  $\Delta$  Bs was obtained by a self-cyclizing the resulting DNA with T4 DNA ligase. The pCRrSt12 obtained in Example 1 was digested with restriction enzyme HindIII and KpnI. The DNA comprising the present rSt12DNA was isolated. Plasmid pKF19  $\Delta$  Bs was digested with restriction enzymes HindIII and KpnI to obtain a DNA of about 2160bp. The 5' termini of said DNA were dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). The DNA comprising the present rSt12DNA obtained from pCRrSt12 was inserted thereto to obtain pKFrSt12 (Fig. 20). Next, the plasmids pCR657Bs and pCR657FBs obtained in Example 16(1) were each digested with restriction enzymes BspHI and SacI to isolate DNA comprising the present invention DNA (A1). Each of these DNA were inserted between the restriction site of BspHI and restriction site of SacI of plasmid pKFrSt12 to obtain plasmid pKFrSt12-657 (Fig. 21) and plasmid pKFrSt12-657F (Fig. 22), which contained a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons.

[0224] Next, each of plasmids pKFrSt12-657 and pKFrSt12-657F was digested with BamHI and SacI to obtain DNA comprising the present invention DNA (A1). Each of these DNA were inserted between the BglII restriction site and SacI restriction site of plasmid pNdG6- $\Delta$ T obtained in Example 16(2) to obtain plasmids pSUM-NdG6-rSt12-657 (Fig. 23) and pSUM-NdG6-rSt12-657F (Fig. 24) wherein the chimeric DNA, in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons, was connected downstream of promoter CR16G6.

**Example 17 Introduction of the Present Invention DNA (A1) into Soybean****(1) Preparation of proliferative somatic embryos**

**[0225]** After dipping pods of soybeans (cultivar: Fayette and Jack) in 1% sodium hypochlorite solution to sterilize, the immature seeds were taken out. The seed coat was exfoliated from the seed to remove the immature embryo having a diameter of 2 to 5 mm. The embryonic axis of the obtained immature embryo was excised with a scalpel to prepare the immature cotyledon. The immature cotyledon was divided into 2 cotyledon parts. Each cotyledon part was placed in the somatic embryo development medium, respectively. The somatic embryo development medium was a solidified medium where 0.2%(w/v) Gelrite was added to Murashige-Skoog medium (described in Murashige T. and Skoog F., *Physiol. Plant* (1962) 15, p473; hereinafter referred to as "MS medium") that was set to a pH of 7.0 and that had 180 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. About 1 month after the placement, the formed globular embryo was transplanted to the somatic embryo growth medium. The somatic embryo growth medium was a solidified medium where 0.2%(w/v) Gelrite was added to MS medium that was set to pH5.8 and that had 90 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. The globular embryo was thereafter transplanted to fresh somatic embryo growth medium 5 to 8 times at intervals of 2 to 3 weeks. Each of the culturing conditions utilizing the above somatic embryo development medium and somatic embryo growth medium was 23 hours of light with 1 hour of darkness and 23 to 25°C for the whole day.

**(2) Introduction of the gene to proliferative somatic embryos**

**[0226]** After the globular embryo obtained in Example 17(1) is transplanted to fresh somatic embryo growth medium and cultured for 2 to 3 days, the globular embryo was utilized to introduce the gene. Plasmids pSUM-NdG6-rSt657, pSUM-NdG6-rSt657F, pSUM-NdG6-rSt12657 and pSUM-NdG6-rSt12657F were coated onto gold particles of a diameter of 1.0 $\mu$ m to conduct the gene introduction employing the particle gun method. The amount of the plasmids was 1.66 $\mu$ g for 1mg of the gold particles. After introducing the gene, the embryo was cultured further for 2 to 3 days. Each of the culturing conditions was 23 hours of light with 1 hour of darkness and 23 to 25°C for the whole day.

**(3) Selection of an somatic embryo with hygromycin**

**[0227]** The globular embryo after introducing the gene obtained in Example 17(2) was transplanted to an somatic embryo selection medium. The somatic embryo selection medium was a solidified medium where 0.2%(w/v) Gelrite and 15mg/L of hygromycin were added to MS medium that was set to pH5.8 and that had 90 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. The surviving globular embryo was thereafter transplanted to fresh somatic embryo selection medium 5 to 8 times at intervals of 2 to 3 weeks. In that time, the somatic embryo selection medium was a solidified medium where 0.2%(w/v) Gelrite and 30mg/L of hygromycin were added to MS medium that was set to pH5.8 and that had 90 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. Each of the culturing conditions utilizing the above somatic embryo selection medium was 23 hours of light with 1 hour of darkness and 23 to 25°C for the whole day.

**(4) Selection of somatic embryo with compound (II)**

**[0228]** The globular embryo after introducing the gene obtained in Example 17(2) was transplanted to an somatic embryo selection medium. The somatic embryo selection medium was a solidified medium where 0.2%(w/v) Gelrite and 0.1mg/L of compound (II) were added to MS medium that was set to pH5.8 and that had 90 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. The surviving globular embryo was thereafter transplanted to fresh somatic embryo selection medium 5 to 8 times at intervals of 2 to 3 weeks. In that time, the somatic embryo selection medium was a solidified medium where 0.2%(w/v) Gelrite and 0.3 to 1mg/L of compound (II) were added to MS medium that was set to pH5.8 and that had 90 $\mu$ M of 2,4-D and 30g/L of sucrose added thereto. Each of the culturing conditions utilizing the above somatic embryo selection medium was 23 hours of light with 1 hour of darkness and 23 to 25°C for the whole day.

**(5) Plant regeneration from the somatic embryo**

**[0229]** The globular embryos selected in Example 17(3) or 17(4) are transplanted to development medium and are cultured for 4 weeks in 23 hours of light with 1 hour of darkness and at 23 to 25°C for the whole day. The development medium is a solidified medium where 0.8% (w/v) of agar (Wako Pure Chemical Industries, Ltd., use for plant tissue cultures) is added to MS medium that is set to pH5.8 and that has 60g/L of maltose added thereto. White to yellow colored cotyledon-type embryos are obtained 6 to 8 weeks thereafter. These cotyledon-type embryos are transplanted to germination medium and cultured for 2 weeks. The germination medium is a solidified medium where 0.2% (w/v) of

Gelrite was added to MS medium that is set to pH5.8 and has 30g/L of sucrose added thereto. As a result, there can be obtained a soybean that has developed leaves and has roots.

#### (6) Acclimation and cultivation of the regenerated plant

[0230] The soybean obtained in Example 17(5) is transplanted to gardening soil and acclimated in an incubation chamber of 23 hours of light with 1 hour of darkness and 23 to 25°C for the whole day. Two (2) weeks thereafter, the rooted plant is transferred to a pot having a diameter of 9cm and cultivated at room temperature. The cultivation conditions at room temperature are natural light conditions at 23°C to 25°C for the whole day. Two to four (2 to 4) months thereafter, the soybean seeds are gathered.

#### (7) Evaluation of the resistance to herbicidal compound (II)

[0231] Leaves of the regenerated plant are gathered and are split equally into 2 pieces along the main vein. Compound (II) is spread onto the full surface of one of the leaf pieces. The other leaf piece is left untreated. These leaf pieces are placed on MS medium containing 0.8% agar and allowed to stand at room temperature for 7 days in light place. Then, each leaf piece is grounded with pestle and mortar in 5 ml of 80% aqueous acetone solution to extract chlorophyll. The extract liquid is diluted 10 fold with 80% aqueous acetone solution and the absorbance is measured at 750 nm, 663nm and 645nm to calculate total chlorophyll content according to the method described by Mackenney G., J. Biol. Chem. (1941) 140, p 315. The degree of resistance to compound (II) can be comparatively evaluated by showing in percentiles the total chlorophyll content of the treated leaf piece with the total chlorophyll content of the untreated leaf piece.

[0232] Further, soil is packed into a plastic pot having a diameter of 10cm and a depth of 10cm. Seeds of the above-described plant are seeded and cultivated in a greenhouse. An emulsion is prepared by mixing 5 parts of compound (II), 6 parts of sorpo13005X (Toho chemicals) and 89 parts of xylene. A certain amount thereof was diluted with water containing 0.1% (v/v) of a sticking agent at a proportion of 1000L for 1 hectare and is spread uniformly with a spray-gun onto the all sides of the foliage from above the plant cultivated in the above pot. After cultivating the plants for 16 days in a greenhouse, the damage to the plants is investigated, and the resistance to compound (II) is evaluated.

#### Example 18 Construction of a Chloroplast Expression Plasmid Having the Present Invention DNA (A1) for Agrobacterium Introduction

[0233] A plasmid for introducing the present invention DNA (A1) into a plant with the agrobacterium method was constructed. First, after binary plasmid vector pBI121 (Clontech Company) was digested with restriction enzyme NotI, the DNA termini were blunt ended by adding nucleotides to the double stranded gap, utilizing DNA polymerase I (Takara Shuzo Corporation). T4 DNA ligase was utilized for self-cyclization. After the obtained plasmid was digested with restriction enzyme EcoRI, the DNA termini were blunt ended by adding nucleotides to the double stranded gap, utilizing DNA polymerase I (Takara Shuzo Corporation). T4 DNA ligase was utilized for self-cyclization to obtain plasmid pBI121 Δ NotIEcoRI. After digesting the plasmid with HindIII, the 5' DNA terminus of the obtained DNA was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). A HindIII-NotI-EcoRI linker (Fig. 25) obtained by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 98 with the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 99 was inserted thereto. Binary plasmid vector pBI121S (Fig. 26) was obtained by self-cyclization. Said plasmid has a structure in which the HindIII-NotI-EcoRI linker was inserted in a direction in which the HindIII restriction site, the NotI restriction site, and the EcoRI restriction site line up in turn from a location close to the β-glucuronidase gene.

[0234] Next, each of plasmids pSUM-NdG6-rSt-657 and pSUM-NdG6-rSt-657F was digested with restriction enzymes HindIII and EcoRI, to obtain from each thereof a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons. These DNA were inserted between the HindIII restriction site and EcoRI restriction site of the above binary plasmid vector pBI121S to obtain plasmids pBI-NdG6-rSt-657 (Fig. 27) and pBI-NdG6-rSt-657F (Fig. 28). Further, each of the above plasmids pSUM-NdG6-rSt12-657 and pSUM-NdG6-rSt12-657F was digested with restriction enzymes HindIII and EcoRI, to obtain from each a chimeric DNA in which the present invention DNA (A1) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. These DNA were inserted between the HindIII restriction site and EcoRI restriction site of the above binary plasmid vector pBI121S to obtain plasmids pBI-NdG6-rSt12-657 (Fig. 29) and pBI-NdG6-rSt12-657F (Fig. 30).

**Example 19 Introduction of the Present Invention DNA (A1) to Tobacco**

[0235] The present invention DNA (A1) was introduced into tobacco with the agrobacterium method, utilizing plasmid pBI-NdG6-rSt-657, plasmid pBI-NdG6-rSt-657F, plasmid pBI-NdG6-rSt12-657 and plasmid pBI-NdG6-rSt12-657F, obtained in Example 18.

[0236] First, the plasmids pBI-NdG6-rSt-657, pBI-NdG6-rSt-657F, pBI-NdG6-rSt12-657 and pBI-NdG6-rSt12-657F were introduced into *Agrobacterium tumefaciens* LBA4404 (Clontech Company), respectively. Transformed agrobacterium strains bearing pBI-NdG6-rSt-657, pBI-NdG6-rSt-657F, pBI-NdG6-rSt12-657 or pBI-NdG6-rSt12-657F were isolated by culturing the resultant transformants in LB agar medium (0.5% yeast extract, 1.0% Bacto tryptone, 0.5% NaCl) containing 300 mg/L streptomycin, 100 mg/L rifampicin and 25 mg/L kanamycin and by selecting the resistant colonies.

[0237] Then, according to the method described in Manual for Gene Manipulation of Plant (by Hirofumi UCHIMIYA, Kodan-sha Scientific, 1992), the gene was introduced into tobacco. Agrobacterium strains bearing the above plasmids were each cultured at 28°C overnight in LB medium containing 300 mg/L streptomycin, 100 mg/L rifampicin and 25 mg/L kanamycin, and then leaf pieces of tobacco (*Nicotiana tabacum* strain SR1) cultured sterily were dipped in the liquid culture medium. The leaf pieces were planted and cultured at room temperature for 2 days in the light in MS agar medium (MS inorganic salts, MS vitamins, 3% sucrose and 0.8% agar; described in Murashige T. and Skoog F., *Physiol. Plant.* (1962) 15, p 473) containing 0.1 mg/L of naphthalene acetic acid and 1.0 mg/L of benzyl aminopurine. Then, the leaf pieces were washed with sterilized water and cultured for 7 days on MS agar medium containing 0.1 mg/L of naphthalene acetic acid, 1.0 mg/L of benzyl aminopurine and 500mg/L of cefotaxime. Next, the leaf pieces were transplanted and cultured in MS agar medium containing 0.1 mg/L of naphthalene acetic acid, 1.0mg/L of benzyl aminopurine, 500mg/L of cefotaxime and 100mg/L of kanamycin. The culture was conducted continuously for 4 months while transplanting the leaf pieces to fresh medium of the same composition at intervals of 4 weeks. At that time, the unfixed buds developing from the leaf pieces were transplanted and rooted in MS agar medium containing 300mg/L of cefotaxime and 50mg/L of kanamycin to obtain regenerated bodies. The regenerated bodies were transplanted to and cultured in MS agar medium containing 50mg/L of kanamycin to obtain, respectively, a transgenic tobacco to which the T-DNA region of pBI-NdG6-rSt-657, pBI-NdG6-rSt-657F, pBI-NdG6-rSt12-657 or pBI-NdG6-rSt12-657F has been introduced.

[0238] Further, the plasmid pBI121S obtained in Example 18 was introduced into tobacco with the agrobacterium method. A transformed agrobacterium strain bearing pBI121S was isolated similarly to the above, other than utilizing plasmid pBI121S instead of pBI-NdG6-rSt-657, pBI-NdG6-rSt-657F, pBI-NdG6-rSt12-657 and pBI-NdG6-rSt12-657F. Next, a transgenic tobacco to which the T-DNA region of plasmid pBI121S has been introduced was obtained similarly to the above, utilizing said transformed agrobacterium.

[0239] Three (3) leaves were taken from the transgenic tobacco. Each leaf was divided into 4 pieces in which each piece was 5 to 7mm wide. Each of the leaf pieces were planted onto MS agar medium containing 0.1mg/L of compound (II) and cultured in the light at room temperature. On the 7th day of culturing, the herbicidal damage of each of the leaf pieces was observed. The leaf pieces derived from the tobacco to which the control DNA (T-DNA region of plasmid pBI121S) was introduced turned white and withered. In contrast, the leaf pieces derived from the tobacco to which the present invention DNA (A1) (the T-DNA region of plasmid pBI-NdG6-rSt-657, plasmid pBI-NdG6-rSt12-657, pBI-NdG6-rSt-657F or pBI-NdG6-rSt12-657F) was introduced grew continuously.

**Example 20 Introduction of the Present Invention DNA into a Plant**

[0240] Plasmids were constructed for introducing the present invention DNA (A2) with the particle gun method and the agrobacterium method. First, the present invention DNA (A2) having the nucleotide sequence shown in SEQ ID NO: 7 was amplified by PCR. The PCR was conducted by utilizing as the template the genomic DNA of *Actinomyces Saccharopolyspora taberi* JCM9383t and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 100 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 101. Said PCR utilized the Expand High Fidelity PCR System (Boehringer Company). There were conducted after maintaining once 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 60 seconds; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds were added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. Plasmids pCR923Sp (Fig. 31) was produced by inserting the amplified DNA into the PCR product cloning region of pCR2.1-TOPO (Invitrogen Company). Next, the plasmid was introduced into *E. Coli* JM109 competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v2.0 (PE Applied Biosystems Company) and DNA sequencer 373S (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pCR923Sp has the nucleotide sequence shown in SEQ ID NO: 7.

[0241] Plasmid pKFrSt12, designed in Example 16(3), was digested with restriction enzymes BamHI and SacI to isolate a DNA comprising the present rSt12DNA. Said DNA was inserted between the BglII restriction site and SacI restriction site of pNdG6-Δ T obtained in Example 16(2) to obtain plasmid pNdG6-rSt12 (Fig. 32). Plasmid pCR923Sp was digested with restriction enzymes SphI and KpnI to obtain the DNA comprising the present invention DNA (A2).  
 5 Plasmid pNdG6-rSt12 was digested with restriction enzymes SphI and KpnI to remove the DNA encoding the 12 amino acids of the mature protein of soybean (cv. Jack) RuBPC small subunit. In its place, the above DNA containing the present invention DNA (A2) obtained from plasmid pCR923Sp was inserted to obtain pSUM-NdG6-rSt-923 (Fig. 33) wherein the CR16G6 promoter has connected downstream therefrom the chimeric DNA in which said DNA was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit, without a change of frame in the codons.

[0242] Next, plasmid pCR923Sp was digested with restriction enzyme SphI. After blunting the ends of the obtained DNA with KOD DNA polymerase, said DNA is further digested with restriction enzyme KpnI to isolate a DNA containing the present invention DNA (A2). Plasmid pKFrSt12 produced in Example 16(3) was digested with restriction enzyme BspHI. After blunting the ends of the obtained DNA with KOD DNA polymerase, said DNA is further digested with  
 15 restriction enzyme KpnI to remove DNA of about 20bp. In its place, the above DNA containing the present invention DNA (A2) obtained from plasmid pCR923Sp was inserted to obtain plasmid pKFrSt12-923 (Fig. 34) comprising the chimeric DNA in which the present invention DNA (A2) was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. pKFrSt12-923 was digested with restriction  
 20 enzymes SphI and KpnI to obtain the chimeric DNA in which the present invention DNA (A2) and the DNA encoding the first 12 amino acids of the mature protein of soybean (cv. Jack) RuBPC small subunit are connected. Plasmid pNdG6-rSt12 was digested with restriction enzymes SphI and KpnI to remove the DNA encoding the 12 amino acids of the mature protein of soybean (cv. Jack) RuBPC small subunit. In its place, the above chimeric DNA obtained from plasmid pKFrSt12-923 was inserted to obtain plasmid pSUM-NdG6-rSt12-923 (Fig. 35) in which the CR16G6 promoter has connected downstream therefrom the chimeric DNA in which said DNA containing the present invention DNA (A2)  
 25 was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frame in the codons.

[0243] The present invention DNA (A2) was introduced into soybean with the particle gun method with the identical procedures of the method described in Example 17, utilizing the obtained plasmids pSUM-NdG6-rSt-923 and  
 30 pSUM-NdG6-rSt12-923.

[0244] The above plasmid pSUM-NdG6-rSt-923 was digested with restriction enzymes HindIII and EcoRI to isolate the DNA comprising the chimeric DNA in which said DNA containing the present invention DNA (A2) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit, without a change of frame in the codons. As in producing pBI-NdG6-rSt657 in Example 18, the above DNA containing  
 35 the chimeric DNA obtained from plasmid pSUM-NdG6-rSt-923 was inserted between the HindIII restriction site and the EcoRI restriction site of binary vector pBI121S to obtain pBI-NdG6-rSt-923 (Fig. 36). Further, the above plasmid pSUM-NdG6-rSt12-923 was digested with HindIII and EcoRI, to isolate the DNA containing chimeric DNA in which said DNA containing the present invention DNA (A2) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the  
 40 mature protein, without a change of frame in the codons. The chimeric DNA obtained from pSUM-NdG6-rSt12-923 was inserted between the HindIII restriction site and EcoRI restriction sites of binary vector pBI121S to obtain pBI-NdG6-rSt12-923 (Fig. 37).

[0245] Each of the plasmids pBI-NdG6-rSt-923 and pBI-NdG6-rSt12-923 was introduced into *Agrobacterium tumefaciens* LBA4404. The resultant transformants were cultured in LB medium containing 300μg/ml of streptomycin, 100μg/  
 45 ml of rifampicin and 25μg/ml of kanamycin. The transformants were selected to isolate *agrobacterium* strains bearing pBI-NdG6-rSt-923 or pBI-NdG6-rSt12-923.

[0246] Leaf pieces of sterily cultured tobacco were infected with each of the *agrobacterium* strain bearing pBI-NdG6-rSt-923 and the *agrobacterium* strain bearing pBI-NdG6-rSt12-923. Tobaccos in which the present invention DNA (A2) has been introduced were obtained under the procedures similar to the methods described in Example 19.

[0247] Three (3) leaves were taken from the obtained transgenic tobacco. Each leaf was divided into 4 pieces in which each piece was 5 to 7mm wide. Each of the leaf pieces were planted onto MS agar medium containing 0.1mg/L of compound (II) and cultured in the light at room temperature. On the 7th day of culturing, the herbicidal damage of  
 50 each of the leaf pieces was observed. The leaf pieces derived from the tobacco to which the control DNA (T-DNA region of plasmid pBI121S) was introduced turned white and withered. In contrast, the leaf pieces derived from the tobacco to which the present invention DNA (A2) (the T-DNA region of plasmid pBI-NdG6-rSt923 or plasmid pBI-NdG6-rSt12-923) was introduced grew continuously.

**Example 21 Introduction of the Present Invention DNA (A3) into Tobacco**

**[0248]** Plasmids were constructed for introducing the present invention DNA (A3) into a plant with the particle gun method and with the agrobacterium method.

**[0249]** First, the present invention DNA (A3) having the nucleotide sequence shown in SEQ ID NO: 8 was amplified by PCR. The PCR was conducted by utilizing as the template the genomic DNA of *Actinomyces Streptomyces testaceus* ATCC21469 and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 102 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 103. Said PCR utilized the Expand High Fidelity PCR System (Boehringer Company). There were conducted after maintaining once 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds were added to the maintenance at 72°C for each cycle); and then maintaining once 72°C for 7 minutes. Plasmid pCR671ET (Fig. 38) was produced by inserting the amplified DNA into the PCR product cloning region of pCR2.1 (Invitrogen Company). Further, plasmid pCR671Bs (Fig. 39) was obtained with the procedures similar to the method described above, other than utilizing as the PCR primers, the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 104 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 103. Next, the plasmids were introduced into *E. Coli* JM109 competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v2.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmids pCR671ET and pCR671Bs have the nucleotide sequence shown in SEQ ID NO: 8.

**[0250]** Plasmid pCR671ET was digested with restriction enzymes EcoT221 and KpnI to isolate DNA comprising the present invention DNA (A3). Said DNA was inserted between the EcoT221 restriction site and the KpnI restriction site to obtain plasmid pUCrSt671 (Fig. 40) comprising the chimeric DNA in which the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit, without a change of frame in the codons. Plasmid pUCrSt671 was digested with restriction enzymes NheI and KpnI to isolate DNA comprising the present invention DNA (A3). Plasmid pNdG6-rSt12, obtained in Example 16(2), was digested with restriction enzymes NheI and KpnI to remove DNA of about 80bp. In its place, the above DNA containing the present invention DNA (A3) obtained from plasmid pUCrSt671 was inserted to obtain pSUM-NdG6-rSt-671 (Fig. 41) wherein the CR16G6 promoter has connected downstream therefrom the chimeric DNA in which the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit, without a change of frame in the codons.

**[0251]** Plasmid pCR671 Bs was digested with restriction enzymes BspHI and KpnI to isolate a DNA comprising the present invention DNA (A3). Said DNA was inserted between the BspHI restriction site and KpnI restriction site of pKFrSt12 obtained in Example 16(3) to obtain plasmid pKFrSt12-671 (Fig. 42) containing the chimeric DNA in which the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frame in the codons. Plasmid pNdG6-rSt12 obtained in Example 20 was digested with restriction enzymes NheI and KpnI to remove DNA of about 80bp. In its place, the above DNA containing the present invention DNA (A3) obtained from plasmid pKFrSt12-671 was inserted to obtain pSUM-NdG6-rSt12-671 (Fig. 43) wherein the CR16G6 promoter has connected downstream therefrom the chimeric DNA in which the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frame in the codons.

**[0252]** The present invention DNA (A3) was introduced into soybean with the particle gun method with procedures similar to the method described in Example 17, utilizing the obtained plasmids pSUM-NdG6-rSt-671 and pSUM-NdG6-rSt12-671.

**[0253]** The above plasmid pSUM-NdG6-rSt-671 was digested with restriction enzymes HindIII and EcoRI to isolate the chimeric DNA in which the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit, without a change of frame in the codons. The above DNA containing the chimeric DNA obtained from plasmid pSUM-NdG6-rSt-671 was inserted between the HindIII restriction site and the EcoRI restriction site of binary vector plasmid pBI121S obtained in Example 18, to obtain pBI-NdG6-rSt-671 (Fig. 44). Further, the above plasmid pSUM-NdG6-rSt12-671 was digested with restriction enzymes HindIII and EcoRI, to isolate the DNA containing chimeric DNA in which said DNA containing the present invention DNA (A3) was connected immediately after the sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frame in the codons. The chimeric DNA obtained from pSUM-NdG6-rSt12-671 was inserted between the HindIII restriction site and EcoRI restriction sites of binary plasmid vector pBI121S to obtain pBI-NdG6-rSt12-671 (Fig. 45).

[0254] Each of the plasmids pBI-NdG6-rSt-671 and pBI-NdG6-rSt12-671 were introduced into *Agrobacterium tumefaciens* LBA4404. The resultant transformants were cultured in LB medium containing 300µg/ml of streptomycin, 100µg/ml of rifampicin and 25µg/ml of kanamycin. The transformants were selected to isolate agrobacterium strains bearing pBI-NdG6-rSt-671 or pBI-NdG6-rSt12-671.

[0255] Leaf pieces of sterily cultured tobacco were infected with each of the agrobacterium strain bearing pBI-NdG6-rSt-671 and the agrobacterium strain bearing pBI-NdG6-rSt12-671. Tobaccos in which the present invention DNA (A3) has been introduced were obtained under the procedures similar to the methods described in Example 19.

[0256] Three (3) leaves are taken from the transgenic tobaccos. Each leaf is divided into 4 pieces in which each piece was 5 to 7mm wide. Each of the leaf pieces are planted onto MS agar medium containing 0.1mg/L of compound (II) and cultured in the light at room temperature. On the 7th day of culturing, the herbicidal damage of each of the leaf pieces is observed.

## Example 22 Expression of the Present Invention Protein (B1) in E. Coli

### (1) Production of a transformed E. coli of the present invention DNA (B1)

[0257] PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Streptomyces phaeochromogenes* IFO12898 in Example 3(1). The PCR reaction solution amounted to 50µl by adding 300ng of the above chromosomal DNA, 4µl of dNTP mix (a mixture of 2.5mM of each of the 4 types of dNTP), 5µl of 10x ExTaq buffer, 0.5µl of ExTaq polymerase (Takara Shuzo Company), distilled water and 200nM of each of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 105 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 53. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes; repeating 25 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 90seconds; and then maintaining 72°C for 4 minutes. The reaction solution after the maintenance and the vector pCR2.1-TOPO (Invitrogen Company) were ligated according to the instructions attached to said vector and were introduced into E. Coli TOP10F'. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). Sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 67 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 68. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 15 was designated as pCR657FD.

[0258] Next, pCR657FD was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 200bp was cut from the gel. The DNA was purified from the recovered gels by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 15, in which the DNA of about 200bp encoding the present invention protein (B1) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN657FD. The plasmid pKSN657FD was introduced into E. coli JM109. The obtained E. coli transformant was designated JM109/pKSN657FD. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

### (2) Expression of the present invention protein (B1) in E. coli and recovery of said protein

[0259] E. coli JM109/pKSN657FD and E. Coli JM109/pKSN2 were each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. Thirty (30) minutes after the OD660 reached about 0.5, IPTG was added to a final concentration of 1 mM, and there was further culturing for 20 hours.

[0260] The cells were recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of said buffer containing 1mM PMSF. The obtained cell suspensions were subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants were recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the

supernatant fraction obtained from *E. coli* JM109/pKSN657FD is referred to as "*E. coli* pKSN657FD extract" and the supernatant fraction obtained from *E. coli* JM109/pKSN2 is referred to as "*E. coli* pKSN2 extract". A microliter (1 $\mu$ l) of the above supernatant fractions was analyzed on a 15% to 25% SDS-PAGE and stained with CBB. As a result, notably more intense bands were identified in the *E. coli* pKSN657FD extract than the *E. coli* pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 7kDa. It was shown that *E. coli* JM109/pKSN657FD expressed the present invention protein (B1).

### (3) Use of the present invention protein (B1) for a reaction system of converting compound (II) to compound (III)

**[0261]** Reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with  $^{14}$ C, 2mM of  $\beta$ -NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 9 $\mu$ l of the *E. coli* pKSN657FD extract recovered in Example 22(2), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 15 $\mu$ l of the *E. coli* pKSN657F extract recovered in Example 4(2) (hereinafter referred to as "component D"). Further, there were prepared reaction solutions in which 2mg/ml of ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company) was added in the place of the *E. coli* pKSN657FD extract and a reaction solution in which nothing was added in the place of the *E. coli* pKSN657FD extract. Such reaction solutions were maintained similarly. Three microliters (3 $\mu$ l) of 2N HCl and 90  $\mu$ l of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75 $\mu$ l of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0 $\mu$ l of ethyl acetate. Five microliters (5.0 $\mu$ l) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with  $^{14}$ C were examined (Rf value 0.24 and 0.29). The results are shown in Table 13.

Table 13

Reaction components						spot of compound (III)
component A	<i>E. coli</i> extract	component B	component C	component D	compound (II) labeled with $^{14}$ C	
+	pKSN657FD	-	+	+	+	+
+	-	-	+	+	+	-
+	-	+	+	+	+	+

### Example 23 Expression of the Present Invention Protein (B2) in *E. Coli*

#### (1) Production of a transformed *E. coli* having the present invention DNA (B2)

**[0262]** PCR is conducted by utilizing as a template the chromosomal DNA prepared from *Saccharopolyspora taberi* JCM9383t in Example 6(1). The PCR reaction solution amounts to 50 $\mu$ l by adding 300ng of the above chromosomal DNA, 4 $\mu$ l of dNTP mix (a mixture of 2.5mM of each of the 4 types of dNTP), 5 $\mu$ l of 10x ExTaq buffer, 0.5 $\mu$ l of ExTaq polymerase (Takara Shuzo Company), distilled water and 200nM of each of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 106 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 63. The reaction conditions of the PCR are after maintaining 97°C for 2 minutes; repeating 25 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 90seconds; and then maintaining 72°C for 4 minutes. The reaction solution after the maintenance and the vector pCR2.1-TOPO (Invitrogen Company) are ligated according to the instructions attached to said vector and introduced into *E. Coli* TOP10F'. The plasmid DNA are prepared from the obtained *E. coli* transformants, utilizing QIAprep Spin Miniprep Kit (Qiagen Company). Sequencing reactions are conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 67 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 68. The sequencing reactions utilize the obtained plasmid DNA as the template. The

reaction products are analyzed with a DNA sequencer 373A (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 16 is designated as pCR923FD.

[0263] Next, plasmid pCR923FD is digested with restriction enzymes NdeI and HindIII. The digestion products are subjected to agarose gel electrophoresis. The gel area containing a DNA of about 200bp is cut from the gel. The DNA is purified from the recovered gels by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII are ligated with ligation kit Ver. 1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. Coli JM109. The plasmid DNA are prepared from the obtained E. coli transformants. The structures thereof are analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 16, in which the DNA of about 200bp encoding the present invention protein (B2) is inserted between the NdeI site and the HindIII site of pKSN2 is designated as pKSN923FD. The plasmid pKSN923FD is introduced into E. coli JM109. The obtained E. coli transformant is designated as JM109/pKSN923FD. Further, plasmid pKSN2 is introduced into E. coli JM109. The obtained E. coli transformant is designated as JM109/pKSN2.

## (2) Expression of the present invention protein (B2) in E. coli and recovery of said protein

[0264] E. coli JM109/pKSN923FD and E. Coli JM109/pKSN2 are each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM of dipotassium hydrogenphosphate) containing 50μg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium is transferred to 100ml of TB medium containing 50μg/ml of ampicillin and cultured at 26°C. Thirty (30) minutes after the OD660 reached about 0.5, IPTG is added to a final concentration of 1mM, and there is further culturing for 20 hours.

[0265] The cells are recovered from each of the culture mediums, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of said buffer containing 1mM PMSF. The obtained cell suspensions are subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants are recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN923FD is referred to as "E. coli pKSN923FD extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract"). A microliter (1μl) of the above supernatant fractions is analyzed on a 15% to 25% SDS-PAGE and stained with CBB. By detecting notably more intense bands in the E. coli pKSN923FD extract than the E. coli pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 7kDa, it is possible to confirm to E. coli expression of the present invention protein (B2).

## (3) Use of the present invention protein (B2) for a reaction system of converting compound (II) to compound (III)

[0266] Reaction solutions of 30μl are prepared and maintained for 10 minutes at 30°C. The reaction solutions consist of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 9μl of the E. coli pKSN923FD extract recovered in Example 23(3), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 15μl of the E. coli pKSN657F extract recovered in Example 4(2) (hereinafter referred to as "component D"). Further, there are prepared reaction solutions in which 2mg/ml of ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company) is added in the place of the E. coli pKSN923FD extract and a reaction solution in which nothing is added in the place of the E. coli pKSN923FD extract. Such reaction solutions are maintained similarly. Three microliters (3μl) of 2N HCl and 90 μl of ethyl acetate are added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions are centrifuged at 8,000xg to recover 75μl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue is dissolved in 6.0μl of ethyl acetate. Five microliters (5.0μl) thereof is spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate is developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents are then allowed to evaporate. The TLC plate is exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate is analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C are examined (Rf value 0.24 and 0.29). By confirming that compound (III) is produced in the reaction including component A, E. coli pKSN923FD extract, component C and component D, it can be confirmed that the present invention protein (B2) can be used instead of the ferredoxin derived from spinach in a reaction system of converting compound (II) to compound (III).

**Example 24 Expression of the Present Invention Protein (B3) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA (B3)**

5 [0267] PCR is conducted similarly to the methods described in Example 23(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces testaceus* ATCC 21469 in Example 11(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 107 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 72. Plasmid pCR671FD having the nucleotide sequence shown in SEQ ID NO: 17 is obtained similarly to the method described in Example 23(1) utilizing the obtained reaction solution.

10 [0268] Next, utilizing said plasmid, plasmid pKSN671FD in which the present invention DNA (B3) is inserted between the *Nde*I site and *Hind*III site of pKSN2 is obtained similarly to the method described in Example 23(1). By introducing the plasmid into E. coli JM109, E. coli JM109/pKSN671FD having the present invention DNA (B3) can be obtained.

**(2) Expression of the present invention protein (B3) in E. coli and recovery of said protein**

15 [0269] Utilizing E. coli JM109/pKSN671FD, supernatant fractions (hereinafter referred to as "E. coli pKSN671FD extract") are recovered similarly to the method described in Example 23(2). A microliter (1 $\mu$ l) of the above supernatant fractions is analyzed on a 15% to 25% SDS-PAGE and stained with CBB. As a result, by detecting notably more intense bands in the E. coli pKSN671FD extract than the E. coli pKSN2 extract, at the electrophoresis location corresponding to the molecular weight of 7kDa, it is possible to confirm the expression of the present invention protein (B3) in E. coli.

**(3) Use of the present invention protein (B3) for a reaction system of converting compound (II) to compound (III),**

25 [0270] Other than utilizing E. coli pKSN671FD extract recovered in Example 24(2), the spot corresponding to compound (III) labeled with  $^{14}$ C (Rf values 0.24 and 0.29) is confirmed similarly to the method described in Example 23(3). By confirming that compound (III) is produced in the reaction including component A, E. coli pKSN671FD extract, component C and component D, it can be confirmed that the present invention protein (B3) can be used instead of the ferredoxin derived from spinach in a reaction system of converting compound (II) to compound (III).

**Example 25 Preparation of the present invention protein (A4)****(1) Preparation of the crude cell extract**

35 [0271] A frozen stock of *Streptomyces achromogenes* IFO12735 was added to 10ml of A medium (0.1%(w/v) of glucose, 0.5%(w/v) tryptone, 0.5%(w/v) yeast extract, 0.1%(w/v) of dipotassium hydrogenphosphate, pH7.0) in a large test tube and incubated with shaking at 30°C for 1 day to obtain a pre-culture. Eight milliliters (8ml) of the pre-culture was added to 200ml of A medium and was incubated with rotary shaking in a 500ml baffled flask at 30°C for 2 days. Cell pellets were recovered by centrifuging (3,000xg, 10 min.) the resulting culture. These cell pellets were suspended in 100ml of B medium (1%(w/v) glucose, 0.1% beef extract, 0.2%(w/v) tryptose) containing compound (II) at 100ppm and were incubated with reciprocal shaking in a 500ml Sakaguchi flask for 20 hours at 30°C. Cell pellets were recovered by centrifuging (3,000xg, 10 min.) 2L of the resulting culture. The resulting cell pellets were washed twice with 1L of 0.1M potassium phosphate buffer (pH7.0) to provide 136g of the cell pellets.

45 [0272] These cell pellets were suspended in 0.1M potassium phosphate buffer (pH7.0) at 1ml to 2ml for 1g of the cell pellets. A millimolar of (1mM) PMSF, 5mM of benzamidine HCl, 1mM of EDTA, 3 $\mu$ g/ml of leupeptin, 3 $\mu$ g/ml of pepstatin and 1mM of dithiothritol were added to the cell suspension. A cell lysate solution was obtained by disrupting twice repetitively the suspension with a French press (1000kg/cm<sup>2</sup>) (Ohtake Seisakusho). After centrifuging the cell lysate solution (40,000xg, 30 minutes), the supernatant was recovered and centrifuged for 1 hour at 150,000xg to recover the supernatant (hereinafter referred to as the "crude cell extract")

**(2) Determination of the ability of converting compound (II) to compound (III)**

55 [0273] There was prepared 30 $\mu$ l of a reaction solution consisting of 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with  $^{14}$ C, 2.4mM of  $\beta$ -NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 0.5mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 15 $\mu$ l of the crude cell extract recovered in Example 25(1). The reaction solution was maintained at 30°C for a hour. Further, there was prepared and maintained similarly a reaction solution having no addition of at least one component utilized

in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3 $\mu$ l) of 2N HCl and 90  $\mu$ l of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 75 $\mu$ l of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 6.0 $\mu$ l of ethyl acetate. Five microliters (5.0 $\mu$ l) thereof was spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate was developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents were then allowed to evaporate. The TLC plate was exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). The results are shown in Table 14.

Table 14

Reaction components					spot of compound (III)
component A	component B	component C	crude cell extract	compound (II) labeled with <sup>14</sup> C	
+	+	+	-	+	-
+	+	+	+	+	+
-	+	+	+	+	-
+	-	-	+	+	-

### (3) Fractionation of the crude cell extract

[0274] Ammonium sulfate was added to the crude cell extract obtained in Example 25(1) to amount to 45% saturation. After stirring in ice-cooled conditions, the supernatant was recovered by centrifuging for 30 minutes at 12,000xg. After adding ammonium sulfate to the obtained supernatant to amount to 55% saturation and stirring in ice-cooled conditions, a pellet was recovered by centrifuging for 10 minutes at 12,000xg. The pellet was dissolved with 12.5ml of 20mM bistrispropane buffer (pH7.0). This solution was subjected to a PD10 column (Amersham Pharmacia Company) and eluted with 20mM of bistrispropane buffer (pH7.0) to recover 17.5ml of fractions containing proteins (hereinafter referred to as the "45-55% ammonium sulfate fraction").

### (4) Isolation of the present invention protein (A4)

[0275] The 45-55% ammonium sulfate fraction prepared in Example 25(3) was injected into a HiLoad26/10 Q Sepharose HP column (Amersham Pharmacia Company). Next, after flowing 100ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.004M/minute, range of NaCl concentration was from 0M to 1M, flow rate was 4ml/minute) to fraction recover 30ml of fractions eluting at the NaCl concentration of from 0.12M to 0.165M. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 20mM bistrispropane buffer (pH7.0) to recover the fractions containing protein.

[0276] The recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) with the elution with Buffer A (2mM potassium phosphate buffer containing 1.5mM of NaCl, pH 7.0), in order to recover the fractions containing protein. Next, the fractions were injected into a Bio-Scale Ceramic Hydroxyapatite Type I column CHT10-I (BioRad Company). Twenty milliliters (20ml) of Buffer A was flown into the column. Subsequently, Buffer A was flown with a linear gradient of Buffer B (100mM potassium phosphate buffer containing 0.03mM of NaCl; the linear gradient started at 100% Buffer A to increase to 50% Buffer B over a 100 minute period, flow rate was 2ml/minute) to fraction recover the fractions eluting at a Buffer B concentration of from 4% to 6%. Further, the recovered fractions were subjected to a PD10 column (Amersham Pharmacia Biotech Company) and eluted with 0.05M potassium phosphate buffer (pH7.0) to recover the fractions containing protein.

[0277] A similar amount of 0.05M potassium phosphate buffer (pH7.0) containing 2.0M ammonium sulfate was added and mixed into the recovered fractions. The recovered fractions were then injected into a 1ml RESOURCE PHE column (Amersham Pharmacia Biotech Company). After flowing 5ml of 0.05M potassium phosphate buffer (pH7.0) containing 1M ammonium sulfate, the 0.05M potassium phosphate buffer (pH7.0) was flown with a linear gradient of ammonium sulfate (gradient of the ammonium sulfate concentration was 0.1M/minute, range of NaCl concentration was 1M to 0M, flow rate was 2ml/minute) to fraction recover the fractions eluting at an ammonium sulfate concentration of from about

0.4M to 0.5M. The protein contained in each of the fractions were analyzed on a 10%-20% SDS-PAGE.

[0278] Instead of the crude cell extract in the reaction solutions described in Example 25(2), the recovered fractions were added and maintained in the presence of component A, component B, component C and compound (II) labeled with  $^{14}\text{C}$ , similarly to Example 25(2). The reaction solutions after the maintenance were TLC analyzed to examine the intensity of the spots corresponding to compound (III) labeled with  $^{14}\text{C}$ . Said protein moving to a location of about 45kDa in the above SDS-PAGE was recovered from the gel and was subjected to an amino acid sequence analysis with a protein sequencer (Applied Biosystems Company, Procise 494HT, pulsed liquid method) to sequence the N terminus amino acid sequence. As a result, the amino acid sequence shown in SEQ ID NO: 113 was provided.

## Example 26 Obtaining the Present Invention DNA (A4)

### (1) Preparation of the chromosomal DNA of *Streptomyces achromogenes* IFO 12735

[0279] *Streptomyces achromogenes* IFO 12735 cultured with shaking at 30°C for 1 day to 3 days in 50ml of YEME medium (0.3%(w/v) yeast extract, 0.5%(w/v) bacto-peptone, 0.3%(w/v) malt extract, 1.0%(w/v) glucose, 34%(w/v) sucrose and 0.2%(v/v) 2.5M  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ ). The cells were recovered. The obtained cells were suspended in YEME medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was resuspended in buffer (100mM Tris-HCl (pH8.0), 100mM EDTA, 10mM NaCl) at 1ml per 200mg of the cells. Two hundred micrograms per milliliter (200 $\mu\text{g}/\text{ml}$ ) of egg-white lysozyme were added. The cell suspension was shaken at 30°C for a hour. Further, 0.5% of SDS and 1mg/ml of Proteinase K was added. The cell suspension was incubated at 55°C for 3 hours. The cell suspension was extracted twice with phenol-chloroform-isoamyl alcohol to recover each of the aqueous layers. Next, there was one extraction with chloroform-isoamyl alcohol to recover the aqueous layer. The chromosomal DNA was obtained by ethanol precipitating the aqueous layer.

### (2) Preparation of the chromosomal DNA library of *Streptomyces achromogenes* IFO 12735

[0280] Thirty-eight micrograms (38 $\mu\text{g}$ ) of the chromosomal DNA prepared in Example 26(1) were digested with 3.2U of restriction enzyme *Sau3A1* at 37°C for 60 minutes. The obtained digestion solution was separated with 1% agarose gel electrophoresis. The DNA of about 2.0kbp was recovered from the gel. The DNA was purified with QIAquick Gel Extraction Kit (Qiagen Company) according to the instructions attached to said kit and was concentrated with an ethanol precipitation to obtain 20 $\mu\text{l}$  of the solution containing the target DNA. Eight microliters (8 $\mu\text{l}$ ) of the DNA solution, 100ng of plasmid vector pUC118 digested with restriction enzyme *Bam*HI and treated with dephosphorylation and 16 $\mu\text{l}$  of the I solution from Ligation Kit Ver. 2 (Takara Shuzo Company) were mixed and maintained for 3 hours at 16°C. *E. coli* DH5  $\alpha$  were transformed utilizing the ligation solution and were spread onto LB agar medium containing 50mg/l of ampicillin to culture overnight at 37°C. The obtained colonies were recovered from an agar medium. The plasmid was extracted. The obtained plasmids were designated as the chromosomal DNA library.

### (3) Isolation of the present invention DNA (A4)

[0281] PCR was conducted by utilizing the chromosomal DNA prepared in Example 26(2) as the template. As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 114 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 57. The nucleotide sequence shown in SEQ ID NO: 114 was designed based on the amino acid sequence shown in SEQ ID NO: 113. The Expand HiFi PCR System (Boehringer Mannheim Company) was utilized to prepare the reaction solution. The PCR reaction solution amounted to 25 $\mu\text{l}$  by adding 2.5 $\mu\text{l}$  of the above chromosomal DNA library, the 2 primers each amounting to 7.5pmol, 0.2 $\mu\text{l}$  of dNTP mix (a mixture of 2mM of each of the 4 types of dNTP), 0.2 $\mu\text{l}$  of 10x buffer (containing  $\text{MgCl}_2$ ), 0.38 $\mu\text{l}$  of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minute, repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 65°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, 2.5 $\mu\text{l}$  of the reaction solution was utilized as a template solution for conducting PCR for a second time. As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 115 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 57. The nucleotide sequence shown in SEQ ID NO: 115 was designed based on the amino acid sequence shown in SEQ ID NO: 113. Similar to the above method, the Expand HiFi PCR System (Boehringer Mannheim Company) was utilized to conduct PCR. The reaction solution after the maintenance was subjected to 2% agarose gel electrophoresis. The gel area containing the DNA of about 800bp was recovered.

The DNA was purified from the recovered gel by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to the TA cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and was introduced into E. Coli TOP10F'. The plasmid DNA was prepared from the obtained E. coli transformant, utilizing Qiagen Tip20 (Qiagen Company). A sequencing reaction was conducted with Big Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing a primers having the nucleotide sequence shown in SEQ ID NO: 67 and a primer having the nucleotide sequence shown in SEQ ID NO: 68. The obtained plasmid was utilized as a template in the sequencing reaction. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 57 to 832 of the nucleotide sequence shown in SEQ ID NO: 110 was provided. In the provided nucleotide sequence, nucleotides 58-60 of the nucleotide sequence shown in SEQ ID NO: 110 encoded amino acid 20 in the amino acid sequence shown in SEQ ID NO: 113.

**[0282]** Next, PCR was conducted with the Expand HiFi PCR System (Boehringer Mannheim Company) under the above-described conditions, utilizing as a template the chromosomal DNA library prepared in Example 26(2). As the primers, there was utilized a primer pairing of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 116 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 59. The amplified DNA of about 1.4kbp was cloned into the cloning vector pCRII-TOPO. The plasmid DNA was prepared from the obtained E. coli transformants, utilizing Qiagen Tip20 (Qiagen Company). A sequencing reaction was conducted with Big Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 67 and a primer having the nucleotide sequence shown in SEQ ID NO: 68. The obtained plasmid was utilized as a template in the sequencing reaction. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 1 to 58 in the nucleotide sequence shown in SEQ ID NO: 110 was provided.

**[0283]** The cloning of the DNA elongating downstream from the 3' terminus of the nucleotide shown as nucleotide 832 of the nucleotide sequence shown in SEQ ID NO: 110 was conducted. Specifically, 13μg of the chromosomal DNA of *Streptomyces achromogenes* IFO 12735 prepared in Example 26(1) was digested overnight with 200U of restriction enzyme HincII at 37°C. After a phenol extraction, the DNA was purified by an ethanol precipitation. The obtained DNA was used to produce 20μl of an aqueous solution. Four microliters (4μl) thereof, 1.9μl of 15μM Genome Walker Adaptor, 1.6μl of 10x ligation buffer and 0.5μl of 6U/μl T4 ligase were mixed and maintained overnight at 16°C. After that, there was a maintenance at 70°C for 5 minutes and an addition of 72μl of distilled water to provide a Genome Walker library. PCR was conducted by utilizing said library as a template. A PCR reaction solution amounting to 50μl was provided by adding 1 μl of Genome Walker library and primer AP1 (provided with Universal Genome Walker Kit) and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 117 to each amount to 200nM, adding 1μl of dNTP mix (a mixture of 10mM each of the 4 types of dNTPs), 10μl of 5xGC genomic PCR buffer, 2.2μl of 25mM Mg(OAc)<sub>2</sub>, 10μl of 5M GC-Melt and 1μl of Advantage-GC genomic polymerase mix and adding distilled water. The reaction conditions of the PCR were after maintaining 95°C for 1 minute; conducting 7 cycles of a cycle that included maintaining 94°C for 10 seconds and then 72°C for 3 minutes; 36 cycles of a cycle that included maintaining 94°C for 10 seconds and then 68°C for 3 minutes; and maintaining 68°C for 7 minutes. The reaction solution after the maintenance was diluted 50 fold with distilled water. The PCR products were designated as the first PCR products and were utilized as a template to conduct another PCR. The PCR amounting 50μl was provided by adding 1μl of the first PCR products and primer AP2 (provided with Universal Genome Walker Kit) and the oligonucleotide shown in SEQ ID NO: 118 to each amount to 200nM, adding 1μl of dNTP mix (a mixture of 10mM each of the 4 types of dNTPs), 10μl of 5xGC genomic PCR buffer, 2.2μl of 25mM Mg(OAc)<sub>2</sub>, 10μl of 5M GC-Melt and 1μl of Advantage-GC genomic polymerase mix and adding distilled water. The reaction conditions of the PCR were after maintaining 95°C for 1 minute; conducting 5 cycles of a cycle that included maintaining 94°C for 10 seconds and then 72°C for 3 minutes; 20 cycles of a cycle that included maintaining 94°C for 10 seconds and then 68°C for 3 minutes; and maintaining 68°C for 7 minutes. The reaction solution after the maintenance was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1300bp was recovered. The DNA was purified from the recovered gel by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and was introduced into E. Coli TOP10F'. The plasmid DNA was prepared from the E. coli transformant by utilizing Qiagen Tip20 (Qiagen Company). A sequencing reaction was conducted with Big Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotide shown in SEQ ID NO: 67 and the oligonucleotide shown in SEQ ID NO: 68. The obtained plasmid was utilized as a template in the sequencing reaction. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 644 to 1454 in the nucleotide sequence shown in SEQ ID NO: 110 was provided. As a result of connecting all of the analyzed nucleotide sequences,

the nucleotide sequence shown in SEQ ID No: 110 was provided. Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 109) consisting of 1236 nucleotides (inclusive of the stop codon) and encoding a 411 amino acid residue (SEQ ID NO: 108) and a nucleotide sequence (SEQ ID NO: 112) consisting of 192 nucleotides (inclusive of the stop codon) and encoding a 63 amino acid residue (SEQ ID NO: 111). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 108) encoded by the nucleotide sequence shown in SEQ ID NO: 109 was calculated to be 45465Da. Further, the amino acid sequence encoded by said nucleotide sequence contained the amino acid sequence (SEQ ID NO: 113) determined from the amino acid sequencing of from the N terminus of the present invention protein (A4). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 111) encoded by the nucleotide sequence shown in SEQ ID NO: 112 was calculated to be 6871Da.

## Example 27 The Expression of the Present Invention Protein (A4) in E. Coli

### (1) Production of a transformed E. coli having the present invention DNA(A4)

[0284] PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Streptomyces achromogenes* IFO 12735 in Example 26(1) and by utilizing Expand HiFi PCR System (Boehringer Mannheim Company). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 119 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 120 (hereinafter referred to as "primer pairing 25") or a pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 119 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 121 (hereinafter referred to as "primer pairing 26"). The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 300nM, 50ng of the above chromosomal DNA, 5.0 $\mu$ l of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP), 5.0 $\mu$ l of 10x Expand HF buffer (containing MgCl<sub>2</sub>) and 0.75 $\mu$ l of Expand HiFi enzyme mix and distilled water. The reaction conditions of the PCR were after maintaining 97°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 1 minute (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. After the maintenance, the reaction solution was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1.3kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 25. The gel area containing the DNA of about 1.6kbp was recovered from the gel which was subjected the reaction solution utilizing primer pairing 26. The DNA were purified from each of the recovered gels by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA were ligated to the cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and were introduced into E. coli TOP10F'. The plasmid DNA were prepared from the obtained E. coli transformants, utilizing Qiagen Tip20 (Qiagen Company). Next, sequencing reactions were conducted with Big Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotides shown in SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 122 and SEQ ID NO: 123. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 109 was designated as pCR646 and the plasmid having the nucleotide sequence shown in SEQ ID NO: 110 was designated as pCR646F.

[0285] Next, each of plasmids pCR646 and pCR646F was digested with restriction enzymes NdeI and HindIII. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.3kbp was cut from the gel subjected to the digestion products of pCR646. The gel area containing a DNA of about 1.6kbp was cut from the gel subjected to the digestion products of pCR646F. The DNA were purified from each of the recovered gels by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. Each of the obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated with ligation kit Ver.1 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into E. coli JM109. The plasmid DNA were prepared from the obtained E. coli transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 109, in which the DNA of about 1.3kbp encoding the present invention protein (A4) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN646. Further, the plasmid containing the nucleotide sequence shown in SEQ ID NO: 110, in which the DNA of about 1.6kbp encoding the present invention protein (A4) is inserted between the NdeI site and the HindIII site of pKSN2 was designated as pKSN646F. Each of the above plasmids of pKSN646 and pKSN646F was introduced into E. coli JM109. The obtained E. coli transformants were designated, respectively, JM109/pKSN646 and JM109/pKSN646F. Further, plasmid pKSN2 was introduced into E. coli JM109. The obtained E. coli transformant was designated as JM109/pKSN2.

**(2) Expression of the present invention protein (A4) in E. coli and recovery of said protein**

[0286] E. coli JM109/pKSN646, JM109/pKSN646F and JM109/pKSN2 are each cultured overnight at 37°C in 10ml of TB medium (1.2%(w/v) tryptone, 2.4%(w/v) yeast extract, 0.4%(w/v) glycerol, 17mM potassium dihydrogenphosphate, 72mM dipotassium hydrogenphosphate) containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium is transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reaches about 0.5, 5-aminolevulinic acid is added to the final concentration of 500µM, and the culturing is continued. Thirty (30) minutes thereafter, IPTG is added to a final concentration of 1mM, and there is further culturing for 17 hours.

[0287] The cells are recovered from each of the culture mediums, washed with 0.1 M tris-HCl buffer (pH7.5) and suspended in 10 ml of the above buffer containing 1mM PMSF. The obtained cell suspensions are subjected 6 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 3 minutes each under the conditions of output 3, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (1,200xg, 5 minutes) the supernatants are recovered and centrifuged (150,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN646 is referred to as "E. coli pKSN646 extract", the supernatant fraction obtained from E. coli JM109/pKSN646F is referred to as "E. coli pKSN646F extract", and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract"). A microliter (1µl) of the above supernatant fractions is analyzed on a 15% to 25% SDS-PAGE and stained with CBB. As a result, by detecting notably more intense bands in both E. coli pKSN646 extract and E. coli pKSN646F extract than the E. coli pKSN2 extract, at the electrophoresis locations corresponding to the molecular weight of 45kDa, it can be confirmed that the present invention protein (A4) is expressed in E. coli.

**(3) Detection of the ability to convert compound (II) to compound (III)**

[0288] Reaction solutions of 30µl are prepared and maintained for 10 minutes at 30°C. The reaction solutions consist of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.1U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 18µl of the supernatant fraction recovered in Example 27(2). Further, there are prepared and maintained similarly reaction solutions having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B and component C. Three microliters (3µl) of 2N HCl and 90 µl of ethyl acetate are added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions are centrifuged at 8,000xg to recover 75µl of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue is dissolved in 6.0µl of ethyl acetate. Five microliters (5.0µl) thereof is spotted to a silica gel TLC plate (TLC plate silica gel 60F<sub>254</sub>, 20cm x 20cm, 0.25mm thick, Merck Company). The TLC plate is developed with a 6: 1: 2 mixture of chloroform, acetic acid and ethyl acetate for about 1 hour. The solvents are then allowed to evaporate. The TLC plate is exposed overnight to an imaging plate (Fuji Film Company). Next, the imaging plate was analyzed on Image Analyzer BAS2000 (Fuji Film Company). The presence of a spot corresponding to compound (III) labeled with <sup>14</sup>C is examined (Rf value 0.24 and 0.29). The production of compound (III) in reaction solutions containing component A, component B, component C and E. coli pKSN646 extract, or in reaction solutions containing component A, component B, component C and E. coli pKSN646F extract can be confirmed.

**Example 28 Sequence Identity Relating to the Present Invention Protein**

[0289] The sequence identity relating to the proteins of the present invention and the DNA of the present invention was analyzed by utilizing GENETYX-WIN Ver. 5 (Software Development Company). The alignments were produced by conducting the homology analysis with the Lipman-Pearson method (Lipman, D.J. and Pearson, W.R., Science, 227, 1435-1441, (1985)).

[0290] In regards to amino acid sequences of the present invention proteins (A1) to (A4), there were determined the sequence identities to each other and to known proteins of the highest homology. The results are shown in Table 15.

Table 15

	present invention protein (A1)	present invention protein (A2)	present invention protein (A3)	present invention protein (A4)	known proteins of the highest homology*
present invention protein (A1)	100%	47%	64%	48%	73% AAC25766
present invention protein (A2)	47%	100%	48%	51%	52% CAB46536
present invention protein (A3)	64%	48%	100%	46%	67% AAC25766
present invention protein (A4)	48%	51%	46%	100%	50% CAB46536

\*the sequence identity is shown on top and the accession number of the provided protein in the Entrez database (provided by Center for Biotechnology Information, <http://www3.ncbi.nlm.nih.gov/Entrez/>) is shown on the bottom.

**[0291]** In regards to the nucleotide sequences of the present invention DNA (A1) having the nucleotide sequence shown in SEQ ID NO: 6, the present invention DNA (A2) having the nucleotide sequence shown in SEQ ID NO: 7, the present invention DNA (A3) having the nucleotide sequence shown in SEQ ID NO: 8 and the present invention DNA (A4) having the nucleotide sequence shown in SEQ ID NO: 109, there were determined the sequence identities to each other and to known genes of the highest homology. The results are shown in Table 16.

Table 16

	SEQ ID NO: 6 [present invention DNA (A1)]	SEQ ID NO: 7 [present invention DNA (A2)]	SEQ ID NO: 8 [present invention DNA (A3)]	SEQ ID NO: 109 [present invention DNA (A4)]	known genes of the highest homology*
SEQ ID NO: 6 [present invention DNA (A1)]	100%	61%	74%	62%	77% AF072709
SEQ ID NO: 7 [present invention DNA (A2)]	61%	100%	64%	65%	66% Y18574
SEQ ID NO: 8 [present invention DNA (A3)]	74%	64%	100%	63%	75% AF072709
SEQ ID NO: 109 [present invention DNA (A4)]	62%	65%	63%	100%	64% Y18574

\*the sequence identity is shown on top and the accession number of the provided gene in the Entrez database (provided by Center for Biotechnology Information, <http://www3.ncbi.nlm.nih.gov/Entrez/>) is shown on the bottom.

**[0292]** In regards to the amino acid sequences of the present invention proteins (B1) to (B4), there were determined the sequence identities to each other and to known proteins of the highest homology. The results are shown in Table 17.

Table 17

	present invention protein (B1)	present invention protein (B2)	present invention protein (B3)	present invention protein (B4)	known proteins of the highest homology*
present invention protein (B1)	100%	45%	78%	41%	76% AAC25765
present invention protein (B2)	45%	100%	40%	41 %	60% AAF71770
present invention protein (B3)	78%	40%	100%	40%	73% AAC25765
present invention protein (B4)	41%	41%	40%	100%	55% AAA26824

\*the sequence identity is shown on top and the accession number of the provided protein in the Entrez database (provided by Center for Biotechnology Information, <http://www3.ncbi.nlm.nih.gov/Entrez/>) is shown on the bottom.

**[0293]** In regards to the nucleotide sequences of the present invention DNA (B1) having the nucleotide sequence shown in SEQ ID NO: 15, the present invention DNA (B2) having the nucleotide sequence shown in SEQ ID NO: 16, the present invention DNA (B3) having the nucleotide sequence shown in SEQ ID NO: 17 and the present invention DNA (B4) having the nucleotide sequence shown in SEQ ID NO: 112, there were determined the sequence identities to each other and to known genes of the highest homology. The results are shown in Table 18.

Table 18

	SEQ ID NO: 15 [present invention DNA (B1)]	SEQ ID NO: 16 [present invention DNA (B2)]	SEQ ID NO: 17 [present invention DNA (B3)]	SEQ ID NO: 112 [present invention DNA (B4)]	known genes of the highest homology*
SEQ ID NO: 15 [present invention DNA (B1)]	100%	60%	80%	59%	84% AF072709
SEQ ID NO: 16 [present invention DNA (B2)]	60%	100%	60%	59%	66% M32238
SEQ ID NO: 17 [present invention DNA (B3)]	80%	60%	100%	65%	79% AF072709
SEQ ID NO: 112 [present invention DNA (B4)]	59%	59%	65%	100%	66% M32239

\*the sequence identity is shown on top and the accession number of the provided gene in the Entrez database (provided by Center for Biotechnology Information, <http://www3.ncbi.nlm.nih.gov/Entrez/>) is shown on the bottom.

**Example 29 PCR Utilizing an Oligonucleotide Having a Partial Nucleotide Sequence of the Present Invention DNA (A) as a Primer**

[0294] PCR was conducted by utilizing as a template each of: the chromosomal DNA of *Streptomyces phaeochromogenes* IFO 12898 prepared in Example 2; the chromosomal DNA of *Saccharopolyspora taberi* JCM 9383t prepared in Example 5; the chromosomal DNA of *Streptomyces griseolus* ATCC 11796 prepared in Example 9; the chromosomal DNA of *Streptomyces testaceus* ATCC 21469 prepared in Example 11; the chromosomal DNA of *Streptomyces achromogenes* IFO 12735 prepared in Example 26; and each of the chromosomal DNA of *Streptomyces griseofuscus* IFO 12870t, *Streptomyces thermocoeruleus* IFO 14273t and *Streptomyces nogalater* IFO 13445 prepared similarly to the method described in Example 2. As the primers, the 5 pairings of primers shown in Table 19 were utilized. The predicted size of the DNA amplified by the PCR utilizing each of the primer pairings based on the nucleotide sequence shown in SEQ ID NO: 6 is shown in Table 19.

Table 19

primer pairing	primer	primer	amplified DNA
14	SEQ ID NO: 124	SEQ ID NO: 129	about 800bp
15	SEQ ID NO: 125	SEQ ID NO: 129	about 600bp
16	SEQ ID NO: 126	SEQ ID NO: 129	about 600bp
17	SEQ ID NO: 127	SEQ ID NO: 129	about 580bp
18	SEQ ID NO: 128	SEQ ID NO: 129	about 580bp

[0295] The PCR reaction solution amounted to 25 $\mu$ l by adding 200nM of each of the 2 primers of the pairing shown in Table 19, adding 10ng of the chromosomal DNA, 0.5 $\mu$ l of dNTP mix (a mixture of 10mM of each of the 4 types of dNTP), 5 $\mu$ l of 5xGC genomic PCR buffer, 1.1 $\mu$ l of 25mM Mg(OAc)<sub>2</sub>, 5 $\mu$ l of 5M GC-Melt and 0.5 $\mu$ l of Advantage-GC genomic polymerase mix and adding water. The reaction conditions were maintaining 95°C for 1 minute; repeating 30 cycles of a cycle that included maintaining 94°C for 15 seconds, followed by 60°C for 30 seconds, and followed by 72°C for 1 minute; and maintaining 72°C for 5 minutes. Each of the reaction solutions after the maintenance was analyzed with 3% agarose gel electrophoresis. The results are shown in Fig. 46 and in Table 20 and Table 21. The amplification of the predicted size of the DNA was observed in each or all of the cases with primer pairings 14, 15, 16, 17 and 18 as well as in the cases of utilizing the chromosomal DNA prepared from any of the strains as a template.

Table 20

	Reagents		
Lane	origin of the template chromosomal DNA	primer pairing	amplification of DNA*
2	<i>Streptomyces phaeochromogenes</i> IFO 12898	14	+
3	<i>Streptomyces phaeochromogenes</i> IFO 12898	15	+
4	<i>Streptomyces phaeochromogenes</i> IFO 12898	16	+
5	<i>Streptomyces phaeochromogenes</i> IFO 12898	17	+
6	<i>Streptomyces phaeochromogenes</i> IFO 12898	18	+
9	<i>Streptomyces testaceus</i> ATCC 21469	14	+
10	<i>Saccharopolyspora taberi</i> JCM 9393t	14	+
11	<i>Streptomyces griseolus</i> ATCC 11796	14	+
13	<i>Streptomyces testaceus</i> ATCC 21469	15	+
14	<i>Saccharopolyspora taberi</i> JCM 9393t	15	+
15	<i>Streptomyces griseolus</i> ATCC 11796	15	+
16	<i>Streptomyces testaceus</i> ATCC 21469	16	+
17	<i>Saccharopolyspora taberi</i> JCM 9393t	16	+

\* "+" represents that the predicted size of the DNA was detected and "-" represents that there was no detection.

Table 20 (continued)

	Reagents		
Lane	origin of the template chromosomal DNA	primer pairing	amplification of DNA*
18	<i>Streptomyces griseolus</i> ATCC 11796	16	+
20	<i>Streptomyces testaceus</i> ATCC 21469	17	+
21	<i>Saccharopolyspora taberi</i> JCM 9393t	17	+
22	<i>Streptomyces griseolus</i> ATCC 11796	17	+
23	<i>Streptomyces testaceus</i> ATCC 21469	18	+
24	<i>Saccharopolyspora taberi</i> JCM 9393t	18	+
25	<i>Streptomyces griseolus</i> ATCC 11796	18	+

\* "+" represents that the predicted size of the DNA was detected and "-" represents that there was no detection.

Table 21

	Reagents		
Lane	Origin of template chromosomal DNA	primer pairing	amplification of DNA*
28	<i>Streptomyces griseofuscus</i> IFO 12870t	14	+
29	<i>Streptomyces thermocoerulescens</i> IFO 14273t	14	+
30	<i>Streptomyces achromogenes</i> IFO 12735	14	-
31	<i>Streptomyces nogalater</i> IFO 13445	14	+
33	<i>Streptomyces griseofuscus</i> IFO 12870t	15	+
34	<i>Streptomyces thermocoerulescens</i> IFO 14273t	15	+
35	<i>Streptomyces achromogenes</i> IFO 12735	15	-
36	<i>Streptomyces nogalater</i> IFO 13445	15	+
38	<i>Streptomyces griseofuscus</i> IFO 12870t	16	+
39	<i>Streptomyces thermocoerulescens</i> IFO 14273t	16	+
40	<i>Streptomyces achromogenes</i> IFO 12735	16	+
41	<i>Streptomyces nogalater</i> IFO 13445	16	+
43	<i>Streptomyces griseofuscus</i> IFO 12870t	17	+
44	<i>Streptomyces thermocoerulescens</i> IFO 14273t	17	+
45	<i>Streptomyces achromogenes</i> IFO 12735	17	+
46	<i>Streptomyces nogalater</i> IFO 13445	17	+
48	<i>Streptomyces griseofuscus</i> IFO 12870t	18	-
49	<i>Streptomyces thermocoerulescens</i> IFO 14273t	18	+
50	<i>Streptomyces achromogenes</i> IFO 12735	18	-
51	<i>Streptomyces nogalater</i> IFO 13445	18	+

\* "+" represents that the predicted size of the DNA was detection and "-" represents that there was no detection.

### Example 30 Hybridization Utilizing as a Probe a DNA Consisting of a Partial Nucleotide Sequence of the Present DNA (A) and the Present Invention DNA (A)

#### (1) Preparation of a Probe

[0296] DNA consisting of a partial nucleotide sequence of the present invention DNA (A1) or a partial nucleotide sequence of the present invention DNA (A1) was produced as a probe labeled with digoxigenin (DIG labeled probe). PCR was conducted with PCR DIG Probe synthesis kit (Roche Diagnostics GmbH Company) according to the attached manual by utilizing as a template the chromosomal DNA of *Streptomyces phaeochromogenes* IFO 12898 prepared in Example 3 and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 93 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 94. The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 200nM, adding 50ng of the chromosomal DNA, 2.5 $\mu$ l of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP), 2.5 $\mu$ l of PCR DIG mix (a mixture of 2.0mM of each of the 4 types of dNTP labeled with DIG), 5 $\mu$ l of 10x PCR buffer and 0.75 $\mu$ l of Expand HiFi enzyme mix and adding distilled water. The reaction conditions were after maintaining 95°C for 2 minutes; repeating 10 cycles of a cycle that included maintaining 95°C for 10 seconds, followed by 60°C for 30 seconds and followed by 72°C for 2 minutes; then conducting 15 cycles of a cycle that included maintaining 95°C for 10 seconds, followed by 60°C for 30 seconds and followed by 72°C for 2 minutes (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. The reaction solution after the maintenance was subjected to 1% agarose gel electrophoresis. As a result, amplification of a DNA of about 1.3kb was confirmed. The amplified DNA was recovered to obtain a DNA labeled with digoxigenin and having the nucleotide sequence shown in SEQ ID NO: 6. Under a similar method, PCR was conducted by utilizing as a template the chromosomal DNA of *Streptomyces phaeochromogenes* IFO 12898 and by utilizing as the primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 130 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 131. The DNA amplified by said PCR was recovered to obtain a DNA labeled with digoxigenin and having the nucleotide sequence shown in nucleotides 57 to 730 of the nucleotide sequence shown in SEQ ID NO: 6.

[0297] Under a similar method, PCR was conducted by utilizing as a template the chromosomal DNA of *Saccharopolyspora taberi* JCM 9393t prepared in Example 6 and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 61 and the oligonucleotide sequence consisting of the nucleotide sequence shown in SEQ ID NO: 62. The DNA amplified by said PCR was recovered to obtain a DNA labeled with digoxigenin and having the nucleotide sequence shown in SEQ ID NO: 7.

[0298] Further, under a similar method, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces testaceus* ATCC 21469 prepared in Example 11 and by utilizing as primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 70 and the oligonucleotide sequence consisting of the nucleotide sequence shown in SEQ ID NO: 71. The DNA amplified by said PCR was recovered to obtain a DNA labeled with digoxigenin and having the nucleotide sequence shown in SEQ ID NO: 8. Further, PCR was conducted by utilizing the above-mentioned chromosomal DNA as the template and by utilizing as the primers the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 132 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 133. The DNA amplified by said PCR was recovered to obtain a DNA labeled with digoxigenin and having the nucleotide sequence shown in nucleotides 21 to 691 of the nucleotide sequence shown in SEQ ID NO: 8.

#### (2) Dot-blot Hybridization

[0299] Each of the DNA of pKSN657 prepared in Example 4 (the DNA comprising the present invention DNA (A1)), the DNA of pKSN923 prepared in Example 7 (the DNA comprising the present invention DNA (A2)), the DNA of pKSN671 prepared in Example 12 (the DNA comprising the present invention DNA (A3)), the DNA of pKSN5CA prepared in Example 14 (the DNA comprising the present DNA (A9)) and the DNA of pKSN11796 prepared in Example 10 (the DNA comprising the present DNA (A10)) was blotted onto a nylon membrane Hybond N+ (Amersham Pharmacia Company) to amount to 100ng and 10ng. Ultraviolet light was directed at the obtained membranes with a transilluminator for 5 minutes.

[0300] DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche Diagnostics GmbH Company) was utilized for the hybridization and detection according to the attached manual. As the probes, each of the DNA labeled with digoxigenin and produced in Example 30(1) which were maintained at 100°C for 5 minutes and then quickly cooled in ice (hereinafter, referred to as "DIG labeled probe") was utilized. The dotted above membrane was shaken at 42°C for 30 minutes in 2.0ml of DIGEasyHyb that was provided with said kit. Next, 2.0ml of Dig Easy Hyb, 5.0 $\mu$ l of the DIG labeled probes and the membrane were enclosed in a plastic bag for hybridization and maintained at 42°C for 18 hours. The membrane was recovered, was shaken twice in 2x SSC containing 0.1% SDS for 5 minutes at room temperature and was then shaken twice in 0.5xSSC containing 0.1%SDS at 65°C for 15 minutes. Subsequently, the membrane

was shaken in 50ml of washing buffer for 2 minutes, then shaken in 50ml of blocking solution at room temperature for 30 minutes, then shaken in 2.0ml of antibody solution for 30 minutes, and then shaken twice in 50ml of washing buffer for 15 minutes. Further, after shaking in 50ml of detection buffer for 5 minutes, the membrane was enclosed in a hybridization bag with 2.0ml of Color Substrate solution and maintained at room temperature for 18 hours. A signal was detected in each of the cases of conducting hybridization with each of the reagents of 10ng and 100ng of each of pKSN657, pKSN923, pKSN671, pKSN5CA and pKSN11796.

### Example 31 Obtaining the Present Invention DNA (A11)

#### (1) Preparation of the chromosomal DNA of *Streptomyces nogalator* IFO13445

[0301] *Streptomyces nogalator* IFO 13445 was cultivated with shaking at 30°C for 3 days in 50ml of YGY medium (0.5%(w/v) yeast extract, 0.5%(w/v) tryptone, 0.1%(w/v) glucose and 0.1%(w/v)  $K_2HPO_4$ , pH7.0). The cells were recovered. The obtained cells were suspended in YGY medium containing 1.4%(w/v) glycine and 60mM EDTA and further incubated with shaking for a day. The cells were recovered from the culture medium. After washing once with distilled water, it was suspended in 3.5ml of Buffer B 1 (50mM Tris-HCl (pH8.0), 50mM EDTA, 0.5% of Tween-20 and 0.5% Triton X-100). Eighty microliters (80μl) of a 100μg/ml lysozyme solution and 100μl of Qiagen Protease (600mAU/ml, Qiagen Company) were added to the suspension and maintained at 37°C for a hour. Next, 1.2ml of Buffer B2 (3M guanidine HCl and 20% tween-20) was added, mixed and maintained at 50°C for 30 minutes. The obtained cell lysate solution added to a Qiagen genomic chip 100G (Qiagen Company) equalized in Buffer QBT (750mM NaCl, 50mM MOPS (pH7.0), 15% isopropanol and 0.15% Triton X-100). Next, after the chip was washed twice with 7.5ml of Buffer QC (50mM MOPS (pH7.0) and 15% isopropanol), the DNA was eluted by flowing 5ml of Buffer QF (1.25M NaCl, 50mM Tris HCl (pH8.5), 15% isopropanol). Three and five-tenths milliliters (3.5ml) of isopropanol was mixed into the obtained DNA solution to precipitate and recover the chromosomal DNA. After washing with 70% ethanol, the recovered chromosomal DNA was dissolved in 1ml of TB buffer.

#### (2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A11)

[0302] PCR was conducted by utilizing as the template the chromosomal DNA prepared in Example 31(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. The amplified DNA was ligated to cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and was then introduced into *E. Coli* TOP10F'. The plasmid DNA was prepared from the obtained *E. coli* transformant, utilizing Qiagen Tip20 (Qiagen Company). A sequencing reaction was conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 57 and a primer having the nucleotide sequence shown in SEQ ID NO: 59. The sequence reaction utilized the obtained plasmid as a template. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). As a result, the nucleotide sequence shown in nucleotides 316 to 1048 of the nucleotide sequence shown in SEQ ID NO: 139 was provided.

[0303] Further, the chromosomal DNA prepared in Example 31(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 161 and primer AP1 (Universal Genome Walker Kit (Clontech Company)). Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 162 and primer AP2 (Universal Genome Walker Kit (Clontech Company)). The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 330 of the nucleotide sequence shown in SEQ ID NO: 144 was provided.

[0304] Further, the chromosomal DNA prepared in Example 31(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 163 and primer AP1 (Universal Genome Walker Kit (Clontech Company)). Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 164 and primer AP2 (Universal Genome Walker Kit (Clontech Company)). The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 983 to 1449 of the nucleotide sequence shown in SEQ ID NO: 144 was provided.

**(3) Sequence analysis of the present invention DNA (A11)**

**[0305]** The nucleotide sequence shown in SEQ ID NO: 144 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 31(2). Two open reading frames (ORF) were present. As such, there was contained a nucleotide sequence (SEQ ID NO: 139) consisting of 1230 nucleotides (inclusive of the stop codon) and encoding a 409 amino acid residue (SEQ ID NO: 159) and a nucleotide sequence (SEQ ID NO: 154) consisting of 207 nucleotides (inclusive of the stop codon) and encoding a 68 amino acid residue (SEQ ID NO: 149). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 159) encoded by the nucleotide sequence shown in SEQ ID NO: 139 was calculated to be 45177Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 149) encoded by the nucleotide sequence shown in SEQ ID NO: 154 was calculated to be 7147Da.

**Example 32 Expression of the Present Invention Protein (A11) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA(A11)**

**[0306]** PCR was conducted by utilizing as a template the chromosomal DNA prepared from *Streptomyces nogalator* IFO13445 in Example 31(1) and by utilizing Expand HiFi PCR System (Boehringer Mannheim Company). As the primers, there was utilized the pairing of an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 165 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 166. The reaction solution composition and the maintenance were similar to the conditions described in Example 27(1). The reaction solution after the maintenance was subjected to 1% agarose gel electrophoresis. The gel area containing the DNA of about 1.5kbp was recovered. The DNA was purified from the recovered gel by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA was ligated to the cloning vector pCRII-TOPO (Invitrogen Company) according to the instructions attached to said vector and was introduced into *E. Coli* TOP 10F'. The plasmid DNA was prepared from the obtained *E. coli* transformants, utilizing Qiagen Tip20 (Qiagen Company). Sequencing reactions were conducted with Dye terminator cycle sequencing FS ready reaction kit (Applied Biosystems Japan Company) according to the instructions attached to said kit, utilizing as primers the oligonucleotides having the nucleotide sequences shown in, respectively, SEQ ID NOs: 57, 59, and 186. The sequencing reactions utilized the obtained plasmid DNA as the template. The reaction products were analyzed with a DNA sequencer 3100 (Applied Biosystems Japan Company). Based on the results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 144 was designated as pCR849AF.

**[0307]** Next, pCR849AF was digested with restriction enzymes *Nde*I and *Hind*III. The digestion products were subjected to agarose gel electrophoresis. The gel area containing a DNA of about 1.5kbp was cut from the gel. The DNA was purified from the recovered gels by utilizing QIA quick gel extraction kit (Qiagen Company) according to the attached instructions. The obtained DNA and the plasmid pKSN2 digested with *Nde*I and *Hind*III were ligated with ligation kit Ver.2 (Takara Shuzo Company) according to the instructions attached to said kit and introduced into *E. Coli* JM109. The plasmid DNA were prepared from the obtained *E. coli* transformants. The structures thereof were analyzed. The plasmid containing the nucleotide sequence shown in SEQ ID NO: 144, in which the DNA of about 1.5kbp encoding the present invention protein (A11) is inserted between the *Nde*I site and the *Hind*III site of pKSN2 was designated as pKSN849AF. Plasmid pKSN849AF was introduced into *E. coli* JM109. The obtained *E. coli* transformant was designated JM109/pKSN849AF. Further, plasmid pKSN2 was introduced into *E. coli* JM109. The obtained *E. coli* transformant was designated as JM109/pKSN2.

**(2) Expression of the present invention protein (A11) in E. coli and recovery of said protein**

**[0308]** Similarly to Example 4(2), each of *E. coli* JM109/pKSN849AF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from *E. coli* JM109/pKSN849AF is referred to as "*E. coli* pKSN849AF extract" and the supernatant fraction obtained from JM109/pKSN2 is referred to as "*E. coli* pKSN2 extract").

**(3) Detection of the ability to convert compound (II) to compound (III)**

**[0309]** Reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. The reaction solutions consisted of a 0.1M potassium phosphate buffer (pH7.0) containing 3ppm of compound (II) labeled with <sup>14</sup>C, 2mM of  $\beta$ -NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 2mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.1U/ml of ferredoxin reductase (hereinafter,

referred to as "component C") (Sigma Company) and 23 $\mu$ l of the supernatant fraction recovered in Example 32(2). Similarly to Example 4(3), the reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN849AF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

### Example 33 Obtaining the Present Invention DNA (A12)

#### (1) Preparation of the chromosomal DNA of Streptomyces tsusimaensis IFO 13782

[0310] Under the method described in Example 31(1), the chromosomal DNA of Streptomyces tsusimaensis IFO 13782 was prepared.

#### (2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A12)

[0311] PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces tsusimaensis IFO 13782 prepared in Example 33(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 364 to 1096 of the nucleotide sequence shown in SEQ ID NO: 140 was provided.

[0312] Further, the chromosomal DNA prepared in Example 33(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 167 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 168 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 392 of the nucleotide sequence shown in SEQ ID NO: 145 was provided.

[0313] Further, the chromosomal DNA prepared in Example 33(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 169 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 170 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1048 to 1480 of the nucleotide sequence shown in SEQ ID NO: 145 was provided.

#### (3) Sequence analysis of the present invention DNA (A12)

[0314] The nucleotide sequence shown in SEQ ID NO: 145 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 33(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 140) consisting of 1278 nucleotides (inclusive of the stop codon) and encoding a 425 amino acid residue (SEQ ID NO: 160) and a nucleotide sequence (SEQ ID NO: 155) consisting of 198 nucleotides (inclusive of the stop codon) and encoding a 65 amino acid residue (SEQ ID NO: 150). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 160) encoded by the nucleotide sequence shown in SEQ ID NO: 140 was calculated to be 46549Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 150) encoded by the nucleotide sequence shown in SEQ ID NO: 155 was calculated to be 6510Da.

### Example 34 Expression of the Present Invention DNA (A12) in E. Coli

#### (1) Production of a transformed E. coli having the present invention DNA (A12)

[0315] PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA prepared from Streptomyces tsusimaensis IFO 13782 in Example 33(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 171 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 172. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and

cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed with oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 171, 172 and 187. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 145 was designated as pCR1618F. Similarly to Example 32(1), pCR1618F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 145, in which the DNA encoding the present invention protein (A12) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1618F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1618F.

## **(2) Expression of the present invention protein (A12) in E. coli and recovery of said protein**

**[0316]** Similarly to Example 4(2), each of E. coli JM109/pKSN1618F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1618F is referred to as "E. coli pKSN1618F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

## **(3) Detection of the ability to convert compound (II) to compound (III)**

**[0317]** Reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. Other than utilizing the supernatant fractions recovered in Example 34(2) (E. coli pKSN1618F extract or E. coli pKSN2 extract), the reaction solutions were prepared similarly to Example 32(3). The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1618F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

## **Example 35 Obtaining the Present Invention DNA (A13)**

### **(1) Preparation of the chromosomal DNA of Streptomyces thermocoerulesces IFO 14273t**

**[0318]** Under the method described in Example 31(1), the chromosomal DNA of Streptomyces thermocoerulesces IFO 14273t was prepared.

### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A13)**

**[0319]** PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces thermocoerulesces IFO 14273t prepared in Example 35(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 295 to 1027 of the nucleotide sequence shown in SEQ ID NO: 141 was provided.

**[0320]** Further, the chromosomal DNA prepared in Example 35(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 173 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 174 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 370 of the nucleotide sequence shown in SEQ ID NO: 146 was provided.

**[0321]** Further, the chromosomal DNA prepared in Example 35(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 175 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 176 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 960 to 1473 of the nucleotide sequence shown in SEQ ID NO: 146 was provided.

**(3) Sequence analysis of the present invention DNA (A13)**

**[0322]** The nucleotide sequence shown in SEQ ID NO: 146 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 35(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 141) consisting of 1209 nucleotides (inclusive of the stop codon) and encoding a 402 amino acid residue (SEQ ID NO: 136) and a nucleotide sequence (SEQ ID NO: 156) consisting of 252 nucleotides (inclusive of the stop codon) and encoding a 83 amino acid residue (SEQ ID NO: 151). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 136) encoded by the nucleotide sequence shown in SEQ ID NO: 141 was calculated to be 44629Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 151) encoded by the nucleotide sequence shown in SEQ ID NO: 156 was calculated to be 8635Da.

**Example 36 Expression of the Present Invention DNA (A13) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA (A13)**

**[0323]** PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces thermocoerulesces* IFO 14273t in Example 35(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 177 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 178. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed with oligonucleotides having nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 173, 175 and 188. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 146 was designated as pCR474F. Similarly to Example 32(1), pCR474F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 146, in which the DNA encoding the present invention protein (A13) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN474F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN474F.

**(2) Expression of the present invention protein (A13) in E. coli and recovery of said protein**

**[0324]** Similarly to Example 4(2), each of E. coli JM109/pKSN474F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN474F is referred to as "E. coli pKSN474F extract" and the supernatant fraction obtained from JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

**(3) Detection of the ability to convert compound (II) to compound (III)**

**[0325]** Reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. Other than utilizing the supernatant fractions recovered in Example 36(2) (E. coli pKSN474F extract or E. coli pKSN2 extract), the reaction solutions were prepared similarly to Example 32(3). The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN474F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

**Example 37 Obtaining the Present Invention DNA (A14)****(1) Preparation of the chromosomal DNA of *Streptomyces thermocoerulesces* IFO 14273t**

**[0326]** Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces glomerochromogenes* IFO 13673t was prepared.

**(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A13)**

**[0327]** PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces glomerochromogenes*

nes IFO 13673t prepared in Example 37(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 316 to 1048 of the nucleotide sequence shown in SEQ ID NO: 142 was provided.

**[0328]** Further, the chromosomal DNA prepared in Example 37(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 179 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 180 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 330 of the nucleotide sequence shown in SEQ ID NO: 147 was provided.

**[0329]** Further, the chromosomal DNA prepared in Example 37(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 181 and primer AP 1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 182 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 982 to 1449 of the nucleotide sequence shown in SEQ ID NO: 147 was provided.

### **(3) Sequence analysis of the present invention DNA (A14)**

**[0330]** The nucleotide sequence shown in SEQ ID NO: 147 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 37(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 142) consisting of 1230 nucleotides (inclusive of the stop codon) and encoding a 409 amino acid residue (SEQ ID NO: 137) and a nucleotide sequence (SEQ ID NO: 157) consisting of 207 nucleotides (inclusive of the stop codon) and encoding a 68 amino acid residue (SEQ ID NO: 152). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 137) encoded by the nucleotide sequence shown in SEQ ID NO: 142 was calculated to be 45089Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 152) encoded by the nucleotide sequence shown in SEQ ID NO: 157 was calculated to be 7174Da.

### **Example 38 Expression of the Present Invention DNA (A14) in E. Coli**

#### **(1) Production of a transformed E. coli having the present invention DNA (A14)**

**[0331]** PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA of *Streptomyces glomerochromogenes* IFO 13673t prepared in Example 37(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 183 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 184. Similarly to Example 32(1), the DNA was purified from the PCR reaction solution and cloned into cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed with oligonucleotides having nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59 and 189. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 147 was designated as pCR1491AF. Similarly to Example 32(1), pCR1491AF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 147, in which the DNA encoding the present invention protein (A14) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1491AF"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1491AF.

#### **(2) Expression of the present invention protein (A14) in E. coli and recovery of said protein**

**[0332]** Similarly to Example 4(2), each of E. coli JM109/pKSN1491AF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1491AF is referred to as "E. coli pKSN1491AF extract" and the supernatant fraction obtained from JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

**(3) Detection of the ability to convert compound (II) to compound (III)**

[0333] Reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. Other than utilizing the supernatant fractions recovered in Example 38(2) (E. coli pKSN1491AF extract or E. coli pKSN2 extract), the reaction solutions were prepared similarly to Example 32(3). The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1491AF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

**Example 39 Obtaining the Present Invention DNA (A15)****(1) Preparation of the chromosomal DNA of Streptomyces olivochromogenes IFO 12444**

[0334] Under the method described in Example 31(1), the chromosomal DNA of Streptomyces olivochromogenes IFO 12444 was prepared.

**(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A15)**

[0335] PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces olivochromogenes IFO 12444 prepared in Example 39(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 316 to 1048 of the nucleotide sequence shown in SEQ ID NO: 143 was provided.

[0336] Further, the chromosomal DNA prepared in Example 37(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained DNA as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 179 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 180 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 330 of the nucleotide sequence shown in SEQ ID NO: 148 was provided.

[0337] Further, the chromosomal DNA prepared in Example 39(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 181 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 182 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 982 to 1449 of the nucleotide sequence shown in SEQ ID NO: 148 was provided.

**(3) Sequence analysis of the present invention DNA (A15)**

[0338] The nucleotide sequence shown in SEQ ID NO: 148 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 39(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 143) consisting of 1230 nucleotides (inclusive of the stop codon) and encoding a 409 amino acid residue (SEQ ID NO: 138) and a nucleotide sequence (SEQ ID NO: 158) consisting of 207 nucleotides (inclusive of the stop codon) and encoding a 68 amino acid residue (SEQ ID NO: 153). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 138) encoded by the nucleotide sequence shown in SEQ ID NO: 143 was calculated to be 45116Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 153) encoded by the nucleotide sequence shown in SEQ ID NO: 158 was calculated to be 7179Da.

**Example 40 Expression of the Present Invention DNA (A15) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA (A15)**

[0339] PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA of

Streptomyces olivochromogenes IFO 12444 prepared in Example 39(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 184 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 185. Similarly to Example 32(1), the DNA was purified from the PCR reaction solution and cloned into cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed with oligonucleotides having nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59 and 189. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 148 was designated as pCR1555AF. Similarly to Example 32(1), pCR1555AF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 148, in which the DNA encoding the present invention protein (A15) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1555AF"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1555AF.

## (2) Expression of the present invention protein (A15) in E. coli and recovery of said protein

[0340] Similarly to Example 4(2), each of E. coli JM109/pKSN1555AF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1555AF is referred to as "E. coli pKSN1555AF extract" and the supernatant fraction obtained from JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

## (3) Detection of the ability to convert compound (II) to compound (III)

[0341] Reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. Other than utilizing the supernatant fractions recovered in Example 40(2) (E. coli pKSN1555AF extract or E. coli pKSN2 extract), the reaction solutions were prepared similarly to Example 32(3). The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1555AF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

## Example 41 Metabolism of Compounds by the Present Invention Protein (A1)

### (1) Preparation of plastid fractions

[0342] A hundred grams (100g) of Radish greens seeds (Takii Seed) were sawed into a dampened paper laboratory wipe in a tray, cultivated at 25°C for 6 days in the dark and then cultivated for 4 hours under a fluorescent lamp. Thirty grams (30g) of the newly greened cotyledons were ground with a Nissei AM-8 homogenizer (Nihonseiki Seisakusho; 18,000 to 20,000rpm, 4°C, 5 seconds) in disruption buffer (1mM magnesium chloride, 20mM N-tris (hydroxymethyl) methyl-2-aminoethanesulfonate, 10mM N-2-hydroxyethylpiperidine-N'-2-ethanesulfonate, 0.5mM EDTA, 5mM cysteine, 0.5M sucrose; pH7.7). The obtained cell lysate solution was passed through 4 layers of nylon gauze. The obtained solution was centrifuged (13,170xg, 4°C, 1 minute). The obtained residue fractions were suspended with 60ml of disruption buffer and centrifuged (2,640xg, 4°C, 2 minutes). The residue fractions were resuspended in 10ml of disruption buffer, were layered with the high density buffer (1mM magnesium chloride, 20mM N-tris (hydroxymethyl) methyl-2-aminoethanesulfonate, 30mM N-2-hydroxyethylpiperidine-N'-2-ethanesulfonate, 0.5mM EDTA, 5mM cysteine, 0.6M sucrose; pH7.7) in a centrifuge tube, and were centrifuged (675xg, 4°C, 15 minutes). The residues were suspended in 3ml of suspension buffer (1mM magnesium chloride, 20mM N-tris (hydroxymethyl)methyl-2-aminoethanesulfonate, 30mM N-2-hydroxyethylpiperidine-N'-2-ethanesulfonate, 0.5mM EDTA; pH7.7) and were designated as a plastid fraction.

### (2) Metabolism of compound (XII) by the present invention protein (A1)

[0343] There was prepared 100μl of a reaction solution of 50mM potassium phosphate buffer (pH7.0) containing 5ppm of compound (XII), 3mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 1mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.15U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 20μl of the supernatant fraction recovered in Example 4(2). The reaction solution was maintained at 30°C for 10 minutes. Further, there was prepared and maintained similarly 100μl of a reaction solution of a 50mM potassium phosphate buffer (pH 7.0) having

no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B, component C and the supernatant fraction prepared in Example 4(2). Ten microliters (10 $\mu$ l) of 2N HCl and 500 $\mu$ l of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The resulting reaction solutions were centrifuged at 8,000xg to recover 490 $\mu$ l of the ethyl acetate layer. After drying the ethyl acetate layers under reduced pressure, the residue was dissolved in 100 $\mu$ l of 50mM of potassium phosphate buffer (pH7.0). Forty microliters (40 $\mu$ l) of the fraction solutions (hereinafter, the fraction solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 4(2) is referred to as "(XII) metabolism solution (A1)"; further, the fraction solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 4(2) is referred to as "(XII) control solution (A1)") were analyzed on a HPLC. Compared to the concentration of compound (XII) detected from (XII) control solution (A1), the concentration of compound (XII) detected from (XII) metabolism solution (A1) was lower. Further a peak, which was not detected from the (XII) control solution (A1), was detected from the (XII) metabolism solution (A1). Mass spectrometry was conducted for the compound contained in such a peak. The mass of the compound contained in such a peak was 14 smaller than the mass of compound (XII).

**[0344]** Twenty microliters (20 $\mu$ l) of a 32-fold dilution of the above (XII) metabolism solution (A1) and 60 $\mu$ l of the plastid fraction prepared in Example 41(1) were mixed. In darkened conditions, 20  $\mu$ l of substrate solution (10mM adenosine triphosphate, 5mM aminolevulinic acid, 4mM glutathion reductase and 0.6mM NAD<sup>+</sup>; pH6.5; hereinafter, such a substrate solution is referred to as "PPO substrate solution") were added and maintained at 30°C for 1.5 hours. Further, instead of said 20 $\mu$ l of the 32-fold dilution of (XII) metabolism solution (A1), a reaction solution to which 20 $\mu$ l of the 32-fold dilution of (XII) control solution (A1) was added was prepared, and the PPO substrate solution was added and maintained similarly. Three hundred (300 $\mu$ l) of a dimethylsulfoxide-methanol mixture (dimethylsulfoxide: methanol = 7:3) was added to each of the reaction solutions after the maintenance and centrifuged (8000xg, 4°C, 10 minutes). The supernatants were recovered and were subjected to reverse phase HPLC analysis under the analysis conditions below to measure the amount of PPIX. The PPIX amount in the reaction solution to which (XII) metabolism solution (A1) was added was more than the PPIX amount in the reaction solution to which (XII) control solution (A1) was added.

(HPLC analysis condition 2)

#### **[0345]**

column	SUMIPAX ODS212 (Sumika Chemical Analysis Service)
flow rate	2ml/minute
detection wave length	fluorescent Ex:410nm Em:630nm
eluent	95:5 mixture of methanol and 1M ammonium acetate (pH5.7)

### **(3) Metabolism of compound (XIII) by the present invention protein (A1)**

**[0346]** Other than utilizing 5ppm of compound (XIII) instead of 5ppm of compound (XII), reaction solutions were prepared and maintained similarly to the method described in Example 41(2). Similarly to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residues were dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 4(2) is referred to as "(XIII) metabolism solution (A1)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 4(2) is referred to as "(XIII) control solution (A1)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A1), the concentration of compound (XIII) detected from (XIII) metabolism solution (A1) was lower. Further a peak, which was not detected from the (XIII) control solution (A1), was detected from the (XIII) metabolism solution (A1). Mass spectrometry was conducted for the compound contained in such a peak. The mass of the compound contained in such a peak was 14 smaller than the mass of compound (XIII).

**[0347]** Twenty microliters (20 $\mu$ l) of a 128-fold dilution of the above (XIII) metabolism solution (A1) and 60 $\mu$ l of the plastid fraction were mixed. In darkened conditions, 20  $\mu$ l of PPO substrate solution were added and maintained at 30°C for 1.5 hours. Further, instead of said 20 $\mu$ l of the 128-fold dilution of (XIII) metabolism solution (A1), a reaction solution to which 20 $\mu$ l of the 128-fold dilution of (XIII) control solution (A1) was added was prepared, and the PPO substrate solution was added and maintained similarly. Similar to Example 41(2), each of the reaction solutions after the maintenance were prepared and subjected to reverse phase HPLC analysis under the above analysis condition 2 to measure the amount of PPIX. The PPIX amount in the reaction solution to which (XIII) metabolism solution (A1) was added was more than the PPIX amount in the reaction solution to which (XIII) control solution (A1) was added.

**(4) Metabolism of compound (XVI) by the present invention protein (A1)**

**[0348]** Other than utilizing 12.5ppm of compound (XVI) instead of 5ppm of compound (XII), reaction solutions were prepared and maintained similarly to the method described in Example 41(2). Similarly to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residues were dissolved in 200μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 4(2) is referred to as "(XVI) metabolism solution (A1)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 4(2) is referred to as "(XVI) control solution (A1)".

Compared to the concentration of compound (XVI) detected from (XVI) control solution (A1), the concentration of compound (XVI) detected from (XVI) metabolism solution (A1) was lower. Further a peak, which was not detected from the (XVI) control solution (A1), was detected from the (XVI) metabolism solution (A1).

**[0349]** Twenty microliters (20μl) of a 8-fold dilution of the above (XVI) metabolism solution (A1) and 60μl of the plastid fraction were mixed. In darkened conditions, 20 μl of PPO substrate solution were added and maintained at 30°C for 1.5 hours. Further, instead of said 20μl of the 8-fold dilution of (XVI) metabolism solution (A1), a reaction solution to which 20μl of the 8-fold dilution of (XVI) control solution (A1) was added was prepared, and the PPO substrate solution was added and maintained similarly. Similar to Example 41(2), each of the reaction solutions after the maintenance were prepared and subjected to reverse phase HPLC analysis under the above analysis condition 2 to measure the amount of PPIX. The PPIX amount in the reaction solution to which (XVI) metabolism solution (A1) was added was more than the PPIX amount in the reaction solution to which (XVI) control solution (A1) was added.

**(5) Metabolism of compound (XVII) by the present invention protein (A1)**

**[0350]** Other than utilizing 12.5ppm of compound (XVII) instead of 5ppm of compound (XII), reaction solutions were prepared and maintained similarly to the method described in Example 41(2). Similarly to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residues were dissolved in 200μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 4(2) is referred to as "(XVII) metabolism solution (A1)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 4(2) is referred to as "(XVII) control solution (A1)".

Compared to the concentration of compound (XVII) detected from (XVII) control solution (A1), the concentration of compound (XVII) detected from (XVII) metabolism solution (A1) was lower. Further a peak, which was not detected from the (XVII) control solution (A1), was detected from the (XVII) metabolism solution (A1).

**[0351]** Twenty microliters (20μl) of a 32-fold dilution of the above (XVII) metabolism solution (A1) and 60μl of the plastid fraction were mixed. In darkened conditions, 20μl of PPO substrate solution were added and maintained at 30°C for 1.5 hours. Further, instead of said 20μl of the 32-fold dilution of (XVII) metabolism solution (A1), a reaction solution to which 20μl of the 32-fold dilution of (XVII) control solution (A1) was added was prepared, and the PPO substrate solution was added and maintained similarly. Similar to Example 41(2), each of the reaction solutions after the maintenance were prepared and subjected to reverse phase HPLC analysis under the above analysis condition 2 to measure the amount of PPIX. The PPIX amount in the reaction solution to which (XVII) metabolism solution (A1) was added was more than the PPIX amount in the reaction solution to which (XVII) control solution (A1) was added.

**(6) Metabolism of compound (VI) by the present invention protein (A1)**

**[0352]** *E. coli* JM109/pKSN657F was cultured overnight at 37°C in 3ml of TB medium containing 50μg/ml of ampicillin. A milliliter (1ml) of the obtained culture medium was transferred to 100ml of TB medium containing 50μg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5-aminolevulinic acid was added to the final concentration of 500μM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing for 20 hours.

**[0353]** The cells were recovered from the culture medium, washed with 0.1M tris-HCl buffer (pH7.5) and suspended in 10ml of 0.1M Tris-HCl buffer containing 1% glucose. Compound (VI) was added to the obtained cell suspension to a final concentration of 100ppm and that was incubated with shaking at 30°C. At each of 0 hours after and 1 day after the start of shaking, 2ml of the cell suspension were fractioned. Fifty microliters (50μl) of 2N HCl were added to each and those were extracted with 2ml of ethyl acetate. The obtained ethyl acetate layers were analyzed on a HPLC under reaction condition 1. Compared to the concentration of compound (VI) detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, the concentration of compound (VI) detected from the

ethyl acetate later prepared from the cell suspension at 1 day after the start of shaking was lower. Further a peak, which was not detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, was detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking. Mass spectrometry of the compound contained in said peak was conducted. The mass of the compound contained in said peak was 14 less than the mass of compound (VI).

#### (7) Metabolism of compound (VIII) by the present protein (A1)

[0354] Other than utilizing compound (VIII) instead of compound (VI), there was conducted in accordance with the method described in Example 41(6), a culturing of *E. coli* JM109/pKSN657F, preparation of the cell suspension solution, incubation with shaking of the cell suspension solution to which compound (VIII) was added, reagent preparation from the cell suspension solution and HPLC analysis of the reagents. Compared to the concentration of compound (VIII) detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, the concentration of compound (VIII) detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking was lower. Further two peaks, which were not detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, were detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking. Mass spectrometry of the compounds contained in said peaks was conducted. The mass of the compound contained in one of said peaks was 14 less and the mass of the compound contained in the other peak was 28 less than the mass of compound (VIII).

#### (8) Metabolism of compound (X) by the present invention protein (A1)

[0355] Other than utilizing compound (X) instead of compound (VI), there was conducted in accordance with the method described in Example 41(6), a culturing of *E. coli* JM109/pKSN657F, preparation of the cell suspension solution, shake culturing of the cell suspension solution to which compound (X) was added, reagent preparation from the cell suspension solution and HPLC analysis of the reagents. Compared to the concentration of compound (X) detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, the concentration of compound (X) detected from the ethyl acetate later prepared from the cell suspension at 1 day after the start of shaking was lower. Further two peaks, which were not detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, were detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking. Mass spectrometry of the compounds contained in said peaks was conducted. The mass of the compound contained in one of said peaks was 40 less and the mass of the compound contained in the other peak was 54 less than the mass of compound (X).

#### (9) Metabolism of compound (XI) by the present invention protein (A1)

[0356] Other than utilizing compound (XI) instead of compound (VI), there was conducted in accordance with the method described in Example 41(6), a culturing of *E. coli* JM109/pKSN657F, preparation of the cell suspension solution, shake culturing of the cell suspension solution to which compound (XI) was added, reagent preparation from the cell suspension solution and HPLC analysis of the reagents. Compared to the concentration of compound (XI) detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, the concentration of compound (XI) detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking was lower. Further two peaks, which were not detected from the ethyl acetate layer prepared from the cell suspension at 0 hours after the start of shaking, were detected from the ethyl acetate layer prepared from the cell suspension at 1 day after the start of shaking. Mass spectrometry of the compounds contained in said peaks was conducted. The mass of the compound contained in one of said peaks was 14 less and the mass of the compound contained in the other peak was 16 less than the mass of compound (XI).

#### Example 42 Metabolism of Compounds by the Present Invention Protein (A11)

##### (1) Metabolism of compound (X) by the present invention compound (A11)

[0357] Each of *E. coli* JM109/pKSN849AF and *E. coli* JM109/pKSN2 was cultured overnight at 37°C in 3ml of TB culture containing 50µg/ml of ampicillin. A milliliter (1ml) of the obtained culture mediums was transferred to 100ml of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. When OD660 reached about 0.5, 5-aminolevulinic acid was added to the final concentration of 500µM, and the culturing was continued. Thirty (30) minutes thereafter, IPTG was added to a final concentration of 1mM, and there was further culturing for 18 hours.

[0358] The cells were recovered from the culture medium, washed with 0.1M tris-HCl buffer (pH7.5) and suspended

in 10ml of 0.1M Tris-HCl buffer containing 1% glucose. Compound (X) was added to the obtained cell suspension to a final concentration of 25ppm and that was incubated with shaking at 30°C. At each of 0 hours after and 4 days after the start of shaking, 2ml of the cell suspension were fractioned. Fifty microliters (50μl) of 2N HCl were added to each and those were extracted with 2ml of ethyl acetate. The obtained ethyl acetate layers were analyzed on a HPLC under reaction condition 1. Compared to the concentration of compound (X) detected from the ethyl acetate layer prepared from the JM109/pKSN2 cell suspension, the concentration of compound (X) detected from the ethyl acetate layer prepared from the JM109/pKSN849AF cell suspension was lower. Further 3 peaks, which were not detected from the ethyl acetate layer prepared from the JM109/pKSN2 cell suspension, were detected from the ethyl acetate layer prepared from the JM109/pKSN849AF cell suspension. Of the 3 peaks, the elution time in the HPLC of 1 of the peaks matched with the elution time of a peak of a compound that has a mass of 40 less than compound (X) detected in Example 41(8). Further, the elution time in the HPLC of another peak matched with the elution time of a peak of a compound that has a mass of 54 less than compound (X) detected in Example 41(8).

[0359] After drying, respectively, 1ml of the ethyl acetate layer prepared from the above JM109/pKSN2 cell suspension and 1ml of the ethyl acetate layer prepared from the above JM109/pKSN849AF cell suspension, the residues were dissolved in 1ml of dimethylsulfoxide (hereinafter, the solution derived from the ethyl acetate layer prepared from JM109/pKSN849AF is referred to as "(X) metabolism solution (A11)"; further, the solution derived from the ethyl acetate layer prepared from JM109/pKSN2 cell suspension is referred to as "(X) control solution (A11)").

[0360] Twenty microliters (20μl) of a 128-fold dilution of the above (X) metabolism solution (A11) and 60μl of the plastid fraction were mixed. In darkened conditions, 20μl of PPO substrate solution were added and maintained at 30°C for 1.5 hours. Further, instead of said 20μl of the 128-fold dilution of (X) metabolism solution (A11), a reaction solution to which 20μl of the 128-fold dilution of (X) control solution (A11) was added was prepared, and the PPO substrate solution was added and maintained similarly. Similar to Example 41(2), each of the reaction solutions after the maintenance were prepared and subjected to reverse phase HPLC analysis under the above analysis condition 2 to measure the amount of PPIX. The PPIX amount in the reaction solution to which (X) metabolism solution (A11) was added was more than the PPIX amount in the reaction solution to which (X) control solution (A11) was added.

## (2) Metabolism of compound (XII) by the present invention protein (A11)

[0361] Other than utilizing 20μl of the supernatant fraction recovered in Example 32(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 32(2) is referred to as "(XII) metabolism solution (A11)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 32(2) is referred to as "(XII) control solution (A11)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A11), the concentration of compound (XII) detected from (XII) metabolism solution (A11) was lower. Further a peak, which was not detected from the (XII) control solution (A11), was detected from the (XII) metabolism solution (A11). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

## (3) Metabolism of compound (XIII) by the present invention protein (A11)

[0362] Other than utilizing 20μl of the supernatant fraction recovered in Example 32(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 32(2) is referred to as "(XIII) metabolism solution (A11)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 32(2) is referred to as "(XIII) control solution (A11)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A11), the concentration of compound (XIII) detected from (XIII) metabolism solution (A11) was lower. Further a peak, which was not detected from the (XIII) control solution (A11), was detected from the (XIII) metabolism solution (A11). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A11) in Example 41(3).

**(4) Metabolism of compound (XVI) by the present invention protein (A11)**

**[0363]** Other than utilizing 20μl of the supernatant fraction recovered in Example 32(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(4). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 200μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 32(2) is referred to as "(XVI) metabolism solution (A11)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 32(2) is referred to as "(XVI) control solution (A11)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XVI) detected from (XVI) control solution (A11), the concentration of compound (XVI) detected from (XVI) metabolism solution (A11) was lower. Further a peak, which was not detected from the (XVI) control solution (A11), was detected from the (XVI) metabolism solution (A11). The elution time of said peak on the HPLC matched an elution time of a peak in Example 41(4) which was detected from (XVI) metabolism solution (A11) and not detected in (XVI) control solution (A11).

**(5) Metabolism of compound (XVII) by the present invention protein (A11)**

**[0364]** Other than utilizing 20μl of the supernatant fraction recovered in Example 32(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(5). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 200μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 32(2) is referred to as "(XVII) metabolism solution (A11)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 32(2) is referred to as "(XVII) control solution (A11)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XVII) detected from (XVII) control solution (A11), the concentration of compound (XVII) detected from (XVII) metabolism solution (A11) was lower. Further a peak, which was not detected from the (XVII) control solution (A11), was detected from the (XVII) metabolism solution (A11). The elution time of said peak on the HPLC matched an elution time of a peak in Example 41(5) which was detected from (XVII) metabolism solution (A11) and not detected in (XVII) control solution (A11).

**Example 43 Metabolism of compounds by the present invention protein (A2), (A3), (A12), (A13), (A14) or (A15) or the present protein (A10)****(1) Metabolism of compound (XII) by the present invention protein (A2)**

**[0365]** Other than utilizing 20μl of the supernatant fraction recovered in Example 7(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 7(2) is referred to as "(XII) metabolism solution (A2)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 7(2) is referred to as "(XII) control solution (A2)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A2), the concentration of compound (XII) detected from (XII) metabolism solution (A2) was lower. Further a peak, which was not detected from the (XII) control solution (A2), was detected from the (XII) metabolism solution (A2). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

**(2) Metabolism of compound (XII) by the present invention protein (A3)**

**[0366]** Other than utilizing 20μl of the supernatant fraction recovered in Example 12(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance

was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 12(2) is referred to as "(XII) metabolism solution (A3)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 7(2) is referred to as "(XII) control solution (A3)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A3), the concentration of compound (XII) detected from (XII) metabolism solution (A3) was lower. Further a peak, which was not detected from the (XII) control solution (A3), was detected from the (XII) metabolism solution (A3). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### (3) Metabolism of compound (XII) by the present protein (A10)

[0367] Other than utilizing 20μl of the supernatant fraction recovered in Example 10(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 10(2) is referred to as "(XII) metabolism solution (A10)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 12(3) is referred to as "(XII) control solution (A10)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A10), the concentration of compound (XII) detected from (XII) metabolism solution (A10) was lower. Further a peak, which was not detected from the (XII) control solution (A10), was detected from the (XII) metabolism solution (A10). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### (4) Metabolism of compound (XII) by the present invention protein (A12)

[0368] Other than utilizing 20μl of the supernatant fraction recovered in Example 34(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 34(2) is referred to as "(XII) metabolism solution (A12)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 34(2) is referred to as "(XII) control solution (A12)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A12), the concentration of compound (XII) detected from (XII) metabolism solution (A12) was lower. Further a peak, which was not detected from the (XII) control solution (A12), was detected from the (XII) metabolism solution (A12). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### (5) Metabolism of compound (XII) by the present invention protein (A13)

[0369] Other than utilizing 20μl of the supernatant fraction recovered in Example 36(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 36(2) is referred to as "(XII) metabolism solution (A13)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 36(2) is referred to as "(XII) control solution (A13)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A13), the concentration of compound (XII) detected from (XII)

metabolism solution (A13) was lower. Further a peak, which was not detected from the (XII) control solution (A13), was detected from the (XII) metabolism solution (A13). The elution time of the said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### (6) Metabolism of compound (XII) by the present invention protein (A14)

[0370] Other than utilizing 20μl of the supernatant fraction recovered in Example 38(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 38(2) is referred to as "(XII) metabolism solution (A14)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 38(2) is referred to as "(XII) control solution (A14)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A14), the concentration of compound (XII) detected from (XII) metabolism solution (A14) was lower. Further a peak, which was not detected from the (XII) control solution (A14), was detected from the (XII) metabolism solution (A14). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### (7) Metabolism of compound (XII) by the present invention protein (A15)

[0371] Other than utilizing 20μl of the supernatant fraction recovered in Example 40(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(2). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of 50mM potassium phosphate buffer (pH7.0). The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 40(2) is referred to as "(XII) metabolism solution (A15)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 40(2) is referred to as "(XII) control solution (A15)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A15), the concentration of compound (XII) detected from (XII) metabolism solution (A15) was lower. Further a peak, which was not detected from the (XII) control solution (A15), was detected from the (XII) metabolism solution (A15). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### (8) Metabolism of compound (XIII) by the present invention protein (A2)

[0372] Other than utilizing 20μl of the supernatant fraction recovered in Example 7(2) instead of 20μl of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100μl of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 7(2) is referred to as "(XIII) metabolism solution (A2)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 7(2) is referred to as "(XIII) control solution (A2)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A2), the concentration of compound (XIII) detected from (XIII) metabolism solution (A2) was lower. Further a peak, which was not detected from the (XIII) control solution (A2), was detected from the (XIII) metabolism solution (A2). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### (9) Metabolism of compound (XIII) by the present invention protein (A3)

[0373] Other than utilizing 20μl of the supernatant fraction recovered in Example 12(2) instead of 20μl of the super-

natant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 12(2) is referred to as "(XIII) metabolism solution (A3)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 12(2) is referred to as "(XIII) control solution (A3)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A3), the concentration of compound (XIII) detected from (XIII) metabolism solution (A3) was lower. Further a peak, which was not detected from the (XIII) control solution (A3), was detected from the (XIII) metabolism solution (A3). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### (10) Metabolism of compound (XIII) by the present protein (A10)

**[0374]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 10(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 10(2) is referred to as "(XIII) metabolism solution (A10)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 10(2) is referred to as "(XIII) control solution (A10)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A10), the concentration of compound (XIII) detected from (XIII) metabolism solution (A10) was lower. Further a peak, which was not detected from the (XIII) control solution (A10), was detected from the (XIII) metabolism solution (A10). The elution time of the said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### (11) Metabolism of compound (XIII) by the present invention protein (A12)

**[0375]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 34(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 34(2) is referred to as "(XIII) metabolism solution (A12)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 34(2) is referred to as "(XIII) control solution (A12)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A12), the concentration of compound (XIII) detected from (XIII) metabolism solution (A12) was lower. Further a peak, which was not detected from the (XIII) control solution (A12), was detected from the (XIII) metabolism solution (A12). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### (12) Metabolism of compound (XIII) by the present invention protein (A13)

**[0376]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 36(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 36(2) is referred to as "(XIII) metabolism solution (A13)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 36(2) is referred to as "(XIII) control solution (A13)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A13), the concentration of compound (XIII) detected from (XIII) metabolism solution (A13) was lower. Further a peak, which was not detected from the (XIII) control solution (A13), was detected from the (XIII) me-

tabolism solution (A13). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

### **(13) Metabolism of compound (XIII) by the present invention protein (A14)**

**[0377]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 38(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 4(2), the reaction solution were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 38(2) is referred to as "(XIII) metabolism solution (A14)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 38(2) is referred to as "(XIII) control solution (A14)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A14), the concentration of compound (XIII) detected from (XIII) metabolism solution (A14) was lower. Further a peak, which was not detected from the (XIII) control solution (A14), was detected from the (XIII) metabolism solution (A14). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

### **(14) Metabolism of compound (XIII) by the present invention protein (A15)**

**[0378]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 40(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 4(2), the reaction solutions were prepared and maintained in accordance with the method described in Example 41(3). Similar to Example 41(2), each of the reaction solutions after the maintenance was extracted with ethyl acetate and the obtained residue was dissolved in 100 $\mu$ l of dimethylsulfoxide. The obtained solutions (hereinafter, the solution derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 40(2) is referred to as "(XIII) metabolism solution (A15)"; further, the solution derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 40(2) is referred to as "(XIII) control solution (A15)") were analyzed on a HPLC under the above analysis condition I. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A15), the concentration of compound (XIII) detected from (XIII) metabolism solution (A15) was lower. Further a peak, which was not detected from the (XIII) control solution (A15), was detected from the (XIII) metabolism solution (A15). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

## **Example 44 Preparation of the Present Invention Antibody (A) Recognizing the Present Invention Protein (A1)** (hereinafter referred to as "present invention antibody (A1)")

### **(1) Preparation of the extract of an E. coli expressing the present invention protein (A1)**

**[0379]** In accordance with the method described in Example 4(2), E. coli JM109/pKSN657F, which expresses the present invention protein (A1), was pre-cultured overnight and then cultured in IL of TB medium containing 50 $\mu$ g/ml of ampicillin. After recovering and disrupting the cells, supernatant fractions (E. coli pKSN657F extract) were prepared from the obtained cell lysate solution.

### **(2) Purification of the present invention protein (A1)**

**[0380]** The present invention protein (A1) was purified according to the method described in Example 2(4) by subjecting the supernatant fraction obtained in Example 44(1) (E. coli pKSN657F extract) in turn to a HiLoad HiLoad26/10 Q Sepharose HP column and then a Bio-Scale Ceramic Hydroxyapatite, Type I column CHT10-1 column. The purified fractions were analyzed on a 10% to 20% SDS-PAGE, to confirm that those were fractions of only the present invention protein (A1).

### **(3) Preparation of the present invention antibody (A1)**

**[0381]** The present invention protein (A1) prepared in Example 44(2) was dissolved in 0.05M potassium phosphate buffer (pH7.0) so that the concentration was 1mg/ml. Forty microliters (40 $\mu$ l) of RAS (MPL (Monophosphoryl lipid A) + TDM (Synthetic Trehalose Dicorynomycolate) + CWS (Cell Wall Skeleton) Adjuvant System (Sigma Company)) al-

ready incubated at 42°C to 43°C was added and well mixed into 2ml of the obtained solution. The obtained mixture was administered, respectively, to New Zealand White rabbits (female, 14 weeks old, average of 2.4kg) at 1ml per rabbit. As such, 100µl was injected subcutaneously at 10 locations on the back. About 1/2 of the amount of the first administration was administered after each of 3 weeks and 5 weeks. During such time, the antibody titer was measured by sampling the blood from a ear vein of the rabbit. Since the antibody titer increased after the third administration, the immunized rabbit at 2 weeks after the third administration was exsanguinated from the neck. The obtained blood was added into a Separapit Tube (Sekisui Chemical Company), incubated at 37°C for 2 hours and was then centrifuged (3000rpm, 20 minutes, room temperature). The antiserum (containing the present invention antibody (A1)) was obtained by recovering the supernatant.

#### **Example 45 Detection of the Present Protein by the Present Invention Antibody (A1) and Detection of a Cell Expressing the Present Protein**

**[0382]** An immunoblot was conducted by utilizing the present invention antibody (A1) obtained in Example 44 with each of the E. coli extracts. There was a SDS polyacrylamide electrophoresis (40mA, 1 hour) of: the E. coli pKSN657F extract obtained in Example 4(2) (containing about 0.5pmol of the present invention protein (A1), containing about 0.78mg of protein); the E. coli pKSN2 extract obtained in Example 4(2) (containing about 0.78mg of protein) the E. coli pKSN923F extract obtained in Example 7(2) (containing about 2pmol of the present invention protein (A2)); the E. coli pKSN671F extract obtained in Example 12(2) (containing about 2pmol of the present invention protein (A3)); the E. coli pKSN646F extract obtained in Example 27(2) (containing about 2pmol of the present invention protein (A4)); the E. coli pKSN 11796F extract obtained in Example 10(2) (containing about 2pmol of the present protein (A10)); the E. coli pKSNCA extract obtained in Example 14(2) (containing about 2pmol of the present protein (A9)); the E. coli pKSN849AF extract obtained in Example 32(2) (containing about 2pmol of the present invention protein (A11)); the E. coli pKSN1618F extract obtained in Example 34(2) (containing about 2pmol of the present invention protein (A12)); the E. coli pKSN474F extract obtained in Example 36(2) (containing about 2pmol of the present invention protein (A13)); the E. coli pKSN1491AF extract obtained in Example 38(2) (containing about 2pmol of the present invention protein (A14)); and the E. coli pKSN1555AF extract obtained in Example 40(2) (containing about 2pmol of the present invention protein (A15)). A PVDF membrane was placed on the gel. The proteins in the gel were transferred onto the PVDF membrane by a treatment with a BioRad blotting device at 4°C, 30V for 2 hours, while in the condition of being soaked in transfer buffer (25mM Tris, 192mM glycine, 10% methanol). After washing with TBS + Tween 20 solution (50mM Tris-HCl (pH7.5), 200mM NaCl, 0.05% Tween 20), the obtained PVDF membrane was incubated for 30 minutes in TBS + Tween 20 solution containing 3% BSA and was then utilized for a reaction with the above antiserum diluted 30,000 fold for 30 minutes in TBS + Tween 20 solution containing 3% BSA. After the reaction, the PVDF membrane was washed twice with TBS + Tween 20 solution. The PVDF membrane was then utilized for a reaction in TBS + Tween 20 solution containing 3% BSA for 30 minutes with a 3000 fold dilution of anti-rabbit IgG goat anti-serum labeled with alkaline phosphatase (Santa Cruz Biotechnology Company). After the reaction, the PVDF membrane was washed twice with TBS + Tween 20 solution and was soaked in NBT-BCIP solution (Sigma Company). There was detected a stain for a band corresponding to each of the present invention proteins (A1), (A2), (A3), (A4), (A11), (A12), (A 13), (A 14) and (A 15) as well as the present proteins (A9) and (A10). No stained band was detected with the reagent of E. coli pKSN2 extract (containing about 0.78mg of protein) obtained in Example 4(2).

#### **Example 46 Preparation and Expression of the Present Invention DNA (A1) in which the Codon usage has been Adjusted for Expression in Soybean (hereinafter referred to as the "present invention DNA (A1)S")**

##### **(1) Preparation of the present invention DNA (A1)S**

**[0383]** PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing a primer having a nucleotide sequence shown in SEQ ID NO: 192 and a primer having a nucleotide sequence shown in SEQ ID NO: 213. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 191 and a primer having the nucleotide sequence shown in SEQ ID NO: 212. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 190 and a primer having the nucleotide sequence shown in SEQ ID NO: 211. The obtained reaction solution was designated as reaction solution 1.

**[0384]** PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing a primer having a nucleotide sequence shown in SEQ ID NO: 195 and a primer having a nucleotide sequence shown in SEQ ID NO:210. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 194 and a primer having

the nucleotide sequence shown in SEQ ID NO: 209. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 193 and a primer having the nucleotide sequence shown in SEQ ID NO: 208. The obtained reaction solution was designated as reaction solution 2.

[0385] PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual by utilizing a primer having a nucleotide sequence shown in SEQ ID NO: 198 and a primer having a nucleotide sequence shown in SEQ ID NO: 207. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 197 and a primer having the nucleotide sequence shown in SEQ ID NO: 206. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 196 and a primer having the nucleotide sequence shown in SEQ ID NO: 205. The obtained reaction solution was designated as reaction solution 3.

[0386] PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing a primer having a nucleotide sequence shown in SEQ ID NO: 201 and a primer having a nucleotide sequence shown in SEQ ID NO: 204. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 200 and a primer having the nucleotide sequence shown in SEQ ID NO: 203. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing a primer having the nucleotide sequence shown in SEQ ID NO: 199 and a primer having the nucleotide sequence shown in SEQ ID NO: 202. The obtained reaction solution was designated as reaction solution 4.

[0387] The reaction solutions 1 to 4 obtained in such a way were mixed. PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as a template an aliquot of the mixture thereof and by utilizing a primer having a nucleotide sequence shown in SEQ ID NO: 190 and a primer having a nucleotide sequence shown in SEQ ID NO: 202. The nucleotide sequence of the amplified DNA was confirmed. There was obtained a DNA having a sequence in which the nucleotide sequence 5'-cat-3' is connected upstream of the 5' terminus and the nucleotide sequence 5'-aagctt-3' is connected downstream of the 3' terminus of the nucleotide sequence shown in SEQ ID NO: 214.

[0388] The codon usage of the present invention DNA (A1) having the nucleotide sequence shown in SEQ ID NO: 6 (GC content of 70.58%) is shown in Table 22 and Table 23. The codon usage of soybean (GC content of 46.12%, Codon Usage Database published by Kazusa DNA Research Institute (<http://www.kazusa.or.jp/codon>)) is shown in Table 24 and Table 25. The codon usage of the present invention DNA (A1) having the nucleotide sequence shown in SEQ ID NO: 214 (GC content of 51.59%) is shown in Table 26 and Table 27.

Table 22

codon	%	codon	%
TTT	0.00	TCT	0.00
TTC	3.18	TCC	1.71
TTA	0.00	TCA	0.00
TTG	1.22	TCG	2.20
CTT	0.00	CCT	0.00
CTC	3.67	CCC	4.16
CTA	0.00	CCA	0.00
CTG	7.09	CCG	2.69
ATT	0.24	ACT	0.24
ATC	4.16	ACC	2.69
ATA	0.00	ACA	0.24
ATG	2.69	ACG	1.96
GTT	0.24	GCT	0.00
GTC	3.67	GCC	7.58
GTA	0.00	GCA	0.49

# EP 1 457 558 A1

Table 22 (continued)

codon	%	codon	%
GTG	3.18	GCG	3.42

Table 23

codon	%	codon	%
TAT	0.00	TGT	0.24
TAC	1.47	TGC	0.98
TAA	0.00	TGA	0.00
TAG	0.24	TGG	0.98
CAT	0.24	CGT	1.22
CAC	2.20	CGC	4.40
CAA	0.24	CGA	0.24
CAG	2.93	CGG	4.16
AAT	0.00	AGT	0.00
AAC	1.22	AGC	0.49
AAA	0.24	AGA	0.00
AAG	0.98	AGG	0.00
GAT	0.98	GGT	0.98
GAC	7.82	GGC	3.42
GAA	0.73	GGA	0.24
GAG	5.38	GGG	1.22

Table 24

codon	%	codon	%
TTT	2.03	TCT	1.71
TTC	2.09	TCC	1.21
TTA	0.82	TCA	1.45
TTG	2.21	TCG	0.44
CTT	2.36	CCT	2.00
CTC	1.66	CCC	1.01
CTA	0.82	CCA	2.05
CTG	1.22	CCG	0.40
ATT	2.61	ACT	1.78
ATC	1.64	ACC	1.49
ATA	1.27	ACA	1.51
ATG	2.27	ACG	0.41
GTT	2.67	GCT	2.81
GTC	1.24	GCC	1.69
GTA	0.73	GCA	2.27

EP 1 457 558 A1

Table 24 (continued)

codon	%	codon	%
GTG	2.20	GCG	0.59

Table 25

codon	%	codon	%
TAT	1.61	TGT	0.72
TAC	1.53	TGC	0.75
TAA	0.11	TGA	0.09
TAG	0.06	TGG	1.21
CAT	1.33	CGT	0.72
CAC	1.09	CGC	0.63
CAA	2.04	CGA	0.38
CAG	1.71	CGG	0.27
AAT	2.10	AGT	1.21
AAC	2.27	AGC	1.08
AAA	2.63	AGA	1.42
AAG	3.83	AGG	1.35
GAT	3.29	GGT	2.17
GAC	2.06	GGC	1.38
GAA	3.35	GGA	2.23
GAG	3.46	GGG	1.29

Table 26

codon	%	codon	%
TTT	1.71	TCT	0.98
TTC	1.47	TCC	0.73
TTA	0.98	TCA	0.98
TTG	2.93	TCG	0.24
CTT	3.18	CCT	2.44
CTC	2.20	CCC	1.22
CTA	0.98	CCA	2.69
CTG	1.71	CCG	0.49
ATT	2.20	ACT	1.71
ATC	1.22	ACC	1.47
ATA	0.98	ACA	1.47
ATG	2.69	ACG	0.49
GTT	2.93	GCT	4.16
GTC	1.22	GCC	2.69
GTA	0.73	GCA	3.67

Table 26 (continued)

codon	%	codon	%
GTG	2.20	GCG	0.98

Table 27

codon	%	codon	%
TAT	0.73	TGT	0.73
TAC	0.73	TGC	0.49
TAA	0.00	TGA	0.00
TAG	0.24	TGG	0.98
CAT	1.47	CGT	1.47
CAC	0.98	CGC	1.47
CAA	1.71	CGA	0.73
CAG	1.47	CGG	0.49
AAT	0.73	AGT	0.73
AAC	0.49	AGC	0.73
AAA	0.49	AGA	2.93
AAG	0.73	AGG	2.93
GAT	5.38	GGT	1.71
GAC	3.42	GGC	1.22
GAA	2.69	GGA	1.96
GAG	3.42	GGG	0.98

## (2) Production of a transformed E. coli having the present invention protein (A1)S

[0389] The DNA having the nucleotide sequence shown in SEQ ID NO: 214 obtained in Example 46(1) was digested with restriction enzymes NdeI and HindIII. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid in which the DNA having the nucleotide sequence shown in SEQ ID NO: 214 is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN657 soy"). Said plasmid was introduced into E. coli JM109. The obtained E. coli transformant was designated JM109/pKSN657soy.

## (3) Expression of the present invention protein (A1) in E. coli and recovery of said protein

[0390] Similarly to Example 4(2), each of E. coli JM109/pKSN657soy obtained in Example 46(2) and E. coli JM109/pKSN657 obtained in Example 4(1) was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN657soy is referred to as "E. coli pKSN849soy extract" and the supernatant fraction obtained from E. coli JM109/pKSN657 is referred to as "E. coli pKSN657 extract"). The amount of P450 per the protein amount contained in E. coli pKSN657soy extract was compared to and was higher than the amount of P450 per the protein amount contained in E. coli pKSN657 extract.

## Example 47 Introduction of the Present Invention DNA (A1)S into a Plant

### (1) Construction of a Chloroplast Expression Plasmid Containing the Present Invention DNA (A1)S for Direct Introduction - part 1

[0391] A plasmid containing a chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit

without a change of frames in the codons was constructed as a plasmid for introducing the present invention DNA (A1) S into a plant with the particle gun method.

[0392] First, DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 was amplified by PCR. The PCR was conducted by utilizing as a template pKSN657soy obtained in Example 46(2) and by utilizing as primers an oligo-nucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 394 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 395. The PCR utilized KOD-plus (Toyobo Company). The PCR carried out after conducting a maintenance at 94°C for 2 minutes; 30 cycles of a cycle that included maintaining 94°C for 30 seconds, followed by 50°C for 30 seconds, and followed by 68°C for 60 seconds; and a final maintenance at 68°C for 30 seconds. The amplified DNA was recovered and purified with MagExtractor-PCR & Gel-Clean up (Toyobo Company) by conducting the procedures according to the attached manual. After digesting the purified DNA with restriction enzymes EcoT22I and SacI, the DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 was recovered. After digesting plasmid pUCrSt657 obtained in Example 16(2) with restriction enzymes EcoT22I and SacI, there was isolated a DNA of about 2.9kbp having a nucleotide sequence derived from pUC19 and a sequence encoding a chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit. The obtained DNA and the above DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 were ligated to obtain pUCrSt657soy (Fig. 48) containing a chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

[0393] The obtained plasmid pUCrSt657soy was digested with restriction enzymes BamHI and SacI to isolate a DNA comprising a nucleotide sequence shown in SEQ ID NO: 214. Said DNA was inserted between the restriction enzyme site of BglII and the restriction enzyme site of SacI of plasmid pNdG6- Δ T obtained in Example 16(2) to obtain plasmid pSUM-NdG6-rSt-657soy (Fig. 49) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

[0394] Next, the plasmid was introduced into E. coli DH5 α competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the selected ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt-657soy had the nucleotide sequence shown in SEQ ID NO: 214.

## (2) Construction of a chloroplast expression plasmid having the present invention DNA (A1)S for direct introduction - part (2)

[0395] A plasmid was constructed for introducing the present invention DNA (A1)S into a plant with the particle gun method. The plasmid contained a chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. First, DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 was amplified by PCR. The PCR was conducted by utilizing as a template pKSN657soy obtained in Example 46(2) and by utilizing as primers an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 395 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 396. The PCR utilized KOD-plus (Toyobo Company). The PCR carried out after conducting a maintenance at 94°C for 2 minutes; 25 cycles of a cycle that included maintaining 94°C for 30 seconds, followed by 46°C for 30 seconds, and followed by 68°C for 60 seconds; and a final maintenance at 68°C for 3 minutes. The amplified DNA was recovered and purified with MagExtractor-PCR & Gel-Clean up (Toyobo Company) by conducting the procedures according to the attached manual. After digesting the purified DNA with restriction enzyme SacI, the DNA comprising the nucleotide sequence shown in SEQ ID NO: 214 was recovered.

[0396] Plasmid pKFrSt12-657 obtained in Example 16(3) was digested with restriction enzyme BspHI. The DNA was then blunt ended and the 5' terminus was dephosphorylated by utilizing TaKaRa BKLKit (Takara Shuzo Company) in accordance with the attached manual. Next, after the DNA was digested with restriction enzyme SacI, the DNA derived from plasmid pKFrSt12 was isolated. Said DNA was ligated with the DNA which was digested with SacI and which comprises the nucleotide sequence shown in SEQ ID NO: 214, in order to obtain plasmid pKFrSt12-657soy (Fig. 50) containing the chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons.

[0397] The obtained plasmid pKFrSt12-657soy was digested with restriction enzymes BamHI and SacI to isolate DNA comprising the nucleotide sequence shown in SEQ ID NO: 214. Said DNA was inserted between the restriction enzyme site of BglII and the restriction enzyme site of SacI of plasmid pNdG6- Δ T to obtain plasmid pSUM-NdG6-rSt12-657soy (Fig. 51) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which said DNA was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of

soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

[0398] Next, the plasmid was introduced into *E. coli* DH5  $\alpha$  competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt12-657soy had the nucleotide sequence shown in SEQ ID NO: 214.

### (3) Introduction of the present invention DNA (A1)S into soybean

[0399] The globular embryos of soybeans (cultivar: Fayette and Jack) were prepared according to the method described in Example 17(1), other than substituting the vitamin source of MS medium with the vitamin source of B5 medium (O. L. Gamborg et al., Exp. Cell Res. (1986) 50 p151).

[0400] The obtained globular embryo was transplanted into fresh somatic embryo growth medium and cultured for 2 to 3 days. In accordance with the method described in Example 17(2), plasmid pSUM-NdG6-rSt-657soy constructed in Example 47(1) or plasmid pSUM-NdG6-rSt12-657soy constructed in Example 47(2) was introduced to said globular embryos.

### (4) Selection of somatic embryo with hygromycin

[0401] Selection by hygromycin of a globular embryo after the gene introduction obtained in Example 47(3) was conducted according to the method described in Example 17(3), other than substituting the vitamin source of MS medium with the vitamin source of B5 medium. However, after the second transplant, a medium to which 0.2(w/v)% of Gelrite was added or a liquid medium to which no Gelrite was added was utilized as the somatic embryo selection medium. In the case of the liquid medium, the culturing had 90gentle revolutions per minute.

### (5) Selection of somatic embryo with compound (II)

[0402] Selection by compound (II) of a globular embryo after the gene introduction obtained in Example 47(3) is conducted according to the method described in Example 17(4), other than substituting the vitamin source of MS medium with the vitamin source of B5 medium.

### (6) Plant regeneration from the somatic embryo, acclimation and cultivation

[0403] In accordance with the method described in Example 17(5), the plant regeneration is conducted from the globular embryos selected in Example 47(4) or 47(5). However, the agar concentration in the development medium is adjusted to 0.8(w/v)% or 1.0(w/v)%. Further, the vitamin source of the MS medium of the germination medium is substituted with the vitamin source of B5 medium.

[0404] The plant with roots and developed leaves undergo the acclimation and cultivation accordingly with the method described in Example 17(6) and are harvested.

### (7) Evaluation of the resistance to herbicidal compound (II)

[0405] The degree of resistance against compound (II) of the regenerated plant obtained in Example 47(6) is evaluated in accordance with the method described in Example 17(4).

### (8) Construction of a chloroplast expression plasmid having the present invention DNA (A1)S for agrobacterium introduction

[0406] A plasmid for introducing the present invention DNA (A1)S into a plant with the agrobacterium method is constructed. Plasmid pSUM-NdG6-rSt-657soy was digested with restriction enzyme NotI, to obtain a chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons. Said DNA was inserted into the NotI restriction site of the above binary plasmid vector pBI121S obtained in Example 18 to obtain plasmid pBI-NdG6-rSt-657soy (Fig. 52). Further, plasmid pSUM-NdG6-rSt12-657soy was digested with restriction enzyme NotI, to isolate a chimeric DNA in which the present invention DNA (A1)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. Such a DNA was inserted into the NotI restriction site of the above binary plasmid vector pBI121S to obtain plasmid pBI-NdG6-rSt12-657soy

(Fig. 53).

#### **(9) Introduction of the present invention DNA (A1)S to tobacco**

**[0407]** The present invention DNA (A1)S was introduced into tobacco with the agrobacterium method, utilizing plasmid pBI-NdG6-rSt-657soy and pBI-NdG6-rSt12-657soy obtained in Example 47(8).

**[0408]** First, in accordance with the method described in Example 19, each of the plasmids pBI-NdG6-rSt-657soy and pBI-NdG6-rSt12-657soy was introduced into *Agrobacterium tumefaciens* LBA4404 (Clontech Company). The transgenic agrobacterium bearing pBI-NdG6-rSt-657soy or pBI-NdG6-rSt12-657soy were isolated.

**[0409]** Next, other than culturing overnight the transgenic agrobacterium bearing the above plasmid at 30°C in LB liquid medium containing 25mg/L kanamycin, said agrobacterium were utilized to introduce genes into tobacco according to the method described in Example 19. There were obtained, respectively, transgenic tobaccos which have incorporated the T-DNA region of pBI-NdG6-rSt-657soy or pBI-NdG6-rSt12-657soy.

#### **(10) Evaluation of the resistance utilizing a leaf piece of the present invention DNA (A1)S transgenic tobacco**

**[0410]** Leaves were taken from 35 transgenic tobaccos obtained in Example 47(9). Each leaf was divided into pieces in which each piece was 5 to 7mm wide. Leaf pieces were planted onto MS agar medium containing 0, 0.05, 0.1 or 0.2mg/L of compound (II) and cultured in the light at room temperature. On the 11th day of culturing, the herbicidal damage of each of the leaf pieces was observed. Further, leaf pieces were planted onto MS agar mediums containing 0, 0.01, 0.02, 0.05 or 0.1mg/L of compound (XII) and cultured in the light at room temperature. On the 7th day of culturing, the herbicidal damage of each of the leaf pieces was observed. As a control, 20 leaf pieces of tobacco to which no genetic introduction has been conducted (hereinafter, referred to as "wild type tobacco") were utilized on each concentration. An average score for each group was determined by scoring 1 point to a leaf piece that continuously grew, 0.5 points to a halfly withered leaf piece in which chemical damage was observed, and 0 points to a leaf piece which turned white and had withered. The leaf pieces of the tobacco to which the present invention DNA (A1)S (the T-DNA region of plasmid pBI-NdG6-rSt-657soy or pBI-NdG6-rSt12-657soy) has been introduced provided a higher score than the wild type tobacco with each of compound (II) and compound (XII).

#### **Example 48 Obtaining the Present Invention DNA (A16)**

##### **(1) Preparation of the chromosomal DNA of *Streptomyces ornatus* IFO 13069t**

**[0411]** Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces ornatus* IFO 13069t was prepared.

##### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A11)**

**[0412]** PCR was conducted by utilizing as the template the chromosomal DNA prepared from *Streptomyces ornatus* IFO 13069t in Example 48(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned into cloning vector pCRII-TOPO (Invitrogen Company). The sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 343 to 1069 of the nucleotide sequence shown in SEQ ID NO: 225 was provided.

**[0413]** Further, the chromosomal DNA prepared in Example 48(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 265 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 266 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 501 of the nucleotide sequence shown in SEQ ID NO: 235 was provided.

**[0414]** Further, the chromosomal DNA prepared in Example 48(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 267 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 268 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide se-

quence shown in nucleotides 1044 to 1454 of the nucleotide sequence shown in SEQ ID NO: 235 was provided.

### (3) Sequence analysis of the present invention DNA (A16)

[0415] The nucleotide sequence shown in SEQ ID NO: 235 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 48(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 225) consisting of 1251 nucleotides (inclusive of the stop codon) and encoding a 416 amino acid residue (SEQ ID NO: 215) and a nucleotide sequence (SEQ ID NO: 255) consisting of 198 nucleotides (inclusive of the stop codon) and encoding a 65 amino acid residue (SEQ ID NO: 245). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 215) encoded by the nucleotide sequence shown in SEQ ID NO: 225 was calculated to be 46013Da. Further, the molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 245) encoded by the nucleotide sequence shown in SEQ ID NO: 255 was calculated to be 6768Da.

### Example 49 Expression of the Present Invention DNA (A16) in E. Coli

#### (1) Production of a transformed E. coli having the present invention DNA (A16)

[0416] PCR was conducted by utilizing the GeneAmp High Fidelity PCR System (Applied Biosystems Japan Company) and by utilizing as the template the chromosomal DNA prepared from *Streptomyces omatus* IFO 13069t in Example 48(1). As the primers, there was utilized a pairing of the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 269 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 286. The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 200nM, 50ng of the above chromosomal DNA, 5.0 $\mu$ l of dNTP mix (a mixture of 2.0mM of each of the 4 types of dNTP; Clontech Company), 5.0 $\mu$ l of 10X buffer (containing MgCl<sub>2</sub>) and 0.5 $\mu$ l of GeneAmp HF enzyme mix and by adding distilled water. The reaction conditions of the PCR were after maintaining 97°C for 1 minute; repeating 10 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds, and followed by 72°C for 90 seconds; then conducting 15 cycles of a cycle that included maintaining 97°C for 15 seconds, followed by 60°C for 30 seconds and followed by 72°C for 90seconds (wherein 20 seconds was added to the maintenance at 72°C for each cycle); and then maintaining 72°C for 7 minutes. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 267, 286 and 288. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 235 was designated as pCR452F. Similarly to Example 32(1), pCR452F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 235, in which the DNA encoding the present invention protein (A 16) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN452F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN452F.

#### (2) Expression of the present invention protein (A16) in E. coli and recovery of said protein

[0417] Similarly to Example 4(2), each of E. coli JM109/pKSN452F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN452F is referred to as "E. coli pKSN452F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

#### (3) Detection of the ability to convert compound (II) to compound (III)

[0418] Similarly to Example 32(3), reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 49(2) (E. coli pKSN452F extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN452F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

**Example 50 Obtaining the Present Invention DNA (A17)****(1) Preparation of the chromosomal DNA of Streptomyces griseus ATCC 10137**

5 [0419] Under the method described in Example 31(1), the chromosomal DNA of Streptomyces griseus ATCC 10137 was prepared.

**(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A17)**

10 [0420] PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces griseus ATCC 10137 prepared in Example 50(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 343 to 1069 of the nucleotide sequence shown in SEQ ID NO: 226 was provided.

15 [0421] Further, the chromosomal DNA prepared in Example 50(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 270 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 271 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 361 of the nucleotide sequence shown in SEQ ID NO: 236 was provided.

20 [0422] Further, the chromosomal DNA prepared in Example 50(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 272 and primer AP 1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 273 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1035 to 1454 of the nucleotide sequence shown in SEQ ID NO: 236 was provided.

**(3) Sequence analysis of the present invention DNA (A17)**

35 [0423] The nucleotide sequence shown in SEQ ID NO: 236 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 50(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 226) consisting of 1251 nucleotides (inclusive of the stop codon) and encoding a 416 amino acid residue (SEQ ID NO: 216) and a nucleotide sequence (SEQ ID NO: 256) consisting of 198 nucleotides (inclusive of the stop codon) and encoding a 65 amino acid residue (SEQ ID NO: 246). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 216) encoded by the nucleotide sequence shown in SEQ ID NO: 226 was calculated to be 46082Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 246) encoded by the nucleotide sequence shown in SEQ ID NO: 256 was calculated to be 6768Da. The nucleotide sequence shown in SEQ ID NO: 256 is 100% identical to the nucleotide sequence shown in SEQ ID NO: 255. The amino acid sequence shown in SEQ ID NO: 246 is 100% identical to the amino acid sequence shown in SEQ ID NO: 245.

**Example 51 Expression of the Present Invention DNA (A17) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA (A17)**

50 [0424] PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA prepared from Streptomyces griseus ATCC 10137 in Example 50(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 274 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 275. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was sequenced by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 274, 276 and 277. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 236 was designated as pCR608F. Similarly to Example 32(1), pCR608F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained

DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 236, in which the DNA encoding the present invention protein (A17) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN608F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN608F.

## **(2) Expression of the present invention protein (A17) in E. coli and recovery of said protein**

**[0425]** Similarly to Example 4(2), each of E. coli JM109/pKSN608F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN608F is referred to as "E. coli pKSN608F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

## **(3) Detection of the ability to convert compound (II) to compound (III)**

**[0426]** Similarly to Example 32(3), reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 51(2) (E. coli pKSN608F extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with  $^{14}$ C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN608F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

## **Example 52 Obtaining the Present Invention DNA (A18)**

### **(1) Preparation of the chromosomal DNA of Streptomyces achromogenes IFO 12735**

**[0427]** Under the method described in Example 31(1), the chromosomal DNA of Streptomyces achromogenes IFO 12735 was prepared.

### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A18)**

**[0428]** PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces achromogenes IFO 12735 prepared in Example 52(1) and by utilizing primer pairing 17, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 526 to 1048 of the nucleotide sequence shown in SEQ ID NO: 227 was provided.

**[0429]** Further, the chromosomal DNA prepared in Example 52(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 278 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 279 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 600 of the nucleotide sequence shown in SEQ ID NO: 237 was provided.

**[0430]** Further, the chromosomal DNA prepared in Example 52(1) was digested with restriction enzyme Ball. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 163 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 164 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 983 to 1449 of the nucleotide sequence shown in SEQ ID NO: 237 was provided.

### **(3) Sequence analysis of the present invention DNA (A18)**

**[0431]** The nucleotide sequence shown in SEQ ID NO: 237 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 52(2). Two open reading frames (ORF) were present in said nucleotide

sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 227) consisting of 1230 nucleotides (inclusive of the stop codon) and encoding a 409 amino acid residue (SEQ ID NO: 217) and a nucleotide sequence (SEQ ID NO: 257) consisting of 207 nucleotides (inclusive of the stop codon) and encoding a 68 amino acid residue (SEQ ID NO: 247). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 217) encoded by the nucleotide sequence shown in SEQ ID NO: 227 was calculated to be 45099Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 247) encoded by the nucleotide sequence shown in SEQ ID NO: 257 was calculated to be 7193Da.

#### **Example 53 Expression of the Present Invention DNA (A18) in E. Coli**

##### **(1) Production of a transformed E. coli having the present invention DNA (A18)**

[0432] PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces achromogenes* IFO 12735 in Example 52(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 183 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 280. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68, 163, 279 and 281. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 237 was designated as pCR646BF. Similarly to Example 32(1), pCR646BF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 237, in which the DNA encoding the present invention protein (A18) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN646BF"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN646BF.

##### **(2) Expression of the present invention protein (A18) in E. coli and recovery of said protein**

[0433] Similarly to Example 4(2), each of E. coli JM109/pKSN646BF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN646BF is referred to as "E. coli pKSN646BF extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

##### **(3) Detection of the ability to convert compound (II) to compound (III)**

[0434] Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 53(2) (E. coli pKSN646BF extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN646BF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

#### **Example 54 Obtaining the Present Invention DNA (A19)**

##### **(1) Preparation of the chromosomal DNA of *Streptomyces griseus* IFO 13849T**

[0435] Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces griseus* IFO 13849T was prepared.

##### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A19)**

[0436] PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces griseus* IFO 13849T prepared in Example 54(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 343 to 1069 of the nucleotide sequence shown in SEQ ID NO: 228 was provided.

**[0437]** Further, the chromosomal DNA prepared in Example 54(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 282 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 283 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 358 of the nucleotide sequence shown in SEQ ID NO: 238 was provided.

**[0438]** Further, the chromosomal DNA prepared in Example 54(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 284 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 285 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1005 to 1454 of the nucleotide sequence shown in SEQ ID NO: 238 was provided.

### **(3) Sequence analysis of the present invention DNA (A19)**

**[0439]** The nucleotide sequence shown in SEQ ID NO: 238 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 54(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 228) consisting of 1251 nucleotides (inclusive of the stop codon) and encoding a 416 amino acid residue (SEQ ID NO: 218) and a nucleotide sequence (SEQ ID NO: 258) consisting of 156 nucleotides (inclusive of the stop codon) and encoding a 51 amino acid residue (SEQ ID NO: 248). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 218) encoded by the nucleotide sequence shown in SEQ ID NO: 228 was calculated to be 45903Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 248) encoded by the nucleotide sequence shown in SEQ ID NO: 258 was calculated to be 5175Da.

### **Example 55 Expression of the Present Invention DNA (A19) in E. Coli**

#### **(1) Production of a transformed E. coli having the present invention DNA (A19)**

**[0440]** PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces griseus* IFO 13849T in Example 54(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 286 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 287. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 284, 286 and 288. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 238 was designated as pCR1502F. Similarly to Example 32(1), pCR1502F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 238, in which the DNA encoding the present invention protein (A19) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1502F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1502F.

#### **(2) Expression of the present invention protein (A18) in E. coli and recovery of said protein**

**[0441]** Similarly to Example 4(2), each of E. coli JM109/pKSN1502F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1502F is referred to as "E. coli pKSN1502F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

#### **(3) Detection of the ability to convert compound (II) to compound (III)**

**[0442]** Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C.

However, as the supernatant fraction, the supernatant fraction prepared in Example 55(2) (*E. coli* pKSN1502F extract or *E. coli* pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with  $^{14}\text{C}$  were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing *E. coli* pKSN1502F extract. In contrast, such a spot was not detected from the reaction solution containing *E. coli* pKSN2 extract.

#### Example 56 Obtaining the Present Invention DNA (A20)

##### (1) Preparation of the chromosomal DNA of *Streptomyces lanatus* IFO 12787T

[0443] Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces lanatus* IFO 12787T was prepared.

##### (2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A20)

[0444] PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces lanatus* IFO 12787T prepared in Example 56(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 304 to 1036 of the nucleotide sequence shown in SEQ ID NO: 229 was provided.

[0445] Further, the chromosomal DNA prepared in Example 56(1) was digested with restriction enzyme Pmacl. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 278 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 289 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 318 of the nucleotide sequence shown in SEQ ID NO: 239 was provided.

[0446] Further, the chromosomal DNA prepared in Example 56(1) was digested with restriction enzyme Stul. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26(3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 290 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 291 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 969 to 1461 of the nucleotide sequence shown in SEQ ID NO: 239 was provided.

##### (3) Sequence analysis of the present invention DNA (A20)

[0447] The nucleotide sequence shown in SEQ ID NO: 239 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 56(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 229) consisting of 1218 nucleotides (inclusive of the stop codon) and encoding a 405 amino acid residue (SEQ ID NO: 219) and a nucleotide sequence (SEQ ID NO: 259) consisting of 231 nucleotides (inclusive of the stop codon) and encoding a 76 amino acid residue (SEQ ID NO: 249). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 219) encoded by the nucleotide sequence shown in SEQ ID NO: 229 was calculated to be 45071Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 249) encoded by the nucleotide sequence shown in SEQ ID NO: 259 was calculated to be 7816Da.

#### Example 57 Expression of the Present Invention DNA (A20) in *E. Coli*

##### (1) Production of a transformed *E. coli* having the present invention DNA (A20)

[0448] PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces lanatus* IFO 12787T in Example 56(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 292 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 293. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and

cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68, 188, 278 and 290. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 239 was designated as pCR1525F. Similarly to Example 32(1), pCR1525F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 239, in which the DNA encoding the present invention protein (A20) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1525F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1525F.

## **(2) Expression of the present invention protein (A20) in E. coli and recovery of said protein**

**[0449]** Similarly to Example 4(2), each of E. coli JM109/pKSN1525F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1525F is referred to as "E. coli pKSN1525F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

## **(3) Detection of the ability to convert compound (II) to compound (III)**

**[0450]** Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 57(2) (E. coli pKSN1525F extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1525F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

## **Example 58 Obtaining the Present Invention DNA (A21)**

### **(1) Preparation of the chromosomal DNA of Streptomyces misawanensis IFO 13855T**

**[0451]** Under the method described in Example 31(1), the chromosomal DNA of Streptomyces misawanensis IFO 13855T was prepared.

### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A21)**

**[0452]** PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces misawanensis IFO 13855T prepared in Example 58(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 328 to 1063 of the nucleotide sequence shown in SEQ ID NO: 230 was provided.

**[0453]** Further, the chromosomal DNA prepared in Example 58(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 294 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 295 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 341 of the nucleotide sequence shown in SEQ ID NO: 240 was provided.

**[0454]** Further, the chromosomal DNA prepared in Example 58(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 296 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 297 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1017 to 1458 of the nucleotide sequence shown in SEQ ID NO: 240 was provided.

**(3) Sequence analysis of the present invention DNA (A21)**

[0455] The nucleotide sequence shown in SEQ ID NO: 240 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 58(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 230) consisting of 1245 nucleotides (inclusive of the stop codon) and encoding a 414 amino acid residue (SEQ ID NO: 220) and a nucleotide sequence (SEQ ID NO: 260) consisting of 201 nucleotides (inclusive of the stop codon) and encoding a 66 amino acid residue (SEQ ID NO: 250). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 220) encoded by the nucleotide sequence shown in SEQ ID NO: 230 was calculated to be 45806Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 250) encoded by the nucleotide sequence shown in SEQ ID NO: 260 was calculated to be 6712Da.

**Example 59 Expression of the Present Invention DNA (A21) in E. Coli****(1) Production of a transformed E. coli having the present invention DNA (A21)**

[0456] PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces misawanensis* IFO 13855T in Example 58(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 298 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 299. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 57, 59, 296, 298 and 300. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 240 was designated as pCR1543BF. Similarly to Example 32(1), pCR1543BF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 240, in which the DNA encoding the present invention protein (A21) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1543BF"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1543BF.

**(2) Expression of the present invention protein (A21) in E. coli and recovery of said protein**

[0457] Similarly to Example 4(2), each of E. coli JM109/pKSN1543BF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1543BF is referred to as "E. coli pKSN1543BF extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

**(3) Detection of the ability to convert compound (II) to compound (III)**

[0458] Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 59(2) (E. coli pKSN1543BF extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1543BF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

**Example 60 Obtaining the Present Invention DNA (A22)****(1) Preparation of the chromosomal DNA of *Streptomyces pallidus* IFO 13434T**

[0459] Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces pallidus* IFO 13434T was prepared.

**(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A22)**

[0460] PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces pallidus* IFO 13434T

prepared in Example 60(1) and by utilizing primer pairing 15, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 483 to 1048 of the nucleotide sequence shown in SEQ ID NO: 231 was provided.

**[0461]** Further, the chromosomal DNA prepared in Example 60(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 301 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 302 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 68 to 516 of the nucleotide sequence shown in SEQ ID NO: 241 was provided.

**[0462]** Further, the chromosomal DNA prepared in Example 60(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 302 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 303 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 270 of the nucleotide sequence shown in SEQ ID NO: 241 was provided.

**[0463]** Further, the chromosomal DNA prepared in Example 60(1) was digested with restriction enzyme HincII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 304 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 305 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 982 to 1448 of the nucleotide sequence shown in SEQ ID NO: 241 was provided.

### **(3) Sequence analysis of the present invention DNA (A22)**

**[0464]** The nucleotide sequence shown in SEQ ID NO: 241 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 60(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 231) consisting of 1230 nucleotides (inclusive of the stop codon) and encoding a 409 amino acid residue (SEQ ID NO: 221) and a nucleotide sequence (SEQ ID NO: 261) consisting of 195 nucleotides (inclusive of the stop codon) and encoding a 64 amino acid residue (SEQ ID NO: 251). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 221) encoded by the nucleotide sequence shown in SEQ ID NO: 231 was calculated to be 45050Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 251) encoded by the nucleotide sequence shown in SEQ ID NO: 261 was calculated to be 6914Da.

### **Example 61 Expression of the Present Invention DNA (A22) in E. Coli**

#### **(1) Production of a transformed E. coli having the present invention DNA (A22)**

**[0465]** PCR was conducted similarly to Example 32(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces pallidus* IFO 13434T in Example 60(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 306 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 307. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68 and 308. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 241 was designated as pCR1558BF. Similarly to Example 32(1), pCR.1558BF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 241, in which the DNA encoding the present invention protein (A22) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1558BF"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1558BF.

**(2) Expression of the present invention protein (A22) in E. coli and recovery of said protein**

**[0466]** Similarly to Example 4(2), each of E. coli JM109/pKSN1558BF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1558BF is referred to as "E. coli pKSN1558BF extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

**(3) Detection of the ability to convert compound (II) to compound (III)**

**[0467]** Similarly to Example 32(3), reaction solutions of 30 $\mu$ l were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 61(2) (E. coli pKSN1558BF extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with  $^{14}$ C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1558BF extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

**Example 62 Obtaining the Present Invention DNA (A23)****(1) Preparation of the chromosomal DNA of Streptomyces roseorubens IFO 13682T**

**[0468]** Under the method described in Example 31(1), the chromosomal DNA of Streptomyces roseorubens IFO 13682T was prepared.

**(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A23)**

**[0469]** PCR was conducted by utilizing as the template the chromosomal DNA of Streptomyces roseorubens IFO 13682T prepared in Example 62(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 289 to 1015 of the nucleotide sequence shown in SEQ ID NO: 232 was provided.

**[0470]** Further, the chromosomal DNA prepared in Example 62(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 309 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 310 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 354 of the nucleotide sequence shown in SEQ ID NO: 242 was provided.

**[0471]** Further, the chromosomal DNA prepared in Example 62(1) was digested with restriction enzyme PvuII. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 311 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 312 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 966 to 1411 of the nucleotide sequence shown in SEQ ID NO: 242 was provided.

**(3) Sequence analysis of the present invention DNA (A23)**

**[0472]** The nucleotide sequence shown in SEQ ID NO: 242 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 62(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 232) consisting of 1197 nucleotides (inclusive of the stop codon) and encoding a 398 amino acid residue (SEQ ID NO: 222) and a nucleotide sequence (SEQ ID NO: 262) consisting of 201 nucleotides (inclusive of the stop codon) and encoding a 66 amino acid residue (SEQ ID NO: 252). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 222) encoded by the nucleotide sequence shown in SEQ ID NO: 232 was calculated to be 43624Da. The molecular weight

of the protein consisting of the amino acid sequence (SEQ ID NO: 252) encoded by the nucleotide sequence shown in SEQ ID NO: 262 was calculated to be 6797Da.

#### **Example 63 Expression of the Present Invention DNA (A23) in E. Coli**

##### **(1) Production of a transformed E. coli having the present invention DNA (A23)**

[0473] PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces roseorubens* IFO 13682T in Example 62(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 313 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 314. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was analyzed by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68, 309, 311 and 315. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 242 was designated as pCR1584F. Similarly to Example 32(1), pCR1584F was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 242, in which the DNA encoding the present invention protein (A23) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1584F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1584F.

##### **(2) Expression of the present invention protein (A23) in E. coli and recovery of said protein**

[0474] Similarly to Example 4(2), each of E. coli JM109/pKSN1584F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1584F is referred to as "E. coli pKSN1584F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

##### **(3) Detection of the ability to convert compound (II) to compound (III)**

[0475] Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 63(2) (E. coli pKSN1584F extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (R<sub>f</sub> value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1584F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

#### **Example 64 Obtaining the Present Invention DNA (A24)**

##### **(1) Preparation of the chromosomal DNA of *Streptomyces rutgersensis* IFO 15875T**

[0476] Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces rutgersensis* IFO 15875T was prepared.

##### **(2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A24)**

[0477] PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces rutgersensis* IFO 15875T prepared in Example 64(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 322 to 1057 of the nucleotide sequence shown in SEQ ID NO: 233 was provided.

[0478] Further, the chromosomal DNA prepared in Example 64(1) was digested with restriction enzyme SmaI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 316 and primer AP 1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing

the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 317 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 384 of the nucleotide sequence shown in SEQ ID NO: 243 was provided.

[0479] Further, the chromosomal DNA prepared in Example 64(1) was digested with restriction enzyme NaeI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 318 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 319 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 992 to 1466 of the nucleotide sequence shown in SEQ ID NO: 243 was provided.

### (3) Sequence analysis of the present invention DNA (A24)

[0480] The nucleotide sequence shown in SEQ ID NO: 243 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 64(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 233) consisting of 1245 nucleotides (inclusive of the stop codon) and encoding a 414 amino acid residue (SEQ ID NO: 223) and a nucleotide sequence (SEQ ID NO: 263) consisting of 198 nucleotides (inclusive of the stop codon) and encoding a 65 amino acid residue (SEQ ID NO: 253). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 223) encoded by the nucleotide sequence shown in SEQ ID NO: 233 was calculated to be 45830Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 253) encoded by the nucleotide sequence shown in SEQ ID NO: 263 was calculated to be 7034Da.

### Example 65 Expression of the Present Invention DNA (A24) in E. Coli

#### (1) Production of a transformed E. coli having the present invention DNA (A24)

[0481] PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces rutgersensis* IFO 15875T in Example 64(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 320 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 321. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was sequenced by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68 and 322. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 243 was designated as pCR1589BF. Similarly to Example 32(1), pCR1589BF was digested with restriction enzymes NdeI and HindIII. A DNA of about 1.5kbp was purified from the digestion products. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 243, in which the DNA encoding the present invention protein (A24) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1589BF"). Said plasmid was introduced into E. coli JM109. The obtained E. coli transformant was designated JM109/pKSN1589BF.

#### (2) Expression of the present invention protein (A24) in E. coli and recovery of said protein

[0482] Similarly to Example 4(2), each of E. coli JM 109/pKSN1589BF and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1589BF is referred to as "E. coli pKSN1589BF extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

#### (3) Detection of the ability to convert compound (II) to compound (III)

[0483] Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 65(2) (E. coli pKSN1589BF extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1589BF extract. In contrast, such a spot

was not detected from the reaction solution containing *E. coli* pKSN2 extract.

#### Example 66 Obtaining the Present Invention DNA (A25)

##### (1) Preparation of the chromosomal DNA of *Streptomyces steffisburgensis* IFO 13446T

[0484] Under the method described in Example 31(1), the chromosomal DNA of *Streptomyces steffisburgensis* IFO 13446T was prepared.

##### (2) Isolation of DNA having a partial nucleotide sequence of the present invention DNA (A25)

[0485] PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces steffisburgensis* IFO 13446T prepared in Example 66(1) and by utilizing primer pairing 14, in accordance with the method described in Example 29. Similarly to Example 31(2), the amplified DNA was cloned to cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence thereof was analyzed. As a result, the nucleotide sequence shown in nucleotides 289 to 1015 of the nucleotide sequence shown in SEQ ID NO: 234 was provided.

[0486] Further, the chromosomal DNA prepared in Example 66(1) was digested with restriction enzyme *Sma*I. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 323 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 324 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 1 to 303 of the nucleotide sequence shown in SEQ ID NO: 244 was provided.

[0487] Further, the chromosomal DNA prepared in Example 66(1) was digested with restriction enzyme *Pma*CI. A genome walker library was produced by utilizing the obtained DNA, according to the method described in Example 26 (3). PCR was conducted under the conditions described in Example 26(3) to obtain the first PCR products, by utilizing the obtained library as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 311 and primer AP1. Next, PCR was conducted under the conditions described in Example 26(3), by utilizing the first PCR products as the template and by utilizing the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 325 and primer AP2. The nucleotide sequence of the obtained DNA was analyzed. The nucleotide sequence shown in nucleotides 966 to 1411 of the nucleotide sequence shown in SEQ ID NO: 244 was provided.

##### (3) Sequence analysis of the present invention DNA (A25)

[0488] The nucleotide sequence shown in SEQ ID NO: 244 was obtained by connecting the nucleotide sequences provided by the DNA obtained in Example 66(2). Two open reading frames (ORF) were present in said nucleotide sequence. As such, there was contained a nucleotide sequence (SEQ ID NO: 234) consisting of 1197 nucleotides (inclusive of the stop codon) and encoding a 398 amino acid residue (SEQ ID NO: 224) and a nucleotide sequence (SEQ ID NO: 264) consisting of 201 nucleotides (inclusive of the stop codon) and encoding a 66 amino acid residue (SEQ ID NO: 254). The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 224) encoded by the nucleotide sequence shown in SEQ ID NO: 234 was calculated to be 44175Da. The molecular weight of the protein consisting of the amino acid sequence (SEQ ID NO: 254) encoded by the nucleotide sequence shown in SEQ ID NO: 264 was calculated to be 6685Da.

#### Example 67 Expression of the Present Invention DNA (A25) in *E. Coli*

##### (1) Production of a transformed *E. coli* having the present invention DNA (A25)

[0489] PCR was conducted similarly to Example 49(1), other than utilizing as a template the chromosomal DNA prepared from *Streptomyces steffisburgensis* IFO 13446T in Example 66(1) and utilizing as the primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 326 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 327. Similarly to Example 32(1), the DNA was purified from the reaction solution of PCR and cloned into the cloning vector pCRII-TOPO (Invitrogen Company). The nucleotide sequence of the obtained plasmid DNA was sequenced by utilizing as primers the oligonucleotides having the nucleotide sequences shown, respectively, in SEQ ID NOs: 67, 68, 311, 315 and 323. Based on the obtained results, the plasmid having the nucleotide sequence shown in SEQ ID NO: 244 was designated as pCR1609F. Similarly to Example 32(1), pCR1609F was digested with restriction enzymes *Nde*I and *Hind*III. A DNA of about 1.5kbp was purified from the digestion products.

The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid containing the nucleotide sequence shown in SEQ ID NO: 244, in which the DNA encoding the present invention protein (A25) is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1609F"). Said plasmid was introduced into E. Coli JM109. The obtained E. coli transformant was designated JM109/pKSN1609F.

## (2) Expression of the present invention protein (A25) in E. coli and recovery of said protein

[0490] Similarly to Example 4(2), each of E. coli JM109/pKSN1609F and JM109/pKSN2 was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1609F is referred to as "E. coli pKSN1609F extract" and the supernatant fraction obtained from E. coli JM109/pKSN2 is referred to as "E. coli pKSN2 extract").

## (3) Detection of the ability to convert compound (II) to compound (III)

[0491] Similarly to Example 32(3), reaction solutions of 30μl were prepared and maintained for 10 minutes at 30°C. However, as the supernatant fraction, the supernatant fraction prepared in Example 67(2) (E. coli pKSN1609F extract or E. coli pKSN2 extract) was utilized. The reaction solutions after the maintenance were extracted with ethyl acetate and the extracted layers were TLC analyzed. After developing the TLC plate, the presence of a spot thereon corresponding to compound (III) labeled with <sup>14</sup>C were examined (Rf value 0.24 and 0.29). A spot corresponding to compound (III) was detected from the reaction solution containing E. coli pKSN1609F extract. In contrast, such a spot was not detected from the reaction solution containing E. coli pKSN2 extract.

## Example 68 Metabolism of Compounds by the Present Invention Protein (A16), (A17), (A18), (A19), (A20), (A21), (A22), (A23), (A24) or (A25)

### (1) Metabolism of compound (XII) by the present invention protein (A16)

[0492] There was prepared 100μl of a reaction solution of 50mM potassium phosphate buffer (pH7.0) containing 12.5ppm of compound (XII), 3mM of β-NADPH (hereinafter, referred to as "component A") (Oriental Yeast Company), 1mg/ml of a ferredoxin derived from spinach (hereinafter referred to as "component B") (Sigma Company), 0.15U/ml of ferredoxin reductase (hereinafter, referred to as "component C") (Sigma Company) and 20μl of the supernatant fraction recovered in Example 49(2). The reaction solution was maintained at 30°C for 10 minutes. Further, there was prepared and maintained similarly 100μl of a reaction solution of a 50mM potassium phosphate buffer (pH 7.0) having no addition of at least one component utilized in the composition of the above reaction solution, selected from component A, component B, component C and the supernatant fraction prepared in Example 49(2). Five microliters (5μl) of 2N HCl and 100μl of ethyl acetate were added and mixed into each of the reaction solutions after the maintenance. The supernatant centrifuged at 8,000xg was filtered with UltraFree MC 0.22μm filter unit (Millipore Company). Forty microliters (40μl) of the liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 49(2) is referred to as "(XII) metabolism solution (A16)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 49(2) is referred to as "(XII) control solution (A16)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A16), the concentration of compound (XII) detected from (XII) metabolism solution (A16) was lower. Further a peak, which was not detected from the (XII) control solution (A16), was detected from the (XII) metabolism solution (A16). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### (2) Metabolism of compound (XII) by the present invention protein (A17)

[0493] Other than utilizing 20μl of the supernatant fraction recovered in Example 51(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), the reaction solution after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 51(2) is referred to as "(XII) metabolism solution (A17)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 51

(2) is referred to as "(XII) control solution (A17)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A17), the concentration of compound (XII) detected from (XII) metabolism solution (A17) was lower. Further a peak, which was not detected from the (XII) control solution (A17), was detected from the (XII) metabolism solution (A17). The elution time of the said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### **(3) Metabolism of compound (XII) by the present invention protein (A18)**

[0494] Other than utilizing 20μl of the supernatant fraction recovered in Example 53(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 53(2) is referred to as "(XII) metabolism solution (A18)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 53(2) is referred to as "(XII) control solution (A18)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A18), the concentration of compound (XII) detected from (XII) metabolism solution (A18) was lower. Further a peak, which was not detected from the (XII) control solution (A18), was detected from the (XII) metabolism solution (A18). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### **(4) Metabolism of compound (XII) by the present invention protein (A19)**

[0495] Other than utilizing 20μl of the supernatant fraction recovered in Example 55(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 55(2) is referred to as "(XII) metabolism solution (A19)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 55(2) is referred to as "(XII) control solution (A19)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A19), the concentration of compound (XII) detected from (XII) metabolism solution (A19) was lower. Further a peak, which was not detected from the (XII) control solution (A19), was detected from the (XII) metabolism solution (A19). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### **(5) Metabolism of compound (XII) by the present invention protein (A20)**

[0496] Other than utilizing 20μl of the supernatant fraction recovered in Example 57(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 57(2) is referred to as "(XII) metabolism solution (A20)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 57(2) is referred to as "(XII) control solution (A20)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A20), the concentration of compound (XII) detected from (XII) metabolism solution (A20) was lower. Further a peak, which was not detected from the (XII) control solution (A20), was detected from the (XII) metabolism solution (A20). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

### **(6) Metabolism of compound (XII) by the present invention protein (A21)**

[0497] Other than utilizing 20μl of the supernatant fraction recovered in Example 59(2) instead of 20μl of the super-

natant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 59(2) is referred to as "(XII) metabolism solution (A21)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 59(2) is referred to as "(XII) control solution (A21)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A21), the concentration of compound (XII) detected from (XII) metabolism solution (A21) was lower. Further a peak, which was not detected from the (XII) control solution (A21), was detected from the (XII) metabolism solution (A21). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### **(7) Metabolism of compound (XII) by the present invention protein (A22)**

[0498] Other than utilizing 20μl of the supernatant fraction recovered in Example 61(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 61(2) is referred to as "(XII) metabolism solution (A22)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 61(2) is referred to as "(XII) control solution (A22)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A22), the concentration of compound (XII) detected from (XII) metabolism solution (A22) was lower. Further a peak, which was not detected from the (XII) control solution (A22), was detected from the (XII) metabolism solution (A22). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### **(8) Metabolism of compound (XII) by the present invention protein (A23)**

[0499] Other than utilizing 20μl of the supernatant fraction recovered in Example 63(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 63(2) is referred to as "(XII) metabolism solution (A23)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 63(2) is referred to as "(XII) control solution (A23)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A23), the concentration of compound (XII) detected from (XII) metabolism solution (A23) was lower. Further a peak, which was not detected from the (XII) control solution (A23), was detected from the (XII) metabolism solution (A23). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

#### **(9) Metabolism of compound (XII) by the present invention protein (A24)**

[0500] Other than utilizing 20μl of the supernatant fraction recovered in Example 65(2) instead of 20μl of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 65(2) is referred to as "(XII) metabolism solution (A24)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 65(2) is referred to as "(XII) control solution (A24)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A24), the concentration of compound (XII) detected from (XII) metabolism solution (A24) was lower. Further a peak, which was not detected from the (XII) control solution (A24), was detected from the (XII) metabolism solution (A24). The elution time of said peak on

the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

**(10) Metabolism of compound (XII) by the present invention protein (A25)**

[0501] Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 67(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 49(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(1). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40 $\mu$ l) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 67(2) is referred to as "(XII) metabolism solution (A25)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 67(2) is referred to as "(XII) control solution (A25)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XII) detected from (XII) control solution (A25), the concentration of compound (XII) detected from (XII) metabolism solution (A25) was lower. Further a peak, which was not detected from the (XII) control solution (A25), was detected from the (XII) metabolism solution (A25). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XII) detected from (XII) metabolism solution (A1) in Example 41(2).

**(11) Metabolism of compound (XIII) by the present invention protein (A17)**

[0502] Other than utilizing 12.5ppm of compound (XIII) instead of 12.5ppm of compound (XII), the reaction solution was prepared and maintained in accordance with the method described in Example 68(2). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40 $\mu$ l) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 51(2) is referred to as "(XIII) metabolism solution (A17)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 51(2) is referred to as "(XIII) control solution (A17)") were analyzed on a HPLC under the above analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A17), the concentration of compound (XIII) detected from (XIII) metabolism solution (A17) was lower. Further a peak, which was not detected from the (XIII) control solution (A17), was detected from the (XIII) metabolism solution (A17). The elution time of the said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

**(12) Metabolism of compound (XIII) by the present invention protein (A18)**

[0503] Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 53(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40 $\mu$ l) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 53(2) is referred to as "(XIII) metabolism solution (A18)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 53(2) is referred to as "(XIII) control solution (A18)") was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A18), the concentration of compound (XIII) detected from (XIII) metabolism solution (A18) was lower. Further a peak, which was not detected from the (XIII) control solution (A18), was detected from the (XIII) metabolism solution (A18). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

**(13) Metabolism of compound (XIII) by the present invention protein (A19)**

[0504] Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 55(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40 $\mu$ l) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 55(2) is referred to as "(XIII) metabolism solution (A19)"; further, the liquid filtrate derived from the reaction

solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 55(2) is referred to as "(XIII) control solution (A19)" was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A19), the concentration of compound (XIII) detected from (XIII) metabolism solution (A19) was lower. Further a peak, which was not detected from the (XIII) control solution (A19), was detected from the (XIII) metabolism solution (A19). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### **(14) Metabolism of compound (XIII) by the present invention protein (A20)**

[0505] Other than utilizing 20μl of the supernatant fraction recovered in Example 57(2) instead of 20μl of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 57(2) is referred to as "(XIII) metabolism solution (A20)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 57(2) is referred to as "(XIII) control solution (A20)" was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A20), the concentration of compound (XIII) detected from (XIII) metabolism solution (A20) was lower. Further a peak, which was not detected from the (XIII) control solution (A20), was detected from the (XIII) metabolism solution (A20). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### **(15) Metabolism of compound (XIII) by the present invention protein (A21)**

[0506] Other than utilizing 20μl of the supernatant fraction recovered in Example 59(2) instead of 20μl of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 59(2) is referred to as "(XIII) metabolism solution (A21)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 59(2) is referred to as "(XIII) control solution (A21)" was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A21), the concentration of compound (XIII) detected from (XIII) metabolism solution (A21) was lower. Further a peak, which was not detected from the (XIII) control solution (A21), was detected from the (XIII) metabolism solution (A21). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

#### **(16) Metabolism of compound (XIII) by the present invention protein (A23)**

[0507] Other than utilizing 20μl of the supernatant fraction recovered in Example 63(2) instead of 20μl of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40μl) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20μl of supernatant fraction recovered in Example 63(2) is referred to as "(XIII) metabolism solution (A23)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 63(2) is referred to as "(XIII) control solution (A23)" was analyzed on a HPLC under analysis condition 1. Compared to the concentration of compound (XIII) detected from (XIII) control solution (A23), the concentration of compound (XIII) detected from (XIII) metabolism solution (A23) was lower. Further a peak, which was not detected from the (XIII) control solution (A23), was detected from the (XIII) metabolism solution (A23). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

**(17) Metabolism of compound (XIII) by the present invention protein (A25)**

**[0508]** Other than utilizing 20 $\mu$ l of the supernatant fraction recovered in Example 67(2) instead of 20 $\mu$ l of the supernatant fraction recovered in Example 51(2), the reaction solution was prepared and maintained in accordance with the method described in Example 68(11). Similar to Example 68(1), each of the reaction solutions after the maintenance was prepared. Forty microliters (40 $\mu$ l) of the obtained liquid filtrate (hereinafter, the liquid filtrate derived from the reaction solution containing component A, component B, component C and 20 $\mu$ l of supernatant fraction recovered in Example 67(2) is referred to as "(XIII) metabolism solution (A25)"; further, the liquid filtrate derived from the reaction solution containing no component A, no component B, no component C and no supernatant fraction recovered in Example 67(2) is referred to as "(XIII) control solution (A25)".

Compared to the concentration of compound (XIII) detected from (XIII) control solution (A25), the concentration of compound (XIII) detected from (XIII) metabolism solution (A25) was lower. Further a peak, which was not detected from the (XIII) control solution (A25), was detected from the (XIII) metabolism solution (A25). The elution time of said peak on the HPLC matched an elution time of a peak of a compound in which the mass is 14 less than said compound (XIII) detected from (XIII) metabolism solution (A1) in Example 41(3).

**Example 69 Hybridization in which the Present Invention DNA (A1), (A2), (A3) or (A4) was a Probe****(1) Preparation of a probe**

**[0509]** PCR was conducted in accordance with the method described in Example 30(1). However, as the template, 10ng of the chromosomal DNA of *Streptomyces achromogenes* IFO 12735 prepared in Example 26(1) was utilized instead of said 50ng of the chromosomal DNA of *Streptomyces phaeochromogenes* IFO12898 prepared in Example 3(1). As the primers, there was utilized an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 328 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 329. The DNA amplified by said PCR was recovered to produce a probe having the nucleotide sequence shown in SEQ ID NO: 109 labeled with digoxigenin (hereinafter referred to as "DIG labeled probe (A4)").

**(2) Preparation of the plasmid solution**

**[0510]** PCR was conducted by utilizing Advantage-GC genomic polymerase mix (Clontech Company) and by utilizing as the template the chromosomal DNA of *Streptomyces nogalator* IFO13445 prepared in Example 31(1). As the primers, there was utilized the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 330 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331. The PCR reaction solution amounted to 50 $\mu$ l by adding the 2 primers each amounting to 200nM, 10ng of the chromosomal DNA, 4.0 $\mu$ l of dNTP mix (a mixture of 2.5mM of each of the 4 types of dNTP; Clontech Company), 10.0 $\mu$ l of 5xGC buffer, 2.2 $\mu$ l of 25mM Mg(OAc)<sub>2</sub>, 10.0 $\mu$ l of 5M GC-Melt and 1.0 $\mu$ l of Advantage-GC genomic polymerase mix (Clontech Company) and distilled water. The reaction conditions of the PCR were after maintaining 94°C for 1 minute; repeating 7 cycles of a cycle that included maintaining 94°C for 10 seconds and then 72°C for 3 minutes; repeating 36 cycles of a cycle that included 94°C for 10 seconds and then 67°C for 3 minutes; and then maintaining 67°C for 7 minutes. The DNA was purified from the PCR reaction solution with QIAquick PCR Purification Kit (Qiagen Company) according to the instructions attached to said kit. The obtained DNA was ligated to TA cloning vector pCR2.1 (Invitrogen Company), according to the attached manual, and was introduced into *E. coli* TOP10F' (Invitrogen Company). The plasmid DNA was prepared from the obtained *E. coli* transformant, utilizing QIAprep Spin Miniprep Kit (Qiagen Company) to obtain a plasmid solution containing the present invention DNA (A11).

**[0511]** Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces tsusimaensis* IFO 13782 prepared in Example 33(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 332 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 333. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A12).

**[0512]** Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces thermo-coerulesces* IFO 14273t prepared in Example 35(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 334. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A13).

**[0513]** Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces glomero-*

chromogenes IFO 13673t prepared in Example 37(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 330 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A14).

[0514] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces olivochromogenes* IFO 12444 prepared in Example 39(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 330 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A15).

[0515] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces omatus* IFO 13069t prepared in Example 48(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 335 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 336. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A16).

[0516] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces griseus* ATCC 10137 prepared in Example 50(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 335 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 336. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A17).

[0517] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces achromogenes* IFO 12735 prepared in Example 52(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 330 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A18).

[0518] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces griseus* IFO 13849T prepared in Example 54(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 333 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 335. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A19).

[0519] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces lanatus* IFO 12787T prepared in Example 56(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 337. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A20).

[0520] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces misawanensis* IFO 13855T prepared in Example 58(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 338. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A21).

[0521] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces roseorubens* IFO 13682T prepared in Example 62(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 339. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A23).

[0522] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces steffisburgensis* IFO 13446T prepared in Example 66(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 331 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 339. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present in-

vention DNA (A25).

[0523] Further, similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces pallidus* IFO 13434T prepared in Example 60(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 340 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 341. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A22).

[0524] Similarly, PCR was conducted by utilizing as the template the chromosomal DNA of *Streptomyces rutgersensis* IFO 15875T prepared in Example 64(1) and by utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 342 and the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 343. The DNA obtained by the PCR was ligated to the vector similar to the above. *E. coli* was then transformed. The plasmid was prepared from the obtained *E. coli* transformant to obtain a plasmid solution containing the present invention DNA (A24).

## (2) Dot blot hybridization

[0525] About 100ng and 10ng of each of the plasmids prepared in Example 69(2) was blotted on a Hybond N+ Nylon Membrane (Amersham Biosciences Company). The plasmids were: the plasmid DNA containing the present invention DNA (A11), the plasmid DNA containing the present invention DNA (A12), the plasmid DNA containing the present invention DNA (A13), the plasmid DNA containing the present invention DNA (A14), the plasmid DNA containing the present invention DNA (A15), the plasmid DNA containing the present invention DNA (A16), the plasmid DNA containing the present invention DNA (A17), the plasmid DNA containing the present invention DNA (A18), the plasmid DNA containing the present invention DNA (A19), the plasmid DNA containing the present invention DNA (A20), the plasmid DNA containing the present invention DNA (A21), the plasmid DNA containing the present invention DNA (A23), and the plasmid DNA containing the present invention DNA (A25). Ultraviolet light was directed at the obtained membranes with a transilluminator for 5 minutes.

[0526] Hybridization and detection were conducted according to the method described in Example 30(2). The probes prepared in Example 30(1) were maintained at 100°C for 5 minutes and then cooled on ice. As the probes, there was utilized the DNA having the nucleotide sequence shown in SEQ ID NO: 6 labeled with digoxigenin (hereinafter referred to as "DIG labeled probe (A1)"), the DNA having the nucleotide sequence shown in SEQ ID NO: 7 labeled with digoxigenin (hereinafter referred to as "DIG labeled probe (A2)"), the DNA having the nucleotide sequence shown in SEQ ID NO: 8 labeled with digoxigenin (hereinafter referred to as "DIG labeled probe (A3)") or the DIG labeled probe (A4) produced in Example 69(1). In the events of utilizing any one of the DIG labeled probe (A1), (A2), (A3) or (A4) for hybridization, a signal was detected for each of the reagents of the 10ng and 100ng of each of the above plasmid DNA.

[0527] Further, similarly, about 10ng and 100ng of each of the plasmid DNA containing the present invention DNA (A22) prepared in Example 69(2) and the plasmid DNA containing the present invention DNA (A24) are blotted onto a Hybond N+ nylon membrane (Amersham Biosciences Company). Hybridization and detection are conducted accordingly to Example 30(2).

## Example 70 Preparation of the Present Invention DNA (A23) in which the Codon Usage has been Adjusted for Expression in Soybean (hereinafter, referred to as the "present invention DNA (A23)S")

### (1) Preparation of the present invention DNA (A23)S

[0528] PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 346 and the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 367. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 345 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 366. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 344 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 365. The obtained reaction solution was designated as reaction solution 1.

[0529] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 349 and the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 364. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 348 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 363. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing

as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 347 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 362. The obtained reaction solution was designated as reaction solution 2.

[0530] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 352 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 361. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers having the nucleotide sequence shown in SEQ ID NO: 351 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 360. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 350 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 359. The obtained reaction solution was designated as reaction solution 3.

[0531] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 355 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 358. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 354 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 357. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 353 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 356. The obtained reaction solution was designated as reaction solution 4.

[0532] The reaction solutions 1 to 4 obtained in such a way were mixed. PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as a template an aliquot of the mixture thereof and by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 344 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 356. The nucleotide sequence of the amplified DNA was confirmed. There was obtained a DNA having a sequence in which the nucleotide sequence 5'-cat-3' is connected upstream of the 5' terminus and the nucleotide sequence 5'-aagctt-3' is connected downstream of the 3' terminus of the nucleotide sequence shown in SEQ ID NO: 368.

[0533] The codon usage of the present invention DNA (A23) having the nucleotide sequence shown in SEQ ID NO: 232 (GC content of 73.10%) is shown in Table 28 and Table 29. The codon usage of soybean (GC content of 46.12%) is shown in Table 24 and Table 25. The codon usage of the present invention DNA (A23)S having the nucleotide sequence shown in SEQ ID NO: 368 (GC content of 52.38%) is shown in Table 30 and Table 31.

Table 28

codon	%	codon	%
TTT	0.00	TCT	0.00
TTC	4.01	TCC	1.50
TTA	0.00	TCA	0.00
TTG	0.00	TCG	0.50
CTT	0.00	CCT	0.00
CTC	4.26	CCC	5.76
CTA	0.00	CCA	0.00
CTG	7.77	CCG	2.26
ATT	0.00	ACT	0.00
ATC	4.51	ACC	3.76
ATA	0.00	ACA	0.00
ATG	2.26	ACG	2.76
GTT	0.00	GCT	0.25
GTC	3.51	GCC	9.27
GTA	0.00	GCA	0.75
GTG	2.51	GCG	1.75

# EP 1 457 558 A1

Table 29

codon	%	codon	%
TAT	0.00	TGT	0.00
TAC	1.00	TGC	0.75
TAA	0.25	TGA	0.00
TAG	0.00	TGG	0.75
CAT	0.00	CGT	0.50
CAC	2.26	CGC	6.02
CAA	0.50	CGA	0.25
CAG	2.51	CGG	3.01
AAT	0.00	AGT	0.00
AAC	1.00	AGC	1.25
AAA	0.25	AGA	0.00
AAG	0.50	AGG	0.50
GAT	0.00	GGT	0.98
GAC	7.27	GGC	6.27
GAA	1.25	GGA	0.25
GAG	5.26	GGG	1.00

Table 30

codon	%	codon	%
TTT	2.01	TCT	0.75
TTC	2.01	TCC	0.50
TTA	1.00	TCA	0.75
TTG	3.01	TCG	0.25
CTT	3.26	CCT	3.01
CTC	2.26	CCC	1.50
CTA	1.00	CCA	3.01
CTG	1.50	CCG	0.50
ATT	2.26	ACT	2.26
ATC	1.25	ACC	1.75
ATA	1.00	ACA	2.01
ATG	2.26	ACG	0.50
GTT	2.26	GCT	4.51
GTC	1.00	GCC	2.76
GTA	0.75	GCA	3.76
GTG	2.01	GCG	1.00

Table 31

codon	%	codon	%
TAT	0.50	TGT	0.25
TAG	0.50	TGC	0.50
TAA	0.25	TGA	0.00
TAG	0.00	TGG	0.75
CAT	1.25	CGT	1.50
CAC	1.00	CGC	1.25
CAA	1.75	CGA	0.75
CAG	1.25	CGG	0.50
AAT	0.50	ACT	0.50
AAC	0.50	AGC	0.50
AAA	0.25	AGA	3.26
AAG	0.50	AGG	3.01
GAT	4.51	GGT	2.26
GAC	2.76	GGC	1.50
GAA	3.26	GGA	2.26
GAG	3.26	GGG	1.50

**(2) Production of a transformed E. coli having the present invention protein (A23)S**

**[0534]** The DNA having the nucleotide sequence shown in SEQ ID NO: 368 obtained in Example 70(1) was digested with restriction enzymes NdeI and HindIII. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid in which the DNA having the nucleotide sequence shown in SEQ ID NO: 368 is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1584soy"). Said plasmid was introduced into E. coli JM109. The obtained E. coli transformant was designated JM109/pKSN1584soy.

**(3) Expression of the present invention protein (A23)S in E. coli and recovery of said protein**

**[0535]** Similarly to Example 4(2), each of E. coli JM109/pKSN1584soy obtained in Example 70(2) and E. coli JM109/pKSN1584F obtained in Example 63(1) was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1584soy is referred to as "E. coli pKSN1584soy extract" and the supernatant fraction obtained from E. coli JM109/pKSN1584F is referred to as "E. coli pKSN1584F extract"). The amount of P450 per the protein amount contained in E. coli pKSN 1584soy extract was compared to and was higher than the amount of P450 per the protein amount contained in E. coli pKSN1584F extract.

**Example 71 Preparation and Expression of the Present Invention DNA (A25) in which the Codon Usage has been Adjusted for Expression in Soybean (hereinafter, referred to as the "present invention DNA (A25)S")**

**(1) Preparation of the present invention DNA (A25)S**

**[0536]** PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 371 and the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 392. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 370 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 391. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 369 and oligonucleotide having the nucleotide

sequence shown in SEQ ID NO: 390. The obtained reaction solution was designated as reaction solution 1.

[0537] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 374 and the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 389. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 373 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 383. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 372 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 387. The obtained reaction solution was designated as reaction solution 2.

[0538] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 377 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 386. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers having the nucleotide sequence shown in SEQ ID NO: 376 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 385. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 375 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 384. The obtained reaction solution was designated as reaction solution 3.

[0539] Further, PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 380 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 383. An aliquot of the obtained PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 379 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 382. Further, an aliquot of that PCR product was utilized as a template for a PCR conducted similarly utilizing as primers the oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 378 and oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 381. The obtained reaction solution was designated as reaction solution 4.

[0540] The reaction solutions 1 to 4 obtained in such a way were mixed. PCR was conducted with Pyrobest DNA polymerase (Takara Shuzo Company) according to the attached manual, by utilizing as a template an aliquot of the mixture thereof and by utilizing as primers the oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 369 and oligonucleotide having a nucleotide sequence shown in SEQ ID NO: 381. The nucleotide sequence of the amplified DNA was confirmed. There was obtained a DNA having a sequence in which the nucleotide sequence 5'-cat-3' is connected upstream of the 5' terminus and the nucleotide sequence 5'-aagctt-3' is connected downstream of the 3' terminus of the nucleotide sequence shown in SEQ ID NO: 393.

[0541] The codon usage of the present invention DNA (A25) having the nucleotide sequence shown in SEQ ID NO: 234 (GC content of 71.93%) is shown in Table 32 and Table 33. The codon usage of soybean (GC content of 46.12%) is shown in Table 24 and Table 25. The codon usage of the present invention DNA (A25)S having the nucleotide sequence shown in SEQ ID NO: 393 (GC content of 52.05%) is shown in Table 34 and Table 35.

Table 32

codon	%	codon	%
TTT	0.00	TCT	0.00
TTC	3.76	TCC	1.25
TTA	0.00	TCA	0.25
TTG	0.00	TCG	0.75
CTT	0.00	CCT	0.25
CTC	4.01	CCC	4.01
CTA	0.00	CCA	0.25
CTG	9.52	CCG	2.76
ATT	0.00	ACT	0.25
ATC	4.26	ACC	4.01
ATA	0.25	ACA	0.00
ATG	2.26	ACG	1.75

# EP 1 457 558 A1

Table 32 (continued)

codon	%	codon	%
GTT	0.00	GCT	0.00
GTC	3.01	GCC	8.52
GTA	0.00	GCA	0.50
GTG	2.51	GCG	3.01

Table 33

codon	%	codon	%
TAT	0.00	TGT	0.25
TAC	1.25	TGC	0.50
TAA	0.25	TGA	0.00
TAG	0.00	TGG	1.00
CAT	0.25	CGT	0.75
CAC	2.26	CGC	5.51
CAA	0.00	CGA	1.25
CAG	3.01	CGG	3.26
AAT	0.00	AGT	0.00
AAC	1.00	AGC	1.00
AAA	0.25	AGA	0.25
AAG	1.00	AGG	0.00
GAT	0.00	GGT	0.25
GAC	7.52	GGC	4.76
GAA	1.00	GGA	0.25
GAG	4.76	GGG	1.25

Table 34

codon	%	codon	%
TTT	1.75	TCT	1.25
TTC	2.01	TCC	0.50
TTA	1.25	TCA	0.50
TTG	3.26	TCG	0.00
CTT	3.51	CCT	2.76
CTC	2.51	CCC	1.25
CTA	1.25	CCA	2.76
CTG	1.75	CCG	0.50
ATT	2.26	ACT	2.01
ATC	1.25	ACC	1.75
ATA	1.00	ACA	1.75
ATG	2.26	ACG	0.50

Table 34 (continued)

codon	%	codon	%
GTT	2.26	GCT	4.51
GTC	1.00	GCC	2.76
GTA	0.50	GCA	3.76
GTG	1.75	GCG	1.00

Table 35

codon	%	codon	%
TAT	0.50	TGT	0.25
TAC	0.75	TGC	0.50
TAA	0.25	TGA	0.00
TAG	0.00	TGG	1.00
CAT	1.25	CGT	1.75
CAC	1.25	CGC	1.50
CAA	1.50	CGA	0.75
CAG	1.50	CGG	0.75
AAT	0.50	AGT	0.50
AAC	0.50	AGC	0.50
AAA	0.50	AGA	3.26
AAG	0.75	AGG	3.01
GAT	4.76	GGT	2.01
GAC	2.76	GGC	1.25
GAA	2.76	GGA	2.01
GAG	3.01	GGG	1.25

## (2) Production of a transformed E. coli having the present invention protein (A25)S

[0542] The DNA having the nucleotide sequence shown in SEQ ID NO: 393 obtained in Example 71(1) was digested with restriction enzymes NdeI and HindIII. The obtained DNA and the plasmid pKSN2 digested with NdeI and HindIII were ligated to obtain a plasmid in which the DNA having the nucleotide sequence shown in SEQ ID NO: 393 is inserted between the NdeI site and the HindIII site of pKSN2 (hereinafter referred to as "pKSN1609soy"). Said plasmid was introduced into E. coli JM109. The obtained E. coli transformant was designated JM 109/pKSN 1609soy.

## (3) Expression of the present invention protein (A25)S in E. coli and recovery of said protein

[0543] Similarly to Example 4(2), each of E. coli JM109/pKSN1609soy obtained in Example 71(2) and E. coli JM109/pKSN1609F obtained in Example 67(1) was cultured. The cells were recovered. Cell lysate solutions were prepared. Under the method described in Example 4(2), supernatant fractions were prepared from the cell lysate solutions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1609soy is referred to as "E. coli pKSN1609soy extract" and the supernatant fraction obtained from E. coli JM109/pKSN1609F is referred to as "E. coli pKSN1609F extract"). The amount of P450 per the protein amount contained in E. coli pKSN1609soy extract was compared to and was higher than the amount of P450 per the protein amount contained in E. coli pKSN1609F extract.

**Example 72 Preparation of the Present Invention Antibody (A) Recognizing the Present Invention Protein (A25)**  
(hereinafter referred to as "present invention antibody (A25)")

**(1) Preparation of the extract of an E. coli expressing the present invention protein (A25)**

[0544] In accordance with the method described in Example 4(2), E. coli JM109/pKSN1609soy, produced in Example 71(2), was pre-cultured overnight. The obtained cultured medium was inoculated to 1L of TB medium containing 50µg/ml of ampicillin and cultured at 26°C. Then 5-aminolevulinic acid was added to the final concentration of 500µM, and IPTG was added to a final concentration of 1mM, and that was further cultured. The cells were recovered from the cultured medium, were washed with 0.05M Tris-HCl Buffer (pH7.5) and then suspended in 100ml of said buffer containing 1mM PMSF. The obtained cell culture medium was subjected 3 times to a sonicator (Sonifier (Branson Sonic Power Company)) at 10 minutes each under the conditions of output 5, duty cycle 30%, in order to obtain cell lysate solutions. After centrifuging the cell lysate solutions (9,000xg, 10 minutes) the supernatants were recovered and centrifuged (200,000xg, 70 minutes) to recover supernatant fractions (hereinafter, the supernatant fraction obtained from E. coli JM109/pKSN1609soy is referred to as "E. coli pKSN1609soy extract"

**(2) Purification of the present invention protein (A25)**

[0545] The supernatant fraction obtained in Example 72(1) (E. coli pKSN1609soy extract) was injected into a HiLoad16/10 Q Sepharose HP column (Amersham Bioscience Company). Next, after flowing 40ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.00125M/minute, range of NaCl concentration was from 0M to 0.375M, flow rate was 3ml/minute) to fraction recover 10ml of fractions eluting at the NaCl concentration of from 0.088M to 0.100M.

[0546] The recovered fractions were subjected to a PD-10 column (Amersham Biosciences Company) and eluted with 20mM bistrispropane buffer (pH7.0) to recover the fractions containing protein. Next, said fractions were injected into a MonoQ HR 10/10 (Amersham Biosciences Company). Sixteen milliliters (16ml) of 20mM bistrispropane buffer was flown into the column. Next, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.001042M/minute, range of NaCl concentration was from 0M to 0.25M, flow rate was 4ml/minute) to fraction recover 8ml of fractions eluting at the NaCl concentration of from 0.060M to 0.069M.

[0547] The recovered fractions were diluted 2.5 fold with 20mM bistrispropane buffer (pH7.0) and injected into a MonoQ HR 5/5 column (Amersham Biosciences Company). Next, after flowing 2ml of 20mM bistrispropane buffer (pH7.0) into the column, 20mM bistrispropane buffer was flown with a linear gradient of NaCl (gradient of NaCl was 0.008333M/minute, range of NaCl concentration was from 0M to 0.25M, flow rate was 1ml/minute) to fraction recover 0.5ml of fractions eluting at the NaCl concentration of from 0.073M to 0.077M.

[0548] The fractions purified in such a way were analyzed with SDS-PAGE by utilizing a "PAG mini Daiichi 10/20" (Daiichi Pure Chemicals Co., Ltd.) to confirm that those fractions were fractions which mainly contain the present invention protein (A25).

**(3) Preparation of the present invention antibody (A25)**

[0549] Preparation of the present invention antibody was conducted accordingly to the method described in Example 44(3). However, instead of utilizing the present invention protein (A1), the present invention protein (A25) obtained in Example 72(2) was utilized to obtain antiserum containing the present invention antibody (A25).

**Example 73 Detection of the Present Invention Protein by the Present Invention Antibody (A25)**

[0550] An immunoblot was conducted by utilizing the present invention antibody (A25) obtained in Example 72(3) with each of the E. coli extracts. There was a SDS polyacrylamide electrophoresis (40mA, 1 hour) of: the E. coli pKSN452F extract obtained in Example 49(2) (containing about 2pmol of the present invention protein (A16)); the E. coli pKSN608F extract obtained in Example 51(2) (containing about 2pmol of the present invention protein (A17)); the E. coli pKSN646BF extract obtained in Example 53(2) (containing about 2pmol of the present invention protein (A18)); the E. coli pKSN1502F extract obtained in Example 55(2) (containing about 2pmol of the present invention protein (A19)); the E. coli pKSN1525F extract obtained in Example 57(2) (containing about 2pmol of the present invention protein (A20)); the E. coli pKSN1543BF extract obtained in Example 59(2) (containing about 2pmol of the present invention protein (A21)); the E. coli pKSN1558BF extract obtained in Example 61(2) (containing about 2pmol of the present invention protein (A22)); the E. coli pKSN1584F extract obtained in Example 63(2) (containing about 2pmol of the present invention protein (A23)); the E. coli pKSN1589BF extract obtained in Example 65(2) (containing about 2pmol of the present invention protein (A24)); the E. coli pKSN1609F extract obtained in Example 67(2) (containing

about 0.5pmol of the present invention protein (A25)); the E. coli pKSN1584soy extract obtained in Example 70(3) (containing about 2pmol of the present invention protein (A23)); the E. coli pKSN1609soy extract obtained in Example 71(3) (containing about 0.5pmol of the present invention protein (A25)); and the E. coli pKSN2 extract obtained in Example 67(2) (containing about 0.8mg of protein). The proteins in said gel were transferred to a PVDF membrane according to the method described in Example 45. The PDVF membrane obtained in Example 45 (hereinafter referred to as "PDVF membrane (A)") and the PDVF membrane obtained from the above method (hereinafter referred to as "PDVF membrane (B)") were reacted with the antiserum obtained in Example 72(3), according to the method described Example 45. Subsequently, there was conducted a reaction with the secondary antibody, a washing and a staining in accordance with the method described in Example 45. Stains for bands corresponding to the present invention proteins (A1), (A2), (A3), (A4), (A11), (A12), (A13), (A14) and (A15) as well as the present proteins (A9) and (A10) were detected on the PDVF membrane (A). Stains for bands corresponding to the present invention proteins (A16), (A17), (A18), (A19), (A20), (A21), (A22), (A23), (A24) and (A25) were detected on the PDVF membrane (B). No stained band was detected with the reagent of E. coli pKSN2 extract obtained in Example 4(2) (containing 0.78mg of protein) of PVDF membrane (A) and with the reagent of E. coli pKSN2 extract obtained in Example 67(2) (containing 0.8mg of protein) of PVDF membrane (B).

#### Example.74 Introduction of the Present Invention DNA (A23)S into a Plant

##### (1) Construction of a Chloroplast Expression Plasmid Containing the Present Invention DNA (A23)S for Direct Introduction - part 1

**[0551]** A plasmid containing a chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons was constructed as a plasmid for introducing the present invention DNA (A23)S into a plant with the particle gun method.

**[0552]** First, DNA comprising the nucleotide sequence shown in SEQ ID NO: 398 was amplified by PCR. The PCR was conducted by utilizing as a template pKSN1584soy obtained in Example 70(2) and by utilizing as primers an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 397 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 398. The PCR utilized KOD-plus (Toyobo Company). The PCR carried out after conducting once a maintenance at 94°C for 2 minutes; 20 cycles of a cycle that included maintaining 94°C for 30 seconds, followed by 53°C for 30 seconds, and followed by 68°C for 90 seconds; and a final maintenance at 68°C for 3 minutes. The amplified DNA was recovered and purified with MagExtractor-PCR & Gel-Clean up (Toyobo Company) by conducting the procedures according to the attached manual. By treating the obtained DNA with TaKaRa BKLKit (Takara Shuzo Company) according to the attached manual, the DNA was blunt ended and had the 5' terminus phosphorylated. A DNA comprising a nucleotide sequence shown in SEQ ID NO: 368 was recovered. After digesting plasmid pUC19 (Takara Shuzo Company) with SmaI, the 5' terminus was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). A plasmid was produced by ligating the resulting dephosphorylated DNA and the DNA comprising the nucleotide sequence shown in SEQ ID NO: 368. After digesting the obtained plasmid with restriction enzymes EcoT22I and SacI, the DNA comprising the nucleotide sequence shown in SEQ ID NO: 368 was recovered. After digesting plasmid pUCrSt657 obtained in Example 16(2) with restriction enzymes EcoT22I and SacI, there was isolated a DNA of about 2.9kbp having a nucleotide sequence derived from pUC19 and a sequence encoding a chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit. The obtained DNA and the above DNA comprising the nucleotide sequence shown in SEQ ID NO: 368 were ligated to obtain pUCrSt1584soy (Fig. 54) containing a chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0553]** The obtained plasmid pUCrSt1584soy was digested with restriction enzymes BamHI and SacI to isolate a DNA comprising a nucleotide sequence shown in SEQ ID NO: 368. Said DNA was inserted between the BglII restriction site and the SacI restriction site of plasmid pNdG6- Δ T obtained in Example 16(2) to obtain plasmid pSUM-NdG6-rSt-1584soy (Fig. 55) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which said DNA was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0554]** Next, the plasmid was introduced into E. coli DH5 α competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt-1584soy has the nucleotide sequence shown in SEQ ID NO: 368.

**(2) Construction of a chloroplast expression plasmid having the present invention DNA (A23)S for direct introduction - part (2)**

**[0555]** A plasmid was constructed for introducing the present invention DNA (A23)S into a plant with the particle gun method. The plasmid contained a chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. First, DNA comprising the nucleotide sequence shown in SEQ ID NO: 368 was amplified by PCR. The PCR was conducted by utilizing as a template pKSN1584soy obtained in Example 70 and by utilizing as primers an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 399 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 398. The PCR utilized KOD-plus (Toyobo Company). The PCR carried out after conducting once a maintenance at 94°C for 2 minutes; 25 cycles of a cycle that included maintaining 94°C for 30 seconds, followed by 46°C for 30 seconds, and followed by 68°C for 90 seconds; and a final maintenance at 68°C for 3 minutes. The amplified DNA was recovered and purified with MagExtractor-PCR & Gel-Clean up (Toyobo Company) by conducting the procedures according to the attached manual. By treating the obtained DNA with TaKaRa BKLKit (Takara Shuzo Company) according to the attached manual, the DNA was blunt ended and had the 5' terminus phosphorylated. A DNA comprising a nucleotide sequence shown in SEQ ID NO: 368 was recovered. After digesting plasmid pKF19  $\Delta$  Bs obtained in Example 15(3) with SmaI, the 5' terminus was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). A plasmid was produced by ligating the resulting dephosphorylated DNA and the DNA comprising the nucleotide sequence shown in SEQ ID NO: 368. After digesting the obtained plasmid with restriction enzymes BspHI and SacI, the DNA comprising the nucleotide sequence shown in SEQ ID NO: 368 was recovered. Next, plasmid pKFrSt12-657 obtained in Example 16(3) was digested with restriction enzymes BspHI and SacI to isolate the DNA derived from plasmid pKFrSt12. Said DNA was ligated with the DNA which was digested with restriction enzymes SacI and BspHI and which comprises the nucleotide sequence shown in SEQ ID NO: 368, in order to obtain plasmid pKFrSt12-1584soy (Fig. 56) containing the chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons.

**[0556]** The obtained plasmid pKFrSt12-1584soy was digested with restriction enzymes BamHI and SacI to isolate the DNA comprising the nucleotide sequence shown in SEQ ID NO: 368. Said DNA was inserted between the BgIII restriction site and the SacI restriction site of plasmid pNdG6- $\Delta$  T to obtain plasmid pSUM-NdG6-rSt 12-1584soy (Fig. 57) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which said DNA was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0557]** Next, the plasmid was introduced into E. coli DH5  $\alpha$  competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt12-1584soy has the nucleotide sequence shown in SEQ ID NO: 368.

**(3) Introduction of the present invention DNA (A23)S into soybean**

**[0558]** The globular embryos of soybeans (cultivar: Fayette and Jack) were prepared according to the method described in Example 47(3).

**[0559]** The obtained globular embryo was transplanted into fresh somatic embryo growth medium and cultured for 2 to 3 days. The plasmid pSUM-NdG6-rSt-1584soy produced in Example 74(1) or the plasmid pSUM-NdG6-rSt12-1584soy produced in Example 74(2) were introduced into those globular embryos according to the method described in Example 17(2).

**(4) Selection of somatic embryo with hygromycin**

**[0560]** Selection by hygromycin of a spherica-type1 embryo after the introduction of the gene, obtained in Example 74(3), is conducted according to the method described in Example 47(4).

**(5) Selection of somatic embryo with compound (II)**

**[0561]** Selection by compound (II) of a globular embryo after the introduction of the gene, obtained in Example 74(3), is conducted according to the method described in Example 47(5).

**(6) Plant regeneration from the somatic embryo, acclimation and cultivation**

[0562] In accordance with the method described in Example 47(6), the plant regeneration is conducted from the globular embryos selected in Examples 74(4) or 74(5).

[0563] The plant with roots and developed leaves undergo the acclimation and cultivation accordingly with the method described in Example 17(6) and are harvested.

**(7) Evaluation of the resistance to herbicidal compound (II)**

[0564] The degree of resistance against compound (II) of the regenerated plant obtained in Example 74(6) is evaluated in accordance with the method described in Example 17(4).

**(8) Construction of a chloroplast expression plasmid having the present invention DNA (A23)S for agrobacterium introduction**

[0565] A plasmid for introducing the present invention DNA (A23)S into a plant with the agrobacterium method is constructed. Plasmid pSUM-NdG6-rSt-1584soy was digested with restriction enzymes HindIII and EcoRI, to isolate the chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons. Said DNA was inserted into between the HindIII restriction site and the EcoRI restriction site of the above binary plasmid vector pBI121S obtained in Example 18 to obtain plasmid pBI-NdG6-rSt-1584soy (Fig. 58). Further, plasmid pSUM-NdG6-rSt12-1584soy was digested with restriction enzyme NotI, to isolate a chimeric DNA in which the present invention DNA (A23)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. Such a DNA was inserted between the HindIII restriction site and EcoRI restriction site of the above binary plasmid vector pBI121S to obtain plasmids pBI-NdG6-rSt12-1584soy (Fig. 59).

**(9) Introduction of the present invention DNA (A23)S to tobacco**

[0566] The present invention DNA (A23)S was introduced into tobacco with the agrobacterium method, utilizing plasmid pBI-NdG6-rSt-1584soy and pBI-NdG6-rSt12-1584soy obtained in Example 74(8).

[0567] First, in accordance with the method described in Example 19, each of the plasmids pBI-NdG6-rSt-1584soy and pBI-NdG6-rSt12-1584soy was introduced into *Agrobacterium tumefaciens* LBA4404 (Clontech Company). Each of the transgenic agrobacterium bearing pBI-NdG6-rSt-1584soy or pBI-NdG6-rSt12-1584soy were isolated.

[0568] Next, said agrobacterium bearing the plasmids are utilized to introduce genes into tobacco according to the method described in Example 47(9) to obtain, respectively, transgenic tobaccos which have incorporated the T-DNA region of pBI-NdG6-rSt-1584soy or pBI-NdG6-rSt12-1584soy.

**(10) Evaluation of the resistance utilizing a leaf piece of the present invention DNA (A23)S transgenic tobacco**

[0569] Leaves are taken from 35 transgenic tobaccos obtained in Example 74(9). Each leaf is divided into pieces in which each piece is 5 to 7mm wide. Leaf pieces are planted onto MS agar medium containing compound (II) or compound (XII) and cultured in the light at room temperature. After several days of culturing, the herbicidal damage of each of the leaf pieces is observed. As a control, leaf pieces of wild type tobacco are utilized. The resistance of the transgenic tobacco is evaluated by scoring the leaf pieces which continuously grow, leaf pieces which have chemical damage, and leaf pieces which turned white and have withered.

**Example 75 Introduction of the Present Invention DNA (A25)S into a Plant****(1) Construction of a Chloroplast Expression Plasmid Containing the Present Invention DNA (A25)S for Direct Introduction - part 1**

[0570] A plasmid containing a chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons was constructed as a plasmid for introducing the present invention DNA (A25)S into a plant with the particle gun method.

[0571] First, DNA comprising the nucleotide sequence shown in SEQ ID NO: 393 was amplified by PCR. The PCR was conducted by utilizing as a template pKSN1609soy obtained in Example 71(2) and by utilizing as primers an

oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 400 and an oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 401. The PCR utilized KOD-plus (Toyobo Company). The PCR carried out after conducting once a maintenance at 94°C for 2 minutes; 20 cycles of a cycle that included maintaining 94°C for 30 seconds, followed by 53°C for 30 seconds, and followed by 68°C for 90 seconds; and a final maintenance at 68°C for 3 minutes. The amplified DNA was recovered and purified with MagExtractor-PCR & Gel-Clean up (Toyobo Company) by conducting the procedures according to the attached manual. By treating the obtained DNA with TaKaRa BKLKit (Takara Shuzo Company) according to the attached manual, the DNA was blunt ended and had the 5' terminus phosphorylated. A DNA comprising a nucleotide sequence shown in SEQ ID NO: 393 was recovered. After digesting plasmid pUC 19 (Takara Shuzo Company) with SmaI, the 5' terminus was dephosphorylated with calf intestine alkaline phosphatase (Takara Shuzo Company). A plasmid was produced by ligating the resulting dephosphorylated DNA and the DNA comprising the nucleotide sequence shown in SEQ ID NO: 393. After digesting the obtained plasmid with restriction enzymes EcoT22I and SacI, the DNA comprising the nucleotide sequence shown in SEQ ID NO: 393 was recovered. After digesting plasmid pUCrSt657 obtained in Example 16(2) with restriction enzymes EcoT22I and SacI, there was isolated a DNA of about 2.9kbp having a nucleotide sequence derived from pUC 19 and a sequence encoding a chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit. The obtained DNA and the above DNA comprising the nucleotide sequence shown in SEQ ID NO: 393 were ligated to obtain pUCrSt1609soy (Fig. 60) containing a chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0572]** The obtained plasmid pUCrSt1609soy was digested with restriction enzymes BamHI and SacI to isolate a DNA comprising a nucleotide sequence shown in SEQ ID NO: 393. Said DNA was inserted between the BglII restriction site and the SacI restriction site of plasmid pNdG6-Δ T to obtain plasmid pSUM-NdG6-rSt-1609soy (Fig. 61) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which said DNA was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0573]** Next, the plasmid was introduced into *E. coli* DH5 α competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt-1609soy has the nucleotide sequence shown in SEQ ID NO: 393.

## **(2) Construction of a chloroplast expression plasmid having the present invention DNA (A25)S for direct introduction - part (2)**

**[0574]** A plasmid was constructed for introducing the present invention DNA (A25)S into a plant with the particle gun method. The plasmid contained a chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. First, plasmid pUCrSt1609soy obtained in Example 75(1) has inserted into its EcoT22I restriction site, the linker EcoT22I-12aa-EcoT22I (Fig. 62) obtained by annealing the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 402 and the oligonucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 403. There was obtained plasmid pUCrSt12-1609soy (Fig. 63) containing the chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons.

**[0575]** The obtained plasmid pUCrSt12-1609soy was digested with restriction enzymes BamHI and SacI to isolate the DNA comprising the nucleotide sequence shown in SEQ ID NO: 393. Said DNA was inserted between the BglII restriction site and the SacI restriction site of plasmid pNdG6-Δ T, obtained in Example 16(2), to obtain plasmid pSUM-NdG6-rSt12-1609soy (Fig. 64) wherein the CR16G6 promoter has connected downstream the chimeric DNA in which said DNA was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons.

**[0576]** Next, the plasmid was introduced into *E. coli* DH5 α competent cells (Takara Shuzo Company) and the ampicillin resistant cells were selected. Further, the nucleotide sequences of the plasmids contained in the ampicillin resistant strains were determined by utilizing BigDye Terminator Cycle Sequencing Ready Reaction kit v3.0 (PE Applied Biosystems Company) and DNA sequencer 3100 (PE Applied Biosystems Company). As a result, it was confirmed that plasmid pSUM-NdG6-rSt12-1609soy has the nucleotide sequence shown in SEQ ID NO: 393.

**(3) Introduction of the present invention DNA (A23)S into soybean**

[0577] The globular embryos of soybeans (cultivar: Fayette and Jack) were prepared according to the method described in Example 47(3).

[0578] The obtained globular embryo was transplanted into fresh somatic embryo growth medium and cultured for 2 to 3 days. The plasmid pSUM-NdG6-rSt-1609soy produced in Example 75(1) or the plasmid pSUM-NdG6-rSt12-1609soy produced in Example 75(2) were introduced into those globular embryos according to the method described in Example 17(2).

**(4) Selection of somatic embryo with hygromycin**

[0579] Selection by hygromycin of a globular embryo after the introduction of the gene, obtained in Example 75(3), is conducted according to the method described in Example 47(4).

**(5) Selection of somatic embryo with compound (II)**

[0580] Selection by compound (II) of a globular embryo after the introduction of the gene, obtained in Example 75(3), is conducted according to the method described in Example 47(5).

**(6) Plant regeneration from the somatic embryo, acclimation and cultivation**

[0581] In accordance with the method described in Example 47(6), the plant regeneration is conducted from the globular embryos selected in Examples 74(4) or 74(5).

[0582] The plant with roots and developed leaves undergo the acclimation and cultivation accordingly with the method described in Example 17(6) and are harvested.

**(7) Evaluation of the resistance to herbicidal compound (II)**

[0583] The degree of resistance against compound (II) of the regenerated plant obtained in Example 75(6) is evaluated in accordance with the method described in Example 17(4).

**(8) Construction of a chloroplast expression plasmid having the present invention DNA (A25)S for agrobacterium introduction**

[0584] A plasmid for introducing the present invention DNA (A25)S into a plant with the agrobacterium method is constructed. Plasmid pSUM-NdG6-rSt-1609soy was digested with restriction enzymes HindIII and EcoRI, to isolate the chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequence encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit without a change of frames in the codons. Said DNA was inserted into between the HindIII restriction site and the EcoRI restriction site of the binary plasmid vector pBI121S obtained in Example 18 to obtain plasmid pBI-NdG6-rSt-1609soy (Fig. 65). Further, plasmid pSUM-NdG6-rSt12-1609soy was digested with restriction enzyme NotI, to isolate a chimeric DNA in which the present invention DNA (A25)S was connected immediately after the nucleotide sequences encoding the chloroplast transit peptide of soybean (cv. Jack) RuBPC small subunit and encoding thereafter 12 amino acids of the mature protein, without a change of frames in the codons. Such a DNA was inserted between the HindIII restriction site and EcoRI restriction site of the above binary plasmid vector pBI121S to obtain plasmids pBI-NdG6-rSt12-1609soy (Fig. 66).

**(9) Introduction of the present invention DNA (A23)S to tobacco**

[0585] The present invention DNA (A25)S was introduced into tobacco with the agrobacterium method, utilizing plasmid pBI-NdG6-rSt-1609soy and pBI-NdG6-rSt12-1609soy obtained in Example 75(8).

[0586] First, in accordance with the method described in Example 19, each of the plasmids pBI-NdG6-rSt-1609soy and pBI-NdG6-rSt12-1609soy was introduced into *Agrobacterium tumefaciens* LBA4404 (Clontech Company). Each of the transgenic agrobacterium bearing pBI-NdG6-rSt-1609soy or pBI-NdG6-rSt12-1609soy were isolated.

[0587] Next, said agrobacterium bearing the plasmids are utilized to introduce genes into tobacco according to the method described in Example 47(9) to obtain, respectively, transgenic tobaccos which have incorporated the T-DNA region of pBI-NdG6-rSt-1609soy or pBI-NdG6-rSt12-1609soy.

**(10) Evaluation of the resistance utilizing a leaf piece of the present invention DNA (A25)S transgenic tobacco**

**[0588]** Leaves are taken from the transgenic tobaccos obtained in Example 75(9). Such leaves are utilized to evaluate the resistance of the transgenic tobacco against compound (II) or compound (XII) according to the method of Example 74(10).

**APPLICABILITY TO INDUSTRY**

**[0589]** With the present invention, it is possible to provide a protein having the ability to metabolize a PPO inhibiting herbicidal compound and to convert such a compound to a compound of lower herbicidal activity; a DNA encoding such a protein; and a plant resistant to a herbicidal compound expressing such a protein.

**SEQUENCE FREE TEXT**

**[0590]**

SEQ ID NO: 35

Designed oligonucleotide primer for PCR

SEQ ID NO: 36

Designed oligonucleotide primer for PCR

SEQ ID NO: 37

Designed oligonucleotide primer for PCR

SEQ ID NO: 38

Designed oligonucleotide primer for PCR

SEQ ID NO: 39

Designed oligonucleotide primer for PCR

SEQ ID NO: 40

Designed oligonucleotide primer for PCR

SEQ ID NO: 41

Designed oligonucleotide primer for PCR

SEQ ID NO: 42

Designed oligonucleotide primer for PCR

SEQ ID NO: 43

Designed oligonucleotide primer for PCR

SEQ ID NO: 44

Designed oligonucleotide primer for PCR

SEQ ID NO: 45

Designed oligonucleotide primer for PCR

SEQ ID NO: 46

Designed oligonucleotide primer for PCR

SEQ ID NO: 47

Designed oligonucleotide primer for PCR

SEQ ID NO: 48

Designed oligonucleotide primer for PCR

SEQ ID NO: 49

Designed oligonucleotide primer for PCR

SEQ ID NO: 50

Designed oligonucleotide primer for PCR

SEQ ID NO: 51

Designed oligonucleotide primer for PCR

SEQ ID NO: 52

Designed oligonucleotide primer for PCR

SEQ ID NO: 53

Designed oligonucleotide primer for PCR

SEQ ID NO: 54

Designed oligonucleotide primer for PCR

SEQ ID NO: 55

Designed oligonucleotide primer for PCR

SEQ ID NO: 56

Designed oligonucleotide primer for PCR

SEQ ID NO: 57

Designed oligonucleotide primer for PCR

5 SEQ ID NO: 58

Designed oligonucleotide primer for PCR

SEQ ID NO: 59

Designed oligonucleotide primer for PCR

SEQ ID NO: 60

10 Designed oligonucleotide primer for PCR

SEQ ID NO: 61

Designed oligonucleotide primer for PCR

SEQ ID NO: 62

Designed oligonucleotide primer for PCR

15 SEQ ID NO: 63

Designed oligonucleotide primer for PCR

SEQ ID NO: 64

Designed oligonucleotide primer for PCR

SEQ ID NO: 65

20 Designed oligonucleotide primer for PCR

SEQ ID NO: 66

Designed oligonucleotide primer for PCR

SEQ ID NO: 67

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 68

Designed oligonucleotide primer for PCR

SEQ ID NO: 70

Designed oligonucleotide primer for PCR

SEQ ID NO: 71

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 72

Designed oligonucleotide primer for PCR

SEQ ID NO: 73.

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 74

Designed oligonucleotide primer for PCR

SEQ ID NO: 75

Designed oligonucleotide primer for PCR

SEQ ID NO: 76

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 77

Designed oligonucleotide primer for PCR

SEQ ID NO: 79

Designed oligonucleotide primer for PCR

45 SEQ ID NO: 80

Designed oligonucleotide primer for PCR

SEQ ID NO: 81

Designed oligonucleotide primer for PCR

SEQ ID NO: 82

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 83

Designed oligonucleotide primer for PCR

SEQ ID NO: 86

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 87

Designed oligonucleotide primer for PCR

SEQ ID NO: 89

Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 90

Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 91

Designed oligonucleotide linker for construction of expression vector

5 SEQ ID NO: 92

Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 93

Designed oligonucleotide primer for PCR

SEQ ID NO: 94

10 Designed oligonucleotide primer for PCR

SEQ ID NO: 95

Designed oligonucleotide primer for PCR

SEQ ID NO: 96

Designed oligonucleotide primer for PCR

15 SEQ ID NO: 97

Designed oligonucleotide primer for PCR

SEQ ID NO: 98

Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 99

20 Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 100

Designed oligonucleotide primer for PCR

SEQ ID NO: 101

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 102

Designed oligonucleotide primer for PCR

SEQ ID NO: 103

Designed oligonucleotide primer for PCR

SEQ ID NO: 104

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 105

Designed oligonucleotide primer for PCR

SEQ ID NO: 106

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 107

Designed oligonucleotide primer for PCR

SEQ ID NO: 114

Designed oligonucleotide primer for PCR

SEQ ID NO: 115

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 116

Designed oligonucleotide primer for PCR

SEQ ID NO: 117

Designed oligonucleotide primer for PCR

45 SEQ ID NO: 118

Designed oligonucleotide primer for PCR

SEQ ID NO: 119

Designed oligonucleotide primer for PCR

SEQ ID NO: 120

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 121

Designed oligonucleotide primer for PCR

SEQ ID NO: 122

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 123

Designed oligonucleotide primer for PCR

SEQ ID NO: 124

Designed oligonucleotide primer for PCR

SEQ ID NO: 125

Designed oligonucleotide primer for PCR

SEQ ID NO: 126

Designed oligonucleotide primer for PCR

5 SEQ ID NO: 127

Designed oligonucleotide primer for PCR

SEQ ID NO: 128

Designed oligonucleotide primer for PCR

10 SEQ ID NO: 129

Designed oligonucleotide primer for PCR

SEQ ID NO: 130

Designed oligonucleotide primer for PCR

SEQ ID NO: 131

Designed oligonucleotide primer for PCR

15 SEQ ID NO: 132

Designed oligonucleotide primer for PCR

SEQ ID NO: 133

Designed oligonucleotide primer for PCR

SEQ ID NO: 134

20 Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 135

Designed oligonucleotide linker for construction of expression vector

SEQ ID NO: 161

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 162

Designed oligonucleotide primer for PCR

SEQ ID NO: 163

Designed oligonucleotide primer for PCR

SEQ ID NO: 164

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 165

Designed oligonucleotide primer for PCR

SEQ ID NO: 166

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 167

Designed oligonucleotide primer for PCR

SEQ ID NO: 168

Designed oligonucleotide primer for PCR

SEQ ID NO: 169

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 170

Designed oligonucleotide primer for PCR

SEQ ID NO: 171

Designed oligonucleotide primer for PCR

45 SEQ ID NO: 172

Designed oligonucleotide primer for PCR

SEQ ID NO: 173

Designed oligonucleotide primer for PCR

SEQ ID NO: 174

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 175

Designed oligonucleotide primer for PCR

SEQ ID NO: 176

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 177

Designed oligonucleotide primer for PCR

SEQ ID NO: 178

Designed oligonucleotide primer for PCR

SEQ ID NO: 179

Designed oligonucleotide primer for PCR

SEQ ID NO: 180

Designed oligonucleotide primer for PCR

SEQ ID NO: 181

Designed oligonucleotide primer for PCR

SEQ ID NO: 182

Designed oligonucleotide primer for PCR

SEQ ID NO: 183

Designed oligonucleotide primer for PCR

SEQ ID NO: 184

Designed oligonucleotide primer for PCR

SEQ ID NO: 185

Designed oligonucleotide primer for PCR

SEQ ID NO: 186

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 187

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 188

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 189

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 190

Designed oligonucleotide primer for PCR

SEQ ID NO: 191

Designed oligonucleotide primer for PCR

SEQ ID NO: 192

Designed oligonucleotide primer for PCR

SEQ ID NO: 193

Designed oligonucleotide primer for PCR

SEQ ID NO: 194

Designed oligonucleotide primer for PCR

SEQ ID NO: 195

Designed oligonucleotide primer for PCR

SEQ ID NO: 196

Designed oligonucleotide primer for PCR

SEQ ID NO: 197

Designed oligonucleotide primer for PCR

SEQ ID NO: 198

Designed oligonucleotide primer for PCR

SEQ ID NO: 199

Designed oligonucleotide primer for PCR

SEQ ID NO: 200

Designed oligonucleotide primer for PCR

SEQ ID NO: 201

Designed oligonucleotide primer for PCR

SEQ ID NO: 202

Designed oligonucleotide primer for PCR

SEQ ID NO: 203

Designed oligonucleotide primer for PCR

SEQ ID NO: 204

Designed oligonucleotide primer for PCR

SEQ ID NO: 205

Designed oligonucleotide primer for PCR

SEQ ID NO: 206

Designed oligonucleotide primer for PCR

SEQ ID NO: 207

Designed oligonucleotide primer for PCR

SEQ ID NO: 208

Designed oligonucleotide primer for PCR

SEQ ID NO: 209

Designed oligonucleotide primer for PCR

SEQ ID NO: 210

Designed oligonucleotide primer for PCR

SEQ ID NO: 211

Designed oligonucleotide primer for PCR

SEQ ID NO: 212

Designed oligonucleotide primer for PCR

SEQ ID NO: 213

Designed oligonucleotide primer for PCR

SEQ ID NO: 214

Designed polynucleotide encoding amino acid sequence of SEQ ID No.1

SEQ ID NO: 265

Designed oligonucleotide primer for PCR

SEQ ID NO: 266

Designed oligonucleotide primer for PCR

SEQ ID NO: 267

Designed oligonucleotide primer for PCR

SEQ ID NO: 268

Designed oligonucleotide primer for PCR

SEQ ID NO: 269

Designed oligonucleotide primer for PCR

SEQ ID NO: 270

Designed oligonucleotide primer for PCR

SEQ ID NO: 271

Designed oligonucleotide primer for PCR

SEQ ID NO: 272

Designed oligonucleotide primer for PCR

SEQ ID NO: 273

Designed oligonucleotide primer for PCR

SEQ ID NO: 274

Designed oligonucleotide primer for PCR

SEQ ID NO: 275

Designed oligonucleotide primer for PCR

SEQ ID NO: 276

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 277

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 278

Designed oligonucleotide primer for PCR

SEQ ID NO: 279

Designed oligonucleotide primer for PCR

SEQ ID NO: 280

Designed oligonucleotide primer for PCR

SEQ ID NO: 281

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 282

Designed oligonucleotide primer for PCR

SEQ ID NO: 283

Designed oligonucleotide primer for PCR

SEQ ID NO: 284

Designed oligonucleotide primer for PCR

SEQ ID NO: 285

Designed oligonucleotide primer for PCR

SEQ ID NO: 286

Designed oligonucleotide primer for PCR

SEQ ID NO: 287

Designed oligonucleotide primer for PCR

SEQ ID NO: 288

Designed oligonucleotide primer for DNA sequencing

5 SEQ ID NO: 289

Designed oligonucleotide primer for PCR

SEQ ID NO: 290

Designed oligonucleotide primer for PCR

SEQ ID NO: 291

10 Designed oligonucleotide primer for PCR

SEQ ID NO: 292

Designed oligonucleotide primer for PCR

SEQ ID NO: 293

Designed oligonucleotide primer for PCR

15 SEQ ID NO: 294

Designed oligonucleotide primer for PCR

SEQ ID NO: 295

Designed oligonucleotide primer for PCR

SEQ ID NO: 296

20 Designed oligonucleotide primer for PCR

SEQ ID NO: 297

Designed oligonucleotide primer for PCR

SEQ ID NO: 298

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 299

Designed oligonucleotide primer for PCR

SEQ ID NO: 300

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 301

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 302

Designed oligonucleotide primer for PCR

SEQ ID NO: 303

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 304

Designed oligonucleotide primer for PCR

SEQ ID NO: 305

Designed oligonucleotide primer for PCR

SEQ ID NO: 306

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 307

Designed oligonucleotide primer for PCR

SEQ ID NO: 308

Designed oligonucleotide primer for DNA sequencing

45 SEQ ID NO: 309

Designed oligonucleotide primer for PCR

SEQ ID NO: 310

Designed oligonucleotide primer for PCR

SEQ ID NO: 311

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 312

Designed oligonucleotide primer for PCR

SEQ ID NO: 313

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 314

Designed oligonucleotide primer for PCR

SEQ ID NO: 315

Designed oligonucleotide primer for DNA sequencing

SEQ ID NO: 316

Designed oligonucleotide primer for PCR

SEQ ID NO: 317

Designed oligonucleotide primer for PCR

5 SEQ ID NO: 318

Designed oligonucleotide primer for PCR

SEQ ID NO: 319

Designed oligonucleotide primer for PCR

SEQ ID NO: 320

10 Designed oligonucleotide primer for PCR

SEQ ID NO: 321

Designed oligonucleotide primer for PCR

SEQ ID NO: 322

Designed oligonucleotide primer for DNA sequencing

15 SEQ ID NO: 323

Designed oligonucleotide primer for PCR

SEQ ID NO: 324

Designed oligonucleotide primer for PCR

SEQ ID NO: 325

20 Designed oligonucleotide primer for PCR

SEQ ID NO: 326

Designed oligonucleotide primer for PCR

SEQ ID NO: 327

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 328

Designed oligonucleotide primer for PCR

SEQ ID NO: 329

Designed oligonucleotide primer for PCR

SEQ ID NO: 330

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 331

Designed oligonucleotide primer for PCR

SEQ ID NO: 332

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 333

Designed oligonucleotide primer for PCR

SEQ ID NO: 334

Designed oligonucleotide primer for PCR

SEQ ID NO: 335

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 336

Designed oligonucleotide primer for PCR

SEQ ID NO: 337

Designed oligonucleotide primer for PCR

45 SEQ ID NO: 338

Designed oligonucleotide primer for PCR

SEQ ID NO: 339

Designed oligonucleotide primer for PCR

SEQ ID NO: 340

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 341

Designed oligonucleotide primer for PCR

SEQ ID NO: 342

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 343

Designed oligonucleotide primer for PCR

SEQ ID NO: 344

Designed oligonucleotide primer for PCR

SEQ ID NO: 345

Designed oligonucleotide primer for PCR

SEQ ID NO: 346

Designed oligonucleotide primer for PCR

5 S EQ ID NO: 347

Designed oligonucleotide primer for PCR

SEQ ID NO: 348

Designed oligonucleotide primer for PCR

SEQ ID NO: 349

10 Designed oligonucleotide primer for PCR

SEQ ID NO: 350

Designed oligonucleotide primer for PCR

SEQ ID NO: 351

Designed oligonucleotide primer for PCR

15 SEQ ID NO: 352

Designed oligonucleotide primer for PCR

SEQ ID NO: 353

Designed oligonucleotide primer for PCR

SEQ ID NO: 354

20 Designed oligonucleotide primer for PCR

SEQ ID NO: 355

Designed oligonucleotide primer for PCR

SEQ ID NO: 356

Designed oligonucleotide primer for PCR

25 SEQ ID NO: 357

Designed oligonucleotide primer for PCR

SEQ ID NO: 358

Designed oligonucleotide primer for PCR

SEQ ID NO: 359

30 Designed oligonucleotide primer for PCR

SEQ ID NO: 360

Designed oligonucleotide primer for PCR

SEQ ID NO: 361

Designed oligonucleotide primer for PCR

35 SEQ ID NO: 362

Designed oligonucleotide primer for PCR

SEQ ID NO: 363

Designed oligonucleotide primer for PCR

SEQ ID NO: 364

40 Designed oligonucleotide primer for PCR

SEQ ID NO: 365

Designed oligonucleotide primer for PCR

SEQ ID NO: 366

Designed oligonucleotide primer for PCR

45 SEQ ID NO: 367

Designed oligonucleotide primer for PCR

SEQ ID NO: 368

Designed polynucleotide encoding amino acid sequence of SEQ ID No.222

SEQ ID NO: 369

50 Designed oligonucleotide primer for PCR

SEQ ID NO: 370

Designed oligonucleotide primer for PCR

SEQ ID NO: 371

Designed oligonucleotide primer for PCR

55 SEQ ID NO: 372

Designed oligonucleotide primer for PCR

SEQ ID NO: 373

Designed oligonucleotide primer for PCR

SEQ ID NO: 374

Designed oligonucleotide primer for PCR

SEQ ID NO: 375

Designed oligonucleotide primer for PCR

SEQ ID NO: 376

Designed oligonucleotide primer for PCR

SEQ ID NO: 377

Designed oligonucleotide primer for PCR

SEQ ID NO: 378

Designed oligonucleotide primer for PCR

SEQ ID NO: 379

Designed oligonucleotide primer for PCR

SEQ ID NO: 380

Designed oligonucleotide primer for PCR

SEQ ID NO: 381

Designed oligonucleotide primer for PCR

SEQ ID NO: 382

Designed oligonucleotide primer for PCR

SEQ ID NO: 383

Designed oligonucleotide primer for PCR

SEQ ID NO: 384

Designed oligonucleotide primer for PCR

SEQ ID NO: 385

Designed oligonucleotide primer for PCR

SEQ ID NO: 386

Designed oligonucleotide primer for PCR

SEQ ID NO: 387

Designed oligonucleotide primer for PCR

SEQ ID NO: 388

Designed oligonucleotide primer for PCR

SEQ ID NO: 389

Designed oligonucleotide primer for PCR

SEQ ID NO: 390

Designed oligonucleotide primer for PCR

SEQ ID NO: 391

Designed oligonucleotide primer for PCR

SEQ ID NO: 392

Designed oligonucleotide primer for PCR

SEQ ID NO: 393

Designed polynucleotide encoding amino acid sequence of SEQ ID No.224

SEQ ID NO: 394

Designed oligonucleotide primer for PCR

SEQ ID NO: 395

Designed oligonucleotide primer for PCR

SEQ ID NO: 396

Designed oligonucleotide primer for PCR

SEQ ID NO: 397

Designed oligonucleotide primer for PCR

SEQ ID NO: 398

Designed oligonucleotide primer for PCR

SEQ ID NO: 399

Designed oligonucleotide primer for PCR

SEQ ID NO:400

Designed oligonucleotide primer for PCR

SEQ ID NO:401

Designed oligonucleotide primer for PCR

SEQ ID NO:402

Designed oligonucleotide linker for construction of expression vector

**EP 1 457 558 A1**

SEQ ID NO:403

Designed oligonucleotide linker for construction of expression vector

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

<110> Sumitomo Chemical Co., Ltd.

<120> A HERBICIDE METABOLIZING PROTEIN, A GENE THEREOF AND USE THEREOF

<130> K 1664 EP

<150> JP 2001/321307

<151> 2001-10-19

<150> JP 2002/167239

<151> 2002-06-07

<160> 403

<210> 1

<211> 408

<212> PRT

<213> Streptomyces phaeochromogenes IFO 12898

<400> 1

Met	Thr	Asp	Met	Thr	Asp	Thr	Ala	Asp	Val	Lys	Pro	Leu	Ser	Ala	Pro
1				5					10					15	
Val	Ala	Phe	Pro	Gln	Asp	Arg	Thr	Cys	Pro	Phe	Gln	Pro	Pro	Thr	Gly
			20					25					30		
Tyr	Asp	Pro	Leu	Arg	Glu	Ala	Arg	Pro	Leu	Ala	Arg	Val	Thr	Leu	Tyr
		35				40						45			
Asp	Gly	Arg	Ala	Ile	Trp	Leu	Val	Thr	Gly	Arg	Asp	Leu	Ala	Arg	Ser
	50					55					60				
Leu	Leu	Ala	Asp	Ser	Arg	Leu	Ser	Ser	Asp	Arg	Leu	Arg	Pro	Gly	Phe
	65				70					75					80
Pro	Ala	Thr	Ser	Pro	Arg	Ile	Val	Ala	Phe	Arg	Asp	Arg	Arg	Ala	Ala
				85					90					95	
Leu	Leu	Asn	Val	Asp	Asp	Pro	Glu	His	Thr	Gln	Arg	Arg	Met	Leu	
		100					105					110			
Val	Pro	Ser	Phe	Thr	Leu	Lys	Arg	Ala	Ala	Ala	Leu	Arg	Pro	Ala	Ile
		115					120					125			
Gln	Arg	Ile	Val	Asp	Glu	Cys	Ile	Asp	Ala	Met	Leu	Ala	Lys	Gly	Pro
	130					135					140				
Pro	Ala	Glu	Leu	Val	Asn	Ala	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val
	145				150					155					160
Ile	Cys	Glu	Leu	Leu	Gly	Val	Pro	Tyr	Ala	Asp	His	Glu	Phe	Phe	Glu
			165						170					175	
Glu	Gln	Ser	Arg	Arg	Leu	Leu	Arg	Gly	Arg	Asp	Val	Asp	Glu	Val	Arg
			180					185					190		
Asp	Ala	Arg	Asp	Gln	Leu	Asp	Cys	Tyr	Leu	Gly	Ala	Leu	Ile	Asp	Arg
		195				200						205			
Lys	Ser	Glu	Ser	Ser	Val	Gly	Asp	Gly	Val	Leu	Asp	Ala	Leu	Val	His
	210					215					220				
Glu	Gln	Leu	Arg	Glu	Gly	Ala	Val	Asp	Arg	Gln	Glu	Ala	Ile	Ser	Leu
	225				230					235					240
Ala	Thr	Ile	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	Ile
			245						250					255	
Ser	Leu	Gly	Thr	Tyr	Thr	Leu	Leu	Gln	His	Pro	Glu	Arg	Leu	Ala	Glu
		260						265					270		
Leu	Arg	Asp	Asp	Pro	Ser	Leu	Trp	Pro	Ala	Ala	Val	Asp	Glu	Leu	Met
		275					280					285			
Arg	Met	Leu	Ser	Ile	Ala	Asp	Gly	Leu	Met	Arg	Gln	Ala	Thr	Glu	Asp
	290					295					300				
Ile	Glu	Val	Ala	Gly	Thr	Thr	Ile	Arg	Ala	Gly	Glu	Gly	Val	Val	Phe
	305				310					315					320
Ala	Thr	Ser	Val	Ile	Asn	Arg	Asp	Gly	Glu	Val	Tyr	Ala	Glu	Pro	Asp
				325					330					335	

EP 1 457 558 A1

Ala Leu Asp Trp His Arg Pro Thr Arg His His Val Ala Phe Gly Phe  
 340 345 350  
 Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu  
 355 360 365  
 5 Ile Ala Leu Arg Ser Leu Phe Glu Arg Val Pro Gly Leu Arg Leu Asp  
 370 375 380  
 Ile Ala Pro Asp Ala Val Arg Phe Lys Pro Gly Asp Thr Ile Gln Gly  
 385 390 395 400  
 Met Leu Asp Leu Pro Val Ala Trp  
 405

<210> 2  
 <211> 401  
 <212> PRT  
 <213> Saccharopolyspora taberi JCM 9383t

<400> 2  
 Met Pro Ala Ser Ser Glu Ala Leu Thr Tyr Pro Ile Pro Arg Thr Cys  
 1 5 10 15  
 Pro Tyr Ser Pro Pro Asp Ser Tyr Ala Glu Leu Arg Arg Glu Gln Pro  
 20 25 30  
 Val Arg Arg Val Pro Thr Leu Ala Gly Gly Ser Val Trp Leu Val Ser  
 35 40 45  
 Arg His Glu Asp Val Arg Ala Val Leu Ser Asp Pro Arg Met Ser Ser  
 50 55 60  
 Asp Arg Arg Lys Pro Gly Phe Pro Arg Leu Val Pro Gly Gln Ser Asp  
 65 70 75 80  
 25 Leu Ile Phe Ser Ser Lys Pro Ser Met Ile Gly Met Asp Gly Arg Glu  
 85 90 95  
 His Ser Ala Ala Arg Arg Ala Val Leu Gly Glu Phe Thr Val Arg Arg  
 100 105 110  
 Ile Asn Ala Leu Arg Pro Arg Val Gln Glu Ile Val Asp Glu Ala Ile  
 115 120 125  
 30 Asp Ala Met Leu Ala Ala Gly Gly Pro Val Asp Leu Val Arg Met Leu  
 130 135 140  
 Ser Leu Pro Val Pro Ser Leu Val Ile Cys Glu Leu Leu Gly Val Pro  
 145 150 155 160  
 Tyr Ala Asp His Glu Phe Phe Gln Gln Arg Ser Gly Arg Ile Ile Ser  
 165 170 175  
 35 Arg Ala Thr Pro Gly Ala Glu Arg Glu Ala Phe Phe Glu Leu Arg  
 180 185 190  
 Ala Tyr Leu Ser Asp Leu Val Ala Asp Lys Val Arg Ala Pro Gly Asp  
 195 200 205  
 Asp Leu Leu Gly Arg Gln Val Ala Lys Gln Arg Ala Glu Gly Glu Val  
 210 215 220  
 40 Asp Gln Glu Ala Leu Val Ser Leu Ala Phe Leu Leu Leu Val Ala Gly  
 225 230 235 240  
 His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Ser Leu Ala Leu Leu  
 245 250 255  
 Asp Asp Ser Ala Arg Trp Ala Glu Ile Ala Ala Asp Pro Ala Lys Thr  
 260 265 270  
 45 Pro Gly Ala Val Glu Glu Met Leu Arg Phe Phe Ser Ile Val Asp Asn  
 275 280 285  
 Ala Thr Ala Arg Thr Ala Thr Glu Asp Val Glu Ile Gly Gly Val Val  
 290 295 300  
 50 Ile Gly Glu Gly Asp Gly Val Ile Ala Met Gly Tyr Ser Ala Asn His  
 305 310 315 320  
 Asp Pro Glu Val Phe Asp Arg Pro Gly Asp Leu Asp Phe Ser Arg Ala  
 325 330 335  
 Ala Arg Gln His Val Ala Phe Gly Phe Gly Ala His Gln Cys Leu Gly  
 340 345 350  
 Gln Asn Leu Ala Arg Val Glu Leu Gln Ile Val Phe Asp Thr Leu Val  
 355 360 365  
 55 Arg Arg Ile Pro Asp Leu Arg Leu Ala Val Gly Phe Asp Asp Ile Arg

EP 1 457 558 A1

370 375 380  
Phe Lys Glu Glu Ser Ala Ile Tyr Gly Ile His Glu Leu Met Val Thr  
385 390 395 400  
Trp

<210> 3  
<211> 395  
<212> PRT  
<213> Streptomyces testaceus ATCC 21469

<400> 3  
Met Thr Glu Ala Ile Ala Tyr Phe Gln Asp Arg Thr Cys Pro Tyr His  
1 5 10 15  
Pro Pro Ala Gly Tyr Gln Pro Leu Arg Asp Ala Gly Pro Leu Ala His  
20 25 30  
Val Thr Leu Tyr Asp Gly Arg Lys Val Trp Ala Val Thr Gly His Thr  
35 40 45  
Glu Ala Arg Ala Leu Leu Ser Asp Pro Arg Leu Ser Ser Asp Arg Gln  
50 55 60  
Asn Pro Ala Phe Pro Ala Pro Phe Ala Arg Phe Ala Ala Leu Arg Gln  
65 70 75 80  
Val Arg Ser Pro Leu Ile Gly Val Asp Asp Pro Glu His Asn Thr Gln  
85 90 95  
Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys Arg Thr Ala Ala Leu  
100 105 110  
Arg Pro Gln Ile Gln Gln Ile Val Asp Gly Leu Leu Asp Arg Met Leu  
115 120 125  
Ala Gln Gly Pro Pro Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val  
130 135 140  
Pro Ser Met Val Ile Cys Ser Leu Leu Gly Val Pro Tyr Ser Asp His  
145 150 155 160  
Glu Phe Phe Glu Glu Ala Ser Arg Arg Leu Leu Arg Ser Arg Thr Ala  
165 170 175  
Glu Glu Ala Glu Glu Ala Arg Leu Arg Leu Glu Asp Tyr Phe Asp Glu  
180 185 190  
Leu Ile Ala His Lys Glu Lys Thr Pro Arg Glu Gly Leu Leu Asp Glu  
195 200 205  
Leu Val His Asp Glu Leu Arg Thr Gly Ala Leu Glu Arg Glu Asp Leu  
210 215 220  
Val Arg Leu Ala Met Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala  
225 230 235 240  
Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Glu His Pro Gly Gln  
245 250 255  
Leu Ala Arg Leu Lys Ala Glu Glu Gly Leu Leu Pro Ala Ala Val Glu  
260 265 270  
Glu Leu Leu Arg Phe Leu Ser Ile Ala Asp Gly Leu Leu Arg Val Ala  
275 280 285  
Met Ala Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Asp Asp Gly  
290 295 300  
Val Leu Phe Pro Thr Ser Leu Ile Asn Arg Asp Gly Ala Tyr Pro  
305 310 315 320  
Thr Pro Asp Glu Leu Asp Val Gly Arg Ser Ala Arg His His Val Ala  
325 330 335  
Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala  
340 345 350  
Glu Met Glu Ile Ala Leu Arg Ser Leu Phe Asp Arg Ile Pro Asp Leu  
355 360 365  
Arg Leu Ala Val Pro Ala Ala Glu Ile Pro Phe Lys Pro Gly Asp Thr  
370 375 380  
Leu Gln Gly Met Ile Glu Leu Pro Leu Ala Trp  
385 390 395

<210> 4  
<211> 410

EP 1 457 558 A1

<212> PRT

<213> Streptomyces carbophilus SANK 62585

<400> 4

5 Met Thr Glu Met Thr Glu Lys Ala Thr Thr Phe Leu Thr Ser Gln Glu  
1 5 10 15  
Ala Pro Ala Phe Pro Ala Asp Arg Thr Cys Pro Tyr Gln Leu Pro Thr  
20 25 30  
Ala Tyr Ser Arg Leu Arg Asp Glu Pro Asp Ala Leu Arg Pro Val Thr  
35 40 45  
10 Leu Tyr Asp Gly Arg Arg Ala Trp Val Val Thr Lys His Glu Ala Ala  
50 55 60  
Arg Arg Leu Leu Ala Asp Pro Arg Leu Ser Ser Asp Arg Leu His Ala  
65 70 75 80  
Asp Phe Pro Ala Thr Ser Pro Arg Phe Lys Ala Phe Arg Gln Gly Ser  
85 90 95  
15 Pro Ala Phe Ile Gly Met Asp Pro Pro Glu His Gly Thr Arg Arg Arg  
100 105 110  
Met Thr Ile Ser Glu Phe Thr Val Lys Arg Ile Lys Gly Met Arg Pro  
115 120 125  
Asp Val Glu Arg Ile Val His Gly Phe Ile Asp Asp Met Leu Ala Ala  
130 135 140  
20 Gly Pro Thr Ala Asp Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser  
145 150 155 160  
Met Val Ile Cys His Met Leu Gly Val Pro Tyr Ala Asp His Glu Phe  
165 170 175  
Phe Gln Asp Ala Ser Lys Arg Leu Val Gln Ala Val Asp Ala Asp Ser  
180 185 190  
25 Ala Val Ala Ala Arg Asp Asp Phe Glu Arg Tyr Leu Asp Gly Leu Ile  
195 200 205  
Thr Lys Leu Glu Ser Glu Pro Gly Thr Gly Leu Leu Gly Lys Leu Val  
210 215 220  
30 Thr His Gln Leu Ala Asp Gly Glu Ile Asp Arg Ala Glu Leu Ile Ser  
225 230 235 240  
Thr Ala Leu Leu Leu Val Ala Gly His Glu Thr Thr Ala Ser Met  
245 250 255  
Thr Ser Leu Ser Val Ile Thr Leu Leu Glu His Pro Asp Gln His Ala  
260 265 270  
35 Ala Leu Arg Ala Asp Pro Ser Leu Val Pro Gly Ala Val Glu Glu Leu  
275 280 285  
Leu Arg Val Leu Ala Ile Ala Asp Ile Ala Gly Gly Arg Ile Ala Thr  
290 295 300  
Ala Asp Ile Glu Ile Asp Gly Gln Leu Ile Arg Ala Gly Glu Gly Val  
305 310 315 320  
40 Ile Val Thr Asn Ser Ile Ala Asn Arg Asp Ser Ser Val Phe Glu Asn  
325 330 335  
Pro Asp Arg Leu Asp Val His Arg Ser Ala Arg His His Leu Ser Phe  
340 345 350  
Gly Tyr Gly Val His Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu  
355 360 365  
45 Leu Glu Val Ile Leu Thr Val Leu Phe Asp Arg Ile Pro Thr Leu Arg  
370 375 380  
Leu Ala Val Pro Val Glu Gln Leu Thr Leu Arg Pro Gly Thr Thr Ile  
385 390 395 400  
Gln Gly Val Asn Glu Leu Pro Val Thr Trp  
405 410

<210> 5

<211> 406

<212> PRT

<213> Streptomyces griseolus ATCC 11796

<400> 5

Met Thr Asp Thr Ala Thr Thr Pro Gln Thr Thr Asp Ala Pro Ala Phe

EP 1 457 558 A1

1 5 10 15  
Pro Ser Asn Arg Ser Cys Pro Tyr Gln Leu Pro Asp Gly Tyr Ala Gln  
20 25 30  
Leu Arg Asp Thr Pro Gly Pro Leu His Arg Val Thr Leu Tyr Asp Gly  
35 40 45  
Arg Gln Ala Trp Val Val Thr Lys His Glu Ala Ala Arg Lys Leu Leu  
50 55 60  
Gly Asp Pro Arg Leu Ser Ser Asn Arg Thr Asp Asp Asn Phe Pro Ala  
65 70 75 80  
Thr Ser Pro Arg Phe Glu Ala Val Arg Glu Ser Pro Gln Ala Phe Ile  
85 90 95  
Gly Leu Asp Pro Pro Glu His Gly Thr Arg Arg Arg Met Thr Ile Ser  
100 105 110  
Glu Phe Thr Val Lys Arg Ile Lys Gly Met Arg Pro Glu Val Glu Glu  
115 120 125  
Val Val His Gly Phe Leu Asp Glu Met Leu Ala Ala Gly Pro Thr Ala  
130 135 140  
Asp Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys  
145 150 155 160  
Arg Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Gln Asp Ala  
165 170 175  
Ser Lys Arg Leu Val Gln Ser Thr Asp Ala Gln Ser Ala Leu Thr Ala  
180 185 190  
Arg Asn Asp Leu Ala Gly Tyr Leu Asp Gly Leu Ile Thr Gln Phe Gln  
195 200 205  
Thr Glu Pro Gly Ala Gly Leu Val Gly Ala Leu Val Ala Asp Gln Leu  
210 215 220  
Ala Asn Gly Glu Ile Asp Arg Glu Glu Leu Ile Ser Thr Ala Met Leu  
225 230 235 240  
Leu Leu Ile Ala Gly His Glu Thr Thr Ala Ser Met Thr Ser Leu Ser  
245 250 255  
Val Ile Thr Leu Leu Asp His Pro Glu Gln Tyr Ala Ala Leu Arg Ala  
260 265 270  
Asp Arg Ser Leu Val Pro Gly Ala Val Glu Glu Leu Leu Arg Tyr Leu  
275 280 285  
Ala Ile Ala Asp Ile Ala Gly Gly Arg Val Ala Thr Ala Asp Ile Glu  
290 295 300  
Val Glu Gly Gln Leu Ile Arg Ala Gly Glu Gly Val Ile Val Val Asn  
305 310 315 320  
Ser Ile Ala Asn Arg Asp Gly Thr Val Tyr Glu Asp Pro Asp Ala Leu  
325 330 335  
Asp Ile His Arg Ser Ala Arg His His Leu Ala Phe Gly Phe Gly Val  
340 345 350  
His Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu Leu Glu Val Ile  
355 360 365  
Leu Asn Ala Leu Met Asp Arg Val Pro Thr Leu Arg Leu Ala Val Pro  
370 375 380  
Val Glu Gln Leu Val Leu Arg Pro Gly Thr Thr Ile Gln Gly Val Asn  
385 390 395 400  
Glu Leu Pro Val Thr Trp  
405

<210> 6

<211> 1227

<212> DNA

<213> Streptomyces phaeochromogenes IFO 12898

<220>

<221> CDS

<222> (1)..(1227)

<400> 6

atg aca gac atg acg gat acg gca gac gtg aag ccg ctc tcg gca ccc  
Met Thr Asp Met Thr Asp Thr Ala Asp Val Lys Pro Leu Ser Ala Pro

48

EP 1 457 558 A1

	1		5		10		15	
5	gtc gcc ttc ccc cag gac cgc acc tgc ccc ttc cag ccc ccc acg ggc							96
	Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Phe Gln Pro Pro Thr Gly		20		25		30	
10	tac gac ccc ctg cgt gag gcc cgg ccg ctc gcc cgc gtg acc ctc tac							144
	Tyr Asp Pro Leu Arg Glu Ala Arg Pro Leu Ala Arg Val Thr Leu Tyr		35		40		45	
15	gac ggc cgg gcc atc tgg ctg gtc acc ggc cgt gac ctg gcc cgc agc							192
	Asp Gly Arg Ala Ile Trp Leu Val Thr Gly Arg Asp Leu Ala Arg Ser		50		55		60	
20	ctg ctc gcc gat tcc cgc ctg tcg tcc gac cgc ctg cgc ccc ggc ttc							240
	Leu Leu Ala Asp Ser Arg Leu Ser Ser Asp Arg Leu Arg Pro Gly Phe		65		70		75	80
25	ccg gcc acc tcg ccg cgc atc gtg gcg ttc cgc gac cgc cgg gcc gcc							288
	Pro Ala Thr Ser Pro Arg Ile Val Ala Phe Arg Asp Arg Arg Ala Ala		85		90		95	
30	ctg ctg aac gtc gac gac ccc gag cac cac acc cag cgg cgg atg ctg							336
	Leu Leu Asn Val Asp Asp Pro Glu His His Thr Gln Arg Arg Met Leu		100		105		110	
35	gtc ccg agc ttc acc ctc aag cgc gcc gcc gcg ttg cgg ccg gcc atc							384
	Val Pro Ser Phe Thr Leu Lys Arg Ala Ala Ala Leu Arg Pro Ala Ile		115		120		125	
40	cag cgg atc gtc gac gaa tgc atc gac gcg atg ctc gcg aag ggc ccg							432
	Gln Arg Ile Val Asp Glu Cys Ile Asp Ala Met Leu Ala Lys Gly Pro		130		135		140	
45	ccc gcc gag ttg gtg aac gcc ttc gcg ctc ccc gtt ccc tcg atg gtg							480
	Pro Ala Glu Leu Val Asn Ala Phe Ala Leu Pro Val Pro Ser Met Val		145		150		155	160
50	atc tgc gaa ctg ctc ggt gtc ccg tac gcc gat cac gag ttc ttc gag							528
	Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu		165		170		175	
55	gag cag tcc cgt cgg ctg ctg cgc ggc cgg gac gtg gac gag gtg cgg							576
	Glu Gln Ser Arg Arg Leu Leu Arg Gly Arg Asp Val Asp Glu Val Arg		180		185		190	
60	gac gcg cgg gac cag ctc gac tgc tac ctc ggg gcg ctg atc gac cgc							624
	Asp Ala Arg Asp Gln Leu Asp Cys Tyr Leu Gly Ala Leu Ile Asp Arg		195		200		205	
65	aag tcc gag tcg tcc gtc ggt gac ggt gtc ctc gac gcc ctg gtc cac							672
	Lys Ser Glu Ser Ser Val Gly Asp Gly Val Leu Asp Ala Leu Val His		210		215		220	
70	gag cag ttg cgc gag ggc gcg gtg gac cgg cag gag gcc atc tcg ctg							720
	Glu Gln Leu Arg Glu Gly Ala Val Asp Arg Gln Glu Ala Ile Ser Leu		225		230		235	240
75	gcc acg atc ctg ctg gtc gcc ggc cac gag acc acc gcc aac atg atc							768
	Ala Thr Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met Ile		245		250		255	
80	tcg ctg ggc act tac acc ctg ctc caa cac ccc gag cga ctg gcg gag							816
	Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala Glu							

EP 1 457 558 A1

	260	265	270	
5	ttg cgg gac gac ccg tcc ctg tgg ccc gcc gcc gtc gac gag ttg atg Leu Arg Asp Asp Pro Ser Leu Trp Pro Ala Ala Val Asp Glu Leu Met 275 280 285	864		
10	cgg atg ctg tcc atc gcg gac ggg ctg atg cgg cag gcc acg gag gac Arg Met Leu Ser Ile Ala Asp Gly Leu Met Arg Gln Ala Thr Glu Asp 290 295 300	912		
15	atc gag gtg gcc ggg acg acg atc cgc gcc ggt gag ggc gtg gtc ttc Ile Glu Val Ala Gly Thr Thr Ile Arg Ala Gly Glu Gly Val Val Phe 305 310 315 320	960		
20	gcg acc tcc gtc atc aac cgc gac ggg gag gtc tac gcc gaa ccc gac Ala Thr Ser Val Ile Asn Arg Asp Gly Glu Val Tyr Ala Glu Pro Asp 325 330 335	1008		
25	gcc ctc gac tgg cac cgg ccc acc cgc cat cac gtg gcg ttc ggc ttc Ala Leu Asp Trp His Arg Pro Thr Arg His His Val Ala Phe Gly Phe 340 345 350	1056		
30	ggc atc cac cag tgt ctc ggc cag aac ctg gcc cgt gcc gag atg gag Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu 355 360 365	1104		
35	atc gcc ctg cgt tcc ctg ttc gag cgg gtg ccc ggg ctg cgc ctc gac Ile Ala Leu Arg Ser Leu Phe Glu Arg Val Pro Gly Leu Arg Leu Asp 370 375 380	1152		
40	att gcg ccg gac gcg gtc cgc ttc aaa ccg ggc gac acg atc cag gga Ile Ala Pro Asp Ala Val Arg Phe Lys Pro Gly Asp Thr Ile Gln Gly 385 390 395 400	1200		
45	atg ctg gat ctg ccc gtg gcc tgg tag Met Leu Asp Leu Pro Val Ala Trp 405	1227		
50	<210> 7 <211> 1206 <212> DNA <213> Saccharopolyspora taberi JCM 9383t			
55	<220> <221> CDS <222> (1)..(1206)			
60	<400> 7 atg ccg gca tct tct gaa gct ctg acc tat ccg atc ccc cgg acc tgt Met Pro Ala Ser Ser Glu Ala Leu Thr Tyr Pro Ile Pro Arg Thr Cys 1 5 10 15			48
65	ccg tac tcc ccg ccc gac tcc tac gcc gaa ctc cgg cgc gag cag ccg Pro Tyr Ser Pro Pro Asp Ser Tyr Ala Glu Leu Arg Arg Glu Gln Pro 20 25 30			96
70	gtc cgc cgg gtg ccg acg ctg gcg gga ggc agc gtg tgg ctg gtg tcc Val Arg Arg Val Pro Thr Leu Ala Gly Gly Ser Val Trp Leu Val Ser 35 40 45			144
75	cgg cac gag gac gtg cgc gcg gtc ctc agc gac ccg cgg atg agc tcc Arg His Glu Asp Val Arg Ala Val Leu Ser Asp Pro Arg Met Ser Ser 50 55 60			192

EP 1 457 558 A1

		gac	cgc	cgc	aag	ccc	ggg	ttc	ccg	cgg	ctc	gtg	ccg	ggg	cag	agc	gac	240
		Asp	Arg	Arg	Lys	Pro	Gly	Phe	Pro	Arg	Leu	Val	Pro	Gly	Gln	Ser	Asp	
		65					70					75					80	
5		ctg	atc	ttc	agc	tcc	aag	ccg	tcg	atg	atc	ggc	atg	gac	ggg	cgc	gag	288
		Leu	Ile	Phe	Ser	Ser	Lys	Pro	Ser	Met	Ile	Gly	Met	Asp	Gly	Arg	Glu	
					85					90					95			
		cac	tcg	gcg	gcc	cgg	cgg	gcg	gtt	ctc	ggg	gag	ttc	acc	gtc	cgg	cgg	336
		His	Ser	Ala	Ala	Arg	Arg	Ala	Val	Leu	Gly	Glu	Phe	Thr	Val	Arg	Arg	
10					100					105					110			
		atc	aac	gcg	ctg	cgc	ccg	cgc	gtg	cag	gag	atc	gtc	gac	gag	gcc	atc	384
		Ile	Asn	Ala	Leu	Arg	Pro	Arg	Val	Gln	Glu	Ile	Val	Asp	Glu	Ala	Ile	
				115					120					125				
15		gac	gcg	atg	ctg	gcc	gcg	ggc	ggg	ccg	gtc	gac	ctg	gtg	cgg	atg	ctc	432
		Asp	Ala	Met	Leu	Ala	Ala	Gly	Gly	Pro	Val	Asp	Leu	Val	Arg	Met	Leu	
			130					135					140					
		tcg	ctt	ccg	gtg	ccg	tcg	ctg	gtg	atc	tgc	gag	ctg	ctc	ggc	gtt	ccc	480
20		Ser	Leu	Pro	Val	Pro	Ser	Leu	Val	Ile	Cys	Glu	Leu	Leu	Gly	Val	Pro	
		145					150					155					160	
		tac	gcc	gac	cac	gag	ttc	ttc	cag	cag	cgc	agc	ggc	cgc	atc	atc	agc	528
		Tyr	Ala	Asp	His	Glu	Phe	Phe	Gln	Gln	Arg	Ser	Gly	Arg	Ile	Ile	Ser	
					165						170					175		
25		cgg	gcg	acg	ccg	ggg	gcc	gag	cgg	gag	gag	gcg	ttc	ttc	gaa	ctc	cgc	576
		Arg	Ala	Thr	Pro	Gly	Ala	Glu	Arg	Glu	Glu	Ala	Phe	Phe	Glu	Leu	Arg	
					180					185					190			
		gcc	tac	ctg	tcg	gat	ctg	gtc	gcg	gac	aag	gtc	cgc	gca	ccg	ggc	gac	624
30		Ala	Tyr	Leu	Ser	Asp	Leu	Val	Ala	Asp	Lys	Val	Arg	Ala	Pro	Gly	Asp	
				195					200					205				
		gac	ctg	ctc	ggc	agg	cag	gtg	gcc	aag	cag	cgg	gcc	gag	ggc	gag	gtc	672
		Asp	Leu	Leu	Gly	Arg	Gln	Val	Ala	Lys	Gln	Arg	Ala	Glu	Gly	Glu	Val	
			210				215						220					
35		gac	cag	gag	gcg	ctg	gtc	agc	ctc	gcg	ttc	ctg	ctg	ctg	gtc	gcc	ggg	720
		Asp	Gln	Glu	Ala	Leu	Val	Ser	Leu	Ala	Phe	Leu	Leu	Leu	Val	Ala	Gly	
			225				230					235					240	
		cac	gag	acc	acc	gcg	aac	atg	atc	tcg	ctt	ggg	agc	ctg	gcg	ctg	ctg	768
40		His	Glu	Thr	Thr	Ala	Asn	Met	Ile	Ser	Leu	Gly	Ser	Leu	Ala	Leu	Leu	
					245						250					255		
		gac	gat	tcc	gcc	cgg	tgg	gcg	gag	atc	gcc	gcg	gat	ccg	gcg	aag	acg	816
		Asp	Asp	Ser	Ala	Arg	Trp	Ala	Glu	Ile	Ala	Ala	Asp	Pro	Ala	Lys	Thr	
45					260					265					270			
		ccc	ggc	gcg	gtg	gag	gag	atg	ctg	cgg	ttc	ttc	tcg	atc	gtc	gac	aac	864
		Pro	Gly	Ala	Val	Glu	Glu	Met	Leu	Arg	Phe	Phe	Ser	Ile	Val	Asp	Asn	
				275					280					285				
		gcg	acc	gcg	cgc	acc	gcg	acc	gag	gac	gtg	gag	atc	ggc	ggc	gtg	gtc	912
50		Ala	Thr	Ala	Arg	Thr	Ala	Thr	Glu	Asp	Val	Glu	Ile	Gly	Gly	Val	Val	
			290					295					300					
		atc	ggg	gag	ggc	gac	ggg	gtg	atc	gcg	atg	ggc	tat	tcg	gcc	aac	cac	960
55		Ile	Gly	Glu	Gly	Asp	Gly	Val	Ile	Ala	Met	Gly	Tyr	Ser	Ala	Asn	His	
		305					310					315					320	

EP 1 457 558 A1

	gac ccc gag gtc ttc gac cgc ccc ggg gac ctc gac ttc tcc cgg gcc	1008
	Asp Pro Glu Val Phe Asp Arg Pro Gly Asp Leu Asp Phe Ser Arg Ala	
	325 330 335	
5	gcc cgc cag cac gtc gcc ttc ggc ttc ggc gcg cac cag tgc ctg ggc	1056
	Ala Arg Gln His Val Ala Phe Gly Phe Gly Ala His Gln Cys Leu Gly	
	340 345 350	
	cag aac ctc gcg cgg gtg gag ttg cag atc gtc ttc gac acg ctg gtg	1104
	Gln Asn Leu Ala Arg Val Glu Leu Gln Ile Val Phe Asp Thr Leu Val	
10	355 360 365	
	cgg cgg atc ccg gac ctg cgg ctg gcg gtc ggc ttc gac gac atc cgg	1152
	Arg Arg Ile Pro Asp Leu Arg Leu Ala Val Gly Phe Asp Asp Ile Arg	
	370 375 380	
15	ttc aag gag gag tcg gcg atc tac gga atc cac gaa ctg atg gtc act	1200
	Phe Lys Glu Glu Ser Ala Ile Tyr Gly Ile His Glu Leu Met Val Thr	
	385 390 395 400	
	tgg tga	1206
20	Trp	
	<210> 8	
	<211> 1188	
	<212> DNA	
	<213> Streptomyces testaceus ATCC 21469	
25	<220>	
	<221> CDS	
	<222> (1)..(1188)	
	<400> 8	
30	atg acc gaa gcc atc gcg tat ttc cag gac cgc acc tgc ccc tac cac	48
	Met Thr Glu Ala Ile Ala Tyr Phe Gln Asp Arg Thr Cys Pro Tyr His	
	1 5 10 15	
	ccg ccg gcc ggc tat cag ccg ctg cgt gac gca ggc ccg ctg gcc cat	96
35	Pro Pro Ala Gly Tyr Gln Pro Leu Arg Asp Ala Gly Pro Leu Ala His	
	20 25 30	
	gtc acc ctc tac gac ggc cgc aag gtg tgg gcg gtg acc ggc cac acc	144
	Val Thr Leu Tyr Asp Gly Arg Lys Val Trp Ala Val Thr Gly His Thr	
	35 40 45	
40	gag gcg cgg gcg ctg ctg agc gac ccg cgg ctg tcc tcc gac cgg cag	192
	Glu Ala Arg Ala Leu Leu Ser Asp Pro Arg Leu Ser Ser Asp Arg Gln	
	50 55 60	
	aac ccg gcc ttc ccg gcg ccg ttc gcc cgc ttc gcg gcg ctg cgc cag	240
45	Asn Pro Ala Phe Pro Ala Pro Phe Ala Arg Phe Ala Ala Leu Arg Gln	
	65 70 75 80	
	gtc agg tcg ccg ctg atc ggc gtg gac gac ccc gag cac aac acc cag	288
	Val Arg Ser Pro Leu Ile Gly Val Asp Asp Pro Glu His Asn Thr Gln	
50	85 90 95	
	cgc cgg atg ctg atc ccc agc ttc agc gtc aag cgg acc gcg gcg ctg	336
	Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys Arg Thr Ala Ala Leu	
	100 105 110	
55	cgg ccg cag atc cag cag atc gtc gac ggg ctg ctg gac cgg atg ctg	384
	Arg Pro Gln Ile Gln Gln Ile Val Asp Gly Leu Leu Asp Arg Met Leu	
	115 120 125	

EP 1 457 558 A1

	gcg cag ggg ccg ccc gcc gag ctg gtc tcc gcg ttc gcg ctg ccg gtg	432
	Ala Gln Gly Pro Pro Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val	
	130 135 140	
5	ccc tcg atg gtg atc tgc tgc ctg ctc ggc gtc ccc tac tcc gac cac	480
	Pro Ser Met Val Ile Cys Ser Leu Leu Gly Val Pro Tyr Ser Asp His	
	145 150 155 160	
10	gag ttc ttc gag gag gcc tcc cgc cgg ctc ctg cgc agc cgg acg gcc	528
	Glu Phe Phe Glu Glu Ala Ser Arg Arg Leu Leu Arg Ser Arg Thr Ala	
	165 170 175	
15	gag gag gcg gag gag gcc cgc ctc cgg ctg gag gac tac ttc gac gag	576
	Glu Glu Ala Glu Glu Ala Arg Leu Arg Leu Glu Asp Tyr Phe Asp Glu	
	180 185 190	
20	ctg atc gcc cac aag gag aag acc ccg cgc gag ggc ctg ctc gac gag	624
	Leu Ile Ala His Lys Glu Lys Thr Pro Arg Glu Gly Leu Leu Asp Glu	
	195 200 205	
25	ctg gtc cac gac gag ctg cgc acc ggc gcc ctg gag cgc gag gat ctg	672
	Leu Val His Asp Glu Leu Arg Thr Gly Ala Leu Glu Arg Glu Asp Leu	
	210 215 220	
30	gtc cgg ctc gcg atg atc ctg ctg gtg gcc ggc cac gag acc acc gcc	720
	Val Arg Leu Ala Met Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala	
	225 230 235 240	
35	aac atg atc tcg ctc ggc acc ttc acc ctg ctg gag cac ccc gga cag	768
	Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Glu His Pro Gly Gln	
	245 250 255	
40	ctg gcc cgg ctg aag gcc gag gag ggg ctg ctg ccg gcc gcc gtc gag	816
	Leu Ala Arg Leu Lys Ala Glu Glu Gly Leu Leu Pro Ala Ala Val Glu	
	260 265 270	
45	gag ctg ttg cgg ttc ctg tcc atc gcg gac ggc ctg ctg cgg gtg gcc	864
	Glu Leu Leu Arg Phe Leu Ser Ile Ala Asp Gly Leu Leu Arg Val Ala	
	275 280 285	
50	atg gcg gac atc gag atc ggc ggg cag gtc atc cgt gcc gac gac ggc	912
	Met Ala Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Asp Asp Gly	
	290 295 300	
55	gtg ctg ttc ccc acc tcg ctg atc aac cgg gac gac ggc gcc tat ccg	960
	Val Leu Phe Pro Thr Ser Leu Ile Asn Arg Asp Asp Gly Ala Tyr Pro	
	305 310 315 320	
60	aca ccg gac gag ctg gac gtc ggc cgg tcc gcc cgc cat cac gtg gcg	1008
	Thr Pro Asp Glu Leu Asp Val Gly Arg Ser Ala Arg His His Val Ala	
	325 330 335	
65	ttc ggg ttc ggc atc cac cag tgc ctg ggg cag aac ctc gcc cgg gcg	1056
	Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala	
	340 345 350	
70	gag atg gag atc gcg ctg cgc tgc ctg ttc gac cgg atc ccg gat ctg	1104
	Glu Met Glu Ile Ala Leu Arg Ser Leu Phe Asp Arg Ile Pro Asp Leu	
	355 360 365	
75	cga ctc gcc gtg ccg gct gcc gag atc ccc ttc aag ccg ggg gac act	1152
	Arg Leu Ala Val Pro Ala Ala Glu Ile Pro Phe Lys Pro Gly Asp Thr	
	370 375 380	

EP 1 457 558 A1

ctg caa gga atg atc gaa ctg ccg ctg gcc tgg tag 1188  
 Leu Gln Gly Met Ile Glu Leu Pro Leu Ala Trp  
 385 390 395

<210> 9  
 <211> 1439  
 <212> DNA  
 <213> Streptomyces phaeochromogenes IFO 12898

<220>  
 <221> CDS  
 <222> (1)..(1227)

<220>  
 <221> CDS  
 <222> (1239)..(1439)

<400> 9  
 atg aca gac atg acg gat acg gca gac gtg aag ccg ctc tcg gca ccc 48  
 Met Thr Asp Met Thr Asp Thr Ala Asp Val Lys Pro Leu Ser Ala Pro  
 1 5 10 15

gtc gcc ttc ccc cag gac cgc acc tgc ccc ttc cag ccc ccc acg ggc 96  
 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Phe Gln Pro Pro Thr Gly  
 20 25 30

tac gac ccc ctg cgt gag gcc cgc ctc gcc cgc gtg acc ctc tac 144  
 Tyr Asp Pro Leu Arg Glu Ala Arg Pro Leu Ala Arg Val Thr Leu Tyr  
 35 40 45

gac ggc cgg gcc atc tgg ctg gtc acc ggc cgt gac ctg gcc cgc agc 192  
 Asp Gly Arg Ala Ile Trp Leu Val Thr Gly Arg Asp Leu Ala Arg Ser  
 50 55 60

ctg ctc gcc gat tcc cgc ctg tcg tcc gac cgc ctg cgc ccc ggc ttc 240  
 Leu Leu Ala Asp Ser Arg Leu Ser Ser Asp Arg Leu Arg Pro Gly Phe  
 65 70 75 80

ccg gcc acc tcg ccg cgc atc gtg gcg ttc cgc gac cgc cgg gcc gcc 288  
 Pro Ala Thr Ser Pro Arg Ile Val Ala Phe Arg Asp Arg Arg Ala Ala  
 85 90 95

ctg ctg aac gtc gac gac ccc gag cac cac acc cag cgg cgg atg ctg 336  
 Leu Leu Asn Val Asp Asp Pro Glu His His Thr Gln Arg Arg Met Leu  
 100 105 110

gtc ccg agc ttc acc ctc aag cgc gcc gcc gcg ttg cgg ccg gcc atc 384  
 Val Pro Ser Phe Thr Leu Lys Arg Ala Ala Leu Arg Pro Ala Ile  
 115 120 125

cag cgg atc gtc gac gaa tgc atc gac gcg atg ctc gcg aag ggc ccg 432  
 Gln Arg Ile Val Asp Glu Cys Ile Asp Ala Met Leu Ala Lys Gly Pro  
 130 135 140

ccc gcc gag ttg gtg aac gcc ttc gcg ctc ccc gtt ccc tcg atg gtg 480  
 Pro Ala Glu Leu Val Asn Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155 160

atc tgc gaa ctg ctc ggt gtc ccg tac gcc gat cac gag ttc ttc gag 528  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 165 170 175

gag cag tcc cgt cgg ctg ctg cgc ggc cgg gac gtg gac gag gtg cgg 576

EP 1 457 558 A1

	Glu	Gln	Ser	Arg	Arg	Leu	Leu	Arg	Gly	Arg	Asp	Val	Asp	Glu	Val	Arg	
				180					185					190			
5	gac	gcg	cgg	gac	cag	ctc	gac	tgc	tac	ctc	ggg	gcg	ctg	atc	gac	cgc	624
	Asp	Ala	Arg	Asp	Gln	Leu	Asp	Cys	Tyr	Leu	Gly	Ala	Leu	Ile	Asp	Arg	
			195					200					205				
	aag	tcc	gag	tcg	tcc	gtc	ggg	gac	ggg	gtc	ctc	gac	gcc	ctg	gtc	cac	672
	Lys	Ser	Glu	Ser	Ser	Val	Gly	Asp	Gly	Val	Leu	Asp	Ala	Leu	Val	His	
		210					215					220					
10	gag	cag	ttg	cgc	gag	ggc	gcg	gtg	gac	cgg	cag	gag	gcc	atc	tcg	ctg	720
	Glu	Gln	Leu	Arg	Glu	Gly	Ala	Val	Asp	Arg	Gln	Glu	Ala	Ile	Ser	Leu	
	225					230					235					240	
	gcc	acg	atc	ctg	ctg	gtc	gcc	ggc	cac	gag	acc	acc	gcc	aac	atg	atc	768
15	Ala	Thr	Ile	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	Ile	
					245					250					255		
	tcg	ctg	ggc	act	tac	acc	ctg	ctc	caa	cac	ccc	gag	cga	ctg	gcg	gag	816
20	Ser	Leu	Gly	Thr	Tyr	Thr	Leu	Leu	Gln	His	Pro	Glu	Arg	Leu	Ala	Glu	
				260					265					270			
	ttg	cgg	gac	gac	ccg	tcg	ctg	tgg	ccc	gcc	gcc	gtc	gac	gag	ttg	atg	864
	Leu	Arg	Asp	Asp	Pro	Ser	Leu	Trp	Pro	Ala	Ala	Val	Asp	Glu	Leu	Met	
			275					280					285				
25	cgg	atg	ctg	tcc	atc	gcg	gac	ggg	ctg	atg	cgg	cag	gcc	acg	gag	gac	912
	Arg	Met	Leu	Ser	Ile	Ala	Asp	Gly	Leu	Met	Arg	Gln	Ala	Thr	Glu	Asp	
		290					295					300					
	atc	gag	gtg	gcc	ggg	acg	acg	atc	cgc	gcc	ggg	gag	ggc	gtg	gtc	ttc	960
30	Ile	Glu	Val	Ala	Gly	Thr	Thr	Ile	Arg	Ala	Gly	Glu	Gly	Val	Val	Phe	
	305					310					315					320	
	gcg	acc	tcg	gtc	atc	aac	cgc	gac	ggg	gag	gtc	tac	gcc	gaa	ccc	gac	1008
	Ala	Thr	Ser	Val	Ile	Asn	Arg	Asp	Gly	Glu	Val	Tyr	Ala	Glu	Pro	Asp	
					325					330					335		
35	gcc	ctc	gac	tgg	cac	cgg	ccc	acc	cgc	cat	cac	gtg	gcg	ttc	ggc	ttc	1056
	Ala	Leu	Asp	Trp	His	Arg	Pro	Thr	Arg	His	His	Val	Ala	Phe	Gly	Phe	
				340					345					350			
	ggc	atc	cac	cag	tgt	ctc	ggc	cag	aac	ctg	gcc	cgt	gcc	gag	atg	gag	1104
40	Gly	Ile	His	Gln	Cys	Leu	Gly	Gln	Asn	Leu	Ala	Arg	Ala	Glu	Met	Glu	
			355					360					365				
	atc	gcc	ctg	cgt	tcc	ctg	ttc	gag	cgg	gtg	ccc	ggg	ctg	cgc	ctc	gac	1152
	Ile	Ala	Leu	Arg	Ser	Leu	Phe	Glu	Arg	Val	Pro	Gly	Leu	Arg	Leu	Asp	
		370					375					380					
45	att	gcg	ccg	gac	gcg	gtc	cgc	ttc	aaa	ccg	ggc	gac	acg	atc	cag	gga	1200
	Ile	Ala	Pro	Asp	Ala	Val	Arg	Phe	Lys	Pro	Gly	Asp	Thr	Ile	Gln	Gly	
		385				390					395					400	
	atg	ctg	gat	ctg	ccc	gtg	gcc	tgg	tag	gggggtccact	c	atg	cac	atc	gac	1250	
50	Met	Leu	Asp	Leu	Pro	Val	Ala	Trp				Met	His	Ile	Asp		
					405							1					
	atc	gac	acg	gac	gtg	tgc	atc	ggc	gcc	ggc	cag	tgc	gcg	ctg	tcc	gcc	1298
	Ile	Asp	Thr	Asp	Val	Cys	Ile	Gly	Ala	Gly	Gln	Cys	Ala	Leu	Ser	Ala	
	5					10					15					20	
55	ccg	gcc	gtc	ttc	acg	cag	gac	gac	gac	ggc	ttc	agc	acc	ctc	ctg	ccc	1346

EP 1 457 558 A1

	Pro	Ala	Val	Phe	Thr	Gln	Asp	Asp	Asp	Gly	Phe	Ser	Thr	Leu	Leu	Pro	
					25					30					35		
5	gga	cag	gag	gac	agc	ggc	gac	ccg	atg	gtc	cgg	gag	gcg	gcc	cga	gcc	1394
	Gly	Gln	Glu	Asp	Ser	Gly	Asp	Pro	Met	Val	Arg	Glu	Ala	Ala	Arg	Ala	
				40				45						50			
	tgc	ccg	gtc	ggc	gcc	atc	aag	gtc	tcg	gaa	acc	gcg	cga	ccg	tga		1439
	Cys	Pro	Val	Gly	Ala	Ile	Lys	Val	Ser	Glu	Thr	Ala	Arg	Pro			
			55					60					65				
10																	
	<210> 10																
	<211> 1415																
	<212> DNA																
	<213> Saccharopolyspora taberi JCM 9383t																
15																	
	<220>																
	<221> CDS																
	<222> (1)..(1206)																
20																	
	<220>																
	<221> CDS																
	<222> (1218)..(1415)																
25																	
	<400> 10																
	atg	ccg	gca	tct	tct	gaa	gct	ctg	acc	tat	ccg	atc	ccc	cgg	acc	tgt	48
	Met	Pro	Ala	Ser	Ser	Glu	Ala	Leu	Thr	Tyr	Pro	Ile	Pro	Arg	Thr	Cys	
	1				5					10					15		
	ccg	tac	tcg	ccg	ccc	gac	tcc	tac	gcc	gaa	ctc	cgg	cgc	gag	cag	ccg	96
	Pro	Tyr	Ser	Pro	Pro	Asp	Ser	Tyr	Ala	Glu	Leu	Arg	Arg	Glu	Gln	Pro	
				20					25					30			
30	gtc	cgc	cgg	gtg	ccg	acg	ctg	gcg	gga	ggc	agc	gtg	tgg	ctg	gtg	tcg	144
	Val	Arg	Arg	Val	Pro	Thr	Leu	Ala	Gly	Gly	Ser	Val	Trp	Leu	Val	Ser	
			35				40						45				
	cgg	cac	gag	gac	gtg	cgc	gcg	gtc	ctc	agc	gac	ccg	cgg	atg	agc	tcc	192
	Arg	His	Glu	Asp	Val	Arg	Ala	Val	Leu	Ser	Asp	Pro	Arg	Met	Ser	Ser	
		50					55					60					
	gac	cgc	cgc	aag	ccc	ggg	ttc	ccg	cgg	ctc	gtg	ccg	ggg	cag	agc	gac	240
	Asp	Arg	Arg	Lys	Pro	Gly	Phe	Pro	Arg	Leu	Val	Pro	Gly	Gln	Ser	Asp	
		65				70					75					80	
40	ctg	atc	ttc	agc	tcc	aag	ccg	tcg	atg	atc	ggc	atg	gac	ggg	cgc	gag	288
	Leu	Ile	Phe	Ser	Ser	Lys	Pro	Ser	Met	Ile	Gly	Met	Asp	Gly	Arg	Glu	
					85					90					95		
	cac	tcg	gcg	gcc	cgg	cgg	gcg	gtt	ctc	ggc	gag	ttc	acc	gtc	cgg	cgg	336
	His	Ser	Ala	Ala	Arg	Arg	Ala	Val	Leu	Gly	Glu	Phe	Thr	Val	Arg	Arg	
				100					105					110			
	atc	aac	gcg	ctg	cgc	ccg	cgc	gtg	cag	gag	atc	gtc	gac	gag	gcc	atc	384
	Ile	Asn	Ala	Leu	Arg	Pro	Arg	Val	Gln	Glu	Ile	Val	Asp	Glu	Ala	Ile	
			115					120					125				
50	gac	gcg	atg	ctg	gcc	gcg	ggc	ggg	ccg	gtc	gac	ctg	gtg	cgg	atg	ctc	432
	Asp	Ala	Met	Leu	Ala	Ala	Gly	Gly	Pro	Val	Asp	Leu	Val	Arg	Met	Leu	
			130				135					140					
	tcg	ctt	ccg	gtg	ccg	tcg	ctg	gtg	atc	tgc	gag	ctg	ctc	ggc	gtt	ccc	480
	Ser	Leu	Pro	Val	Pro	Ser	Leu	Val	Ile	Cys	Glu	Leu	Leu	Gly	Val	Pro	
						150					155					160	

EP 1 457 558 A1

	tac gcc gac cac gag ttc ttc cag cag cgc agc ggc cgc atc atc agc	528
	Tyr Ala Asp His Glu Phe Phe Gln Gln Arg Ser Gly Arg Ile Ile Ser	
	165 170 175	
5	cgg gcg acg ccg ggg gcc gag cgg gag gag gcg ttc ttc gaa ctc cgc	576
	Arg Ala Thr Pro Gly Ala Glu Arg Glu Glu Ala Phe Phe Glu Leu Arg	
	180 185 190	
10	gcc tac ctg tcg gat ctg gtc gcg gac aag gtc cgc gca ccg ggc gac	624
	Ala Tyr Leu Ser Asp Leu Val Ala Asp Lys Val Arg Ala Pro Gly Asp	
	195 200 205	
15	gac ctg ctc ggc agg cag gtg gcc aag cag cgg gcc gag ggc gag gtc	672
	Asp Leu Leu Gly Arg Gln Val Ala Lys Gln Arg Ala Glu Gly Glu Val	
	210 215 220	
20	gac cag gag gcg ctg gtc agc ctc gcg ttc ctg ctg ctg gtc gcc ggg	720
	Asp Gln Glu Ala Leu Val Ser Leu Ala Phe Leu Leu Leu Val Ala Gly	
	225 230 235 240	
25	cac gag acc acc gcg aac atg atc tcg ctt ggt agc ctg gcg ctg ctg	768
	His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Ser Leu Ala Leu Leu	
	245 250 255	
30	gac gat tcc gcc cgg tgg gcg gag atc gcc gcg gat ccg gcg aag acg	816
	Asp Asp Ser Ala Arg Trp Ala Glu Ile Ala Ala Asp Pro Ala Lys Thr	
	260 265 270	
35	ccc ggc gcg gtg gag gag atg ctg cgg ttc ttc tcg atc gtc gac aac	864
	Pro Gly Ala Val Glu Glu Met Leu Arg Phe Phe Ser Ile Val Asp Asn	
	275 280 285	
40	gcg acc gcg cgc acc gcg acc gag gac gtg gag atc ggc ggc gtg gtc	912
	Ala Thr Ala Arg Thr Ala Thr Glu Asp Val Glu Ile Gly Gly Val Val	
	290 295 300	
45	atc ggg gag ggc gac ggg gtg atc gcg atg ggc tat tcg gcc aac cac	960
	Ile Gly Glu Gly Asp Gly Val Ile Ala Met Gly Tyr Ser Ala Asn His	
	305 310 315 320	
50	gac ccc gag gtc ttc gac cgc ccc ggg gac ctc gac ttc tcc cgg gcc	1008
	Asp Pro Glu Val Phe Asp Arg Pro Gly Asp Leu Asp Phe Ser Arg Ala	
	325 330 335	
55	gcc cgc cag cac gtc gcc ttc ggc ttc ggc gcg cac cag tgc ctg ggc	1056
	Ala Arg Gln His Val Ala Phe Gly Phe Gly Ala His Gln Cys Leu Gly	
	340 345 350	
60	cag aac ctc gcg cgg gtg gag ttg cag atc gtc ttc gac acg ctg gtg	1104
	Gln Asn Leu Ala Arg Val Glu Leu Gln Ile Val Phe Asp Thr Leu Val	
	355 360 365	
65	cgg cgg atc ccg gac ctg cgg ctg gcg gtc ggc ttc gac gac atc cgg	1152
	Arg Arg Ile Pro Asp Leu Arg Leu Ala Val Gly Phe Asp Asp Ile Arg	
	370 375 380	
70	ttc aag gag gag tcg gcg atc tac gga atc cac gaa ctg atg gtc act	1200
	Phe Lys Glu Glu Ser Ala Ile Tyr Gly Ile His Glu Leu Met Val Thr	
	385 390 395 400	
75	tgg tga ggagagtcgg g atg agg atc cag gcg gac gtg gag cgc tgc gtc	1250
	Trp Met Arg Ile Gln Ala Asp Val Glu Arg Cys Val	
	1 5 10	

EP 1 457 558 A1

	gga gcg ggt cag tgc gtg ctc gcc gcg gac gcg ctg ttc gac cag cgc	1298
	Gly Ala Gly Gln Cys Val Leu Ala Ala Asp Ala Leu Phe Asp Gln Arg	
	15 20 25	
5	gac gac gac ggc acc gtg gtg gtg ctc gcg acc gag gtc ggc gac ggg	1346
	Asp Asp Asp Gly Thr Val Val Val Leu Ala Thr Glu Val Gly Asp Gly	
	30 35 40	
10	gac gcc gac gcg gtc cgg gac gcg gtg acg ctc tgc ccg tcg ggc gtg	1394
	Asp Ala Asp Ala Val Arg Asp Ala Val Thr Leu Cys Pro Ser Gly Val	
	45 50 55	
	ttg tcg ctc gtg gag gac tga	1415
	Leu Ser Leu Val Glu Asp	
	60 65	
15	<210> 11	
	<211> 1418	
	<212> DNA	
	<213> Streptomyces testaceus ATCC 21469	
20	<220>	
	<221> CDS	
	<222> (1)..(1188)	
	<220>	
25	<221> CDS	
	<222> (1224)..(1418)	
	<400> 11	
	atg acc gaa gcc atc gcg tat ttc cag gac cgc acc tgc ccc tac cac	48
	Met Thr Glu Ala Ile Ala Tyr Phe Gln Asp Arg Thr Cys Pro Tyr His	
30	1 5 10 15	
	ccg ccg gcc ggc tat cag ccg ctg cgt gac gca ggc ccg ctg gcc cat	96
	Pro Pro Ala Gly Tyr Gln Pro Leu Arg Asp Ala Gly Pro Leu Ala His	
	20 25 30	
35	gtc acc ctc tac gac ggc cgc aag gtg tgg gcg gtg acc ggc cac acc	144
	Val Thr Leu Tyr Asp Gly Arg Lys Val Trp Ala Val Thr Gly His Thr	
	35 40 45	
40	gag gcg cgg gcg ctg ctg agc gac ccg cgg ctg tcc tcc gac cgg cag	192
	Glu Ala Arg Ala Leu Leu Ser Asp Pro Arg Leu Ser Ser Asp Arg Gln	
	50 55 60	
	aac ccg gcc ttc ccg gcg ccg ttc gcc cgc ttc gcg gcg ctg cgc cag	240
	Asn Pro Ala Phe Pro Ala Pro Phe Ala Arg Phe Ala Ala Leu Arg Gln	
	65 70 75 80	
45	gtc agg tcg ccg ctg atc ggc gtg gac gac ccc gag cac aac acc cag	288
	Val Arg Ser Pro Leu Ile Gly Val Asp Asp Pro Glu His Asn Thr Gln	
	85 90 95	
50	cgc cgg atg ctg atc ccc agc ttc agc gtc aag cgg acc gcg gcg ctg	336
	Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys Arg Thr Ala Ala Leu	
	100 105 110	
	cgg ccg cag atc cag cag atc gtc gac ggg ctg ctg gac cgg atg ctg	384
	Arg Pro Gln Ile Gln Gln Ile Val Asp Gly Leu Leu Asp Arg Met Leu	
	115 120 125	
55	gcg cag ggg ccg ccc gcc gag ctg gtc tcc gcg ttc gcg ctg ccg gtg	432

EP 1 457 558 A1

	Ala	Gln	Gly	Pro	Pro	Ala	Glu	Leu	Val	Ser	Ala	Phe	Ala	Leu	Pro	Val	
	130						135					140					
5	ccc	tcg	atg	gtg	atc	tgc	tcg	ctg	ctc	ggc	gtc	ccc	tac	tcc	gac	cac	480
	Pro	Ser	Met	Val	Ile	Cys	Ser	Leu	Leu	Gly	Val	Pro	Tyr	Ser	Asp	His	
	145					150					155					160	
	gag	ttc	ttc	gag	gag	gcc	tcc	cgc	cgg	ctc	ctg	cgc	agc	cgg	acg	gcc	528
	Glu	Phe	Phe	Glu	Glu	Ala	Ser	Arg	Arg	Leu	Leu	Arg	Ser	Arg	Thr	Ala	
10					165					170					175		
	gag	gag	gcg	gag	gag	gcc	cgc	ctc	cgg	ctg	gag	gac	tac	ttc	gac	gag	576
	Glu	Glu	Ala	Glu	Glu	Ala	Arg	Leu	Arg	Leu	Glu	Asp	Tyr	Phe	Asp	Glu	
					180				185					190			
15	ctg	atc	gcc	cac	aag	gag	aag	acc	ccg	cgc	gag	ggc	ctg	ctc	gac	gag	624
	Leu	Ile	Ala	His	Lys	Glu	Lys	Thr	Pro	Arg	Glu	Gly	Leu	Leu	Asp	Glu	
			195					200					205				
	ctg	gtc	cac	gac	gag	ctg	cgc	acc	ggc	gcc	ctg	gag	cgc	gag	gat	ctg	672
	Leu	Val	His	Asp	Glu	Leu	Arg	Thr	Gly	Ala	Leu	Glu	Arg	Glu	Asp	Leu	
20		210						215				220					
	gtc	cgg	ctc	gcg	atg	atc	ctg	ctg	gtg	gcc	ggc	cac	gag	acc	acc	gcc	720
	Val	Arg	Leu	Ala	Met	Ile	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	Thr	Ala	
	225					230					235					240	
25	aac	atg	atc	tcg	ctc	ggc	acc	ttc	acc	ctg	ctg	gag	cac	ccc	gga	cag	768
	Asn	Met	Ile	Ser	Leu	Gly	Thr	Phe	Thr	Leu	Leu	Glu	His	Pro	Gly	Gln	
					245					250					255		
	ctg	gcc	cgg	ctg	aag	gcc	gag	gag	ggg	ctg	ctg	ccg	gcc	gcc	gtc	gag	816
	Leu	Ala	Arg	Leu	Lys	Ala	Glu	Glu	Gly	Leu	Leu	Pro	Ala	Ala	Val	Glu	
30					260				265					270			
	gag	ctg	ttg	cgg	ttc	ctg	tcc	atc	gcg	gac	ggc	ctg	ctg	cgg	gtg	gcc	864
	Glu	Leu	Leu	Arg	Phe	Leu	Ser	Ile	Ala	Asp	Gly	Leu	Leu	Arg	Val	Ala	
					275			280					285				
35	atg	gcg	gac	atc	gag	atc	ggc	ggg	cag	gtc	atc	cgt	gcc	gac	gac	ggc	912
	Met	Ala	Asp	Ile	Glu	Ile	Gly	Gly	Gln	Val	Ile	Arg	Ala	Asp	Asp	Gly	
		290					295					300					
	gtg	ctg	ttc	ccc	acc	tcg	ctg	atc	aac	cgg	gac	gac	ggc	gcc	tat	ccg	960
	Val	Leu	Phe	Pro	Thr	Ser	Leu	Ile	Asn	Arg	Asp	Asp	Gly	Ala	Tyr	Pro	
40	305					310					315					320	
	aca	ccg	gac	gag	ctg	gac	gtc	ggc	cgg	tcc	gcc	cgc	cat	cac	gtg	gcg	1008
	Thr	Pro	Asp	Glu	Leu	Asp	Val	Gly	Arg	Ser	Ala	Arg	His	His	Val	Ala	
					325					330					335		
45	ttc	ggg	ttc	ggc	atc	cac	cag	tgc	ctg	ggg	cag	aac	ctc	gcc	cgg	gcg	1056
	Phe	Gly	Phe	Gly	Ile	His	Gln	Cys	Leu	Gly	Gln	Asn	Leu	Ala	Arg	Ala	
				340					345					350			
	gag	atg	gag	atc	gcg	ctg	cgc	tcg	ctg	ttc	gac	cgg	atc	ccg	gat	ctg	1104
	Glu	Met	Glu	Ile	Ala	Leu	Arg	Ser	Leu	Phe	Asp	Arg	Ile	Pro	Asp	Leu	
50					355			360					365				
	cga	ctc	gcc	gtg	ccg	gct	gcc	gag	atc	ccc	ttc	aag	ccg	ggg	gac	act	1152
	Arg	Leu	Ala	Val	Pro	Ala	Ala	Glu	Ile	Pro	Phe	Lys	Pro	Gly	Asp	Thr	
		370					375					380					
55	ctg	caa	gga	atg	atc	gaa	ctg	ccg	ctg	gcc	tgg	tag	ccg	cgg	tgca	cccggc	1204

EP 1 457 558 A1

Leu Gln Gly Met Ile Glu Leu Pro Leu Ala Trp  
385 390 395

cgaacgaagg ggttttgga atg cgg atc acc atc gac acc gac gtc tgc atc 1256  
Met Arg Ile Thr Ile Asp Thr Asp Val Cys Ile  
1 5 10

ggc gcc ggc cag tgc gcg ctg acc gcg ccc ggg gtg ttc acc cag gac 1304  
Gly Ala Gly Gln Cys Ala Leu Thr Ala Pro Gly Val Phe Thr Gln Asp  
15 20 25

gac gac ggc ttc agc gag ctg ctg ccc ggc cgc gag gac ggc gcg ggc 1352  
Asp Asp Gly Phe Ser Glu Leu Leu Pro Gly Arg Glu Asp Gly Ala Gly  
30 35 40

gac ccg atg ctg cgg gag gcc gtg cgt gcc tgc ccc gtg cag gcc atc 1400  
Asp Pro Met Leu Arg Glu Ala Val Arg Ala Cys Pro Val Gln Ala Ile  
45 50 55

acc gtc gcg gac gac tga 1418  
Thr Val Ala Asp Asp  
60 64

<210> 12  
<211> 66  
<212> PRT  
<213> Streptomyces phaeochromogenes IFO 12898

<400> 12  
Met His Ile Asp Ile Asp Thr Asp Val Cys Ile Gly Ala Gly Gln Cys  
1 5 10 15  
Ala Leu Ser Ala Pro Ala Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
20 25 30  
Thr Leu Leu Pro Gly Gln Glu Asp Ser Gly Asp Pro Met Val Arg Glu  
35 40 45  
Ala Ala Arg Ala Cys Pro Val Gly Ala Ile Lys Val Ser Glu Thr Ala  
50 55 60  
Arg Pro  
65

<210> 13  
<211> 65  
<212> PRT  
<213> Saccharopolyspora taberi JCM 9383t

<400> 13  
Met Arg Ile Gln Ala Asp Val Glu Arg Cys Val Gly Ala Gly Gln Cys  
1 5 10 15  
Val Leu Ala Ala Asp Ala Leu Phe Asp Gln Arg Asp Asp Asp Gly Thr  
20 25 30  
Val Val Val Leu Ala Thr Glu Val Gly Asp Gly Asp Ala Asp Ala Val  
35 40 45  
Arg Asp Ala Val Thr Leu Cys Pro Ser Gly Ala Leu Ser Leu Val Glu  
50 55 60  
Asp  
65

<210> 14  
<211> 64  
<212> PRT  
<213> Streptomyces testaceus ATCC 21469

<400> 14  
Met Arg Ile Thr Ile Asp Thr Asp Val Cys Ile Gly Ala Gly Gln Cys

EP 1 457 558 A1

1 5 10 15  
Ala Leu Thr Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
20 25 30  
Glu Leu Leu Pro Gly Arg Glu Asp Gly Ala Gly Asp Pro Met Leu Arg  
35 40 45  
5 Glu Ala Val Arg Ala Cys Pro Val Gln Ala Ile Thr Val Ala Asp Asp  
50 55 60

<210> 15  
<211> 201  
10 <212> DNA  
<213> Streptomyces phaeochromogenes IFO 12898

<220>  
<221> CDS  
15 <222> (1)..(201)

<400> 15  
atg cac atc gac atc gac acg gac gtg tgc atc ggc gcc ggc cag tgc 48  
Met His Ile Asp Ile Asp Thr Asp Val Cys Ile Gly Ala Gly Gln Cys  
1 5 10 15

20 gcg ctg tcc gcc ccg gcc gtc ttc acg cag gac gac gac ggc ttc agc 96  
Ala Leu Ser Ala Pro Ala Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
20 25 30

25 acc ctc ctg ccc gga cag gag gac agc ggc gac ccg atg gtc cgg gag 144  
Thr Leu Leu Pro Gly Gln Glu Asp Ser Gly Asp Pro Met Val Arg Glu  
35 40 45

30 gcg gcc cga gcc tgc ccg gtc ggt gcc atc aag gtc tcg gaa acc gcg 192  
Ala Ala Arg Ala Cys Pro Val Gly Ala Ile Lys Val Ser Glu Thr Ala  
50 55 60

cga ccg tga 201  
Arg Pro  
65

35 <210> 16  
<211> 198  
<212> DNA  
<213> Saccharopolyspora taberi JCM 9383t

<220>  
40 <221> CDS  
<222> (1)..(198)

<400> 16  
atg agg atc cag gcg gac gtg gag cgc tgc gtc gga gcg ggt cag tgc 48  
Met Arg Ile Gln Ala Asp Val Glu Arg Cys Val Gly Ala Gly Gln Cys  
1 5 10 15

45 gtg ctc gcc gcg gac gcg ctg ttc gac cag cgc gac gac gac ggc acc 96  
Val Leu Ala Ala Asp Ala Leu Phe Asp Gln Arg Asp Asp Asp Gly Thr  
20 25 30

50 gtg gtg gtg ctc gcg acc gag gtc ggc gac ggg gac gcc gac gcg gtc 144  
Val Val Val Leu Ala Thr Glu Val Gly Asp Gly Asp Ala Asp Ala Val  
35 40 45

55 cgg gac gcg gtg acg ctc tgc ccg tcg ggc gcg ttg tcg ctc gtg gag 192  
Arg Asp Ala Val Thr Leu Cys Pro Ser Gly Ala Leu Ser Leu Val Glu  
50 55 60

gac tga 198  
 Asp  
 65

5

<210> 17  
 <211> 195  
 <212> DNA  
 <213> Streptomyces testaceus ATCC 21469

10

<220>  
 <221> CDS  
 <222> (1)..(195)

<400> 17

15  
 atg cgg atc acc atc gac acc gac gtc tgc atc ggc gcc ggc cag tgc 48  
 Met Arg Ile Thr Ile Asp Thr Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15

gcg ctg acc gcg ccc ggg gtg ttc acc cag gac gac gac ggc ttc agc 96  
 Ala Leu Thr Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
 20 25 30

20

gag ctg ctg ccc ggc cgc gag gac ggc gcg ggc gac ccg atg ctg cgg 144  
 Glu Leu Leu Pro Gly Arg Glu Asp Gly Ala Gly Asp Pro Met Leu Arg  
 35 40 45

25

gag gcc gtg cgt gcc tgc ccc gtg cag gcc atc acc gtc gcg gac gac 192  
 Glu Ala Val Arg Ala Cys Pro Val Gln Ala Ile Thr Val Ala Asp Asp  
 50 55 60

tga 195

30

<210> 18  
 <211> 23  
 <212> PRT  
 <213> Streptomyces phaeochromogenes IFO 12898

<400> 18

35  
 Thr Asp Met Thr Asp Thr Ala Asp Val Lys Pro Leu Ser Ala Pro Val  
 1 5 10 15  
 Ala Phe Pro Gln Asp Arg Thr  
 20

40

<210> 19  
 <211> 7  
 <212> PRT  
 <213> Streptomyces phaeochromogenes IFO 12898

<400> 19

45  
 Val Thr Leu Tyr Asp Gly Arg  
 1 5

<210> 20  
 <211> 19  
 <212> PRT  
 <213> Saccharopolyspora taberi JCM 9383T

50

<400> 20  
 Pro Ala Ser Ser Glu Ala Leu Thr Tyr Pro Ile Pro Arg Thr Cys Pro  
 1 5 10 15  
 Tyr Ser Pro

55

<210> 21  
 <211> 8

<212> PRT  
 <213> Saccharopolyspora taberi JCM 9383T

<400> 21  
 Gly Ala Val Glu Glu Met Leu Arg  
           1                          5

<210> 22  
 <211> 19  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 22  
 Thr Asp Thr Ala Thr Thr Pro Gln Thr Thr Asp Ala Pro Ala Phe Pro  
           1                          5                          10                          15  
 Ser Asn Arg

<210> 23  
 <211> 15  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 23  
 Arg Ser Cys Pro Tyr Gln Leu Pro Asp Gly Tyr Ala Gln Leu Arg  
           1                          5                          10                          15

<210> 24  
 <211> 15  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 24  
 Asp Thr Pro Gly Pro Leu His Arg Val Thr Leu Tyr Asp Gly Arg  
           1                          5                          10                          15

<210> 25  
 <211> 7  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 25  
 Gln Ala Trp Val Val Thr Lys  
           1                          5

<210> 26  
 <211> 11  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 26  
 Thr Asp Asp Asn Phe Pro Ala Thr Ser Pro Arg  
           1                          5                          10

<210> 27  
 <211> 17  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 27  
 Glu Ser Pro Gln Ala Phe Ile Gly Leu Asp Pro Pro Glu His Gly Thr  
           1                          5                          10                          15  
 Arg

<210> 28

EP 1 457 558 A1

<211> 9  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

5 <400> 28  
 Met Thr Ile Ser Glu Phe Thr Val Lys  
 1 5

<210> 29  
 <211> 14  
 10 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 29  
 Leu Val Gln Ser Thr Asp Ala Gln Ser Ala Leu Thr Ala Arg  
 1 5 10

<210> 30  
 <211> 12  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

20 <400> 30  
 Ser Leu Val Pro Gly Ala Val Glu Glu Leu Leu Arg  
 1 5 10

<210> 31  
 <211> 11  
 25 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

<400> 31  
 Tyr Leu Ala Ile Ala Asp Ile Ala Gly Gly Arg  
 1 5 10

<210> 32  
 <211> 14  
 <212> PRT  
 35 <213> Streptomyces griseolus ATCC11796

<400> 32  
 Ala Gly Glu Gly Val Ile Val Val Asn Ser Ile Ala Asn Arg  
 1 5 10

40 <210> 33  
 <211> 15  
 <212> PRT  
 <213> Streptomyces griseolus ATCC11796

45 <400> 33  
 Asp Gly Thr Val Tyr Glu Asp Pro Asp Ala Leu Asp Ile His Arg  
 1 5 10 15

<210> 34  
 <211> 13  
 <212> PRT  
 50 <213> Streptomyces griseolus ATCC11796

<400> 34  
 Leu Glu Leu Glu Val Ile Leu Asn Ala Leu Met Asp Arg  
 1 5 10

55 <210> 35  
 <211> 32

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 35  
acsgayatga csgayacsgc sgaygtnaag cc 32

<210> 36  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 36  
vcgscgctcg tagagcgtca c 21

<210> 37  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 37  
atatgaccga taccgcggat gtgaagccgc tct 33

<210> 38  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 38  
aacaatttca cacaggaaac agctatgacc 30

<210> 39  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 39  
ctggaagggg caggtgcggt cctgggggaa 30

<210> 40  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 40  
cagtcacgac gttgtaaaac gacggccagt 30

<210> 41  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

5

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 41  
 cttccccag gaccgcacct gccccttcca 30

10

<210> 42  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

15

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 42  
 tgcggtcctg ggggaaggcg acgggtgccg aga 33

20

<210> 43  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

25

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 43  
 acgaatgcat cgacgcgatg ct 22

30

<210> 44  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

35

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 44  
 agttggtgaa cgccttcgag ct 22

40

<210> 45  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

45

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 45  
 cctcgatggt gatctgcgaa ct 22

50

<210> 46  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

55

<220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 46

EP 1 457 558 A1

acttacaccc tgctccaaca 20

<210> 47

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 47

acgagttgat gcggatgctg tccat 25

<210> 48

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 48

tctccgagcg cgaataccgt ga 22

<210> 49

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 49

ttcgacctgg acgcgctcgt cat 23

<210> 50

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 50

tttccgagac cttgatggca ccga 24

<210> 51

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 51

ctcatatgac agacatgacg gatacggca 29

<210> 52

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 52  
 gaagcttcta ccaggccacg ggcagatcca 30

5 <210> 53  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 53  
 aaagctttca cggtcgcgcg gtttccga 28

15 <210> 54  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 54  
 gaggcctsa cstatccgat 20

25 <210> 55  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 55  
 catctcctcc accgcgcc 18

35 <210> 56  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 56  
 gtgccgcgac accagccaca cg 22

45 <210> 57  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

50 <400> 57  
 caggaaacag ctatgac 17

55 <210> 58  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 58  
 5 tcgacctggt gcggatgctc tcg 23  
  
 <210> 59  
 <211> 17  
 <212> DNA  
 10 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 59  
 15 gttttcccag tcacgac 17  
  
 <210> 60  
 <211> 23  
 <212> DNA  
 20 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 60  
 25 catgatctcg cttggtagcc tgg 23  
  
 <210> 61  
 <211> 29  
 <212> DNA  
 30 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 61  
 35 cccatatgcc ggcattctct gaagctctg 29  
  
 <210> 62  
 <211> 32  
 <212> DNA  
 40 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 62  
 45 gaagctttca ccaagtgacc atcagttcgt gg 32  
  
 <210> 63  
 <211> 31  
 <212> DNA  
 50 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 63  
 55 ctaagctttc agtcctccac gagcgacaac a 31  
  
 <210> 64  
 <211> 20  
 <212> DNA

<213> Artificial Sequence  
 <220>  
 5 <223> Designed oligonucleotide primer for PCR  
 <400> 64  
 agtgcctggg ccagaacctc 20  
 <210> 65  
 10 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 15 <223> Designed oligonucleotide primer for PCR  
 <400> 65  
 cgggaggaac tcgtgaccga agccatcgcg 30  
 <210> 66  
 20 <211> 33  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 25 <223> Designed oligonucleotide primer for PCR  
 <400> 66  
 gagggcgccg gctcagtcgt ccgcgacggt gat 33  
 <210> 67  
 30 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 35 <223> Designed oligonucleotide primer for PCR  
 <400> 67  
 caggaaacag ctatgaccat gattacgcca 30  
 <210> 68  
 40 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 45 <223> Designed oligonucleotide primer for PCR  
 <400> 68  
 tgtaaaacga cggccagtga attgtaatac 30  
 <210> 69  
 50 <211> 1418  
 <212> DNA  
 <213> Streptomyces testaceus ATCC 21469  
 <220>  
 <221> CDS  
 <222> (1)..(1188)  
 55 <220>  
 <221> CDS  
 <222> (1224)..(1418)

EP 1 457 558 A1

	<400> 69																
	gtg	acc	gaa	gcc	atc	gcg	tat	ttc	cag	gac	cgc	acc	tgc	ccc	tac	cac	48
	Val	Thr	Glu	Ala	Ile	Ala	Tyr	Phe	Gln	Asp	Arg	Thr	Cys	Pro	Tyr	His	
5	1				5				10						15		
	ccg	ccg	gcc	ggc	tat	cag	ccg	ctg	cgt	gac	gca	ggc	ccg	ctg	gcc	cat	96
	Pro	Pro	Ala	Gly	Tyr	Gln	Pro	Leu	Arg	Asp	Ala	Gly	Pro	Leu	Ala	His	
				20					25					30			
10	gtc	acc	ctc	tac	gac	ggc	cgc	aag	gtg	tgg	gcg	gtg	acc	ggc	cac	acc	144
	Val	Thr	Leu	Tyr	Asp	Gly	Arg	Lys	Val	Trp	Ala	Val		Gly	His	Thr	
			35					40					45				
	gag	gcg	cgg	gcg	ctg	ctg	agc	gac	ccg	cgg	ctg	tcc	tcc	gac	cgg	cag	192
15	Glu	Ala	Arg	Ala	Leu	Leu	Ser	Asp	Pro	Arg	Leu	Ser	Ser	Asp	Arg	Gln	
	50						55					60					
	aac	ccg	gcc	ttc	ccg	gcg	ccg	ttc	gcc	cgc	ttc	gcg	gcg	ctg	cgc	cag	240
	Asn	Pro	Ala	Phe	Pro	Ala	Pro	Phe	Ala	Arg	Phe	Ala	Ala	Leu	Arg	Gln	
	65					70					75					80	
20	gtc	agg	tcg	ccg	ctg	atc	ggc	gtg	gac	gac	ccc	gag	cac	aac	acc	cag	288
	Val	Arg	Ser	Pro	Leu	Ile	Gly	Val	Asp	Asp	Pro	Glu	His	Asn	Thr	Gln	
					85					90					95		
	cgc	cgg	atg	ctg	atc	ccc	agc	ttc	agc	gtc	aag	cgg	acc	gcg	gcg	ctg	336
25	Arg	Arg	Met	Leu	Ile	Pro	Ser	Phe	Ser	Val	Lys	Arg	Thr	Ala	Ala	Leu	
				100					105					110			
	cgg	ccg	cag	atc	cag	cag	atc	gtc	gac	ggg	ctg	ctg	gac	cgg	atg	ctg	384
	Arg	Pro	Gln	Ile	Gln	Gln	Ile	Val	Asp	Gly	Leu	Leu	Asp	Arg	Met	Leu	
			115					120					125				
30	gcg	cag	ggg	ccg	ccc	gcc	gag	ctg	gtc	tcc	gcg	ttc	gcg	ctg	ccg	gtg	432
	Ala	Gln	Gly	Pro	Pro	Ala	Glu	Leu	Val	Ser	Ala	Phe	Ala	Leu	Pro	Val	
	130						135					140					
	ccc	tcg	atg	gtg	atc	tgc	tcg	ctg	ctc	ggc	gtc	ccc	tac	tcc	gac	cac	480
35	Pro	Ser	Met	Val	Ile	Cys	Ser	Leu	Leu	Gly	Val	Pro	Tyr	Ser	Asp	His	
	145					150					155					160	
	gag	ttc	ttc	gag	gag	gcc	tcc	cgc	cgg	ctc	ctg	cgc	agc	cgg	acg	gcc	528
	Glu	Phe	Phe	Glu	Glu	Ala	Ser	Arg	Arg	Leu	Leu	Arg	Ser	Arg	Thr	Ala	
				165						170					175		
40	gag	gag	gcg	gag	gag	gcc	cgc	ctc	cgg	ctg	gag	gac	tac	ttc	gac	gag	576
	Glu	Glu	Ala	Glu	Glu	Ala	Arg	Leu	Arg	Leu	Glu	Asp	Tyr	Phe	Asp	Glu	
				180				185						190			
	ctg	atc	gcc	cac	aag	gag	aag	acc	ccg	cgc	gag	ggc	ctg	ctc	gac	gag	624
45	Leu	Ile	Ala	His	Lys	Glu	Lys	Thr	Pro	Arg	Glu	Gly	Leu	Leu	Asp	Glu	
			195					200					205				
	ctg	gtc	cac	gac	gag	ctg	cgc	acc	ggc	gcc	ctg	gag	cgc	gag	gat	ctg	672
50	Leu	Val	His	Asp	Glu	Leu	Arg	Thr	Gly	Ala	Leu	Glu	Arg	Glu	Asp	Leu	
		210					215					220					
	gtc	cgg	ctc	gcg	atg	atc	ctg	ctg	gtg	gcc	ggc	cac	gag	acc	acc	gcc	720
	Val	Arg	Leu	Ala	Met	Ile	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	Thr	Ala	
	225					230					235					240	
55	aac	atg	atc	tcg	ctc	ggc	acc	ttc	acc	ctg	ctg	gag	cac	ccc	gga	cag	768
	Asn	Met	Ile	Ser	Leu	Gly	Thr	Phe	Thr	Leu	Leu	Glu	His	Pro	Gly	Gln	

EP 1 457 558 A1

	245	250	255	
5	ctg gcc cgg ctg aag gcc gag gag ggg ctg ctg ccg gcc gcc gtc gag Leu Ala Arg Leu Lys Ala Glu Glu Gly Leu Leu Pro Ala Ala Val Glu 260 265 270			816
	gag ctg ttg cgg ttc ctg tcc atc gcg gac ggc ctg ctg cgg gtg gcc Glu Leu Leu Arg Phe Leu Ser Ile Ala Asp Gly Leu Leu Arg Val Ala 275 280 285			864
10	atg gcg gac atc gag atc ggc ggg cag gtc atc cgt gcc gac gac ggc Met Ala Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Asp Asp Gly 290 295 300			912
15	gtg ctg ttc ccc acc tcg ctg atc aac cgg gac gac ggc gcc tat ccg Val Leu Phe Pro Thr Ser Leu Ile Asn Arg Asp Asp Gly Ala Tyr Pro 305 310 315 320			960
	aca ccg gac gag ctg gac gtc ggc cgg tcc gcc cgc cat cac gtg gcg Thr Pro Asp Glu Leu Asp Val Gly Arg Ser Ala Arg His His Val Ala 325 330 335			1008
20	ttc ggg ttc ggc atc cac cag tgc ctg ggg cag aac ctc gcc cgg gcg Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala 340 345 350			1056
25	gag atg gag atc gcg ctg cgc tcg ctg ttc gac cgg atc ccg gat ctg Glu Met Glu Ile Ala Leu Arg Ser Leu Phe Asp Arg Ile Pro Asp Leu 355 360 365			1104
	cga ctc gcc gtg ccg gct gcc gag atc ccc ttc aag ccg ggg gac act Arg Leu Ala Val Pro Ala Ala Glu Ile Pro Phe Lys Pro Gly Asp Thr 370 375 380			1152
30	ctg caa gga atg atc gaa ctg ccg ctg gcc tgg tag ccgcggtgca cccggc Leu Gln Gly Met Ile Glu Leu Pro Leu Ala Trp 385 390 395			1204
35	cgaacgaagg gggttttgga atg cgg atc acc atc gac acc gac gtc tgc atc Met Arg Ile Thr Ile Asp Thr Asp Val Cys Ile 1 5 10			1256
	ggc gcc ggc cag tgc gcg ctg acc gcg ccc ggg gtg ttc acc cag gac Gly Ala Gly Gln Cys Ala Leu Thr Ala Pro Gly Val Phe Thr Gln Asp 15 20 25			1304
40	gac gac ggc ttc agc gag ctg ctg ccc ggc cgc gag gac ggc gcg ggc Asp Asp Gly Phe Ser Glu Leu Leu Pro Gly Arg Glu Asp Gly Ala Gly 30 35 40			1352
45	gac ccg atg ctg cgg gag gcc gtg cgt gcc tgc ccc gtg cag gcc atc Asp Pro Met Leu Arg Glu Ala Val Arg Ala Cys Pro Val Gln Ala Ile 45 50 55			1400
	acc gtc gcg gac gac tga Thr Val Ala Asp Asp 60 64			1418
50	<210> 70 <211> 30 <212> DNA <213> Artificial Sequence			
55	<220>			

<223> Designed oligonucleotide primer for PCR  
 <400> 70  
 5 cgggaggaac atatgaccga agccatcgcg 30  
 <210> 71  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 71  
 15 gcaaagcttc taccaggcca gcggcagttc gat 33  
 <210> 72  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 72  
 25 gaggaagctt gctcagtcgt ccgcgacggt gat 33  
 <210> 73  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 73  
 gtgccctcga tggatgatctg ctcgctgctc 30  
 <210> 74  
 35 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 74  
 tcgagggttc atatgaccga gatgacagag 30  
 <210> 75  
 45 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 75  
 gatgtggcag atcaccatgg acgggacggg 30  
 <210> 76  
 55 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

5 <400> 76  
 cccgtcccgt ccatggtgat ctgccacatg 30

<210> 77  
 <211> 33  
 <212> DNA  
 10 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

15 <400> 77  
 ggcaagcttt caccaggtga ccgggagttc gtt 33

<210> 78  
 <211> 1233  
 <212> DNA  
 20 <213> Streptomyces carbophilus SANK 62585

<220>  
 <221> CDS  
 <222> (1)..(1233)

25 <400> 78  
 atg acc gag atg aca gag aaa gcc acc aca ttc ctc acg tcg cag gag 48  
 Met Thr Glu Met Thr Glu Lys Ala Thr Thr Phe Leu Thr Ser Gln Glu  
 1 5 10 15

30 gca ccg gcc ttc ccg gcg gac cgc aca tgt ccc tac caa cta ccc acg 96  
 Ala Pro Ala Phe Pro Ala Asp Arg Thr Cys Pro Tyr Gln Leu Pro Thr  
 20 25 30

gcc tac agt ccg ttg agg gac gag ccg gat gcg ctg cgc ccg gtg acg 144  
 Ala Tyr Ser Arg Leu Arg Asp Glu Pro Asp Ala Leu Arg Pro Val Thr  
 35 40 45

35 ctc tac gac ggc cgc cgc gcc tgg gtg gtg acc aag cac gag gcg gcg 192  
 Leu Tyr Asp Gly Arg Arg Ala Trp Val Val Thr Lys His Glu Ala Ala  
 50 55 60

40 cgg ccg tta ctc gcg gac ccc ccg ctg tcc tcc gac cgc ctg cac gcc 240  
 Arg Arg Leu Leu Ala Asp Pro Arg Leu Ser Ser Asp Arg Leu His Ala  
 65 70 75 80

gac ttc ccc gcc acc tcg cca cgc ttc aag gcg ttc ccg cag ggc agc 288  
 Asp Phe Pro Ala Thr Ser Pro Arg Phe Lys Ala Phe Arg Gln Gly Ser  
 85 90 95

45 ccc gcg ttc atc ggg atg gat ccc ccc gag cac ggg acg cgt cgc cgc 336  
 Pro Ala Phe Ile Gly Met Asp Pro Pro Glu His Gly Thr Arg Arg Arg  
 100 105 110

50 atg acg atc agc gag ttc acc gtg aag cgc atc aag ggc atg cgc ccg 384  
 Met Thr Ile Ser Glu Phe Thr Val Lys Arg Ile Lys Gly Met Arg Pro  
 115 120 125

gac gtc gaa cgc atc gtg cac ggc ttc atc gac gac atg ctc gcc gcg 432  
 Asp Val Glu Arg Ile Val His Gly Phe Ile Asp Asp Met Leu Ala Ala  
 130 135 140

EP 1 457 558 A1

	gga ccc acc gcc gat ctg gtc agc cag ttc gcc ctg ccc gtc ccg tcc	480
	Gly Pro Thr Ala Asp Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser	
	145 150 155 160	
5	atg gtg atc tgc cac atg ctc ggc gtc ccc tac gcc gac cac gag ttc	528
	Met Val Ile Cys His Met Leu Gly Val Pro Tyr Ala Asp His Glu Phe	
	165 170 175	
10	ttc cag gac gcg agc aag cgc ctg gtg cag gcg gtg gac gcc gac agt	576
	Phe Gln Asp Ala Ser Lys Arg Leu Val Gln Ala Val Asp Ala Asp Ser	
	180 185 190	
	gcc gtc gcc gcc cgg gac gac ttc gag cgc tac ctg gac ggg ctg atc	624
	Ala Val Ala Ala Arg Asp Asp Phe Glu Arg Tyr Leu Asp Gly Leu Ile	
	195 200 205	
15	acc aag ctg gag tcc gaa ccc ggg acc ggg ctc ctc ggc aaa ctg gtc	672
	Thr Lys Leu Glu Ser Glu Pro Gly Thr Gly Leu Leu Gly Lys Leu Val	
	210 215 220	
20	acc cac cag ctg gcg gac ggc gag atc gac cgc gcg gag ctg atc tcc	720
	Thr His Gln Leu Ala Asp Gly Glu Ile Asp Arg Ala Glu Leu Ile Ser	
	225 230 235 240	
	acc gcc ctg ctg ctg ctc gtc gcc ggt cat gag acc acg gcc tcg atg	768
	Thr Ala Leu Leu Leu Val Ala Gly His Glu Thr Thr Ala Ser Met	
	245 250 255	
25	acc tcg ctc agc gtc atc acc ctg ctc gaa cac ccc gac cag cac gcc	816
	Thr Ser Leu Ser Val Ile Thr Leu Leu Glu His Pro Asp Gln His Ala	
	260 265 270	
30	gcc ctg cgc gcc gac ccg tcc ctc gtg ccc gga gcg gtc gag gaa ctg	864
	Ala Leu Arg Ala Asp Pro Ser Leu Val Pro Gly Ala Val Glu Glu Leu	
	275 280 285	
	ctg cgc gtc ctg gcc atc gcg gac atc gcg ggc ggc cgc atc gcc acc	912
	Leu Arg Val Leu Ala Ile Ala Asp Ile Ala Gly Gly Arg Ile Ala Thr	
	290 295 300	
35	gcc gac atc gag atc gac gga cag ctc atc cgg gcc ggt gaa gga gtg	960
	Ala Asp Ile Glu Ile Asp Gly Gln Leu Ile Arg Ala Gly Glu Gly Val	
	305 310 315 320	
40	atc gtc acc aac tcc atc gcc aac cgc gac agt tcg gtg ttc gag aac	1008
	Ile Val Thr Asn Ser Ile Ala Asn Arg Asp Ser Ser Val Phe Glu Asn	
	325 330 335	
	ccg gac cgc ctc gat gtg cac cgc tcg gca cgc cac cac ctc tcc ttc	1056
	Pro Asp Arg Leu Asp Val His Arg Ser Ala Arg His His Leu Ser Phe	
	340 345 350	
45	ggg tac ggg gtg cac cag tgc ctg ggc cag aac ctg gcc cgc ctc gaa	1104
	Gly Tyr Gly Val His Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu	
	355 360 365	
50	ctc gaa gtc atc ctc acc gtg ttg ttc gac cgc att ccg acc ctg cgc	1152
	Leu Glu Val Ile Leu Thr Val Leu Phe Asp Arg Ile Pro Thr Leu Arg	
	370 375 380	
55	ctg gcc gtc ccc gtg gag cag ctg acg ctg cgt ccg ggc acg acg atc	1200
	Leu Ala Val Pro Val Glu Gln Leu Thr Leu Arg Pro Gly Thr Thr Ile	
	385 390 395 400	

EP 1 457 558 A1

cag ggc gtc aac gaa ctc ccg gtc acc tgg tga 1233  
Gln Gly Val Asn Glu Leu Pro Val Thr Trp  
405 410

5 <210> 79  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
10 <223> Designed oligonucleotide primer for PCR

<400> 79  
gccatatgac cgataccgcc acgacgcc 28

<210> 80  
15 <211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
20 <223> Designed oligonucleotide primer for PCR

<400> 80  
gcaagctttc accaggtgac cgggagttc 29

<210> 81  
25 <211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
30 <223> Designed oligonucleotide primer for PCR

<400> 81  
gcaagcttct attccgtgtc ctcgacga 28

<210> 82  
35 <211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
40 <223> Designed oligonucleotide primer for PCR

<400> 82  
cacggcttcc tcgacgagat 20

<210> 83  
45 <211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
50 <223> Designed oligonucleotide primer for PCR

<400> 83  
gtggaggaac tgctccgcta 20

<210> 84  
55 <211> 1221  
<212> DNA  
<213> Streptomyces griseolus ATCC 11796

EP 1 457 558 A1

<220>  
<221> CDS  
<222> (1)..(1221)

5	<400> 84	
	atg acc gat acc gcc acg acg ccc cag acc acg gac gca ccc gcc ttc	48
	Met Thr Asp Thr Ala Thr Thr Pro Gln Thr Thr Asp Ala Pro Ala Phe	
	1 5 10 15	
10	ccg agc aac cgg agc tgt ccc tac cag tta ccg gac ggc tac gcc cag	96
	Pro Ser Asn Arg Ser Cys Pro Tyr Gln Leu Pro Asp Gly Tyr Ala Gln	
	20 25 30	
15	ctc cgg gac acc ccc ggc ccc ctg cac cgg gtg acg ctc tac gac ggc	144
	Leu Arg Asp Thr Pro Gly Pro Leu His Arg Val Thr Leu Tyr Asp Gly	
	35 40 45	
20	cgt cag gcg tgg gtg gtg acc aag cac gag gcc gcg cgc aaa ctg ctc	192
	Arg Gln Ala Trp Val Val Thr Lys His Glu Ala Ala Arg Lys Leu Leu	
	50 55 60	
25	ggc gac ccc cgg ctg tcc tcc aac cgg acg gac gac aac ttc ccc gcc	240
	Gly Asp Pro Arg Leu Ser Ser Asn Arg Thr Asp Asp Asn Phe Pro Ala	
	65 70 75 80	
30	acg tca ccg cgc ttc gag gcc gtc cgg gag agc ccg cag gcg ttc atc	288
	Thr Ser Pro Arg Phe Glu Ala Val Arg Glu Ser Pro Gln Ala Phe Ile	
	85 90 95	
35	ggc ctg gac ccg ccc gag cac ggc acc cgg cgg cgg atg acg atc agc	336
	Gly Leu Asp Pro Pro Glu His Gly Thr Arg Arg Arg Met Thr Ile Ser	
	100 105 110	
40	gag ttc acc gtc aag cgg atc aag ggc atg cgc ccc gag gtc gag gag	384
	Glu Phe Thr Val Lys Arg Ile Lys Gly Met Arg Pro Glu Val Glu Glu	
	115 120 125	
45	gtg gtg cac ggc ttc ctc gac gag atg ctg gcc gcc ggc ccg acc gcc	432
	Val Val His Gly Phe Leu Asp Glu Met Leu Ala Ala Gly Pro Thr Ala	
	130 135 140	
50	gac ctg gtc agt cag ttc gcg ctg ccg gtg ccc tcc atg gtg atc tgc	480
	Asp Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys	
	145 150 155 160	
55	cga ctc ctc ggc gtg ccc tac gcc gac cac gag ttc ttc cag gac gcg	528
	Arg Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Gln Asp Ala	
	165 170 175	
60	agc aag cgg ctg gtg cag tcc acg gac gcg cag agc gcg ctc acc gcg	576
	Ser Lys Arg Leu Val Gln Ser Thr Asp Ala Gln Ser Ala Leu Thr Ala	
	180 185 190	
65	cgg aac gac ctc gcg ggt tac ctg gac ggc ctc atc acc cag ttc cag	624
	Arg Asn Asp Leu Ala Gly Tyr Leu Asp Gly Leu Ile Thr Gln Phe Gln	
	195 200 205	
70	acc gaa ccg ggc gcg ggc ctg gtg ggc gct ctg gtc gcc gac cag ctg	672
	Thr Glu Pro Gly Ala Gly Leu Val Gly Ala Leu Val Ala Asp Gln Leu	
	210 215 220	
75	gcc aac ggc gag atc gac cgt gag gaa ctg atc tcc acc gcg atg ctg	720
	Ala Asn Gly Glu Ile Asp Arg Glu Glu Leu Ile Ser Thr Ala Met Leu	
	225 230 235 240	

EP 1 457 558 A1

	ctc ctc atc gcc ggc cac gag acc acg gcc tcg atg acc tcc ctc agc	768
	Leu Leu Ile Ala Gly His Glu Thr Thr Ala Ser Met Thr Ser Leu Ser	
	245 250 255	
5	gtg atc acc ctg ctg gac cac ccc gag cag tac gcc gcc ctg cgc gcc	816
	Val Ile Thr Leu Leu Asp His Pro Glu Gln Tyr Ala Ala Leu Arg Ala	
	260 265 270	
10	gac cgc agc ctc gtg ccc ggc gcg gtg gag gaa ctg ctc cgc tac ctc	864
	Asp Arg Ser Leu Val Pro Gly Ala Val Glu Glu Leu Leu Arg Tyr Leu	
	275 280 285	
	gcc atc gcc gac atc gcg ggc ggc cgc gtc gcc acg gcg gac atc gag	912
	Ala Ile Ala Asp Ile Ala Gly Gly Arg Val Ala Thr Ala Asp Ile Glu	
	290 295 300	
15	gtc gag ggg cag ctc atc cgg gcc ggc gag ggc gtg atc gtc gtc aac	960
	Val Glu Gly Gln Leu Ile Arg Ala Gly Glu Gly Val Ile Val Val Asn	
	305 310 315 320	
20	tcg ata gcc aac cgg gac ggc acg gtg tac gag gac ccg gac gcc ctc	1008
	Ser Ile Ala Asn Arg Asp Gly Thr Val Tyr Glu Asp Pro Asp Ala Leu	
	325 330 335	
	gac atc cac cgc tcc gcg cgc cac cac ctc gcc ttc ggc ttc ggc gtg	1056
	Asp Ile His Arg Ser Ala Arg His His Leu Ala Phe Gly Phe Gly Val	
	340 345 350	
25	cac cag tgc ctg ggc cag aac ctc gcc cgg ctg gag ctg gag gtc atc	1104
	His Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu Leu Glu Val Ile	
	355 360 365	
30	ctc aac gcc ctc atg gac cgc gtc ccg acg ctg cga ctg gcc gtc ccc	1152
	Leu Asn Ala Leu Met Asp Arg Val Pro Thr Leu Arg Leu Ala Val Pro	
	370 375 380	
	gtc gag cag ttg gtg ctg cgg ccg ggt acg acg atc cag ggc gtc aac	1200
	Val Glu Gln Leu Val Leu Arg Pro Gly Thr Thr Ile Gln Gly Val Asn	
	385 390 395 400	
35	gaa ctc ccg gtc acc tgg tga	1221
	Glu Leu Pro Val Thr Trp	
	405	
40	<210> 85	
	<211> 1451	
	<212> DNA	
	<213> Streptmyces griseolus ATCC 11796	
	<220>	
45	<221> CDS	
	<222> (1)..(1221)	
	<220>	
	<221> CDS	
	<222> (1242)..(1451)	
50	<400> 85	
	atg acc gat acc gcc acg acg ccc cag acc acg gac gca ccc gcc ttc	48
	Met Thr Asp Thr Ala Thr Thr Pro Gln Thr Thr Asp Ala Pro Ala Phe	
	1 5 10 15	
55	ccg agc aac cgg agc tgt ccc tac cag tta ccg gac ggc tac gcc cag	96

EP 1 457 558 A1

	Pro	Ser	Asn	Arg	Ser	Cys	Pro	Tyr	Gln	Leu	Pro	Asp	Gly	Tyr	Ala	Gln	
				20					25					30			
5	ctc	cgg	gac	acc	ccc	ggc	ccc	ctg	cac	cgg	gtg	acg	ctc	tac	gac	ggc	144
	Leu	Arg	Asp	Thr	Pro	Gly	Pro	Leu	His	Arg	Val	Thr	Leu	Tyr	Asp	Gly	
			35					40					45				
	cgt	cag	gcg	tgg	gtg	gtg	acc	aag	cac	gag	gcc	gcg	cgc	aaa	ctg	ctc	192
	Arg	Gln	Ala	Trp	Val	Val	Thr	Lys	His	Glu	Ala	Ala	Arg	Lys	Leu	Leu	
10		50					55					60					
	ggc	gac	ccc	cgg	ctg	tcc	tcc	aac	cgg	acg	gac	gac	aac	ttc	ccc	gcc	240
	Gly	Asp	Pro	Arg	Leu	Ser	Ser	Asn	Arg	Thr	Asp	Asp	Asn	Phe	Pro	Ala	
	65					70					75				80		
15	acg	tca	ccg	cgc	ttc	gag	gcc	gtc	cgg	gag	agc	ccg	cag	gcg	ttc	atc	288
	Thr	Ser	Pro	Arg	Phe	Glu	Ala	Val	Arg	Glu	Ser	Pro	Gln	Ala	Phe	Ile	
				85						90					95		
	ggc	ctg	gac	ccg	ccc	gag	cac	ggc	acc	cgg	cgg	cgg	atg	acg	atc	agc	336
	Gly	Leu	Asp	Pro	Pro	Glu	His	Gly	Thr	Arg	Arg	Arg	Met	Thr	Ile	Ser	
20				100					105					110			
	gag	ttc	acc	gtc	aag	cgg	atc	aag	ggc	atg	cgc	ccc	gag	gtc	gag	gag	384
	Glu	Phe	Thr	Val	Lys	Arg	Ile	Lys	Gly	Met	Arg	Pro	Glu	Val	Glu	Glu	
			115					120					125				
25	gtg	gtg	cac	ggc	ttc	ctc	gac	gag	atg	ctg	gcc	gcc	ggc	ccg	acc	gcc	432
	Val	Val	His	Gly	Phe	Leu	Asp	Glu	Met	Leu	Ala	Ala	Gly	Pro	Thr	Ala	
			130				135					140					
	gac	ctg	gtc	agt	cag	ttc	gcg	ctg	ccg	gtg	ccc	tcc	atg	gtg	atc	tgc	480
	Asp	Leu	Val	Ser	Gln	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val	Ile	Cys	
30	145					150					155					160	
	cga	ctc	ctc	ggc	gtg	ccc	tac	gcc	gac	cac	gag	ttc	ttc	cag	gac	gcg	528
	Arg	Leu	Leu	Gly	Val	Pro	Tyr	Ala	Asp	His	Glu	Phe	Phe	Gln	Asp	Ala	
				165						170					175		
35	agc	aag	cgg	ctg	gtg	cag	tcc	acg	gac	gcg	cag	agc	gcg	ctc	acc	gcg	576
	Ser	Lys	Arg	Leu	Val	Gln	Ser	Thr	Asp	Ala	Gln	Ser	Ala	Leu	Thr	Ala	
				180					185					190			
	cgg	aac	gac	ctc	gcg	ggt	tac	ctg	gac	ggc	ctc	atc	acc	cag	ttc	cag	624
	Arg	Asn	Asp	Leu	Ala	Gly	Tyr	Leu	Asp	Gly	Leu	Ile	Thr	Gln	Phe	Gln	
40			195					200					205				
	acc	gaa	ccg	ggc	gcg	ggc	ctg	gtg	ggc	gct	ctg	gtc	gcc	gac	cag	ctg	672
	Thr	Glu	Pro	Gly	Ala	Gly	Leu	Val	Gly	Ala	Leu	Val	Ala	Asp	Gln	Leu	
			210				215					220					
45	gcc	aac	ggc	gag	atc	gac	cgt	gag	gaa	ctg	atc	tcc	acc	gcg	atg	ctg	720
	Ala	Asn	Gly	Glu	Ile	Asp	Arg	Glu	Glu	Leu	Ile	Ser	Thr	Ala	Met	Leu	
	225					230					235					240	
	ctc	ctc	atc	gcc	ggc	cac	gag	acc	acg	gcc	tcg	atg	acc	tcc	ctc	agc	768
	Leu	Leu	Ile	Ala	Gly	His	Glu	Thr	Thr	Ala	Ser	Met	Thr	Ser	Leu	Ser	
50				245						250					255		
	gtg	atc	acc	ctg	ctg	gac	cac	ccc	gag	cag	tac	gcc	gcc	ctg	cgc	gcc	816
	Val	Ile	Thr	Leu	Leu	Asp	His	Pro	Glu	Gln	Tyr	Ala	Ala	Leu	Arg	Ala	
				260					265					270			
55	gac	cgc	agc	ctc	gtg	ccc	ggc	gcg	gtg	gag	gaa	ctg	ctc	cgc	tac	ctc	864

EP 1 457 558 A1

	Asp	Arg	Ser	Leu	Val	Pro	Gly	Ala	Val	Glu	Glu	Leu	Leu	Arg	Tyr	Leu	
			275					280					285				
5	gcc	atc	gcc	gac	atc	gcg	ggc	ggc	cgc	gtc	gcc	acg	gcg	gac	atc	gag	912
	Ala	Ile	Ala	Asp	Ile	Ala	Gly	Gly	Arg	Val	Ala	Thr	Ala	Asp	Ile	Glu	
		290					295					300					
	gtc	gag	ggg	cag	ctc	atc	cgg	gcc	ggc	gag	ggc	gtg	atc	gtc	gtc	aac	960
	Val	Glu	Gly	Gln	Leu	Ile	Arg	Ala	Gly	Glu	Gly	Val	Ile	Val	Val	Asn	
		305				310						315				320	
10	tcg	ata	gcc	aac	cgg	gac	ggc	acg	gtg	tac	gag	gac	ccg	gac	gcc	ctc	1008
	Ser	Ile	Ala	Asn	Arg	Asp	Gly	Thr	Val	Tyr	Glu	Asp	Pro	Asp	Ala	Leu	
					325					330					335		
15	gac	atc	cac	cgc	tcc	gcg	cgc	cac	cac	ctc	gcc	ttc	ggc	ttc	ggc	gtg	1056
	Asp	Ile	His	Arg	Ser	Ala	Arg	His	His	Leu	Ala	Phe	Gly	Phe	Gly	Val	
					340					345				350			
	cac	cag	tgc	ctg	ggc	cag	aac	ctc	gcc	cgg	ctg	gag	ctg	gag	gtc	atc	1104
	His	Gln	Cys	Leu	Gly	Gln	Asn	Leu	Ala	Arg	Leu	Glu	Leu	Glu	Val	Ile	
			355					360					365				
20	ctc	aac	gcc	ctc	atg	gac	cgc	gtc	ccg	acg	ctg	cga	ctg	gcc	gtc	ccc	1152
	Leu	Asn	Ala	Leu	Met	Asp	Arg	Val	Pro	Thr	Leu	Arg	Leu	Ala	Val	Pro	
			370				375					380					
25	gtc	gag	cag	ttg	gtg	ctg	cgg	ccg	ggc	acg	acg	atc	cag	ggc	gtc	aac	1200
	Val	Glu	Gln	Leu	Val	Leu	Arg	Pro	Gly	Thr	Thr	Ile	Gln	Gly	Val	Asn	
						390					395					400	
	gaa	ctc	ccg	gtc	acc	tgg	tga	cggggggagag	gggcaaggac	atg	acc	atg	cgg				1253
	Glu	Leu	Pro	Val	Thr	Trp				Met	Thr	Met	Arg				
					405					1							
30	gtg	agt	gcg	gat	cgg	acg	gtc	tgc	gtc	ggc	ggg	ctg	tgt	gcg	ctg		1301
	Val	Ser	Ala	Asp	Arg	Thr	Val	Cys	Val	Gly	Ala	Gly	Leu	Cys	Ala	Leu	
		5				10				15					20		
35	acg	gcg	ccg	ggc	gtc	ctc	gac	cag	gac	gac	gac	ggg	atc	gtc	acg	gtg	1349
	Thr	Ala	Pro	Gly	Val	Leu	Asp	Gln	Asp	Asp	Asp	Gly	Ile	Val	Thr	Val	
					25					30					35		
	ctg	acg	gcc	gaa	ccc	gcc	gcc	gac	gac	gac	cgg	cgc	acc	gcg	cgc	gag	1397
	Leu	Thr	Ala	Glu	Pro	Ala	Ala	Asp	Asp	Asp	Arg	Arg	Thr	Ala	Arg	Glu	
				40						45				50			
40	gcc	ggc	cat	ctc	tgt	ccg	tcc	ggc	gcg	gtc	cgc	gtc	gtc	gag	gac	acg	1445
	Ala	Gly	His	Leu	Cys	Pro	Ser	Gly	Ala	Val	Arg	Val	Val	Glu	Asp	Thr	
			55					60					65				
45	gaa	tag															1451
	Glu																
		69															
	<210>	86															
	<211>	37															
50	<212>	DNA															
	<213>	Artificial Sequence															
	<220>																
	<223>	Designed oligonucleotide primer for PCR															
55	<400>	86															

```

gaaagcttag aggatccaaa tggcttcctc aatgac 37
<210> 87
<211> 38
5 <212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

10 <400> 87
cgaggtaccg caagtaggaa agagtcatga acttcctc 38

<210> 88
<211> 248
<212> DNA
15 <213> Glycine max (L.) Merrill

<220>
<221> CDS
<222> (20)..(220)

20 <400> 88
gaaagcttag aggatccaa atg gct tcc tca atg atc tcc tcc cca gct gtt 52
Met Ala Ser Ser Met Ile Ser Ser Pro Ala Val
1 5 10

25 acc acc gtc aac cgt gcc ggt gcc ggc atg gtt gct cca ttc acc ggc 100
Thr Thr Val Asn Arg Ala Gly Ala Gly Met Val Ala Pro Phe Thr Gly
15 20 25

ctc aaa tcc atg gct ggc ttc ccc acg agg aag acc aac aat gac att 148
Leu Lys Ser Met Ala Gly Phe Pro Thr Arg Lys Thr Asn Asn Asp Ile
30 30 35 40

acc tcc att gct agc aac ggt gga aga gta caa tgc atg cag gtg tgg 196
Thr Ser Ile Ala Ser Asn Gly Gly Arg Val Gln Cys Met Gln Val Trp
45 50 55

35 cca cca att ggc aag aag aag ttc atgactcttt cctacttgcg gtacctcg 248
Pro Pro Ile Gly Lys Lys Lys Phe
60 65

<210> 89
<211> 9
40 <212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide linker for construction of expression vector

45 <400> 89
gcggccgcg 9

<210> 90
<211> 13
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Designed oligonucleotide linker for construction of expression vector

55 <400> 90
aattcgcggc cgc 13

```

<210> 91  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide linker for construction of expression vector

<400> 91  
 agcttgccgc cgc 13

<210> 92  
 <211> 11  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide linker for construction of expression vector

<400> 92  
 tagcggccgc a 11

<210> 93  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 93  
 tcatgcatga cagacatgac ggatacggca 30

<210> 94  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 94  
 ggagctccta ccaggccacg ggcagatcca 30

<210> 95  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 95  
 ggagctctca cggtcgcgcg gtttccgag a 30

<210> 96  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 96  
 tctttcatga cagacatgac ggatacggca 30  
 <210> 97  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 97  
 ggagctctca cggtcgcgcg gtttccgag a 30  
 <210> 98  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide linker for construction of expression vector  
 <400> 98  
 agcttgccgc cgcgaattc 19  
 <210> 99  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide linker for construction of expression vector  
 <400> 99  
 agctgaattc gcggccgca 19  
 <210> 100  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 100  
 ccaagcttgc atgccggcat cttctgaagc tctga 35  
 <210> 101  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 101  
 gaagcttggt acctcaccaa gtgaccatca gttcg 35  
 <210> 102  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

<223> Designed oligonucleotide primer for PCR  
 <400> 102  
 5 aatgcatgac cgaagccatc gcgtatttc 29  
 <210> 103  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 103  
 15 ggggtaccgc ggctaccagg ccag 24  
 <210> 104  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 104  
 aactcatgac cgaagccatc gcgtatttc 29  
 25  
 <210> 105  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 105  
 ggtccacata tgcacatcga catcgacacg 30  
 35  
 <210> 106  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 106  
 agagtccata tgaggatcca ggcggacgtg 30  
 45  
 <210> 107  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 107  
 ggttttcata tgcggatcac catcgacacc 30  
 55  
 <210> 108  
 <211> 411  
 <212> PRT  
 <213> Streptomyces achromogenes IFO 12735

<400> 108  
 Met Thr Gln Ser Ala Asp Ala Val Pro Glu Ala Glu Ala Pro Pro Val  
 1 5 10 15  
 5 Gln Phe Pro Leu Arg Arg Thr Cys Pro Phe Ala Glu Pro Pro Glu Tyr  
 20 25 30  
 Ala Gly Leu Arg Ala Asp Thr Pro Val Ala Arg Ala Ala Leu Lys Val  
 35 40 45  
 Asn Gly Lys Pro Ala Trp Leu Val Thr Arg His Glu His Val Arg Gln  
 50 55 60  
 10 Val Leu Gly Asp Ser Arg Val Ser Ser Asn Leu Lys Leu Pro Gly Tyr  
 65 70 75 80  
 Pro His Gln Phe His Ile Pro Glu Glu Leu Leu Ala Gln Val Arg Leu  
 85 90 95  
 Met Met Leu Asn Met Asp Pro Pro Glu His Thr Ala His Arg Arg Met  
 100 105 110  
 15 Leu Ile Pro Glu Phe Thr Ala Arg Val Arg Glu Leu Arg Pro Arg  
 115 120 125  
 Ile Gln Gln Ile Val Asp Glu His Val Asp Ala Met Leu Ala Ala Gly  
 130 135 140  
 Gly Pro Val Asp Leu Val Thr Ala Leu Ala Leu Pro Val Pro Ser Leu  
 145 150 155 160  
 20 Val Ile Cys Glu Leu Leu Gly Val Pro Tyr Glu Asp His Ala Arg Phe  
 165 170 175  
 Glu Glu Trp Ser Ala Ala Leu Met Asn His Asp Leu Ser Pro Gln Glu  
 180 185 190  
 Tyr Gly Ala Ala Val Gln Ala Leu Asp Thr Tyr Leu Asp Gln Leu Val  
 195 200 205  
 25 Thr Leu Lys Glu Asn Glu Pro Gly Asp Asp Leu Ile Ser Arg Phe Leu  
 210 215 220  
 Glu Lys Asn Arg Thr Glu Arg Val Ala Asp His Thr Asp Val Val Thr  
 225 230 235 240  
 Met Ala Arg Leu Met Leu Val Gly Gly His Glu Thr Thr Ala Asn Met  
 245 250 255  
 30 Ile Ala Leu Gly Val Leu Ala Leu Leu Arg His Pro Glu Gln Met Ala  
 260 265 270  
 Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Asn Ala Val Glu Glu Leu  
 275 280 285  
 Leu Arg Val Phe Ser Ile Ser Asp Ser Gly Thr Ala Arg Val Ala Val  
 290 295 300  
 35 Ala Asp Ile Glu Val Gly Asp Val Thr Ile Arg Ala Gly Glu Gly Ile  
 305 310 315 320  
 Leu Ala Leu Asn Asn Ala Ala Asp His Asp Glu Ser Val Phe Pro Asp  
 325 330 335  
 Pro Asp Thr Leu Asp Ile His Arg Lys Glu Ala Arg Ser His Leu Ala  
 340 345 350  
 40 Phe Gly Tyr Gly Val His Gln Cys Ile Gly Ala Asn Leu Ala Arg Ala  
 355 360 365  
 Glu Leu Glu Ala Val Tyr Gly Thr Leu Leu Arg Arg Val Pro Gly Leu  
 370 375 380  
 Arg Leu Ala Ala Glu Pro Glu Asp Leu Arg Phe Lys Asp Asp Ala Met  
 385 390 395 400  
 45 Val Tyr Gly Val Tyr Glu Leu Pro Val Thr Trp  
 405 410

<210> 109

<211> 1236

<212> DNA

<213> Streptomyces achromogenes IFO 12735

<220>

<221> CDS

<222> (1)..(1236)

**EP 1 457 558 A1**

[illegible]

EP 1 457 558 A1

	atc gcc ctc ggg gtg ctg gcc ctg ctg cgg cac ccg gag cag atg gcc	816
	Ile Ala Leu Gly Val Leu Ala Leu Leu Arg His Pro Glu Gln Met Ala	
	260 265 270	
5	gag ttg cgg gcc gat ccg gcc ctg ctg ccg aac gcc gtg gag gag ttg	864
	Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Asn Ala Val Glu Glu Leu	
	275 280 285	
10	ctg cgc gtc ttc tcc atc tcc gac tcc ggc acc gcc cgg gtc gcg gtg	912
	Leu Arg Val Phe Ser Ile Ser Asp Ser Gly Thr Ala Arg Val Ala Val	
	290 295 300	
15	gcg gac atc gag gtc ggt gac gtc acc atc cgc gcg ggt gag ggc atc	960
	Ala Asp Ile Glu Val Gly Asp Val Thr Ile Arg Ala Gly Glu Gly Ile	
	305 310 315 320	
	ctc gcc ctg aac aac gcg gcc gac cac gac gag tgc gtc ttc ccg gac	1008
	Leu Ala Leu Asn Asn Ala Ala Asp His Asp Glu Ser Val Phe Pro Asp	
	325 330 335	
20	ccg gac acc ctc gac atc cac cgc aag gag gcc cgc tcc cac ctg gcc	1056
	Pro Asp Thr Leu Asp Ile His Arg Lys Glu Ala Arg Ser His Leu Ala	
	340 345 350	
25	ttc ggc tac ggc gtc cac cag tgc atc ggc gcc aac ctc gcc cgg gcg	1104
	Phe Gly Tyr Gly Val His Gln Cys Ile Gly Ala Asn Leu Ala Arg Ala	
	355 360 365	
	gag ctg gag gcg gtc tac ggc acg ctg ctg cgc cgc gtc ccc ggc ctg	1152
	Glu Leu Glu Ala Val Tyr Gly Thr Leu Leu Arg Arg Val Pro Gly Leu	
	370 375 380	
30	cgg ctg gcc gcc gag ccg gag gac ctg cgg ttc aag gac gac gcc atg	1200
	Arg Leu Ala Ala Glu Pro Glu Asp Leu Arg Phe Lys Asp Asp Ala Met	
	385 390 395 400	
35	gtc tac ggc gtc tac gaa ctc ccc gtc acc tgg tga	1236
	Val Tyr Gly Val Tyr Glu Leu Pro Val Thr Trp	
	405 410	
	<210> 110	
	<211> 1454	
	<212> DNA	
	<213> Streptomyces achromogenes IFO 12735	
40	<220>	
	<221> CDS	
	<222> (1)..(1236)	
45	<220>	
	<221> CDS	
	<222> (1263)..(1454)	
	<400> 110	
50	atg acc cag tcc gcc gac gcc gta ccc gag gcg gaa gca ccg ccg gtg	48
	Met Thr Gln Ser Ala Asp Ala Val Pro Glu Ala Glu Ala Pro Pro Val	
	1 5 10 15	
	cag ttc ccc ctg cgg cgc acc tgt ccg ttc gcc gag ccg ccc gag tac	96
	Gln Phe Pro Leu Arg Arg Thr Cys Pro Phe Ala Glu Pro Pro Glu Tyr	
	20 25 30	
55	gcc ggg ctg cgc gcc gac aca ccc gtc gcc cgc gcc gcc ctg aaa gtg	144

EP 1 457 558 A1

	Ala	Gly	Leu	Arg	Ala	Asp	Thr	Pro	Val	Ala	Arg	Ala	Ala	Leu	Lys	Val	
			35					40					45				
5	aac	ggc	aag	ccg	gcc	tgg	ctg	gtc	acc	cgg	cac	gag	cac	gtc	cgg	cag	192
	Asn	Gly	Lys	Pro	Ala	Trp	Leu	Val	Thr	Arg	His	Glu	His	Val	Arg	Gln	
		50					55					60					
	gtg	ctg	ggc	gac	agc	cgg	gtc	agc	tcc	aac	ctc	aaa	ctg	ccg	ggc	tat	240
10	Val	Leu	Gly	Asp	Ser	Arg	Val	Ser	Ser	Asn	Leu	Lys	Leu	Pro	Gly	Tyr	
	65					70					75					80	
	ccc	cac	cag	ttc	cac	atc	ccc	gag	gaa	ctg	ctg	gcg	cag	gtc	cgg	ctg	288
	Pro	His	Gln	Phe	His	Ile	Pro	Glu	Glu	Leu	Leu	Ala	Gln	Val	Arg	Leu	
					85					90					95		
15	atg	atg	ctg	aac	atg	gac	ccg	ccg	gaa	cac	acc	gcc	cac	cgg	cgc	atg	336
	Met	Met	Leu	Asn	Met	Asp	Pro	Pro	Glu	His	Thr	Ala	His	Arg	Arg	Met	
				100					105					110			
	ctg	ata	ccg	gag	ttc	acg	gcc	cgc	cgg	gtg	cgg	gag	ttg	cgc	ccg	cgg	384
20	Leu	Ile	Pro	Glu	Phe	Thr	Ala	Arg	Arg	Val	Arg	Glu	Leu	Arg	Pro	Arg	
			115					120					125				
	atc	cag	cag	atc	gtg	gac	gag	cac	gtg	gac	gcg	atg	ctg	gcc	gcg	ggc	432
	Ile	Gln	Gln	Ile	Val	Asp	Glu	His	Val	Asp	Ala	Met	Leu	Ala	Ala	Gly	
		130					135					140					
25	ggc	ccg	gtg	gac	ctg	gtc	acc	gcc	ctc	gcg	ctg	ccg	gtg	ccc	tcg	ctg	480
	Gly	Pro	Val	Asp	Leu	Val	Thr	Ala	Leu	Ala	Leu	Pro	Val	Pro	Ser	Leu	
		145				150					155					160	
	gtg	atc	tgc	gaa	ctg	ctc	ggc	gtg	ccc	tac	gag	gac	cac	gcg	cgg	ttc	528
30	Val	Ile	Cys	Glu	Leu	Leu	Gly	Val	Pro	Tyr	Glu	Asp	His	Ala	Arg	Phe	
				165						170					175		
	gag	gag	tgg	tcg	gcg	gcg	ctg	atg	aac	cac	gat	ctg	agc	ccg	cag	gag	576
	Glu	Glu	Trp	Ser	Ala	Ala	Leu	Met	Asn	His	Asp	Leu	Ser	Pro	Gln	Glu	
				180					185					190			
35	tac	ggg	gcg	gcc	gtg	cag	gcc	ctg	gac	acg	tac	ctc	gac	cag	ctc	gtc	624
	Tyr	Gly	Ala	Ala	Val	Gln	Ala	Leu	Asp	Thr	Tyr	Leu	Asp	Gln	Leu	Val	
			195					200					205				
	acc	ctg	aag	gag	aac	gag	ccg	ggc	gac	gac	ctc	atc	agc	cgc	ttc	ctg	672
40	Thr	Leu	Lys	Glu	Asn	Glu	Pro	Gly	Asp	Asp	Leu	Ile	Ser	Arg	Phe	Leu	
		210					215					220					
	gag	aag	aac	cgc	acc	gag	cgg	gtc	gcc	gac	cac	acc	gat	gtg	gtg	acg	720
	Glu	Lys	Asn	Arg	Thr	Glu	Arg	Val	Ala	Asp	His	Thr	Asp	Val	Val	Thr	
		225				230					235					240	
45	atg	gcc	cgg	ctg	atg	ctg	gtc	ggc	ggc	cac	gag	acc	acc	gcc	aac	atg	768
	Met	Ala	Arg	Leu	Met	Leu	Val	Gly	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	
				245						250					255		
	atc	gcc	ctc	ggg	gtg	ctg	gcc	ctg	ctg	cgg	cac	ccg	gag	cag	atg	gcc	816
50	Ile	Ala	Leu	Gly	Val	Leu	Ala	Leu	Leu	Arg	His	Pro	Glu	Gln	Met	Ala	
				260					265					270			
	gag	ttg	cgg	gcc	gat	ccg	gcc	ctg	ctg	ccg	aac	gcc	gtg	gag	gag	ttg	864
	Glu	Leu	Arg	Ala	Asp	Pro	Ala	Leu	Leu	Pro	Asn	Ala	Val	Glu	Glu	Leu	
			275				280						285				
55	ctg	cgc	gtc	ttc	tcc	atc	tcc	gac	tcc	ggc	acc	gcc	cgg	gtc	gcg	gtg	912

EP 1 457 558 A1

	Leu	Arg	Val	Phe	Ser	Ile	Ser	Asp	Ser	Gly	Thr	Ala	Arg	Val	Ala	Val	
	290						295					300					
5	gcg	gac	atc	gag	gtc	ggg	gac	gtc	acc	atc	cgc	gcg	ggg	gag	ggc	atc	960
	Ala	Asp	Ile	Glu	Val	Gly	Asp	Val	Thr	Ile	Arg	Ala	Gly	Glu	Gly	Ile	
	305					310					315					320	
10	ctc	gcc	ctg	aac	aac	gag	gcc	gac	cac	gac	gag	tcg	gtc	ttc	ccg	gac	1008
	Leu	Ala	Leu	Asn	Asn	Ala	Ala	Asp	His	Asp	Glu	Ser	Val	Phe	Pro	Asp	
					325					330					335		
	ccg	gac	acc	ctc	gac	atc	cac	cgc	aag	gag	gcc	cgc	tcc	cac	ctg	gcc	1056
	Pro	Asp	Thr	Leu	Asp	Ile	His	Arg	Lys	Glu	Ala	Arg	Ser	His	Leu	Ala	
				340					345					350			
15	ttc	ggc	tac	ggc	gtc	cac	cag	tgc	atc	ggc	gcc	aac	ctc	gcc	cgg	gcg	1104
	Phe	Gly	Tyr	Gly	Val	His	Gln	Cys	Ile	Gly	Ala	Asn	Leu	Ala	Arg	Ala	
			355					360					365				
20	gag	ctg	gag	gcg	gtc	tac	ggc	acg	ctg	ctg	cgc	cgc	gtc	ccc	ggc	ctg	1152
	Glu	Leu	Glu	Ala	Val	Tyr	Gly	Thr	Leu	Leu	Arg	Arg	Val	Pro	Gly	Leu	
		370					375					380					
	cgg	ctg	gcc	gcc	gag	cgc	gag	gac	ctg	cgc	ttc	aag	gac	gac	gcc	atg	1200
	Arg	Leu	Ala	Ala	Glu	Pro	Glu	Asp	Leu	Arg	Phe	Lys	Asp	Asp	Ala	Met	
	385					390					395					400	
25	gtc	tac	ggc	gtc	tac	gaa	ctc	ccc	gtc	acc	tgg	tga	cgcccgacgc	gaacgg			1252
	Val	Tyr	Gly	Val	Tyr	Glu	Leu	Pro	Val	Thr	Trp						
					405					410							
30	actgcccctg	atg	cgt	gtc	tcc	gcc	gaa	cgc	gac	cgc	tgc	gtg	ggc	tcc			1301
		Met	Arg	Val	Ser	Ala	Glu	Arg	Asp	Arg	Cys	Val	Gly	Ser			
		1				5					10						
	ggc	cag	tgc	gcg	ctg	ctg	agc	ccc	gag	gtg	ttc	gac	cag	gac	gcc	gac	1349
	Gly	Gln	Cys	Ala	Leu	Leu	Ser	Pro	Glu	Val	Phe	Asp	Gln	Asp	Ala	Asp	
		15					20					25					
35	ggc	ctg	gtc	acc	ctg	ctg	agc	gag	gag	ccg	gcc	gag	gag	ctg	cgc	gag	1397
	Gly	Leu	Val	Thr	Leu	Leu	Ser	Glu	Glu	Pro	Ala	Glu	Glu	Leu	Arg	Glu	
		30				35					40					45	
40	cag	gtc	gct	cag	gcc	gcg	gac	ctg	tgc	ccg	tcc	cgc	tcg	atc	cgc	gtg	1445
	Gln	Val	Ala	Gln	Ala	Ala	Asp	Leu	Cys	Pro	Ser	Arg	Ser	Ile	Arg	Val	
					50					55					60		
	cac	gac	tga														1454
	His	Asp															
45	<210>	111															
	<211>	63															
	<212>	PRT															
	<213>	Streptomyces achromogenes IFO 12735															
	<400>	111															
50	Met	Arg	Val	Ser	Ala	Glu	Arg	Asp	Arg	Cys	Val	Gly	Ser	Gly	Gln	Cys	
	1				5					10					15		
	Ala	Leu	Leu	Ser	Pro	Glu	Val	Phe	Asp	Gln	Asp	Ala	Asp	Gly	Leu	Val	
				20					25					30			
	Thr	Leu	Leu	Ser	Glu	Glu	Pro	Ala	Glu	Glu	Leu	Arg	Glu	Gln	Val	Ala	
			35					40					45				
55	Gln	Ala	Ala	Asp	Leu	Cys	Pro	Ser	Arg	Ser	Ile	Arg	Val	His	Asp		
		50					55					60					

5 <210> 112  
 <211> 192  
 <212> DNA  
 <213> Streptomyces achromogenes IFO 12735  
  
 <220>  
 <221> CDS  
 10 <222> (1)..(192)  
  
 <400> 112  
 atg cgt gtc tcc gcc gaa cgc gac cgg tgc gtg ggc tcc ggc cag tgc 48  
 Met Arg Val Ser Ala Glu Arg Asp Arg Cys Val Gly Ser Gly Gln Cys  
 1 5 10 15  
 15 gcg ctg ctg agc ccc gag gtg ttc gac cag gac gcc gac ggc ctg gtc 96  
 Ala Leu Leu Ser Pro Glu Val Phe Asp Gln Asp Ala Asp Gly Leu Val  
 20 25 30  
 acc ctg ctg agc gag gag ccg gcc gag gag ctg cgc gag cag gtc gct 144  
 Thr Leu Leu Ser Glu Glu Pro Ala Glu Glu Leu Arg Glu Gln Val Ala  
 35 40 45  
 cag gcc gcg gac ctg tgc ccg tcc cgc tgc atc cgc gtg cac gac tga 192  
 Gln Ala Ala Asp Leu Cys Pro Ser Arg Ser Ile Arg Val His Asp  
 50 55 60  
 25 <210> 113  
 <211> 20  
 <212> PRT  
 <213> Streptomyces achromogenes IFO 12735  
  
 30 <400> 113  
 Met Thr Gln Ser Ala Asp Ala Val Pro Glu Ala Glu Ala Pro Pro Val  
 1 5 10 15  
 Gln Phe Pro Leu  
 20  
 35 <210> 114  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 40 <223> Designed oligonucleotide primer for PCR  
  
 <400> 114  
 gacgcsgtsc csgaggcsga agc 23  
  
 45 <210> 115  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 50 <400> 115  
 gaggcscsc csgtscagtt ccc 23  
  
 <210> 116  
 <211> 25  
 55 <212> DNA  
 <213> Artificial Sequence

	<220>	
5	<223> Designed oligonucleotide primer for PCR	
	<400> 116	
	tcggcgaacg gacaggtgcg ccgca	25
	<210> 117	
	<211> 27	
10	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
15	<400> 117	
	ccctcgctgg tgatctgcga actgctc	27
	<210> 118	
	<211> 27	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
25	<400> 118	
	agctcgtcac cctgaaggag aacgagc	27
	<210> 119	
	<211> 28	
	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
35	<400> 119	
	accatatgac ccagtccgcc gacgccgt	28
	<210> 120	
	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 120	
	gtaagctttc accaggtgac ggggagtt	28
45	<210> 121	
	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 121	
	cgaagctttc agtcgtgcac gcggatcg	28
55	<210> 122	
	<211> 27	

	<212> DNA	
5	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 122	
10	ttcctggaga agaaccgcac cgagcgg	27
	<210> 123	
	<211> 26	
	<212> DNA	
	<213> Artificial Sequence	
15	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 123	
	cacccggagc agatggccga gttgcg	26
20	<210> 124	
	<211> 26	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
25	<223> Designed oligonucleotide primer for PCR	
	<400> 124	
	tgmtcggcvt sgacgacccc gagcac	26
30	<210> 125	
	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Designed oligonucleotide primer for PCR	
	<400> 125	
	cgctgccsgt gccstcsatg gtgatctg	28
	<210> 126	
40	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
45	<223> Designed oligonucleotide primer for PCR	
	<400> 126	
	cgctgccggt gccgtcsctg gtgatctg	28
	<210> 127	
50	<211> 30	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
55	<223> Designed oligonucleotide primer for PCR	
	<400> 127	
	ggcgtscctt acgccgacca cgagttcttc	30

5 <210> 128  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 10 <400> 128  
 ggcgtscctt acgaggacca cgssttcttc 30  
  
 <210> 129  
 <211> 28  
 <212> DNA  
 15 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 20 <400> 129  
 aggacttgtt gsacscggaa sccgaagg 28  
  
 <210> 130  
 <211> 30  
 <212> DNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 30 <400> 130  
 cttccccag gaccgcacct gcccttcca 30  
  
 <210> 131  
 <211> 30  
 <212> DNA  
 35 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 40 <400> 131  
 ggatcgtggc cagcgagatg gcctcctgcc 30  
  
 <210> 132  
 <211> 30  
 <212> DNA  
 45 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 50 <400> 132  
 tttccaggac cgcacctgcc cctaccaccc 30  
  
 <210> 133  
 <211> 30  
 <212> DNA  
 55 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 133

ggatcatcgc gagccggacc agatcctcgc 30

5 <210> 134  
 <211> 72  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Designed oligonucleotide linker for construction of expression vector

<400> 134  
 agctatTTTT taataaaatc aggaggaaaa aacatatgag caagcttggc tgttttggcg 60  
 gatgagagaa ga 72

15 <210> 135  
 <211> 68  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <223> Designed oligonucleotide linker for construction of expression vector

<400> 135  
 tcttctctca tccgccaaaa cagccaagct tgctcatatg ttttttcttc ctgattttat 60  
 taaaaaat 68

25 <210> 136  
 <211> 402  
 <212> PRT  
 <213> Streptomyces thermocoerulescens IFO 14273t

30 <400> 136  
 Met Thr Asp Met Thr Glu Thr Pro Thr Val Ala Phe Pro Gln Ser Arg  
 1 5 10 15  
 Thr Cys Pro Tyr His Pro Pro Ala Ala Tyr Ala Pro Leu Arg Asp Thr  
 20 25 30  
 Arg Pro Leu Ala Arg Ala Arg Leu Tyr Asp Gly Arg Leu Val Trp Thr  
 35 40 45  
 Val Thr Gly His Gly Leu Ala Arg Thr Leu Leu Ala Asp Pro Arg Leu  
 50 55 60  
 Ser Thr Asp Pro Thr Arg Pro Glu Phe Pro Ala Thr Thr Glu Arg Ile  
 65 70 75 80  
 Ala Arg Ile Arg Arg Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro  
 85 90 95  
 40 Glu His Arg Val Gln Arg Arg Met Met Val Pro Ser Phe Thr Leu Gln  
 100 105 110  
 Arg Ala Thr Ala Leu Arg Pro Arg Ile Gln Arg Val Val Asp Glu Arg  
 115 120 125  
 Leu Asp Ala Met Ile Ala Gly Gly Pro Pro Ala Asp Leu Val Thr Ala  
 130 135 140  
 45 Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val  
 145 150 155 160  
 Pro Tyr Glu Asp His Asp Phe Phe Glu Glu Gln Ser Arg Arg Leu Leu  
 165 170 175  
 Arg Gly Pro Thr Ala Glu Asp Ser Met Asp Ala Arg Ala Arg Met Glu  
 180 185 190  
 50 Ala Tyr Phe Asp Glu Leu Ile Asp Arg Lys Gln Arg Gln Asp Ala Pro  
 195 200 205  
 Gly Asp Gly Val Leu Asp Glu Leu Val His Gln Arg Leu Ala Ala Gly  
 210 215 220  
 Glu Leu Asp Arg Glu Gly Leu Ile Ala Met Ala Ile Ile Leu Leu Val  
 225 230 235 240  
 55 Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr  
 245 250 255

Leu Leu Gly His Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Asp  
 260 265 270  
 5 Leu Val Pro Ala Ala Val Glu Glu Leu Leu Arg Met Leu Ser Ile Ala  
 275 280 285  
 Asp Gly Leu Leu Arg Val Ala Val Glu Asp Ile Glu Val Ala Gly Glu  
 290 295 300  
 Thr Ile Arg Ala Gly Asp Gly Val Ile Phe Ser Thr Ser Val Ile Asn  
 305 310 315 320  
 10 Arg Asp Glu Ala Val Tyr Pro Glu Pro Asp Thr Leu Asp Leu His Arg  
 325 330 335  
 Pro Ala Arg His His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu  
 340 345 350  
 Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu Arg Thr Leu  
 355 360 365  
 15 Phe Gly Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Pro Glu Glu Ile  
 370 375 380  
 Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val  
 385 390 395 400  
 Thr Trp  
  
 20 <210> 137  
 <211> 409  
 <212> PRT  
 <213> Streptomyces glomerochromogenes IFO 13673T  
  
 <400> 137  
 25 Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Gly Gln Ala Gln Pro  
 1 5 10 15  
 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
 20 25 30  
 Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
 35 40 45  
 30 Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Ala  
 50 55 60  
 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Asp Gly Phe  
 65 70 75 80  
 Pro Val Pro Ser Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Leu Ala  
 85 90 95  
 35 Leu Leu Gly Leu Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu  
 100 105 110  
 Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
 115 120 125  
 Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro  
 130 135 140  
 40 Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155 160  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 165 170 175  
 Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu  
 180 185 190  
 45 Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala  
 195 200 205  
 Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Val Leu Asp Asp Leu Val  
 210 215 220  
 His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser  
 225 230 235 240  
 50 Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met  
 245 250 255  
 Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala  
 260 265 270  
 Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu  
 275 280 285  
 55 Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Leu Ala Leu Glu  
 290 295 300

EP 1 457 558 A1

5 Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu  
 305 310 315 320  
 Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro  
 325 330 335  
 Asp Asp Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly  
 340 345 350  
 Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu  
 355 360 365  
 10 Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu  
 370 375 380  
 Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln  
 385 390 395 400  
 Gly Met Leu Glu Leu Pro Val Thr Trp  
 405

<210> 138  
 <211> 409  
 <212> PRT  
 <213> Streptomyces olivochromogenes IFO 12444

20 <400> 138  
 Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Gly Gln Ala Glu Pro  
 1 5 10 15  
 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
 20 25 30  
 25 Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
 35 40 45  
 Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Ala  
 50 55 60  
 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe  
 65 70 75 80  
 30 Pro Val Pro Ser Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Leu Ala  
 85 90 95  
 Leu Leu Gly Leu Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu  
 100 105 110  
 Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
 115 120 125  
 35 Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro  
 130 135 140  
 Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155 160  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 165 170 175  
 40 Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu  
 180 185 190  
 Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala  
 195 200 205  
 Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val  
 210 215 220  
 45 His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser  
 225 230 235 240  
 Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met  
 245 250 255  
 Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala  
 260 265 270  
 50 Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu  
 275 280 285  
 Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu  
 290 295 300  
 Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu  
 305 310 315 320  
 Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro  
 325 330 335  
 55 Asp Gly Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly

EP 1 457 558 A1

340 345 350  
 Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu  
 355 360 365  
 5 Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu  
 370 375 380  
 Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln  
 385 390 395 400  
 Gly Met Leu Glu Leu Pro Val Thr Trp  
 405  
 10  
 <210> 139  
 <211> 1230  
 <212> DNA  
 <213> Streptomyces nogalater IFO 13445  
 15  
 <220>  
 <221> CDS  
 <222> (1)..(1230)  
 <400> 139  
 20 atg acg gaa ctg acg gac acc acc ggc ccg gcc gac gcg gcc gaa ccc 48  
 Met Thr Glu Leu Thr Asp Thr Thr Gly Pro Ala Asp Ala Ala Glu Pro  
 1 5 10 15  
 gtc gca ttc ccc cag gac cgc acc tgc ccc tac cac ccc ccg acc ggc 96  
 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
 25 20 25 30  
 tac gac ccg ctg cgc gac ggg cgg ccc ctg tcc cgg gtc acc ctc tac 144  
 Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
 35 40 45  
 30 gac ggc cgt gag gtc tgg ctg gtc acc gcg cag gcc acc gcc cgc acc 192  
 Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Thr  
 50 55 60  
 ctg ctc gcc gac ccc cgg ctg tcc acc gac cgc cgc cgc gac ggc ttc 240  
 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe  
 35 65 70 75 80  
 ccc gtg ccc acc ccc cgc ttc gag ggc gga cgc gac cgc aag ctg gcc 288  
 Pro Val Pro Thr Pro Arg Phe Glu Gly Gly Arg Asp Arg Lys Leu Ala  
 85 90 95  
 40 ctg ctc gga ctg gac gac ccc gag cac cag cag cag cgc cgg atg ctg 336  
 Leu Leu Gly Leu Asp Asp Pro Glu His Gln Gln Gln Arg Arg Met Leu  
 100 105 110  
 atc ccg tcg ttc acc gtg aaa cgc gcc acc gcg cta cgc ccc tgg atc 384  
 Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
 45 115 120 125  
 cag cgg atc gtc gac gga ctg ctg gac gcc atg atc acc cgg ggg ccg 432  
 Gln Arg Ile Val Asp Gly Leu Leu Asp Ala Met Ile Thr Arg Gly Pro  
 130 135 140  
 50 gtc gcc gac ctc gtg tcc gcc ttc gcg ctg ccc gtg ccg tcc atg gtc 480  
 Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155 160  
 atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag 528  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 55 165 170 175

EP 1 457 558 A1

5	gag cag tcc cgc cga ctg ctg agc gcc tcg acc agc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Ser Ala Ser Thr Ser Ala Asp Thr Leu 180 185 190	576
	gac gcc cgg gac cgg ctg gag acg tac ctc ggc gac ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Thr Tyr Leu Gly Asp Leu Ile Asp Ala 195 200 205	624
10	aag gcc aag gag gcc gag ccc ggc gac ggc atc ctg gac gag ctc gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Glu Leu Val 210 215 220	672
15	cac aac cgg ctc cgc aag ggc gag ctg gac cgg acc gac ctg gtg tcg His Asn Arg Leu Arg Lys Gly Glu Leu Asp Arg Thr Asp Leu Val Ser 225 230 235 240	720
	ctc gcc gtc atc ctg ctg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255	768
20	atc tcc ctg ggc acc tac acg ctg ctc cag cac ccc gag cgc ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala 260 265 270	816
25	gag ctg cgc gcc gac ccc gcg ctg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu 275 280 285	864
	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300	912
30	gac atc gag atc gac ggc acc acc atc cgg gcc ggc gac ggc gtc ctc Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320	960
35	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccg Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335	1008
	gac gac ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Asp Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350	1056
40	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcc cgc gcg gaa ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365	1104
45	gag atc gct ctc ggc agc ctg ttc acc cgc ttg ccc ggg ctc cgt ctg Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380	1152
	gcc gta ccg gcg aag gac att ccc ttc aaa ccg ggc gac acg atc cag Ala Val Pro Ala Lys Asp Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400	1200
50	ggg atg ctg gaa ctc ccc gtg acc tgg taa Gly Met Leu Glu Leu Pro Val Thr Trp 405 410	1230
55	<p>&lt;210&gt; 140</p> <p>&lt;211&gt; 1278</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Streptomyces tsusimaensis IFO 13782T</p>	

EP 1 457 558 A1

5 <220>  
 <221> CDS  
 <222> (1)..(1278)  
  
 <400> 140  
 atg acg gaa tcc acg aca gat ccg acg acc cgc cag gcc ctc ggc tcc 48  
 Met Thr Glu Ser Thr Thr Asp Pro Thr Thr Arg Gln Ala Leu Gly Ser  
 1 5 10 15  
 acc acc ccc gcc gct gcc acc gcg acc gcc atc gac ccg acc ctc gcg 96  
 Thr Thr Pro Ala Ala Ala Thr Ala Thr Ala Ile Asp Pro Thr Leu Ala  
 20 25 30  
 15 aca ccc ttc ccg cag gac ccg ggg tgc ccg tac cac ccg ccc gcc ggg 144  
 Thr Pro Phe Pro Gln Asp Arg Gly Cys Pro Tyr His Pro Pro Ala Gly  
 35 40 45  
 20 tac gcg ccg ctg cgt gag ggc cga ccg ctc agc agg gtc gcc ctc ttc 192  
 Tyr Ala Pro Leu Arg Glu Gly Arg Pro Leu Ser Arg Val Ala Leu Phe  
 50 55 60  
 gac ggg cgc ccg gtc tgg gcg gtc acc gga cac gcc ctg gcc cgc ccg 240  
 Asp Gly Arg Pro Val Trp Ala Val Thr Gly His Ala Leu Ala Arg Arg  
 65 70 75 80  
 25 ttg ctg gcc gat cca ccg ctc tcc acc gac cgt acc cac ccg gac ttc 288  
 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Thr His Pro Asp Phe  
 85 90 95  
 ccc gcc ccg gcc ccg cgc ttc gcc aac gcg aac ccg cgc cgc gtg gcc 336  
 Pro Ala Pro Ala Pro Arg Phe Ala Asn Ala Asn Arg Arg Arg Val Ala  
 100 105 110  
 30 ctg ctc ggc gtc gac gac ccc gag cac aac acc cag cgc aga atg ctc 384  
 Leu Leu Gly Val Asp Asp Pro Glu His Asn Thr Gln Arg Arg Met Leu  
 115 120 125  
 35 atc ccg gcc ttc tcc gtg aag ccg atc aac gct ctc cgc ccc cgc atc 432  
 Ile Pro Ala Phe Ser Val Lys Arg Ile Asn Ala Leu Arg Pro Arg Ile  
 130 135 140  
 cag gag acc gtg gac ccg ttg ctc gac gcg atg gag cgc cag ggg cca 480  
 Gln Glu Thr Val Asp Arg Leu Leu Asp Ala Met Glu Arg Gln Gly Pro  
 145 150 155 160  
 ccg gcc gag ctg gtg agc gcg ttc gcc ctg ccg gtg ccg tcg atg gtg 528  
 Pro Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 165 170 175  
 45 atc tgc tcc ctg ctc gga gtg ccg tac gcc gac cac gag ttc ttc gag 576  
 Ile Cys Ser Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 180 185 190  
 gag cgc tcg ccg ccg ctc ctg cgc ggc ccc ggc gcg gcc gac gtg gac 624  
 Glu Arg Ser Arg Arg Leu Leu Arg Gly Pro Gly Ala Ala Asp Val Asp  
 195 200 205  
 50 agg gcc ctc gac gaa ctc gag gag tac ctc ggc gcg ctg atc gac cgc 672  
 Arg Ala Leu Asp Glu Leu Glu Glu Tyr Leu Gly Ala Leu Ile Asp Arg  
 210 215 220  
 55 aag cgt acg gaa ccg ggc gac ggc ctc ctc gac gag ctg atc cac cgc 720  
 Lys Arg Thr Glu Pro Gly Asp Gly Leu Leu Asp Glu Leu Ile His Arg

EP 1 457 558 A1

	225	230	235	240	
5	gac cac ccc ggc gga ccg gtc gac cgc gag gag ctg gtc tcg ttc gcc Asp His Pro Gly Gly Pro Val Asp Arg Glu Glu Leu Val Ser Phe Ala	245	250	255	768
10	gtg atc ctg ctc atc gcg ggg cac gag acg acg gcg aac atg atc tcg Val Ile Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser	260	265	270	816
15	ctc ggc acc ttc acc ctg ctg cgc cac ccc gaa cag ctc gcg gcg ctg Leu Gly Thr Phe Thr Leu Leu Arg His Pro Glu Gln Leu Ala Ala Leu	275	280	285	864
20	cgg gcc ggc ggg acg acc acg gcc gtg gcg gtc gag gaa ctg ttg cgg Arg Ala Gly Gly Thr Thr Thr Ala Val Ala Val Glu Glu Leu Leu Arg	290	295	300	912
25	ttc ctc tcc atc gcc gac ggc ctg cag cgg ctg gcg acc gag gac atc Phe Leu Ser Ile Ala Asp Gly Leu Gln Arg Leu Ala Thr Glu Asp Ile	305	310	315	960
30	gag gtg ccg gac gcc ggg gtg acg atc cgc aag ggc gaa ggt gtg gtc Glu Val Pro Asp Ala Gly Val Thr Ile Arg Lys Gly Glu Gly Val Val	325	330	335	1008
35	ttc tcg acc tcg ctc atc aac cgc gac gac ggc gtg ttc ccg cag ccc Phe Ser Thr Ser Leu Ile Asn Arg Asp Asp Gly Val Phe Pro Gln Pro	340	345	350	1056
40	gaa acg ctc gac tgg gac cgc ccg gcc cgt cac cat ctc gcc ttc ggc Glu Thr Leu Asp Trp Asp Arg Pro Ala Arg His His Leu Ala Phe Gly	355	360	365	1104
45	ttc ggc gta cac cag tgc ctg ggg cag aac ctg gcc cgc gcg gaa ctc Phe Gly Val His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu	370	375	380	1152
50	gac atc gcg atg cgc acg ctc ttc gag cgg ctg ccg ggc ctc cgg ctc Asp Ile Ala Met Arg Thr Leu Phe Glu Arg Leu Pro Gly Leu Arg Leu	385	390	395	1200
55	gcc gta ccc gcg cag gag atc ccc cat aaa ccg ggg gac acg atc cag Ala Val Pro Ala Gln Glu Ile Pro His Lys Pro Gly Asp Thr Ile Gln	405	410	415	1248
	ggc atg ctc gaa ctg ccc gtg gcc tgg tga Gly Met Leu Glu Leu Pro Val Ala Trp	420	425		1278
45	<210> 141 <211> 1209 <212> DNA <213> Streptomyces thermocoerulescens IFO 14273t				
50	<220> <221> CDS <222> (1)..(1209)				
55	<400> 141 atg acg gac atg acg gaa acc ccc acc gtc gcc ttt ccc cag agc cgg Met Thr Asp Met Thr Glu Thr Pro Thr Val Ala Phe Pro Gln Ser Arg				
	1	5	10	15	48

EP 1 457 558 A1

5	acc	tgt	ccg	tac	cac	ccg	ccc	gcc	gcc	tac	gcc	ccg	ctg	cgc	gac	acc	96
	Thr	Cys	Pro	Tyr	His	Pro	Pro	Ala	Ala	Tyr	Ala	Pro	Leu	Arg	Asp	Thr	
				20					25					30			
10	cgc	ccg	ctg	gcc	cgc	gcc	cgt	ctc	tac	gac	ggc	cgc	ctc	gtc	tgg	acg	144
	Arg	Pro	Leu	Ala	Arg	Ala	Arg	Leu	Tyr	Asp	Gly	Arg	Leu	Val	Trp	Thr	
			35					40					45				
15	gtc	acc	ggc	cac	ggc	ctc	gcc	cgc	acc	ctg	ctc	gcc	gac	ccc	cgc	ctg	192
	Val	Thr	Gly	His	Gly	Leu	Ala	Arg	Thr	Leu	Leu	Ala	Asp	Pro	Arg	Leu	
		50					55					60					
20	tcc	acc	gac	ccc	acc	cgg	ccg	gag	ttc	ccc	gcc	acc	acg	gaa	cgc	atc	240
	Ser	Thr	Asp	Pro	Thr	Arg	Pro	Glu	Phe	Pro	Ala	Thr	Thr	Glu	Arg	Ile	
	65					70				75						80	
25	gcc	cgg	atc	cgg	cgc	cgc	cgg	acc	gcc	ctg	ctg	ggc	gtc	gac	gac	ccc	288
	Ala	Arg	Ile	Arg	Arg	Arg	Arg	Thr	Ala	Leu	Leu	Gly	Val	Asp	Asp	Pro	
				85						90					95		
30	gaa	cac	cgc	gtc	cag	cgg	cgc	atg	atg	gtc	ccc	agc	ttc	acc	ctc	cag	336
	Glu	His	Arg	Val	Gln	Arg	Arg	Met	Met	Val	Pro	Ser	Phe	Thr	Leu	Gln	
				100				105						110			
35	cgc	gcc	acc	gcg	ctg	cgc	ccc	cgg	atc	cag	cgg	gtc	gtc	gac	gaa	cgc	384
	Arg	Ala	Thr	Ala	Leu	Arg	Pro	Arg	Ile	Gln	Arg	Val	Val	Asp	Glu	Arg	
			115				120						125				
40	ctc	gac	gcg	atg	atc	gcc	ggc	ggc	ccg	ccc	gcc	gat	ctc	gtc	acc	gcg	432
	Leu	Asp	Ala	Met	Ile	Ala	Gly	Gly	Pro	Pro	Ala	Asp	Leu	Val	Thr	Ala	
		130					135					140					
45	ttc	gcg	ctg	ccg	gtg	ccg	tcc	atg	gtg	atc	tgc	gcc	ctg	ctc	ggc	gtg	480
	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val	Ile	Cys	Ala	Leu	Leu	Gly	Val	
	145					150					155					160	
50	ccc	tac	gag	gac	cac	gac	ttc	ttc	gag	gag	cag	tca	cgc	cgg	ctg	ctg	528
	Pro	Tyr	Glu	Asp	His	Asp	Phe	Phe	Glu	Glu	Gln	Ser	Arg	Arg	Leu	Leu	
				165					170						175		
55	cgc	ggc	ccg	acg	gcc	gag	gac	tcc	atg	gac	gcc	cgc	gcc	cga	atg	gag	576
	Arg	Gly	Pro	Thr	Ala	Glu	Asp	Ser	Met	Asp	Ala	Arg	Ala	Arg	Met	Glu	
			180					185					190				
60	gcc	tac	ttc	gac	gag	ctg	atc	gac	cgc	aag	cag	cgg	cag	gac	gcg	ccc	624
	Ala	Tyr	Phe	Asp	Glu	Leu	Ile	Asp	Arg	Lys	Gln	Arg	Gln	Asp	Ala	Pro	
			195				200						205				
65	ggc	gac	ggc	gtc	ctg	gac	gaa	ctc	gtc	cac	cag	cgg	ctg	gcc	gcg	ggc	672
	Gly	Asp	Gly	Val	Leu	Asp	Glu	Leu	Val	His	Gln	Arg	Leu	Ala	Ala	Gly	
		210					215					220					
70	gag	ctg	gac	cgc	gag	ggg	ctc	atc	gcc	atg	gcg	atc	atc	ctg	ctc	gtc	720
	Glu	Leu	Asp	Arg	Glu	Gly	Leu	Ile	Ala	Met	Ala	Ile	Ile	Leu	Leu	Val	
	225					230					235					240	
75	gcc	ggc	cac	gag	acg	acc	gcc	aac	atg	atc	tgc	ctc	ggc	acc	ttc	acg	768
	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	Ile	Ser	Leu	Gly	Thr	Phe	Thr	
				245					250						255		
80	ctg	ctc	ggg	cac	ccc	gag	cgg	ctg	gcc	gag	ctg	cgc	gcc	gac	ccg	gac	816
	Leu	Leu	Gly	His	Pro	Glu	Arg	Leu	Ala	Glu	Leu	Arg	Ala	Asp	Pro	Asp	
				260					265					270			

EP 1 457 558 A1

5	ctg gtg ccc gcg gcc gtc gag gag ctg ctg cgc atg ctg tcc atc gcg Leu Val Pro Ala Ala Val Glu Glu Leu Leu Arg Met Leu Ser Ile Ala 275 280 285	864
	gac ggc ctg ctg cgc gtc gcc gtc gag gac atc gag gtg gcc ggg gag Asp Gly Leu Leu Arg Val Ala Val Glu Asp Ile Glu Val Ala Gly Glu 290 295 300	912
10	acg atc cgc gcg ggc gac ggc gtc atc ttc tgc acg tgc gtc atc aac Thr Ile Arg Ala Gly Asp Gly Val Ile Phe Ser Thr Ser Val Ile Asn 305 310 315 320	960
15	cgg gac gag gcc gtc tac ccc gaa ccc gac acc ctg gac ctg cac cgc Arg Asp Glu Ala Val Tyr Pro Glu Pro Asp Thr Leu Asp Leu His Arg 325 330 335	1008
	ccg gcc cgg cac cac gtc gcc ttc ggg ttc ggc atc cac cag tgc ctc Pro Ala Arg His His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu 340 345 350	1056
20	ggg cag aac ctg gcc cgc gcc gag atg gag atc gcc ctg cgc acc ctg Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu Arg Thr Leu 355 360 365	1104
25	ttc ggc cgc ctg ccc gga ctg cgt ctg gcg gtc ccc ccg gag gaa atc Phe Gly Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Pro Glu Glu Ile 370 375 380	1152
	ccg ttc aaa ccc ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val 385 390 395 400	1200
30	acc tgg taa Thr Trp	1209
35	<210> 142 <211> 1230 <212> DNA <213> Streptomyces glomerochromogenes IFO 13673T	
40	<220> <221> CDS <222> (1)..(1230)	
	<400> 142 atg acg gaa ctg acg gac atc acc ggc ccg gct ggc cag gcc caa ccc Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Gly Gln Ala Gln Pro 1 5 10 15	48
45	gtc gca ttc ccc cag gac cgc acc tgt ccc tac cac ccc ccc acc gga Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly 20 25 30	96
50	tac gac ccg ctg cgc gac ggg cga ccc ctg tcc cgc gtc acc ctc tac Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr 35 40 45	144
	gac ggc cgc gag gtc tgg ctg gtc acc gcc cag gcc acc gcc cgc gcc Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Ala 50 55 60	192
55	ctg ctc gcc gac ccc cgg ctg tcc acc gac cgc cgc cgc gac ggc ttt Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe	240

EP 1 457 558 A1

	65	70	75	80	
5	ccc gtg ccc agc ccc cgc ttc gag gcc ggc cgc gac cgc aaa ctg gcc Pro Val Pro Ser Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Leu Ala	85	90	95	288
10	ctg ctc ggg ctg gac gac ccc gag cac cac cag cag cgc cgg atg ctg Leu Leu Gly Leu Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu	100	105	110	336
15	atc ccg tcg ttc acc gtc aaa cgc gcc acc ggc cta cgc ccc tgg atc Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile	115	120	125	384
20	cag cgg atc gtc gac gaa ctg ctg gac gac atg atc gcc cgg ggg ccg Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro	130	135	140	432
25	gtc gcc gac ctc gtg tcc gcg ttc gcg ctg ccc gtg ccg tcc atg gtc Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val	145	150	155	480
30	atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu	165	170	175	528
35	gaa cag tcc cgc cgg ctg ctg cgc ggc ccg ggc ggc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu	180	185	190	576
40	gac gcc cgg gac cgg ctg gag gcg tac ctc ggc gag ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala	195	200	205	624
45	aag gcc aag gag gcc gag ccc ggc gac ggc gtt ctg gac gac ctg gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Val Leu Asp Asp Leu Val	210	215	220	672
50	cac aac cgg ctc cgc gcg ggc gag ctg gac cgg acc gac ctg gtg tcg His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser	225	230	235	720
55	ctc gcc ctc atc ctg ctg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met	245	250	255	768
60	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gaa cgg ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala	260	265	270	816
65	gag ctg cgt gcc gac ccc acg gtg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu	275	280	285	864
70	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg ctg gcg ctg gag Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Leu Ala Leu Glu	290	295	300	912
75	gac atc gag atc gac ggc acc acc atc cgg gcc ggt gac ggc gtc ctc Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu	305	310	315	960
80	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro				1008

**EP 1 457 558 A1**

5	gac	gac	ctg	gac	ttc	cac	cgc	gcc	gac	cgg	cac	cac	gtg	gcg	ttc	ggc	1056
	Asp	Asp	Leu	Asp	Phe	His	Arg	Ala	Asp	Arg	His	His	Val	Ala	Phe	Gly	
				340					345					350			
10	ttc	ggc	atc	cac	cag	tgc	ctg	ggc	cag	aac	ctg	gcc	cgc	gcg	gaa	ctg	1104
	Phe	Gly	Ile	His	Gln	Cys	Leu	Gly	Gln	Asn	Leu	Ala	Arg	Ala	Glu	Leu	
			355					360					365				
15	gag	atc	gcc	ctc	ggc	agc	ctc	ttc	acc	cgg	ctg	ccc	ggg	ctg	cgt	ctt	1152
	Glu	Ile	Ala	Leu	Gly	Ser	Leu	Phe	Thr	Arg	Leu	Pro	Gly	Leu	Arg	Leu	
			370				375					380					
20	ggc	gcc	ccg	gcc	gag	gag	atc	ccc	ttc	aaa	ccg	ggc	gac	acg	atc	cag	1200
	Ala	Ala	Pro	Ala	Glu	Glu	Ile	Pro	Phe	Lys	Pro	Gly	Asp	Thr	Ile	Gln	
			385			390					395					400	
25	ggg	atg	ctg	gaa	ctc	ccc	gtg	acc	tgg	taa							1230
	Gly	Met	Leu	Glu	Leu	Pro	Val	Thr	Trp								
				405						410							
	<210>	143															
	<211>	1230															
	<212>	DNA															
	<213>	Streptomyces olivochromogenes IFO 12444															
	<220>																
	<221>	CDS															
	<222>	(1)..(1230)															
30	<400>	143															
	atg	acg	gaa	ctg	acg	gac	atc	acc	ggc	ccg	gct	ggc	cag	gcc	gaa	ccc	48
	Met	Thr	Glu	Leu	Thr	Asp	Ile	Thr	Gly	Pro	Ala	Gly	Gln	Ala	Glu	Pro	
	1				5					10					15		
35	gtc	gca	ttc	ccc	cag	gac	cgc	acc	tgt	ccc	tac	cac	ccc	ccc	acc	gga	96
	Val	Ala	Phe	Pro	Gln	Asp	Arg	Thr	Cys	Pro	Tyr	His	Pro	Pro	Thr	Gly	
				20					25					30			
40	tac	gac	ccg	ctg	cgc	gac	ggg	cga	ccc	ctg	tcc	cgc	gtc	acc	ctc	tac	144
	Tyr	Asp	Pro	Leu	Arg	Asp	Gly	Arg	Pro	Leu	Ser	Arg	Val	Thr	Leu	Tyr	
			35				40						45				
45	gac	ggc	cgc	gag	gtc	tgg	ctg	gtc	acc	gcc	cag	gcc	acc	gcc	cgc	gcc	192
	Asp	Gly	Arg	Glu	Val	Trp	Leu	Val	Thr	Ala	Gln	Ala	Thr	Ala	Arg	Ala	
		50					55					60					
50	ctg	ctc	gcc	gac	ccc	cgg	ctg	tcc	acc	gac	cgc	cgc	cgc	gac	ggg	ttt	240
	Leu	Leu	Ala	Asp	Pro	Arg	Leu	Ser	Thr	Asp	Arg	Arg	Arg	Asp	Gly	Phe	
		65				70					75				80		
55	ccc	gtg	ccc	agc	ccc	cgc	ttc	gag	gcc	ggc	cgc	gac	cgc				

EP 1 457 558 A1

5	cag cgg atc gtc gac gaa ctg ctg gac gac atg atc gcc cgg ggg ccg	432
	Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro 130 135 140	
10	gtc gcc gac ctc gtg tcc gcg ttc gcg ctg ccc gtg ccg tcc atg gtc	480
	Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val 145 150 155 160	
15	atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag	528
	Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu 165 170 175	
20	gaa cag tcc cgc cgg ctg ctg cgc ggc ccg ggc ggc gcc gac aca ctg	576
	Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu 180 185 190	
25	gac gcc cgg gac cgg ctg gag gcg tac ctc ggc gag ctg atc gac gcc	624
	Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala 195 200 205	
30	aag gcc aag gag gcc gag ccc ggc gac ggc att ctg gac gat ctg gtc	672
	Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val 210 215 220	
35	cac aac cgg ctc cgc gcg ggc gag ctg gac cgg acc gac ctg gtg tcg	720
	His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser 225 230 235 240	
40	ctc gcc ctc atc ctg ctg gtc gcc ggg cac gag aca acc gcc aac atg	768
	Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255	
45	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gaa cgg ctg gcc	816
	Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala 260 265 270	
50	gag ctg cgt gcc gac ccc acg gtg ctg ccc gcc gtc gtc gag gaa ctg	864
	Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu 275 280 285	
55	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag	912
	Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300	
60	gac atc gag atc gac ggc acc acc atc cgg gcc ggt gac ggc gtc ctc	960
	Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320	
65	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc	1008
	Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335	
70	gac ggc ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc	1056
	Asp Gly Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350	
75	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcc cgc gcg gaa ctg	1104
	Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365	
80	gag atc gcc ctc ggc agc ctc ttc acc cgg ctg ccc gga ctg cgt ctt	1152
	Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380	

EP 1 457 558 A1

5 gcc gcc ccg gcc gag gag atc ccc ttc aaa ccg ggc gac acg atc cag 1200  
Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln  
385 390 395 400

ggg atg ctg gaa ctc ccc gtg acc tgg taa 1230  
Gly Met Leu Glu Leu Pro Val Thr Trp  
405 410

10 <210> 144  
<211> 1449  
<212> DNA  
<213> Streptomyces nogalater IFO 13445

15 <220>  
<221> CDS  
<222> (1)..(1230)

20 <220>  
<221> CDS  
<222> (1243)..(1449)

<400> 144  
atg acg gaa ctg acg gac acc acc ggc ccg gcc gac gcg gcc gaa ccc 48  
Met Thr Glu Leu Thr Asp Thr Thr Gly Pro Ala Asp Ala Ala Glu Pro  
1 5 10 15

25 gtc gca ttc ccc cag gac cgc acc tgc ccc tac cac ccc ccg acc ggc 96  
Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
20 25 30

30 tac gac ccg ctg cgc gac ggg cgg ccc ctg tcc cgg gtc acc ctc tac 144  
Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
35 40 45

gac ggc cgt gag gtc tgg ctg gtc acc gcg cag gcc acc gcc cgc acc 192  
Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Thr  
50 55 60

35 ctg ctc gcc gac ccc cgg ctg tcc acc gac cgc cgc cgc gac ggc ttc 240  
Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe  
65 70 75 80

40 ccc gtg ccc acc ccc cgc ttc gag ggc gga cgc gac cgc aag ctg gcc 288  
Pro Val Pro Thr Pro Arg Phe Glu Gly Gly Arg Asp Arg Lys Leu Ala  
85 90 95

ctg ctc gga ctg gac gac ccc gag cac cag cag cag cgc cgg atg ctg 336  
Leu Leu Gly Leu Asp Asp Pro Glu His Gln Gln Gln Arg Arg Met Leu  
100 105 110

45 atc ccg tcg ttc acc gtg aaa cgc gcc acc gcg cta cgc ccc tgg atc 384  
Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
115 120 125

50 cag cgg atc gtc gac gga ctg ctg gac gcc atg atc acc cgg ggg ccg 432  
Gln Arg Ile Val Asp Gly Leu Leu Asp Ala Met Ile Thr Arg Gly Pro  
130 135 140

gtc gcc gac ctc gtg tcc gcc ttc gcg ctg ccc gtg ccg tcc atg gtc 480  
Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
145 150 155 160

55 atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag 528  
Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu

EP 1 457 558 A1

	165	170	175	
5	gag cag tcc cgc cga ctg ctg agc gcc tcg acc agc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Ser Ala Ser Thr Ser Ala Asp Thr Leu 180 185 190			576
10	gac gcc cgg gac cgg ctg gag acg tac ctc ggc gac ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Thr Tyr Leu Gly Asp Leu Ile Asp Ala 195 200 205			624
15	aag gcc aag gag gcc gag ccc ggc gac ggc atc ctg gac gag ctc gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Glu Leu Val 210 215 220			672
20	cac aac cgg ctc cgc aag ggc gag ctg gac cgg acc gac ctg gtg tcg His Asn Arg Leu Arg Lys Gly Glu Leu Asp Arg Thr Asp Leu Val Ser 225 230 235 240			720
25	ctc gcc gtc atc ctg ctg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255			768
30	atc tcc ctg ggc acc tac acg ctg ctc cag cac ccc gag cgc ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala 260 265 270			816
35	gag ctg cgc gcc gac ccc gcg ctg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu 275 280 285			864
40	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300			912
45	gac atc gag atc gac ggc acc acc atc cgg gcc ggc gac ggc gtc ctc Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320			960
50	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccg Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335			1008
55	gac gac ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Asp Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350			1056
60	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcc cgc gcg gaa ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365			1104
65	gag atc gct ctc ggc agc ctg ttc acc cgc ttg ccc ggg ctc cgt ctg Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380			1152
70	gcc gta ccg gcg aag gac att ccc ttc aaa ccg ggc gac acg atc cag Ala Val Pro Ala Lys Asp Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400			1200
75	ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggttcgt tc atg cac atc Gly Met Leu Glu Leu Pro Val Thr Trp 410 Met His Ile			1251
80	gac atc gat atc gac cag gac gtc tgc atc ggc gcc ggg cag tgc gcg Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly Gln Cys Ala			1299

EP 1 457 558 A1

	415	420	425	
5	ctg gcg gca ccc ggc gtc ttc acc cag gac gac gac ggc tac agc acc			1347
	Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly Tyr Ser Thr			
	430	435	440	445
10	ctg ctg ccc ggc cag gag aac ggc gtg acc gac ccg atg gtc cgg gag			1395
	Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met Val Arg Glu			
		450	455	460
	gcc gcc cgc gcc tgc ccg gtc agc gcg atc acc gtg cgg gag cgc acc			1443
	Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg Glu Arg Thr			
		465	470	475
15	gcc tga			1449
	Ala			
20	<210> 145			
	<211> 1480			
	<212> DNA			
	<213> Streptomyces tsusimaensis IFO 13782T,			
25	<220>			
	<221> CDS			
	<222> (1)..(1278)			
	<220>			
	<221> CDS			
	<222> (1284)..(1480)			
30	<400> 145			
	atg acg gaa tcc acg aca gat ccg acg acc cgc cag gcc ctc ggc tcc			48
	Met Thr Glu Ser Thr Asp Pro Thr Thr Arg Gln Ala Leu Gly Ser			
	1	5	10	15
35	acc acc ccc gcc gct gcc acc gcg acc gcc atc gac ccg acc ctc gcg			96
	Thr Thr Pro Ala Ala Thr Ala Thr Ala Ile Asp Pro Thr Leu Ala			
		20	25	30
	aca ccc ttc ccg cag gac cgg ggg tgc ccg tac cac ccg ccc gcc ggg			144
	Thr Pro Phe Pro Gln Asp Arg Gly Cys Pro Tyr His Pro Pro Ala Gly			
		35	40	45
40	tac gcg ccg ctg cgt gag ggc cga ccg ctc agc agg gtc gcc ctc ttc			192
	Tyr Ala Pro Leu Arg Glu Gly Arg Pro Leu Ser Arg Val Ala Leu Phe			
		50	55	60
45	gac ggg cgc ccg gtc tgg gcg gtc acc gga cac gcc ctg gcc cgc cgg			240
	Asp Gly Arg Pro Val Trp Ala Val Thr Gly His Ala Leu Ala Arg Arg			
		65	70	75
	ttg ctg gcc gat cca cgg ctc tcc acc gac cgt acc cac ccg gac ttc			288
	Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Thr His Pro Asp Phe			
		85	90	95
50	ccc gcc ccg gcc ccg cgc ttc gcc aac gcg aac ccg cgc cgc gtg gcc			336
	Pro Ala Pro Ala Pro Arg Phe Ala Asn Ala Asn Arg Arg Arg Val Ala			
		100	105	110
55	ctg ctc ggc gtc gac gac ccc gag cac aac acc cag cgc aga atg ctc			384
	Leu Leu Gly Val Asp Asp Pro Glu His Asn Thr Gln Arg Arg Met Leu			
		115	120	125

EP 1 457 558 A1

5	atc ccg gcc ttc tcc gtg aag cgg atc aac gct ctc cgc ccc cgc atc Ile Pro Ala Phe Ser Val Lys Arg Ile Asn Ala Leu Arg Pro Arg Ile 130 135 140	432
	cag gag acc gtg gac cgg ttg ctc gac gcg atg gag cgc cag ggg cca Gln Glu Thr Val Asp Arg Leu Leu Asp Ala Met Glu Arg Gln Gly Pro 145 150 155 160	480
10	ccg gcc gag ctg gtg agc gcg ttc gcc ctg ccg gtg ccg tcg atg gtg Pro Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val 165 170 175	528
15	atc tgc tcc ctg ctc gga gtg ccg tac gcc gac cac gag ttc ttc gag Ile Cys Ser Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu 180 185 190	576
	gag cgc tcg cgg cgg ctc ctg cgc ggc ccc ggc gcg gcc gac gtg gac Glu Arg Ser Arg Arg Leu Leu Arg Gly Pro Gly Ala Ala Asp Val Asp 195 200 205	624
20	agg gcc ctc gac gaa ctc gag gag tac ctc ggc gcg ctg atc gac cgc Arg Ala Leu Asp Glu Leu Glu Glu Tyr Leu Gly Ala Leu Ile Asp Arg 210 215 220	672
25	aag cgt acg gaa ccg ggc gac ggc ctc ctc gac gag ctg atc cac cgc Lys Arg Thr Glu Pro Gly Asp Gly Leu Leu Asp Glu Leu Ile His Arg 225 230 235 240	720
	gac cac ccc ggc gga ccg gtc gac cgc gag gag ctg gtc tcg ttc gcc Asp His Pro Gly Gly Pro Val Asp Arg Glu Glu Leu Val Ser Phe Ala 245 250 255	768
30	gtg atc ctg ctc atc gcg ggg cac gag acg acg gcg aac atg atc tcg Val Ile Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser 260 265 270	816
35	ctc ggc acc ttc acc ctg ctg cgc cac ccc gaa cag ctc gcg gcg ctg Leu Gly Thr Phe Thr Leu Leu Arg His Pro Glu Gln Leu Ala Ala Leu 275 280 285	864
	cgg gcc ggc ggg acg acc acg gcc gtg gcg gtc gag gaa ctg ttg cgg Arg Ala Gly Gly Thr Thr Thr Ala Val Ala Val Glu Glu Leu Leu Arg 290 295 300	912
40	ttc ctc tcc atc gcc gac ggc ctg cag cgg ctg gcg acc gag gac atc Phe Leu Ser Ile Ala Asp Gly Leu Gln Arg Leu Ala Thr Glu Asp Ile 305 310 315 320	960
45	gag gtg ccg gac gcc ggg gtg acg atc cgc aag ggc gaa ggt gtg gtc Glu Val Pro Asp Ala Gly Val Thr Ile Arg Lys Gly Glu Gly Val Val 325 330 335	1008
	ttc tcg acc tcg ctc atc aac cgc gac gac ggc gtg ttc ccg cag ccc Phe Ser Thr Ser Leu Ile Asn Arg Asp Asp Gly Val Phe Pro Gln Pro 340 345 350	1056
50	gaa acg ctc gac tgg gac cgc ccg gcc cgt cac cat ctc gcc ttc ggc Glu Thr Leu Asp Trp Asp Arg Pro Ala Arg His His Leu Ala Phe Gly 355 360 365	1104
55	ttc ggc gta cac cag tgc ctg ggg cag aac ctg gcc cgc gcg gaa ctc Phe Gly Val His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 370 375 380	1152

**EP 1 457 558 A1**

5	gac atc cgc atg cgc acg ctc ttc gag cgg ctg ccg ggc ctc cgg ctc Asp Ile Ala Met Arg Thr Leu Phe Glu Arg Leu Pro Gly Leu Arg Leu 385 390 395 400	1200
	gcc gta ccc gcg cag gag atc ccc cat aaa ccg ggg gac acg atc cag Ala Val Pro Ala Gln Glu Ile Pro His Lys Pro Gly Asp Thr Ile Gln 405 410 415	1248
10	ggc atg ctc gaa ctg ccc gtg gcc tgg tga gcggc atg ggc gtc cag gtc Gly Met Leu Glu Leu Pro Val Ala Trp Met Gly Val Gln Val 420 425 430	1298
15	gac agg gaa cgc tgc gtg ggg gcg ggc atg tgc gcg ctg acc gcg ccg Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys Ala Leu Thr Ala Pro 435 440 445	1346
	gac gtg ttc acg cag gac gac gac ggc ctc agc gag gtg ctc ccg ggc Asp Val Phe Thr Gln Asp Asp Asp Gly Leu Ser Glu Val Leu Pro Gly 450 455 460	1394
20	cgc gcg gag acc gct gga gga cat ccc ttg gtg ggg gag gct gta cgg Arg Ala Glu Thr Ala Gly His Pro Leu Val Gly Glu Ala Val Arg 465 470 475	1442
25	gcc tgc ccg gtg ggg gcg gtg gcc ctg tcc gcc gac tg Ala Cys Pro Val Gly Ala Val Ala Leu Ser Ala Asp 480 485 490	1480
30	<210> 146 <211> 1473 <212> DNA <213> Streptomyces thermocoerulescens IFO 14273t	
	<220> <221> CDS <222> (1)..(1209)	
35	<220> <221> CDS <222> (1222)..(1473)	
40	<400> 146 atg acg gac atg acg gaa acc ccc acc gtc gcc ttt ccc cag agc cgg Met Thr Asp Met Thr Glu Thr Pro Thr Val Ala Phe Pro Gln Ser Arg 1 5 10 15	48
	acc tgt ccg tac cac ccg ccc gcc gcc tac gcc ccg ctg cgc gac acc Thr Cys Pro Tyr His Pro Pro Ala Ala Tyr Ala Pro Leu Arg Asp Thr 20 25 30	96
45	cgc ccg ctg gcc cgc gcc cgt ctc tac gac ggc cgc ctc gtc tgg acg Arg Pro Leu Ala Arg Ala Arg Leu Tyr Asp Gly Arg Leu Val Trp Thr 35 40 45	144
50	gtc acc ggt cac ggc ctc gcc cgc acc ctg ctc gcc gac ccc cgc ctg Val Thr Gly His Gly Leu Ala Arg Thr Leu Leu Ala Asp Pro Arg Leu 50 55 60	192
	tcc acc gac ccc acc cgg ccg gag ttc ccc gcc acc acg gaa cgc atc Ser Thr Asp Pro Thr Arg Pro Glu Phe Pro Ala Thr Thr Glu Arg Ile 65 70 75 80	240
55	gcc cgg atc cgg cgc cgc cgg acc gcc ctg ctg ggc gtc gac gac ccc Ala Arg Ile Arg Arg Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro 85 90 95 100	288

EP 1 457 558 A1

	85	90	95	
5	gaa cac cgc gtc cag cgg cgc atg atg gtc ccc agc ttc acc ctc cag Glu His Arg Val Gln Arg Arg Met Met Val Pro Ser Phe Thr Leu Gln 100 105 110			336
10	cgc gcc acc gcg ctg cgc ccc cgg atc cag cgg gtc gtc gac gaa cgc Arg Ala Thr Ala Leu Arg Pro Arg Ile Gln Arg Val Val Asp Glu Arg 115 120 125			384
	ctc gac gcg atg atc gcc ggc ggc ccg ccc gcc gat ctc gtc acc gcg Leu Asp Ala Met Ile Ala Gly Gly Pro Pro Ala Asp Leu Val Thr Ala 130 135 140			432
15	ttc gcg ctg ccg gtg ccg tcc atg gtg atc tgc gcc ctg ctc ggc gtg Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val 145 150 155 160			480
20	ccc tac gag gac cac gac ttc ttc gag gag cag tca cgc cgg ctg ctg Pro Tyr Glu Asp His Asp Phe Phe Glu Glu Gln Ser Arg Arg Leu Leu 165 170 175			528
	cgc ggc ccg acg gcc gag gac tcc atg gac gcc cgc gcc cga atg gag Arg Gly Pro Thr Ala Glu Asp Ser Met Asp Ala Arg Ala Arg Met Glu 180 185 190			576
25	gcc tac ttc gac gag ctg atc gac cgc aag cag cgg cag gac gcg ccc Ala Tyr Phe Asp Glu Leu Ile Asp Arg Lys Gln Arg Gln Asp Ala Pro 195 200 205			624
30	ggt gac ggc gtc ctg gac gaa ctc gtc cac cag cgg ctg gcc gcg ggc Gly Asp Gly Val Leu Asp Glu Leu Val His Gln Arg Leu Ala Ala Gly 210 215 220			672
	gag ctg gac cgc gag ggg ctc atc gcc atg gcg atc atc ctg ctc gtc Glu Leu Asp Arg Glu Gly Leu Ile Ala Met Ala Ile Ile Leu Leu Val 225 230 235 240			720
35	gcc ggt cac gag acg acc gcc aac atg atc tgc ctc ggc acc ttc acg Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr 245 250 255			768
40	ctg ctc ggg cac ccc gag cgg ctg gcc gag ctg cgc gcc gac ccg gac Leu Leu Gly His Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Asp 260 265 270			816
	ctg gtg ccc gcg gcc gtc gag gag ctg ctg cgc atg ctg tcc atc gcg Leu Val Pro Ala Ala Val Glu Glu Leu Leu Arg Met Leu Ser Ile Ala 275 280 285			864
45	gac ggc ctg ctg cgc gtc gcc gtc gag gac atc gag gtg gcc ggc gag Asp Gly Leu Leu Arg Val Ala Val Glu Asp Ile Glu Val Ala Gly Glu 290 295 300			912
50	acg atc cgc gcg ggc gac ggc gtc atc ttc tgc acg tgc gtc atc aac Thr Ile Arg Ala Gly Asp Gly Val Ile Phe Ser Thr Ser Val Ile Asn 305 310 315 320			960
	cgg gac gag gcc gtc tac ccc gaa ccc gac acc ctg gac ctg cac cgc Arg Asp Glu Ala Val Tyr Pro Glu Pro Asp Thr Leu Asp Leu His Arg 325 330 335			1008
55	ccg gcc cgg cac cac gtc gcc ttc ggg ttc ggc atc cac cag tgc ctc Pro Ala Arg His His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu			1056

EP 1 457 558 A1

		340		345		350	
5	ggg cag aac ctg gcc cgc gcc gag atg gag atc gcc ctg cgc acc ctg						1104
	Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu Arg Thr Leu						
		355		360		365	
	ttc ggc cgc ctg ccc gga ctg cgt ctg gcg gtc ccc ccg gag gaa atc						1152
10	Phe Gly Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Pro Glu Glu Ile						
		370		375		380	
	ccg ttc aaa ccc ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg						1200
	Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val						
		385		390		395	400
15	acc tgg taa gaggtcccg tc atg cac aac gaa acg cat gag aca cac gag						1251
	Thr Trp Met His Asn Glu Thr His Glu Thr His Glu						
			405			410	
	acc acc gcg gcg gcc tcc ggg acc cgt atc gac atc gac cac gac ctc						1299
20	Thr Thr Ala Ala Ala Ser Gly Thr Arg Ile Asp Ile Asp His Asp Leu						
		415		420		425	
	tgc gtc ggc gcc ggg cag tgc gcc ctg gtc gcc ccg tcc gtc ttc acc						1347
	Cys Val Gly Ala Gly Gln Cys Ala Leu Val Ala Pro Ser Val Phe Thr						
		430		435		440	445
25	cag gac gac gac ggc ttc agc gag ctg atc ccc ggc cgc gag gac ggt						1395
	Gln Asp Asp Asp Gly Phe Ser Glu Leu Ile Pro Gly Arg Glu Asp Gly						
		450		455		460	
	gcc ggc gac ccg atg gtc cgg gag gcc gtc cgc gcc tgc ccc gtc agc						1443
30	Ala Gly Asp Pro Met Val Arg Glu Ala Val Arg Ala Cys Pro Val Ser						
		465		470		475	
	gcc atc acc gtg acg gag gcc gcc gtc tga						1473
	Ala Ile Thr Val Thr Glu Ala Ala Val						
		480		485			
35	<210> 147						
	<211> 1449						
	<212> DNA						
	<213> Streptomyces glomerochromogenes IFO 13673T						
	<220>						
40	<221> CDS						
	<222> (1)..(1230)						
	<220>						
	<221> CDS						
	<222> (1243)..(1449)						
45	<400> 147						
	atg acg gaa ctg acg gac atc acc ggc ccg gct ggc cag gcc caa ccc						48
	Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Gly Gln Ala Gln Pro						
		1		5		10	15
50	gtc gca ttc ccc cag gac cgc acc tgt ccc tac cac ccc ccc acc gga						96
	Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly						
		20		25		30	
	tac gac ccg ctg cgc gac ggg cga ccc ctg tcc cgc gtc acc ctc tac						144
55	Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr						
		35		40		45	

EP 1 457 558 A1

5	gac ggc cgc gag gtc tgg ctg gtc acc gcc cag gcc acc gcc cgc gcc Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Ala 50 55 60	192
10	ctg ctc gcc gac ccc cgg ctg tcc acc gac cgc cgc cgc gac ggc ttt Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe 65 70 75 80	240
15	ccc gtg ccc agc ccc cgc ttc gag gcc ggc cgc gac cgc aaa ctg gcc Pro Val Pro Ser Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Leu Ala 85 90 95	288
20	ctg ctc ggg ctg gac gac ccc gag cac cag cag cgc cgc atg ctg Leu Leu Gly Leu Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu 100 105 110	336
25	atc ccg tcg ttc acc gtc aaa cgc gcc acc gcg cta cgc ccc tgg atc Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile 115 120 125	384
30	cag cgg atc gtc gac gaa ctg ctg gac gac atg atc gcc cgg ggg ccg Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro 130 135 140	432
35	gtc gcc gac ctc gtg tcc gcg ttc gcg ctg ccc gtg ccg tcc atg gtc Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val 145 150 155 160	480
40	atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu 165 170 175	528
45	gaa cag tcc cgc cgg ctg ctg cgc ggc ccg ggc ggc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu 180 185 190	576
50	gac gcc cgg gac cgg ctg gag gcg tac ctc ggc gag ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala 195 200 205	624
55	aag gcc aag gag gcc gag ccc ggc gac ggc gtt ctg gac gac ctg gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Val Leu Asp Asp Leu Val 210 215 220	672
60	cac aac cgg ctc cgc gcg ggc gag ctg gac cgg acc gac ctg gtg tcg His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser 225 230 235 240	720
65	ctc gcc ctc atc ctg ctg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255	768
70	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gaa cgg ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala 260 265 270	816
75	gag ctg cgt gcc gac ccc acg gtg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu 275 280 285	864
80	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg ctg gcg ctg gag Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Leu Ala Leu Glu 290 295 300	912

EP 1 457 558 A1

5	gac atc gag atc gac ggc acc acc atc cgg gcc ggt gac ggc gtc ctc Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320	960
	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335	1008
10	gac gac ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Asp Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350	1056
15	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcc cgc gcg gaa ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365	1104
	gag atc gcc ctc ggc agc ctc ttc acc cgg ctg ccc ggg ctg cgt ctt Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380	1152
20	gcc gcc ccg gcc gag gag atc ccc ttc aaa ccg gcc gac acg atc cag Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400	1200
25	ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggcttcgc tc atg cac atg Gly Met Leu Glu Leu Pro Val Thr Trp Met His Met 405 410	1251
	gac atc gac atc gac cag gac gtc tgt atc gcc gcc ggg cag tgc gcg Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly Gln Cys Ala 415 420 425	1299
30	ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac ggc tac agc acc Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly Tyr Ser Thr 430 435 440 445	1347
35	ctg ctg ccc ggc cag gag aac ggc gtc acc gac ccg atg gtc cgg gag Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met Val Arg Glu 450 455 460	1395
	gcc gcc cgc gcc tgc ccg gtc agc gcc atc acc gta ccg gag cgc acc Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg Glu Arg Thr 465 470 475	1443
40	gcc tga Ala	1449
45	<p>&lt;210&gt; 148            &lt;211&gt; 1449            &lt;212&gt; DNA            &lt;213&gt; Streptomyces olivochromogenes IFO 12444</p>	
50	<p>&lt;220&gt;            &lt;221&gt; CDS            &lt;222&gt; (1)..(1230)</p>	
	<p>&lt;220&gt;            &lt;221&gt; CDS            &lt;222&gt; (1243)..(1449)</p>	
55	atg acg gaa ctg acg gac atc acc ggc ccg gct ggc cag gcc gaa ccc Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Gly Gln Ala Glu Pro	48

EP 1 457 558 A1

	1		5		10		15	
5	gtc gca ttc ccc cag gac cgc acc tgt ccc tac cac ccc ccc acc gga							96
	Val Ala Phe Pro 20		Gln Asp Arg Thr Cys 25		Pro Tyr His Pro 30		Thr Gly	
	tac gac ccg ctg cgc gac ggg cga ccc ctg tcc cgc gtc acc ctc tac							144
10	Tyr Asp Pro 35		Leu Arg Asp Gly Arg 40		Pro Leu Ser Arg Val 45		Thr Leu Tyr	
	gac ggc cgc gag gtc tgg ctg gtc acc gcc cag gcc acc gcc cgc gcc							192
	Asp Gly Arg Glu Val Trp 50		Leu Val Thr Ala Gln Ala 60		Thr Ala Arg Ala			
15	ctg ctc gcc gac ccc cgg ctg tcc acc gac cgc cgc cgc gac ggt ttt							240
	Leu Leu Ala Asp Pro Arg 70		Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe 80					
	ccc gtg ccc agc ccc cgc ttc gag gcc ggc cgc gac cgc aaa ctg gcc							288
20	Pro Val Pro Ser Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Leu Ala 95							
	ctg ctc ggg ctg gac gac ccc gag cac cac cag cag cgc cgg atg ctg							336
	Leu Leu Gly Leu Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu 110							
25	atc ccg tcg ttc acc gtc aaa cgc gcc acc gcg cta cgc ccc tgg atc							384
	Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile 125							
	cag cgg atc gtc gac gaa ctg ctg gac gac atg atc gcc cgg ggg ccg							432
30	Gln Arg Ile Val Asp Glu Leu Leu Asp Asp Met Ile Ala Arg Gly Pro 140							
	gtc gcc gac ctc gtg tcc gcg ttc gcg ctg ccc gtg ccg tcc atg gtc							480
	Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val 160							
35	atc tgc gaa ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag							528
	Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu 175							
	gaa cag tcc cgc cgg ctg ctg cgc ggc ccg ggc ggc gcc gac aca ctg							576
40	Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Gly Gly Ala Asp Thr Leu 190							
	gac gcc cgg gac cgg ctg gag gcg tac ctc ggc gag ctg atc gac gcc							624
	Asp Ala Arg Asp Arg Leu Glu Ala Tyr Leu Gly Glu Leu Ile Asp Ala 205							
45	aag gcc aag gag gcc gag ccc ggc gac ggc att ctg gac gat ctg gtc							672
	Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val 220							
	cac aac cgg ctc cgc gcg ggc gag ctg gac cgg acc gac ctg gtg tcg							720
50	His Asn Arg Leu Arg Ala Gly Glu Leu Asp Arg Thr Asp Leu Val Ser 240							
	ctc gcc ctc atc ctg ctg gtc gcc ggg cac gag aca acc gcc aac atg							768
	Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 255							
55	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gaa cgg ctg gcc							816
	Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala							

EP 1 457 558 A1

	260	265	270	
5	gag ctg cgt gcc gac ccc acg gtg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Thr Val Leu Pro Ala Val Val Glu Glu Leu 275 280 285			864
10	ctg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300			912
15	gac atc gag atc gac ggc acc acc atc cgg gcc ggt gac ggc gtc ctc Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320			960
20	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335			1008
25	gac ggc ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Gly Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350			1056
30	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcc cgc gcg gaa ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365			1104
35	gag atc gcc ctc ggc agc ctc ttc acc cgg ctg ccc gga ctg cgt ctt Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380			1152
40	gcc gcc ccg gcc gag gag atc ccc ttc aaa ccg ggc gac acg atc cag Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400			1200
45	ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggcttcgc tc atg cac atg Gly Met Leu Glu Leu Pro Val Thr Trp 410 Met His Met			1251
50	gac atc gac atc gac cag gac atc tgt atc ggc gcc ggg cag tgc gcg Asp Ile Asp Ile Asp Gln Asp Ile Cys Ile Gly Ala Gly Gln Cys Ala 415 420 425			1299
55	ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac ggc tac agc acc Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly Tyr Ser Thr 430 435 440 445			1347
60	ctg ctg ccc ggc cag gag aac ggc gtc acc gac ccg atg gtc cgg gag Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met Val Arg Glu 450 455 460			1395
65	gcc gcc cgc gcc tgc ccg gtc agc gcc atc acc gta cgg gag cgc acc Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg Glu Arg Thr 465 470 475			1443
70	gcc tga Ala			1449
75	<210> 149 <211> 68 <212> PRT <213> Streptomyces nogalater IFO 13445			
80	<400> 149			

Met His Ile Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
 1 5 10 15  
 5 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
 20 25 30  
 Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met  
 35 40 45  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
 50 55 60  
 10 Glu Arg Thr Ala  
 65

&lt;210&gt; 150

&lt;211&gt; 65

&lt;212&gt; PRT

15 <213> Streptomyces tsusimaensis IFO 13782T

&lt;400&gt; 150

Met Gly Val Gln Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
 1 5 10 15  
 20 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Leu Ser  
 20 25 30  
 Glu Val Leu Pro Gly Arg Ala Glu Thr Ala Gly Gly His Pro Leu Val  
 35 40 45  
 Gly Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ala Leu Ser Ala  
 50 55 60  
 25 Asp  
 65

&lt;210&gt; 151

&lt;211&gt; 83

&lt;212&gt; PRT

30 <213> Streptomyces thermocoeruleus IFO 14273t

&lt;400&gt; 151

Met His Asn Glu Thr His Glu Thr His Glu Thr Thr Ala Ala Ala Ser  
 1 5 10 15  
 Gly Thr Arg Ile Asp Ile Asp His Asp Leu Cys Val Gly Ala Gly Gln  
 20 25 30  
 35 Cys Ala Leu Val Ala Pro Ser Val Phe Thr Gln Asp Asp Asp Gly Phe  
 35 40 45  
 Ser Glu Leu Ile Pro Gly Arg Glu Asp Gly Ala Gly Asp Pro Met Val  
 50 55 60  
 Arg Glu Ala Val Arg Ala Cys Pro Val Ser Ala Ile Thr Val Thr Glu  
 65 70 75 80  
 40 Ala Ala Val

&lt;210&gt; 152

&lt;211&gt; 68

&lt;212&gt; PRT

45 <213> Streptomyces glomerochromogenes IFO 13673T

&lt;400&gt; 152

Met His Met Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
 1 5 10 15  
 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
 20 25 30  
 50 Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met  
 35 40 45  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
 50 55 60  
 Glu Arg Thr Ala  
 65

55

5 <210> 153  
 <211> 68  
 <212> PRT  
 <213> Streptomyces olivochromogenes IFO 12444  
  
 <400> 153  
 Met His Met Asp Ile Asp Ile Asp Gln Asp Ile Cys Ile Gly Ala Gly  
 1 5 10 15  
 10 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
 20 25 30  
 Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met  
 35 40 45  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
 50 55 60  
 15 Glu Arg Thr Ala  
 65  
  
 <210> 154  
 <211> 207  
 <212> DNA  
 20 <213> Streptomyces nogalater IFO 13445  
  
 <220>  
 <221> CDS  
 <222> (1)..(207)  
  
 25 <400> 154  
 atg cac atc gac atc gat atc gac cag gac gtc tgc atc ggc gcc ggg 48  
 Met His Ile Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
 1 5 10 15  
  
 30 cag tgc gcg ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac ggc 96  
 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
 20 25 30  
  
 tac agc acc ctg ctg ccc ggc cag gag aac ggc gtg acc gac ccg atg 144  
 Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met  
 35 40 45  
  
 35 gtc cgg gag gcc gcc cgc gcc tgc ccg gtc agc gcg atc acc gtg cgg 192  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
 50 55 60  
  
 40 gag cgc acc gcc tga 207  
 Glu Arg Thr Ala  
 65  
  
 <210> 155  
 <211> 198  
 <212> DNA  
 45 <213> Streptomyces tsusimaensis IFO 13782T  
  
 <220>  
 <221> CDS  
 <222> (1)..(198)  
  
 50 <400> 155  
 atg ggc gtc cag gtc gac agg gaa cgc tgc gtg ggg gcg ggc atg tgc 48  
 Met Gly Val Gln Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
 1 5 10 15  
  
 55 gcg ctg acc gcg ccg gac gtg ttc acg cag gac gac gac ggc ctc agc 96  
 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Leu Ser  
 20 25 30

5 gag gtg ctc ccg ggc cgc gcg gag acc gct gga gga cat ccc ttg gtg 144  
 Glu Val Leu Pro Gly Arg Ala Glu Thr Ala Gly Gly His Pro Leu Val  
                   35                                  40                                  45

ggg gag gct gta cgg gcc tgc ccg gtg ggg gcg gtg gcc ctg tcc gcc 192  
 Gly Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ala Leu Ser Ala  
                   50                                  55                                  60

10 gac tga 198  
 Asp  
      65

15 <210> 156  
 <211> 252  
 <212> DNA  
 <213> Streptomyces thermocoerulescens IFO 14273t

20 <220>  
 <221> CDS  
 <222> (1)..(252)

<400> 156  
 atg cac aac gaa acg cat gag aca cac gag acc acc gcg gcg gcc tcc 48  
 Met His Asn Glu Thr His Glu Thr His Glu Thr Thr Ala Ala Ala Ser  
      1                                  5                                  10                                  15

25 ggg acc cgt atc gac atc gac cac gac ctc tgc gtc ggc gcc ggg cag 96  
 Gly Thr Arg Ile Asp Ile Asp His Asp Leu Cys Val Gly Ala Gly Gln  
                   20                                  25                                  30

30 tgc gcc ctg gtc gcc ccg tcc gtc ttc acc cag gac gac gac ggc ttc 144  
 Cys Ala Leu Val Ala Pro Ser Val Phe Thr Gln Asp Asp Asp Gly Phe  
                   35                                  40                                  45

35 agc gag ctg atc ccc ggc cgc gag gac ggt gcc ggc gac ccg atg gtc 192  
 Ser Glu Leu Ile Pro Gly Arg Glu Asp Gly Ala Gly Asp Pro Met Val  
                   50                                  55                                  60

40 cgg gag gcc gtc cgc gcc tgc ccc gtc agc gcc atc acc gtg acg gag 240  
 Arg Glu Ala Val Arg Ala Cys Pro Val Ser Ala Ile Thr Val Thr Glu  
                   65                                  70                                  75                                  80

gcc gcc gtc tga 252  
 Ala Ala Val

45 <210> 157  
 <211> 207  
 <212> DNA  
 <213> Streptomyces glomerochromogenes IFO 13673T

<220>  
 <221> CDS  
 <222> (1)..(207)

50 <400> 157  
 atg cac atg gac atc gac atc gac cag gac gtc tgt atc ggc gcc ggg 48  
 Met His Met Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
      1                                  5                                  10                                  15

55 cag tgc gcg ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac ggc 96  
 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
                   20                                  25                                  30

**EP 1 457 558 A1**

5	tac agc acc ctg ctg ccc ggc cag gag aac ggc gtc acc gac ccg atg Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met	144
	35 40 45	
	gtc cgg gag gcc gcc cgc gcc tgc ccg gtc agc gcc atc acc gta cgg Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg	192
	50 55 60	
10	gag cgc acc gcc tga Glu Arg Thr Ala	207
	65	
15	<210> 158 <211> 207 <212> DNA <213> Streptomyces olivochromogenes IFO 12444	
	<220> <221> CDS <222> (1)..(207)	
20	<400> 158 atg cac atg gac atc gac atc gac cag gac atc tgt atc ggc gcc ggg Met His Met Asp Ile Asp Ile Asp Gln Asp Ile Cys Ile Gly Ala Gly	48
	1 5 10 15	
25	cag tgc gcg ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac gcc Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly	96
	20 25 30	
30	tac agc acc ctg ctg ccc ggc cag gag aac ggc gtc acc gac ccg atg Tyr Ser Thr Leu Leu Pro Gly Gln Glu Asn Gly Val Thr Asp Pro Met	144
	35 40 45	
	gtc cgg gag gcc gcc cgc gcc tgc ccg gtc agc gcc atc acc gta cgg Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg	192
	50 55 60	
35	gag cgc acc gcc tga Glu Arg Thr Ala	207
	65	
40	<210> 159 <211> 409 <212> PRT <213> Streptomyces nogalater IFO 13445	
	<400> 159 Met Thr Glu Leu Thr Asp Thr Thr Gly Pro Ala Asp Ala Ala Glu Pro 1 5 10 15 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly 20 25 30 Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr 35 40 45 Asp Gly Arg Glu Val Trp Leu Val Thr Ala Gln Ala Thr Ala Arg Thr 50 55 60 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Asp Gly Phe 65 70 75 80 Pro Val Pro Thr Pro Arg Phe Glu Gly Gly Arg Asp Arg Lys Leu Ala 85 90 95 Leu Leu Gly Leu Asp Asp Pro Glu His Gln Gln Gln Arg Arg Met Leu 100 105 110 Ile Pro Ser Phe Thr Val Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile	
55		

115 120 125  
 Gln Arg Ile Val Asp Gly Leu Leu Asp Ala Met Ile Thr Arg Gly Pro  
 130 135 140  
 5 Val Ala Asp Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 165 170 175  
 Glu Gln Ser Arg Arg Leu Leu Ser Ala Ser Thr Ser Ala Asp Thr Leu  
 180 185 190  
 10 Asp Ala Arg Asp Arg Leu Glu Thr Tyr Leu Gly Asp Leu Ile Asp Ala  
 195 200 205  
 Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Glu Leu Val  
 210 215 220  
 15 His Asn Arg Leu Arg Lys Gly Glu Leu Asp Arg Thr Asp Leu Val Ser  
 225 230 235  
 Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met  
 245 250 255  
 Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala  
 260 265 270  
 20 Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu  
 275 280 285  
 Leu Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu  
 290 295 300  
 Asp Ile Glu Ile Asp Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu  
 305 310 315  
 Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro  
 325 330 335  
 25 Asp Asp Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly  
 340 345 350  
 Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu  
 355 360 365  
 30 Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu  
 370 375 380  
 Ala Val Pro Ala Lys Asp Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln  
 385 390 395 400  
 Gly Met Leu Glu Leu Pro Val Thr Trp  
 405  
 35 <210> 160  
 <211> 425  
 <212> PRT  
 <213> Streptomyces tsusimaensis IFO 13782T  
 <400> 160  
 40 Met Thr Glu Ser Thr Thr Asp Pro Thr Thr Arg Gln Ala Leu Gly Ser  
 1 5 10 15  
 Thr Thr Pro Ala Ala Ala Thr Ala Thr Ala Ile Asp Pro Thr Leu Ala  
 20 25 30  
 Thr Pro Phe Pro Gln Asp Arg Gly Cys Pro Tyr His Pro Pro Ala Gly  
 35 40 45  
 45 Tyr Ala Pro Leu Arg Glu Gly Arg Pro Leu Ser Arg Val Ala Leu Phe  
 50 55 60  
 Asp Gly Arg Pro Val Trp Ala Val Thr Gly His Ala Leu Ala Arg Arg  
 65 70 75 80  
 Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Thr His Pro Asp Phe  
 85 90 95  
 50 Pro Ala Pro Ala Pro Arg Phe Ala Asn Ala Asn Arg Arg Arg Val Ala  
 100 105 110  
 Leu Leu Gly Val Asp Asp Pro Glu His Asn Thr Gln Arg Arg Met Leu  
 115 120 125  
 Ile Pro Ala Phe Ser Val Lys Arg Ile Asn Ala Leu Arg Pro Arg Ile  
 130 135 140  
 55 Gln Glu Thr Val Asp Arg Leu Leu Asp Ala Met Glu Arg Gln Gly Pro  
 145 150 155 160

5 Pro Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 Ile Cys Ser Leu 165 Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 Glu Arg Ser Arg Arg Leu Leu Arg Gly Pro Gly Ala Ala Asp Val Asp  
 Arg Ala Leu Asp Glu Leu Glu Tyr Leu Gly Ala Leu Ile Asp Arg  
 10 Lys Arg Thr Glu Pro Gly Asp Gly Leu Leu Asp Glu Leu Ile His Arg  
 Asp His Pro Gly Gly Pro Val Asp Arg Glu Glu Leu Val Ser Phe Ala  
 Val Ile Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser  
 15 Leu Gly Thr Phe Thr Leu Leu Arg His Pro Glu Gln Leu Ala Ala Leu  
 Arg Ala Gly Gly Thr Thr Thr Ala Val Ala Val Glu Glu Leu Leu Arg  
 Phe Leu Ser Ile Ala Asp Gly Leu Gln Arg Leu Ala Thr Glu Asp Ile  
 20 Glu Val Pro Asp Ala Gly Val Thr Ile Arg Lys Gly Glu Gly Val Val  
 Phe Ser Thr Ser Leu Ile Asn Arg Asp Asp Gly Val Phe Pro Gln Pro  
 Glu Thr Leu Asp Trp Asp Arg Pro Ala Arg His His Leu Ala Phe Gly  
 25 Phe Gly Val His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu  
 Asp Ile Ala Met Arg Thr Leu Phe Glu Arg Leu Pro Gly Leu Arg Leu  
 Ala Val Pro Ala Gln Glu Ile Pro His Lys Pro Gly Asp Thr Ile Gln  
 30 Gly Met Leu Glu Leu Pro Val Ala Trp  
 170 175 180 185 190 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425

<210> 161

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 161

agcagttcgc agatgaccat ggacggca

28

<210> 162

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 162

tttcacggtg aacgacggga tcagcat

27

<210> 163

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

	<400> 163	
5	acgagacgac cgccaacatg atctccct	28
	<210> 164	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 164	
	tcctcttctc cacctcggtc atcaacc	27
15	<210> 165	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 165	
	ttcatatgac ggaactgacg gacacca	27
25	<210> 166	
	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 166	
	cgaagctttc aggcggtgcg ctcccgca	28
35	<210> 167	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 167	
	agcaaccggt ccacggtctc ctggatg	27
45	<210> 168	
	<211> 28	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 168	
	gagagcgttg atccgcttca cggagaag	28
55	<210> 169	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	

5 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 169  
 caagggcgaa ggtgtggtct tctcgac 27

10 <210> 170  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

15 <400> 170  
 ctcacatcaacc gcgacgacgg cgtgttc 27

<210> 171  
 <211> 27  
 <212> DNA  
 20 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

25 <400> 171  
 accatatgac ggaatccacg acagatc 27

<210> 172  
 <211> 29  
 <212> DNA  
 30 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

35 <400> 172  
 cgaagctttc agtcggcgga cagggccac 29

<210> 173  
 <211> 27  
 <212> DNA  
 40 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 173  
 ctccctgaag aagtcgtggt cctcgta 27

45 <210> 174  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

50 <400> 174  
 atcatcgcggt cgaggcggttc gtcgacga 28

<210> 175  
 <211> 27  
 <212> DNA  
 55

<213> Artificial Sequence  
 <220>  
 5 <223> Designed oligonucleotide primer for PCR  
 <400> 175  
 ccaacatgat ctcgctcggc accttca 27  
 <210> 176  
 10 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 15 <223> Designed oligonucleotide primer for PCR  
 <400> 176  
 cgtcatcttc tcgacgtcgg tcatcaa 27  
 <210> 177  
 20 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 25 <223> Designed oligonucleotide primer for PCR  
 <400> 177  
 ctcatatgac ggacatgacg gaaaccccca 30  
 <210> 178  
 30 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 35 <223> Designed oligonucleotide primer for PCR  
 <400> 178  
 cgaagctttc agacggcggc ctccgtca 28  
 <210> 179  
 40 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 45 <223> Designed oligonucleotide primer for PCR  
 <400> 179  
 cagttcgtcg acgatccgct ggatcca 27  
 <210> 180  
 50 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 55 <223> Designed oligonucleotide primer for PCR  
 <400> 180  
 tttgacggtg aacgacggga tcagcat 27  
 <210> 181

	<211> 27	
5	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
10	<400> 181	
	gacatcgaga tcgacggcac caccatc	27
	<210> 182	
	<211> 27	
	<212> DNA	
15	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
20	<400> 182	
	gtcctcttct ccacctcggt catcaac	27
	<210> 183	
	<211> 33	
	<212> DNA	
	<213> Artificial Sequence	
25	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 183	
	cgaggtcttc atatgacgga actgacggac atc	33
30	<210> 184	
	<211> 33	
	<212> DNA	
	<213> Artificial Sequence	
35	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 184	
	ccgccgaagc tttcaggcgg tgcgctcccg tac	33
40	<210> 185	
	<211> 30	
	<212> DNA	
	<213> Artificial Sequence	
45	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 185	
	cgaggtcata tgacggaact gacggacatc	30
50	<210> 186	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for DNA sequencing	
55	<400> 186	
	atgctgatcc cgtcgttcac cgtqaaa	27

5  
 <210> 187  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for DNA sequencing

10  
 <400> 187  
 cttctccgtg aagcggatca acgctctc 28

<210> 188  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing

20  
 <400> 188  
 tcgtcgacga acgcctcgac gcgatgat 28

<210> 189  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing

30  
 <400> 189  
 atggatcatct gcgaactgct cggcgtg 27

<210> 190  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> Designed oligonucleotide primer for PCR

40  
 <400> 190  
 cgggatccca tatgacagat atgacagata ctgcagacgt taaaccacta tctgcaccag 60  
 ttgcatttcc tcaagata 78

<210> 191  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Designed oligonucleotide primer for PCR

50  
 <400> 191  
 agttgcattt cctcaagata gaacctgtcc attccagcct cctactgggt atgatccact 60  
 tcgtgaagct 70

<210> 192  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

55  
 <220>

<223> Designed oligonucleotide primer for PCR

5 <400> 192  
atgatccact tcgtgaagct aggcctcttg ctagagttac actttacgat ggaagggcta 60  
tctggcttgt 70

<210> 193  
<211> 70  
10 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

15 <400> 193  
gttgatgacc ctgaacatca cactcaaagg cggatgtag ttcttagctt tacactcaag 60  
cgcgctgctg 70

<210> 194  
<211> 70  
20 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

25 <400> 194  
tacactcaag cgcgctgctg cggtgaggcc agccattcag aggattgtcg atgagtgcac 60  
agatgctatg 70

<210> 195  
<211> 70  
30 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

35 <400> 195  
atgagtgcac agatgctatg ttagctaagg gaccacctgc agagttgggt aacgccttcg 60  
cacttcccgt 70

<210> 196  
<211> 70  
40 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

45 <400> 196  
tgctacttag gagcactgat tgaccgcaag tccgaatcat ccgttggtga tgggtgcctc 60  
gacgccttgg 70

<210> 197  
<211> 70  
50 <212> DNA  
<213> Artificial Sequence

<220>  
55 <223> Designed oligonucleotide primer for PCR

5 <400> 197  
 tgggtgcctc gacgccttgg ttcacgagca attgagagaa ggagctgtgg ataggcagga 60  
 ggctatcagc 70

10 <210> 198  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

15 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 198  
 ataggcagga ggctatcagc ttggccacga ttctgttggc cgctgggtcat gaaaccactg 60  
 ctaatatgat 70

20 <210> 199  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

25 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 199  
 caagccacag aggacatcga ggtggcaggt actactatta gagccggtga aggcgtggtc 60  
 tttgcgacct 70

30 <210> 200  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 200  
 aggcgtggtc tttgcgacct ctgtaataca cagagatggg gaggtttacg cagaacccga 60  
 cgccctcgat 70

40 <210> 201  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 201  
 cagaacccga cgccctcgat tggcatagga ccaccagaca tcacgtggca ttcggctttg 60  
 gcattcatca 70

50 <210> 202  
 <211> 79  
 <212> DNA  
 <213> Artificial Sequence

55 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 202  
 accagatgct gtccgcttta aaccaggtga cacgattcag ggaatgctgg atcttcccgt 60  
 ggcttggtag aagcttggg 79

5	<210> 203	
	<211> 80	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
10	<223> Designed oligonucleotide primer for PCR	
	<400> 203	
	gatggagata gcacttcgta gttgttcga gagagtgcct gggttgagac tcgacattgc	60
	accagatgct gtccgcttta	80
	<210> 204	
15	<211> 70	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
20	<223> Designed oligonucleotide primer for PCR	
	<400> 204	
	ttcggctttg gcattcatca atgtctcga cagaatctag cacgtgccga gatggagata	60
	gcacttcgta	70
	<210> 205	
25	<211> 70	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
30	<223> Designed oligonucleotide primer for PCR	
	<400> 205	
	ctgttgatga gttgatgagg atgctttcta tagcggacgg gctgatgaga caagccacag	60
	aggacatcga	70
	<210> 206	
35	<211> 70	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
40	<223> Designed oligonucleotide primer for PCR	
	<400> 206	
	ccccgagcga ctggcggaat tgagggatga cccgagtttg tggcctgctg ctgttgatga	60
	gttgatgagg	70
	<210> 207	
45	<211> 70	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
50	<223> Designed oligonucleotide primer for PCR	
	<400> 207	
	gaaaccactg ctaatatgat ctcatggggc acttatacat tactccaaca ccccgagcga	60
	ctggcggaat	70
	<210> 208	
55	<211> 70	
	<212> DNA	

<213> Artificial Sequence

5     <220>  
       <223> Designed oligonucleotide primer for PCR

      <400> 208  
       tacgcgacg ggatgtggac gaggtgctg atgcaaggga ccagctcgat tgctacttag     60  
       gagcactgat     70

10    <210> 209  
       <211> 70  
       <212> DNA  
       <213> Artificial Sequence

15    <220>  
       <223> Designed oligonucleotide primer for PCR

      <400> 209  
       tgtaccgtat gccgatcatg aattctttga ggaacaaagt cgtaggcttc tacgcgacg     60  
       ggatgtggac     70

20    <210> 210  
       <211> 70  
       <212> DNA  
       <213> Artificial Sequence

25    <220>  
       <223> Designed oligonucleotide primer for PCR

      <400> 210  
       aacgccttcg cacttcccgt tccatcaatg gtgatatgtg aactgctcgg tgtaccgtat     60  
       gccgatcatg     70

30    <210> 211  
       <211> 70  
       <212> DNA  
       <213> Artificial Sequence

35    <220>  
       <223> Designed oligonucleotide primer for PCR

      <400> 211  
       cctctccacg cattgtagca ttcagagacc gcagggtgc ccttcttaat gttgatgacc     60  
       ctgaacatca     70

40    <210> 212  
       <211> 70  
       <212> DNA  
       <213> Artificial Sequence

45    <220>  
       <223> Designed oligonucleotide primer for PCR

      <400> 212  
       cgcagattca cgactatcgt ccgatagact tcgacctggc tttccagcta cctctccacg     60  
       cattgtagca     70

50    <210> 213  
       <211> 70  
       <212> DNA  
       <213> Artificial Sequence

55    <220>  
       <223> Designed oligonucleotide primer for PCR

5 <400> 213  
 ggaagggcta tctggcttgt taccggacgt gaccttgcta gaagcctgct cgcagattca 60  
 cgactatcgt 70

<210> 214  
 <211> 1227  
 <212> DNA  
 10 <213> Artificial Sequence

<220>  
 <221> CDS  
 <222> (1)..(1227)  
 15 <223> Designed polynucleotide encoding amino acid sequence of SEQ ID No.1

<400> 214  
 atg aca gat atg aca gat act gca gac gtt aaa cca cta tct gca cca 48  
 Met Thr Asp Met Thr Asp Thr Ala Asp Val Lys Pro Leu Ser Ala Pro  
 1 5 10 15

20 gtt gca ttt cct caa gat aga acc tgt cca ttc cag cct cct act ggg 96  
 Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Phe Gln Pro Pro Thr Gly  
 20 25 30

25 tat gat cca ctt cgt gaa gct agg cct ctt gct aga gtt aca ctt tac 144  
 Tyr Asp Pro Leu Arg Glu Ala Arg Pro Leu Ala Arg Val Thr Leu Tyr  
 35 40 45

gat gga agg gct atc tgg ctt gtt acc gga cgt gac ctt gct aga agc 192  
 Asp Gly Arg Ala Ile Trp Leu Val Thr Gly Arg Asp Leu Ala Arg Ser  
 50 55 60

30 ctg ctc gca gat tca cga cta tcg tcc gat aga ctt cga cct ggc ttt 240  
 Leu Leu Ala Asp Ser Arg Leu Ser Ser Asp Arg Leu Arg Pro Gly Phe  
 65 70 75 80

35 cca gct acc tct cca cgc att gta gca ttc aga gac cgc agg gct gcc 288  
 Pro Ala Thr Ser Pro Arg Ile Val Ala Phe Arg Asp Arg Arg Ala Ala  
 85 90 95

ctt ctt aat gtt gat gac cct gaa cat cac act caa agg cgg atg tta 336  
 Leu Leu Asn Val Asp Asp Pro Glu His Thr Gln Arg Arg Met Leu  
 100 105 110

40 gtt cct agc ttt aca ctc aag cgc gct gct gcg ttg agg cca gcc att 384  
 Val Pro Ser Phe Thr Leu Lys Arg Ala Ala Ala Leu Arg Pro Ala Ile  
 115 120 125

45 cag agg att gtc gat gag tgc ata gat gct atg tta gct aag gga cca 432  
 Gln Arg Ile Val Asp Glu Cys Ile Asp Ala Met Leu Ala Lys Gly Pro  
 130 135 140

cct gca gag ttg gtt aac gcc ttc gca ctt ccc gtt cca tca atg gtg 480  
 Pro Ala Glu Leu Val Asn Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 145 150 155 160

50 ata tgt gaa ctg ctc ggt gta ccg tat gcc gat cat gaa ttc ttt gag 528  
 Ile Cys Glu Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 165 170 175

55 gaa caa agt cgt agg ctt cta cgc gga cgg gat gtg gac gag gtg cgt 576  
 Glu Gln Ser Arg Arg Leu Leu Arg Gly Arg Asp Val Asp Glu Val Arg  
 180 185 190

EP 1 457 558 A1

	gat gca agg gac cag ctc gat tgc tac tta gga gca ctg att gac cgc	624
	Asp Ala Arg Asp Gln Leu Asp Cys Tyr Leu Gly Ala Leu Ile Asp Arg	
5	195 200 205	
	aag tcc gaa tca tcc gtt ggt gat ggt gtc ctc gac gcc ttg gtt cac	672
	Lys Ser Glu Ser Ser Val Gly Asp Gly Val Leu Asp Ala Leu Val His	
	210 215 220	
10	gag caa ttg aga gaa gga gct gtg gat agg cag gag gct atc agc ttg	720
	Glu Gln Leu Arg Glu Gly Ala Val Asp Arg Gln Glu Ala Ile Ser Leu	
	225 230 235 240	
	gcc acg att ctg ttg gtc gct ggt cat gaa acc act gct aat atg atc	768
	Ala Thr Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met Ile	
15	245 250 255	
	tca ttg ggc act tat aca tta ctc caa cac ccc gag cga ctg gcg gaa	816
	Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Glu Arg Leu Ala Glu	
	260 265 270	
20	ttg agg gat gac ccg agt ttg tgg cct gct gct gtt gat gag ttg atg	864
	Leu Arg Asp Asp Pro Ser Leu Trp Pro Ala Ala Val Asp Glu Leu Met	
	275 280 285	
	agg atg ctt tct ata gcg gac ggg ctg atg aga caa gcc aca gag gac	912
	Arg Met Leu Ser Ile Ala Asp Gly Leu Met Arg Gln Ala Thr Glu Asp	
25	290 295 300	
	atc gag gtg gca ggt act act att aga gcc ggt gaa ggc gtg gtc ttt	960
	Ile Glu Val Ala Gly Thr Thr Ile Arg Ala Gly Glu Gly Val Val Phe	
	305 310 315 320	
30	gcg acc tct gta atc aac aga gat ggg gag gtt tac gca gaa ccc gac	1008
	Ala Thr Ser Val Ile Asn Arg Asp Gly Glu Val Tyr Ala Glu Pro Asp	
	325 330 335	
	gcc ctc gat tgg cat agg ccc acc aga cat cac gtg gca ttc ggc ttt	1056
	Ala Leu Asp Trp His Arg Pro Thr Arg His His Val Ala Phe Gly Phe	
35	340 345 350	
	ggc att cat caa tgt ctc gga cag aat cta gca cgt gcc gag atg gag	1104
	Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu	
	355 360 365	
40	ata gca ctt cgt agt ttg ttc gag aga gtg cct ggg ttg aga ctc gac	1152
	Ile Ala Leu Arg Ser Leu Phe Glu Arg Val Pro Gly Leu Arg Leu Asp	
	370 375 380	
	att gca cca gat gct gtc cgc ttt aaa cca ggt gac acg att cag gga	1200
	Ile Ala Pro Asp Ala Val Arg Phe Lys Pro Gly Asp Thr Ile Gln Gly	
45	385 390 395 400	
	atg ctg gat ctt ccc gtg gcc tgg tag	1227
	Met Leu Asp Leu Pro Val Ala Trp	
	405	
50	<210> 215	
	<211> 416	
	<212> PRT	
	<213> Streptomyces ornatus IFO 13069t	
	<400> 215	
55	Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Pro Ala Pro Thr	
	1 5 10 15	

5 Ala Pro Pro Thr Gln Pro Thr Ser Thr Thr Pro Phe Pro Gln Asn Arg  
 20 25 30  
 Asp Cys Pro Tyr His Pro Pro Thr Gly Tyr Gln Pro Leu Arg Ala Asp  
 35 40 45  
 Arg Pro Leu Ser Arg Val Thr Leu Phe Asp Gly Arg Pro Val Trp Ala  
 50 55 60  
 Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu  
 65 70 75 80  
 10 Ser Thr Asp Arg Thr His Pro Asp Phe Pro Val Pro Ala Glu Arg Phe  
 85 90 95  
 Ala Asn Val Glu Arg Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro  
 100 105 110  
 Glu His Asn Ala Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys  
 115 120 125  
 15 Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Gly Leu  
 130 135 140  
 Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp  
 145 150 155 160  
 Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val  
 165 170 175  
 20 Pro Tyr Ala Asp His Glu Phe Phe Glu Gly Cys Ser Arg Arg Leu Leu  
 180 185 190  
 Gln Gly Pro Gly Ala Ala Asp Val Asn Glu Ala Arg Ile Glu Leu Glu  
 195 200 205  
 Gly Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Val Glu Pro Gly Glu  
 210 215 220  
 25 Gly Leu Leu Asp Glu Leu Ile His Arg Asp His Pro Gly Gly Pro Val  
 225 230 235 240  
 Asp Arg Glu Asp Leu Val Ser Phe Ala Val Ile Leu Leu Val Ala Gly  
 245 250 255  
 His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu  
 260 265 270  
 30 Asn His Pro Glu Gln Leu Glu Ala Leu Arg Ser Gly Ser Thr Thr Thr  
 275 280 285  
 Ala Ala Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly  
 290 295 300  
 Leu Gln Arg Leu Ala Thr Glu Asp Ile Glu Val Ala Gly Thr Thr Ile  
 305 310 315 320  
 35 Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Ile Asn Arg Asp  
 325 330 335  
 Thr Glu Val Tyr Glu Asn Pro Glu Thr Leu Asp Trp Asp Arg Pro Ser  
 340 345 350  
 Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln  
 355 360 365  
 40 Asn Leu Ala Arg Thr Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu  
 370 375 380  
 Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Ala His Glu Ile Arg His  
 385 390 395 400  
 Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu His Leu Pro Val Ala Trp  
 405 410 415  
 45  
 <210> 216  
 <211> 416  
 <212> PRT  
 <213> Streptomyces griseus ATCC 10137  
 50  
 <400> 216  
 Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Pro Ala Pro Thr  
 1 5 10 15  
 Ala Pro Pro Thr Gln Pro Thr Ser Thr Thr Pro Phe Pro Gln Asn Arg  
 20 25 30  
 Asp Cys Pro Tyr His Pro Pro Thr Gly Tyr Gln Pro Leu Arg Ala Asp  
 35 40 45  
 55 Arg Pro Leu Ser Arg Val Thr Leu Phe Asp Gly Arg Pro Val Trp Ala

EP 1 457 558 A1

50 55 60  
Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu  
65 70 75 80  
5 Ser Thr Asp Arg Thr His Pro Asp Phe Pro Val Pro Ala Glu Arg Phe  
85 90 95  
Ala Asn Val Glu Arg Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro  
100 105 110  
Glu His Asn Ala Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys  
115 120 125  
10 Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Gly Leu  
130 135 140  
Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp  
145 150 155 160  
Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val  
15 165 170 175  
Pro Tyr Ala Asp His Glu Phe Phe Glu Gly Cys Ser Arg Arg Leu Leu  
180 185 190  
Gln Gly Pro Gly Ala Ala Asp Val Asn Glu Ala Arg Ile Glu Leu Glu  
195 200 205  
20 Gly Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Val Glu Pro Gly Glu  
210 215 220  
Gly Leu Leu Asp Glu Leu Ile His Arg Asp His Pro Gly Gly Pro Val  
225 230 235 240  
Asp Arg Glu Asp Leu Val Ser Phe Ala Val Ile Leu Leu Val Ala Gly  
245 250 255  
25 His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu  
260 265 270  
Asn His Pro Glu Gln Leu Glu Ala Leu Arg Ser Gly Arg Thr Thr Thr  
275 280 285  
Ala Ala Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly  
290 295 300  
30 Leu Gln Arg Leu Ala Thr Glu Asp Ile Glu Val Ala Gly Thr Thr Ile  
305 310 315 320  
Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Ile Asn Arg Asp  
325 330 335  
Thr Glu Val Tyr Glu Asn Pro Glu Thr Leu Asp Trp Asp Arg Pro Ser  
340 345 350  
35 Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln  
355 360 365  
Asn Leu Ala Arg Thr Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu  
370 375 380  
Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Ala His Glu Ile Arg His  
385 390 395 400  
40 Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu His Leu Pro Val Ala Trp  
405 410 415

<210> 217

<211> 409

<212> PRT

<213> Streptomyces achromogenes IFO 12735

45  
400> 217  
Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Ala Glu Ala Glu Pro  
1 5 10 15  
Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
20 25 30  
50 Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
35 40 45  
Asp Gly Arg Glu Ala Trp Leu Val Thr Gly Gln Ala Thr Ala Arg Ala  
50 55 60  
Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Asp Gly Phe  
65 70 75 80  
55 Pro Val Pro Thr Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Val Ala  
85 90 95

EP 1 457 558 A1

5 Leu Leu Gly Val Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu  
 Ile Pro Ser Phe Thr Leu Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
 Gln Arg Ile Val Asp Glu Leu Leu Asp Ala Met Ile Glu Arg Gly Pro  
 Gly Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
 10 Ile Cys Gly Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu  
 Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Thr Ser Ala Asp Thr Leu  
 Asp Ala Arg Asp Arg Leu Glu Arg Phe Leu Gly Asp Leu Ile Asp Ala  
 15 Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val  
 His His Arg Leu Arg Glu Gly Glu Leu Asp Arg Gly Asp Leu Val Ser  
 Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met  
 20 Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Asp Arg Leu Ala  
 Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu  
 Met Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu  
 25 Asp Val Glu Ile Ala Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu  
 Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro  
 Asp Ala Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly  
 30 Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu  
 Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu  
 Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln  
 35 Gly Met Leu Glu Leu Pro Val Thr Trp  
 405

<210> 218

<211> 416

<212> PRT

<213> Streptomyces griseus IFO 13849T

<400> 218

45 Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Ala Ala Leu Thr  
 Gly Ala Thr Thr Glu Pro Thr Ser Ala Pro Pro Phe Pro Gln Asp Arg  
 Glu Cys Pro Tyr His Pro Pro Thr Gly Tyr Glu Pro Leu Arg Ala Asp  
 Arg Pro Leu Ser Arg Val Thr Leu Tyr Asp Gly Arg Pro Val Trp Ala  
 Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu  
 50 Ser Thr Asp Arg Thr His Pro Ala Phe Pro Val Pro Ala Glu Arg Phe  
 Ala Gln Thr Arg Gln Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro  
 Glu His Asn Thr Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys  
 55 Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Arg Leu

EP 1 457 558 A1

130 135 140  
 Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp  
 145 150 155 160  
 5 Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val  
 165 170 175  
 Pro Tyr Ala Asp His Ala Leu Phe Glu Gly Cys Ser Arg Arg Leu Leu  
 180 185 190  
 Arg Gly Pro Gly Ala Asp Asp Val Asp Ala Ala Arg Val Glu Leu Glu  
 195 200 205  
 10 Glu Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Ala Asp Pro Gly Glu  
 210 215 220  
 Gly Leu Leu Asp Glu Leu Ile His Arg Asp Arg Pro Asp Gly Pro Val  
 225 230 235 240  
 Ser Arg Glu Asp Leu Val Ser Phe Ala Leu Ile Leu Leu Val Ala Gly  
 245 250 255  
 15 His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu  
 260 265 270  
 Arg His Pro Gly Gln Leu Ala Ala Leu Arg Ser Gly Glu Thr Thr Thr  
 275 280 285  
 Ala Val Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly  
 290 295 300  
 20 Leu Gln Arg Leu Ala Ile Glu Asp Ile Glu Val Asp Gly Thr Thr Ile  
 305 310 315 320  
 Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Val Asn Arg Asp  
 325 330 335  
 Ala Asp Val Phe Ala Asp Pro Glu Thr Leu Asp Trp Glu Arg Ser Ala  
 340 345 350  
 25 Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln  
 355 360 365  
 Asn Leu Ala Arg Ala Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu  
 370 375 380  
 Arg Leu Pro Ala Leu Arg Leu Ala Val Pro Ala Asp Glu Val Arg His  
 385 390 395 400  
 30 Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu Glu Leu Pro Val Ala Trp  
 405 410 415  
  
 <210> 219  
 <211> 405  
 <212> PRT  
 <213> Streptomyces lanatus IFO 12787T  
  
 <400> 219  
 Met Thr Asp Met Thr Asp Met Thr Arg Pro Pro Thr Val Ala Phe Pro  
 1 5 10 15  
 40 Gln Asn Arg Thr Cys Pro Tyr His Pro Pro Thr Ala Tyr Asp Pro Leu  
 20 25 30  
 Arg Asp Thr Arg Pro Leu Ala Arg Ile Thr Leu Tyr Asp Gly Arg Pro  
 35 40 45  
 Val Trp Leu Val Thr Gly His Ala Leu Ala Arg Thr Leu Leu Ala Asp  
 50 55 60  
 45 Pro Arg Leu Ser Ser Asp Arg Gly Arg Pro Gly Phe Pro Ala Pro Asn  
 65 70 75 80  
 Glu Arg Phe Ala Val Arg Asp Arg Lys Ser Ala Leu Leu Gly Val  
 85 90 95  
 Asp Asp Pro Glu His Arg Val Gln Arg Arg Met Met Val Pro Ser Phe  
 100 105 110  
 50 Thr Leu Arg Arg Ala Ala Glu Leu Arg Pro Gln Ile Gln Arg Ile Val  
 115 120 125  
 Asp Glu Arg Leu Asp Ala Met Ile Asp Gln Gly Ala Pro Ala Glu Leu  
 130 135 140  
 Val Asn Ala Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu  
 145 150 155 160  
 55 Leu Gly Val Pro Tyr Ala Asp His Asp Phe Glu Gly Glu Ser Arg  
 165 170 175

EP 1 457 558 A1

5 Arg Leu Leu Arg Gly Ala Thr Ala Ala Glu Ala Met Asp Ala Arg Asp  
 180 185 190  
 Arg Leu Glu Asn Tyr Phe Ile Glu Leu Ile Asp Arg Lys Gln Lys Asp  
 195 200 205  
 Pro Glu Pro Gly Asp Gly Val Leu Asp Glu Leu Val His Arg Gln Leu  
 210 215 220  
 Arg Asp Gly Asp Leu Asp Arg Glu Glu Val Val Ala Leu Ser Thr Ile  
 225 230 235 240  
 10 Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly  
 245 250 255  
 Thr Phe Thr Leu Leu Gln His Pro Glu Glu Leu Ala Glu Leu Arg Ala  
 260 265 270  
 Asp Ala Gly Leu Leu Pro Ala Ala Val Glu Glu Leu Met Arg Met Leu  
 275 280 285  
 15 Ser Ile Ala Asp Gly Leu Leu Arg Val Ala Ser Glu Asp Ile Glu Ala  
 290 295 300  
 Gly Gly Glu Thr Ile Arg Ala Gly Asp Gly Val Val Phe Ser Thr Ser  
 305 310 315 320  
 Val Ile Asn Arg Asp Glu Ser Val Tyr Pro Asp Pro Asp Ala Ile Asp  
 325 330 335  
 20 Trp His Arg Pro Thr Arg His His Ile Ala Phe Gly Phe Gly Ile His  
 340 345 350  
 Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu  
 355 360 365  
 Arg Thr Leu Phe Glu Arg Leu Pro Thr Leu Arg Leu Ala Val Pro Ala  
 370 375 380  
 25 Gly Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu  
 385 390 395 400  
 Leu Pro Val Thr Trp  
 405  
 <210> 220  
 <211> 414  
 <212> PRT  
 <213> Streptomyces misawanensis IFO 13855T  
 <400> 220  
 35 Met Lys Glu Leu Thr Asp Leu Thr Glu Pro Ile Ser Pro Ala Gly Gln  
 1 5 10 15  
 Ala Asp Pro Val Ala Trp Pro Gln Asp Arg Thr Cys Pro Tyr His Pro  
 20 25 30  
 Pro Thr Gly Tyr Asp Pro Leu Arg Asp Gly Thr Pro Leu Ser Arg Val  
 35 40 45  
 40 Thr Leu Tyr Asp Gly Arg Thr Val Trp Ala Val Thr Gly His Gly Thr  
 50 55 60  
 Ala Arg Ala Leu Leu Ser Asp Pro Arg Leu Ser Ser Asp Arg Arg Arg  
 65 70 75 80  
 Asp Asp Phe Pro Met Pro Asn Ala Arg Phe Ala Ala Ala Arg Glu Arg  
 85 90 95  
 45 Arg Gln Leu Ala Leu Leu Gly Leu Asp Pro Glu His Gln Ile Gln  
 100 105 110  
 Arg Arg Met Leu Ile Pro Asp Phe Thr Leu Lys Arg Ala Thr Val Met  
 115 120 125  
 Arg Pro Ala Ile Gln Arg Ile Val Asp Asp Leu Leu Asp Arg Met Ile  
 130 135 140  
 50 Ala Ala Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala Leu Pro Val  
 145 150 155 160  
 Pro Ser Met Val Ile Cys Asp Leu Leu Gly Val Pro Tyr Ala Asp His  
 165 170 175  
 Glu Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly Pro Ala Pro  
 180 185 190  
 55 Ala Asp Ser Leu Asp Ala Arg Asp Gln Leu Glu Ala Tyr Leu Gly Asp  
 195 200 205  
 Leu Ala Asp Arg Lys Ser Arg Asp Ala Val Pro Gly Asp Gly Val Leu

EP 1 457 558 A1

210 215 220  
 Asp Asp Leu Val His Gln Arg Leu Arg Asp Gly Ala Leu Asp Arg Ala  
 225 230 235 240  
 5 Glu Val Val Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr  
 245 250 255  
 Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln Gln Pro  
 260 265 270  
 Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Ala Leu Val Pro Ala Ala  
 275 280 285  
 10 Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu Arg  
 290 295 300  
 Val Ala Leu Glu Asp Ile Glu Thr Asp Gly Gly Thr Thr Ile Arg Lys  
 305 310 315 320  
 Gly Glu Gly Val Leu Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Ser  
 325 330 335  
 15 Val Tyr Asp Asp Pro Asp Ala Leu Asp Trp His Arg Pro Ala Arg His  
 340 345 350  
 His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu  
 355 360 365  
 Ala Arg Thr Glu Leu Glu Ile Ala Leu Arg Thr Leu Trp Glu Arg Leu  
 370 375 380  
 20 Pro Asp Leu Arg Leu Ala Ala Pro Pro Glu Glu Ile Pro Phe Lys Pro  
 385 390 395 400  
 Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp  
 405 410  
  
 25 <210> 221  
 <211> 409  
 <212> PRT  
 <213> Streptomyces pallidus IFO 13434T  
  
 <400> 221  
 30 Met Ala Asp Thr Leu Ala Gly Ala Thr Pro Asp Ala Ala Ala Thr Val  
 1 5 10 15  
 Pro Ala Tyr Pro Met Ala Arg Ala Ala Gly Cys Pro Phe Asp Pro Pro  
 20 25 30  
 Pro Asp Leu Thr Ala Arg Gln Asp Glu Gly Arg Leu Val Arg Val Arg  
 35 35 40 45  
 Leu Trp Asp Gly Ser Thr Pro Trp Leu Val Thr Arg Tyr Glu Asp Gln  
 50 55 60  
 Arg Ala Leu Leu Leu Asp Pro Arg Val Ser Ala Asp Ile Thr Arg Pro  
 65 70 75 80  
 Gly Tyr Pro Leu Gln Ala Ala Gly Ala Gly Glu Asn Asn Ala Ser Phe  
 85 90 95  
 40 Ile Leu Met Asp Asp Pro Glu His Ala Arg Leu Arg Arg Met Val Thr  
 100 105 110  
 Ala Pro Phe Ala Ile Lys Arg Val Glu Ala Met Arg Pro Gly Val Gln  
 115 120 125  
 Gln Leu Val Asp Asp Leu Ile Asp Gly Met Leu Ala Gly Pro Lys Pro  
 130 135 140  
 45 Val Asp Leu Val Glu Ala Phe Ala Leu Pro Val Pro Ser Leu Val Ile  
 145 150 155 160  
 Cys Arg Met Leu Gly Val Pro Tyr Glu Asp His Asp Phe Phe Gln Glu  
 165 170 175  
 Asn Ser Arg Ile Leu Ile Lys Arg Asp Ala Ala Met Glu Asp Arg Met  
 180 185 190  
 50 Ala Ala His Gly Arg Leu Ile Ala Tyr Leu Asp Glu Leu Met Gly Glu  
 195 200 205  
 Lys Thr Ala Arg Pro Ala Asp Asp Leu Leu Ser Gly Leu Val Glu Arg  
 210 215 220  
 Val Arg Thr Gly Glu Leu Thr Arg Arg Glu Ser Ala Arg Met Gly Val  
 225 230 235 240  
 55 Leu Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met Ile Ala Leu  
 245 250 255

Gly Thr Leu Ala Leu Leu Glu His Pro Asp Gln Leu Ala Leu Leu Arg  
 260 265 270  
 5 Asp Thr Asp Asp Pro Lys Leu Val Ala Gly Ala Ala Glu Glu Leu Leu  
 275 280 285  
 Arg Tyr Leu Thr Ile Val His Asn Gly Arg Arg Arg Ala Ala Leu Ala  
 290 295 300  
 Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Gly Glu Gly Met Ile  
 305 310 315 320  
 10 Met Pro Asn Asp Leu Ala Asn Arg Asp Pro Gly Ala Phe Thr Asp Pro  
 325 330 335  
 Asp Arg Leu Asp Leu Arg Arg Asp Ala Arg Arg His Ile Ala Phe Gly  
 340 345 350  
 Phe Gly Val His Gln Cys Leu Gly Gln Pro Leu Ala Arg Met Glu Leu  
 355 360 365  
 15 Gln Val Val Tyr Gly Thr Leu Tyr Arg Arg Ile Pro Thr Leu Arg Leu  
 370 375 380  
 Ala Ala Pro Val Glu Ser Leu Ser Phe Lys His Asp Gly Ser Val Tyr  
 385 390 395 400  
 Gly Val Tyr Glu Leu Pro Val Thr Trp  
 405  
 20  
 <210> 222  
 <211> 398  
 <212> PRT  
 <213> Streptomyces roseorubens IFO 13682T  
 25  
 <400> 222  
 Met Thr Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys  
 1 5 10 15  
 Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro  
 20 25 30  
 30 Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser  
 35 40 45  
 Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser  
 50 55 60  
 Asp Arg Asp Arg Pro Gly Phe Pro Thr Pro Thr Ala Arg Phe Ala Gly  
 65 70 75 80  
 35 Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His  
 85 90 95  
 Arg Ala Gln Arg Arg Met Val Val Gly Asp Phe Thr Leu Lys Arg Ala  
 100 105 110  
 Ala Ala Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Glu Arg Leu Asp  
 115 120 125  
 40 Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ala Phe Ala  
 130 135 140  
 Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr  
 145 150 155 160  
 Ala Asp His Asp Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly  
 165 170 175  
 45 Pro Gly Thr Ala Asp Val Gln Asp Ala Arg Ser Arg Leu Glu Tyr  
 180 185 190  
 Phe Gly Glu Leu Ile Asp Arg Lys Arg Glu Asp Pro Gly Thr Gly Leu  
 195 200 205  
 Leu Asp Asp Leu Val Gln Arg Gln Pro Gly Asp Gly Gly Pro Asp Arg  
 210 215 220  
 50 Glu Gly Leu Ile Ala Met Ala Leu Ile Leu Leu Val Ala Gly His Glu  
 225 230 235 240  
 Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His  
 245 250 255  
 Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Ser Glu Val Met Pro Ala  
 260 265 270  
 55 Ala Val Glu Glu Leu Met Arg Leu Leu Ser Ile Ala Asp Gly Leu Leu  
 275 280 285  
 Arg Ile Ala Val Glu Asp Val Glu Val Ala Gly Thr Thr Ile Arg Ala

EP 1 457 558 A1

290 295 300  
 Gly Glu Gly Val Val Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Thr  
 305 310 315 320  
 5 Val Phe Ala Glu Pro Asp Thr Leu Asp Trp Ser Arg Pro Ala Arg His  
 325 330 335  
 His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu  
 340 345 350  
 Ala Arg Ala Glu Leu Glu Ile Ala Leu Gly Thr Leu Phe Gly Arg Leu  
 355 360 365  
 10 Pro Thr Leu Arg Leu Ala Ala Pro Pro Asp Glu Ile Pro Phe Lys Pro  
 370 375 380  
 Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp  
 385 390 395  
  
 15 <210> 223  
 <211> 414  
 <212> PRT  
 <213> Streptomyces rutgersensis IFO 15875T  
  
 20 <400> 223  
 Met Thr Glu Thr Leu Ala Glu Thr Thr Thr Glu Ala Glu Glu Pro Leu  
 1 5 10 15  
 Pro Glu Phe Pro Met Pro Arg Ala Asn Gly Cys Pro Phe Ala Pro Pro  
 20 25 30  
 Pro Thr Ala Arg Ala Leu His Thr Glu Arg Pro Val Thr Arg Val Arg  
 35 40 45  
 25 Leu Trp Asp Gly Ser Ala Pro Trp Leu Val Thr Arg Tyr Ala Asp Gln  
 50 55 60  
 Arg Ala Leu Leu Gly Asp Pro Arg Val Ser Ser Glu Ala Thr Arg Pro  
 65 70 75 80  
 Gly Phe Pro His Ala Ser Ala Gly Phe Arg Glu Asn Ala Arg Arg Arg  
 85 90 95  
 30 Arg Ser Phe Ile Thr Met Asp Asp Pro Glu His Ala Arg Ile Arg Arg  
 100 105 110  
 Met Val Thr Ala Pro Phe Ala Ile Lys Arg Val Glu Ala Met Arg Pro  
 115 120 125  
 Asp Ile Gln Lys Ile Thr Asp Asp Leu Ile Asp Ser Met Leu Ala Gly  
 130 135 140  
 35 Pro Thr Pro Val Asp Leu Val Arg Ala Leu Ala Leu Pro Leu Pro Ser  
 145 150 155 160  
 Leu Val Ile Cys Arg Leu Leu Gly Val Pro Tyr Glu Asp His Asp Phe  
 165 170 175  
 Phe Gln Arg Asn Ser Ser Leu Leu Ile Asn Arg Asn Ser Thr Thr Glu  
 180 185 190  
 40 Glu Val Val Gly Ala Asn Glu Ala Leu Thr Asp Tyr Leu Asp Glu Leu  
 195 200 205  
 Val Ser Ala Lys Leu Ala Asn Pro Ala Asp Asp Met Leu Ser Glu Leu  
 210 215 220  
 Ala Ala Arg Val Thr Ala Gly Glu Leu Thr Gln Arg Glu Ala Ala Asn  
 225 230 235 240  
 45 Met Gly Val Leu Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met  
 245 250 255  
 Ile Ala Leu Gly Thr Val Ala Leu Leu Glu Asn Pro Asp Gln Leu Ala  
 260 265 270  
 Val Leu Arg Glu Thr Asp Asp Pro Lys Ala Val Ala Lys Ala Val Glu  
 275 280 285  
 50 Glu Leu Leu Arg Tyr Leu Thr Ile Val His Thr Gly Arg Arg Arg Val  
 290 295 300  
 Ala Arg Glu Asp Ile Glu Ile Gly Gly Glu Thr Ile Arg Ala Gly Asp  
 305 310 315 320  
 Gly Ile Ile Ile Tyr Thr Gly Thr Gly Asn Trp Asp Ala Glu Val Phe  
 325 330 335  
 55 Pro Glu Pro Glu Arg Leu Asp Ile Gly Arg Asp Ala Arg Arg His Met  
 340 345 350

EP 1 457 558 A1

5 Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln Pro Leu Ala Arg  
355 360 365  
Val Glu Leu Gln Val Val Tyr Gly Thr Leu Tyr Arg Arg Ile Pro Thr  
370 375 380  
Leu Arg Leu Ala Thr Gly Val Asp Gln Leu Pro Phe Lys Asp Asp Gly  
385 390 395 400  
Leu Val Tyr Gly Val Tyr Glu Leu Pro Val Thr Trp Thr Ser  
405 410

10 <210> 224  
<211> 398  
<212> PRT  
<213> Streptomyces steffisburgensis IFO 13446T

15 <400> 224  
Met Ser Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys  
1 5 10 15  
Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro  
20 20 25 30  
Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser  
35 40 45  
Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser  
50 55 60  
Asp Arg Asp Arg Pro Gly Phe Pro Ala Pro Thr Ala Arg Phe Ala Gly  
65 70 75 80  
Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His  
25 85 90 95  
Arg Val Gln Arg Arg Met Val Ala Gly Asp Phe Thr Leu Lys Arg Ala  
100 105 110  
Ala Gly Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Arg Arg Leu Asp  
115 120 125  
Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala  
30 130 135 140  
Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr  
145 150 155 160  
Ala Asp His Asp Phe Phe Glu Thr Gln Ser Arg Arg Leu Leu Arg Gly  
165 170 175  
Pro Gln Thr Ala Asp Val Met Asp Ala Arg Ala Arg Leu Asp Glu Tyr  
35 180 185 190  
Phe Gly Glu Leu Ile Asp Arg Lys Arg Lys Glu Pro Gly Ala Gly Leu  
195 200 205  
Leu Asp Asp Leu Val Gln Arg Gln Leu Arg Asp Gly Ala Leu Asp Arg  
210 215 220  
Glu Gly Leu Ile Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu  
40 225 230 235 240  
Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His  
245 250 255  
Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Arg Leu Leu Pro Ala  
260 265 270  
Ala Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu  
45 275 280 285  
Arg Leu Ala Val Glu Asp Ile Glu Val Ala Gly Thr Thr Ile Arg Lys  
290 295 300  
Gly Asp Gly Val Val Phe Leu Thr Ser Val Ile Asn Arg Asp Glu Thr  
305 310 315 320  
Val Tyr Pro Glu Pro Asp Thr Leu Asp Trp His Arg Ser Ala Arg His  
50 325 330 335  
His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu  
340 345 350  
Ala Arg Ala Glu Leu Glu Ile Ala Leu Trp Thr Leu Phe Asp Arg Leu  
355 360 365  
Pro Thr Leu Arg Leu Ala Ala Pro Ala Glu Glu Ile Ala Phe Lys Pro  
55 370 375 380  
Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp

EP 1 457 558 A1

385 390 395

5 <210> 225  
 <211> 1251  
 <212> DNA  
 <213> Streptomyces ornatus IFO 13069t

10 <220>  
 <221> CDS  
 <222> (1)..(1251)

<400> 225

15	atg acg gaa tcc acg acg gaa ccg gcc cgc cag gac ccc gct ccc acc	48
	Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Pro Ala Pro Thr	
	1 5 10 15	
	gcc cct ccg acg caa ccg acc tcc acg aca ccc ttc ccc cag aac cgc	96
	Ala Pro Pro Thr Gln Pro Thr Ser Thr Thr Pro Phe Pro Gln Asn Arg	
	20 25 30	
20	gac tgc ccc tac cac ccg ccc acc ggg tac caa ccg ctc cgc gcg gac	144
	Asp Cys Pro Tyr His Pro Pro Thr Gly Tyr Gln Pro Leu Arg Ala Asp	
	35 40 45	
	cgg ccg ctc agc cgg gtc acc ctc ttc gac ggg cgt ccg gtc tgg gcc	192
	Arg Pro Leu Ser Arg Val Thr Leu Phe Asp Gly Arg Pro Val Trp Ala	
25	50 55 60	
	gtc acc ggc cac gcc ctg gcc cgc cgg cta ctg gcg gat ccg cgc ctg	240
	Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu	
	65 70 75 80	
30	tcc acc gat cgc acc cac ccc gac ttc ccc gtt ccg gcc gag cgg ttc	288
	Ser Thr Asp Arg Thr His Pro Asp Phe Pro Val Pro Ala Glu Arg Phe	
	85 90 95	
	gcg aac gtc gag cgg cgg cgc gtg gcc ctg ctc ggc gtc gac gac ccc	336
	Ala Asn Val Glu Arg Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro	
35	100 105 110	
	gag cac aac gcc cag cgc agg atg ctc atc ccg agc ttc tcc gtg aag	384
	Glu His Asn Ala Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys	
	115 120 125	
40	cgg ata gcc gcg ctg cgc ccc cgc atc cag gag acg gtg gac gga ctg	432
	Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Gly Leu	
	130 135 140	
	ctg gac gcg atg gag cgg cag ggc ccg ccg tcc gaa ctg gtc gcc gac	480
	Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp	
45	145 150 155 160	
	ttc gcg ctg ccg gtg ccg tcg atg gtg atc tgc gcg ctc ctc ggt gtg	528
	Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val	
	165 170 175	
50	ccg tac gcc gac cac gag ttc ttc gag ggc tgc tcc ccg cgg ctc ctg	576
	Pro Tyr Ala Asp His Glu Phe Phe Glu Gly Cys Ser Arg Arg Leu Leu	
	180 185 190	
	cag ggc ccg ggc gcg gcc gat gtg aac gag gcc cgg atc gag ctg gag	624
	Gln Gly Pro Gly Ala Ala Asp Val Asn Glu Ala Arg Ile Glu Leu Glu	
55	195 200 205	

EP 1 457 558 A1

5	ggc tat ctg ggc gcc ctg atc gac cgc aag cgg gtg gag ccg ggg gag Gly Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Val Glu Pro Gly Glu 210 215 220	672
10	ggg ctc ctg gac gaa ctg atc cac cgg gac cac ccc ggc gga ccc gtc Gly Leu Leu Asp Glu Leu Ile His Arg Asp His Pro Gly Gly Pro Val 225 230 235 240	720
15	gac cgc gag gac ctc gtc tcg ttc gcg gtg atc ctc ctc gtc gcg ggg Asp Arg Glu Asp Leu Val Ser Phe Ala Val Ile Leu Leu Val Ala Gly 245 250 255	768
20	cac gag acg acg gcg aac atg atc tcg ctc ggc acg ttc acg ctg ctg His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu 260 265 270	816
25	aac cac ccg gaa cag ctg gag gcg ctg cgg tcc ggg agc acg acg acg Asn His Pro Glu Gln Leu Glu Ala Leu Arg Ser Gly Ser Thr Thr Thr 275 280 285	864
30	gcc gcg gtg gtc gag gaa ctg ctg cgg ttc ctc tcc atc gcc gag gga Ala Ala Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly 290 295 300	912
35	ctg caa cgg ctg gcc acc gag gac atc gag gtg gcc ggg acg acg atc Leu Gln Arg Leu Ala Thr Glu Asp Ile Glu Val Ala Gly Thr Thr Ile 305 310 315 320	960
40	cgc gag gga gag ggc gtg ttc ttc tcg acc tcg ctc atc aac cgc gac Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Thr Ser Leu Ile Asn Arg Asp 325 330 335	1008
45	acc gag gtc tac gag aat ccg gag acg ctc gac tgg gac cgg cct tcc Thr Glu Val Tyr Glu Asn Pro Glu Thr Leu Asp Trp Asp Arg Pro Ser 340 345 350	1056
50	cgg cac cac ctc gcc ttc ggc ttc ggc gtc cat cag tgc ctg ggc cag Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln 355 360 365	1104
55	aat ctg gcc cgc acc gag ctc gac atc gcc ctg cgc act ctc ttc gag Asn Leu Ala Arg Thr Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu 370 375 380	1152
60	cgg ctg ccg gga ctc agg ctc gcc gtg ccc gcg cac gag atc cgg cac Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Ala His Glu Ile Arg His 385 390 395 400	1200
65	aaa ccc ggg gac acg atc cag ggc ctt ctg cac ctg ccc gtg gcc tgg Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu His Leu Pro Val Ala Trp 405 410 415	1248
70	tga	1251
75	<210> 226 <211> 1251 <212> DNA <213> Streptomyces griseus ATCC 10137	
80	<220> <221> CDS <222> (1)..(1251)	
85	<400> 226	

EP 1 457 558 A1

5	atg acg gaa tcc acg acg gaa ccg gcc cgc cag gac ccc gct ccc acc Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Pro Ala Pro Thr 1 5 10 15	48
10	gcc cct ccg acg caa ccg acc tcc acg aca ccc ttc ccc cag aac cgc Ala Pro Pro Thr Gln Pro Thr Ser Thr Thr Pro Phe Pro Gln Asn Arg 20 25 30	96
15	gac tgc ccc tac cac ccg ccc acc ggg tac caa ccg ctc cgc gcg gac Asp Cys Pro Tyr His Pro Pro Thr Gly Tyr Gln Pro Leu Arg Ala Asp 35 40 45	144
20	cgg ccg ctc agc cgg gtc acc ctc ttc gac ggg cgt ccg gtc tgg gcc Arg Pro Leu Ser Arg Val Thr Leu Phe Asp Gly Arg Pro Val Trp Ala 50 55 60	192
25	gtc acc ggc cac gcc ctg gcc cgc cgg cta ctg gcg gat ccg cgc ctg Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu 65 70 75 80	240
30	tcc acc gat cgc acc cac ccc gac ttc ccc gtt ccg gcc gag cgg ttc Ser Thr Asp Arg Thr His Pro Asp Phe Pro Val Pro Ala Glu Arg Phe 85 90 95	288
35	gcg aac gtc gag cgg agg cga gtg gcc ctg ctc ggc gtc gac gac ccc Ala Asn Val Glu Arg Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro 100 105 110	336
40	gag cac aac gcc cag cgc agg atg ctc atc ccg agc ttc tcc gtg aag Glu His Asn Ala Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys 115 120 125	384
45	cgg ata gcc gcg ctg cgc ccc cgc atc cag gag acg gtg gac gga ctg Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Gly Leu 130 135 140	432
50	ctg gac gcg atg gag cgg cag ggc ccg ccg tcc gaa ctg gtc gcc gac Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp 145 150 155 160	480
55	ttc gcg ctg ccg gtg ccg tcg atg gtg atc tgc gcg ctc ctc ggt gtg Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val 165 170 175	528
60	ccg tac gcc gac cac gag ttc ttc gag ggc tgc tcc ccg ccg ctc ctg Pro Tyr Ala Asp His Glu Phe Phe Glu Gly Cys Ser Arg Arg Leu Leu 180 185 190	576
65	cag ggc ccg ggc gcg gcc gat gtg aac gag gcc ccg atc gag ctg gag Gln Gly Pro Gly Ala Ala Asp Val Asn Glu Ala Arg Ile Glu Leu Glu 195 200 205	624
70	ggc tat ctg ggc gcc ctg atc gac cgc aag ccg gtg gag ccg ggg gag Gly Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Val Glu Pro Gly Glu 210 215 220	672
75	ggg ctc ctg gac gaa ctg atc cac ccg gac cac ccc ggc gga ccc gtc Gly Leu Leu Asp Glu Leu Ile His Arg Asp His Pro Gly Gly Pro Val 225 230 235 240	720
80	gac cgc gag gac ctc gtc tcg ttc gcg gtg atc ctc ctc gtc gcg ggg Asp Arg Glu Asp Leu Val Ser Phe Ala Val Ile Leu Leu Val Ala Gly 245 250 255	768

EP 1 457 558 A1

5	cac gag acg acg gcg aac atg atc tcg ctc ggc acg ttc acg ctg ctg His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu 260 265 270	816
	aac cac ccg gaa cag ctg gag gcg ctg cgc tcc ggg agg acg acg acg Asn His Pro Glu Gln Leu Glu Ala Leu Arg Ser Gly Arg Thr Thr Thr 275 280 285	864
10	gcc gcg gtg gtc gag gaa ctg ctg cgg ttc ctc tcc atc gcc gag gga Ala Ala Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly 290 295 300	912
15	ctg caa cgg ctg gcc acc gag gac atc gag gtg gcc ggg acg acg atc Leu Gln Arg Leu Ala Thr Glu Asp Ile Glu Val Ala Gly Thr Thr Ile 305 310 315 320	960
	cgc gag gga gag ggc gtg ttc ttc tcg acc tcg ctc atc aac cgc gac Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Ile Asn Arg Asp 325 330 335	1008
20	acc gag gtc tac gag aat ccg gag acg ctc gac tgg gac cgg cct tcc Thr Glu Val Tyr Glu Asn Pro Glu Thr Leu Asp Trp Asp Arg Pro Ser 340 345 350	1056
25	cgg cac cac ctc gcc ttc ggc ttc ggc gtc cac cag tgc ctg ggc cag Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln 355 360 365	1104
	aat ctg gcc cgc acc gag ctc gac atc gcc ctg cgc act ctc ttc gag Asn Leu Ala Arg Thr Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu 370 375 380	1152
30	cgg ctg ccg gga ctc agg ctc gcc gtg ccc gcg cac gag atc cgg cac Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Ala His Glu Ile Arg His 385 390 395 400	1200
35	aaa ccc ggg gac acg atc cag ggc ctt ctg cac ctg ccc gtg gcc tgg Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu His Leu Pro Val Ala Trp 405 410 415	1248
	tga	1251
40	<210> 227 <211> 1230 <212> DNA <213> Streptomyces achromogenes IFO 12735	
45	<220> <221> CDS <222> (1)..(1230)	
	<400> 227 atg acg gaa ctg acg gac atc acc ggc ccg gct gcc gag gcc gaa ccc Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Ala Glu Ala Glu Pro 1 5 10 15	48
50	gtc gcc ttc ccc cag gac cgc acc tgt ccc tac cac ccc ccc acc gga Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly 20 25 30	96
55	tac gac ccg ctg cgc gac ggg cga ccc ctg tcc cgc gtc acc ctc tac Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr 35 40 45	144

EP 1 457 558 A1

5	gac ggc cgc gag gcc tgg ctg gtc acc ggc cag gcc acc gcc cgc gcc Asp Gly Arg Glu Ala Trp Leu Val Thr Gly Gln Ala Thr Ala Arg Ala 50 55 60	192
10	ctg ctc gcc gac ccg cgg ctg tcc acc gac cgc cgc cgc gac ggc ttc Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe 65 70 75 80	240
15	ccc gtg ccc acc ccc cgc ttc gag gcc ggc cgc gac cgc aag gtg gcc Pro Val Pro Thr Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Val Ala 85 90 95	288
20	ctg ctc ggg gtg gac gat ccc gag cac cac cag cag cgc cgg atg ctg Leu Leu Gly Val Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu 100 105 110	336
25	atc ccg tcc ttc acc ctc aaa cgc gcc acc gcg ctg cgc ccc tgg atc Ile Pro Ser Phe Thr Leu Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile 115 120 125	384
30	cag cgg atc gtg gac gaa ctg ctg gac gcg atg atc gag cgg ggg ccg Gln Arg Ile Val Asp Glu Leu Leu Asp Ala Met Ile Glu Arg Gly Pro 130 135 140	432
35	ggg gcc gaa ctg gtc tcc gcc ttc gcg ctg ccc gtg ccg tcc atg gtc Gly Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val 145 150 155 160	480
40	atc tgc ggc ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag Ile Cys Gly Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu 165 170 175	528
45	gag cag tcc cgc cgg ctg ctg cgc ggg ccg acc agc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Thr Ser Ala Asp Thr Leu 180 185 190	576
50	gac gcc cgg gac cgg ctg gag cgg ttc ctc ggc gac ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Arg Phe Leu Gly Asp Leu Ile Asp Ala 195 200 205	624
55	aag gcc aag gag gcc gag ccc ggc gac ggc att ctg gac gac ctc gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val 210 215 220	672
60	cac cac cgg ctc cgc gag ggc gaa ctg gac cgg ggt gac ctg gtg tcc His His Arg Leu Arg Glu Gly Glu Leu Asp Arg Gly Asp Leu Val Ser 225 230 235 240	720
65	ctc gcc gtg atc ctg ttg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255	768
70	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gac cgg ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Asp Arg Leu Ala 260 265 270	816
75	gag ctg cgg gcc gac ccc gcg ctg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu 275 280 285	864
80	atg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag Met Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300	912

EP 1 457 558 A1

5	gac gtc gag atc gcc ggc acc acc atc cgg gcc ggc gac ggc gtc ctg Asp Val Glu Ile Ala Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320	960
	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335	1008
10	gac gcg ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Ala Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350	1056
15	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcg cgc gcg gag ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365	1104
	gag atc gcc ctc ggc agc ctg ttc acc cgg ttg ccc ggg ctg cgg ctc Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380	1152
20	gcc gct ccg gcc gag gag atc ccc ttc aaa ccg ggc gac acg atc cag Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400	1200
25	ggg atg ctg gaa ctc ccc gtg acc tgg taa Gly Met Leu Glu Leu Pro Val Thr Trp 405	1230
30	<p>&lt;210&gt; 228            &lt;211&gt; 1251            &lt;212&gt; DNA            &lt;213&gt; Streptomyces griseus IFO 13849T</p> <p>&lt;220&gt;            &lt;221&gt; CDS            &lt;222&gt; (1)..(1251)</p> <p>&lt;400&gt; 228</p>	
35	atg acg gaa tcc acg acg gaa ccg gcc cgc cag gac gcc gcc ctc acc Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Ala Ala Leu Thr 1 5 10 15	48
40	ggc gcc acc acc gaa ccg acc tcc gcc cca ccg ttc ccg cag gac cgc Gly Ala Thr Thr Glu Pro Thr Ser Ala Pro Pro Phe Pro Gln Asp Arg 20 25 30	96
	gag tgc ccc tac cac ccg ccc acc ggg tac gaa ccg ctg cgc gcg gac Glu Cys Pro Tyr His Pro Pro Thr Gly Tyr Glu Pro Leu Arg Ala Asp 35 40 45	144
45	cgg ccg ttg agc cgg gtc acg ctc tac gac gga cgc ccg gtc tgg gcc Arg Pro Leu Ser Arg Val Thr Leu Tyr Asp Gly Arg Pro Val Trp Ala 50 55 60	192
50	gtc acc gga cac gcc ctg gcc cgc cgc ctc ctg gcc gac ccc cga ctc Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu 65 70 75 80	240
	tcc acc gac cgc acc cac ccc gcc ttc ccc gtc ccg gcc gag cgg ttc Ser Thr Asp Arg Thr His Pro Ala Phe Pro Val Pro Ala Glu Arg Phe 85 90 95	288
55	gcg cag acc ccg cag ccg cgc gtg gcc ctg ctc ggc gtc gac gac ccc Ala Gln Thr Arg Gln Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro	336

EP 1 457 558 A1

	100	105	110	
5	gag cac aac acc cag cgc agg atg ctc atc ccg agc ttc tcc gtg aaa Glu His Asn Thr Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys 115 120 125	384		
10	cgg atc gcc gcg ctg cgc ccc cgt atc cag gag acg gtg gac cgg ctg Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Arg Leu 130 135 140	432		
15	ctg gac gcc atg gag cgg cag ggg ccg ccg tcc gaa ctg gtc gcc gac Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp 145 150 155 160	480		
20	ttc gcg ctg ccg gtg ccg tcc atg gtg atc tgc gcc ctc ctc ggc gtg Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val 165 170 175	528		
25	ccc tac gcc gac cac gcg ctc ttc gag ggc tgt tgc cgc cgg ctc ctg Pro Tyr Ala Asp His Ala Leu Phe Glu Gly Cys Ser Arg Arg Leu Leu 180 185 190	576		
30	cgc ggt ccg ggc gcg gac gac gtg gac gcg gcc cgc gtc gaa ctg gag Arg Gly Pro Gly Ala Asp Asp Val Asp Ala Ala Arg Val Glu Leu Glu 195 200 205	624		
35	gag tac ctc ggc gcg ttg atc gac cgc aaa cgc gcc gat ccg ggg gag Glu Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Ala Asp Pro Gly Glu 210 215 220	672		
40	ggg ctg ctg gac gag ctg atc cac cgg gac cgt ccg gac gga ccc gtg Gly Leu Leu Asp Glu Leu Ile His Arg Asp Arg Pro Asp Gly Pro Val 225 230 235 240	720		
45	agc cgg gag gac ctc gtc tcc ttc gcc ctg atc ctg ctc gtc gcc gga Ser Arg Glu Asp Leu Val Ser Phe Ala Leu Ile Leu Leu Val Ala Gly 245 250 255	768		
50	cac gag acg acc gcg aac atg atc tgc ctc ggc acg ttc acc ctg ctg His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu 260 265 270	816		
55	cgc cac ccc ggt caa ctg gcg gcg ctg cgc tgc ggg gag acc acg acg Arg His Pro Gly Gln Leu Ala Ala Leu Arg Ser Gly Glu Thr Thr Thr 275 280 285	864		
60	gcc gtc gtg gtc gag gag ttg ctg cgc ttc ctc tcc atc gcc gag ggg Ala Val Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly 290 295 300	912		
65	ctg caa cgc ctc gcg atc gag gac atc gag gtg gac ggg acg acg atc Leu Gln Arg Leu Ala Ile Glu Asp Ile Glu Val Asp Gly Thr Thr Ile 305 310 315 320	960		
70	cgc gag ggg gag ggc gtc ttc ttc tcc acc tgc ctc gtc aac cgc gac Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Val Asn Arg Asp 325 330 335	1008		
75	gcc gac gtg ttc gcg gac ccg gag acc ctg gac tgg gag cgg tcc gcc Ala Asp Val Phe Ala Asp Pro Glu Thr Leu Asp Trp Glu Arg Ser Ala 340 345 350	1056		
80	cgg cac cac ctc gcg ttc ggc ttc ggc gtc cac cag tgc ctg gga cag Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln	1104		

EP 1 457 558 A1

	355	360	365	
5	aac ctg gcc cgc gcc gaa ctc gac atc gcg ctc cgc acg ctc ttc gaa Asn Leu Ala Arg Ala Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu 370 375 380			1152
10	cgg ctg ccc gcg ctc agg ctc gcc gta ccg gcg gac gag gtg agg cac Arg Leu Pro Ala Leu Arg Leu Ala Val Pro Ala Asp Glu Val Arg His 385 390 395 400			1200
15	aag ccc ggc gac acc atc cag ggc ctg ctc gaa ctg ccc gtg gcc tgg Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu Glu Leu Pro Val Ala Trp 405 410 415			1248
20	tga <210> 229 <211> 1218 <212> DNA <213> Streptomyces lanatus IFO 12787T			1251
25	<220> <221> CDS <222> (1)..(1218)  <400> 229			
30	atg acg gac atg acc gat atg acg cga ccc ccc acc gtc gcc ttc ccc Met Thr Asp Met Thr Asp Met Thr Arg Pro Pro Thr Val Ala Phe Pro 1 5 10 15			48
35	cag aac cgc acc tgc ccc tac cac cca ccc acc gcc tac gac ccg ctc Gln Asn Arg Thr Cys Pro Tyr His Pro Thr Ala Tyr Asp Pro Leu 20 25 30			96
40	cgc gac acc cgc ccc ctg gcg cgc atc acc ctc tac gac ggc cgc ccg Arg Asp Thr Arg Pro Leu Ala Arg Ile Thr Leu Tyr Asp Gly Arg Pro 35 40 45			144
45	gtc tgg ctg gtc acc ggg cac gcc ctc gcc cgc acc ctg ctc gcc gac Val Trp Leu Val Thr Gly His Ala Leu Ala Arg Thr Leu Leu Ala Asp 50 55 60			192
50	cct cgg ctg tcc tcc gac cgc ggc cgg ccc ggc ttc ccc gcg ccc aac Pro Arg Leu Ser Ser Asp Arg Gly Arg Pro Gly Phe Pro Ala Pro Asn 65 70 75 80			240
55	gag cgg ttc gcg gcg gta cgc gac cgc aag tcc gcg ctg ctc ggc gtc Glu Arg Phe Ala Ala Val Arg Asp Arg Lys Ser Ala Leu Leu Gly Val 85 90 95			288
60	gac gac ccc gaa cac cgg gtc cag cga cgg atg atg gtc ccc agc ttc Asp Asp Pro Glu His Arg Val Gln Arg Arg Met Met Val Pro Ser Phe 100 105 110			336
65	act ctc cgc cga gcc gcc gaa ctg cgc ccg cag atc cag cgg atc gtg Thr Leu Arg Arg Ala Ala Glu Leu Arg Pro Gln Ile Gln Arg Ile Val 115 120 125			384
70	gac gaa cgg ctc gac gcg atg atc gac cag ggg gcg ccc gcc gag ctg Asp Glu Arg Leu Asp Ala Met Ile Asp Gln Gly Ala Pro Ala Glu Leu 130 135 140			432
75	gtg aac gcc ttc gcg ctg ccc gtg ccc tcg atg gtc atc tgc gcc ctg Val Asn Ala Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu			480

EP 1 457 558 A1

	145		150		155		160	
5	ctg ggc gtg ccc tat gcc gac cac gac ttc ttc gag ggg gag tcc cgg							528
	Leu Gly Val Pro Tyr 165		Ala Asp His Asp Phe Phe Glu Gly Glu Ser Arg 175					
10	cgc ctg ctg cgc ggt gcc acg gcg gcc gag gcc atg gac gcc cgg gac							576
	Arg Leu Leu Arg Gly Ala Thr Ala Ala Glu Ala Met Asp Ala Arg Asp 190							
15	cgg ctg gag aac tac ttc atc gag ctg atc gac cgc aag cag aag gac							624
	Arg Leu Glu Asn Tyr Phe Ile Glu Leu Ile Asp Arg Lys Gln Lys Asp 205							
20	ccg gag ccc ggc gac ggc gtc ctc gac gaa ctc gtc cac cgg cag ctg							672
	Pro Glu Pro Gly Asp Gly Val Leu Asp Glu Leu Val His Arg Gln Leu 220							
25	cgc gac ggc gac ctc gac cgc gag gaa gtc gtc gcc ctc tcg acc atc							720
	Arg Asp Gly Asp Leu Asp Arg Glu Glu Val Val Ala Leu Ser Thr Ile 240							
30	ctg ctg gtc gcc ggc cac gag acg acc gcc aac atg atc tcg ctg ggt							768
	Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly 255							
35	acc ttc aca ctg ctc caa cac ccg gag cag ctg gcc gag ttg cgc gcc							816
	Thr Phe Thr Leu Gln His Pro Glu Gln Leu Ala Glu Leu Arg Ala 270							
40	gac gcc ggg ttg ctg ccc gcc gcg gtc gag gag ctc atg cgg atg ctg							864
	Asp Ala Gly Leu Leu Pro Ala Ala Val Glu Glu Leu Met Arg Met Leu 285							
45	tcg atc gcg gac ggg ctg ctg cgc gtc gcc tcc gag gac atc gag gcg							912
	Ser Ile Ala Asp Gly Leu Leu Arg Val Ala Ser Glu Asp Ile Glu Ala 300							
50	ggc ggc gag acg atc cgg gcg ggc gac ggc gtg gtc ttc tcg acc tcg							960
	Gly Gly Glu Thr Ile Arg Ala Gly Asp Gly Val Val Phe Ser Thr Ser 320							
55	gtc atc aac cgc gac gag tcc gtc tac ccc gac ccc gat gcc atc gac							1008
	Val Ile Asn Arg Asp Glu Ser Val Tyr Pro Asp Pro Asp Ala Ile Asp 335							
60	tgg cac cgc ccc acc cgc cac cac atc gcc ttc ggg ttc ggc atc cac							1056
	Trp His Arg Pro Thr Arg His His Ile Ala Phe Gly Phe Gly Ile His 350							
65	cag tgc ctc ggc cag aac ctg gcc cgc gcc gag atg gag atc gcc ctg							1104
	Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu 365							
70	cgc acc ctc ttc gag cgc ctg ccc acc ctg cgc ctt gcc gtc ccg gcg							1152
	Arg Thr Leu Phe Glu Arg Leu Pro Thr Leu Arg Leu Ala Val Pro Ala 380							
75	ggg gaa atc ccc ttc aaa ccc ggc gac acg atc cag ggg atg ctg gaa							1200
	Gly Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu 400							
80	ctc ccc gtg acc tgg taa							1218
	Leu Pro Val Thr Trp							

405

5 <210> 230  
 <211> 1245  
 <212> DNA  
 <213> Streptomyces misawanensis IFO 13855T  
  
 10 <220>  
 <221> CDS  
 <222> (1)..(1245)  
  
 <400> 230  
 atg aaa gaa ctg acg gac ctg acg gaa ccc atc tct ccc gcc ggc cag 48  
 Met Lys Glu Leu Thr Asp Leu Thr Glu Pro Ile Ser Pro Ala Gly Gln  
 1 5 10 15  
  
 gcc gac ccc gtg gcc tgg ccg cag gac cgc acg tgc ccc tac cac ccg 96  
 Ala Asp Pro Val Ala Trp Pro Gln Asp Arg Thr Cys Pro Tyr His Pro  
 20  
  
 ccc acc ggc tac gac ccg ctc cgc gac ggc acc ccg ctg tcc cgc gtc 144  
 Pro Thr Gly Tyr Asp Pro Leu Arg Asp Gly Thr Pro Leu Ser Arg Val  
 35 40 45  
  
 acc ctc tac gac ggc cgc acc gtc tgg gcg gtc acc ggc cac ggc acg 192  
 Thr Leu Tyr Asp Gly Arg Thr Val Trp Ala Val Thr Gly His Gly Thr  
 50 55 60  
  
 gcc cgg gcg ctg ctc tcc gac ccc cgc ctc tcc agc gac cgc cgg cgc 240  
 Ala Arg Ala Leu Leu Ser Asp Pro Arg Leu Ser Ser Asp Arg Arg Arg  
 65 70 75 80  
  
 30 gac gac ttc ccg atg ccg aac gcc cgg ttc gcg gcg gcc cgg gag cgc 288  
 Asp Asp Phe Pro Met Pro Asn Ala Arg Phe Ala Ala Ala Arg Glu Arg  
 85 90 95  
  
 cga cag ctc gcc ctg ctg ggc ctc gac gac ccc gag cac cag atc cag 336  
 Arg Gln Leu Ala Leu Leu Gly Leu Asp Pro Glu His Gln Ile Gln  
 100 105 110  
  
 cgc cgg atg ctg atc ccg gac ttc acc ctc aag cgg gcg acc gtg atg 384  
 Arg Arg Met Leu Ile Pro Asp Phe Thr Leu Lys Arg Ala Thr Val Met  
 115 120 125  
  
 40 cgg ccg gcc atc cag cgg atc gtc gac gat ctg ctc gac agg atg atc 432  
 Arg Pro Ala Ile Gln Arg Ile Val Asp Asp Leu Leu Asp Arg Met Ile  
 130 135 140  
  
 gcc gcg ggc ccg ccc gcc gac ctg gtg agc tcc ttc gcg ctg ccc gtg 480  
 Ala Ala Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala Leu Pro Val  
 145 150 155 160  
  
 ccg tcc atg gtc atc tgt gac ctg ctc ggc gtg ccc tac gcc gac cac 528  
 Pro Ser Met Val Ile Cys Asp Leu Leu Gly Val Pro Tyr Ala Asp His  
 165 170 175  
  
 50 gag ttc ttc gag gcg cag tcc cgg cgg ctg ctg cgc ggt ccg gcg ccc 576  
 Glu Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly Pro Ala Pro  
 180 185 190  
  
 gcc gac tcc ctg gac gcg cgc gac cag ctg gag gcc tat ctg ggc gac 624  
 Ala Asp Ser Leu Asp Ala Arg Asp Gln Leu Glu Ala Tyr Leu Gly Asp  
 195 200 205

EP 1 457 558 A1

	ctg gcc gac cgc aag agc cgg gac gcg gtc ccc ggc gac ggc gtc ctc	672
	Leu Ala Asp Arg Lys Ser Arg Asp Ala Val Pro Gly Asp Gly Val Leu	
	210 215 220	
5		
	gac gac ctc gtc cac cag cgg ctg cgg gac ggc gcc ctg gac cgc gcc	720
	Asp Asp Leu Val His Gln Arg Leu Arg Asp Gly Ala Leu Asp Arg Ala	
	225 230 235 240	
10		
	gag gtc gtc gcg ctg gcc ctc atc ctg ctg gtc gcc ggc cac gag acc	768
	Glu Val Val Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu Thr	
	245 250 255	
	acc gcc aac atg atc tcg ctc ggc acc ttc acc ctg ctc cag cag ccc	816
	Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln Gln Pro	
	260 265 270	
15		
	gaa cgg ctc gcc gaa ctg cgc gcc gac ccc gcg ctg gtg ccc gcc gcc	864
	Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Ala Leu Val Pro Ala Ala	
	275 280 285	
20		
	gtc gag gaa ctg atg cgg atg ctg tcc atc gcc gac ggg ctg ctg cgc	912
	Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu Arg	
	290 295 300	
	gtc gca ctg gag gac atc gag acg gac ggc ggc acc acc atc cgc aag	960
	Val Ala Leu Glu Asp Ile Glu Thr Asp Gly Gly Thr Thr Ile Arg Lys	
	305 310 315 320	
25		
	ggc gag ggc gtg ctc ttc gcg acc tcg gtc atc aac cgt gac gag tcc	1008
	Gly Glu Gly Val Leu Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Ser	
	325 330 335	
30		
	gtg tac gac gac ccc gac gcc ctc gac tgg cac cgc ccg gcc cgc cac	1056
	Val Tyr Asp Asp Pro Asp Ala Leu Asp Trp His Arg Pro Ala Arg His	
	340 345 350	
	cac gtg gcc ttc ggc ttc ggc atc cac cag tgc ctg ggc cag aac ctg	1104
	His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu	
	355 360 365	
35		
	gcc cgc acc gag ctg gag atc gcc ctg cgc acc ctg tgg gag cgg ctc	1152
	Ala Arg Thr Glu Leu Glu Ile Ala Leu Arg Thr Leu Trp Glu Arg Leu	
	370 375 380	
40		
	ccg gac ctg cgg ctc gcc gca ccg ccg gag gag att ccc ttc aaa ccc	1200
	Pro Asp Leu Arg Leu Ala Ala Pro Pro Glu Glu Ile Pro Phe Lys Pro	
	385 390 395 400	
	ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg acc tgg taa	1245
	Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp	
	405 410	
45		
	<210> 231	
	<211> 1230	
	<212> DNA	
	<213> Streptomyces pallidus IFO 13434T	
50		
	<220>	
	<221> CDS	
	<222> (1)..(1230)	
	<400> 231	
55		
	atg gcc gac acc ctc gcc ggc gcc acg ccc gac gcc gcc gcg acg gtc	48
	Met Ala Asp Thr Leu Ala Gly Ala Thr Pro Asp Ala Ala Ala Thr Val	

EP 1 457 558 A1

	1		5		10		15	
5	ccc gcg tac	ccc atg gcc cgg gcc	gcg ggc tgc ccc ttc gac ccg ccc	96				
	Pro Ala Tyr	Pro Met Ala Arg Ala	Ala Gly Cys Pro Phe Asp Pro Pro					
		20	25	30				
	ccg gac ctc	acc gcc cgg cag gac	gag ggt cgg ctc gtc agg gtg cgc	144				
10	Pro Asp Leu	Thr Ala Arg Gln Asp	Glu Gly Arg Leu Val Arg Val Arg					
	35	40	45					
	ctc tgg gac	ggc agt acg ccc tgg	ctc gtg acc cgc tac gag gac cag	192				
	Leu Trp Asp	Gly Ser Thr Pro Trp	Leu Val Thr Arg Tyr Glu Asp Gln					
	50	55	60					
15	cgc gcc ctg	ctc ctc gac ccc agg	gtc agt gcc gac atc acc agg ccc	240				
	Arg Ala Leu	Leu Leu Asp Pro Arg	Val Ser Ala Asp Ile Thr Arg Pro					
	65	70	75	80				
	gga tac ccc	ctc cag gcc gcc ggc	gcc ggc gag aac aac gcc agc ttc	288				
20	Gly Tyr Pro	Leu Gln Ala Ala Gly	Ala Gly Glu Asn Asn Ala Ser Phe					
		85	90	95				
	atc ctc atg	gac gac ccg gag cac	gca cgg ctg cgc cgc atg gtg acc	336				
	Ile Leu Met	Asp Asp Pro Glu His	Ala Arg Leu Arg Arg Met Val Thr					
		100	105	110				
25	gcg ccc ttc	gcg atc aag cgc gtc	gag gcg atg cgg ccg ggc gtg cag	384				
	Ala Pro Phe	Ala Ile Lys Arg Val	Glu Ala Met Arg Pro Gly Val Gln					
	115	120	125					
	cag ctc gtg	gac gac ctc atc gac	ggc atg ctc gcc ggg ccc aag ccg	432				
30	Gln Leu Val	Asp Asp Leu Ile Asp	Gly Met Leu Ala Gly Pro Lys Pro					
	130	135	140					
	gtc gac ctg	gtg gag gcg ttc gcg	ctg ccg gtg ccc tcg ctg gtc atc	480				
	Val Asp Leu	Val Glu Ala Phe Ala	Leu Pro Val Pro Ser Leu Val Ile					
	145	150	155	160				
35	tgc cgg atg	ctc gga gtg ccg tac	gag gac cac gac ttc ttc cag gag	528				
	Cys Arg Met	Leu Gly Val Pro Tyr	Glu Asp His Asp Phe Phe Gln Glu					
		165	170	175				
	aac agc cgg	atc ctc atc aag cgg	gac gcg gcc atg gag gac cgc atg	576				
40	Asn Ser Arg	Ile Leu Ile Lys Arg	Asp Ala Ala Met Glu Asp Arg Met					
		180	185	190				
	gcc gcg cac	ggg cgg ctg atc gcc	tac ctc gac gag ctg atg ggc gag	624				
	Ala Ala His	Gly Arg Leu Ile Ala	Tyr Leu Asp Glu Leu Met Gly Glu					
	195	200	205					
45	aag acg gcc	cgt ccg gcg gac gat	ctg ctc tcc ggg ctc gtc gag cgg	672				
	Lys Thr Ala	Arg Pro Ala Asp Asp	Leu Leu Ser Gly Leu Val Glu Arg					
	210	215	220					
	gtc agg acg	ggg gag ctg acc cgg	cgc gag tcg gcc cgc atg ggc gtg	720				
50	Val Arg Thr	Gly Glu Leu Thr Arg	Arg Glu Ser Ala Arg Met Gly Val					
	225	230	235	240				
	ctc ctg ctc	atc gcc ggg cac gag	acc acc gcc aac atg atc gcg ctc	768				
	Leu Leu Leu	Ile Ala Gly His Glu	Thr Thr Ala Asn Met Ile Ala Leu					
		245	250	255				
55	ggc acg ctc	gcc ctg ctc gaa cac	ccg gac cag ctc gcc ctg ctg cgt	816				
	Gly Thr Leu	Ala Leu Leu Glu His	Pro Asp Gln Leu Ala Leu Leu Arg					

EP 1 457 558 A1

	260	265	270	
5	gac acc gac gac ccg aag ctg gtc gcc gga gcg gcc gag gaa ctg ctg Asp Thr Asp Asp Pro Lys Leu Val Ala Gly Ala Ala Glu Glu Leu Leu 275 280 285			864
10	cgc tat ctg acc atc gtg cac aac gga cgc cgc cgg gcg gcc ctc gcg Arg Tyr Leu Thr Ile Val His Asn Gly Arg Arg Arg Ala Ala Leu Ala 290 295 300			912
15	gac atc gag atc ggc gga cag gtc atc cgg gcc ggc gag ggc atg atc Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Gly Glu Gly Met Ile 305 310 315 320			960
20	atg ccc aac gac ctc gcc aac cgg gac ccc ggc gcc ttc acc gac ccg Met Pro Asn Asp Leu Ala Asn Arg Asp Pro Gly Ala Phe Thr Asp Pro 325 330 335			1008
25	gac cgg ctg gac ctg cgc cgc gac gcc cgc cgg cac atc gcg ttc ggc Asp Arg Leu Asp Leu Arg Arg Asp Ala Arg Arg His Ile Ala Phe Gly 340 345 350			1056
30	ttc ggc gtg cac cag tgc ctg ggc cag ccg ctg gcc cgc atg gaa ctc Phe Gly Val His Gln Cys Leu Gly Gln Pro Leu Ala Arg Met Glu Leu 355 360 365			1104
35	cag gtc gtc tac ggc acc ctc tac cgc cgc atc ccc acg ctg cgg ctc Gln Val Val Tyr Gly Thr Leu Tyr Arg Arg Ile Pro Thr Leu Arg Leu 370 375 380			1152
40	gcc gcc ccg gtg gag agc ctg tcg ttc aag cac gac gga tcg gtc tac Ala Ala Pro Val Glu Ser Leu Ser Phe Lys His Asp Gly Ser Val Tyr 385 390 395 400			1200
45	ggc gtc tac gaa ctg ccc gtc acg tgg tga Gly Val Tyr Glu Leu Pro Val Thr Trp 405 410			1230
50	<210> 232 <211> 1197 <212> DNA <213> Streptomyces roseorubens IFO 13682T			
55	<220> <221> CDS <222> (1)..(1197)			
60	<400> 232			
65	atg acg gac acg acc gca ccc gtc gcc ttc ccc cag agc agg acc tgc Met Thr Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys 1 5 10 15			48
70	ccc tac cac ccg ccc gcc gcc tac gag ccg ctg cgc gcc gag cgc ccc Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro 20 25 30			96
75	ctg acc cgg atc acc ctc ttc gac ggc cgt gag gcc tgg ctg gtc agc Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser 35 40 45			144
80	ggc cac gcc acc gcc cgc gcc ctg ctc gcc gac ccc cgc ctg tcc tcc Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser 50 55 60			192

EP 1 457 558 A1

5	gac cgc gac cgc ccc ggc ttc ccc acc ccc acc gcg cgc ttc gcc ggc Asp Arg Asp Arg Pro Gly Phe Pro Thr Pro Thr Ala Arg Phe Ala Gly 65 70 75 80	240
	atc cgc aac cgc cgt acg gcc ctg ctc ggc gtg gac gac ccc gag cac Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His 85 90 95	288
10	cgc gcc cag cgg cgg atg gtc gtc ggg gac ttc acc ctc aaa cgg gcc Arg Ala Gln Arg Arg Met Val Val Gly Asp Phe Thr Leu Lys Arg Ala 100 105 110	336
15	gcc gca ctg cgg ccc cgc atc cag cgg atc gtc gac gaa cga ctc gac Ala Ala Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Glu Arg Leu Asp 115 120 125	384
	gcg atg atc gcc cag ggc ccg ccc gcc gac ctg gtg agc gcc ttc gcg Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ala Phe Ala 130 135 140	432
20	ctg ccc gtg ccc tcc atg gtg atc tgc gcc ctg ctc ggc gtc ccc tac Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr 145 150 155 160	480
25	gcc gac cac gac ttc ttc gag gct cag tgc cgg cgc ctg ctg cgc ggc Ala Asp His Asp Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly 165 170 175	528
	ccg ggg acc gcc gac gtg cag gac gcc cgg agc agg ctg gag gag tac Pro Gly Thr Ala Asp Val Gln Asp Ala Arg Ser Arg Leu Glu Glu Tyr 180 185 190	576
30	ttc ggc gag ctg atc gac cgc aag cgc gag gac ccc ggc acc ggc ctc Phe Gly Glu Leu Ile Asp Arg Lys Arg Glu Asp Pro Gly Thr Gly Leu 195 200 205	624
35	ctg gac gac ctg gtc caa cgg cag ccc ggc gac ggc gga ccc gac cgc Leu Asp Asp Leu Val Gln Arg Gln Pro Gly Asp Gly Pro Asp Arg 210 215 220	672
	gag ggc ctg atc gcc atg gcc ctc atc ctg ctg gtc gcc ggc cac gag Glu Gly Leu Ile Ala Met Ala Leu Ile Leu Val Ala Gly His Glu 225 230 235 240	720
40	acg acc gcc aac atg atc tcc ctc ggc acc ttc acg ctc ctg cag cac Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255	768
45	ccc gag cgg ctc gcc gaa ctg cgc gcc gac tcc gag gtc atg ccg gcc Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Ser Glu Val Met Pro Ala 260 265 270	816
	gcg gtc gag gaa ctg atg cgg ctg ctg tcc atc gcg gac ggc ctg ctg Ala Val Glu Glu Leu Met Arg Leu Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285	864
50	cgc atc gcc gtc gag gac gtc gag gtg gcc ggg acg acg atc cgc gcc Arg Ile Ala Val Glu Asp Val Glu Val Ala Gly Thr Thr Ile Arg Ala 290 295 300	912
55	ggc gag ggc gtg gtg ttc gcg acg tgc gtc atc aac cgc gac gag acg Gly Glu Gly Val Val Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320	960

EP 1 457 558 A1

5 gtc ttc gcc gag ccg gac acc ctc gac tgg agc cgc ccg gcc cgc cac 1008  
Val Phe Ala Glu Pro Asp Thr Leu Asp Trp Ser Arg Pro Ala Arg His  
325 330 335

10 cac gtg gcg ttc ggc ttc ggc atc cac cag tgc ctc ggc caa aac ctc 1056  
His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu  
340 345 350

15 gca cgc gcc gaa ctg gag atc gcc ctc ggc acc ctc ttc ggc cgg ctg 1104  
Ala Arg Ala Glu Leu Glu Ile Ala Leu Gly Thr Leu Phe Gly Arg Leu  
355 360 365

20 ccc acg ctg cgc ctg gcc gcc ccg ccc gac gag atc ccc ttc aag ccg 1152  
Pro Thr Leu Arg Leu Ala Pro Pro Asp Glu Ile Pro Phe Lys Pro  
370 375 380

25 ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg acc tgg taa 1197  
Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp  
385 390 395

30 <210> 233  
<211> 1245  
<212> DNA  
<213> Streptomyces rutgersensis IFO 15875T

35 <220>  
<221> CDS  
<222> (1)..(1245)

40 <400> 233  
atg acc gaa acg ctg gca gag acc acg acc gag gcg gaa gag ccg ctt 48  
Met Thr Glu Thr Leu Ala Glu Thr Thr Thr Glu Ala Glu Glu Pro Leu  
1 5 10 15

45 ccg gag ttc ccg atg ccg cgg gcg aac ggc tgc ccc ttc gcc ccg ccc 96  
Pro Glu Phe Pro Met Pro Arg Ala Asn Gly Cys Pro Phe Ala Pro Pro  
20 25 30

50 ccg acc gca cgg gcg ctg cac acc gaa cgg ccg gtc acg cgg gta cgg 144  
Pro Thr Ala Arg Ala Leu His Thr Glu Arg Pro Val Thr Arg Val Arg  
35 40 45

55 ctg tgg gac ggc agc gcc ccc tgg ctg gtg acc cgg tac gcc gac cag 192  
Leu Trp Asp Gly Ser Ala Pro Trp Leu Val Thr Arg Tyr Ala Asp Gln  
50 55 60

60 cgc gcc ctg ctc ggc gac ccg cgg gtc agc tcc gag gcc acc cgg ccc 240  
Arg Ala Leu Leu Gly Asp Pro Arg Val Ser Ser Glu Ala Thr Arg Pro  
65 70 75 80

65 ggc ttt ccg cat gcg agc gcc ggc ttc cgc gag aat gcc agg cgg cgg 288  
Gly Phe Pro His Ala Ser Ala Gly Phe Arg Glu Asn Ala Arg Arg Arg  
85 90 95

70 cgc tcc ttc atc acc atg gac gac ccc gag cac gcc cgg atc cgc cgg 336  
Arg Ser Phe Ile Thr Met Asp Asp Pro Glu His Ala Arg Ile Arg Arg  
100 105 110

75 atg gtc acc gcg ccg ttc gcc atc aag cgg gtc gag gcg atg cgg ccc 384  
Met Val Thr Ala Pro Phe Ala Ile Lys Arg Val Glu Ala Met Arg Pro  
115 120 125

80 gac atc cag aag atc acc gac gat ctg atc gac tcc atg ctg gcc ggg 432  
Asp Ile Gln Lys Ile Thr Asp Asp Leu Ile Asp Ser Met Leu Ala Gly

EP 1 457 558 A1

	130	135	140	
5	ccg acc ccg gtc gac ctg gtg cgc gcg ttg gcg ctg ccg ctg ccg tcg Pro Thr Pro Val Asp Leu Val Arg Ala Leu Ala Leu Pro Leu Pro Ser 145 150 155 160	480		
10	ctg gtg atc tgc cgg ctg ctc gga gtg ccg tac gag gac cac gac ttc Leu Val Ile Cys Arg Leu Leu Gly Val Pro Tyr Glu Asp His Asp Phe 165 170 175	528		
	ttc cag cgc aac agc tcg ctc ctg atc aac cgt aac tcc acg acc gaa Phe Gln Arg Asn Ser Ser Leu Leu Ile Asn Arg Asn Ser Thr Thr Glu 180 185 190	576		
15	gag gtg gtc ggc gcc aac gag gcg ctg acc gac tat ctg gac gag ctg Glu Val Val Gly Ala Asn Glu Ala Leu Thr Asp Tyr Leu Asp Glu Leu 195 200 205	624		
20	gtc agc gcc aaa ctc gcc aac ccc gcc gac gac atg ctc tcc gag ctg Val Ser Ala Lys Leu Ala Asn Pro Ala Asp Asp Met Leu Ser Glu Leu 210 215 220	672		
	gcc gcc cgg gtc acg gcc gga gag ctg acc cag cgc gag gcc gcc aat Ala Ala Arg Val Thr Ala Gly Glu Leu Thr Gln Arg Glu Ala Ala Asn 225 230 235 240	720		
25	atg ggc gtg ctg ctg ctg atc gcc ggc cat gag acc acc gcc aac atg Met Gly Val Leu Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255	768		
30	atc gcc ctc ggc acc gtc gcc ctg ctg gag aac ccc gac cag ctc gcc Ile Ala Leu Gly Thr Val Ala Leu Leu Glu Asn Pro Asp Gln Leu Ala 260 265 270	816		
	gtc ctg cgg gag acc gac gac cgg aag gcg gtc gcc aag gcc gtc gag Val Leu Arg Glu Thr Asp Asp Pro Lys Ala Val Ala Lys Ala Val Glu 275 280 285	864		
35	gaa ctg ctg cgc tat ctg acc atc gtg cac acc ggc cgg cgc cgg gtc Glu Leu Leu Arg Tyr Leu Thr Ile Val His Thr Gly Arg Arg Arg Val 290 295 300	912		
40	gcg cgg gag gac atc gag atc ggc ggc gag acc atc cgt gcc ggg gac Ala Arg Glu Asp Ile Glu Ile Gly Gly Glu Thr Ile Arg Ala Gly Asp 305 310 315 320	960		
	ggg atc atc atc tac acc ggc acc ggc aac tgg gac gcg gag gtc ttc Gly Ile Ile Ile Tyr Thr Gly Thr Gly Asn Trp Asp Ala Glu Val Phe 325 330 335	1008		
45	ccc gag ccc gag cgg ctg gac atc ggc cgc gac gcc cgc cgc cac atg Pro Glu Pro Glu Arg Leu Asp Ile Gly Arg Asp Ala Arg Arg His Met 340 345 350	1056		
50	gcg ttc ggt ttc ggc gtc cac cag tgc ctg ggc cag ccg ctg gcc cgg Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln Pro Leu Ala Arg 355 360 365	1104		
	gtg gag ctg cag gtg gtc tac ggc acg ctc tac cgc cgt atc ccc acg Val Glu Leu Gln Val Val Tyr Gly Thr Leu Tyr Arg Arg Ile Pro Thr 370 375 380	1152		
55	ctg cgg ctg gcg acc ggg gtc gac caa cta ccg ttc aag gac gac ggt Leu Arg Leu Ala Thr Gly Val Asp Gln Leu Pro Phe Lys Asp Asp Gly	1200		

EP 1 457 558 A1

	385	390	395	400	
5	ttg gtc tac ggc gtc tat gaa ctg ccc gtc acc tgg acg tct tga Leu Val Tyr Gly Val Tyr Glu Leu Pro Val Thr Trp Thr Ser	405	410		1245
	<210> 234				
	<211> 1197				
10	<212> DNA				
	<213> Streptomyces steffisburgensis IFO 13446T				
	<220>				
	<221> CDS				
	<222> (1)..(1197)				
15	<400> 234				
	atg tcg gac acg acc gca ccc gtg gcc ttc ccc cag agc cgg acc tgc Met Ser Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys	5	10	15	48
20	ccc tac cac ccg ccc gcc gcc tac gag ccg ctg cgc gcc gag cgc ccc Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro	20	25	30	96
25	ctg acc cgt atc acc ctc ttc gac ggc cgt gag gcc tgg ctg gtc agc Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser	35	40	45	144
	ggc cac gcc acc gcc cgc gcg ctg ctc gcc gac ccg cgc ctg tcc tcc Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser	50	55	60	192
30	gac cgc gac cgc ccc gcc ttc ccc gcc ccc acc gcg cgc ttc gcc ggg Asp Arg Asp Arg Pro Gly Phe Pro Ala Pro Thr Ala Arg Phe Ala Gly	65	70	75	240
35	atc cgc aac cgc aga acg gcc ctg ctg ggc gtc gac gac ccc gag cac Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His	85	90	95	288
	cga gtc cag cgg cgg atg gtg gcc ggg gac ttc acc ctc aaa cgg gcc Arg Val Gln Arg Arg Met Val Ala Gly Asp Phe Thr Leu Lys Arg Ala	100	105	110	336
40	gcc gga ctg cga ccc cgc atc cag cgg atc gtg gac cga cga ctc gac Ala Gly Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Arg Arg Leu Asp	115	120	125	384
45	gcg atg atc gcc cag ggc cca ccg gcc gac ctg gtg agc agc ttc gcg Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala	130	135	140	432
	ctg ccc gtc ccg tcc atg gtg atc tgt gcc ctg ctc ggc gtc ccg tac Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr	145	150	155	480
50	gcc gac cac gac ttc ttc gag acc cag tca cgg cgg ctg ctg cgc ggc Ala Asp His Asp Phe Phe Glu Thr Gln Ser Arg Arg Leu Leu Arg Gly	165	170	175	528
55	ccg cag acc gcc gac gtg atg gac gcc cgg gcc cgg ctg gac gag tac Pro Gln Thr Ala Asp Val Met Asp Ala Arg Ala Arg Leu Asp Glu Tyr	180	185	190	576

EP 1 457 558 A1

5	ttc ggc gaa ctg atc gac cgc aag cgg aag gaa ccc ggc gcc ggc ctg Phe Gly Glu Leu Ile Asp Arg Lys Arg Lys Glu Pro Gly Ala Gly Leu 195 200 205	624
	ctg gac gac ctg gtc cag cga cag ctg cgc gac ggc gca ctc gac cgc Leu Asp Asp Leu Val Gln Arg Gln Leu Arg Asp Gly Ala Leu Asp Arg 210 215 220	672
10	gag ggc ctg atc gcc ctg gcg ctc atc ctg ctg gtc gcg ggc cac gag Glu Gly Leu Ile Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu 225 230 235 240	720
15	acg acc gcc aac atg atc tcg ctc ggc acc ttc acc ctg ctg cag cac Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255	768
	ccc gaa cgg ctc gcc gag ctg cgc gcc gac ccg cgg ctg ctg cct gcg Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Arg Leu Leu Pro Ala 260 265 270	816
20	gcg gtc gag gag ctg atg cgc atg ctg tcc atc gcg gac ggt ctg ctc Ala Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285	864
25	cgc ctc gcc gtc gag gac ata gag gtg gcc ggg acc acg atc cgc aag Arg Leu Ala Val Glu Asp Ile Glu Val Ala Gly Thr Thr Ile Arg Lys 290 295 300	912
	ggg gac ggc gtg gtg ttc ctg acg tcc gtc atc aac cgc gac gag acg Gly Asp Gly Val Val Phe Leu Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320	960
30	gtc tac ccc gag ccg gac acc ctc gac tgg cac cgc tcg gcc cgg cat Val Tyr Pro Glu Pro Asp Thr Leu Asp Trp His Arg Ser Ala Arg His 325 330 335	1008
35	cac gtc gcg ttc ggc ttc ggc atc cac cag tgc ctc ggc cag aac ctc His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu 340 345 350	1056
	gcg cgc gcc gag ctg gag atc gcc ctg tgg acc ctc ttc gac cgt ctg Ala Arg Ala Glu Leu Glu Ile Ala Leu Trp Thr Leu Phe Asp Arg Leu 355 360 365	1104
40	ccc acc ctg cgc ctg gcc gcg ccg gcc gag gag atc gcc ttc aag ccg Pro Thr Leu Arg Leu Ala Ala Pro Ala Glu Glu Ile Ala Phe Lys Pro 370 375 380	1152
45	ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg act tgg taa Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp 385 390 395	1197
50	<p>&lt;210&gt; 235</p> <p>&lt;211&gt; 1454</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Streptomyces ornatus IFO 13069t</p>	
55	<p>&lt;220&gt;</p> <p>&lt;221&gt; CDS</p> <p>&lt;222&gt; (1)..(1251)</p>	
	<p>&lt;220&gt;</p> <p>&lt;221&gt; CDS</p> <p>&lt;222&gt; (1257)..(1454)</p>	

EP 1 457 558 A1

5	<400> 235																48
	atg	acg	gaa	tcc	acg	acg	gaa	ccg	gcc	cgc	cag	gac	ccc	gct	ccc	acc	
	Met	Thr	Glu	Ser	Thr	Thr	Glu	Pro	Ala	Arg	Gln	Asp	Pro	Ala	Pro	Thr	
	1				5					10					15		
10	gcc	cct	ccg	acg	caa	ccg	acc	tcc	acg	aca	ccc	ttc	ccc	cag	aac	cgc	96
	Ala	Pro	Pro	Thr	Gln	Pro	Thr	Ser	Thr	Thr	Pro	Phe	Pro	Gln	Asn	Arg	
				20					25				30				
15	gac	tgc	ccc	tac	cac	ccg	ccc	acc	ggg	tac	caa	ccg	ctc	cgc	gcg	gac	144
	Asp	Cys	Pro	Tyr	His	Pro	Pro	Thr	Gly	Tyr	Gln	Pro	Leu	Arg	Ala	Asp	
			35					40					45				
20	cgg	ccg	ctc	agc	cgg	gtc	acc	ctc	ttc	gac	ggg	cgt	ccg	gtc	tgg	gcc	192
	Arg	Pro	Leu	Ser	Arg	Val	Thr	Leu	Phe	Asp	Gly	Arg	Pro	Val	Trp	Ala	
		50					55					60					
25	gtc	acc	ggc	cac	gcc	ctg	gcc	cgc	cgg	cta	ctg	gcg	gat	ccg	cgc	ctg	240
	Val	Thr	Gly	His	Ala	Leu	Ala	Arg	Arg	Leu	Leu	Ala	Asp	Pro	Arg	Leu	
	65					70				75						80	
30	tcc	acc	gat	cgc	acc	cac	ccc	gac	ttc	ccc	gtt	ccg	gcc	gag	cgg	ttc	288
	Ser	Thr	Asp	Arg	Thr	His	Pro	Asp	Phe	Pro	Val	Pro	Ala	Glu	Arg	Phe	
					85				90						95		
35	gcg	aac	gtc	gag	cgg	cgg	cgc	gtg	gcc	ctg	ctc	ggc	gtc	gac	gac	ccc	336
	Ala	Asn	Val	Glu	Arg	Arg	Arg	Val	Ala	Leu	Leu	Gly	Val	Asp	Pro		
			100					105					110				
40	gag	cac	aac	gcc	cag	cgc	agg	atg	ctc	atc	ccg	agc	ttc	tcc	gtg	aag	384
	Glu	His	Asn	Ala	Gln	Arg	Arg	Met	Leu	Ile	Pro	Ser	Phe	Ser	Val	Lys	
			115					120					125				
45	cgg	ata	gcc	gcg	ctg	cgc	ccc	cgc	atc	cag	gag	acg	gtg	gac	gga	ctg	432
	Arg	Ile	Ala	Ala	Leu	Arg	Pro	Arg	Ile	Gln	Glu	Thr	Val	Asp	Gly	Leu	
		130					135					140					
50	ctg	gac	gcg	atg	gag	cgg	cag	ggc	ccg	ccg	tcc	gaa	ctg	gtc	gcc	gac	480
	Leu	Asp	Ala	Met	Glu	Arg	Gln	Gly	Pro	Pro	Ser	Glu	Leu	Val	Ala	Asp	
	145					150					155					160	
55	ttc	gcg	ctg	ccg	gtg	ccg	tcg	atg	gtg	atc	tgc	gcg	ctc	ctc	ggg	gtg	528
	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val	Ile	Cys	Ala	Leu	Leu	Gly	Val	
				165						170					175		
60	ccg	tac	gcc	gac	cac	gag	ttc	ttc	gag	ggc	tgc	tcc	cgg	cgg	ctc	ctg	576
	Pro	Tyr	Ala	Asp	His	Glu	Phe	Phe	Glu	Gly	Cys	Ser	Arg	Arg	Leu	Leu	
			180					185						190			
65	cag	ggc	ccg	ggc	gcg	gcc	gat	gtg	aac	gag	gcc	cgg	atc	gag	ctg	gag	624
	Gln	Gly	Pro	Gly	Ala	Ala	Asp	Val	Asn	Glu	Ala	Arg	Ile	Glu	Leu	Glu	
			195				200						205				
70	ggc	tat	ctg	ggc	gcc	ctg	atc	gac	cgc	aag	cgg	gtg	gag	ccg	ggg	gag	672
	Gly	Tyr	Leu	Gly	Ala	Leu	Ile	Asp	Arg	Lys	Arg	Val	Glu	Pro	Gly	Glu	
		210					215					220					
75	ggg	ctc	ctg	gac	gaa	ctg	atc	cac	cgg	gac	cac	ccc	ggc	gga	ccc	gtc	720
	Gly	Leu	Leu	Asp	Glu	Leu	Ile	His	Arg	Asp	His	Pro	Gly	Gly	Pro	Val	
	225					230					235					240	
80	gac	cgc	gag	gac	ctc	gtc	tcg	ttc	gcg	gtg	atc	ctc	ctc	gtc	gcg	ggg	768
	Asp	Arg	Glu	Asp	Leu	Val	Ser	Phe	Ala	Val	Ile	Leu	Leu	Val	Ala	Gly	

EP 1 457 558 A1

	245	250	255	
5	cac gag acg acg gcg aac atg atc His Glu Thr Thr Ala Asn Met Ile	tcg ctc ggc acg ttc acg ctg ctg Ser Leu Gly Thr Phe Thr Leu Leu	816	
	260	265	270	
10	aac cac ccg gaa cag ctg gag gcg ctg Asn His Pro Glu Gln Leu Glu Ala Leu	cgg tcc ggg agc acg acg acg Arg Ser Gly Ser Thr Thr Thr	864	
	275	280	285	
	gcc gcg gtg gtc gag gaa ctg ctg Ala Ala Val Val Glu Glu Leu Leu	cgg ttc ctc tcc atc gcc gag gga Arg Phe Leu Ser Ile Ala Glu Gly	912	
	290	295	300	
15	ctg caa cgg ctg gcc acc gag gac atc Leu Gln Arg Leu Ala Thr Glu Asp Ile	gag gtg gcc ggg acg acg atc Glu Val Ala Gly Thr Thr Ile	960	
	305	310	315	
20	cgc gag gga gag ggc gtg ttc ttc Arg Glu Gly Glu Gly Val Phe Phe	tcg acc tgc ctc atc aac cgc gac Ser Thr Ser Leu Ile Asn Arg Asp	1008	
	325	330	335	
	acc gag gtc tac gag aat ccg gag Thr Glu Val Tyr Glu Asn Pro Glu	acg ctc gac tgg gac cgg cct tcc Thr Leu Asp Trp Asp Arg Pro Ser	1056	
	340	345	350	
25	cgg cac cac ctc gcc ttc ggc ttc Arg His His Leu Ala Phe Gly Phe	ggc gtc cat cag tgc ctg ggc cag Gly Val His Gln Cys Leu Gly Gln	1104	
	355	360	365	
30	aat ctg gcc cgc acc gag ctc gac Asn Leu Ala Arg Thr Glu Leu Asp	atc gcc ctg cgc act ctc ttc gag Ile Ala Leu Arg Thr Leu Phe Glu	1152	
	370	375	380	
	cgg ctg ccg gga ctc agg ctc gcc Arg Leu Pro Gly Leu Arg Leu Ala	gtg ccc gcg cac gag atc cgg cac Val Pro Ala His Glu Ile Arg His	1200	
	385	390	395	400
35	aaa ccc ggg gac acg atc cag ggc Lys Pro Gly Asp Thr Ile Gln Gly	ctt ctg cac ctg ccc gtg gcc tgg Leu Leu His Leu Pro Val Ala Trp	1248	
	405	410	415	
40	tga gcggc atg ggc gtg cgg gtc Met Gly Val Arg Val Asp Arg	agg gaa cgg tgc gtg ggg gcc ggc Glu Arg Cys Val Gly Ala Gly	1298	
	420	425	430	
	atg tgc gcg ctg acc gcg ccc gac Met Cys Ala Leu Thr Ala Pro Asp	gtg ttc acg cag gac gac gac ggg Val Phe Thr Gln Asp Asp Asp Gly	1346	
	435	440	445	
45	ttc agc gag atg ctt ccc ggg agc Phe Ser Glu Met Leu Pro Gly Ser	acg gcg ggg acg ggg gac cac cca Thr Ala Gly Thr Gly Asp His Pro	1394	
	450	455	460	
50	cgg gtg cgg gag gcc gtt cgg gcc Arg Val Arg Glu Ala Val Arg Ala	tgc ccg gtc ggg gcg gtg tcc ctg Cys Pro Val Gly Ala Val Ser Leu	1442	
	465	470	475	
	acc gac gac tga Thr Asp Asp		1454	
	480			
55	<210> 236 <211> 1454			

&lt;212&gt; DNA

&lt;213&gt; Streptomyces griseus ATCC 10137

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1251)

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1257)..(1454)

&lt;400&gt; 236

	atg acg gaa tcc acg acg gaa ccg gcc cgc cag gac ccc gct ccc acc	48
	Met Thr Glu Ser Thr Thr Glu Pro Ala Arg Gln Asp Pro Ala Pro Thr	
5	1 5 10 15	
	gcc cct ccg acg caa ccg acc tcc acg aca ccc ttc ccc cag aac cgc	96
	Ala Pro Pro Thr Gln Pro Thr Ser Thr Pro Phe Pro Gln Asn Arg	
	20 25 30	
10	gac tgc ccc tac cac ccg ccc acc ggg tac caa ccg ctc cgc gcg gac	144
	Asp Cys Pro Tyr His Pro Pro Thr Gly Tyr Gln Pro Leu Arg Ala Asp	
	35 40 45	
	cgg ccg ctc agc cgg gtc acc ctc ttc gac ggg cgt ccg gtc tgg gcc	192
	Arg Pro Leu Ser Arg Val Thr Leu Phe Asp Gly Arg Pro Val Trp Ala	
15	50 55 60	
	gtc acc ggc cac gcc ctg gcc cgc cgg cta ctg gcg gat ccg cgc ctg	240
	Val Thr Gly His Ala Leu Ala Arg Arg Leu Leu Ala Asp Pro Arg Leu	
	65 70 75 80	
20	tcc acc gat cgc acc cac ccc gac ttc ccc gtt ccg gcc gag cgg ttc	288
	Ser Thr Asp Arg Thr His Pro Asp Phe Pro Val Pro Ala Glu Arg Phe	
	85 90 95	
	gcg aac gtc gag cgg agg cga gtg gcc ctg ctc ggc gtc gac gac ccc	336
	Ala Asn Val Glu Arg Arg Arg Val Ala Leu Leu Gly Val Asp Asp Pro	
25	100 105 110	
	gag cac aac gcc cag cgc agg atg ctc atc ccg agc ttc tcc gtg aag	384
	Glu His Asn Ala Gln Arg Arg Met Leu Ile Pro Ser Phe Ser Val Lys	
	115 120 125	
30	cgg ata gcc gcg ctg cgc ccc cgc atc cag gag acg gtg gac gga ctg	432
	Arg Ile Ala Ala Leu Arg Pro Arg Ile Gln Glu Thr Val Asp Gly Leu	
	130 135 140	
	ctg gac gcg atg gag cgg cag ggc ccg ccg tcc gaa ctg gtc gcc gac	480
	Leu Asp Ala Met Glu Arg Gln Gly Pro Pro Ser Glu Leu Val Ala Asp	
35	145 150 155 160	
	ttc gcg ctg ccg gtg ccg tcg atg gtg atc tgc gcg ctc ctc ggt gtg	528
	Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val	
	165 170 175	
40	ccg tac gcc gac cac gag ttc ttc gag ggc tgc tcc ccg ccg ctc ctg	576
	Pro Tyr Ala Asp His Glu Phe Phe Glu Gly Cys Ser Arg Arg Leu Leu	
	180 185 190	
	cag ggc ccg ggc gcg gcc gat gtg aac gag gcc ccg atc gag ctg gag	624
	Gln Gly Pro Gly Ala Ala Asp Val Asn Glu Ala Arg Ile Glu Leu Glu	
45	195 200 205	

EP 1 457 558 A1

5	ggc tat ctg ggc gcc ctg atc gac cgc aag cgg gtg gag ccg ggg gag Gly Tyr Leu Gly Ala Leu Ile Asp Arg Lys Arg Val Glu Pro Gly Glu 210 215 220	672
10	ggg ctc ctg gac gaa ctg atc cac cgg gac cac ccc ggc gga ccc gtc Gly Leu Leu Asp Glu Leu Ile His Arg Asp His Pro Gly Gly Pro Val 225 230 235 240	720
15	gac cgc gag gac ctc gtc tcg ttc gcg gtg atc ctc ctc gtc gcg ggg Asp Arg Glu Asp Leu Val Ser Phe Ala Val Ile Leu Leu Val Ala Gly 245 250 255	768
20	cac gag acg acg gcg aac atg atc tcg ctc ggc acg ttc acg ctg ctg His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu 260 265 270	816
25	aac cac ccg gaa cag ctg gag gcg ctg cgc tcc ggg agg acg acg acg Asn His Pro Glu Gln Leu Glu Ala Leu Arg Ser Gly Arg Thr Thr Thr 275 280 285	864
30	gcc gcg gtg gtc gag gaa ctg ctg cgg ttc ctc tcc atc gcc gag gga Ala Ala Val Val Glu Glu Leu Leu Arg Phe Leu Ser Ile Ala Glu Gly 290 295 300	912
35	ctg caa cgg ctg gcc acc gag gac atc gag gtg gcc ggg acg acg atc Leu Gln Arg Leu Ala Thr Glu Asp Ile Glu Val Ala Gly Thr Thr Ile 305 310 315 320	960
40	cgc gag gga gag ggc gtg ttc ttc tcg acc tcg ctc atc aac cgc gac Arg Glu Gly Glu Gly Val Phe Phe Ser Thr Ser Leu Ile Asn Arg Asp 325 330 335	1008
45	acc gag gtc tac gag aat ccg gag acg ctc gac tgg gac cgg cct tcc Thr Glu Val Tyr Glu Asn Pro Glu Thr Leu Asp Trp Asp Arg Pro Ser 340 345 350	1056
50	cgg cac cac ctc gcc ttc ggc ttc ggc gtc cac cag tgc ctg ggc cag Arg His His Leu Ala Phe Gly Phe Gly Val His Gln Cys Leu Gly Gln 355 360 365	1104
55	aat ctg gcc cgc acc gag ctc gac atc gcc ctg cgc act ctc ttc gag Asn Leu Ala Arg Thr Glu Leu Asp Ile Ala Leu Arg Thr Leu Phe Glu 370 375 380	1152
60	cgg ctg ccg gga ctc agg ctc gcc gtg ccc gcg cac gag atc cgg cac Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Ala His Glu Ile Arg His 385 390 395 400	1200
65	aaa ccc ggg gac acg atc cag ggc ctt ctg cac ctg ccc gtg gcc tgg Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu His Leu Pro Val Ala Trp 405 410 415	1248
70	tga gcggc atg ggc gtg cgg gtc gac agg gaa cgg tgc gtg ggg gcc ggc Met Gly Val Arg Val Asp Arg Glu Arg Cys Val Gly Ala Gly 420 425 430	1296
75	atg tgc gcg ctg acc gcg ccc gac gtg ttc acg cag gac gac gac ggg Met Cys Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly 435 440 445	1344
80	ttc agc gag atg ctt ccc ggg agc acg gcg ggg acg ggg gac cac cca Phe Ser Glu Met Leu Pro Gly Ser Thr Ala Gly Thr Gly Asp His Pro 450 455 460	1392

EP 1 457 558 A1

5  
cgg gtg cgg gag gcc gtt cgg gcc tgc ccg gtc ggg gcg gtg tcc ctg 1442  
Arg Val Arg Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ser Leu  
465 470 475

acc gac gac tga 1454  
Thr Asp Asp  
480

10  
<210> 237  
<211> 1449  
<212> DNA  
<213> Streptomyces achromogenes IFO 12735

15  
<220>  
<221> CDS  
<222> (1)..(1230)

20  
<220>  
<221> CDS  
<222> (1243)..(1449)

25  
<400> 237  
atg acg gaa ctg acg gac atc acc ggc ccg gct gcc gag gcc gaa ccc 48  
Met Thr Glu Leu Thr Asp Ile Thr Gly Pro Ala Ala Glu Ala Glu Pro  
1 5 10 15

30  
gtc gcc ttc ccc cag gac cgc acc tgt ccc tac cac ccc ccc acc gga 96  
Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Tyr His Pro Pro Thr Gly  
20 25 30

35  
tac gac ccg ctg cgc gac ggg cga ccc ctg tcc cgc gtc acc ctc tac 144  
Tyr Asp Pro Leu Arg Asp Gly Arg Pro Leu Ser Arg Val Thr Leu Tyr  
35 40 45

40  
gac ggc cgc gag gcc tgg ctg gtc acc ggc cag gcc acc gcc cgc gcc 192  
Asp Gly Arg Glu Ala Trp Leu Val Thr Gly Gln Ala Thr Ala Arg Ala  
50 55 60

45  
ctg ctc gcc gac ccg cgg ctg tcc acc gac cgc cgc cgc gac ggc ttc 240  
Leu Leu Ala Asp Pro Arg Leu Ser Thr Asp Arg Arg Arg Asp Gly Phe  
65 70 75 80

50  
ccc gtg ccc acc ccc cgc ttc gag gcc ggc cgc gac cgc aag gtg gcc 288  
Pro Val Pro Thr Pro Arg Phe Glu Ala Gly Arg Asp Arg Lys Val Ala  
85 90 95

55  
ctg ctc ggg gtg gac gat ccc gag cac cac cag cag cgc cgg atg ctg 336  
Leu Leu Gly Val Asp Asp Pro Glu His His Gln Gln Arg Arg Met Leu  
100 105 110

60  
atc ccg tcg ttc acc ctc aaa cgc gcc acc gcg ctg cgc ccc tgg atc 384  
Ile Pro Ser Phe Thr Leu Lys Arg Ala Thr Ala Leu Arg Pro Trp Ile  
115 120 125

65  
cag cgg atc gtg gac gaa ctg ctg gac gcg atg atc gag cgg ggg ccg 432  
Gln Arg Ile Val Asp Glu Leu Leu Asp Ala Met Ile Glu Arg Gly Pro  
130 135 140

70  
ggg gcc gaa ctg gtc tcc gcc ttc gcg ctg ccc gtg ccg tcc atg gtc 480  
Gly Ala Glu Leu Val Ser Ala Phe Ala Leu Pro Val Pro Ser Met Val  
145 150 155 160

75  
atc tgc ggc ctg ctc ggc gtg ccc tac gcc gac cac gag ttc ttc gag 528  
Ile Cys Gly Leu Leu Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu

EP 1 457 558 A1

	165	170	175	
5	gag cag tcc cgc cgg ctg ctg cgc ggg ccg acc agc gcc gac acc ctg Glu Gln Ser Arg Arg Leu Leu Arg Gly Pro Thr Ser Ala Asp Thr Leu 180 185 190			576
10	gac gcc cgg gac cgg ctg gag cgg ttc ctc ggc gac ctg atc gac gcc Asp Ala Arg Asp Arg Leu Glu Arg Phe Leu Gly Asp Leu Ile Asp Ala 195 200 205			624
15	aag gcc aag gag gcc gag ccc ggc gac ggc att ctg gac gac ctc gtc Lys Ala Lys Glu Ala Glu Pro Gly Asp Gly Ile Leu Asp Asp Leu Val 210 215 220			672
20	cac cac cgg ctc cgc gag ggc gaa ctg gac cgg ggt gac ctg gtg tcg His His Arg Leu Arg Glu Gly Glu Leu Asp Arg Gly Asp Leu Val Ser 225 230 235 240			720
25	ctc gcc gtg atc ctg ttg gtc gcc ggg cac gag acg acc gcc aac atg Leu Ala Val Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala Asn Met 245 250 255			768
30	atc tcc ctg ggc acc tac acc ctg ctc cag cac ccc gac cgg ctg gcc Ile Ser Leu Gly Thr Tyr Thr Leu Leu Gln His Pro Asp Arg Leu Ala 260 265 270			816
35	gag ctg cgg gcc gac ccc gcg ctg ctg ccc gcc gtc gtc gag gaa ctg Glu Leu Arg Ala Asp Pro Ala Leu Leu Pro Ala Val Val Glu Glu Leu 275 280 285			864
40	atg cgg atg ctg tcc atc gcc gag ggg ctg caa cgg gtg gcg ctg gag Met Arg Met Leu Ser Ile Ala Glu Gly Leu Gln Arg Val Ala Leu Glu 290 295 300			912
45	gac gtc gag atc gcc ggc acc acc atc cgg gcc ggc gac ggc gtc ctg Asp Val Glu Ile Ala Gly Thr Thr Ile Arg Ala Gly Asp Gly Val Leu 305 310 315 320			960
50	ttc tcc acc tcg gtc atc aac cgg gac acg gcc gtc tac gac gac ccc Phe Ser Thr Ser Val Ile Asn Arg Asp Thr Ala Val Tyr Asp Asp Pro 325 330 335			1008
55	gac gcg ctg gac ttc cac cgc gcc gac cgg cac cac gtg gcg ttc ggc Asp Ala Leu Asp Phe His Arg Ala Asp Arg His His Val Ala Phe Gly 340 345 350			1056
60	ttc ggc atc cac cag tgc ctg ggc cag aac ctg gcg cgc gcg gag ctg Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Leu 355 360 365			1104
65	gag atc gcc ctc ggc agc ctg ttc acc cgg ttg ccc ggg ctg cgg ctc Glu Ile Ala Leu Gly Ser Leu Phe Thr Arg Leu Pro Gly Leu Arg Leu 370 375 380			1152
70	gcc gct ccg gcc gag gag atc ccc ttc aaa ccg ggc gac acg atc cag Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln 385 390 395 400			1200
75	ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggccttcgc tc atg cac atg Gly Met Leu Glu Leu Pro Val Thr Trp 410 Met His Met			1251
80	gac atc gac atc gac cag gac gtc tgt atc ggc gcc ggg cag tgc gcg Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly Gln Cys Ala			1299

**EP 1 457 558 A1**

[illegible]

EP 1 457 558 A1

5	Arg	Ile	Ala	Ala	Leu	Arg	Pro	Arg	Ile	Gln	Glu	Thr	Val	Asp	Arg	Leu	
	130						135					140					
	ctg	gac	gcc	atg	gag	cgg	cag	ggg	ccg	ccg	tcc	gaa	ctg	gtc	gcc	gac	480
	Leu	Asp	Ala	Met	Glu	Arg	Gln	Gly	Pro	Pro	Ser	Glu	Leu	Val	Ala	Asp	
	145					150					155					160	
10	ttc	gcg	ctg	ccg	gtg	ccg	tcc	atg	gtg	atc	tgc	gcc	ctc	ctc	ggc	gtg	528
	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val	Ile	Cys	Ala	Leu	Leu	Gly	Val	
					165					170					175		
	ccc	tac	gcc	gac	cac	gcg	ctc	ttc	gag	ggc	tgt	tcg	cgc	cgg	ctc	ctg	576
	Pro	Tyr	Ala	Asp	His	Ala	Leu	Phe	Glu	Gly	Cys	Ser	Arg	Arg	Leu	Leu	
				180					185					190			
15	cgc	ggt	ccg	ggc	gcg	gac	gac	gtg	gac	gcg	gcc	cgc	gtc	gaa	ctg	gag	624
	Arg	Gly	Pro	Gly	Ala	Asp	Asp	Val	Asp	Ala	Ala	Arg	Val	Glu	Leu	Glu	
			195					200					205				
20	gag	tac	ctc	ggc	gcg	ttg	atc	gac	cgc	aaa	cgc	gcc	gat	ccg	ggg	gag	672
	Glu	Tyr	Leu	Gly	Ala	Leu	Ile	Asp	Arg	Lys	Arg	Ala	Asp	Pro	Gly	Glu	
		210					215					220					
	ggg	ctg	ctg	gac	gag	ctg	atc	cac	cgc	gac	cgt	ccg	gac	gga	ccc	gtg	720
	Gly	Leu	Leu	Asp	Glu	Leu	Ile	His	Arg	Asp	Arg	Pro	Asp	Gly	Pro	Val	
	225					230					235					240	
25	agc	cgc	gag	gac	ctc	gtc	tcc	ttc	gcc	ctg	atc	ctg	ctc	gtc	gcc	gga	768
	Ser	Arg	Glu	Asp	Leu	Val	Ser	Phe	Ala	Leu	Ile	Leu	Leu	Val	Ala	Gly	
					245					250					255		
30	cac	gag	acg	acc	gcg	aac	atg	atc	tcg	ctc	ggc	acg	ttc	acc	ctg	ctg	816
	His	Glu	Thr	Thr	Ala	Asn	Met	Ile	Ser	Leu	Gly	Thr	Phe	Thr	Leu	Leu	
				260					265					270			
	cgc	cac	ccc	ggt	caa	ctg	gcg	gcg	ctg	cgc	tcg	ggg	gag	acc	acg	acg	864
	Arg	His	Pro	Gly	Gln	Leu	Ala	Ala	Leu	Arg	Ser	Gly	Glu	Thr	Thr	Thr	
			275					280					285				
35	gcc	gtc	gtg	gtc	gag	gag	ttg	ctg	cgc	ttc	ctc	tcc	atc	gcc	gag	ggg	912
	Ala	Val	Val	Val	Glu	Glu	Leu	Leu	Arg	Phe	Leu	Ser	Ile	Ala	Glu	Gly	
		290					295					300					
40	ctg	caa	cgc	ctc	gcg	atc	gag	gac	atc	gag	gtg	gac	ggg	acg	acg	atc	960
	Leu	Gln	Arg	Leu	Ala	Ile	Glu	Asp	Ile	Glu	Val	Asp	Gly	Thr	Thr	Ile	
	305					310					315					320	
	cgc	gag	ggg	gag	ggc	gtc	ttc	ttc	tcc	acc	tcg	ctc	gtc	aac	cgc	gac	1008
	Arg	Glu	Gly	Glu	Gly	Val	Phe	Phe	Ser	Thr	Ser	Leu	Val	Asn	Arg	Asp	
					325					330					335		
45	gcc	gac	gtg	ttc	gcg	gac	ccg	gag	acc	ctg	gac	tgg	gag	cgg	tcc	gcc	1056
	Ala	Asp	Val	Phe	Ala	Asp	Pro	Glu	Thr	Leu	Asp	Trp	Glu	Arg	Ser	Ala	
				340					345					350			
50	cgg	cac	cac	ctc	gcg	ttc	ggc	ttc	ggc	gtc	cac	cag	tgc	ctg	gga	cag	1104
	Arg	His	His	Leu	Ala	Phe	Gly	Phe	Gly	Val	His	Gln	Cys	Leu	Gly	Gln	
			355				360						365				
	aac	ctg	gcc	cgc	gcc	gaa	ctc	gac	atc	gcg	ctc	cgc	acg	ctc	ttc	gaa	1152
	Asn	Leu	Ala	Arg	Ala	Glu	Leu	Asp	Ile	Ala	Leu	Arg	Thr	Leu	Phe	Glu	
		370					375					380					
55	cgg	ctg	ccc	gcg	ctc	agg	ctc	gcc	gta	ccg	gcg	gac	gag	gtg	agg	cac	1200

EP 1 457 558 A1

	Arg Leu Pro Ala Leu Arg Leu Ala Val Pro Ala Asp Glu Val Arg His	
	385 390 395 400	
5	aag ccc ggc gac acc atc cag ggc ctg ctc gaa ctg ccc gtg gcc tgg	1248
	Lys Pro Gly Asp Thr Ile Gln Gly Leu Leu Glu Leu Pro Val Ala Trp	
	405 410 415	
10	tga gcggcggtgga cgtccaggta aacaggggaac gctgcgtggg agccggc atg tgc	1304
	Met Cys	
	gcg ctg acc gcg ccg gag gtg ttc aca cag gac gac gac ggt ttc agc	1352
	Ala Leu Thr Ala Pro Glu Val Phe Thr Gln Asp Asp Asp Gly Phe Ser	
	420 425 430 435	
15	gag gtg cgt ccc ggt ggc acg gcc gcc act gct ggc cac ccg ctg gta	1400
	Glu Val Arg Pro Gly Gly Thr Ala Ala Thr Ala Gly His Pro Leu Val	
	440 445 450	
20	cgc gat gcc gca cgg gcc tgc ccg gtc ggg gcg gtg acc ctg acc gac	1448
	Arg Asp Ala Ala Arg Ala Cys Pro Val Gly Ala Val Thr Leu Thr Asp	
	455 460 465	
	gac tga	1454
	Asp	
25	<210> 239	
	<211> 1461	
	<212> DNA	
	<213> Streptomyces lanatus IFO 12787T	
	<220>	
	<221> CDS	
30	<222> (1)..(1218)	
	<220>	
	<221> CDS	
	<222> (1231)..(1461)	
35	<400> 239	
	atg acg gac atg acc gat atg acg cga ccc ccc acc gtc gcc ttc ccc	48
	Met Thr Asp Met Thr Asp Met Thr Arg Pro Pro Thr Val Ala Phe Pro	
	1 5 10 15	
40	cag aac cgc acc tgc ccc tac cac cca ccc acc gcc tac gac ccg ctc	96
	Gln Asn Arg Thr Cys Pro Tyr His Pro Pro Thr Ala Tyr Asp Pro Leu	
	20 25 30	
	cgc gac acc cgc ccc ctg gcg cgc atc acc ctc tac gac ggc cgc ccg	144
	Arg Asp Thr Arg Pro Leu Ala Arg Ile Thr Leu Tyr Asp Gly Arg Pro	
	35 40 45	
45	gtc tgg ctg gtc acc ggg cac gcc ctc gcc cgc acc ctg ctc gcc gac	192
	Val Trp Leu Val Thr Gly His Ala Leu Ala Arg Thr Leu Leu Ala Asp	
	50 55 60	
50	cct cgg ctg tcc tcc gac cgc ggc cgg ccc ggc ttc ccc gcg ccc aac	240
	Pro Arg Leu Ser Ser Asp Arg Gly Arg Pro Gly Phe Pro Ala Pro Asn	
	65 70 75 80	
	gag cgg ttc gcg gcg gta cgc gac cgc aag tcc gcg ctg ctc ggc gtc	288
	Glu Arg Phe Ala Ala Val Arg Asp Arg Lys Ser Ala Leu Leu Gly Val	
	85 90 95	
55	gac gac ccc gaa cac cgg gtc cag cga cgg atg atg gtc ccc agc ttc	336

EP 1 457 558 A1

	Asp	Asp	Pro	Glu	His	Arg	Val	Gln	Arg	Arg	Met	Met	Val	Pro	Ser	Phe	
5				100					105					110			
	act	ctc	cgc	cga	gcc	gcc	gaa	ctg	cgc	ccg	cag	atc	cag	cgg	atc	gtg	384
	Thr	Leu	Arg	Arg	Ala	Ala	Glu	Leu	Arg	Pro	Gln	Ile	Gln	Arg	Ile	Val	
			115					120					125				
10	gac	gaa	cgg	ctc	gac	gcg	atg	atc	gac	cag	ggg	gcg	ccc	gcc	gag	ctg	432
	Asp	Glu	Arg	Leu	Asp	Ala	Met	Ile	Asp	Gln	Gly	Ala	Pro	Ala	Glu	Leu	
		130					135					140					
	gtg	aac	gcc	ttc	gcg	ctg	ccc	gtg	ccc	tcg	atg	gtc	atc	tgc	gcc	ctg	480
	Val	Asn	Ala	Phe	Ala	Leu	Pro	Val	Pro	Ser	Met	Val	Ile	Cys	Ala	Leu	
15	145					150					155					160	
	ctg	ggc	gtg	ccc	tat	gcc	gac	cac	gac	ttc	ttc	gag	ggg	gag	tcc	cgg	528
	Leu	Gly	Val	Pro	Tyr	Ala	Asp	His	Asp	Phe	Phe	Glu	Gly	Glu	Ser	Arg	
					165					170					175		
20	cgc	ctg	ctg	cgc	ggt	gcc	acg	gcg	gcc	gag	gcc	atg	gac	gcc	cgg	gac	576
	Arg	Leu	Leu	Arg	Gly	Ala	Thr	Ala	Ala	Glu	Ala	Met	Asp	Ala	Arg	Asp	
				180					185					190			
	cgg	ctg	gag	aac	tac	ttc	atc	gag	ctg	atc	gac	cgc	aag	cag	aag	gac	624
	Arg	Leu	Glu	Asn	Tyr	Phe	Ile	Glu	Leu	Ile	Asp	Arg	Lys	Gln	Lys	Asp	
25			195					200					205				
	ccg	gag	ccc	ggc	gac	ggc	gtc	ctc	gac	gaa	ctc	gtc	cac	cgg	cag	ctg	672
	Pro	Glu	Pro	Gly	Asp	Gly	Val	Leu	Asp	Glu	Leu	Val	His	Arg	Gln	Leu	
		210					215					220					
30	cgc	gac	ggc	gac	ctc	gac	cgc	gag	gaa	gtc	gtc	gcc	ctc	tcg	acc	atc	720
	Arg	Asp	Gly	Asp	Leu	Asp	Arg	Glu	Glu	Val	Val	Ala	Leu	Ser	Thr	Ile	
		225				230					235					240	
	ctg	ctg	gtc	gcc	ggc	cac	gag	acg	acc	gcc	aac	atg	atc	tcg	ctg	ggc	768
	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	Ile	Ser	Leu	Gly	
35					245					250					255		
	acc	ttc	aca	ctg	ctc	caa	cac	ccg	gag	cag	ctg	gcc	gag	ttg	cgc	gcc	816
	Thr	Phe	Thr	Leu	Leu	Gln	His	Pro	Glu	Gln	Leu	Ala	Glu	Leu	Arg	Ala	
				260					265					270			
40	gac	gcc	ggg	ttg	ctg	ccc	gcc	gcg	gtc	gag	gag	ctc	atg	cgg	atg	ctg	864
	Asp	Ala	Gly	Leu	Leu	Pro	Ala	Ala	Val	Glu	Glu	Leu	Met	Arg	Met	Leu	
			275					280					285				
	tcg	atc	gcg	gac	ggg	ctg	ctg	cgc	gtc	gcc	tcc	gag	gac	atc	gag	gcg	912
	Ser	Ile	Ala	Asp	Gly	Leu	Leu	Arg	Val	Ala	Ser	Glu	Asp	Ile	Glu	Ala	
45			290				295					300					
	ggc	ggc	gag	acg	atc	cgg	gcg	ggc	gac	ggc	gtg	gtc	ttc	tcg	acc	tcg	960
	Gly	Gly	Glu	Thr	Ile	Arg	Ala	Gly	Asp	Gly	Val	Val	Phe	Ser	Thr	Ser	
		305				310					315					320	
50	gtc	atc	aac	cgc	gac	gag	tcc	gtc	tac	ccc	gac	ccc	gat	gcc	atc	gac	1008
	Val	Ile	Asn	Arg	Asp	Glu	Ser	Val	Tyr	Pro	Asp	Pro	Asp	Ala	Ile	Asp	
					325					330				335			
	tgg	cac	cgc	ccc	acc	cgc	cac	cac	atc	gcc	ttc	ggg	ttc	ggc	atc	cac	1056
	Trp	His	Arg	Pro	Thr	Arg	His	His	Ile	Ala	Phe	Gly	Phe	Gly	Ile	His	
55				340					345					350			
	cag	tgc	ctc	ggc	cag	aac	ctg	gcc	cgc	gcc	gag	atg	gag	atc	gcc	ctg	1104

EP 1 457 558 A1

	Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala Glu Met Glu Ile Ala Leu	
	355 360 365	
5	cgc acc ctc ttc gag cgc ctg ccc acc ctg cgc ctt gcc gtc ccg gcg Arg Thr Leu Phe Glu Arg Leu Pro Thr Leu Arg Leu Ala Val Pro Ala	1152
	370 375 380	
10	ggg gaa atc ccc ttc aaa ccc ggc gac acg atc cag ggg atg ctg gaa Gly Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu	1200
	385 390 395 400	
	ctc ccc gtg acc tgg taa gaggtctccgg tc atg cac aac gaa acg cac gaa Leu Pro Val Thr Trp Met His Asn Glu Thr His Glu	1251
	405 410	
15	tca ggc cat atc cac atc gac atc gac cat gac gtc tgc gtc ggc gcc Ser Gly His Ile His Ile Asp Ile Asp His Asp Val Cys Val Gly Ala	1299
	415 420 425	
20	ggg cag tgc gcc ctc gcc gcc ccc tcc gtg ttc acc cag gac gac gac Gly Gln Cys Ala Leu Ala Ala Pro Ser Val Phe Thr Gln Asp Asp Asp	1347
	430 435 440 445	
	ggc ttc agc acc ctg ctt ccc ggc cgc gag gac ggc ggc ggc gac ccc Gly Phe Ser Thr Leu Leu Pro Gly Arg Glu Asp Gly Gly Gly Asp Pro	1395
	450 455 460	
25	atg gtg cgg gag gcg gcc cgg gcg tgc ccg gtc agc gcc atc acc gtg Met Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val	1443
	465 470 475	
30	tcc gaa ggg ggg agt tga Ser Glu Gly Gly Ser	1461
	480	
	<210> 240	
	<211> 1458	
	<212> DNA	
35	<213> Streptomyces misawanensis IFO 13855T	
	<220>	
	<221> CDS	
	<222> (1)..(1245)	
40	<220>	
	<221> CDS	
	<222> (1258)..(1458)	
	<400> 240	
45	atg aaa gaa ctg acg gac ctg acg gaa ccc atc tct ccc gcc ggc cag Met Lys Glu Leu Thr Asp Leu Thr Glu Pro Ile Ser Pro Ala Gly Gln	48
	1 5 10 15	
	gcc gac ccc gtg gcc tgg ccg cag gac cgc acg tgc ccc tac cac ccg Ala Asp Pro Val Ala Trp Pro Gln Asp Arg Thr Cys Pro Tyr His Pro	96
	20 25 30	
50	ccc acc ggc tac gac ccg ctc cgc gac ggc acc ccg ctg tcc cgc gtc Pro Thr Gly Tyr Asp Pro Leu Arg Asp Gly Thr Pro Leu Ser Arg Val	144
	35 40 45	
55	acc ctc tac gac ggc cgc acc gtc tgg gcg gtc acc ggc cac ggc acg Thr Leu Tyr Asp Gly Arg Thr Val Trp Ala Val Thr Gly His Gly Thr	192
	50 55 60	

EP 1 457 558 A1

5	gcc	cgg	gcg	ctg	ctc	tcc	gac	ccc	cgc	ctc	tcc	agc	gac	cgc	cgg	cgc	240
	Ala	Arg	Ala	Leu	Leu	Ser	Asp	Pro	Arg	Leu	Ser	Ser	Asp	Arg	Arg	Arg	
	65					70					75					80	
	gac	gac	ttc	ccg	atg	ccg	aac	gcc	cgg	ttc	gcg	gcg	gcc	cgg	gag	cgc	288
	Asp	Asp	Phe	Pro	Met	Pro	Asn	Ala	Arg	Phe	Ala	Ala	Ala	Arg	Glu	Arg	
10					85					90					95		
	cga	cag	ctc	gcc	ctg	ctg	ggc	ctc	gac	gac	ccc	gag	cac	cag	atc	cag	336
	Arg	Gln	Leu	Ala	Leu	Leu	Gly	Leu	Asp	Asp	Pro	Glu	His	Gln	Ile	Gln	
				100					105					110			
15	cgc	cgg	atg	ctg	atc	ccg	gac	ttc	acc	ctc	aag	cgg	gcg	acc	gtg	atg	384
	Arg	Arg	Met	Leu	Ile	Pro	Asp	Phe	Thr	Leu	Lys	Arg	Ala	Thr	Val	Met	
			115					120					125				
	cgg	ccg	gcc	atc	cag	cgg	atc	gtc	gac	gat	ctg	ctc	gac	agg	atg	atc	432
	Arg	Pro	Ala	Ile	Gln	Arg	Ile	Val	Asp	Asp	Leu	Leu	Asp	Arg	Met	Ile	
20			130				135					140					
	gcc	gcg	ggc	ccg	ccc	gcc	gac	ctg	gtg	agc	tcc	ttc	gcg	ctg	ccc	gtg	480
	Ala	Ala	Gly	Pro	Pro	Ala	Asp	Leu	Val	Ser	Ser	Phe	Ala	Leu	Pro	Val	
	145					150					155					160	
25	ccg	tcc	atg	gtc	atc	tgt	gac	ctg	ctc	ggc	gtg	ccc	tac	gcc	gac	cac	528
	Pro	Ser	Met	Val	Ile	Cys	Asp	Leu	Leu	Gly	Val	Pro	Tyr	Ala	Asp	His	
					165					170					175		
	gag	ttc	ttc	gag	gcg	cag	tcc	cgg	cgg	ctg	ctg	cgc	ggg	ccg	gcg	ccc	576
	Glu	Phe	Phe	Glu	Ala	Gln	Ser	Arg	Arg	Leu	Leu	Arg	Gly	Pro	Ala	Pro	
30				180					185					190			
	gcc	gac	tcc	ctg	gac	gcg	cgc	gac	cag	ctg	gag	gcc	tat	ctg	ggc	gac	624
	Ala	Asp	Ser	Leu	Asp	Ala	Arg	Asp	Gln	Leu	Glu	Ala	Tyr	Leu	Gly	Asp	
			195					200					205				
35	ctg	gcc	gac	cgc	aag	agc	cgg	gac	gcg	gtc	ccc	ggc	gac	ggc	gtc	ctc	672
	Leu	Ala	Asp	Arg	Lys	Ser	Arg	Asp	Ala	Val	Pro	Gly	Asp	Gly	Val	Leu	
		210					215					220					
	gac	gac	ctc	gtc	cac	cag	cgg	ctg	cgg	gac	ggc	gcc	ctg	gac	cgc	gcc	720
	Asp	Asp	Leu	Val	His	Gln	Arg	Leu	Arg	Asp	Gly	Ala	Leu	Asp	Arg	Ala	
40						230					235					240	
	gag	gtc	gtc	gcg	ctg	gcc	ctc	atc	ctg	ctg	gtc	gcc	ggc	cac	gag	acc	768
	Glu	Val	Val	Ala	Leu	Ala	Leu	Ile	Leu	Leu	Val	Ala	Gly	His	Glu	Thr	
					245					250					255		
45	acc	gcc	aac	atg	atc	tcg	ctc	ggc	acc	ttc	acc	ctg	ctc	cag	cag	ccc	816
	Thr	Ala	Asn	Met	Ile	Ser	Leu	Gly	Thr	Phe	Thr	Leu	Leu	Gln	Gln	Pro	
				260					265					270			
	gaa	cgg	ctc	gcc	gaa	ctg	cgc	gcc	gac	ccc	gcg	ctg	gtg	ccc	gcc	gcc	864
	Glu	Arg	Leu	Ala	Glu	Leu	Arg	Ala	Asp	Pro	Ala	Leu	Val	Pro	Ala	Ala	
50			275					280					285				
	gtc	gag	gaa	ctg	atg	cgg	atg	ctg	tcc	atc	gcc	gac	ggg	ctg	ctg	cgc	912
	Val	Glu	Glu	Leu	Met	Arg	Met	Leu	Ser	Ile	Ala	Asp	Gly	Leu	Leu	Arg	
		290					295					300					
55	gtc	gca	ctg	gag	gac	atc	gag	acg	gac	ggc	ggc	acc	acc	atc	cgc	aag	960
	Val	Ala	Leu	Glu	Asp	Ile	Glu	Thr	Asp	Gly	Gly	Thr	Thr	Ile	Arg	Lys	
	305					310					315					320	

EP 1 457 558 A1

5           ggc gag ggc gtg ctc ttc gcg acc tcg gtc atc aac cgt gac gag tcc       1008  
           Gly Glu Gly Val Leu Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Ser  
                                   325                                   330                                   335

          gtg tac gac gac ccc gac gcc ctc gac tgg cac cgc ccg gcc cgc cac       1056  
           Val Tyr Asp Asp Pro Asp Ala Leu Asp Trp His Arg Pro Ala Arg His  
                                   340                                   345                                   350

10           cac gtg gcc ttc gcc ttc gcc atc cac cag tgc ctg gcc cag aac ctg       1104  
           His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu  
                                   355                                   360                                   365

          gcc cgc acc gag ctg gag atc gcc ctg cgc acc ctg tgg gag cgg ctc       1152  
           Ala Arg Thr Glu Leu Glu Ile Ala Leu Arg Thr Leu Trp Glu Arg Leu  
                                   370                                   375                                   380

          ccg gac ctg cgg ctc gcc gca ccg ccg gag gag att ccc ttc aaa ccc       1200  
           Pro Asp Leu Arg Leu Ala Pro Pro Glu Glu Ile Pro Phe Lys Pro  
                                   385                                   390                                   395                                   400

20           ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggc       1250  
           Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp  
                                   405                                   410                                   415

          tcctgcc atg cac atc gag atc gac agt gac gtc tgc atc ggc gcg ggg       1299  
           Met His Ile Glu Ile Asp Ser Asp Val Cys Ile Gly Ala Gly  
                                   420                                   425

          cag tgt gcc ctg acc gcc ccc aac gtc ttc acc cag gac gac gac ggt       1347  
           Gln Cys Ala Leu Thr Ala Pro Asn Val Phe Thr Gln Asp Asp Asp Gly  
                                   430                                   435                                   440                                   445

30           ttc agc acc ctg ctc ccc ggg atg gcg gac gcc gcc gcc gac ccg ctg       1395  
           Phe Ser Thr Leu Leu Pro Gly Met Ala Asp Gly Gly Gly Asp Pro Leu  
                                   450                                   455                                   460

          gtc aag gag gcg gcc cgg gcc tgc ccg gtg cac gcc atc acg gtc gag       1443  
           Val Lys Glu Ala Ala Arg Ala Cys Pro Val His Ala Ile Thr Val Glu  
                                   465                                   470                                   475

          gaa ccg tcg ggt tag   1458  
           Glu Pro Ser Gly  
                                   480

40           <210> 241  
           <211> 1448  
           <212> DNA  
           <213> Streptomyces pallidus IFO 13434T

45           <220>  
           <221> CDS  
           <222> (1)..(1230)

          <220>  
           <221> CDS  
           <222> (1254)..(1448)

50           <400> 241  
           atg gcc gac acc ctc gcc gcc gcc acg ccc gac gcc gcc gcc gcc acg gtc       48  
           Met Ala Asp Thr Leu Ala Gly Ala Thr Pro Asp Ala Ala Ala Thr Val  
                                   1                                   5                                   10                                   15

55           ccc gcg tac ccc atg gcc cgg gcc gcg gcc tgc ccc ttc gac ccg ccc       96

EP 1 457 558 A1

	Pro	Ala	Tyr	Pro	Met	Ala	Arg	Ala	Ala	Gly	Cys	Pro	Phe	Asp	Pro	Pro	
					20					25					30		
5	ccg	gac	ctc	acc	gcc	cgg	cag	gac	gag	ggt	cgg	ctc	gtc	agg	gtg	cgc	144
	Pro	Asp	Leu	Thr	Ala	Arg	Gln	Asp	Glu	Gly	Arg	Leu	Val	Arg	Val	Arg	
			35				40						45				
10	ctc	tgg	gac	ggc	agt	acg	ccc	tgg	ctc	gtg	acc	cgc	tac	gag	gac	cag	192
	Leu	Trp	Asp	Gly	Ser	Thr	Pro	Trp	Leu	Val	Thr	Arg	Tyr	Glu	Asp	Gln	
		50					55					60					
15	cgc	gcc	ctg	ctc	ctc	gac	ccc	agg	gtc	agt	gcc	gac	atc	acc	agg	ccc	240
	Arg	Ala	Leu	Leu	Leu	Asp	Pro	Arg	Val	Ser	Ala	Asp	Ile	Thr	Arg	Pro	
	65					70				75						80	
20	gga	tac	ccc	ctc	cag	gcc	gcc	ggc	gcc	ggc	gag	aac	aac	gcc	agc	ttc	288
	Gly	Tyr	Pro	Leu	Gln	Ala	Ala	Gly	Ala	Gly	Glu	Asn	Asn	Ala	Ser	Phe	
					85					90					95		
25	atc	ctc	atg	gac	gac	ccg	gag	cac	gca	cgg	ctg	cgc	cgc	atg	gtg	acc	336
	Ile	Leu	Met	Asp	Asp	Pro	Glu	His	Ala	Arg	Leu	Arg	Arg	Met	Val	Thr	
				100					105					110			
30	gcg	ccc	ttc	gcg	atc	aag	cgc	gtc	gag	gcg	atg	cgg	ccg	ggc	gtg	cag	384
	Ala	Pro	Phe	Ala	Ile	Lys	Arg	Val	Glu	Ala	Met	Arg	Pro	Gly	Val	Gln	
			115				120						125				
35	cag	ctc	gtg	gac	gac	ctc	atc	gac	ggc	atg	ctc	gcc	ggg	ccc	aag	ccg	432
	Gln	Leu	Val	Asp	Asp	Leu	Ile	Asp	Gly	Met	Leu	Ala	Gly	Pro	Lys	Pro	
		130					135					140					
40	gtc	gac	ctg	gtg	gag	gcg	ttc	gcg	ctg	ccg	gtg	ccc	tcg	ctg	gtc	atc	480
	Val	Asp	Leu	Val	Glu	Ala	Phe	Ala	Leu	Pro	Val	Pro	Ser	Leu	Val	Ile	
	145					150					155					160	
45	tgc	cgg	atg	ctc	gga	gtg	ccg	tac	gag	gac	cac	gac	ttc	ttc	cag	gag	528
	Cys	Arg	Met	Leu	Gly	Val	Pro	Tyr	Glu	Asp	His	Asp	Phe	Phe	Gln	Glu	
					165					170					175		
50	aac	agc	cgg	atc	ctc	atc	aag	cgg	gac	gcg	gcc	atg	gag	gac	cgc	atg	576
	Asn	Ser	Arg	Ile	Leu	Ile	Lys	Arg	Asp	Ala	Ala	Met	Glu	Asp	Arg	Met	
				180					185					190			
55	gcc	gcg	cac	ggg	cgg	ctg	atc	gcc	tac	ctc	gac	gag	ctg	atg	ggc	gag	624
	Ala	Ala	His	Gly	Arg	Leu	Ile	Ala	Tyr	Leu	Asp	Glu	Leu	Met	Gly	Glu	
			195				200						205				
60	aag	acg	gcc	cgt	ccg	gcg	gac	gat	ctg	ctc	tcg	ggg	ctc	gtc	gag	cgg	672
	Lys	Thr	Ala	Arg	Pro	Ala	Asp	Asp	Leu	Leu	Ser	Gly	Leu	Val	Glu	Arg	
			210				215					220					
65	gtc	agg	acg	ggg	gag	ctg	acc	cgg	cgc	gag	tcg	gcc	cgc	atg	ggc	gtg	720
	Val	Arg	Thr	Gly	Glu	Leu	Thr	Arg	Arg	Glu	Ser	Ala	Arg	Met	Gly	Val	
	225					230					235					240	
70	ctc	ctg	ctc	atc	gcc	ggg	cac	gag	acc	acc	gcc	aac	atg	atc	gcg	ctc	768
	Leu	Leu	Leu	Ile	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	Ile	Ala	Leu	
					245					250					255		
75	ggc	acg	ctc	gcc	ctg	ctc	gaa	cac	ccg	gac	cag	ctc	gcc	ctg	ctg	cgt	816
	Gly	Thr	Leu	Ala	Leu	Leu	Glu	His	Pro	Asp	Gln	Leu	Ala	Leu	Leu	Arg	
				260					265					270			
80	gac	acc	gac	gac	ccg	aag	ctg	gtc	gcc	gga	gcg	gcc	gag	gaa	ctg	ctg	864

EP 1 457 558 A1

	Asp	Thr	Asp	Asp	Pro	Lys	Leu	Val	Ala	Gly	Ala	Ala	Glu	Glu	Leu	Leu	
			275					280					285				
5	cgc	tat	ctg	acc	atc	gtg	cac	aac	gga	cgc	cgc	cgg	gcg	gcc	ctc	gcg	912
	Arg	Tyr	Leu	Thr	Ile	Val	His	Asn	Gly	Arg	Arg	Arg	Ala	Ala	Leu	Ala	
		290					295					300					
10	gac	atc	gag	atc	ggc	gga	cag	gtc	atc	cgg	gcc	ggc	gag	ggc	atg	atc	960
	Asp	Ile	Glu	Ile	Gly	Gly	Gln	Val	Ile	Arg	Ala	Gly	Glu	Gly	Met	Ile	
		305				310					315				320		
15	atg	ccc	aac	gac	ctc	gcc	aac	cgg	gac	ccc	ggc	gcc	ttc	acc	gac	ccg	1008
	Met	Pro	Asn	Asp	Leu	Ala	Asn	Arg	Asp	Pro	Gly	Ala	Phe	Thr	Asp	Pro	
					325				330						335		
20	gac	cgg	ctg	gac	ctg	cgc	cgc	gac	gcc	cgc	cgg	cac	atc	gcg	ttc	ggc	1056
	Asp	Arg	Leu	Asp	Leu	Arg	Arg	Asp	Ala	Arg	Arg	His	Ile	Ala	Phe	Gly	
				340					345					350			
25	ttc	ggc	gtg	cac	cag	tgc	ctg	ggc	cag	ccg	ctg	gcc	cgc	atg	gaa	ctc	1104
	Phe	Gly	Val	His	Gln	Cys	Leu	Gly	Gln	Pro	Leu	Ala	Arg	Met	Glu	Leu	
			355					360					365				
30	cag	gtc	gtc	tac	ggc	acc	ctc	tac	cgc	cgc	atc	ccc	acg	ctg	cgg	ctc	1152
	Gln	Val	Val	Tyr	Gly	Thr	Leu	Tyr	Arg	Arg	Ile	Pro	Thr	Leu	Arg	Leu	
			370				375					380					
35	gcc	gcc	ccg	gtg	gag	agc	ctg	tgc	ttc	aag	cac	gac	gga	tcg	gtc	tac	1200
	Ala	Ala	Pro	Val	Glu	Ser	Leu	Ser	Phe	Lys	His	Asp	Gly	Ser	Val	Tyr	
						390					395				400		
40	ggc	gtc	tac	gaa	ctg	ccc	gtc	acg	tgg	tga	cgccgggaacc	ggaggaggca	acc				1253
	Gly	Val	Tyr	Glu	Leu	Pro	Val	Thr	Trp		410						
					405												
45	atg	cga	gtg	gaa	ctg	gac	gag	ccg	aag	tgc	gtc	gcg	tcg	ggg	cag	tgc	1301
	Met	Arg	Val	Glu	Leu	Asp	Glu	Pro	Lys	Cys	Val	Ala	Ser	Gly	Gln	Cys	
					415					420					425		
50	gtg	atg	gcc	gcc	ccc	gag	gtc	ttc	gac	cag	cgc	gag	gag	gac	ggc	atc	1349
	Val	Met	Ala	Ala	Pro	Glu	Val	Phe	Asp	Gln	Arg	Glu	Glu	Asp	Gly	Ile	
				430					435					440			
55	gcc	ttc	gtg	ctg	gac	gag	cgg	ccg	gcg	gcg	gac	gtc	ctg	gcg	gag	gtg	1397
	Ala	Phe	Val	Leu	Asp	Glu	Arg	Pro	Ala	Ala	Asp	Val	Leu	Ala	Glu	Val	
			445					450					455				
60	cgc	gag	gcc	gtg	gcg	atc	tgc	ccc	gcc	gcc	gcg	atc	cgg	ctg	gtg	gag	1445
	Arg	Glu	Ala	Val	Ala	Ile	Cys	Pro	Ala	Ala	Ala	Ile	Arg	Leu	Val	Glu	
		460				465						470					
65	tga																1448
	475																
70	<210>	242															
75	<211>	1411															
80	<212>	DNA															
85	<213>	Streptomyces roseorubens	IFO	13682T													
90	<220>																
95	<221>	CDS															
100	<222>	(1) .. (1197)															

EP 1 457 558 A1

<220>  
 <221> CDS  
 <222> (1211)..(1411)

<400> 242

	atg acg gac acg acc gca ccc gtc gcc ttc ccc cag agc agg acc tgc	48
	Met Thr Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys	
	1 5 10 15	
10	ccc tac cac ccg ccc gcc gcc tac gag ccg ctg cgc gcc gag cgc ccc	96
	Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro	
	20 25 30	
15	ctg acc cgg atc acc ctc ttc gac ggc cgt gag gcc tgg ctg gtc agc	144
	Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser	
	35 40 45	
20	ggc cac gcc acc gcc cgc gcc ctg ctc gcc gac ccc cgc ctg tcc tcc	192
	Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser	
	50 55 60	
25	gac cgc gac cgc ccc ggc ttc ccc acc ccc acc gcg cgc ttc gcc ggc	240
	Asp Arg Asp Arg Pro Gly Phe Pro Thr Pro Thr Ala Arg Phe Ala Gly	
	65 70 75 80	
30	atc cgc aac cgc cgt acg gcc ctg ctc ggc gtg gac gac ccc gag cac	288
	Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His	
	85 90 95	
35	cgc gcc cag cgg cgg atg gtc gtc ggg gac ttc acc ctc aaa cgg gcc	336
	Arg Ala Gln Arg Arg Met Val Val Gly Asp Phe Thr Leu Lys Arg Ala	
	100 105 110	
40	gcc gca ctg cgg ccc cgc atc cag cgg atc gtc gac gaa cga ctc gac	384
	Ala Ala Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Glu Arg Leu Asp	
	115 120 125	
45	gcg atg atc gcc cag ggc ccg ccc gcc gac ctg gtg agc gcc ttc gcg	432
	Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ala Phe Ala	
	130 135 140	
50	ctg ccc gtg ccc tcc atg gtg atc tgc gcc ctg ctc ggc gtc ccc tac	480
	Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr	
	145 150 155 160	
55	gcc gac cac gac ttc ttc gag gct cag tgc cgg cgc ctg ctg cgc ggc	528
	Ala Asp His Asp Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly	
	165 170 175	
60	ccg ggg acc gcc gac gtg cag gac gcc cgg agc agg ctg gag gag tac	576
	Pro Gly Thr Ala Asp Val Gln Asp Ala Arg Ser Arg Leu Glu Glu Tyr	
	180 185 190	
65	ttc ggc gag ctg atc gac cgc aag cgc gag gac ccc ggc acc ggc ctc	624
	Phe Gly Glu Leu Ile Asp Arg Lys Arg Glu Asp Pro Gly Thr Gly Leu	
	195 200 205	
70	ctg gac gac ctg gtc caa cgg cag ccc ggc gac ggc gga ccc gac cgc	672
	Leu Asp Asp Leu Val Gln Arg Gln Pro Gly Asp Gly Gly Pro Asp Arg	
	210 215 220	
75	gag ggc ctg atc gcc atg gcc ctc atc ctg ctg gtc gcc ggc cac gag	720
	Glu Gly Leu Ile Ala Met Ala Leu Ile Leu Leu Val Ala Gly His Glu	
	225 230 235 240	

EP 1 457 558 A1

5	acg acc gcc aac atg atc tcc ctc ggc acc ttc acg ctc ctg cag cac Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255	768
10	ccc gag cgg ctc gcc gaa ctg cgc gcc gac tcc gag gtc atg ccg gcc Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Ser Glu Val Met Pro Ala 260 265 270	816
15	gcg gtc gag gaa ctg atg cgg ctg ctg tcc atc gcg gac ggc ctg ctg Ala Val Glu Glu Leu Met Arg Leu Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285	864
20	cgc atc gcc gtc gag gac gtc gag gtg gcc ggg acg acg atc cgc gcc Arg Ile Ala Val Glu Asp Val Glu Val Ala Gly Thr Thr Ile Arg Ala 290 295 300	912
25	ggc gag ggc gtg gtg ttc gcg acg tcg gtc atc aac cgc gac gag acg Gly Glu Gly Val Val Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320	960
30	gtc ttc gcc gag ccg gac acc ctc gac tgg agc cgc ccg gcc cgc cac Val Phe Ala Glu Pro Asp Thr Leu Asp Trp Ser Arg Pro Ala Arg His 325 330 335	1008
35	cac gtg gcg ttc ggc ttc ggc atc cac cag tgc ctc ggc caa aac ctc His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu 340 345 350	1056
40	gca cgc gcc gaa ctg gag atc gcc ctc ggc acc ctc ttc ggc cgg ctg Ala Arg Ala Glu Leu Glu Ile Ala Leu Gly Thr Leu Phe Gly Arg Leu 355 360 365	1104
45	ccc acg ctg cgc ctg gcc gcc ccg ccc gac gag atc ccc ttc aag ccg Pro Thr Leu Arg Leu Ala Ala Pro Pro Asp Glu Ile Pro Phe Lys Pro 370 375 380	1152
50	ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggc Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp 385 390 395	1202
55	ttgcgggc atg cgc atc gac atc gac aag gac gtc tgc atc ggc gcg ggc Met Arg Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly 400 405 410	1252
60	cag tgc gcc ctg acc gcc ccg gac gtg ttc acc cag gac gac gac ggc Gln Cys Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly 415 420 425	1300
65	tac agc acc ctg ctg ccc ggc cgg gag gac ggc ggc ggc agc ccg ctg Tyr Ser Thr Leu Leu Pro Gly Arg Glu Asp Gly Gly Gly Ser Pro Leu 430 435 440 445	1348
70	ctg cgg gag gcg gcc cgg gcc tgc ccg gtg agc gcc atc acc gtc tcg Leu Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser 450 455 460	1396
75	gag acc gtc ggc tga Glu Thr Val Gly 465	1411
80	<210> 243 <211> 1466 <212> DNA	

&lt;213&gt; Streptomyces rutgersensis IFO 15875T

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1245)

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1269)..(1466)

&lt;400&gt; 243

atg acc gaa acg ctg gca gag acc acg acc gag gcg gaa gag ccg ctt	48
Met Thr Glu Thr Leu Ala Glu Thr Thr Thr Glu Ala Glu Glu Pro Leu	
1 5 10 15	
ccg gag ttc ccg atg ccg cgg gcg aac ggc tgc ccc ttc gcc ccg ccc	96
Pro Glu Phe Pro Met Pro Arg Ala Asn Gly Cys Pro Phe Ala Pro Pro	
20 25 30	
ccg acc gca cgg gcg ctg cac acc gaa cgg ccg gtc acg cgg gta cgg	144
Pro Thr Ala Arg Ala Leu His Thr Glu Arg Pro Val Thr Arg Val Arg	
35 40 45	
ctg tgg gac ggc agc gcc ccc tgg ctg gtg acc cgg tac gcc gac cag	192
Leu Trp Asp Gly Ser Ala Pro Trp Leu Val Thr Arg Tyr Ala Asp Gln	
50 55 60	
cgc gcc ctg ctc ggc gac ccg cgg gtc agc tcc gag gcc acc cgg ccc	240
Arg Ala Leu Leu Gly Asp Pro Arg Val Ser Ser Glu Ala Thr Arg Pro	
65 70 75 80	
ggc ttt ccg cat gcg agc gcc ggc ttc cgc gag aat gcc agg cgg cgg	288
Gly Phe Pro His Ala Ser Ala Gly Phe Arg Glu Asn Ala Arg Arg Arg	
85 90 95	
cgc tcc ttc atc acc atg gac gac ccc gag cac gcc cgg atc cgc cgg	336
Arg Ser Phe Ile Thr Met Asp Asp Pro Glu His Ala Arg Ile Arg Arg	
100 105 110	
atg gtc acc gcg ccg ttc gcc atc aag cgg gtc gag gcg atg cgg ccc	384
Met Val Thr Ala Pro Phe Ala Ile Lys Arg Val Glu Ala Met Arg Pro	
115 120 125	
gac atc cag aag atc acc gac gat ctg atc gac tcc atg ctg gcc ggg	432
Asp Ile Gln Lys Ile Thr Asp Asp Leu Ile Asp Ser Met Leu Ala Gly	
130 135 140	
ccg acc ccg gtc gac ctg gtg cgc gcg ttg gcg ctg ccg ctg ccg tcg	480
Pro Thr Pro Val Asp Leu Val Arg Ala Leu Ala Leu Pro Leu Pro Ser	
145 150 155 160	
ctg gtg atc tgc cgg ctg ctc gga gtg ccg tac gag gac cac gac ttc	528
Leu Val Ile Cys Arg Leu Leu Gly Val Pro Tyr Glu Asp His Asp Phe	
165 170 175	
ttc cag cgc aac agc tcg ctc ctg atc aac cgt aac tcc acg acc gaa	576
Phe Gln Arg Asn Ser Ser Leu Leu Ile Asn Arg Asn Ser Thr Thr Glu	
180 185 190	
gag gtg gtc ggc gcc aac gag gcg ctg acc gac tat ctg gac gag ctg	624
Glu Val Val Gly Ala Asn Glu Ala Leu Thr Asp Tyr Leu Asp Glu Leu	
195 200 205	
gtc agc gcc aaa ctc gcc aac ccc gcc gac gac atg ctc tcc gag ctg	672

EP 1 457 558 A1

	Val	Ser	Ala	Lys	Leu	Ala	Asn	Pro	Ala	Asp	Asp	Met	Leu	Ser	Glu	Leu	
	210						215					220					
5	gcc	gcc	cgg	gtc	acg	gcc	gga	gag	ctg	acc	cag	cgc	gag	gcc	gcc	aat	720
	Ala	Ala	Arg	Val	Thr	Ala	Gly	Glu	Leu	Thr	Gln	Arg	Glu	Ala	Ala	Asn	
	225					230					235					240	
10	atg	ggc	gtg	ctg	ctg	ctg	atc	gcc	ggc	cat	gag	acc	acc	gcc	aac	atg	768
	Met	Gly	Val	Leu	Leu	Leu	Ile	Ala	Gly	His	Glu	Thr	Thr	Ala	Asn	Met	
					245					250					255		
15	atc	gcc	ctc	ggc	acc	gtc	gcc	ctg	ctg	gag	aac	ccc	gac	cag	ctc	gcc	816
	Ile	Ala	Leu	Gly	Thr	Val	Ala	Leu	Leu	Glu	Asn	Pro	Asp	Gln	Leu	Ala	
				260					265					270			
20	gtc	ctg	cgg	gag	acc	gac	gac	ccg	aag	gcg	gtc	gcc	aag	gcc	gtc	gag	864
	Val	Leu	Arg	Glu	Thr	Asp	Asp	Pro	Lys	Ala	Val	Ala	Lys	Ala	Val	Glu	
			275					280					285				
25	gaa	ctg	ctg	cgc	tat	ctg	acc	atc	gtg	cac	acc	ggc	cgg	cgc	cgg	gtc	912
	Glu	Leu	Leu	Arg	Tyr	Leu	Thr	Ile	Val	His	Thr	Gly	Arg	Arg	Arg	Val	
		290					295					300					
30	gcg	cgg	gag	gac	atc	gag	atc	ggc	ggc	gag	acc	atc	cgt	gcc	ggg	gac	960
	Ala	Arg	Glu	Asp	Ile	Glu	Ile	Gly	Gly	Glu	Thr	Ile	Arg	Ala	Gly	Asp	
	305					310					315					320	
35	ggg	atc	atc	atc	tac	acc	ggc	acc	ggc	aac	tgg	gac	gcg	gag	gtc	ttc	1008
	Gly	Ile	Ile	Ile	Tyr	Thr	Gly	Thr	Gly	Asn	Trp	Asp	Ala	Glu	Val	Phe	
					325					330					335		
40	ccc	gag	ccc	gag	cgg	ctg	gac	atc	ggc	cgc	gac	gcc	cgc	cgc	cac	atg	1056
	Pro	Glu	Pro	Glu	Arg	Leu	Asp	Ile	Gly	Arg	Asp	Ala	Arg	Arg	His	Met	
				340					345					350			
45	gcg	ttc	ggt	ttc	ggc	gtc	cac	cag	tgc	ctg	ggc	cag	ccg	ctg	gcc	cgg	1104
	Ala	Phe	Gly	Phe	Gly	Val	His	Gln	Cys	Leu	Gly	Gln	Pro	Leu	Ala	Arg	
			355					360					365				
50	gtg	gag	ctg	cag	gtg	gtc	tac	ggc	acg	ctc	tac	cgc	cgt	atc	ccc	acg	1152
	Val	Glu	Leu	Gln	Val	Val	Tyr	Gly	Thr	Leu	Tyr	Arg	Arg	Ile	Pro	Thr	
		370					375					380					
55	ctg	cgg	ctg	gcg	acc	ggg	gtc	gac	caa	cta	ccg	ttc	aag	gac	gac	ggt	1200
	Leu	Arg	Leu	Ala	Thr	Gly	Val	Asp	Gln	Leu	Pro	Phe	Lys	Asp	Asp	Gly	
	385					390					395					400	
60	ttg	gtc	tac	ggc	gtc	tat	gaa	ctg	ccc	gtc	acc	tgg	acg	tct	tga	gcaac	1250
	Leu	Val	Tyr	Gly	Val	Tyr	Glu	Leu	Pro	Val	Thr	Trp	Thr	Ser			
					405				410						415		
65	ggaggcaagg	gagtcacc	atg	cgt	gtg	gaa	gtc	gat	gtt	ccc	aag	tgt	gtg				1301
			Met	Arg	Val	Glu	Val	Asp	Val	Pro	Lys	Cys	Val				
						420						425					
70	gca	tcg	ggt	cag	tgc	gtg	atg	atc	gca	ccc	gat	gtg	ttc	gac	cag	cgg	1349
	Ala	Ser	Gly	Gln	Cys	Val	Met	Ile	Ala	Pro	Asp	Val	Phe	Asp	Gln	Arg	
				430					435					440			
75	gag	gag	gac	ggc	atc	gtg	atc	ctg	ctg	gac	gag	cag	ccc	gcg	tcc	gaa	1397
	Glu	Glu	Asp	Gly	Ile	Val	Ile	Leu	Leu	Asp	Glu	Gln	Pro	Ala	Ser	Glu	
			445					450					455				
80	ctc	cac	gcc	gat	gtg	cgt	gag	tcc	gcg	gtg	gtc	tgc	ccg	gcg	gcg	gcg	1445

EP 1 457 558 A1

5 Leu His Ala Asp Val Arg Glu Ser Ala Val Val Cys Pro Ala Ala Ala  
 460 465 470  
 ata cgg gtg gtc gag aat tga 1466  
 Ile Arg Val Val Glu Asn  
 475 480  
 <210> 244  
 10 <211> 1411  
 <212> DNA  
 <213> Streptomyces steffisburgensis IFO 13446T  
 <220>  
 15 <221> CDS  
 <222> (1)..(1197)  
 <220>  
 <221> CDS  
 <222> (1211)..(1411)  
 20 <400> 244  
 atg tcg gac acg acc gca ccc gtg gcc ttc ccc cag agc cgg acc tgc 48  
 Met Ser Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys  
 1 5 10 15  
 25 ccc tac cac ccg ccc gcc gcc tac gag ccg ctg cgc gcc gag cgc ccc 96  
 Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro  
 20 25 30  
 ctg acc cgt atc acc ctc ttc gac ggc cgt gag gcc tgg ctg gtc agc 144  
 Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser  
 35 35 40 45  
 ggc cac gcc acc gcc cgc gcg ctg ctc gcc gac ccg cgc ctg tcc tcc 192  
 Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser  
 50 55 60  
 35 gac cgc gac cgc ccc gcc ttc ccc gcc ccc acc gcg cgc ttc gcc ggg 240  
 Asp Arg Asp Arg Pro Gly Phe Pro Ala Pro Thr Ala Arg Phe Ala Gly  
 65 70 75 80  
 atc cgc aac cgc aga acg gcc ctg ctg ggc gtc gac gac ccc gag cac 288  
 Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His  
 40 85 90 95  
 cga gtc cag cgg cgg atg gtg gcc ggg gac ttc acc ctc aaa cgg gcc 336  
 Arg Val Gln Arg Arg Met Val Ala Gly Asp Phe Thr Leu Lys Arg Ala  
 100 105 110  
 45 gcc gga ctg cga ccc cgc atc cag cgg atc gtg gac cga cga ctc gac 384  
 Ala Gly Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Arg Arg Leu Asp  
 115 120 125  
 gcg atg atc gcc cag gcc cca ccg gcc gac ctg gtg agc agc ttc gcg 432  
 Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala  
 50 130 135 140  
 ctg ccc gtc ccg tcc atg gtg atc tgt gcc ctg ctc ggc gtc ccg tac 480  
 Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr  
 145 150 155 160  
 55 gcc gac cac gac ttc ttc gag acc cag tca cgg cgg ctg ctg cgc ggc 528  
 Ala Asp His Asp Phe Phe Glu Thr Gln Ser Arg Arg Leu Leu Arg Gly  
 165 170 175

EP 1 457 558 A1

5	ccg cag acc gcc gac gtg atg gac gcc cgg gcc cgg ctg gac gag tac Pro Gln Thr Ala Asp Val Met Asp Ala Arg Ala Arg Leu Asp Glu Tyr 180 185 190	576
10	ttc ggc gaa ctg atc gac cgc aag cgg aag gaa ccc ggc gcc ggc ctg Phe Gly Glu Leu Ile Asp Arg Lys Arg Lys Glu Pro Gly Ala Gly Leu 195 200 205	624
15	ctg gac gac ctg gtc cag cga cag ctg cgc gac ggc gca ctc gac cgc Leu Asp Asp Leu Val Gln Arg Gln Leu Arg Asp Gly Ala Leu Asp Arg 210 215 220	672
20	gag ggc ctg atc gcc ctg gcg ctc atc ctg ctg gtc gcg ggc cac gag Glu Gly Leu Ile Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu 225 230 235 240	720
25	acg acc gcc aac atg atc tcg ctc ggc acc ttc acc ctg ctg cag cac Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255	768
30	ccc gaa cgg ctc gcc gag ctg cgc gcc gac ccg cgg ctg ctg cct gcg Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Arg Leu Leu Pro Ala 260 265 270	816
35	gcg gtc gag gag ctg atg cgc atg ctg tcc atc gcg gac ggt ctg ctc Ala Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285	864
40	cgc ctc gcc gtc gag gac ata gag gtg gcc ggg acc acg atc cgc aag Arg Leu Ala Val Glu Asp Ile Glu Val Ala Gly Thr Thr Ile Arg Lys 290 295 300	912
45	ggg gac ggc gtg gtg ttc ctg acg tcc gtc atc aac cgc gac gag acg Gly Asp Gly Val Val Phe Leu Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320	960
50	gtc tac ccc gag ccg gac acc ctc gac tgg cac cgc tcg gcc cgg cat Val Tyr Pro Glu Pro Asp Thr Leu Asp Trp His Arg Ser Ala Arg His 325 330 335	1008
55	cac gtc gcg ttc ggc ttc ggc atc cac cag tgc ctc ggc cag aac ctc His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu 340 345 350	1056
60	gcg cgc gcc gag ctg gag atc gcc ctg tgg acc ctc ttc gac cgt ctg Ala Arg Ala Glu Leu Glu Ile Ala Leu Trp Thr Leu Phe Asp Arg Leu 355 360 365	1104
65	ccc acc ctg cgc ctg gcc gcg ccg gcc gag gag atc gcc ttc aag ccg Pro Thr Leu Arg Leu Ala Ala Pro Ala Glu Glu Ile Ala Phe Lys Pro 370 375 380	1152
70	ggc gac acg atc cag ggg atg ctg gaa ctc ccc gtg act tgg taa gaggc Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp 385 390 395	1202
75	ttcccccc atg cac atc gac atc gac aag gac gtc tgc atc ggc gcg ggc Met His Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly 400 405 410	1252
80	cag tgc gcc ctg acc gcc ccg gac gtg ttc acc cag gac gac gac ggc Gln Cys Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly 415 420 425	1300

5 atc agc gcc ctg ctg ccg gga cag gag gac ggc ggc ggc agc ccg ctg 1348  
 Ile Ser Ala Leu Leu Pro Gly Gln Glu Asp Gly Gly Gly Ser Pro Leu  
 430 435 440 445

gtg cgg gag gcg gcc cgt gcc tgc ccg gtg agc gcc atc acc gtg tcg 1396  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser  
 450 455 460

10 gag acg gtg agc tga 1411  
 Glu Thr Val Ser  
 465

15 <210> 245  
 <211> 65  
 <212> PRT  
 <213> Streptomyces ornatus IFO 13069t

20 <400> 245  
 Met Gly Val Arg Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
 1 5 10 15  
 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
 20 25 30  
 Glu Met Leu Pro Gly Ser Thr Ala Gly Thr Gly Asp His Pro Arg Val  
 35 40 45  
 Arg Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ser Leu Thr Asp  
 50 55 60  
 Asp  
 65

30 <210> 246  
 <211> 65  
 <212> PRT  
 <213> Streptomyces griseus ATCC 10137

35 <400> 246  
 Met Gly Val Arg Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
 1 5 10 15  
 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
 20 25 30  
 Glu Met Leu Pro Gly Ser Thr Ala Gly Thr Gly Asp His Pro Arg Val  
 35 40 45  
 Arg Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ser Leu Thr Asp  
 50 55 60  
 Asp  
 65

40 <210> 247  
 <211> 68  
 <212> PRT

45 <213> Streptomyces achromogenes IFO 12735

<400> 247  
 Met His Met Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
 1 5 10 15  
 Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
 20 25 30  
 Tyr Ser Thr Leu Leu Pro Gly Arg Glu Asn Gly Val Thr Asp Pro Met  
 35 40 45  
 Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
 50 55 60  
 Glu Arg Thr Ala  
 65

55

&lt;210&gt; 248

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Streptomyces griseus IFO 13849T

&lt;400&gt; 248

Met Cys Ala Leu Thr Ala Pro Glu Val Phe Thr Gln Asp Asp Asp Gly  
 1 5 10 15  
 Phe Ser Glu Val Arg Pro Gly Gly Thr Ala Ala Thr Ala Gly His Pro  
 20 25 30  
 Leu Val Arg Asp Ala Ala Arg Ala Cys Pro Val Gly Ala Val Thr Leu  
 35 40 45  
 Thr Asp Asp  
 50

&lt;210&gt; 249

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Streptomyces lanatus IFO 12787T

&lt;400&gt; 249

Met His Asn Glu Thr His Glu Ser Gly His Ile His Ile Asp Ile Asp  
 1 5 10 15  
 His Asp Val Cys Val Gly Ala Gly Gln Cys Ala Leu Ala Ala Pro Ser  
 20 25 30  
 Val Phe Thr Gln Asp Asp Asp Gly Phe Ser Thr Leu Leu Pro Gly Arg  
 35 40 45  
 Glu Asp Gly Gly Gly Asp Pro Met Val Arg Glu Ala Ala Arg Ala Cys  
 50 55 60  
 Pro Val Ser Ala Ile Thr Val Ser Glu Gly Gly Ser  
 65 70 75

&lt;210&gt; 250

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Streptomyces misawanensis IFO 13855T

&lt;400&gt; 250

Met His Ile Glu Ile Asp Ser Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15  
 Ala Leu Thr Ala Pro Asn Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
 20 25 30  
 Thr Leu Leu Pro Gly Met Ala Asp Gly Gly Gly Asp Pro Leu Val Lys  
 35 40 45  
 Glu Ala Ala Arg Ala Cys Pro Val His Ala Ile Thr Val Glu Glu Pro  
 50 55 60  
 Ser Gly  
 65

&lt;210&gt; 251

&lt;211&gt; 64

&lt;212&gt; PRT

&lt;213&gt; Streptomyces pallidus IFO 13434T

&lt;400&gt; 251

Met Arg Val Glu Leu Asp Glu Pro Lys Cys Val Ala Ser Gly Gln Cys  
 1 5 10 15  
 Val Met Ala Ala Pro Glu Val Phe Asp Gln Arg Glu Glu Asp Gly Ile  
 20 25 30  
 Ala Phe Val Leu Asp Glu Arg Pro Ala Ala Asp Val Leu Ala Glu Val  
 35 40 45  
 Arg Glu Ala Val Ala Ile Cys Pro Ala Ala Ala Ile Arg Leu Val Glu  
 50 55 60

5  
 <210> 252  
 <211> 66  
 <212> PRT  
 <213> Streptomyces roseorubens IFO 13682T  
 <400> 252  
 Met Arg Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15  
 10 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Tyr Ser  
 20 25 30  
 Thr Leu Leu Pro Gly Arg Glu Asp Gly Gly Gly Ser Pro Leu Leu Arg  
 35 40 45  
 Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser Glu Thr  
 50 55 60  
 15 Val Gly  
 65

20  
 <210> 253  
 <211> 65  
 <212> PRT  
 <213> Streptomyces rutgersensis IFO 15875T  
 <400> 253  
 Met Arg Val Glu Val Asp Val Pro Lys Cys Val Ala Ser Gly Gln Cys  
 1 5 10 15  
 25 Val Met Ile Ala Pro Asp Val Phe Asp Gln Arg Glu Glu Asp Gly Ile  
 20 25 30  
 Val Ile Leu Leu Asp Glu Gln Pro Ala Ser Glu Leu His Ala Asp Val  
 35 40 45  
 Arg Glu Ser Ala Val Val Cys Pro Ala Ala Ala Ile Arg Val Val Glu  
 50 55 60  
 30 Asn  
 65

35  
 <210> 254  
 <211> 66  
 <212> PRT  
 <213> Streptomyces steffisburgensis IFO 13446T  
 <400> 254  
 Met His Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15  
 40 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Ile Ser  
 20 25 30  
 Ala Leu Leu Pro Gly Gln Glu Asp Gly Gly Gly Ser Pro Leu Val Arg  
 35 40 45  
 Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser Glu Thr  
 50 55 60  
 45 Val Ser  
 65

50  
 <210> 255  
 <211> 198  
 <212> DNA  
 <213> Streptomyces ornatus IFO 13069t  
 <220>  
 <221> CDS  
 <222> (1)..(198)

55  
 <400> 255  
 atg ggc gtg cgg gtc gac agg gaa cgg tgc gtg ggg gcc ggc atg tgc  
 Met Gly Val Arg Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
 1 5 10 15

48

5      gcg ctg acc gcg ccc gac gtg ttc acg cag gac gac gac ggg ttc agc      96  
       Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
               20                        25                        30

      gag atg ctt ccc ggg agc acg gcg ggg acg ggg gac cac cca cgg gtg      144  
       Glu Met Leu Pro Gly Ser Thr Ala Gly Thr Gly Asp His Pro Arg Val  
               35                        40                        45

10      cgg gag gcc gtt cgg gcc tgc ccg gtc ggg gcg gtg tcc ctg acc gac      192  
       Arg Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ser Leu Thr Asp  
               50                        55                        60

15      gac tga      198  
       Asp  
       65

20      <210> 256  
       <211> 198  
       <212> DNA  
       <213> Streptomyces griseus ATCC 10137

      <220>  
       <221> CDS  
       <222> (1)..(198)

25      <400> 256  
       atg ggc gtg cgg gtc gac agg gaa cgg tgc gtg ggg gcc ggc atg tgc      48  
       Met Gly Val Arg Val Asp Arg Glu Arg Cys Val Gly Ala Gly Met Cys  
               1                        5                        10                        15

30      gcg ctg acc gcg ccc gac gtg ttc acg cag gac gac gac ggg ttc agc      96  
       Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
               20                        25                        30

      gag atg ctt ccc ggg agc acg gcg ggg acg ggg gac cac cca cgg gtg      144  
       Glu Met Leu Pro Gly Ser Thr Ala Gly Thr Gly Asp His Pro Arg Val  
               35                        40                        45

35      cgg gag gcc gtt cgg gcc tgc ccg gtc ggg gcg gtg tcc ctg acc gac      192  
       Arg Glu Ala Val Arg Ala Cys Pro Val Gly Ala Val Ser Leu Thr Asp  
               50                        55                        60

40      gac tga      198  
       Asp  
       65

45      <210> 257  
       <211> 207  
       <212> DNA  
       <213> Streptomyces achromogenes IFO 12735

      <220>  
       <221> CDS  
       <222> (1)..(207)

50      <400> 257  
       atg cac atg gac atc gac atc gac cag gac gtc tgt atc ggc gcc ggg      48  
       Met His Met Asp Ile Asp Ile Asp Gln Asp Val Cys Ile Gly Ala Gly  
               1                        5                        10                        15

55      cag tgc gcg ctg gcg gca ccg ggc gtc ttc acc cag gac gac gac ggc      96  
       Gln Cys Ala Leu Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Asp Gly  
               20                        25                        30

5      tac agc acc ctg ctg ccc ggc cgg gag aac ggc gtc acc gac ccg atg      144  
       Tyr Ser Thr Leu Leu Pro Gly Arg Glu Asn Gly Val Thr Asp Pro Met  
               35                        40                        45

      gtc cgg gag gcc gcc cgc gcc tgc ccg gtc agc gcc atc acc gta cga      192  
       Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Arg  
               50                        55                        60

10      gag cgc acc gcc tga      207  
       Glu Arg Thr Ala  
               65

15      <210> 258  
       <211> 156  
       <212> DNA  
       <213> Streptomyces griseus IFO 13849T

20      <220>  
       <221> CDS  
       <222> (1)..(156)

      <400> 258  
       atg tgc gcg ctg acc gcg ccg gag gtg ttc aca cag gac gac gac ggt      48  
       Met Cys Ala Leu Thr Ala Pro Glu Val Phe Thr Gln Asp Asp Asp Gly  
               1                        5                        10                        15

25      ttc agc gag gtg cgt ccc ggt ggc acg gcc gcc act gct ggc cac ccg      96  
       Phe Ser Glu Val Arg Pro Gly Gly Thr Ala Ala Thr Ala Gly His Pro  
                       20                        25                        30

30      ctg gta cgc gat gcc gca cgg gcc tgc ccg gtc ggg gcg gtg acc ctg      144  
       Leu Val Arg Asp Ala Ala Arg Ala Cys Pro Val Gly Ala Val Thr Leu  
                       35                        40                        45

      acc gac gac tga      156  
       Thr Asp Asp  
               50

35      <210> 259  
       <211> 231  
       <212> DNA  
       <213> Streptomyces lanatus IFO 12787T

40      <220>  
       <221> CDS  
       <222> (1)..(231)

45      <400> 259  
       atg cac aac gaa acg cac gaa tca ggc cat atc cac atc gac atc gac      48  
       Met His Asn Glu Thr His Glu Ser Gly His Ile His Ile Asp Ile Asp  
               1                        5                        10                        15

      cat gac gtc tgc gtc ggc gcc ggg cag tgc gcc ctc gcc gcc ccc tcc      96  
       His Asp Val Cys Val Gly Ala Gly Gln Cys Ala Leu Ala Ala Pro Ser  
                       20                        25                        30

50      gtg ttc acc cag gac gac gac ggc ttc agc acc ctg ctt ccc ggc cgc      144  
       Val Phe Thr Gln Asp Asp Asp Gly Phe Ser Thr Leu Leu Pro Gly Arg  
                       35                        40                        45

55      gag gac ggc gcc gcc gcc gac ccc atg gtg cgg gag gcg gcc cgg gcg tgc      192  
       Glu Asp Gly Gly Gly Asp Pro Met Val Arg Glu Ala Ala Arg Ala Cys  
               50                        55                        60

5           ccg gtc agc gcc atc acc gtg tcc gaa ggg ggg agt tga           231  
           Pro Val Ser Ala Ile Thr Val Ser Glu Gly Gly Ser  
           65                               70                               75

<210> 260  
 <211> 201  
 <212> DNA  
 10 <213> Streptomyces misawanensis IFO 13855T

<220>  
 <221> CDS  
 <222> (1)..(201)

15 <400> 260  
           atg cac atc gag atc gac agt gac gtc tgc atc ggc gcg ggg cag tgt           48  
           Met His Ile Glu Ile Asp Ser Asp Val Cys Ile Gly Ala Gly Gln Cys  
           1                               5                               10                               15

20           gcc ctg acc gcc ccc aac gtc ttc acc cag gac gac gac ggt ttc agc           96  
           Ala Leu Thr Ala Pro Asn Val Phe Thr Gln Asp Asp Asp Gly Phe Ser  
                                   20                               25                               30

25           acc ctg ctc ccc ggg atg gcg gac ggc ggc ggc gac ccg ctg gtc aag           144  
           Thr Leu Leu Pro Gly Met Ala Asp Gly Gly Gly Asp Pro Leu Val Lys  
                                   35                               40                               45

30           gag gcg gcc cgg gcc tgc ccg gtg cac gcc atc acg gtc gag gaa ccg           192  
           Glu Ala Ala Arg Ala Cys Pro Val His Ala Ile Thr Val Glu Glu Pro  
           50                               55                               60

35           tcg ggt tag           201  
           Ser Gly  
           65

<210> 261  
 <211> 195  
 <212> DNA  
 40 <213> Streptomyces pallidus IFO 13434T

<220>  
 <221> CDS  
 <222> (1)..(195)

45 <400> 261  
           atg cga gtg gaa ctg gac gag ccg aag tgc gtc gcg tcg ggg cag tgc           48  
           Met Arg Val Glu Leu Asp Glu Pro Lys Cys Val Ala Ser Gly Gln Cys  
           1                               5                               10                               15

50           gtg atg gcc gcc ccc gag gtc ttc gac cag cgc gag gag gac ggc atc           96  
           Val Met Ala Ala Pro Glu Val Phe Asp Gln Arg Glu Glu Asp Gly Ile  
                                   20                               25                               30

55           gcc ttc gtg ctg gac gag cgg ccg gcg gcg gac gtc ctg gcg gag gtg           144  
           Ala Phe Val Leu Asp Glu Arg Pro Ala Ala Asp Val Leu Ala Glu Val  
                                   35                               40                               45

60           cgc gag gcc gtg gcg atc tgc ccc gcc gcc gcg atc ccg ctg gtg gag           192  
           Arg Glu Ala Val Ala Ile Cys Pro Ala Ala Ala Ile Arg Leu Val Glu  
           50                               55                               60

65           tga           195  
           <210> 262

<211> 201  
 <212> DNA  
 <213> Streptomyces roseorubens IFO 13682T

<220>  
 <221> CDS  
 <222> (1)..(201)

<400> 262  
 atg cgc atc gac atc gac aag gac gtc tgc atc ggc gcg ggc cag tgc 48  
 Met Arg Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15  
 gcc ctg acc gcc ccg gac gtg ttc acc cag gac gac gac ggc tac agc 96  
 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Tyr Ser  
 20 25 30  
 acc ctg ctg ccc ggc cgg gag gac ggc ggc ggc agc ccg ctg ctg cgg 144  
 Thr Leu Leu Pro Gly Arg Glu Asp Gly Gly Gly Ser Pro Leu Leu Arg  
 35 40 45  
 gag gcg gcc cgg gcc tgc ccg gtg agc gcc atc acc gtc tgc gag acc 192  
 Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser Glu Thr  
 50 55 60  
 gtc ggc tga 201  
 Val Gly  
 65

<210> 263  
 <211> 198  
 <212> DNA  
 <213> Streptomyces rutgersensis IFO 15875T

<220>  
 <221> CDS  
 <222> (1)..(198)

<400> 263  
 atg cgt gtg gaa gtc gat gtt ccc aag tgt gtg gca tcg ggt cag tgc 48  
 Met Arg Val Glu Val Asp Val Pro Lys Cys Val Ala Ser Gly Gln Cys  
 1 5 10 15  
 gtg atg atc gca ccc gat gtg ttc gac cag cgg gag gag gac ggc atc 96  
 Val Met Ile Ala Pro Asp Val Phe Asp Gln Arg Glu Glu Asp Gly Ile  
 20 25 30  
 gtg atc ctg ctg gac gag cag ccc gcg tcc gaa ctc cac gcc gat gtg 144  
 Val Ile Leu Leu Asp Glu Gln Pro Ala Ser Glu Leu His Ala Asp Val  
 35 40 45  
 cgt gag tcc gcg gtg gtc tgc ccg gcg gcg gcg ata cgg gtg gtc gag 192  
 Arg Glu Ser Ala Val Val Cys Pro Ala Ala Ala Ile Arg Val Val Glu  
 50 55 60  
 aat tga 198  
 Asn  
 65

<210> 264  
 <211> 201  
 <212> DNA  
 <213> Streptomyces steffisburgensis IFO 13446T

<220>  
 <221> CDS  
 <222> (1)..(201)  
 5  
 <400> 264  
 atg cac atc gac atc gac aag gac gtc tgc atc ggc gcg ggc cag tgc 48  
 Met His Ile Asp Ile Asp Lys Asp Val Cys Ile Gly Ala Gly Gln Cys  
 1 5 10 15  
 10  
 gcc ctg acc gcc ccg gac gtg ttc acc cag gac gac gac ggc atc agc 96  
 Ala Leu Thr Ala Pro Asp Val Phe Thr Gln Asp Asp Asp Gly Ile Ser  
 20 25 30  
 15  
 gcc ctg ctg ccg gga cag gag gac ggc ggc ggc agc ccg ctg gtg cgg 144  
 Ala Leu Leu Pro Gly Gln Glu Asp Gly Gly Gly Ser Pro Leu Val Arg  
 35 40 45  
 20  
 gag gcg gcc cgt gcc tgc ccg gtg agc gcc atc acc gtg tcg gag acg 192  
 Glu Ala Ala Arg Ala Cys Pro Val Ser Ala Ile Thr Val Ser Glu Thr  
 50 55 60  
 25  
 gtg agc tga 201  
 Val Ser  
 65  
 <210> 265  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 265  
 ctcgaagaac tcgtggtcgg cgtacgg 27  
 35  
 <210> 266  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 266  
 cacaccgagg agcgcgcaga tcaccat 27  
 45  
 <210> 267  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 267  
 cgtgtttcttc tcgacctcgc tcatcaacc 29  
 55  
 <210> 268  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>



5  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 274  
 gccatatgac ggaatccacg acggaac 27  
 <210> 275  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 15  
 <400> 275  
 ccaagctttc agtcgtcggc cagggacac 29  
 <210> 276  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing  
 25  
 <400> 276  
 gagcttctcc gtgaagcgga tag 23  
 <210> 277  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing  
 35  
 <400> 277  
 caaagctttc accaggccac gggcaggtgc 30  
 <210> 278  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 45  
 <400> 278  
 ccaggagat catgttggcg gtcgtct 27  
 <210> 279  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 279  
 cttggcgtcg atcaggtcgc cgaggaa 27  
 55  
 <210> 280  
 <211> 27

5 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 280  
 accgccgaag ctttcaggcg gtgcgct 27  
 10  
 <210> 281  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 15  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing  
  
 <400> 281  
 ggacgaactg ctggacgcga tgatcga 27  
 20  
 <210> 282  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
 25  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 282  
 agcagccggt ccaccgtctc ctggatac 28  
 30  
 <210> 283  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 283  
 cgtttcacgg agaagctcgg gatgagca 28  
 40  
 <210> 284  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 284  
 gatcgaggac atcgaggtgg acgggac 27  
 50  
 <210> 285  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
 55  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 285  
 tctttctctc cacctcgtc gtcaaccg 28

5 <210> 286  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 10 <400> 286  
 atcatatgac ggaatccacg acggaacc 28  
  
 <210> 287  
 <211> 29  
 <212> DNA  
 15 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 20 <400> 287  
 cgaagctttc agtcgtcggc cagggtcac 29  
  
 <210> 288  
 <211> 20  
 <212> DNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing  
  
 30 <400> 288  
 gtatccagga gacggtggac 20  
  
 <210> 289  
 <211> 27  
 <212> DNA  
 35 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 40 <400> 289  
 gcggagagtg aagctgggga ccatcat 27  
  
 <210> 290  
 <211> 27  
 <212> DNA  
 45 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 50 <400> 290  
 cgaggagctc atgcggatgc tgtcgat 27  
  
 <210> 291  
 <211> 27  
 <212> DNA  
 55 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 <400> 291

cgtggtcttc tcgacctcgg tcatcaa

```
<210> 292
<211> 30
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 292  
cgaggtccat atgacggaca tgaccgatat

```
<210> 293
<211> 30
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 293  
gatgccaagc tttcaactcc ccccttcgga

```
<210> 294
<211> 28
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Designed oligonucleotide primer for PCR

```
<400> 294
cgagcagatc gtcgacgac cgctggat
```

```
<210> 295
<211> 27
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Designed oligonucleotide primer for PCR

```
<400> 295
ttgagggtga agtccgggat cagcatc
```

<210> 296  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for PCR

<400> 296  
gaggaactga tgcggatgct gtccatc

```
<210> 297
<211> 27
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Designed oligonucleotide primer for PCR

	<400> 297	
5	catcaaccgt gacgagtcgcg tgtacga	27
	<210> 298	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 298	
	ctcatatgaa agaactgacg gacctga	27
15	<210> 299	
	<211> 29	
	<212> DNA	
	<213> Artificial Sequence .	
20	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 299	
	gcaagcttct aacccgacgg ttcctcgac	29
25	<210> 300	
	<211> 22	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Designed oligonucleotide primer for DNA sequencing	
	<400> 300	
	gatgctgatc ccggacttca cc	22
35	<210> 301	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 301	
	cttctcgccc atcagctcgt cgaggta	27
45	<210> 302	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 302	
	gaggatccgg ctgttctcct ggaagaa	27
55	<210> 303	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	

5 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 303  
 catgaggatg aagctggcgt tgttctc 27  
 <210> 304  
 <211> 27  
 10 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 15 <400> 304  
 gacatcgaga tcggcggaca ggtcatc 27  
 <210> 305  
 <211> 27  
 <212> DNA  
 20 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 25 <400> 305  
 atgatcatgc ccaacgacct cgccaac 27  
 <210> 306  
 <211> 33  
 <212> DNA  
 30 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 35 <400> 306  
 cgaccgagga gacatatggc cgacaccctc gcc 33  
 <210> 307  
 <211> 33  
 <212> DNA  
 40 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 45 <400> 307  
 aaatcgaagc ttctactcca ccagccggat cgc 33  
 <210> 308  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 50 <220>  
 <223> Designed oligonucleotide primer for DNA sequencing  
 <400> 308  
 ggagtgccgt acgaggacca cgacttcttc 30  
 <210> 309  
 <211> 27  
 55 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 309

agcctcgaag aagtcgtggt cggcgta

27

<210> 310

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 310

gagtcgttcg tcgacgatcc gctggat

27

<210> 311

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 311

ccaacatgat ctccctcggc accttca

27

<210> 312

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 312

ggtcacaaac cgcgacgaga cggctctt

27

<210> 313

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 313

gtctgcgagg tccatatgac ggacacgacc gca

33

<210> 314

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 314

tgacaagctt tcagccgacg gtctccgaga

30

<210> 315

5  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for DNA sequencing

10  
 <400> 315  
 cgtcgacgaa cgactcgacg cgatgat 27

<210> 316  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <223> Designed oligonucleotide primer for PCR

20  
 <400> 316  
 cgtggagtta cggttgatca ggagcga 27

<210> 317  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Designed oligonucleotide primer for PCR

30  
 <400> 317  
 cagatcgtcg gtgatcttct ggatgtc 27

<210> 318  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> Designed oligonucleotide primer for PCR

40  
 <400> 318  
 gaactgctgc gctatctgac catcgtg 27

<210> 319  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Designed oligonucleotide primer for PCR

50  
 <400> 319  
 atcatcgtct acaccggcac cggcaact 28

<210> 320  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

55  
 <220>  
 <223> Designed oligonucleotide primer for PCR

<400> 320  
 ccgaggagac atatgaccga aacgctggca 30

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

	<400> 326	
5	gaggtccata tgtcggacac gaccgca	27
	<210> 327	
	<211> 26	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 327	
	tacaagcttt cagctcaccg tctccg	26
15	<210> 328	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 328	
	atgacccagt ccgccgacgc cgtaccc	27
25	<210> 329	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 329	
	tcaccaggtg acggggagtt cgtagac	27
35	<210> 330	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 330	
	atgacggaac tgacggacat caccggc	27
45	<210> 331	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 331	
	ttaccaggtc acggggagtt ccagcat	27
55	<210> 332	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	

<223> Designed oligonucleotide primer for PCR  
 <400> 332  
 5 atgacggaat ccacgacaga tccgacg 27  
 <210> 333  
 <211> 26  
 <212> DNA  
 10 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 333  
 15 tcaccaggcc acgggcagtt cgagca 26  
 <210> 334  
 <211> 27  
 <212> DNA  
 20 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 334  
 25 atgacggaca tgacggaaac ccccacc 27  
 <210> 335  
 <211> 27  
 <212> DNA  
 30 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 335  
 35 atgacggaat ccacgacgga accggcc 27  
 <210> 336  
 <211> 27  
 <212> DNA  
 40 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 336  
 45 tcaccaggcc acgggcaggt gcagaag 27  
 <210> 337  
 <211> 27  
 <212> DNA  
 50 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
 <400> 337  
 55 atgacggaca tgacggaaac ccccacc 27  
 <210> 338  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

5	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 338 atgaaagaac tgacggacct gacggaa	27
10	<210> 339 <211> 27 <212> DNA <213> Artificial Sequence	
15	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 339 atgtcggaca cgaccgaccc cgtggcc	27
20	<210> 340 <211> 27 <212> DNA <213> Artificial Sequence	
25	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 340 atggccgaca ccctcgccgg cgccacg	27
30	<210> 341 <211> 27 <212> DNA <213> Artificial Sequence	
35	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 341 tcaccacgtg acgggcagtt cgtagac	27
40	<210> 342 <211> 27 <212> DNA <213> Artificial Sequence	
45	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 342 atgaccgaaa cgctggcaga gaccacg	27
50	<210> 343 <211> 27 <212> DNA <213> Artificial Sequence	
55	<220> <223> Designed oligonucleotide primer for PCR	
	<400> 343 tcaagacgtc caggtgacgg gcagttc	27
	<210> 344 <211> 70	

<212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 344  
 catatgacag atactactgc acctgttgca tttcctcaga gtaggacctg tccatatcat 60  
 ccacctgctg 70

<210> 345  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 345  
 tccatatcat ccacctgctg catacgaacc acttcgtgct gaacgtcctc tgactaggat 60  
 tactctcttt 70

<210> 346  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 346  
 tgactaggat tactctcttt gatggacgtg aagcatgggt ggtagtggt catgccaccg 60  
 cacgtgctct 70

<210> 347  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 347  
 aggaggatgg tcgttgggga cttcactctc aaacgggcag ctgcattgag gccccgcatt 60  
 cagaggattg 70

<210> 348  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 348  
 gccccgcatt cagaggattg ttgatgaacg actcgatgcg atgattgctc aaggaccacc 60  
 tgcagatttg 70

<210> 349  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>

# EP 1 457 558 A1

<223> Designed oligonucleotide primer for PCR

5 <400> 349  
aaggaccacc tgcagatttg gtgagcgcat ttgcattgcc agtgccttca atggtgatat 60  
gcgctttgct 70

<210> 350

<211> 70

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

15 <400> 350  
aagagagaag atcctggtagc tggattactt gatgaccttg ttcaacggca gccaggagat 60  
ggtggaccgc 70

<210> 351

<211> 70

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

25 <400> 351  
gccaggagat ggtggaccgc atagagaagg actgatagcc atggccctca tcctgcttgt 60  
agcaggccat 70

<210> 352

<211> 70

30 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

35 <400> 352  
tcctgcttgt agcaggccat gagacgaccg ccaacatgat atcactaggc acctttacac 60  
tcttgcaaca 70

<210> 353

<211> 70

40 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

45 <400> 353  
acaacaatcc gagctggaga aggcgtagtg ttgcgcacat cggtcatcaa tagagatgag 60  
acagtctttg 70

<210> 354

<211> 70

50 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

55 <400> 354  
tagagatgag acagtctttg ctgagccgga cactctcgac tggcttagac cagccagaca 60

tcacgtagcg 70

<210> 355  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 355  
 cagccagaca tcacgtagcg ttcggctttg ggattcacca gtgcttaggt caaaacttag 60  
 caagagccga 70

<210> 356  
 <211> 56  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 356  
 aagcttttac caggtcacgg ggagttccaa catcccttgg atcgtgtcgc ctggct 56

<210> 357  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 357  
 ttggatcgtg tcgcctggct tgaagggaat ctcatctgga ggagcggcca atctaagtgt 60  
 gggcaaccta 70

<210> 358  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 358  
 atctaagtgt gggcaaccta ccgaagaggg tgcctaaggc gatctcaagt tcggctcttg 60  
 ctaagttttg 70

<210> 359  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide primer for PCR

<400> 359  
 tctccagctc ggattgttgt cccggccact tcaacatcct caacagcaat gcgcaacaga 60  
 ccatctgcaa 70

<210> 360  
 <211> 70  
 <212> DNA

<213> Artificial Sequence

5

<220>

<223> Designed oligonucleotide primer for PCR

<400> 360

gcgcaacaga ccatctgcaa tggacagcaa cctcataagt tcctcaactg cggccggcat 60  
gacctcggag 70

10

<210> 361

<211> 70

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Designed oligonucleotide primer for PCR

<400> 361

cggccggcat gacctcggag tcagctcgaa gttagctag cctctcaggg tggtgcaaga 60  
gtgtaaaggt 70

20

<210> 362

<211> 70

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Designed oligonucleotide primer for PCR

<400> 362

gtaccaggat cttctctctt gcggtcaata agtcaccga agtactcctc aagcctgctc 60  
ctagatcct 70

30

<210> 363

<211> 70

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Designed oligonucleotide primer for PCR

<400> 363

aagcctgctc ctagatcct gcacatcagc agtccctggt cctctcagaa gtctccttga 60  
ttgagcttca 70

40

<210> 364

<211> 70

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Designed oligonucleotide primer for PCR

<400> 364

gtctccttga ttgagcttca aagaagtcac ggtcagcata gggaacacct agcaaagcgc 60  
atatcaccat 70

50

<210> 365

<211> 70

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Designed oligonucleotide primer for PCR

5 <400> 365  
 tccccaacga ccacccctct ttggggcacgg tgctcaggat cgtccacacc gagaagagct 60  
 gtacgtctat 70

10 <210> 366  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

15 <220>  
 <223> Designed oligonucleotide primer for PCR

20 <400> 366  
 gagaagagct gtacgtctat tgcgtatccc agcaaattctc gcagtagggg ttgggaatcc 60  
 aggtctgtcg 70

25 <210> 367  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Designed oligonucleotide primer for PCR

35 <400> 367  
 ttgggaatcc aggtctgtcg cgatcagaag acaatcttgg atctgctaga agagcacgtg 60  
 cggtagcatg 70

40 <210> 368  
 <211> 1197  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <221> CDS  
 <222> (1)..(1197)  
 <223> Designed polynucleotide encoding amino acid sequence of SEQ ID No.222

50 <400> 368  
 atg aca gat act act gca cct gtt gca ttt cct cag agt agg acc tgt 48  
 Met Thr Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys  
 1 5 10 15

55 cca tat cat cca cct gct gca tac gaa cca ctt cgt gct gaa cgt cct 96  
 Pro Tyr His Pro Pro Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro  
 20 25 30

60 ctg act agg att act ctc ttt gat gga cgt gaa gca tgg ttg gtt agt 144  
 Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser  
 35 40 45

65 ggt cat gcc acc gca cgt gct ctt cta gca gat cca aga ttg tct tct 192  
 Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser  
 50 55 60

70 gat cgc gac aga cct gga ttc cca acc cct act gcg aga ttt gct ggg 240  
 Asp Arg Asp Arg Pro Gly Phe Pro Thr Pro Thr Ala Arg Phe Ala Gly  
 65 70 75 80

75 ata cgc aat aga cgt aca gct ctt ctc ggt gtg gac gat cct gag cac 288  
 Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His  
 85 90 95

EP 1 457 558 A1

5	cgt gcc caa agg agg atg gtc gtt ggg gac ttc act ctc aaa cgg gca Arg Ala Gln Arg Arg Met Val Val Gly Asp Phe Thr Leu Lys Arg Ala 100 105 110	336
	gct gca ttg agg ccc cgc att cag agg att gtt gat gaa cga ctc gat Ala Ala Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Glu Arg Leu Asp 115 120 125	384
10	gcg atg att gct caa gga cca cct gca gat ttg gtg agc gca ttt gca Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ala Phe Ala 130 135 140	432
15	ttg cca gtg cct tca atg gtg ata tgc gct ttg cta ggt gtt ccc tat Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr 145 150 155 160	480
	gct gac cat gac ttc ttt gaa gct caa tca agg aga ctt ctg aga gga Ala Asp His Asp Phe Phe Glu Ala Gln Ser Arg Arg Leu Leu Arg Gly 165 170 175	528
20	cca ggg act gct gat gtg cag gat gct agg agc agg ctt gag gag tac Pro Gly Thr Ala Asp Val Gln Asp Ala Arg Ser Arg Leu Glu Glu Tyr 180 185 190	576
25	ttc ggt gag ctt att gac cgc aag aga gaa gat cct ggt act gga tta Phe Gly Glu Leu Ile Asp Arg Lys Arg Glu Asp Pro Gly Thr Gly Leu 195 200 205	624
	ctt gat gac ctt gtt caa cgg cag cca gga gat ggt gga ccc gat aga Leu Asp Asp Leu Val Gln Arg Gln Pro Gly Asp Gly Gly Pro Asp Arg 210 215 220	672
30	gaa gga ctg ata gcc atg gcc ctc atc ctg ctt gta gca ggc cat gag Glu Gly Leu Ile Ala Met Ala Leu Ile Leu Leu Val Ala Gly His Glu 225 230 235 240	720
35	acg acc gcc aac atg ata tca cta ggc acc ttt aca ctc ttg caa cac Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255	768
	cct gag agg cta gct gaa ctt cga gct gac tcc gag gtc atg ccg gcc Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Ser Glu Val Met Pro Ala 260 265 270	816
40	gca gtt gag gaa ctt atg agg ttg ctg tcc att gca gat ggt ctg ttg Ala Val Glu Glu Leu Met Arg Leu Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285	864
45	cgc att gct gtt gag gat gtt gaa gtg gcc ggg aca aca atc cga gct Arg Ile Ala Val Glu Asp Val Glu Val Ala Gly Thr Thr Ile Arg Ala 290 295 300	912
	gga gaa ggc gta gtg ttc gcg aca tcg gtc atc aat aga gat gag aca Gly Glu Gly Val Val Phe Ala Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320	960
50	gtc ttt gct gag ccg gac act ctc gac tgg tct aga cca gcc aga cat Val Phe Ala Glu Pro Asp Thr Leu Asp Trp Ser Arg Pro Ala Arg His 325 330 335	1008
55	cac gta gcg ttc ggc ttt ggg att cac cag tgc tta ggt caa aac tta His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu 340 345 350	1056

# EP 1 457 558 A1

	gca aga gcc gaa ctt gag atc gcc tta ggc acc ctc ttc ggt agg ttg	1104
	Ala Arg Ala Glu Leu Glu Ile Ala Leu Gly Thr Leu Phe Gly Arg Leu	
	355 360 365	
5	ccc aca ctt aga ttg gcc gct cct cca gat gag att ccc ttc aag cca	1152
	Pro Thr Leu Arg Leu Ala Ala Pro Pro Asp Glu Ile Pro Phe Lys Pro	
	370 375 380	
10	ggc gac acg atc caa ggg atg ttg gaa ctc ccc gtg acc tgg taa	1197
	Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp Stop	
	385 390 395	
	<210> 369	
	<211> 70	
	<212> DNA	
15	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
20	<400> 369	
	catatgtctg atactacagc acctgttgct tttccacaat ctggtacctg cccttatcat	60
	cctcctgctg	70
	<210> 370	
	<211> 70	
25	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
30	<400> 370	
	ccccttatcat cctcctgctg cctatgaacc gttacgtgct gagagaccct tgactagaat	60
	cacactcttt	70
	<210> 371	
	<211> 70	
35	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
40	<400> 371	
	tgactagaat cacactcttt gatggtagag aagcctgggt ggtcagtgga catgccacag	60
	ctagggcatt	70
	<210> 372	
	<211> 70	
45	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
50	<400> 372	
	cgtaggatgg ttgcagggga ctttacactc aaaagagctg caggattgag gccacgcatt	60
	caacggattg	70
	<210> 373	
	<211> 70	
55	<212> DNA	
	<213> Artificial Sequence	

**EP 1 457 558 A1**

	<220>		
5	<223>	Designed oligonucleotide primer for PCR	
	<400>	373	
		gccacgcatt caacggattg tggacaggcg actcgatgcg atgatatgctc aggggtccacc	60
		tgcagacctt	70
10	<210>	374	
	<211>	70	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
15	<223>	Designed oligonucleotide primer for PCR	
	<400>	374	
		agggtccacc tgcagacctt gtgagcagct tcgcgttacc agttccgtcc atgggtgatct	60
		gtgccttgct	70
20	<210>	375	
	<211>	70	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
25	<223>	Designed oligonucleotide primer for PCR	
	<400>	375	
		aaacggaagg aaccaggagc tggactgctt gatgacttgg ttcaacgaca gcttagagat	60
		ggagcattag	70
30	<210>	376	
	<211>	70	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
35	<223>	Designed oligonucleotide primer for PCR	
	<400>	376	
		gcttagagat ggagcattag acaggaagg tctgattgcc cttgcactca tcttgcttgt	60
		tgctggtcac	70
40	<210>	377	
	<211>	70	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
45	<223>	Designed oligonucleotide primer for PCR	
	<400>	377	
		tcttgcttgt tgctggtcac gagacgacag ccaacatgat ctctcttggc accttcaccc	60
		tattgcaaca	70
50	<210>	378	
	<211>	70	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
55	<223>	Designed oligonucleotide primer for PCR	

EP 1 457 558 A1

5      <400> 378  
accacaattc gcaaggggga tggagtgggtg tttctgacta gtgtcatcaa ccgcgatgag      60  
acagtctacc      70

10      <210> 379  
         <211> 70  
         <212> DNA  
         <213> Artificial Sequence

15      <220>  
         <223> Designed oligonucleotide primer for PCR

20      <400> 379  
ccgcgatgag acagtctacc ctgaaccaga caccctcgat tggcaccgtt ctgctagaca      60  
tcacgtagcg      70

25      <210> 380  
         <211> 70  
         <212> DNA  
         <213> Artificial Sequence

30      <220>  
         <223> Designed oligonucleotide primer for PCR

35      <400> 380  
ctgctagaca tcacgtagcg ttcggcttcg gcattcacca gtgcctcggc cagaatcttg      60  
cacgcgctga      70

40      <210> 381  
         <211> 56  
         <212> DNA  
         <213> Artificial Sequence

45      <220>  
         <223> Designed oligonucleotide primer for PCR

50      <400> 381  
aagcttttac caagtcacag gaagttccaa catcccttga atcgtgtcac ctggct      56

55      <210> 382  
         <211> 70  
         <212> DNA  
         <213> Artificial Sequence

55      <220>  
         <223> Designed oligonucleotide primer for PCR

60      <400> 382  
ttgaatcgtg tcacctggct tgaaggcaat ctccctcggt ggagctgcta agcgtagagt      60  
gggcaaacga      70

65      <210> 383  
         <211> 70  
         <212> DNA  
         <213> Artificial Sequence

70      <220>  
         <223> Designed oligonucleotide primer for PCR

75      <400> 383  
agcgtagagt gggcaaacga tcgaagaggg tccaaagtgc aatctcaagc tcagcgcgtg      60  
caagattctg      70

80      <210> 384

5 <211> 70  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 10 <400> 384  
 tcccccttgc gaattgtggt cccagcaact tctatgtcct caacggcgag tctaagcaaa 60  
 ccatccgcta 70  
  
 <210> 385  
 <211> 70  
 <212> DNA  
 15 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 20 <400> 385  
 tctaagcaaa ccatccgcta tggacagcat gcgcatcagt tcttcgactg cagcaggcaa 60  
 tagacgagga 70  
  
 <210> 386  
 <211> 70  
 <212> DNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 30 <400> 386  
 cagcaggcaa tagacgagga tctgtctctca actcagcaag cctttcggga tgttgcaata 60  
 gggagaaggt 70  
  
 <210> 387  
 <211> 70  
 <212> DNA  
 35 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 40 <400> 387  
 gtccttggtt ccttcggtt cctgtcaatc agttctccaa agtactcatc caaccgtgct 60  
 ctagcatcca 70  
  
 <210> 388  
 <211> 70  
 <212> DNA  
 45 <213> Artificial Sequence  
  
 <220>  
 <223> Designed oligonucleotide primer for PCR  
  
 50 <400> 388  
 caaccgtgct ctagcatcca tcacatcggc agtctgagga cctctaagta gtctccttga 60  
 ctgggtctca 70  
  
 <210> 389  
 <211> 70  
 <212> DNA  
 55 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide primer for PCR

&lt;400&gt; 389

gtctccttga ctgggtctca aagaaatcgt gatcggcgta tggaactccg agcaaggcac 60  
 agatcaccat 70

&lt;210&gt; 390

&lt;211&gt; 70

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide primer for PCR

&lt;400&gt; 390

tcccttgcaa ccatactacg ttgtactcga tggtcaggat cgtcaacacc cagtagtgca 60  
 gttctcctat 70

&lt;210&gt; 391

&lt;211&gt; 70

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide primer for PCR

&lt;400&gt; 391

cagtagtgca gttctcctat tccttatccc agcaaaccctt gcagtgggag ctgggaagcc 60  
 aggtctgtca 70

&lt;210&gt; 392

&lt;211&gt; 70

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide primer for PCR

&lt;400&gt; 392

ctgggaagcc aggtctgtca cgatcagatg aaagccttgg atcagcgagt aatgccctag 60  
 ctgtggcatg 70

&lt;210&gt; 393

&lt;211&gt; 1197

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1197)

&lt;223&gt; Designed polynucleotide encoding amino acid sequence of SEQ ID No.224

&lt;400&gt; 393

atg tct gat act aca gca cct gtt gct ttt cca caa tct cgt acc tgc 48  
 Met Ser Asp Thr Thr Ala Pro Val Ala Phe Pro Gln Ser Arg Thr Cys  
     1                    5                    10                    15

ccc tat cat cct cct gct gcc tat gaa ccg tta cgt gct gag aga ccc 96  
 Pro Tyr His Pro Thr Ala Ala Tyr Glu Pro Leu Arg Ala Glu Arg Pro  
                     20                    25                    30

ttg act aga atc aca ctc ttt gat ggt aga gaa gcc tgg ttg gtc agt 144  
 Leu Thr Arg Ile Thr Leu Phe Asp Gly Arg Glu Ala Trp Leu Val Ser

EP 1 457 558 A1

	35	40	45	
5	gga cat gcc aca gct agg gca tta ctc gct gat cca agg ctt tca tct Gly His Ala Thr Ala Arg Ala Leu Leu Ala Asp Pro Arg Leu Ser Ser 50 55 60			192
10	gat cgt gac aga cct ggc ttc cca gct ccc act gca agg ttt gct ggg Asp Arg Asp Arg Pro Gly Phe Pro Ala Pro Thr Ala Arg Phe Ala Gly 65 70 75 80			240
15	ata agg aat agg aga act gca cta ctg ggt gtt gac gat cct gaa cat Ile Arg Asn Arg Arg Thr Ala Leu Leu Gly Val Asp Asp Pro Glu His 85 90 95			288
20	cga gta caa cgt agg atg gtt gca ggg gac ttt aca ctc aaa aga gct Arg Val Gln Arg Arg Met Val Ala Gly Asp Phe Thr Leu Lys Arg Ala 100 105 110			336
25	gca gga ttg agg cca cgc att caa cgg att gtg gac agg cga ctc gat Ala Gly Leu Arg Pro Arg Ile Gln Arg Ile Val Asp Arg Arg Leu Asp 115 120 125			384
30	gcg atg ata gct cag ggt cca cct gca gac ctt gtg agc agc ttc gcg Ala Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val Ser Ser Phe Ala 130 135 140			432
35	tta cca gtt ccg tcc atg gtg atc tgt gcc ttg ctc gga gtt cca tac Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Pro Tyr 145 150 155 160			480
40	gcc gat cac gat ttc ttt gag acc cag tca agg aga cta ctt aga ggt Ala Asp His Asp Phe Phe Glu Thr Gln Ser Arg Arg Leu Leu Arg Gly 165 170 175			528
45	cct cag act gcc gat gtg atg gat gct aga gca cgg ttg gat gag tac Pro Gln Thr Ala Asp Val Met Asp Ala Arg Ala Arg Leu Asp Glu Tyr 180 185 190			576
50	ttt gga gaa ctg att gac agg aaa cgg aag gaa cca gga gct gga ctg Phe Gly Glu Leu Ile Asp Arg Lys Arg Lys Glu Pro Gly Ala Gly Leu 195 200 205			624
55	ctt gat gac ttg gtt caa cga cag ctt aga gat gga gca tta gac agg Leu Asp Asp Leu Val Gln Arg Gln Leu Arg Asp Gly Ala Leu Asp Arg 210 215 220			672
60	gaa ggt ctg att gcc ctt gca ctc atc ttg ctt gtt gct ggt cac gag Glu Gly Leu Ile Ala Leu Ala Leu Ile Leu Leu Val Ala Gly His Glu 225 230 235 240			720
65	acg aca gcc aac atg atc tct ctt ggc acc ttc acc cta ttg caa cat Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Gln His 245 250 255			768
70	ccc gaa agg ctt gct gag ttg aga gca gat cct cgt cta ttg cct gct Pro Glu Arg Leu Ala Glu Leu Arg Ala Asp Pro Arg Leu Leu Pro Ala 260 265 270			816
75	gca gtc gag gaa ctg atg cgc atg ctg tcc ata gcg gat ggt ttg ctt Ala Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala Asp Gly Leu Leu 275 280 285			864
80	aga ctc gcc gtt gag gac ata gaa gtt gct ggg acc aca att cgc aag Arg Leu Ala Val Glu Asp Ile Glu Val Ala Gly Thr Thr Ile Arg Lys			912

EP 1 457 558 A1

	290	295	300	
5	ggg gat gga gtg gtg ttt ctg act agt gtc atc aac cgc gat gag aca Gly Asp Gly Val Val Phe Leu Thr Ser Val Ile Asn Arg Asp Glu Thr 305 310 315 320			960
10	gtc tac cct gaa cca gac acc ctc gat tgg cac cgt tct gct aga cat Val Tyr Pro Glu Pro Asp Thr Leu Asp Trp His Arg Ser Ala Arg His 325 330 335			1008
15	cac gta gcg ttc ggc ttc ggc att cac cag tgc ctc ggc cag aat ctt His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu 340 345 350			1056
20	gca cgc gct gag ctt gag att gca ctt tgg acc ctc ttc gat cgt ttg Ala Arg Ala Glu Leu Glu Ile Ala Leu Trp Thr Leu Phe Asp Arg Leu 355 360 365			1104
25	ccc act cta cgc tta gca gct cca gcc gag gag att gcc ttc aag cca Pro Thr Leu Arg Leu Ala Ala Pro Ala Glu Glu Ile Ala Phe Lys Pro 370 375 380			1152
30	ggt gac acg att caa ggg atg ttg gaa ctt cct gtg act tgg taa Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val Thr Trp Stop 385 390 395			1197
35	<210> 394 <211> 29 <212> DNA <213> Artificial Sequence			
40	<220> <223> Designed oligonucleotide primer for PCR			
45	<400> 394 ggggatgcat gacagatatg acagataact			29
50	<210> 395 <211> 30 <212> DNA <213> Artificial Sequence			
55	<220> <223> Designed oligonucleotide primer for PCR			
60	<400> 395 ggggagctcc taccaggcca cggaagatc			30
65	<210> 396 <211> 18 <212> DNA <213> Artificial Sequence			
70	<220> <223> Designed oligonucleotide primer for PCR			
75	<400> 396 acagatatga cagataact			18
80	<210> 397 <211> 27 <212> DNA <213> Artificial Sequence			

	<220>	
	<223> Designed oligonucleotide primer for PCR	
5	<400> 397	
	ggatgcatga cagatactac tgcacct	27
	<210> 398	
	<211> 27	
10	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
15	<400> 398	
	gagctcttac caggtcacgg ggagttc	27
	<210> 399	
	<211> 27	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
25	<400> 399	
	ggggtcatga cagatactac tgcacct	27
	<210> 400	
	<211> 27	
	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 400	
	ggatgcatgt ctgatactac agcacct	27
35	<210> 401	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> Designed oligonucleotide primer for PCR	
	<400> 401	
	gagctcttac caagtcacag gaagttc	27
45	<210> 402	
	<211> 36	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Designed oligonucleotide linker for construction of expression vector	
	<400> 402	
	tgcagggtgtg gccaccaatt ggcaagaaga aatgca	36
55	<210> 403	
	<211> 36	
	<212> DNA	

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide linker for construction of expression vector

<400> 403


tttcttcttg ccaattggtg gccacacctg catgca

36


## Claims

1. A DNA encoding a herbicide metabolizing protein, wherein said protein is selected from the group consisting of:

- (A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;
- (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;
- (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;
- (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;
- (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II):



to a compound of formula (III):



and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

- (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;
- (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;
- (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;
- (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;
- (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 5 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 10 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;  
 20 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and  
 25 (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces omatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*,  
 30 *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*.

2. A DNA comprising a nucleotide sequence selected from the group consisting of:

(a1) the nucleotide sequence shown in SEQ ID NO: 6;  
 40 (a2) the nucleotide sequence shown in SEQ ID NO: 7;  
 (a3) the nucleotide sequence shown in SEQ ID NO: 8;  
 (a4) the nucleotide sequence shown in SEQ ID NO: 109;  
 (a5) the nucleotide sequence shown in SEQ ID NO: 139;  
 (a6) the nucleotide sequence shown in SEQ ID NO: 140;  
 45 (a7) the nucleotide sequence shown in SEQ ID NO: 141;  
 (a8) the nucleotide sequence shown in SEQ ID NO: 142;  
 (a9) the nucleotide sequence shown in SEQ ID NO: 143;  
 (a10) the nucleotide sequence shown in SEQ ID NO: 225;  
 (a11) the nucleotide sequence shown in SEQ ID NO: 226;  
 50 (a12) the nucleotide sequence shown in SEQ ID NO: 227;  
 (a13) the nucleotide sequence shown in SEQ ID NO: 228;  
 (a14) the nucleotide sequence shown in SEQ ID NO: 229;  
 (a15) the nucleotide sequence shown in SEQ ID NO: 230;  
 (a16) the nucleotide sequence shown in SEQ ID NO: 231;  
 55 (a17) the nucleotide sequence shown in SEQ ID NO: 232;  
 (a18) the nucleotide sequence shown in SEQ ID NO: 233;  
 (a19) the nucleotide sequence shown in SEQ ID NO: 234;  
 (a20) a nucleotide sequence encoding an amino acid sequence of a protein having an ability to convert in the

presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), said nucleotide sequence having at least 80% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 109; and  
 (a21) a nucleotide sequence encoding an amino acid sequence of a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), said nucleotide sequence having at least 90% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233 or SEQ ID NO: 234.

3. The DNA according to claim 1, comprising a nucleotide sequence encoding an amino acid sequence of said protein, wherein the codon usage in said nucleotide sequence is within the range of plus or minus 4% of the codon usage in genes from the species of a host cell to which the DNA is introduced and the GC content of said nucleotide sequence is at least 40% and at most 60%.
4. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 214.
5. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 368.
6. A DNA comprising the nucleotide sequence shown in SEQ ID NO: 393.
7. A DNA in which a DNA having a nucleotide sequence encoding an intracellular organelle transit signal sequence is linked upstream of the DNA according to claim 1 in frame.
8. A DNA in which the DNA according to claim 1 and a promoter functional in a host cell are operably linked.
9. A vector comprising the DNA according to claim 1.
10. A method of producing a vector comprising a step of inserting the DNA according to claim 1 into a vector replicable in a host cell.
11. A transformant in which the DNA according to claim 1 is introduced into a host cell.
12. The transformant according to claim 11, wherein the host cell is a microorganism cell or a plant cell.
13. A method of producing a transformant comprising a step of introducing into a host cell, the DNA according to claim 1.
14. A method of producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a steps of culturing the transformant according to claim 11 and recovering the produced said protein.
15. Use of the DNA according to claim 1 for producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III).
16. A method of giving a plant resistance to a herbicide, said method comprising a step of introducing into and expressing in a plant cell, the DNA according to claim 1.
17. A polynucleotide having a partial nucleotide sequence of a DNA according to claim 1 or a nucleotide sequence complimentary to said partial nucleotide sequence.
18. A method of detecting a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting a DNA to which a probe is hybridized in a hybridization using as the probe the DNA according to claim 1 or the polynucleotide according to claim 17.
19. A method of detecting a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting a DNA amplified in a polymerase chain reaction with the polynucleotide according to claim 17 as a primer.

20. The method according to claim 19, wherein at least one of the primers is selected from the group consisting of a polynucleotide comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128 and a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 129.

21. A method of obtaining a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of recovering the DNA detected by the method according to claim 18 or 19.

22. A method of screening a cell having a DNA encoding a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of detecting said DNA from a test cell by the method according to claim 18 or 19.

23. A herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucle-

otide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-*  
*coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*,  
*Streptomyces olivochromogenes*, *Streptomyces omatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*,  
*Streptomyces steffisburgensis* or *Saccharopolyspora taberi*.

24. An antibody recognizing a herbicide metabolizing protein selected from the group consisting of:

- (A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;
- (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;
- (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;
- (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;
- (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;
- (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;
- (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;
- (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;
- (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;
- (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;
- (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;
- (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;
- (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;
- (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;
- (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;
- (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;
- (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;
- (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;
- (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;
- (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;
- (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;
- (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;
- (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and
- (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-*  
*coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*,

*Streptomyces olivochromogenes*, *Streptomyces ornatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*.

5 25. A method of detecting a herbicide metabolizing protein, said method comprising:

- (3) a step of contacting a test substance with an antibody recognizing said protein and
- (4) a step of detecting a complex of said protein and said antibody, arising from said contact,

10 wherein said protein is selected from the group consisting of:

- (A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;
- (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;
- (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;
- 15 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;
- (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;
- 20 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;
- (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;
- 25 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;
- (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;
- (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;
- (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;
- (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;
- 30 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;
- (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;
- (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;
- (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;
- (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;
- 35 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;
- (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;
- (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;
- (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;
- (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;
- 45 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and
- 50 (A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 1.29 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-*

coerulescens, Streptomyces nogalater, Streptomyces tsusimaensis, Streptomyces glomerochromogenes, Streptomyces olivochromogenes, Streptomyces ornatus, Streptomyces griseus, Streptomyces lanatus, Streptomyces misawanensis, Streptomyces pallidus, Streptomyces roseorubens, Streptomyces rutgersensis, Streptomyces steffisburgensis or Saccharopolyspora taberi.

5

26. An analysis or detection kit comprising the antibody according to claim 24.

27. A DNA encoding a ferredoxin selected from the group consisting of:

- 10 (B1) a protein comprising an amino acid sequence shown in SEQ ID NO: 12;  
 (B2) a protein comprising an amino acid sequence shown in SEQ ID NO: 13;  
 (B3) a protein comprising an amino acid sequence shown in SEQ ID NO: 14;  
 (B4) a protein comprising an amino acid sequence shown in SEQ ID NO: 111;  
 (B5) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino  
 15 acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;  
 (B6) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90%  
 sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ  
 ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;  
 (B7) a protein comprising an amino acid sequence shown in SEQ ID NO: 149;  
 20 (B8) a protein comprising an amino acid sequence shown in SEQ ID NO: 150;  
 (B9) a protein comprising an amino acid sequence shown in SEQ ID NO: 151;  
 (B10) a protein comprising an amino acid sequence shown in SEQ ID NO: 152;  
 (B11) a protein comprising an amino acid sequence shown in SEQ ID NO: 153;  
 (B12) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino  
 25 acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153,  
 SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251,  
 or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with an amino acid  
 sequence shown in any one of SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;  
 (B13) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least  
 30 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of  
 SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245,  
 SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252,  
 SEQ ID NO: 253 or SEQ ID NO: 254;  
 (B14) a protein comprising the amino acid sequence shown in SEQ ID NO: 245;  
 35 (B15) a protein comprising the amino acid sequence shown in SEQ ID NO: 247;  
 (B16) a protein comprising the amino acid sequence shown in SEQ ID NO: 248;  
 (B17) a protein comprising the amino acid sequence shown in SEQ ID NO: 249;  
 (B18) a protein comprising the amino acid sequence shown in SEQ ID NO: 250;  
 (B19) a protein comprising the amino acid sequence shown in SEQ ID NO: 251;  
 40 (B20) a protein comprising the amino acid sequence shown in SEQ ID NO: 252;  
 (B21) a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and  
 (B22) a protein comprising the amino acid sequence shown in SEQ ID NO: 254.

28. A DNA comprising a nucleotide sequence selected from the group consisting of:

45

- (b1) a nucleotide sequence shown in SEQ ID NO: 15;  
 (b2) a nucleotide sequence shown in SEQ ID NO: 16;  
 (b3) a nucleotide sequence shown in SEQ ID NO: 17;  
 (b4) a nucleotide sequence shown in SEQ ID NO: 112;  
 50 (b5) a nucleotide sequence shown in SEQ ID NO: 154;  
 (b6) a nucleotide sequence shown in SEQ ID NO: 155;  
 (b7) a nucleotide sequence shown in SEQ ID NO: 156;  
 (b8) a nucleotide sequence shown in SEQ ID NO: 157;  
 (b9) a nucleotide sequence shown in SEQ ID NO: 158;  
 55 (b10) a nucleotide sequence shown in SEQ ID NO: 255;  
 (b11) a nucleotide sequence shown in SEQ ID NO: 257;  
 (b12) a nucleotide sequence shown in SEQ ID NO: 258;  
 (b13) a nucleotide sequence shown in SEQ ID NO: 259;

(b14) a nucleotide sequence shown in SEQ ID NO: 260;  
 (b15) a nucleotide sequence shown in SEQ ID NO: 261;  
 (b16) a nucleotide sequence shown in SEQ ID NO: 262;  
 (b17) a nucleotide sequence shown in SEQ ID NO: 263;  
 (b18) a nucleotide sequence shown in SEQ ID NO: 264; and  
 (b19) a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence shown in any one of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 112, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263 or SEQ ID NO: 264.

**29.** A vector comprising a DNA according to claim 28.

**30.** A transformant in which the DNA according to claim 28 is introduced into a host cell.

**31.** A ferredoxin selected from the group consisting of:

(B1) a protein comprising an amino acid sequence shown in SEQ ID NO: 12;  
 (B2) a protein comprising an amino acid sequence shown in SEQ ID NO: 13;  
 (B3) a protein comprising an amino acid sequence shown in SEQ ID NO: 14;  
 (B4) a protein comprising an amino acid sequence shown in SEQ ID NO: 111;  
 (B5) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;  
 (B6) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 111;  
 (B7) a protein comprising an amino acid sequence shown in SEQ ID NO: 149;  
 (B8) a protein comprising an amino acid sequence shown in SEQ ID NO: 150;  
 (B9) a protein comprising an amino acid sequence shown in SEQ ID NO: 151;  
 (B10) a protein comprising an amino acid sequence shown in SEQ ID NO: 152;  
 (B11) a protein comprising an amino acid sequence shown in SEQ ID NO: 153;  
 (B12) a ferredoxin comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, or SEQ ID NO: 253 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 150, SEQ ID NO: 252 or SEQ ID NO: 254;  
 (B13) a ferredoxin comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253 or SEQ ID NO: 254;  
 (B14) a protein comprising the amino acid sequence shown in SEQ ID NO: 245;  
 (B15) a protein comprising the amino acid sequence shown in SEQ ID NO: 247;  
 (B16) a protein comprising the amino acid sequence shown in SEQ ID NO: 248;  
 (B17) a protein comprising the amino acid sequence shown in SEQ ID NO: 249;  
 (B18) a protein comprising the amino acid sequence shown in SEQ ID NO: 250;  
 (B19) a protein comprising the amino acid sequence shown in SEQ ID NO: 251;  
 (B20) a protein comprising the amino acid sequence shown in SEQ ID NO: 252;  
 (B21) a protein comprising the amino acid sequence shown in SEQ ID NO: 253; and  
 (B22) a protein comprising the amino acid sequence shown in SEQ ID NO: 254.

**32.** A DNA comprising a nucleotide sequence selected from the group consisting of:

(ab1) a nucleotide sequence shown in SEQ ID NO: 9;  
 (ab2) a nucleotide sequence shown in SEQ ID NO: 10;  
 (ab3) a nucleotide sequence shown in SEQ ID NO: 11;  
 (ab4) a nucleotide sequence shown in SEQ ID NO: 110;  
 (ab5) a nucleotide sequence shown in SEQ ID NO: 144;  
 (ab6) a nucleotide sequence shown in SEQ ID NO: 145;

(ab7) a nucleotide sequence shown in SEQ ID NO: 146;  
 (ab8) a nucleotide sequence shown in SEQ ID NO: 147;  
 (ab9) a nucleotide sequence shown in SEQ ID NO: 148;  
 (ab10) a nucleotide sequence shown in SEQ ID NO: 235;  
 (ab11) a nucleotide sequence shown in SEQ ID NO: 236;  
 (ab12) a nucleotide sequence shown in SEQ ID NO: 237;  
 (ab13) a nucleotide sequence shown in SEQ ID NO: 238;  
 (ab14) a nucleotide sequence shown in SEQ ID NO: 239;  
 (ab15) a nucleotide sequence shown in SEQ ID NO: 240;  
 (ab16) a nucleotide sequence shown in SEQ ID NO: 241;  
 (ab17) a nucleotide sequence shown in SEQ ID NO: 242;  
 (ab18) a nucleotide sequence shown in SEQ ID NO: 243; and  
 (ab19) a nucleotide sequence shown in SEQ ID NO: 244.

**33.** A vector comprising the DNA according to claim 32.

**34.** A transformant in which the DNA according to claim 32 is introduced into a host cell.

**35.** The transformant according to claim 34, wherein the host cell is a microorganism cell or a plant cell.

**36.** A method of producing a transformant comprising a step of introducing into a host cell the DNA according to claim 32.


**37.** A method of producing a protein having the ability to convert a compound of formula (II) to a compound of formula (III), said method comprising a step of culturing the transformant according to claim 34 and recovering the produced said protein.

**38.** A method of controlling weeds comprising a step of applying a compound to a cultivation area of a plant expressing at least one herbicide metabolizing protein selected from the group consisting of:


(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;  
 (A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;  
 (A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;  
 (A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;  
 (A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;  
 (A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to Streptomyces or Saccharopolyspora;  
 (A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;  
 (A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;  
 (A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;


(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224,

wherein said compound is a compound of formula (I):




wherein in formula (I) G represents a group shown in any one of the following G-1 to G-9:







G-4




G-5




G-6



G-7



G-8



G-9

wherein in G-1 to G-9,

X represents an oxygen atom or sulfur atom;

Y represents an oxygen atom or sulfur atom;

R<sup>1</sup> represents a hydrogen atom or halogen atom;

R<sup>2</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, halogen atom, hydroxyl group, -OR<sup>9</sup> group, -SH group, -S(O)<sub>p</sub>R<sup>9</sup> group, -COR<sup>9</sup> group, -CO<sub>2</sub>R<sup>9</sup> group, -C(O)SR<sup>9</sup> group, -C(O)NR<sup>11</sup>R<sup>12</sup> group, -CONH<sub>2</sub> group, -CHO group, -CR<sup>9</sup>=NOR<sup>18</sup> group, -CH=CR<sup>19</sup>CO<sub>2</sub>R<sup>9</sup> group, -CH<sub>2</sub>CHR<sup>19</sup>CO<sub>2</sub>R<sup>9</sup> group, -CO<sub>2</sub>N=CR<sup>13</sup>R<sup>14</sup> group, nitro group, cyano group, -NHSO<sub>2</sub>R<sup>15</sup> group, -NHSO<sub>2</sub>NHR<sup>15</sup> group, -NR<sup>9</sup>R<sup>20</sup> group, -NH<sub>2</sub> group or phenyl group that may be substituted with one or more C<sub>1</sub>-C<sub>4</sub> alkyl groups which may be the same or different;

p represents 0, 1 or 2;

R<sup>3</sup> represents C<sub>1</sub>-C<sub>2</sub> alkyl group, C<sub>1</sub>-C<sub>2</sub> haloalkyl group, -OCH<sub>3</sub> group, -SCH<sub>3</sub> group, -OCHF<sub>2</sub> group, halogen atom, cyano group, nitro group or C<sub>1</sub>-C<sub>3</sub> alkoxy group substituted with a phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, OR<sup>28</sup> group, NR<sup>11</sup>R<sup>28</sup> group, SR<sup>28</sup> group, cyano group, CO<sub>2</sub>R<sup>28</sup> group and nitro group;

R<sup>4</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group or C<sub>1</sub>-C<sub>3</sub> haloalkyl group;

R<sup>5</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, cyclopropyl group, vinyl group, C<sub>2</sub> alkynyl group, cyano group, -C(O)R<sup>20</sup> group, -CO<sub>2</sub>R<sup>20</sup> group, -C(O)NR<sup>20</sup>R<sup>21</sup> group, -CHR<sup>16</sup>R<sup>17</sup>CN group, -CR<sup>16</sup>R<sup>17</sup>C(O)R<sup>20</sup> group, -C<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>20</sup> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NR<sup>20</sup>R<sup>21</sup> group, -CHR<sup>16</sup>OH group, -CHR<sup>16</sup>OC(O)R<sup>20</sup> group or -OCHR<sup>16</sup>OC(O)NR<sup>20</sup>R<sup>21</sup> group, or, when G represents G-2 or G-6, R<sup>4</sup> and R<sup>5</sup> may represent C=O group together with the carbon atom to which they are attached;


R<sup>6</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group or C<sub>3</sub>-C<sub>6</sub> alkynyl group;

R<sup>7</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, halogen atom, -S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl) group or -C(=O)R<sup>22</sup> group;

R<sup>8</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>3</sub>-C<sub>8</sub> cycloalkyl group, C<sub>3</sub>-C<sub>8</sub> alkenyl group, C<sub>3</sub>-C<sub>8</sub>

alkynyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, C<sub>3</sub>-C<sub>8</sub> alkoxyalkoxyalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkynyl group, C<sub>3</sub>-C<sub>8</sub> haloalkenyl group, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl group, C<sub>1</sub>-C<sub>8</sub> haloalkylsulfonyl group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, -S(O)<sub>2</sub>NH(C<sub>1</sub>-C<sub>8</sub> alkyl) group, -C(O)R<sup>23</sup> group or benzyl group which may be substituted with R<sup>24</sup> on the phenyl ring;

R<sup>9</sup> represents C<sub>1</sub>-C<sub>8</sub> alkyl group, C<sub>3</sub>-C<sub>8</sub> cycloalkyl group, C<sub>3</sub>-C<sub>8</sub> alkenyl group, C<sub>3</sub>-C<sub>8</sub> alkynyl group, C<sub>1</sub>-C<sub>8</sub> haloalkyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylthioalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylsulfinylalkyl group, C<sub>2</sub>-C<sub>8</sub> alkylsulfonylalkyl group, C<sub>4</sub>-C<sub>8</sub> alkoxyalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkylalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> alkenyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> alkynyloxyalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkoxyalkyl group, C<sub>4</sub>-C<sub>8</sub> haloalkenyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> haloalkynyloxyalkyl group, C<sub>4</sub>-C<sub>8</sub> cycloalkylthioalkyl group, C<sub>4</sub>-C<sub>8</sub> alkenylthioalkyl group, C<sub>4</sub>-C<sub>8</sub> alkynylthioalkyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group substituted with a phenoxy group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group substituted with a benzyloxy group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group, C<sub>4</sub>-C<sub>8</sub> trialkylsilylalkyl group, C<sub>2</sub>-C<sub>8</sub> cyanoalkyl group, C<sub>3</sub>-C<sub>8</sub> halocycloalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkenyl group, C<sub>5</sub>-C<sub>8</sub> alkoxyalkenyl group, C<sub>5</sub>-C<sub>8</sub> haloalkoxyalkenyl group, C<sub>5</sub>-C<sub>8</sub> alkylthioalkenyl group, C<sub>3</sub>-C<sub>8</sub> haloalkynyl group, C<sub>5</sub>-C<sub>8</sub> alkoxyalkynyl group, C<sub>5</sub>-C<sub>8</sub> haloalkoxyalkynyl group, C<sub>5</sub>-C<sub>8</sub> alkylthioalkynyl group, C<sub>2</sub>-C<sub>8</sub> alkylcarbonyl group, benzyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>1</sub>-C<sub>3</sub> haloalkyl group, -OR<sup>28</sup> group, -NR<sup>11</sup>R<sup>28</sup> group, -SR<sup>28</sup> group, cyano group, -CO<sub>2</sub>R<sup>28</sup> group and nitro group, -CR<sup>16</sup>R<sup>17</sup>COR<sup>10</sup> group, -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>20</sup> group, -CR<sup>16</sup>R<sup>17</sup>P(O)(OR<sup>10</sup>)<sub>2</sub> group, -CR<sup>16</sup>R<sup>17</sup>P(S)(OR<sup>10</sup>)<sub>2</sub> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NR<sup>11</sup>R<sup>12</sup> group, -CR<sup>16</sup>R<sup>17</sup>C(O)NH<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)COR<sup>10</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)CO<sub>2</sub>R<sup>20</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)P(O)(OR<sup>10</sup>)<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)P(S)(OR<sup>10</sup>)<sub>2</sub> group, -C(=CR<sup>26</sup>R<sup>27</sup>)C(O)NR<sup>11</sup>R<sup>12</sup> group, -C(=CR<sup>26</sup>R<sup>27</sup>)C(O)NH<sub>2</sub> group, or any one of rings shown in Q-1 to Q-7:



which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>2</sub>-C<sub>6</sub> alkenyl group, C<sub>2</sub>-C<sub>6</sub> haloalkenyl group, C<sub>2</sub>-C<sub>6</sub> alkynyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl group, -OR<sup>28</sup> group, -SR<sup>28</sup> group, -NR<sup>11</sup>R<sup>28</sup> group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, C<sub>2</sub>-C<sub>4</sub> carboxyalkyl group, -CO<sub>2</sub>R<sup>28</sup> group and cyano group;

R<sup>10</sup> represents a C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>2</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group or tetrahydrofuran group;

R<sup>11</sup> and R<sup>13</sup> independently represent a hydrogen atom or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>12</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group and C<sub>1</sub>-C<sub>4</sub> alkoxy group or -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>25</sup> group; or,

R<sup>11</sup> and R<sup>12</sup> together may represent -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>4</sub>- or -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>-, or in that case the resulting ring may be substituted with a substituent selected from a C<sub>1</sub>-C<sub>3</sub> alkyl group, a phenyl group and benzyl group;

R<sup>14</sup> represents a C<sub>1</sub>-C<sub>4</sub> alkyl group or phenyl group which may be substituted on the ring with a substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group; or,

R<sup>13</sup> and R<sup>14</sup> may represent C<sub>3</sub>-C<sub>8</sub> cycloalkyl group together with the carbon atom to which they are attached;

R<sup>15</sup> represents C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group or C<sub>3</sub>-C<sub>6</sub> alkenyl group;

R<sup>16</sup> and R<sup>17</sup> independently represent a hydrogen atom or C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>2</sub>-C<sub>4</sub> haloalkenyl group, C<sub>2</sub>-C<sub>4</sub> alkynyl group, C<sub>3</sub>-C<sub>4</sub> haloalkynyl group; or,

R<sup>16</sup> and R<sup>17</sup> may represent C<sub>3</sub>-C<sub>6</sub> cycloalkyl group with the carbon atom to which they are attached, or the ring thus formed may be substituted with at least one substituent selected from a halogen atom, a C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group;

R<sup>18</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group or C<sub>3</sub>-C<sub>6</sub> alkynyl group;

R<sup>19</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group or halogen atom,

R<sup>20</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, phenyl group which may be substituted on the ring with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group and -OR<sup>28</sup> group, or -CR<sup>16</sup>R<sup>17</sup>CO<sub>2</sub>R<sup>25</sup> group;

R<sup>21</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>2</sub> alkyl group or -CO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) group;

R<sup>22</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group or NH(C<sub>1</sub>-C<sub>6</sub> alkyl) group;

R<sup>23</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, NH(C<sub>1</sub>-C<sub>6</sub> alkyl) group, benzyl group, C<sub>2</sub>-C<sub>8</sub> dialkylamino group or phenyl group which may be substituted with R<sup>24</sup>;

R<sup>24</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, 1 to 2 halogen atoms, C<sub>1</sub>-C<sub>6</sub> alkoxy group or CF<sub>3</sub> group;

R<sup>25</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group or C<sub>3</sub>-C<sub>6</sub> haloalkynyl group;

R<sup>26</sup> and R<sup>27</sup> each represent independently a hydrogen atom, C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> haloalkyl group, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>2</sub>-C<sub>4</sub> haloalkenyl group, C<sub>2</sub>-C<sub>4</sub> alkynyl group, C<sub>3</sub>-C<sub>4</sub> haloalkynyl group, -OR<sup>28</sup> group, -NHR<sup>28</sup> group, or -SR<sup>28</sup> group; or,

R<sup>26</sup> and R<sup>27</sup> may represent C<sub>3</sub>-C<sub>8</sub> cycloalkyl group with the carbon atom to which they are attached, or each of the ring thus formed may be substituted with at least one substituent selected from a halogen atom, C<sub>1</sub>-C<sub>3</sub> alkyl group and C<sub>1</sub>-C<sub>3</sub> haloalkyl group; and,

R<sup>28</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> haloalkyl group, C<sub>3</sub>-C<sub>6</sub> alkenyl group, C<sub>3</sub>-C<sub>6</sub> haloalkenyl group, C<sub>3</sub>-C<sub>6</sub> alkynyl group, C<sub>3</sub>-C<sub>6</sub> haloalkynyl group, C<sub>2</sub>-C<sub>4</sub> carboxyalkyl group, C<sub>3</sub>-C<sub>8</sub> alkoxycarbonylalkyl group, C<sub>3</sub>-C<sub>8</sub> haloalkoxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> alkenyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> haloalkenyloxy-carbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> alkynyloxycarbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> haloalkynyloxy-carbonylalkyl group, C<sub>5</sub>-C<sub>9</sub> cycloalkoxycarbonylalkyl group or C<sub>5</sub>-C<sub>9</sub> halocycloalkoxycarbonylalkyl group.

39. A method of controlling weeds comprising a step of applying a compound to a cultivation area of a plant expressing at least one protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224;

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid

sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(A28) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising the nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, a primer comprising the nucleotide sequence shown in SEQ ID NO: 129 and as a template a chromosomal DNA of *Streptomyces phaeochromogenes*, *Streptomyces testaceus*, *Streptomyces achromogenes*, *Streptomyces griseofuscus*, *Streptomyces thermo-coerulescens*, *Streptomyces nogalater*, *Streptomyces tsusimaensis*, *Streptomyces glomerochromogenes*, *Streptomyces olivochromogenes*, *Streptomyces omatus*, *Streptomyces griseus*, *Streptomyces lanatus*, *Streptomyces misawanensis*, *Streptomyces pallidus*, *Streptomyces roseorubens*, *Streptomyces rutgersensis*, *Streptomyces steffisburgensis* or *Saccharopolyspora taberi*.

40. A method of evaluating the resistance of a cell to a compound of formula (I), said method comprising:

(3) a step of contacting said compound with a cell expressing at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;  
 (A26) a protein having an ability to convert in the presence of an electron transport system containing an  
 5 electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ  
 ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219,  
 SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90%  
 10 sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215,  
 SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and  
 (A27) a protein having the ability to convert in the presence of an electron transport system containing an  
 electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide  
 15 sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160,  
 SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO:  
 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID  
 NO: 223 or SEQ ID NO: 224; and

(4) a step of evaluating the degree of damage to the cell which contacted the compound in the above step (1).

41. The method according to claim 40, wherein the cell is a microorganism cell or plant cell.

42. A method of selecting a cell resistant to a compound of formula (I), said method comprising a step of selecting a  
 cell based on the resistance evaluated in the method according to claim 40.

43. The cell resistant to herbicide selected by the method according to claim 42, or the culture thereof,

44. A method of evaluating the resistance of a plant to a compound of formula (I), said method comprising:

(3) a step of contacting said compound with a plant expressing at least one herbicide metabolizing protein  
 selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an  
 electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid  
 sequence having at least 80% sequence identity with an amino acid sequences shown in any one of SEQ  
 ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an  
 electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide  
 sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID  
 NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an  
 electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide  
 sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or  
 SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an  
 electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid  
 sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a  
 nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in  
 any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to  
 Streptomyces or Saccharopolyspora;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;  
 (A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;  
 (A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;  
 (A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;  
 (A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;  
 (A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;  
 (A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;  
 (A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;  
 (A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;  
 (A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;  
 (A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;  
 (A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;  
 (A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;  
 (A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224; and

(4) a step of evaluating the degree of damage to the plant which contacted the compound described in step (1).

45. A method of selecting a plant resistant to a compound of formula (I), said method comprising a step of selecting a plant based on the resistance evaluated in the method according to claim 44.

46. A herbicidally resistant plant selected from the method according to claim 45, or the progeny thereof.

47. A method of treating a compound of formula (I), said method comprising reacting said compound in the presence of an electron transport system containing an electron donor, with at least one herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an

electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224.

48. The method according to claim 47, wherein reacting the compound with the herbicide metabolizing protein by contacting the compound with a transformant in which a DNA encoding the herbicide metabolizing protein is introduced into a host cell in a position enabling its expression in said cell.

49. Use for treating the compound of formula (I) of a herbicide metabolizing protein selected from the group consisting of:

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding any one of the amino acid sequences shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid

sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template chromosome of a microorganism belonging to Streptomyces or Saccharopolyspora;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding the amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224.

50. Use for treating a compound of formula (I) of a polynucleotide encoding a herbicide metabolizing protein selected from the group consisting of

(A1) a protein comprising the amino acid sequence shown in SEQ ID NO: 1;

(A2) a protein comprising the amino acid sequence shown in SEQ ID NO: 2;

(A3) a protein comprising the amino acid sequence shown in SEQ ID NO: 3;

(A4) a protein comprising the amino acid sequence shown in SEQ ID NO: 108;

(A5) a protein having an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III) and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A6) a protein having an ability to convert in the presence of an electron transport system containing an electron donor a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 80% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A7) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA that hybridizes, under stringent conditions, to a DNA comprising a nucleotide

sequence encoding an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 108;

(A8) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a DNA amplifiable by a polymerase chain reaction with a primer comprising a nucleotide sequence shown in SEQ ID NO: 129, a primer comprising a nucleotide sequence shown in any one of SEQ ID NOs: 124 to 128, and as a template a chromosome of a microorganism belonging to *Streptomyces* or *Saccharopolyspora*;

(A9) a protein comprising an amino acid sequence shown in SEQ ID NO: 4;

(A11) a protein comprising the amino acid sequence shown in SEQ ID NO: 159;

(A12) a protein comprising the amino acid sequence shown in SEQ ID NO: 160;

(A13) a protein comprising the amino acid sequence shown in SEQ ID NO: 136;

(A14) a protein comprising the amino acid sequence shown in SEQ ID NO: 137;

(A15) a protein comprising the amino acid sequence shown in SEQ ID NO: 138;

(A16) a protein comprising the amino acid sequence shown in SEQ ID NO: 215;

(A17) a protein comprising the amino acid sequence shown in SEQ ID NO: 216;

(A18) a protein comprising the amino acid sequence shown in SEQ ID NO: 217;

(A19) a protein comprising the amino acid sequence shown in SEQ ID NO: 218;

(A20) a protein comprising the amino acid sequence shown in SEQ ID NO: 219;

(A21) a protein comprising the amino acid sequence shown in SEQ ID NO: 220;

(A22) a protein comprising the amino acid sequence shown in SEQ ID NO: 221;

(A23) a protein comprising the amino acid sequence shown in SEQ ID NO: 222;

(A24) a protein comprising the amino acid sequence shown in SEQ ID NO: 223;

(A25) a protein comprising the amino acid sequence shown in SEQ ID NO: 224;

(A26) a protein comprising an ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 223 or an amino acid sequence having at least 90% sequence identity with an amino acid sequence shown in any one of SEQ ID NO: 160, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222 or SEQ ID NO: 224; and

(A27) a protein having the ability to convert in the presence of an electron transport system containing an electron donor, a compound of formula (II) to a compound of formula (III), and comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% sequence identity with a nucleotide sequence encoding an amino acid sequence shown in any one of SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223 or SEQ ID NO: 224.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 1 1




Fig. 1 2




Fig. 13




Fig. 14

GCGGCCGCG  
CGCCGGCGCTTAA

Fig. 15




Fig. 16

AGCTTGCGGCGGC  
ACGCCGGCGAT

Fig. 17




Fig. 18




Fig. 19




Fig. 2 0




Fig. 2 1




Fig. 2 2




Fig. 23




Fig. 2 4




Fig. 2 5

AGCTTGGGGCGCGAATTC  
ACGCGGGGGCTTAAGTCGA

Fig. 2 6





Fig. 2 7



**pBI-NdG6-rSt12-657**

RB

Nost

SUG

NOS

EcoRI NotI SacI

BspHI EcoT22I

SphI

EcoT22I NotI HindIII

CR16Gbp Δ

RuBPCscSCTP

12aa

DNA A1

CR16t Δ

LB

Fig. 31




Fig. 3 2




Fig. 3 3




Fig. 3 4




Fig. 3 5




Fig. 3 6




Fig. 3 7




Fig. 3 8




Fig. 3 9




Fig. 4 0




Fig. 4 1




Fig. 4 2




Fig. 4 3




Fig. 4 4




Fig. 45





Fig. 4 6




BEST AVAILABLE COPY

Fig. 4 7

AGCTATTTTTTAATAAAATCAGGAGGAAAAACATATGAGCAAGCTTGGCTGTTTTGGCGGATGAGAGAAGA  
TAAAAAATTATTTTAGTCCTCCTTTTTGTATACTCGTTCGAACCGACAAAACCGCCTACTCTCTTCT

Fig. 4 8



BEST AVAILABLE COPY

Fig. 49





Fig. 50



REST AVAILABLE COPY

Fig. 5 1




Fig. 5 2




Fig. 5 3




Fig. 5 4




Fig. 5 5





Fig. 5 6



The diagram illustrates the pSUM-NdG6-rSt12-1584soy plasmid construct. The circular map includes the following components and restriction sites:

- ColE1 ori**: Origin of replication, indicated by a black box.
- Amp<sup>r</sup>**: Ampicillin resistance gene, indicated by a black box.
- Multiple Cloning Site (MCS)**: Located between the ori and the insert, containing sites for NotI, EcoT22I, EcoRI, SacI, NotI, and EcoRI.
- Insert Regions**:
  - CR16G6pΔ**: A region with a deletion, flanked by EcoT22I sites.
  - RuBPCssCTP 12aa**: A 12 amino acid region.
  - DNA A23S**: A site-directed mutation region.
  - CR16tΔ**: A terminal region with a deletion, flanked by EcoRI sites.
- Restriction Sites**: BspHI sites are marked at the top and bottom of the plasmid.

Restriction map of the pBI-NdG6-rSt-1584soy plasmid. The map shows a circular plasmid with various restriction sites and fragments. Key features include: EcoRI, NotI, and SacI sites; a CR16tΔ fragment; a DNA A23S fragment; a RuBPCssCTP fragment; a CR16G6pΔ fragment; a SON, GUS, and SON fragment; and a SON, ILTPN, and SON fragment. The plasmid is labeled pBI-NdG6-rSt-1584soy.

**pBI-NdG6-rSt12-1584soy**

LB

tSON 3' UTR dSON

CR16G6pΔ

RuBPCssCTP

12aa

DNA A23S

CR16tΔ

EcoRI NotI SacI BspHI EcoT22I EcoT22I NotI HindIII

RB

tSON 3' UTR dSON

CR16tΔ

The diagram illustrates the structure of the pUCrSt1609soy plasmid. It is a circular vector with the following components:

- ColE1 ori**: Origin of replication, located at the top of the plasmid.
- Amp<sup>r</sup>**: Ampicillin resistance gene, located at the bottom of the plasmid.
- Multiple Cloning Site (MCS)**: Located on the right side of the plasmid, containing several restriction enzyme sites: HindIII, BamHI, EcoT221, SacI, and EcoRI.
- RuBPCssCTP**: A gene located on the left side of the plasmid.
- DNA A25S**: A gene located on the left side of the plasmid, adjacent to RuBPCssCTP.
- pUCrSt1609soy**: The name of the plasmid, centered in the diagram.

Fig. 6 1




Fig. 6 2

TGCAGGTGTGGCCACCAATTGGCAAGAAGAAATGCA  
ACGTACGTCCACACCGGTGGTTAACCGTTCTCTTT

Fig. 6 3





Fig. 6 4



BEST AVAILABLE COPY

Fig. 6 5





Fig. 6 6



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/10789

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int.Cl <sup>7</sup> C12N15/12, C07K14/705, C07K16/28, C12N5/10, A61K38/17, A61K39/395, G01N33/50, G01N33/15, C12P21/02, C12P21/08, A01H5/00// (C12N15/12, C12R1:19), (C12N5/10, C12R1:91), According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N1/00-15/90, C07K14/00-16/46, A61K31/00-48/00, G01N33/00-98, C12P21/08, A01H1/00-17/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) SwissProt/PIR/GeneSeq, MEDLINE(STN), Genbank/EMBL/DDBJ/GeneSeq, WPI (DIALOG), BIOSIS (DIALOG)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	Bentley S.D. et al., "Complete genome sequence of the model actinomycete <i>Streptomyces coelicolor</i> A3(2).", Nature, 09 May, 2002 (09.05.02), Vol.417, pages 141 to 147	1-15, 17, 23, 24, 26-36, 50, 16, 18-22, 25, 38-49
P, A		
Y	Esther Schmid et al., "AUD4, a new amplifiable element from <i>Streptomyces lividans</i> .", Microbiology, 1999, Vol.145, pages 3331 to 3341	1-15, 17, 23, 24, 26-36, 50, 16, 18-22, 25, 38-49
A		
Y	Trower M.K. et al., "Cloning, nucleotide sequence determination and expression of the genes encoding cytochrome P-450 <sub>soy</sub> (soyC) and ferredoxin <sub>soy</sub> (soyB) from <i>Streptomyces griseus</i> .", Mol.Microbiol., (1992), Vol.6, No.15, pages 2125 to 2134	1-3, 5, 7-15, 17, 23, 24, 26-36, 50, 4, 6, 16, 18-22, 25, 38-49
A		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search 03 February, 2003 (03.02.03)		Date of mailing of the international search report 11 March, 2003 (11.03.03)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/10789

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	OMURA S. et al., "Genome sequence of an industrial microorganism <i>Streptomyces avermitilis</i> : deducing the ability of producing secondary metabolites.", Proc.Natl.Acad.Sci.USA, 09 October, 2001 (09.10.01), Vol.98, No.21, pages 12215 to 12220	1-3,7-15,17, 23,24,26-36, 50 4-6,16, 18-22,25, 38-49
Y A	WO 93/12236 A1 (E.I. Du Pont de Nemours & Co.), 24 June, 1993 (24.06.93), & JP 07-502650 A & EP 618972 A1 & US 5466590 A	1-3,5,7-15, 17,23,24, 26-36,50 4,6,16, 18-22,25, 38-49
Y A	WO 91-03561 A1 (E.I. Du Pont de Nemours & Co.), 21 March, 1991 (21.03.91), & JP 3206813 B2 & EP 554240 A1	1-3,7-15,17, 23,24,26-36, 50 4-6,16, 18-22,25, 38-49
Y A	O'Keefe D.P. et al., "Ferredoxins from two sulfonylurea herbicide monooxygenase systems in <i>Streptomyces griseolus</i> ", Biochemistry, (1991), Vol.30, No.2, pages 447 to 455	27-31 1-26,32-50
Y A	Omer C.A. et al., "Genes for two herbicide-inducible cytochromes P-450 from <i>Streptomyces griseolus</i> ", J.Bacteriol., (1990), Vol.172, No.6, pages 3335 to 3345	27-31 1-26,32-50
P,Y P,A	Holmes S.E. et al., "A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2.", Nature Genetics, (Dec.2001), Vol.29, No.4, pages 377 to 378	27-31 1-26,32-50

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/10789

**Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

The amino acid sequences represented by SEQ ID NOS:12 to 14, 111, 149 to 153, 245 and 247 to 254 as set forth in claim 27 specify *Streptomyces*-origin ferredoxins which had been well known per se.

Since the *Streptomyces*-origin ferredoxins cannot be considered as "a special technical feature that defines a contribution which each of the claimed inventions, considered as a whole, makes over the prior art", it is adequate to regard ferredoxins with various *Streptomyces* origins as to different inventions.

Such being the case, the claims of the present case have 19 inventions in total, i.e., an invention relating to (continued to extra sheet)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/10789

Continuation of A. CLASSIFICATION OF SUBJECT MATTER  
(International Patent Classification (IPC))

Int.Cl<sup>7</sup> (C12P21/02, C12R1:91), (C12P21/08, C12R1:91)

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of Box No.II of continuation of first sheet(1)

a *Streptomyces*-origin PPO inhibitory weed controller metabolism protein and 18 inventions relating respectively to ferredoxin proteins having the amino acid sequences represented by the above SE ID NOS.